2016 ANNUAL REPORT
POSITIONED TO ACCELERATE
015479A_02-May-2017_Annual Report 2016.indd 1
5/2/2017 12:01:21 PM
Corporate Overview
Wright Medical Group N.V. is a global medical device company
focused on Extremities and Biologics. The company is committed to
delivering innovative, value-added solutions improving the quality of
life for patients worldwide. Wright is a recognized leader of surgical
solutions for the upper extremities (shoulder, elbow, wrist and hand),
lower extremities (foot and ankle) and biologics markets, three of
the fastest growing segments in orthopaedics.
Our ordinary shares are traded on the NASDAQ Global
Select Market under the symbol “WMGI”.
Our Vision
Your First Choice in Extremities and Biologics
Our Mission
We focus on Extremities and Biologics.
Through our team of passionate and dedicated
people, we deliver innovative, value-added solutions
improving quality of life for patients worldwide.
We are committed to compliance and the highest
standards of ethical conduct.
Our Values
• Think Customer
• Embrace Change
• Alignment
• eMpowerment
• Sustainability
015479A_02-May-2017_Annual Report 2016.indd 2
5/2/2017 12:01:23 PM
alignment “...Our Focused Excellence approach has enabled us
to transform our company to become the leader in
the fastest-growing orthopaedics markets: upper
extremities, lower extremities, and biologics.”
Robert J. Palmisano, President and Chief Executive Officer
To our fellow shareholders, customers,
and employees:
This is an exciting time at Wright Medical. Our Focused
We have already completed more than 80% of some 300
Excellence approach has enabled us to transform our company
integration milestones, accomplished the integration of our
to become the leader in the fastest-growing orthopaedics
global sales forces with minimal disruption, and co-located
markets: upper extremities, lower extremities, and biologics.
most of our major international markets. At the same
These are huge markets that represent about $8 billion of
opportunity—and we are growing at approximately twice
time, we have realized better-than-expected timing of
revenue dis-synergies and are ahead of schedule on
the market rate. We have also made incredible progress a year
capturing cost synergies.
after our merger with Tornier. In fact, we have completed over
80% of our integration milestones in the first year. In addition
2016 highlights
to all of that, we’ve materially improved our balance sheet.
As the recognized leader in the high-growth extremities and
biologics markets—in fact, the only company with a singular
focus on extremities and biologics—we have several key
differentiators that set Wright Medical apart—and in our
Wright Medical had net sales from continuing operations of
$690 million and non-GAAP adjusted EBITDA from continuing
operations of $54 million in 2016. On a same sales day
and constant currency basis, and excluding the impact of
conforming Wright’s methodology for recognizing revenue
business, differentiation really matters. That’s why we decided
in the fourth quarter of 2015, non-GAAP pro-forma global
to focus on these high-growth markets that enable us to
differentiate ourselves from competitors, large or small.
We have a global footprint with the largest specialized
direct sales force. We have leading technologies that play
net sales grew 12% in 2016. Our full-year results reflect the
continued strong underlying growth and positive momentum
in all three of our high-growth businesses and our leadership
positions in these markets.
a powerful role in setting ourselves apart from our competitors.
Highlights for the year included significant overperformance
We have a strong R&D pipeline and we have a strong
emphasis on the fundamentals of running a medical device
company—medical education.
on the top and bottom line in all areas in 2016, and we believe
we are well positioned to continue driving high sales growth
rates and non-GAAP adjusted EBITDA margin expansion.
Tornier merger accomplishments
A year ago, I told you that bringing together the extensive
and innovative capabilities of both Wright and Tornier would
We saw strong contributions from our SIMPLICITI™ shoulder
system and the ongoing rollout of AUGMENT® Bone Graft and
the INFINITY™ Total Ankle Replacement system, which for the
fourth quarter of 2016 drove 14% sales growth in US shoulder
enable us to extend our leadership position to generate long-
replacement, 29% sales growth in US biologics and 23% sales
term value for our shareholders. In fact, that is exactly what
growth in US total ankle replacement. Today, we believe
has occurred. But mergers can be complicated and unforeseen
we have grown to be #1 by a wide margin in US total ankle
difficulties with integration can arise. That’s why I’m very
replacement, #2 in US shoulder replacement and have the
pleased to report that we have made tremendous, measurable
fastest growing biologic product in orthopaedics.
progress one year after the merger.
2016 Annual Report Wright Medical Group N.V. 1
015479A_02-May-2017_Annual Report 2016.indd 3
5/2/2017 12:01:23 PM
In addition to the merger, we materially improved our balance
instruments, and DSO. Lastly, we intend to continue to
sheet and are taking advantage of significant opportunities
leverage our SG&A.
to continue to improve inventory, instrument set utilization,
and days sales outstanding (DSO). We successfully sold
our European hip/knee business and addressed significant
metal-on-metal hip litigation uncertainty through a Master
Settlement Agreement.
Strategic priorities for growth
We believe in following a consistent approach, so it shouldn’t
be too surprising to see that our key financial objectives are
the same as when we announced the merger with Tornier
more than two years ago. Our goal is to have a company
with net sales growing at a rate in the mid-teens, with
margins in the high 70% range and non-GAAP adjusted
EBITDA of 20% three to four years post the close of the
Our focus going forward is very straightforward and comes
merger with Tornier.
down to two key priorities: revenue growth and cash. To drive
revenue growth, we have begun selectively expanding our
Robust product line – today and tomorrow
US sales force. We plan to add about 85 new direct quota-
carrying reps to help us grasp the opportunity in front of us.
It’s important to keep in mind that only about one-third of
these reps will be new hires. The remaining two-thirds are
associate sales reps who will move up to quota-carrying reps.
Another critical aspect of revenue growth is new products,
which I’ll explore more deeply.
Regarding cash, we intend to complete the merger integration
and realize the cost synergies that we have already discussed,
which we anticipate to be in the area of $40 million to $45
million by 2018-2019. We also expect to improve inventory,
“...Our goal is to have a
company with net sales
growing at a rate in the
mid-teens, with margins
in the high 70% range
and non-GAAP adjusted
EBITDA of 20%...”
Of course, one of the best ways to grow revenues is by
offering superior products. We’re very proud that our
products are considered leaders in their categories.
In our upper extremities business, we’ve extended our
leadership position in shoulder with new product launches
and increased sales force productivity. We have a significant
lead in terms of technology and this is a very large market,
in the $2.7 billion range. It’s also growing extremely fast,
at a rate of 8% to 9%—and our growth rate is about
double that.
The lower extremities market, particularly foot and ankle,
is about $1.7 billion but growing at about 8% to 10%.
We intend to accelerate foot and ankle growth through
market expansion and sales force optimization.
Finally, biologics, led by AUGMENT, is the fastest growth
area of our company, and we think it will continue to be
so moving forward. We are leveraging opportunities for
selling biologics across our expanded upper and lower
extremities portfolio.
In addition to our current product line, we have a very robust
product pipeline in every category.
2 2016 Annual Report Wright Medical Group N.V.
015479A_02-May-2017_Annual Report 2016.indd 4
5/2/2017 12:01:24 PM
We believe these are all excellent products—and the market
agrees. But I’d like to single out four products for added
discussion.
PERFORM™ Reversed Glenoid. We plan to launch the
PERFORM Reversed Glenoid in the first half of 2017. This is
an important addition to our PERFORM platform, as it is an
implant with porous metal fixation that is specifically shaped
for treating patients with difficult glenoid anatomy.
SALVATION™ Limb Salvage System. We offered the first
comprehensive solution for Charcot arthropathy and advanced
midfoot reconstruction. This is a fast-growing market, and
we’re the only company that’s cleared by the FDA with a total
system to treat this condition. We spend a lot of time training
physicians in this procedure.
INFINITY™ Total Ankle Replacement System and INVISION™
Revision Ankle. Currently this market is about $90 million—
but we continue to believe the potential market is significantly
underpenetrated and could ultimately grow to be four to
five times its current size. The reason is that some 90% of
the cases that are currently fused could be candidates for
total ankle replacement, giving the patient mobility.
2016 was a record for Wright, both for annual revenue for
total ankles and for the total number of cases performed.
We believe we are driving much of the current market
expansion, and we estimate that well over half the total ankle
replacements in the US in 2016 were performed with Wright
products. In addition, approximately 70% of all our total
ankle replacement procedures were completed with our
PROPHECY™ enabling technology system. Expanding the
total ankle market will continue to be a focus for us, and we
are looking forward to the anticipated launch of our
INVISION™ revision ankle system in the third quarter of 2017.
AUGMENT® Injectable Bone Graft. As I have pointed out,
Biologics is the fastest growth area of our company, and
AUGMENT is a key driver of that growth. We are now working
with the FDA to gain approval for an injectable form of
AUGMENT with a PMA Panel Track Supplement. We already
have an injectable form in some countries, including Australia
and Canada. Physicians in these countries have told us they
prefer the handling characteristics of this injectable form of
AUGMENT, and we anticipate that it will be well received
once approved and available in the US. Of course, we don’t
know how the US market will respond, but we see a large
potential opportunity.
A clear post-merger path to high growth and
profitability
I mentioned that our goal is to achieve a non-GAAP adjusted
EBITDA of 20%. So how do we intend to get there?
First, sustain our revenue growth and minimize disruption.
We can clearly see ourselves as a mid-teens growth company.
We’re very committed to that goal and have a good line of
vision to it.
2016 Annual Report Wright Medical Group N.V. 3
015479A_02-May-2017_Annual Report 2016.indd 5
5/2/2017 12:01:24 PM
Second, deliver on our cost synergies of $40 million to
With all that said, we see ourselves well situated in our
$45 million, which are coming from key areas such as
markets to grow. We have multiple growth drivers in
overlapping systems and support functions, vendor
consolidation and process improvement. Our cost synergies
are well underway. We ended 2016 ahead of schedule on
new products as well as an expanded sales force. Our post-
merger momentum is strong, and we are on a faster path
to profitability with stronger financial profiles than we
cost synergies with about $30 million, which we think is
thought at this time a year ago.
excellent progress.
Lastly, we see the opportunity for significant leverage.
More than 50% of our operating expenses are highly
leverageable. We made great progress in these areas in
2016 as we drove significant SG&A leverage in addition to
our cost synergies, reduced DSO by five days and reduced
inventory days on hand by approximately 250 days for the
legacy Wright Extremities business. We still have a lot of
opportunity to improve going forward.
“...We are very well
positioned to perform,
and to accelerate our
performance.”
Positioned to accelerate
We believe we are very well positioned to perform, and to
accelerate our performance. We are in a great trajectory
with sound fundamentals. Our products, our new product
launches, our sales force, the integration of Tornier—all of
that has gone extremely well.
We have been very busy, and our accomplishments can be tied
directly to the incredible Wright Medical team all around the
world. I am grateful for the many contributions of our people.
As always, I would also like to acknowledge and thank our
shareholders for your support and trust. It has been a fantastic,
transformational journey, and Wright is now positioned to
accelerate.
We are grateful for our successes, but realize much work lies
ahead. We will be keeping you up-to-date on our progress
along the way.
Sincerely yours,
Robert J. Palmisano
President and Chief Executive Officer
4 2016 Annual Report Wright Medical Group N.V.
015479A_02-May-2017_Annual Report 2016.indd 6
5/2/2017 12:01:25 PM
We use certain non-GAAP financial measures, including adjusted EBITDA from continuing operations. These non-GAAP financial measures are not in accordance
with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial
measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of our non-GAAP financial measures may
differ from the definitions of other companies using the same or similar names limiting, to some extent, the usefulness of such measures for comparison purposes.
We believe that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined
in accordance with GAAP and that these measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP measures.
Reconciliation of Non-GAAP Adjusted EBITDA to Net Loss from
Continuing Operations (dollars in thousands - unaudited)
Fiscal Year Ended
December 25, 2016
Net loss from continuing operations
$ (164,934)
Interest expense, net
Benefit (provision) from income taxes
Depreciation
Amortization
Non-GAAP EBITDA:
Reconciling items impacting EBITDA:
Non-cash share-based compensation expense
Other expense (income), net
Inventory step-up amortization
Transaction and transition costs
Management changes
Legal settlement
Costs associated with new convertible debt
58,530
(13,406)
55,830
28,841
$ (35,139)
14,416
(3,148)
37,689
36,374
1,348
1,800
234
Non-GAAP adjusted EBITDA
$ 53,574
2016 Annual Report Wright Medical Group N.V. 5
015479A_02-May-2017_Annual Report 2016.indd 7
5/2/2017 12:01:25 PM
Wright Medical Group N.V.
Reconciliation of Non-GAAP Adjusted Combined Pro Forma Average Sales per Day to Average Sales per Day
(dollars in thousands--unaudited)
Fiscal year ended
December 25, 2016
Fiscal year ended
December 27, 2015
Average
Sales per
Day
Net Sales
Legacy
Wright
Legacy
Tornier (1)
Net sales as
reported
Legacy
Tornier N.V.
standalone
Nine
Months
Ended
9/27/15 (2)
Legacy
Tornier
Stub
Period
(9/28/15 -
9/30/15) (4)
Legacy
Tornier
Net Sales
Divested (3)
Non-GAAP
Pro Forma
Legacy
Tornier
Legacy
Wright
Impact of
Revenue
Recognition (5)
Adjusted
Legacy
Wright
U.S. Sales
Lower Extremities
Upper Extremities
Biologics
Sports Med & Other
222,936
201,579
74,603
8,429
885
800
296
33
180,435
6,661
187,096
29,637
(9,733)
279
26,844
(2,337)
178,098
15,446
43,310
58,756
115,846
50,257
326
50,583
2,133
1,255
3,388
1,290
5,021
-
-
-
1,773
160,929
66
4
1,682
6,280
(165)
(468)
(23)
15,281
49,789
2,110
Non-GAAP
Adjusted
Pro Forma
Combined
Average
Sales per
Day (6)
825
703
207
34
Total U.S.
507,547
2,014
248,271
51,552
299,823
151,794
(9,733)
2,122
195,735
(2,993)
245,278
1,769
U.S. Selling Days
252
251
248
International Sales
Lower Extremities
Upper Extremities
Biologics
Sports Med & Other
Total International
62,701
86,502
18,883
14,729
182,815
241
333
73
57
704
48,651
2,549
7,492
17,297
19,520
132
8,125
1,737
51,200
24,789
19,652
9,862
7,402
51,293
357
5,372
83,788
21,715
105,503
64,424
International Selling Days
260
-
-
-
-
-
152
1,260
13
132
10,103
69,850
502
7,241
1,557
87,696
260
-
-
-
-
-
48,651
7,492
19,520
8,125
83,788
257
Global sales
Lower Extremities
Upper Extremities
Biologics
Sports Med & Other
285,637
288,081
93,486
23,158
1,126
1,133
369
90
229,086
9,210
238,296
37,039
(9,733)
431
36,947
(2,337)
226,749
22,938
60,607
83,545
167,139
69,777
10,258
458
2,992
70,235
13,250
1,647
10,393
-
-
-
3,033
230,779
79
136
2,184
13,521
(165)
(468)
(23)
22,773
69,309
10,235
228
298
78
59
663
1,053
1,001
285
93
Total Global Sales
690,362
2,718
332,059
73,267
405,327
216,218
(9,733)
3,679
283,431
(2,993)
329,066
2,432
Fiscal year
ended
December
25, 2016
Non-GAAP
ASPD
Growth %
Constant
Currency (7)
7%
14%
43%
0%
14%
9%
13%
(4)%
(1)%
9%
8%
14%
30%
(1)%
12%
Impact of FX (8)
Lower Extremities
Upper Extremities
Biologics
Sports Med & Other
Total
2,074
1,365
611
622
4,672
8
5
2
2
17
1 Reflects continuing operations only.
2 Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line “Large Joints and Other” to the product line
associated with those revenues that will be utilized for future revenue reporting.
3 To reduce from Tornier’s historical sales the U.S. sales associated with Tornier’s Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products that were divested prior
to the merger.
4 To add revenues from Legacy Tornier’s fourth quarter for the period prior to the merger closing date when operations became consolidated.
5 Legacy Wright recognized approximately $3 million during the fourth quarter of 2015, as result of conforming its methodology for revenue recognition with Legacy Tornier.
6 Legacy Wright and Legacy Tornier have historically operated on different fiscal periods. In order to calculate pro forma sales growth, we have calculated average sales per day based on the respective
legacy company and the associated geographic region, then added the legacy company ASPD together.
[Example: Q4 2015 Pro Forma Legacy Tornier U.S. Sales / Legacy Tornier U.S. Selling Days = $880K. Q4 2015 Adjusted Legacy Wright U.S. Sales / Legacy Wright U.S. Selling Days = $1,192K. Adjusted Pro
Forma Combined Average Sales per Day = $2,072K]
7 Reflects growth of Q4 2016 Non-GAAP ASPD, excluding the impact of FX, over the Q4 2015 Non-GAAP adjusted combined pro forma ASPD (see Note 8).
8 The impact of FX on net sales is calculated by translating current year results at prior year average foreign currency exchange rates.
6 2016 Annual Report Wright Medical Group N.V.
015479A_02-May-2017_Annual Report 2016.indd 8
5/2/2017 12:01:25 PM
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-K
(Mark One)
(cid:59)(cid:3) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934
For the fiscal year ended December 25, 2016
OR
(cid:134)(cid:3) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from to
Commission file number: 001-35065
WRIGHT MEDICAL GROUP N.V.
(Exact name of registrant as specified in its charter)
The Netherlands
(State or other jurisdiction
of incorporation or organization)
98-0509600
(I.R.S. Employer
Identification No.)
Prins Bernhardplein 200
1097 JB Amsterdam, The Netherlands
(Address of Principal Executive Offices)
None
(Zip code)
Registrant’s telephone number, including area code: (+31) 20 521 4777
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Ordinary shares, par value €0.03 per share
Contingent Value Rights
Name of each exchange on which registered
NASDAQ Global Select Market
NASDAQ Stock Market LLC
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. (cid:59) Yes (cid:134) No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. (cid:134) Yes (cid:59) No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. (cid:59) Yes (cid:134) No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). (cid:59) Yes (cid:134) No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will
not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of
this Form 10-K or any amendment to this Form 10-K. (cid:59)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting
company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer (cid:59)
Accelerated filer (cid:0)
Non-accelerated filer (cid:0)
(Do not check if a smaller
reporting company)
Smaller reporting company (cid:0)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). (cid:134) Yes (cid:59) No
The aggregate market value of the ordinary shares held by non-affiliates of the registrant on June 26, 2016 was $1.7 billion based on the
closing sale price of the ordinary shares on that date, as reported by the NASDAQ Global Select Market. For purposes of the foregoing
calculation only, the registrant has assumed that all executive officers and directors of the registrant, and their affiliated entities, are affiliates.
As of February 17, 2017, there were 103,625,395 ordinary shares outstanding.
None.
DOCUMENTS INCORPORATED BY REFERENCE
7
WRIGHT MEDICAL GROUP N.V.
ANNUAL REPORT ON FORM 10-K
Table of Contents
PART I(cid:3)
Page
Item 1.(cid:3) Business. ...........................................................................................................................................................11(cid:3)
Item 1A.(cid:3) Risk Factors. .................................................................................................................................................... 25(cid:3)
Item 1B.(cid:3) Unresolved Staff Comments. ............................................................................................................................ 48(cid:3)
Properties. ........................................................................................................................................................ 48(cid:3)
Item 2.(cid:3)
Item 3.(cid:3)
Legal Proceedings. ........................................................................................................................................... 49(cid:3)
Item 4.(cid:3) Mine Safety Disclosures. .................................................................................................................................. 53(cid:3)
PART II(cid:3)
Item 5.(cid:3) Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity
Securities. ........................................................................................................................................................ 54(cid:3)
Item 6.(cid:3)
Selected Financial Data. ................................................................................................................................... 56(cid:3)
Item 7.(cid:3) Management’s Discussion and Analysis of Financial Condition and Results of Operations. ............................... 58(cid:3)
Item 7A.(cid:3) Quantitative and Qualitative Disclosures About Market Risk. ............................................................................ 85(cid:3)
Item 8.(cid:3)
Financial Statements and Supplementary Data. ................................................................................................. 88(cid:3)
Item 9.(cid:3) Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. ..............................152(cid:3)
Item 9A.(cid:3) Controls and Procedures. .................................................................................................................................152(cid:3)
Item 9B.(cid:3) Other Information............................................................................................................................................153(cid:3)
PART III(cid:3)
Item 10.(cid:3) Directors, Executive Officers and Corporate Governance. ................................................................................154(cid:3)
Item 11.(cid:3) Executive Compensation. ................................................................................................................................163(cid:3)
Item 12.(cid:3) Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. .............194(cid:3)
Item 13.(cid:3) Certain Relationships and Related Transactions, and Director Independence. ....................................................197(cid:3)
Item 14.(cid:3) Principal Accounting Fees and Services. ..........................................................................................................198(cid:3)
Item 15.(cid:3) Exhibits, Financial Statement Schedules. .........................................................................................................200(cid:3)
Signatures ........................................................................................................................................................................ 201(cid:3)
PART IV(cid:3)
8
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 27A of the Securities
Act of 1933, as amended (Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (Exchange
Act), and that are subject to the safe harbor created by those sections. These statements reflect management’s current
knowledge, assumptions, beliefs, estimates, and expectations and express management’s current view of future performance,
results, and trends. Forward looking statements may be identified by their use of terms such as anticipate, believe, could,
estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-
looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as
of the date of this report, and we undertake no obligation to update such statements after this date. Risks and uncertainties that
could cause our actual results to materially differ from those described in forward-looking statements are discussed in our
filings with the U.S. Securities and Exchange Commission (SEC) (including those described in “Part I. Item 1A. Risk Factors”
of this report). By way of example and without implied limitation, such risks and uncertainties include:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
future actions of the SEC, the United States Attorney’s office, the U.S. Food and Drug Administration (FDA), the
Department of Health and Human Services, or other U.S. or foreign government authorities, including those
resulting from increased scrutiny under the U.S. Foreign Corrupt Practices Act and similar laws, that could delay,
limit, or suspend our development, manufacturing, commercialization, and sale of products, or result in seizures,
injunctions, monetary sanctions, or (cid:70)(cid:85)(cid:76)(cid:80)(cid:76)(cid:81)(cid:68)(cid:79)(cid:3)(cid:82)(cid:85)(cid:3)(cid:70)(cid:76)(cid:89)(cid:76)(cid:79)(cid:3)(cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)
risks associated with the merger between Tornier N.V. (Tornier or legacy Tornier) and Wright Medical Group, Inc.
(WMG or legacy Wright), including the failure to realize intended benefits and anticipated synergies and cost-
savings from the transaction or delay in realization the(cid:85)(cid:72)(cid:82)(cid:73)(cid:30)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:86)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:69)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:69)(cid:76)(cid:81)(cid:72)(cid:71)(cid:3)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:73)(cid:88)(cid:79)(cid:79)(cid:92)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)
such combination may take longer, be more difficult, time-(cid:70)(cid:82)(cid:81)(cid:86)(cid:88)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:85)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:79)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:86)(cid:75)(cid:3)(cid:87)(cid:75)(cid:68)(cid:81)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:70)(cid:87)(cid:72)(cid:71)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
business disruption after the transaction, including adverse effects on employee retention, our sales and
distribution channel, especially in light of territory transitions, and business relationships with third part(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
risks associated with the divestiture of the U.S. rights to certain of legacy Tornier’s ankle and silastic toe
replaceme(cid:81)(cid:87)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
liability for product liability claims on hip/knee (OrthoRecon) products sold by Wright Medical Technology, Inc.
(cid:11)(cid:58)(cid:48)(cid:55)(cid:12)(cid:3)(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:71)(cid:76)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:50)(cid:85)(cid:87)(cid:75)(cid:82)(cid:53)(cid:72)(cid:70)(cid:82)(cid:81)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)(cid:3)(cid:3)
risks and uncertainties associated with the recent metal-on-metal master settlement agreement and the settlement
agreement with the three insurance companies, including without limitation, the final settlement amount and the
final number of claims settled under the master settlement agreement, the resolution of the remaining unresolved
claims, the effect of the broad release of certain insurance coverage for present and future claims, and the
resolution of WMT’(cid:86)(cid:3)(cid:71)(cid:76)(cid:86)(cid:83)(cid:88)(cid:87)(cid:72)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:80)(cid:68)(cid:76)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:68)(cid:85)(cid:85)(cid:76)(cid:72)(cid:85)(cid:86)(cid:30)
failure to realize the anticipated benefits from previous acquisitions and (cid:71)(cid:76)(cid:86)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:68)(cid:71)(cid:89)(cid:72)(cid:85)(cid:86)(cid:72)(cid:3)(cid:82)(cid:88)(cid:87)(cid:70)(cid:82)(cid:80)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:72)(cid:91)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:79)(cid:76)(cid:87)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:3)
(cid:81)(cid:72)(cid:90)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:76)(cid:81)(cid:68)(cid:71)(cid:72)(cid:84)(cid:88)(cid:68)(cid:87)(cid:72)(cid:3)(cid:76)(cid:81)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:30)(cid:3)(cid:3)
copycat claims against our modular hip systems resulting from a competitor’(cid:86)(cid:3)(cid:85)(cid:72)(cid:70)(cid:68)(cid:79)(cid:79)(cid:3)(cid:82)(cid:73)(cid:3)(cid:76)(cid:87)(cid:86)(cid:3)(cid:80)(cid:82)(cid:71)(cid:88)(cid:79)(cid:68)(cid:85)(cid:3)(cid:75)(cid:76)(cid:83)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:30)(cid:3)(cid:3)
the ability of a creditor of any one particular entity within our corporate structure to reach the assets of the other
entities within our corporate structure not liable for the underlying claims of the one particular entity, despite our
corporate structure which is intended to ring-(cid:73)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)
failure to obtain anticipated commercial sales of our AUGMENT® (cid:37)(cid:82)(cid:81)(cid:72)(cid:3)(cid:42)(cid:85)(cid:68)(cid:73)(cid:87)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3)(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:30)
challenges to our intellectual property rights or inability to defend our products against the intellectual property
(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:86)(cid:30)(cid:3)(cid:3)
adverse effects of diverting resources and attention to transition services provided to the purchaser of our Large
(cid:45)(cid:82)(cid:76)(cid:81)(cid:87)(cid:86)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)
(cid:73)(cid:68)(cid:76)(cid:79)(cid:88)(cid:85)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:15)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:85)(cid:88)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:87)(cid:82)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:88)(cid:81)(cid:68)(cid:88)(cid:87)(cid:75)(cid:82)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3)(cid:87)(cid:68)(cid:80)(cid:83)(cid:72)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:15)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3)(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86)(cid:30)(cid:3)
(cid:73)(cid:68)(cid:76)(cid:79)(cid:88)(cid:85)(cid:72)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:72)(cid:79)(cid:68)(cid:92)(cid:3)(cid:76)(cid:81)(cid:3)(cid:82)(cid:69)(cid:87)(cid:68)(cid:76)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3)(cid:41)(cid:39)(cid:36)(cid:3)(cid:82)(cid:85)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
the potentially negative effect of our ongoing compliance efforts on our relationships with customers and on our
(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:71)(cid:72)(cid:79)(cid:76)(cid:89)(cid:72)(cid:85)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:79)(cid:92)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:72)(cid:71)(cid:88)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:70)(cid:79)(cid:76)(cid:81)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:87)(cid:88)(cid:71)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
the possibility of private securities litigati(cid:82)(cid:81)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:79)(cid:71)(cid:72)(cid:85)(cid:3)(cid:71)(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:86)(cid:88)(cid:76)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:76)(cid:81)(cid:86)(cid:88)(cid:73)(cid:73)(cid:76)(cid:70)(cid:76)(cid:72)(cid:81)(cid:87)(cid:3)(cid:71)(cid:72)(cid:80)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3)(cid:68)(cid:70)(cid:70)(cid:72)(cid:83)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:91)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
recently enacted healthcare laws and changes in product reimbursements, which could generate downward
(cid:83)(cid:85)(cid:72)(cid:86)(cid:86)(cid:88)(cid:85)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:3)
(cid:83)(cid:82)(cid:87)(cid:72)(cid:81)(cid:87)(cid:76)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:69)(cid:88)(cid:85)(cid:71)(cid:72)(cid:81)(cid:86)(cid:82)(cid:80)(cid:72)(cid:3)(cid:87)(cid:68)(cid:91)(cid:3)(cid:80)(cid:72)(cid:68)(cid:86)(cid:88)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:79)(cid:68)(cid:70)(cid:78)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:88)(cid:76)(cid:87)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:76)(cid:81)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:70)(cid:68)(cid:83)(cid:76)(cid:87)(cid:68)(cid:79)(cid:76)(cid:93)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
9
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:82)(cid:85)(cid:3)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:3)(cid:86)(cid:68)(cid:73)(cid:72)(cid:87)(cid:92)(cid:3)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:74)(cid:72)(cid:82)(cid:74)(cid:85)(cid:68)(cid:83)(cid:75)(cid:76)(cid:70)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:80)(cid:76)(cid:91)(cid:3)(cid:76)(cid:80)(cid:83)(cid:68)(cid:70)(cid:87)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
in(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:85)(cid:72)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:78)(cid:72)(cid:92)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:15)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:83)(cid:72)(cid:81)(cid:71)(cid:72)(cid:81)(cid:87)(cid:3)(cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81)(cid:81)(cid:72)(cid:79)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:87)(cid:87)(cid:85)(cid:68)(cid:70)(cid:87)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:87)(cid:68)(cid:79)(cid:72)(cid:81)(cid:87)(cid:30)(cid:3)(cid:3)
(cid:76)(cid:81)(cid:89)(cid:72)(cid:81)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:85)(cid:72)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:73)(cid:79)(cid:88)(cid:70)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:69)(cid:88)(cid:92)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:68)(cid:87)(cid:87)(cid:72)(cid:85)(cid:81)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:90)(cid:75)(cid:82)(cid:79)(cid:72)(cid:86)(cid:68)(cid:79)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)(cid:3)
inability to generate sufficient cash flow to satisfy our capital requirements, including future milestone payments,
and existing debt, including the conversion features of our convertible senior notes, or refinance our existing debt
(cid:68)(cid:86)(cid:3)(cid:76)(cid:87)(cid:3)(cid:80)(cid:68)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
risks associated with our credit, security and guara(cid:81)(cid:87)(cid:92)(cid:3)(cid:68)(cid:74)(cid:85)(cid:72)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:72)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:72)(cid:71)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:79)(cid:76)(cid:81)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:85)(cid:72)(cid:71)(cid:76)(cid:87)(cid:30)
(cid:76)(cid:81)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:85)(cid:68)(cid:76)(cid:86)(cid:72)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:90)(cid:75)(cid:72)(cid:81)(cid:3)(cid:81)(cid:72)(cid:72)(cid:71)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:73)(cid:68)(cid:89)(cid:82)(cid:85)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:72)(cid:85)(cid:80)(cid:86)(cid:30)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:81)(cid:72)(cid:74)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:76)(cid:80)(cid:83)(cid:68)(cid:70)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:85)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:85)(cid:72)(cid:71)(cid:76)(cid:87)(cid:3)(cid:72)(cid:81)(cid:89)(cid:76)(cid:85)(cid:82)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:81)(cid:3)(cid:88)(cid:86)(cid:15)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:80)(cid:72)(cid:85)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:88)(cid:83)(cid:83)(cid:79)(cid:76)(cid:72)(cid:85)(cid:86)(cid:30)(cid:3)(cid:3)
deriving a significant portion of our revenues from operations in certain geographic markets that are subject to
political, economic, and social instability, including in particular France, and risks and uncertainties involved in
launching our products in certain new (cid:74)(cid:72)(cid:82)(cid:74)(cid:85)(cid:68)(cid:83)(cid:75)(cid:76)(cid:70)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:73)(cid:79)(cid:88)(cid:70)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:3)(cid:72)(cid:91)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:3)
not successfully developing and marketing new products and technologies and implementing our business
(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:92)(cid:30)(cid:3)(cid:3)
not successfully competing against our existing or potential competitors and the effect of significant recent
(cid:70)(cid:82)(cid:81)(cid:86)(cid:82)(cid:79)(cid:76)(cid:71)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:80)(cid:82)(cid:81)(cid:74)(cid:86)(cid:87)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:79)(cid:76)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:3)(cid:82)(cid:81)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3)(cid:68)(cid:86)(cid:86)(cid:88)(cid:80)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)(cid:3)
our private label manufacturers failing to provide us with sufficient supply of their products, or failing to meet
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:68)(cid:87)(cid:72)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:82)(cid:88)(cid:85)(cid:3)(cid:76)(cid:81)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:79)(cid:92)(cid:3)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:86)(cid:87)(cid:85)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:86)(cid:72)(cid:87)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:72)(cid:87)(cid:3)(cid:71)(cid:72)(cid:80)(cid:68)(cid:81)(cid:71)(cid:30)(cid:3)(cid:3)
our plans to bring the manufacturing of certain of our products in-house and possible disruptions we may
(cid:72)(cid:91)(cid:83)(cid:72)(cid:85)(cid:76)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:81)(cid:81)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:3)
(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:68)(cid:86)(cid:72)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:74)(cid:85)(cid:82)(cid:86)(cid:86)(cid:3)(cid:80)(cid:68)(cid:85)(cid:74)(cid:76)(cid:81)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:87)(cid:68)(cid:78)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:71)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:71)(cid:82)(cid:3)(cid:86)(cid:82)(cid:30)(cid:3)(cid:3)
the loss of key suppliers, which may result in our inability to meet customer orders for our products in a timely
(cid:80)(cid:68)(cid:81)(cid:81)(cid:72)(cid:85)(cid:3)(cid:82)(cid:85)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:76)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:88)(cid:71)(cid:74)(cid:72)(cid:87)(cid:30)(cid:3)(cid:3)
the incurrence of significant expenditures of resources to maintain relatively high levels of inventory, which could
reduce ou(cid:85)(cid:3)(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:73)(cid:79)(cid:82)(cid:90)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:68)(cid:86)(cid:72)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:82)(cid:73)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:81)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:82)(cid:69)(cid:86)(cid:82)(cid:79)(cid:72)(cid:86)(cid:70)(cid:72)(cid:81)(cid:70)(cid:72)(cid:15)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:70)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3)(cid:75)(cid:68)(cid:85)(cid:80)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
consolidation in the healthcare industry that could lead to demands for price concessions or the exclusion of some
suppliers from certain of our markets, which could have an adverse effect on our business, financial condition, or
(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:30)(cid:3)(cid:3)
(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:79)(cid:76)(cid:81)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:87)(cid:85)(cid:76)(cid:68)(cid:79)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:85)(cid:72)(cid:79)(cid:76)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:3)(cid:83)(cid:68)(cid:85)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:70)(cid:82)(cid:81)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:80)(cid:30)(cid:3)(cid:3)
the compliance of our products and activities with the laws and regulations of the countries in which they are
marketed, which compliance may be costly and time-(cid:70)(cid:82)(cid:81)(cid:86)(cid:88)(cid:80)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:3)
the use, misuse or off-label use of our products that may harm our image in the marketplace or result in injuries
that may lead to product liability (cid:86)(cid:88)(cid:76)(cid:87)(cid:86)(cid:15)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:70)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3)(cid:69)(cid:72)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:79)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:3)(cid:76)(cid:81)(cid:3)(cid:74)(cid:82)(cid:89)(cid:72)(cid:85)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:68)(cid:79)(cid:3)(cid:86)(cid:68)(cid:81)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
pending and future other litigation, which could have an adverse effect on our business, financial condition, or
(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
risks in light of the material weakness in our internal control over financial reporting that we have recently
identified.
For more information regarding these and other uncertainties and factors that could cause our actual results to differ materially
from what we have anticipated in our forward-looking statements or otherwise could materially adversely affect our business,
financial condition, or operating results, see “Part I. Item 1A. Risk Factors” of this report. The risks and uncertainties
described above and in “Part I. Item 1A. Risk Factors” of this report are not exclusive and further information concerning us
and our business, including factors that potentially could materially affect our financial results or condition, may emerge from
time to time. We assume no obligation to update, amend, or clarify forward-looking statements to reflect actual results or
changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further
disclosures we make on related subjects in our future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K we file with or furnish to the SEC.
10
Item 1.
Business.
Overview
PART I
Wright Medical Group N.V. (Wright or we) is a global medical device company focused on extremities and biologics products.
We are committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a
recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and
ankle) and biologics markets, three of the fastest growing segments in orthopaedics. We market our products in over 50
countries worldwide. We believe we are differentiated in the marketplace by our strategic focus on extremities and biologics,
our full portfolio of upper and lower extremities and biologics products, and our specialized and focused sales organization.
Our product portfolio consists of the following product categories:
• Upper extremities, which include joint implants and bone fixation devices for the shoulder, elbow, wrist, and
(cid:75)(cid:68)(cid:81)(cid:71)(cid:30)
• Lower extremities, which include joint implants and bone fixation devices for the foot and (cid:68)(cid:81)(cid:78)(cid:79)(cid:72)(cid:30)
• Biologics, which include products used to support treatment of damaged or diseased bone, tendons, and soft
(cid:87)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:86)(cid:87)(cid:76)(cid:80)(cid:88)(cid:79)(cid:68)(cid:87)(cid:72)(cid:3)(cid:69)(cid:82)(cid:81)(cid:72)(cid:3)(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Sports medicine and other, which include products used across several anatomic sites to mechanically repair
tissue-to-tissue or tissue-to-bone injuries and other ancillary products.
Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in
Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative
(cid:68)(cid:70)(cid:87)(cid:76)(cid:89)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:12)(cid:30)(cid:3)(cid:37)(cid:79)(cid:82)(cid:82)(cid:80)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)(cid:11)(cid:88)(cid:83)(cid:83)(cid:72)(cid:85)(cid:3)(cid:72)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:36)(cid:85)(cid:79)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)ssee
(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:78)(cid:79)(cid:76)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:15)(cid:3)
(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:68)(cid:70)(cid:85)(cid:82)(cid:82)(cid:80)(cid:15)(cid:3)(cid:44)(cid:85)(cid:72)(cid:79)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:12)(cid:17)(cid:3)(cid:3)(cid:44)(cid:81)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:79)(cid:82)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:68)(cid:79)es
and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe. For purposes of this report,
references to “international” or “foreign” relate to non-U.S. matters while references to “domestic” relate to U.S. matters.
On October 1, 2015, we became Wright Medical Group N.V. following the merger (the Wright/Tornier merger or the merger) of
Wright Medical Group, Inc. (WMG or legacy Wright) with Tornier N.V. (Tornier or legacy Tornier). Because of the structure
of the merger and the governance of the combined company immediately post-merger, the merger was accounted for as a
“reverse acquisition” under generally accepted accounting principles in the United States (US GAAP), and as such, legacy
Wright was considered the acquiring entity for accounting purposes. Therefore, legacy Wright’s historical results of operations
replaced legacy Tornier’s historical results of operations for all periods prior to the merger. References in this section and
certain other sections of Part I of this report to “we,” “our” and “us” refer to Wright Medical Group N.V. and its subsidiaries
after the Wright/Tornier merger and Wright Medical Group, Inc. and its subsidiaries before the merger.
On October 21, 2016, we sold legacy Tornier’s Large Joints business to Corin Orthopaedics Holdings Limited (Corin) allowing
us to devote our full resources and attention on accelerating growth opportunities in the high-growth extremities and biologics
markets. Legacy Wright sold its hip and knee (OrthoRecon) business to MicroPort Scientific Corporation (MicroPort) on
January 9, 2014. The financial results of legacy Tornier’s Large Joints business and the OrthoRecon business are reflected
within discontinued operations for all periods presented.
For the year ended December 25, 2016, we had net sales of $690.4 million and a net loss from continuing operations of
$164.9 million. As of December 25, 2016, we had total assets of $2,291 million. During the first quarter of 2016, our
management began managing our operations as four operating business segments: U.S. Lower Extremities & Biologics, U.S.
Upper Extremities, International Extremities & Biologics, and Large Joints, based on management’s change to the way it
monitors performance, aligns strategies, and allocates resources. As a result of the sale of our Large Joints business to Corin,
the Large Joints reportable segment is presented in our consolidated statements of operations as discontinued operations and is
not included in segment results for all periods presented. U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and
International Extremities & Biologics are our remaining three reportable segments as of December 25, 2016. Detailed
information on our net sales by product category and operating business segment and our net sales and long-lived assets by
segment and geographic region can be found in Note 20 to our consolidated financial statements contained in “Item 8.
Financial Statements and Supplementary Data.”
11
Orthopaedic Industry
The total worldwide orthopaedic industry is estimated at approximately $47.3 billion in 2016. Five multinational companies
currently dominate the orthopaedic industry, each with approximately $2 billion or more in annual sales. The size of these
companies often allows them to concentrate their marketing and research and development efforts on products they believe will
have a relatively high minimum threshold level of sales. As a result, there is an opportunity for a mid-sized orthopaedic
company, such as us, to focus on less contested, higher-growth sectors of the orthopaedic market.
We have focused our efforts into growing our position in the high-growth extremities and biologics markets. We believe a
more active and aging patient population with higher expectations regarding “quality of life,” an increasing global awareness of
extremities and biologics solutions, improved clinical outcomes as a result of the use of such products, and technological
advances resulting in specific designs for such products that simplify procedures and address unmet needs for early
interventions, and the growing need for revisions and revision related solutions will drive the market for extremities and
biologics products.
The extremities market is one of the fastest growing market segments within orthopaedics, with annual growth rates of 7-10%.
We believe the extremities market will continue to grow by approximately 7-10% annually. We currently estimate the market
for all surgical products used by extremities-focused surgeons to be approximately $3 billion in the United States. We believe
major trends in the extremities market include procedure-specific and anatomy-specific devices, locking plates, and an increase
in total ankle replacement or arthroplasty procedures.
Upper extremities reconstruction involves implanting devices to replace, reconstruct, or fixate injured or diseased joints and
bones in the shoulder, elbow, wrist, and hand. It is estimated that approximately 60% of the upper extremities market is in total
shoulder replacement or arthroplasty implants. We believe major trends in the upper extremities market include next-
generation joint arthroplasty systems, bone preserving solutions, virtual planning systems, and revision of failed previous
shoulder replacements in older patients.
Lower extremities reconstruction involves implanting devices to replace, reconstruct, or fixate injured or diseased joints and
bones in the foot and ankle. A large segment of the lower extremities market is comprised of plating and screw systems for
reconstructing and fusing joints or repairing bones after traumatic injury. We believe major trends in the lower extremities
market include the use of external fixation devices in diabetic patients, total ankle arthroplasty, advanced tissue fixation
devices, and biologics. According to various customer and market surveys, we are a market leader in foot and ankle surgical
products. New technologies have been introduced into the lower extremities market in recent years, including next-generation
total ankle replacement systems. Many of these technologies currently have low levels of market penetration. We believe that
market adoption of total ankle replacement, which currently represents approximately 8% of the U.S. foot and ankle device
market, will result in significant future growth in the lower extremities market.
The field of biologics employs tissue engineering and regenerative medicine technologies focused on remodeling and
regeneration of tendons, ligaments, bone, and cartilage. Biologic products use both biological tissue-based and synthetic
materials to allow the body to regenerate damaged or diseased bone and to repair damaged or diseased soft tissue. These
products aid the body’s natural regenerative capabilities to heal itself. Biologic products provide a lower morbidity solution to
“autografting,” a procedure that involves harvesting a patient’s own bone or soft tissue and transplanting it to a different site.
Following an autografting procedure, the patient typically has pain, and at times, complications result at the harvest site after
surgery. Biologically or synthetically derived soft tissue grafts and scaffolds are used to treat soft tissue injuries and are
complementary to many sports medicine applications, including rotator cuff tendon repair and Achilles tendon repair. Hard
tissue biologics products are used in many bone fusion or trauma cases where healing potential may be compromised and
additional biologic factors are desired to enhance healing, where the surgeon needs additional bone, or in cases where the
surgeon wishes to use materials that are naturally incorporated by the body over time. We estimate that the worldwide
orthobiologics market to be over $3.5 billion, and with annual growth rates of 3-5%. Three multinational companies currently
dominate the orthobiologics industry.
The newest addition to our biologics product portfolio is AUGMENT® Bone Graft, which is based on recombinant human
platelet-derived growth factor (rhPDGF-BB), a synthetic copy of one of the body’s principal healing agents. We obtained FDA
approval of AUGMENT® Bone Graft in the United States for ankle and/or hindfoot fusion indications during the third quarter
of 2015. We estimate the U.S. market opportunity for AUGMENT® Bone Graft for ankle and/or hindfoot fusion indications to
be approximately $300 million. The main competitors for AUGMENT® Bone Graft are autologous bone grafts, allograft, and
synthetic bone growth substitutes. Autologous bone grafts, which account for a significant portion of total graft volume, are
taken directly from the patient. This generally necessitates an additional procedure to obtain the graft, which in turn creates
added expense, and increased pain and recovery time. Allografts, which are currently the second most commonly used bone
grafts, are taken from human cadavers and processed by either bone banks or commercial firms. Although an obvious
advantage to allografts is the fact that a second-site harvesting operation is not required, they carry a slight risk of transmitting
12
pathogens and can also cause immune system reactions. Synthetic grafts are derived from numerous materials, including
polymers, calcium sulfate, calcium phosphate, bovine collagen, and coral.
Product Portfolio
We offer a broad product portfolio of approximately 180 extremities products and over 20 biologics products that are designed
to provide solutions to our surgeon customers, with the goal of improving clinical outcomes and the “quality of life” for their
patients. Our product portfolio consists of the following product categories:
• Upper extremities, which include joint implants and bone fixation devices for the shoulder, elbow, wrist, and
(cid:75)(cid:68)(cid:81)(cid:71)(cid:30)
• Lower extremities, which include joint implants an(cid:71)(cid:3)(cid:69)(cid:82)(cid:81)(cid:72)(cid:3)(cid:73)(cid:76)(cid:91)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:82)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:81)(cid:78)(cid:79)(cid:72)(cid:30)
• Biologics, which include products used to support treatment of damaged or diseased bone, tendons, and soft
(cid:87)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:86)(cid:87)(cid:76)(cid:80)(cid:88)(cid:79)(cid:68)(cid:87)(cid:72)(cid:3)(cid:69)(cid:82)(cid:81)(cid:72)(cid:3)(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Sports medicine and other, which include products used across several anatomic sites to mechanically repair
tissue-to-tissue or tissue-to-bone injuries and other ancillary products.
Upper Extremities
The upper extremities product category includes joint implants and bone fixation devices for the shoulder, elbow, wrist, and
hand. Our global net sales from this product category was $288.1 million, or 41.7% of total net sales, for the year ended
December 25, 2016, as compared to $83.5 million, or 20.6% of total net sales, for the year ended December 27, 2015. Our net
sales in upper extremities increased significantly as a result of the Wright/Tornier merger.
Our shoulder products are used to treat painful shoulder conditions due to arthritis, irreparable rotator cuff tendon tears, bone
disease, fractured humeral heads, or failed previous shoulder replacement surgery. Our shoulder products include the
following:
• Total Shoulder Joint Replacement. Our total shoulder joint replacement products have two components-a humeral
implant consisting of a metal stem or base attached to a metal head, and a plastic implant for the glenoid (shoulder
socket). Together, these two components mimic the function of a natural shoulder joint. Our total shoulder joint
the AEQUALIS ASCEND®, AEQUALIS® PRIMARY™, AEQUALIS®
replacement products
PERFORM™ and SIMPLICITI® shoulder systems. Our recently introduced BLUEPRINT™ 3D Planning
Software can be used with our AEQUALIS® PERFORM™ Glenoid System to assist surgeons in accurately
positioning the glenoid implant and replicating the pre-operative surgical plan. In addition, we received FDA
510(k) clearance in June 2016 of our AEQUALIS® PERFORM™+ Glenoid System, the first anatomic augmented
glenoid. This system was designed to specifically address posterior glenoid deficiencies and deliver bone
preservation.
include
• Hemi Shoulder Joint Replacement. Our hemi shoulder joint replacement products replace only the humeral head
and allow it to articulate against the native glenoid. These products include our PYC HUMERAL HEAD™ and
INSPYRE™. PYC stands for pyrocarbon, which is a biocompatible material that has low joint surface friction
and a high resistance to wear. The PYC HUMERAL HEAD™ is currently available in certain international
markets. The product received FDA approval in 2015 for its investigational device exemption to conduct a
clinical trial in the United States. We anticipate that this single arm study will enroll and implant 157 patients
from up to 20 centers across the United States and will evaluate the safety and effectiveness of the device in
patients with a primary diagnosis of partial shoulder replacement or hemi-arthroplasty. The study design uses a
primary endpoint that is measured at two years.
• Reversed Shoulder Joint Replacement. Our reversed shoulder joint replacement products are used in arthritic
patients lacking rotator cuff function. The components are different from a traditional “total” shoulder in that the
humeral implant has the plastic socket and the glenoid has the metal head. This design has the biomechanical
impact of shifting the pivot point of the joint away from the body centerline and recruiting the deltoid muscles to
enable the patient to elevate the arm. Our reversed joint replacement products include the AEQUALIS®
REVERSED II™ shoulder. We received FDA 510(k) clearance in December 2016 of our AEQUALIS®
PERFORM™ REVERSED Glenoid System, our first reverse augmented glenoid. This system was designed to
specifically address posterior glenoid deficiencies and deliver bone preservation.
• Convertible Shoulder Joint Replacement. Our convertible shoulder joint replacement products are modular
implants that can be converted from a total or hemi shoulder implant to a reversed implant at a later date if the
patient requires it. Our convertible joint replacement products include the AEQUALIS ASCEND® FLEX™
convertible shoulder system, which provides anatomic and reversed options within a single system and is
designed to offer precise intra-operative implant-to-patient fit and easy conversion to reversed if necessary.
13
•
•
Shoulder Resurfacing Implants. An option for some patients is shoulder resurfacing where the damaged humeral
head is sculpted to receive a metal “cap” that fits onto the bone, functioning as a new, smooth humeral head. This
procedure can be less invasive than a total shoulder replacement. Our shoulder resurfacing implants are designed
to preserve bone, which may benefit more active or younger patients with shoulder arthritis. Our resurfacing
implants include the AEQUALIS® RESURFACING HEAD™.
Shoulder Trauma Devices. Our shoulder trauma devices, such as plates, pins, screws, and nails, are non-
articulating implants used to help stabilize fractures of the humerus. Our shoulder trauma products include the
AEQUALIS® IM NAIL™, AEQUALIS® PROXMILA HUMERAL PLATE™, AEQUALIS® FRACTURE™
shoulder and AEQUALIS® REVERSED FRACTURE™ shoulder.
In addition to our shoulder products, our upper extremities product portfolio consist of implants, plates, pins, screws, and nails
that are used to treat the elbow, wrist, and hand, and include the following:
• Total Elbow and Radial Head Replacement. Our total elbow and radial head replacement products address the
need for modularity in the anatomically highly-variable joint of the elbow and give surgeons the ability to
reproduce the natural flexion/extension axis and restore natural kinematics of the elbow. Our total elbow
replacement products include our LATITUDE® EV™ total elbow prosthesis. Our radial head replacement
products include our EVOLVE® modular radial head device, which is a market leading radial head prosthesis that
provides different combinations of heads and stems allowing the surgeon to choose implant heads and stems to
accommodate the unpredictable anatomy of each patient.
• Elbow Fracture Repair. We have several plating and screw products designed to repair a fractured elbow. Our
radial head plating systems and screws are for surgeons who wish to repair rather than replace a damaged radial
head and include our EVOLVE® TRIAD™ fixation system. Our EVOLVE® Elbow Plating System addresses
fractures of the distal humerus and proximal ulna. Composed of polished stainless steel, this system was designed
to accurately match the patient anatomy to reduce the need for intra-operative bending while providing a low
profile design to minimize post-operative irritation. Both of these products and several of our other products
incorporate our ORTHOLOC® 3Di Polyaxial Locking Technology to enable optimal screw placement and
stability.
• Wrist Fracture Repair. We have several plating and screw products designed to repair a fractured wrist. Our
MICRONAIL® II Intramedullary Distal Radius System is a next-generation minimally invasive treatment for
distal radius fractures that is designed to provide immediate fracture stabilization with minimal soft tissue
disruption. Also, as the nail is implanted within the bone, it has no external profile on top of the bone, thereby
reducing the potential for tendon irritation or rupture, which is an appreciable problem with conventional plates
designed to lie on top of the bone. In addition, our RAYHACK® system is comprised of a series of precision
cutting guides and procedure-specific plates for ulnar and radial shortening procedures and the surgical treatment
of radial malunions and Keinbock’s Disease.
• Hand Fixation. Our hand fixation products include our FUSEFORCE® Hand Fixation System, which is a shape-
memory compression-ready fixation system that can be used in fixation for fractures, fusions, or osteotomies of
the bones in the hand.
• Thumb and Finger Joint Replacement. Our Swanson finger joints are used in finger joint replacement for patients
suffering from rheumatoid arthritis of the hand. With nearly 45 years of clinical success, Swanson digit implants
are a foundation in our upper extremities business and are used by a loyal base of hand surgeons worldwide. Our
ORTHOSPHERE® implants are used in thumb joint replacement procedures.
Lower Extremities
The lower extremities product category includes joint implants and bone fusion and fixation devices, including plates, pins,
screws, and nails, for the foot and ankle. Our global net sales from this product category for the year ended December 25, 2016
was $285.6 million, or 41.4% of total net sales, as compared to $238.3 million, or 58.8% of total net sales, for the year ended
December 27, 2015.
We are a recognized leader in the United States for foot and ankle surgical products. Our lower extremities product portfolio
includes:
• Total Ankle Joint Replacement. Total ankle joint replacement, also known as total ankle arthroplasty, is a surgical
procedure that orthopaedic surgeons use to treat ankle arthritis. Our total ankle joint replacement products include
implants for the ankle that involve replacing the joint with an articulating multi-component implant. These joint
implants may be mobile bearing, in which the plastic component is free to slide relative to the metal bearing
surfaces, or fixed bearing, in which this component is constrained. Our INBONE® Total Ankle Systems,
including our third-generation INBONE® II Total Ankle System, are modular prostheses that allow the surgeon to
14
tailor the fixation stems for the tibial and talar components in order to maximize stability of the implant. The
INBONE® II Total Ankle System is the only ankle replacement that offers surgeons multiple implant options with
different articular geometry. Our INFINITY® Total Ankle System is the newest addition to our total ankle
replacement portfolio and features a distinctive talar resurfacing option for preservation of talar bone. The
combination and interchangeability of both the INBONE® and INFINITY® systems provide the surgeon with an
implant continuum of care concept, allowing the surgeon to address a more bone conserving implant option with
INFINITY® all the way to addressing a more complex ankle deformity with INBONE®. Our INBONE® and
INFINITY® Total Ankle Systems can be used with our PROPHECY® Preoperative Navigation Guides, which
combine computer imaging with a patient’s CT scan, and are designed to provide alignment accuracy while
reducing surgical steps. Physician testing of our most recent total ankle replacement product, the INVISIONTM
Total Ankle Revision System, began in 2016 and is expected to reach full commercial launch in the third quarter
of 2017.
• Ankle Fusion. We have several products used in ankle fusion procedures, which fuse together the tibia, fibula,
and talus bones into one bone, and are intended to treat painful, end-stage arthritis in the ankle joint. These
products include our ORTHOLOC® 3Di Ankle Fusion System, which legacy Wright launched successfully in July
2013, VALOR® TTC fusion nail, and the legacy Tornier Maxlock ExtremeTM Plate and Screws System.
• Ankle Fixation and Fracture Repair. We sell a broad range of anatomically designed plates, screws, and nails
used to stabilize and heal fractured ankle bones, including our ORTHOLOC® 3Di Ankle Fracture System, which
is a comprehensive single-tray ankle fracture solution designed to address a wide range of fracture types by
providing the surgeon with multiple anatomically-contoured plates and a comprehensive set of instrumentation.
• Foot Fusion. We have several products used in foot fusion procedures, which fuse together three bones in the
back of the foot into one bone and are used to treat a wide range of conditions, including arthritis, flat feet,
rheumatoid arthritis, and previous injuries, such as fractures caused by wear and tear to bones and cartilage. Our
foot fusion products include our ORTHOLOC® 3Di Midfoot Plating System, VALOR® TTC fusion nail and the
legacy Tornier Maxlock ExtremeTM Plate and Screws System.
• Foot Fixation and Fracture Repair. Our foot fixation and fracture repair products include plates, screws, and
nails used to stabilize and heal foot deformities and fractures. Our CHARLOTTE® CLAW® Compression Plate is
the first ever locking compression plate designed for corrective foot surgeries. Our next-generation CLAW® II
Compression Plating System expands our plate and screw offering by introducing anatomic plates specifically
designed for fusions of the midfoot, and the CLAW® II Polyaxial Compression Plating System incorporates
variable-angle locking screw technology and our ORTHOLOC® 3Di Reconstruction Plating System utilizes our
3Di polyaxial locking technology. In April 2016, we further expanded the ORTHOLOC® 3Di portfolio with the
launch of the ORTHOLOC® 3Di CROSSCHECK® Plating System. This modular addition is comprised of five
uniquely designed plates which offer an inter-fragmentary solution. Our SALVATION™ limb salvage portfolio,
which is designed to address the unique demands of advanced midfoot reconstruction, was also commercially
launched in the first half of 2016. Other foot products include the MAXLOCK®, MINIMAX LOCK™ and
MINIMAX LOCK EXTREME™ plate and screw systems, BIOFOAM® Wedge System, BIOARCH® Subtalar
Arthroereisis Implant, MDI Metatarsal Resurfacing Implant, and TENFUSE® Nail Allograft.
• Hammertoe Correction. Hammertoe is a contracture (bending) of one or both joints of the second, third, fourth,
or fifth (little) toes. Our hammertoe correction products include the PRO-TOE® VO Hammertoe Fixation System,
PRO-TOE® C2 Hammertoe Implant, PHALINX® Hammertoe Fixation System, Cannulink Intraosseous Fixation
System (IFS), and TENFUSE® PIP Hammertoe Allograft.
• Toe Joint Replacement. We also sell our Swanson line of toe joint replacement products.
Biologics
The biologics product category includes a broad line of biologic products that are used to support treatment of damaged or
diseased bone, tendons, and soft tissues and other biological solutions for surgeons and their patients or to stimulate bone
growth. These products focus on supporting biological musculoskeletal repair by utilizing synthetic and human tissue-based
materials. Our biologic products are primarily used in extremities-related procedures as well as in trauma-induced voids of the
long bones and some spine procedures. Internationally, we offer a bone graft product incorporating antibiotic delivery. Our
global net sales from this product category for the year ended December 25, 2016 was $93.5 million, or 13.5% of total net
sales, compared to $70.2 million, or 17.3% of total net sales, for the year ended December 27, 2015.
Our biologics products include the following:
• AUGMENT® Bone Graft. The newest addition to our biologics product portfolio is AUGMENT® Bone Graft. Our
AUGMENT® Bone Graft product line is based on recombinant human platelet-derived growth factor (rhPDGF-
BB), a synthetic copy of one of the body’s principal healing agents. We obtained FDA approval of AUGMENT®
Bone Graft for ankle and/or hindfoot fusion indications in the United States during third quarter of 2015. Prior to
15
FDA approval, this product was available for sale in Canada for foot and ankle fusion indications and in Australia
and New Zealand for hindfoot and ankle fusion indications. We acquired the AUGMENT® Bone Graft product
line from BioMimetic Therapeutics, Inc. (BioMimetic) in March 2013.
IGNITE® Power Mix
• Hard Tissue Repair. Our other bone or hard tissue repair products include our PRO-DENSE® Injectable
Regenerative Graft. PRO-DENSE® is a composite graft composed of surgical grade calcium sulfate and calcium
phosphate, and in animal studies, has demonstrated excellent bone regenerative characteristics, forming new bone
that is over three times stronger than the natural surrounding bone at the 13-week time point. Beyond 13 weeks,
the regenerated bone gradually remodels to natural bone strength. Our PRO-STIM® Injectable Inductive Graft is
built on the PRO-DENSE® material platform, but adds demineralized bone matrix (DBM), and has demonstrated
accelerated healing compared to autograft in pre-clinical testing. Our other hard tissue repair products, including
Injectable Stimulus, FUSIONFLEX™ Demineralized Moldable Scaffold,
our
ALLOMATRIX® Injectable Putty, OSTEOSET® Resorbable Bead Kit, MIIG® Injectable Graft, CANCELLO-
PURE® bone wedge line, and ALLOPURE® Allograft Bone Wedges.
Soft Tissue Repair. Our soft tissue repair products include our GRAFTJACKET® Regenerative Tissue Matrix,
which is a human-derived soft tissue graft designed for augmentation of tendon and ligament repairs, such as
those of the rotator cuff in the shoulder and Achilles tendon in the foot and ankle. GRAFTJACKET® Maxforce
Extreme is our thickest GRAFTJACKET® matrix, which provides excellent suture holding power for augmenting
challenging tendon and ligament repairs. We procure our GRAFTJACKET® product through an exclusive
distribution agreement that expires December 31, 2018. Other soft tissue repair products include our CONEXA™
Reconstructive Tissue Matrix, ACTISHIELD™ and ACTISHIELD™ CF Amniotic Barrier Membranes,
VIAFLOW™ and VIAFLOW™ C Flowable Placental Tissue Matrices, BIOFIBER® biologic absorbable scaffold
products, and PHANTOM FIBER™ high strength, resorbable suture products.
•
Sports Medicine and Other
The sports medicine and other product category includes products used across several anatomic sites to mechanically repair
tissue-to-tissue or tissue-to-bone injuries and other ancillary products. Because of its close relationship to extremities joint
replacement and bone fixation, our sports medicine portfolio is comprised of products used to complement our upper and lower
extremities product portfolios, providing surgeons a variety of products that may be used in upper and lower extremities
surgical procedures. Our global net sales from this product category for the year ended December 25, 2016 was $23.2 million,
or 3.4% of total net sales, compared to $13.3 million, or 3.3% of total net sales, for the year ended December 27, 2015.
Sales, Marketing, and Medical Education
Our sales and marketing efforts are focused primarily on orthopaedic, trauma, and podiatric surgeons. Orthopaedic surgeons
focused on the extremities in many instances have completed upper or lower extremities fellowship programs. We offer
surgeon-to-surgeon education on our products using surgeon advisors in an instructional capacity. We have contractual
relationships with these surgeon advisors, who help us train other surgeons in the safe and effective use of our products and
help other surgeons perfect new surgical techniques. Together with these surgeon advisors, we provide surgeons extensive
“hands on” orthopaedic training and education, including upper and lower extremities fellowships and masters courses that are
not easily accessible through traditional medical training programs. We also offer clinical symposia and seminars, and publish
advertisements and the results of clinical studies in industry publications. We believe that our history of innovation and focus
on quality and improving clinical outcomes and “quality of life” for patients, along with our training programs, allow us to
reach surgeons early in their careers and provide on-going value, which includes experiencing the clinical benefits of our
products.
Due to the nature of specialized training surrounding podiatric and orthopaedic surgeons focused on extremities and biologics,
our target market is well defined. Historically, surgeons are the primary decision-makers in orthopaedic device purchases.
While we market our broad portfolio of products to surgeons, our revenue is generated from sales of our products to healthcare
institutions and stocking distributors.
United States
As of December 25, 2016, our sales and distribution system in the United States consisted of 68 geographic sales territories that
are staffed by approximately 500 direct sales representatives and 24 independent sales agencies or distributors. These sales
representatives and independent sales agencies and distributors are generally aligned to selling either our upper extremities
products or lower extremities products, but, in some cases, certain agencies or direct sales representatives sell products from
both our upper and lower extremities product portfolios in their territories. Our direct sales representatives and independent
sales agencies and distributors are provided opportunities for product training throughout the year. We also have working
relationships with healthcare dealers, including group purchasing organizations, healthcare organizations, and integrated
16
distribution networks. We believe our success in every market sector is dependent upon having a robust and compelling
product offering, and equally as important, a dedicated, highly trained, focused sales organization to service our customers. We
plan to continue to strategically focus on and invest in building a competitively superior U.S. sales organization by training and
certifying our sales representatives on our innovative product portfolio, continuing to develop and implement strong
performance management practices, and enhancing sales productivity. Further, we intend to selectively expand our U.S. sales
force by adding about 85 new direct quota-carrying sales representatives, primarily weighted toward the lower extremities
business.
International
Internationally, we utilize several distribution approaches that are tailored to the needs and requirements of each individual
market. Our international sales and distribution system currently consists of 15 direct sales offices and approximately
90 distributors that sell our products in over 50 countries. We have subsidiaries with direct sales offices in the United
Kingdom, France, Germany, Italy, Denmark, Netherlands, Canada, Japan, Australia, Switzerland, and Norway that employ
direct sales employees, and in some cases, use independent sales representatives to sell our products in their respective markets.
Our products are sold in other countries in Europe, Asia, Africa, and Latin America using stocking distribution partners.
Stocking distributors purchase products directly from us for resale to their local customers, with product ownership generally
passing to the distributor upon shipment.
Manufacturing, Facilities, and Quality
We utilize a combination of internal manufacturing and a network of qualified outsourced manufacturing partners to produce
our products and surgical instrumentation. We manufacture our internally-sourced products in six locations: Arlington,
(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:30)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:78)(cid:79)(cid:76)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:30)(cid:3)(cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:15)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3)(cid:42)(cid:85)(cid:72)(cid:81)(cid:82)(cid:69)(cid:79)(cid:72)(cid:15)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3)(cid:49)(cid:82)(cid:74)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:68)(cid:70)(cid:85)(cid:82)(cid:82)(cid:80)(cid:15)(cid:3)(cid:44)(cid:85)(cid:72)(cid:79)(cid:68)(cid:81)(cid:71)(cid:17)(cid:3)(cid:3)(cid:58)(cid:72)(cid:3)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)
manufacturing facility in Arlington, Tennessee from the Industrial Development Board of the Town of Arlington. Our internal
manufacturing operations are focused on product quality, continuous improvement, and efficient production. Our internal
manufacturing operations have been practicing lean manufacturing concepts for many years with a philosophy focused on high
productivity, flexibility, and capacity optimization. Our operations in France have a long history and deep experience with
orthopaedic manufacturing and process innovation. Additionally, we believe we are the only company to have vertically
integrated operations for the manufacturing of pyrocarbon orthopaedic products. We believe that this capability gives us a
competitive advantage in design for manufacturing and prototyping of this innovative material.
We outsource products to our manufacturing partners when it provides us with cost efficiency, expertise, flexibility, and
instances where we need additional capacity. A significant portion of our lower extremities products and surgical
instrumentation is produced to our specifications by qualified subcontractors who serve medical device companies. We
continuously look for opportunities to optimize our internal manufacturing capacity and insource manufacturing where we
believe it makes sense to do so.
We maintain a comprehensive quality system that is certified to the European standards ISO 9001 and ISO 13485 and to the
Canadian Medical Devices Conformity Assessment System (CMDCAS). We are accredited by the American Association of
Tissue Banks (AATB) and have registrations with the FDA as a medical device establishment and as a tissue establishment.
These certifications and registrations require periodic audits and inspections by various global regulatory entities to determine
if we have systems in place to ensure our products are safe and effective for their intended use and that we are compliant with
applicable regulatory requirements. Our quality system exists so that management has the proper oversight, designs are
evaluated and tested, production processes are established and maintained, and monitoring activities are in place to ensure
products are safe, effective, and manufactured according to our specifications. Consequently, our quality system provides the
way for us to ensure we design and build quality into our products while meeting global requirements. We are committed to
meet or exceed customer needs as we strive to improve patient outcomes.
Supply
We use a diverse and broad range of raw materials in the manufacturing of our products. We purchase all of our raw materials
and select components used in the manufacturing of our products from external suppliers. In addition, we purchase some
supplies from single or limited number of sources for reasons of proprietary know-how, quality assurance, sole source, cost-
effectiveness, or constraints resulting from regulatory requirements. We work closely with our suppliers to ensure continuity of
supply while maintaining high quality and reliability.
We rely on one supplier for the silicone elastomer used in certain number of our extremities products. We are aware of only
two suppliers of silicone elastomer to the medical device industry for permanent implant usage. For certain biologic products,
we depend on one supplier of demineralized bone matrix and cancellous bone matrix. We rely on one supplier for our
GRAFTJACKET® family of soft tissue repair and graft containment products. We believe we maintain adequate stock from
17
these suppliers to meet market demand. We rely on one supplier for a key component of our AUGMENT® Bone Graft. In
December 2013, our supplier notified us of its intent to terminate the supply agreement in December 2015. This supplier was
contractually required to meet our supply requirements until the termination date, and to use commercially reasonable efforts to
assist us in identifying a new supplier and support the transfer of technology and supporting documentation to produce this
component. In April 2016, we entered into a commercial supply agreement with FUJIFILM Diosynth Biotechnologies U.S.A.,
Inc. pursuant to which Fujifilm agreed to manufacture and sell to us and we agreed to purchase the key component of our
AUGMENT® Bone Graft. Pursuant to our supply agreement with Fujifilm, commercial production of the key component is
expected to begin in 2019. Although we believe that our current supply of the key component from our former supplier should
be sufficient to last until after the component becomes available under the new agreement, no assurance can be provided that it
will be sufficient.
Some of our products are provided by suppliers under private-label distribution agreements. Under these agreements, the
supplier generally retains the intellectual property and exclusive manufacturing rights. The supplier private labels the products
under our brands for sale in certain fields of use and geographic territories. These agreements may be subject to minimum
purchase or sales obligations and are terminable by either party upon notice. Our private-label distribution agreements do not,
individually or in the aggregate, represent a material portion of our business and we are not substantially dependent on them.
Our business, and the orthopaedic industry in general, is capital intensive, particularly as it relates to inventory levels and
surgical instrumentation. Our business requires a significant level of inventory driven by our global footprint, the requirement
to provide products within a short period of time, and the number of different sizes of many of our products. In addition, we
must maintain a significant investment in surgical instrumentation as we provide these instruments to healthcare facilities and
surgeons for their use to facilitate the implantation of our products.
Competition
Competition in the orthopaedic device industry is intense and is characterized by extensive research efforts and rapid
technological progress. Competitors include major and mid-sized companies in the orthopaedic and biologics industries, as
well as academic institutions and other public and private research organizations that continue to conduct research, seek patent
protection, and establish arrangements for commercializing products that will compete with our products.
The primary competitive factors facing us include price, quality, innovative design and technical capability, clinical results,
breadth of product line, scale of operations, distribution capabilities, brand reputation, and strong customer service. Our ability
to compete is affected by our ability to accomplish the following:
• (cid:39)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:81)(cid:81)(cid:82)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:72)(cid:86)(cid:30)
• Obtain and maintain regulatory clearances or approvals and reimbursement for our produc(cid:87)(cid:86)(cid:30)
• Manufacture and sell our products cost-(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)
• (cid:48)(cid:72)(cid:72)(cid:87)(cid:3)(cid:68)(cid:79)(cid:79)(cid:3)(cid:85)(cid:72)(cid:79)(cid:72)(cid:89)(cid:68)(cid:81)(cid:87)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:86)(cid:30)
• Respond to competitive pressures specific to each of our geographic markets, including our ability to enforce non-
compete (cid:68)(cid:74)(cid:85)(cid:72)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)
• (cid:51)(cid:85)(cid:82)(cid:87)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:72)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:85)(cid:82)(cid:70)(cid:72)(cid:86)(cid:86)(cid:72)(cid:86)(cid:30)
• (cid:48)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:85)(cid:82)(cid:80)(cid:82)(cid:87)(cid:72)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
• (cid:38)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:68)(cid:76)(cid:81)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:68)(cid:3)(cid:75)(cid:76)(cid:74)(cid:75)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:82)(cid:73)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:72)(cid:71)(cid:88)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:88)(cid:85)(cid:74)(cid:72)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
• Attract and retain qualified scientific, m(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:70)(cid:88)(cid:86)(cid:72)(cid:71)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Support our technology with clinically relevant studies.
Research and Development
Realizing that new product offerings are a key to our future success, we are committed to a strong research and development
program. The intent of our program is to develop new extremities and biologics products and expand our current product
offerings and the markets in which they are offered. Our research and development teams are organized and aligned with our
product marketing teams and are focused on improving clinical outcomes by designing innovative, clinically differentiated
products with improved ease-of-use and by developing new product features and enhanced surgical techniques that can be
leveraged across a broader base of surgeon customers. Our internal research and development teams work closely with
external research and development consultants and a global network of physicians and medical personnel in hospitals and
universities to ensure we have broad access to best-in-class ideas and technologies to drive our product development pipeline.
We also have an active business development team that actively evaluates novel technologies and development stage products.
In addition, our clinical and regulatory departments are devoted to verifying the safety and efficacy of our products according
to regulatory standards enforced by the FDA and other international regulatory bodies. Our research and development
expenses totaled $50.5 million, $39.3 million and $25.0 million in 2016, 2015 and 2014, respectively. Our research and
18
development activities are principally located in (cid:48)(cid:72)(cid:80)(cid:83)(cid:75)(cid:76)(cid:86)(cid:15)(cid:3) (cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:30)(cid:3) (cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:15)(cid:3) (cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:58)(cid:68)(cid:85)(cid:86)(cid:68)(cid:90)(cid:15)(cid:3) (cid:44)(cid:81)(cid:71)(cid:76)(cid:68)(cid:81)(cid:68)(cid:15)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3)
(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:86)(cid:87)(cid:68)(cid:73)(cid:73)(cid:3)(cid:76)(cid:81)(cid:3)(cid:42)(cid:85)(cid:72)(cid:81)(cid:82)(cid:69)(cid:79)(cid:72)(cid:15)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:37)(cid:79)(cid:82)(cid:82)(cid:80)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15) Minnesota.
In the extremities area, our research and development activities focus on building upon our already comprehensive portfolio of
surgical solutions for extremities focused surgeons, including procedure and anatomy specific products. With the ultimate goal
of addressing unmet clinical needs, we often pursue multiple product solutions for a particular application in order to offer
surgeons the ability either to use their preferred procedural technique or to provide options and flexibility in the surgical setting
with the understanding that one solution does not work for every case.
In the biologics area, we have research and development projects underway that are designed to provide differentiation of our
advanced materials in the marketplace. We are particularly focused on the integration of our biologic product platforms into
extremities procedures and potential new applications for our AUGMENT® Bone Graft.
Intellectual Property
Patents, trade secrets, know-how, and other proprietary rights are important to the continued success of our business. We
currently own more than 1,500 patents and pending patents throughout the world. We currently have licenses to use
approximately 800 patents. We seek to aggressively protect technology, inventions, and improvements that we consider
important through the use of patents and trade secrets in the United States and significant foreign markets. We manufacture and
market products under both patents and license agreements with other parties. These patents and license agreements have a
defined life and expire from time to time. We are not materially dependent on any one or more of our patents. In addition to
patents, our knowledge and experience, creative product development, marketing staff and trade secret information, with
respect to manufacturing processes, materials and product design, are as important as our patents in maintaining our proprietary
product lines.
Although we believe that, in the aggregate, our patents are valuable, and patent protection is beneficial to our business and
competitive positioning, our patent protection will not necessarily deter or prevent competitors from attempting to develop
similar products. There can be no assurances that our patents will provide competitive advantages for our products or that
competitors will not challenge or circumvent these rights. In addition, there can be no assurances that the United States Patent
and Trademark Office (USPTO) or foreign patent offices will issue any of our pending patent applications. The USPTO and
foreign patent offices may deny or require a significant narrowing of the claims in our pending patent applications and the
patents issuing from such applications. Any patents issuing from the pending patent applications may not provide us with
significant commercial protection. We could incur substantial costs in proceedings before the USPTO or foreign patent offices,
including opposition and other post-grant proceedings. These proceedings could result in adverse decisions as to the
patentability, priority of our inventions, and the narrowing or invalidation of claims in issued patents. Additionally, the laws of
some of the countries in which our products are or may be sold may not protect our intellectual property to the same extent as
the laws in the United States or at all.
While we do not believe that any of our products infringe any valid claims of patents or other proprietary rights held by others,
we are currently subject to patent infringement litigation and there can be no assurances that we do not infringe any patents or
other proprietary rights held by them. If our products were found to infringe any proprietary right of another party, we could be
required to pay significant damages or license fees to such party and/or cease production, marketing, and distribution of those
products. Litigation also may be necessary to defend infringement claims of third parties or to enforce patent rights we hold or
to protect trade secrets or techniques we own.
We rely on trade secrets and other unpatented proprietary technology. There can be no assurances that we can meaningfully
protect our rights in our unpatented proprietary technology or that others will not independently develop substantially
equivalent proprietary products or processes or otherwise gain access to our proprietary technology.
We protect our proprietary rights through a variety of methods. As a condition of employment, we generally require employees
to execute an agreement relating to the confidential nature of and company ownership of proprietary information and assigning
intellectual property rights to us. We generally require confidentiality agreements with vendors, consultants, and others who
may have access to proprietary information. We generally limit access to our facilities and review the release of company
information in advance of public disclosure. There can be no assurances, however, that confidentiality agreements with
employees, vendors, and consultants will not be breached, adequate remedies for any breach would be available, or competitors
will not discover or independently develop our trade secrets. Litigation also may be necessary to protect trade secrets or
techniques we own.
19
Government Regulation
We are subject to varying degrees of government regulation in the countries in which we conduct business. In some countries,
such as the United States, Europe, Canada, and Japan, government regulation is significant and, we believe there is a general
trend toward increased and more stringent regulation throughout the world. As a manufacturer and marketer of medical
devices, we are subject to extensive regulation by the U.S. Food and Drug Administration, other federal governmental agencies,
and state agencies in the United States and similar foreign governmental authorities in countries located outside the United
(cid:54)(cid:87)(cid:68)(cid:87)(cid:72)(cid:86)(cid:17)(cid:3)(cid:3)(cid:55)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:74)(cid:82)(cid:89)(cid:72)(cid:85)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:87)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:82)(cid:69)(cid:86)(cid:72)(cid:85)(cid:89)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)
respect to the design, manufacture, testing, labeling, promotion, and sales of t(cid:75)(cid:72)(cid:3) (cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:80)(cid:68)(cid:76)(cid:81)(cid:87)(cid:72)(cid:81)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:85)(cid:72)(cid:70)(cid:82)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:85)(cid:68)(cid:70)(cid:78)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:83)(cid:82)(cid:85)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:82)(cid:87)(cid:72)(cid:81)(cid:87)(cid:76)(cid:68)(cid:79)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:71)(cid:72)(cid:73)(cid:72)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:80)(cid:83)(cid:82)(cid:85)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:91)(cid:83)(cid:82)(cid:85)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:86)(cid:3)(cid:90)(cid:72)(cid:79)(cid:79)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)matters.
In addition, as a participant in the healthcare industry, we are also subject to various other U.S. federal, state, and foreign laws.
On September 29, 2010, Wright Medical Technology, Inc. (WMT) entered into a five-year Corporate Integrity Agreement
(CIA) with the Office of the Inspector General of the United States Department of Health and Human Services (OIG-HHS).
The CIA expired on September 29, 2015 and on January 27, 2016, we received notification from the OIG-HHS that the term of
the CIA has concluded. While the term of the CIA has concluded, our failure to continue to maintain compliance with U.S.
healthcare laws, regulations and other requirements in the future could expose us to significant liability, including, but not
limited to, exclusion from federal healthcare program participation, including Medicaid and Medicare, potential prosecution,
civil and criminal fines or penalties, as well as additional litigation cost and expense.
We strive to comply with regulatory requirements governing our products and operations and to conduct our affairs in an
ethical manner. This practice is reflected in our Code of Business Conduct, various other compliance policies and through the
responsibility of the nominating, corporate governance and compliance committee of our board of directors, which oversees
our corporate compliance program and compliance with legal and regulatory requirements as well as our ethical standards and
policies. We devote significant time, effort, and expense to addressing the extensive government and regulatory requirements
applicable to our business. Such regulatory requirements are subject to change and we cannot predict the effect, if any, that
these changes might have on our business, financial condition, and results of operations. Governmental regulatory actions
against us could result in warning letters, delays in approving or refusal to approve a product, the recall or seizure of our
products, suspension or revocation of the authority necessary for the production or sale of our products, litigation expense, and
civil and criminal penalties against us and our officers and employees. If we fail to comply with these regulatory requirements,
our business, financial condition, and results of operations could be harmed.
United States
In the United States, our products are strictly regulated by the FDA under the U.S. Food, Drug and Cosmetic Act (FDC Act).
Some of our products are also regulated by state agencies. FDA regulations and the requirements of the FDC Act affect the
pre-clinical and clinical testing, design, manufacture, safety, efficacy, labeling, storage, recordkeeping, advertising, and
promotion of our medical device products. Our tissue-based products are subject to FDA regulations, the National Organ
Transplant Act (NOTA), and various state agency regulations. We are an accredited member of the American Association of
Tissue Banks and an FDA-registered tissue establishment, which includes the packaging, processing, storage, labeling, and
distribution of tissue products regulated as medical devices and the storage and distribution of tissue products regulated solely
as human cell and tissue products. In addition, we maintain tissue bank licenses in Florida, Maryland, New York, California,
Illinois, Delaware, and Oregon.
Generally, before we can market a new medical device, marketing clearance from the FDA must be obtained through either a
premarket notification under Section 510(k) of the FDC Act or the approval of a de novo or premarket approval (PMA)
application. Most of our products are FDA cleared through the 510(k) premarket notification process. The FDA typically
grants a 510(k) clearance if the applicant can establish that the device is substantially equivalent to a predicate device. It
usually takes about three months from the date of a 510(k) submission to obtain clearance, but it may take longer, particularly if
a clinical trial is required. The FDA may find that a 510(k) is not appropriate or that substantial equivalence has not been
shown and, as a result, require a de novo or PMA application.
PMA applications must be supported by valid scientific evidence to demonstrate the safety and effectiveness of the device,
typically including the results of human clinical trials, bench tests, and laboratory and animal studies. The PMA application
must also contain a complete description of the device and its components, and a detailed description of the methods, facilities,
and controls used to manufacture the device. In addition, the submission must include the proposed labeling and any training
materials. The PMA application process is expensive and generally takes significantly longer than the 510(k) process.
Additionally, the FDA may never approve the PMA application. As part of the PMA application review process, the FDA
generally will conduct an inspection of the manufacturer’s facilities to ensure compliance with applicable quality system
regulatory requirements, which include quality control testing, documentation control, and other quality assurance procedures.
A PMA can include post-approval conditions including, among other things, restrictions on labeling, promotion, sale and
20
distribution, data reporting (surveillance), or requirements to do additional clinical studies post-approval. Even after approval
of a PMA, the FDA must grant subsequent approvals for a new PMA or a PMA supplement to authorize certain modifications
to the device, its labeling, or its manufacturing process.
One or more clinical trials may be required to support a 510(k) application or a de novo submission and almost always are
required to support a PMA application. Clinical trials of unapproved or uncleared medical devices or devices being studied for
uses for which they are not approved or cleared (investigational devices) must be conducted in compliance with FDA
requirements. If human clinical trials of a medical device are required and the device presents a significant risk, the sponsor of
the trial must file an investigational device exemption (IDE) application prior to commencing human clinical trials. The IDE
application must be supported by data, typically including the results of animal and/or laboratory testing. If the IDE application
is approved by the FDA and one or more institutional review boards (IRBs), human clinical trials may begin at a specific
number of institutional investigational sites with the specific number of patients approved by the FDA. If the device presents a
non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for the trial by one or more
IRBs without separate approval from the FDA. Submission of an IDE does not give assurance that the FDA will approve the
IDE. If an IDE is approved, there can be no assurance the FDA will determine that the data derived from the trials support the
safety and effectiveness of the device or warrant the continuation of clinical trials. An IDE supplement must be submitted to
and approved by the FDA before a sponsor or investigator may make a change to the investigational plan in such a way that
may affect its scientific soundness, study indication, or the rights, safety or welfare of human subjects. During the trial, the
sponsor must comply with the FDA’s IDE requirements including, for example, investigator selection, trial monitoring, adverse
event reporting, and recordkeeping. The investigators must obtain patient informed consent, rigorously follow the
investigational plan and trial protocol, control the disposition of investigational devices, and comply with reporting and
recordkeeping requirements. We, the FDA and the IRB at each institution at which a clinical trial is being conducted may
suspend a clinical trial at any time for various reasons, including a belief that the subjects are being exposed to an unacceptable
risk. We are currently conducting a few clinical trials.
After a device is cleared or approved for marketing, numerous and pervasive regulatory requirements continue to apply and we
continue to be subject to inspection by the FDA to determine our compliance with these requirements, as do our suppliers,
contract manufacturers, and contract testing laboratories. These requirements include, among others, the following:
• Quality System regulations, which govern, among other things, how manufacturers design, test, manufacture,
•
modify, label, exercise quality control over and document (cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
labeling and claims regulations, which require that promotion is truthful, not misleading, fairly balanced and
provide adequate directions for use and that all claims are substantiated, and also prohibit the promotion of
products for unapproved or “off-label” (cid:88)(cid:86)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:80)(cid:83)(cid:82)(cid:86)(cid:72)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:85)(cid:72)(cid:86)(cid:87)(cid:85)(cid:76)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:79)(cid:68)(cid:69)(cid:72)(cid:79)(cid:76)(cid:81)(cid:74)(cid:30)
• FDA guidance of off-(cid:79)(cid:68)(cid:69)(cid:72)(cid:79)(cid:3)(cid:71)(cid:76)(cid:86)(cid:86)(cid:72)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:82)(cid:3)(cid:88)(cid:81)(cid:86)(cid:82)(cid:79)(cid:76)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)
• Medical Device Reporting (MDR) regulation, which requires reporting to the FDA certain adverse experiences
(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:88)(cid:86)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:68)(cid:76)(cid:81)(cid:87)(cid:3)(cid:75)(cid:68)(cid:81)(cid:71)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:71)(cid:72)(cid:86)(cid:76)(cid:74)(cid:81)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:85)(cid:68)(cid:70)(cid:78)(cid:15)(cid:3)(cid:80)(cid:82)(cid:81)(cid:76)(cid:87)(cid:82)(cid:85)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:86)(cid:82)(cid:79)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:68)(cid:76)(cid:81)(cid:87)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
•
• Part 806 reporting of certain corrections, removals, enhancemen(cid:87)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:70)(cid:68)(cid:79)(cid:79)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)
•
complying with federal law and regulations requiring Unique Device Identifiers (UDI) on devices and also
requiring the submission of certain information about each device to FDA’s Global Unique Device Identification
Database (G(cid:56)(cid:39)(cid:44)(cid:39)(cid:12)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
in some cases, ongoing monitoring and tracking of our products’ performance and periodic reporting to the FDA
of such performance results.
•
The FDA has statutory authority to regulate allograft-based products, processing, and materials. The FDA and other
international regulatory agencies have been working to establish more comprehensive regulatory frameworks for allograft-
based tissue-containing products, which are principally derived from human cadaveric tissue. The framework developed by the
FDA establishes risk-based criteria for determining whether a particular human tissue-based product will be classified as
human tissue, a medical device, or a biologic drug requiring premarket clearance or approval. All tissue-based products are
subject to extensive FDA regulation, including establishment registration requirements, product listing requirements, good
tissue practice requirements for manufacturing, and screening requirements that ensure that diseases are not transmitted to
tissue recipients. The FDA has also proposed extensive additional requirements that address sub-contracted tissue services,
tracking to the recipient/patient, and donor records review. If a tissue-based product is considered human tissue, the FDA
requirements focus on preventing the introduction, transmission, and spread of communicable diseases to recipients. Neither
clinical data nor review of safety and efficacy is required before the tissue can be marketed. However, if the tissue is
considered a medical device or a biologic drug, then FDA clearance or approval is required.
The FDA and international regulatory authorities periodically inspect us and our third-party manufacturers for compliance with
applicable regulatory requirements. These requirements include labeling regulations, manufacturing regulations, quality
21
system regulations, regulations governing unapproved or off-label uses, and medical device regulations. Medical device
regulations require a manufacturer to report to the FDA serious adverse events or certain types of malfunctions involving its
products.
We are subject to various U.S. federal and state laws concerning healthcare fraud and abuse, including anti-kickback and false
claims laws, and other matters. The U.S. federal Anti-Kickback Statute (and similar state laws) prohibits certain illegal
remuneration to physicians and other health care providers that may financially bias prescription decisions and result in an
over-utilization of goods and services reimbursed by the federal government. The U.S. federal False Claims Act (and similar
state laws) prohibits conduct on the part of a manufacturer which may cause or induce an inappropriate reimbursement for
devices reimbursed by the federal government. We are also subject to the U.S. federal Physician Payments Sunshine Act and
various state laws on reporting remunerative relationships with healthcare providers. These laws impact the kinds of financial
arrangements we may have with hospitals, surgeons or other potential purchasers of our products. They particularly impact
how we structure our sales offerings, including discount practices, customer support, education and training programs,
physician consulting, research grants and other arrangements. These laws are administered by, among others, the U.S.
Department of Justice, the Office of Inspector General of the Department of Health and Human Services and state attorneys
general. Many of these agencies have increased their enforcement activities with respect to medical device manufacturers in
recent years. If our operations are found to be in violation of these laws, we may be subject to penalties, including potentially
significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in
government healthcare programs, contractual damages, reputational harm, administrative burdens, diminished profits and
future earnings, and the curtailment or restructuring of our operations.
We are also subject to data privacy and security regulation by both the U.S. federal government and the states in which we
conduct our business. Health Insurance Portability and Accountability Act of 1996 (HIPAA), as amended by the Health
Information Technology for Economic and Clinical Health Act (HITECH), and their respective implementing regulations,
imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information.
Among other things, HITECH makes HIPAA’s security standards directly applicable to business associates, defined as service
providers of covered entities that create, receive, maintain, or transmit protected health information in connection with
providing a service for or on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties and
gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal
HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, many state laws
govern the privacy and security of health information in certain circumstances, many of which differ from HIPAA and each
other in significant ways and may not have the same effect.
The FDA, in cooperation with U.S. Customs and Border Protection, administers controls over the import of medical devices
into the United States. The U.S. Customs and Border Protection imposes its own regulatory requirements on the import of our
products, including inspection and possible sanctions for noncompliance. We are also subject to foreign trade controls
administered by certain U.S. government agencies, including the Bureau of Industry and Security within the Commerce
Department and the Office of Foreign Assets Control within the Treasury Department.
International
Outside the United States, we are subject to government regulation in the countries in which we operate and sell our products.
We must comply with extensive regulations governing product approvals, product safety, quality, manufacturing, and
reimbursement processes in order to market our products in all major foreign markets. Although many of the regulations
applicable to our products in these countries are similar to those of the FDA, these regulations vary significantly from country
to country and with respect to the nature of the particular medical device. The time required to obtain foreign approvals to
market our products may be longer or shorter than the time required in the United States, and requirements for such approvals
may differ from FDA requirements.
To market our product devices in the member countries of the European Union, we are required to comply with the European
Medical Device Directives and to obtain CE mark certification. CE mark certification is the European symbol of adherence to
quality assurance standards and compliance with applicable European Medical Device Directives. Under the European
Medical Device Directives, all medical devices must qualify for CE marking. To obtain authorization to affix the CE mark to
one of our products, a recognized European Notified Body must assess our quality systems and the product’s conformity to the
requirements of the European Medical Device Directives. We are subject to inspection by the Notified Bodies for compliance
with these requirements. We also are required to comply with regulations of other countries in which our products are sold,
such as obtaining Ministry of Health Labor and Welfare approval in Japan, Health Protection Branch approval in Canada and
Therapeutic Goods Administration approval in Australia.
Our manufacturing facilities are subject to environmental health and safety laws and regulations, including those relating to the
use, registration, handling, storage, disposal, recycling and human exposure to hazardous materials and discharges of
22
substances in the air, water and land. For example, in France, requirements known as the Installations Classées pour la
Protection de l’Environnement regime provide for specific environmental standards related to industrial operations such as
noise, water treatment, air quality, and energy consumption. In Ireland, our manufacturing facilities are likewise subject to
local environmental regulations, such as related to water pollution and water quality, which are administered by the
Environmental Protection Agency.
Our operations in countries outside the United States are subject to various other laws such as those regarding recordkeeping
(cid:68)(cid:81)(cid:71)(cid:3) (cid:83)(cid:85)(cid:76)(cid:89)(cid:68)(cid:70)(cid:92)(cid:30)(cid:3) (cid:79)(cid:68)(cid:90)(cid:86)(cid:3) (cid:85)(cid:72)(cid:74)(cid:68)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:68)(cid:81)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:72)(cid:71)(cid:3) (cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:85)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3) (cid:72)(cid:81)(cid:87)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3) (cid:70)(cid:88)(cid:86)(cid:87)(cid:82)(cid:80)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:76)(cid:80)(cid:83)(cid:82)(cid:85)(cid:87)-export, and laws regarding
transactions in foreign countries. We are also subject to the U.S. Foreign Corrupt Practices Act, which generally prohibits
covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for
the purpose of obtaining or retaining business or other benefits, as well as similar anti-corruption laws of other countries, such
as the UK Bribery Act.
Third-Party Reimbursement
Sales volumes and prices of our products depend in large part on the availability of coverage and reimbursement from third-
party payors. Third-party payors may include governmental programs such as the U.S. Medicare and Medicaid programs,
private insurance plans, and workers’ compensation plans. These third-party payors may deny coverage or reimbursement for a
product or procedure if they determine that the product or procedure is investigational or was not medically appropriate or
necessary. Third-party payors also may place limitations for coverage on products or procedures such as the types of
conditions for which a procedure will be covered, the types of physicians that can perform specific types of procedures or the
care setting in which the procedure may be performed, e.g., out-patient or in-hospital. Also, third-party payors are increasingly
auditing and challenging the prices charged for medical products and services with concern for upcoding, miscoding, using
inappropriate modifiers, or billing for inappropriate care settings. Some third-party payors may require prior-authorization,
pre-determination, and/or prior approval in a determination of coverage for new or innovative devices or procedures before
they will reimburse healthcare providers who use the products or therapies. Even though a new product may have been
approved or cleared for commercial distribution by the FDA, we may find limited demand for the product should any
reimbursement barriers arise from governmental and/or private third-party payors. In the United States, a uniform policy of
coverage does not exist across all third-party payors relative to payment of claims for all products. Therefore, coverage and
payment can be quite different from payor to payor, and from one region of the country to another. This is also true for foreign
countries in that coverage and payment systems vary from country to country. Coverage also depends on our ability to
demonstrate the short-term and long-term clinical effectiveness, and cost-effectiveness of our products. These supportive data
are obtained from surgeon clinical experience, clinical trials, and literature reviews. We pursue and present these results at
major scientific and medical meetings, and publish them in respected, peer-reviewed medical journals because data and
evidence that can support coverage and payment are important to the successful commercialization and market access of our
products.
The Centers for Medicare & Medicaid Services (CMS), the U.S. agency responsible for administering the Medicare program,
sets coverage and reimbursement policies for the Medicare program in the United States. CMS policies may alter coverage and
payment related to our products in the future. These changes may occur as the result of national coverage determinations
issued by CMS or as the result of local coverage determinations by contractors under contract with CMS to review and make
coverage and payment decisions. Medicaid programs are funded by both U.S. federal and state governments, may vary from
state to state and from year to year and will likely play an even larger role in healthcare funding under recently enacted, and
potentially newly enacted, healthcare legislation. A key component in ensuring whether the appropriate payment amount is
received for physician and other services, including procedures using our products, is the existence of a Current Procedural
Terminology (CPT) code. To receive payment, healthcare practitioners must submit claims to insurers using these codes for
payment for medical services. CPT codes are assigned, maintained and annually updated by the American Medical Association
and its CPT Editorial Board. If the CPT codes that apply to procedures performed using our products are changed,
reimbursement for performances of these procedures may be adversely affected.
We believe that the overall escalating cost of medical products and services being paid for by governments and private health
insurance has led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce
the costs of products and services. Third-party payors are developing increasingly sophisticated methods of controlling
healthcare costs through healthcare reform legislation and measures including, but not limited to, government-managed
healthcare systems, bundled payments, episode of care risk sharing methodologies, health technology assessments, coverage
with evidence development processes, quality initiatives, pay-for-performance, comparative effectiveness research, prospective
reimbursement, capitation programs, group purchasing, redesign of benefit offerings, requiring pre-approvals and second
opinions prior to procedures, careful review of bills, encouragement of healthier lifestyles and other preventative services, and
exploration of more cost-effective methods of delivering healthcare. All of these types of health care reform measures and any
others could potentially impact market access for, and pricing structures of our products, which in turn, can impact our future
sales. There can be no assurance that third-party reimbursement will be available or adequate, or that current and future
23
legislation, regulation or reimbursement policies of third-party payors will not adversely affect the demand for our products or
our ability to sell our products on a profitable basis. The unavailability or inadequacy of third-party payor reimbursement could
have a material adverse effect on our business, operating results, and financial condition.
Outside the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries
have instituted price ceilings on specific product lines and procedures. We believe we have received increased requests for
clinical data for the support of registration and reimbursement outside the United States. We have increasingly experienced
local, product specific reimbursement law being applied as an overlay to medical device regulation, which has provided an
additional layer of clearance requirement. Specifically, Australia requires that clinical data for clearance and reimbursement be
in the form of prospective, multi-center studies, a high bar not previously applied. In addition, in France, certain innovative
devices (such as some of our products made from pyrolytic carbon), have been identified as needing to provide clinical
evidence to support a “mark-specific” reimbursement. There can be no assurances that procedures using our products will be
considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by
third-party payors, that an adequate level of reimbursement will be available, or that the third-party payors’ reimbursement
policies will not adversely affect our ability to sell our products profitably.
Environmental
Our operations and properties are subject to extensive U.S. federal, state, local, and foreign environmental protection and health
and safety laws and regulations. These laws and regulations govern, among other things, the generation, storage, handling, use,
and transportation of hazardous materials and the handling and disposal of hazardous waste generated at our facilities. Under
such laws and regulations, we are required to obtain permits from governmental authorities for some of our operations. If we
violate or fail to comply with these laws, regulations or permits, we could be fined or otherwise sanctioned by regulators.
Under some environmental laws and regulations, we could also be held responsible for all of the costs relating to any
contamination at our past or present facilities and at third-party waste disposal sites. We believe our costs of complying with
current and future environmental laws, regulations and permits and our liabilities arising from past or future releases of, or
exposure to, hazardous substances will not materially adversely affect our business, results of operations, or financial condition,
although there can be no assurances of this.
Seasonality
We traditionally experience lower sales volumes in the third quarter than throughout the rest of the year as many of our
products are used in elective procedures, which generally decline during June, July, and August. This typically results in our
selling, general and administrative expenses and research and development expenses as a percentage of our net sales that are
higher during third quarter than throughout the rest of the year. In addition, our first quarter selling, general and administrative
expenses include additional expenses that we incur in connection with the annual meeting held by the American College of
Foot and Ankle Surgeons (ACFAS) and the American Academy of Orthopaedic Surgeons (AAOS). During these three-day
events, we display our most recent and innovative products.
Backlog
The time period between the placement of an order for our products and shipment is generally short. As such, we do not
consider our backlog of firm orders to be material to an understanding of our business.
Employees
As of December 25, 2016, we had 2,394 employees. We believe that we have a good relationship with our employees.
Available Information
We are a public company with limited liability (naamloze vennootschap) organized under the laws of the Netherlands. We
were initially formed as a private company with limited liability (besloten vennootschap) in June 2006. Our principal executive
offices are located at Prins Bernhardplein 200, 1097 JB Amsterdam, the Netherlands. Our telephone number at this address is
(+31) 20 521 4777. Our agent for service of process in the United States is CT Corporation, 1209 Orange Street, Wilmington,
Delaware 19801. Our corporate website is located at www.wright.com. The information contained on our website or connected
to our website is not incorporated by reference into and should not be considered part of this report.
We make available, free of charge and through our Internet corporate website, our Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to any such reports filed or furnished pursuant to
24
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after they are
electronically filed with or furnished to the Securities and Exchange Commission.
Item 1A. Risk Factors.
We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. In addition to
the other information set forth in this report, careful consideration should be taken of the factors described below, which could
materially adversely affect our business, financial condition or operating results. The risk factors described below may relate
solely to one or more of the legal entities contained in our corporate structure and may not necessarily apply to Wright Medical
Group N.V. or one or more of the other legal entities contained in our corporate structure.
Risks Related to the Wright/Tornier Merger
We may be unable to successfully integrate our operations or realize the anticipated cost savings, net sales and other potential
benefits of the Wright/Tornier merger in a timely manner or at all. As a result, the value of our ordinary shares may be
adversely affected.
The success of the merger between legacy Wright and legacy Tornier will depend, in part, on our ability to achieve the
anticipated cost savings, net sales, and other potential benefits of the merger. Achieving the anticipated potential benefits of the
merger will depend in part upon whether we are able to integrate our operations in an efficient and effective manner and
whether we are able to effectively coordinate sales and marketing efforts to communicate our capabilities and coordinate our
sales organizations to sell our combined products. While we have successfully completed a substantial number of integration
activities since the merger, the remainder of our integration activities may not be completed smoothly or successfully. The
necessity of coordinating geographically separated organizations, systems, and facilities and addressing possible differences in
business backgrounds, corporate cultures, and management philosophies may increase the difficulties of integration. We
operate numerous systems, including those involving management information, purchasing, accounting and finance, sales,
billing, payroll, employee benefits, and regulatory compliance. We still have numerous systems which remain to be integrated,
including those involving management information, purchasing, accounting and finance, sales, billing, payroll, employee
benefits, and regulatory compliance. We may still have inconsistencies in standards, controls, procedures or policies that could
affect our ability to maintain relationships with customers and employees or to achieve the anticipated benefits of the merger.
We may also have difficulty in completing the integration of our commercial organizations, including in particular distribution
and sales representative arrangements, some of which will undergo territory transitions during the next several quarters. The
integration of certain operations requires the dedication of significant management resources, which may temporarily distract
management’s attention from our day-to-day business. Employee uncertainty and lack of focus during the integration process
may also disrupt our business. Any inability of our management to integrate successfully our operations or to do so within a
longer time frame than expected could have a material adverse effect on our business and operating results. The integration
also may result in material unanticipated problems, expenses, liabilities, competitive responses, and loss of customer
relationships. Even if the operations of our businesses are integrated successfully, we may not be able to realize the full
benefits of the merger, including the anticipated operating and cost synergies, sales and growth opportunities or long-term
strategic benefits of the merger, within the expected timeframe or at all. In addition, we expect to continue to incur significant
integration and restructuring expenses to realize synergies. However, many of the expenses that remain to be incurred are, by
their nature, difficult to estimate accurately. These expenses could, particularly in the near term, exceed the savings that we
expect to achieve from elimination of duplicative expenses and the realization of economies of scale and cost savings.
Although we expect that the realization of efficiencies related to the integration of the businesses may offset incremental
transaction, merger-related, and restructuring costs over time, we cannot give any assurance that this net benefit will be
achieved in the near term, or at all. An inability to realize the full extent of, or any of, the anticipated benefits of the merger, as
well as any delays encountered in the integration process, could have an adverse effect on our business and operating results,
which may affect the value of our ordinary shares.
Our future success also will depend in part upon our ability to retain key employees. Competition for qualified personnel can
be very intense. In addition, key employees may depart because of issues relating to the uncertainty or difficulty of integration
or a desire not to remain with our company. Accordingly, no assurances can be given that we will retain key employees.
Our future results will suffer if we do not effectively manage our expanded operations as a result of the merger.
As a result of the merger, the size of our business has increased significantly. Our future success depends, in part, upon our
ability to manage this expanded business, which may pose substantial challenges for our management, including challenges
related to the management and monitoring of new operations and associated increased costs and complexity. There can be no
assurances that we will be successful or that we will realize the expected operating efficiencies, cost savings, and other benefits
currently anticipated from the merger.
25
Efforts to integrate our Corporate Compliance Programs require the cooperation of many individuals and will likely require
substantial investment and divert a significant amount of future time and resources from our other business activities.
We are committed to a robust Corporate Compliance Program. In furtherance of this strategic objective, we have devoted a
significant amount of time and resources since the completion of the merger to integrate the Corporate Compliance Programs of
legacy Wright and legacy Tornier. This has required, and will continue to require, a significant amount of time and resources
from our financial, human resources, and compliance personnel, as well as all of our employees. Successful integration of our
Corporate Compliance Programs requires the full and sustained cooperation of all of our employees, distributors, and sales
agents, as well as the healthcare professionals with whom we interact. These efforts require significant expenses and
investments. We also may encounter inefficiencies in the integration of our compliance programs, including delays in medical
education, research and development projects, and clinical studies, which may unfavorably impact our business and
relationships with customers. If we fail to integrate successfully the Corporate Compliance Programs of legacy Wright and
legacy Tornier, our business and operating results may be adversely affected.
In connection with the accounting for the merger, we recorded a significant amount of goodwill and other intangible assets,
which if the acquired business does not perform well, may be subject to future impairment, which would harm our operating
results.
In connection with the accounting for the merger, we recorded a significant amount of goodwill and other intangible assets
within each of our reporting units. As of December 25, 2016, we had $851.0 million in goodwill and $231.8 million in
intangible assets. As part of the Wright/Tornier merger, we recorded $667.3 million in goodwill and $213.6 million in other
intangible assets. Under US GAAP, we must assess, at least annually and potentially more frequently, whether the value of our
goodwill and intangible assets have been impaired. A decrease in the long-term economic outlook and future cash flows of the
legacy Tornier business that we acquired could significantly impact asset values and potentially result in the impairment of
intangible assets, including goodwill. If the operating performance of the legacy Tornier business significantly decreases,
competing or alternative technologies emerge, or if market conditions or future cash flow estimates decline, we could be
required, under current US GAAP, to record a non-cash charge to operating earnings for the amount of the impairment. Any
write-off of a material portion of our unamortized intangible assets would negatively affect our results of operations.
We have incurred and expect to continue to incur significant transaction and integration-related costs in connection with the
merger and the integration of our operations.
We have incurred and expect to continue to incur a number of non-recurring costs associated with the merger and integrating
our operations. The substantial majority of non-recurring expenses resulting from the merger will be comprised of transaction
costs related to the merger, employment-related costs, and facilities and systems consolidation costs. Although we expect that
the elimination of duplicative costs, as well as the realization of other efficiencies related to the integration of our businesses
should allow us to offset incremental transaction and integration-related costs over time, this net benefit may not be achieved in
the near term, or at all.
Risks Related to our Business
We have a history of operating losses and may never achieve or sustain profitability.
We have a history of operating losses and at December 25, 2016, we had an accumulated deficit of $1,206 million. Our ability
to achieve profitability will be influenced by many factors, including, among others, the success of the Wright/Tornier merge(cid:85)(cid:30)
the level and timing of future ne(cid:87)(cid:3) (cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:71)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3) (cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3) (cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:85)(cid:70)(cid:76)(cid:68)(cid:79)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3) (cid:68)(cid:70)(cid:70)(cid:72)(cid:83)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:81)(cid:72)(cid:90)(cid:3)
(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:86)(cid:70)(cid:82)(cid:83)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:81)(cid:74)(cid:82)(cid:76)(cid:81)(cid:74)(cid:3) (cid:85)(cid:72)(cid:86)(cid:72)(cid:68)(cid:85)(cid:70)(cid:75)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:83)(cid:85)(cid:82)(cid:77)(cid:72)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3) (cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3)
(cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3) (cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3) (cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:71)(cid:72)(cid:79)(cid:68)(cid:92)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:83)(cid:72)(cid:81)(cid:71)ing litigation. As a result, we may continue to incur operating
losses for the foreseeable future. These losses will continue to have an adverse impact on our shareholders’ equity, and we may
never achieve or sustain profitability.
We anticipate significant sales during 2017 and in future years from our AUGMENT® Bone Graft product. If we are wrong,
our future operating results, cash flows, and prospects could be adversely affected.
The newest addition to our biologics product portfolio is AUGMENT® Bone Graft, which is based on recombinant human
platelet-derived growth factor (rhPDGF-BB), a synthetic copy of one of the body’s principal healing agents. We obtained FDA
approval of AUGMENT® Bone Graft in the United States for ankle and/or hindfoot fusion indications during third quarter of
2015. AUGMENT® Bone Graft is currently available for sale as an alternative to autograft in the United States for ankle and/or
hindfoot fusion indications, in Canada for foot and ankle fusion indications and in Australia and New Zealand for hindfoot and
ankle fusion indications. We anticipate significant sales during 2017 and in future years from our AUGMENT® Bone Graft
26
product. If we are wrong, our future operating results, cash flows, and prospects could be adversely affected. We acquired the
AUGMENT® Bone Graft product line from BioMimetic Therapeutics, Inc. (BioMimetic) in March 2013 and are subject to
future milestone payments to the holders of the contingent value rights issued in connection with that transaction. If, prior to
March 1, 2019, sales of AUGMENT® Bone Graft reach $40 million over 12 consecutive months, a cash payment would be
required at $1.50 per share, or $42 million. Further, if, prior to March 1, 2019, sales of AUGMENT® Bone Graft reach
$70 million over 12 consecutive months, an additional cash payment would be required at $1.50 per share, or $42 million.
Therefore, even if we achieve significant sales of AUGMENT® Bone Graft, cash proceeds from these sales will be offset in part
by these milestone payment obligations.
We are subject to substantial government regulation that could have a material adverse effect on our business.
The production and marketing of our products and our ongoing research and development, pre-clinical testing, and clinical trial
activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and
abroad. U.S. and foreign regulations govern the testing, marketing, and registration of new medical devices, in addition to
regulating manufacturing practices, reporting, labeling, relationships with healthcare professionals, and recordkeeping
procedures. The regulatory process requires significant time, effort, and expenditures to bring our products to market, and we
cannot be assured that any of our products will be approved. Our failure to comply with applicable regulatory requirements
could result in governmental authorities:
(cid:76)(cid:80)(cid:83)(cid:82)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:73)(cid:76)(cid:81)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:72)(cid:81)(cid:68)(cid:79)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:88)(cid:86)(cid:30)(cid:3)
(cid:83)(cid:85)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:88)(cid:86)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)
brin(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:76)(cid:89)(cid:76)(cid:79)(cid:3)(cid:82)(cid:85)(cid:3)(cid:70)(cid:85)(cid:76)(cid:80)(cid:76)(cid:81)(cid:68)(cid:79)(cid:3)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:3)(cid:68)(cid:74)(cid:68)(cid:76)(cid:81)(cid:86)(cid:87)(cid:3)(cid:88)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:72)(cid:86)(cid:30)(cid:3)
(cid:71)(cid:72)(cid:79)(cid:68)(cid:92)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:87)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:76)(cid:81)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:30)(cid:3)
(cid:85)(cid:72)(cid:70)(cid:68)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:72)(cid:76)(cid:93)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)
•
•
•
•
•
• withdrawing or denying approvals or clearances for our products.
Even if regulatory approval or clearance of a product is granted, this could result in limitations on the uses for which the
product may be labeled and promoted. Further, for a marketed product, its manufacturer, such manufacturer’s suppliers, and
manufacturing facilities are subject to periodic review and inspection. Subsequent discovery of problems with a product,
manufacturer, or facility may result in restrictions on the product, manufacturer or facility, including withdrawal of the product
from the market or other enforcement actions. Our products can only be marketed in accordance with their approved labeling.
If we were to promote the use of our products in an “off-label” manner, we and our directors, officers and employees, would be
subject to civil and criminal sanctions.
We are subject to various U.S. federal and state and foreign laws concerning healthcare fraud and abuse, including false claims
laws, anti-kickback laws and physician self-referral laws. Violations of these laws can result in criminal and/or civil
punishment, including fines, imprisonment and, in the United States, exclusion from participation in government healthcare
programs. Greater scrutiny of marketing practices in our industry has resulted in numerous government investigations by
various government authorities and this industry-wide enforcement activity is expected to continue. If a governmental
authority were to determine that we do not comply with these laws and regulations, then we and our directors, officers and
employees could be subject to criminal and civil penalties, including exclusion from participation in U.S. federal healthcare
reimbursement programs.
In order to market our devices in the member countries of the European Union, we are required to comply with the European
Medical Devices Directive and obtain CE mark certification. CE mark certification is the European symbol of adherence to
quality assurance standards and compliance with applicable European Medical Device Directives. Under the European
Medical Devices Directive, all medical devices including active implants must qualify for CE marking. Our failure to comply
with the European Medical Devices Directive could result in our loss of CE mark certification which would harm our business.
Although legacy Wright divested the hip/knee (OrthoRecon) business, legacy Wright remains responsible, as between it and
MicroPort, for liability claims on OrthoRecon products sold prior to closing, and might still be sued on products sold after
closing.
Although OrthoRecon product liability expenses are accounted for under our discontinued operations, the agreement between
Wright Medical Group, Inc. (WMG) and MicroPort requires that legacy Wright, as between it and MicroPort, retain
responsibility for product liability claims on OrthoRecon products sold prior to closing, and for any resulting settlements,
judgments, or other costs. Moreover, even though MicroPort, as between it and legacy Wright, is responsible for liability
claims on post-closing sales, there can be no assurance we will not be named as a defendant in a lawsuit relating to such post-
closing sales, or that MicroPort will have adequate resources to exonerate legacy Wright from any resulting expenses or
liabilities.
27
We may never realize the expected benefits from the Wright/Tornier merger, the divestiture of the OrthoRecon business, and our
strategy to become a profitable, high-growth, pure-play medical technology company, and command the market valuation
typically accorded such companies.
The Wright/Tornier merger and the divestiture of the OrthoRecon business are part of our strategy to transform ourselves into a
profitable, high-growth, pure-play medical technology company, and command the market valuation typically accorded such
companies. If we are unable to achieve our growth and profitability objectives due to competition, lack of acceptance of our
products, failure to gain regulatory approvals, or other risks as described in this section or other sections of this report, or due to
other events, we will not be successful in transforming our business and will not be accorded the market valuation we seek.
Moreover, the OrthoRecon business generated substantial revenue and cash flow, which we have not replaced. While over time
we expect to replace the OrthoRecon revenue and cash flow by accelerating higher margin revenue streams from extremities
and biologic products, especially in light of the Wright/Tornier merger, there is still a risk we will be unable to replace the
revenue and cash flow that the OrthoRecon business generated, or that the cost of such will be higher than expected. If we are
unable to achieve our profit and growth objectives, such failure will be exacerbated by the loss of revenue and cash flow
generated by the OrthoRecon business, and could result in a decline in our stock price.
We may never realize the expected benefits of our strategic business combinations or acquisition transactions.
In addition to developing new products and growing our business internally, we have sought to grow through business
combinations and acquisitions of complementary businesses. Examples include, in addition to the Wright/Tornier merger,
legacy Wright’s acquisition of BioMimetic in early 2013, as well as its more recent acquisitions of Biotech International in
November 2013, Solana Surgical, LLC (Solana) in January 2014, and OrthoPro, L.L.C. (OrthoPro) in February 2014, and
legacy Tornier’s acquisition of OrthoHelix Surgical Designs, Inc. in 2012. Business combinations and acquiring new businesses
involve a myriad of risks. Whenever new businesses are combined or acquired, there is a risk we may fail to realize some or all
of the anticipated benefits of the transaction. This can occur if integration of the businesses proves to be more complicated than
planned, resulting in failure to realize operational synergies and/or failure to mitigate operational dis-synergies, diversion of
management attention, and loss of key personnel. It can also occur if the combined or acquired business fails to meet our net
sales projections, exposes us to unexpected liabilities, or if our pre-acquisition due diligence fails to uncover issues that
negatively affect the value or cost structure of the acquired enterprise. Although we carefully plan our business combinations
and acquisitions, there can be no assurances that these and other risks will not prevent us from realizing the expected benefits
of these transactions.
Product liability lawsuits could harm our business and adversely affect our operating results or results from discontinued
operations and financial condition if adverse outcomes exceed our product liability insurance coverage.
The manufacture and sale of medical devices expose us to significant risk of product liability claims. We are currently
defendants in a number of product liability matters, including those relating to the OrthoRecon business, which legacy Wright
divested to MicroPort in 2014. Legacy Wright remains responsible, as between it and MicroPort, for claims associated with
products sold before divesting the OrthoRecon business to MicroPort.
We have been named as a defendant, in some cases with multiple other defendants, in lawsuits in which it is alleged that as yet
unspecified defects in the design, manufacture, or labeling of certain metal-on-metal hip replacement products rendered the
products defective. The pre-trial management of certain of these claims has been consolidated in the federal court system, in the
United States District Court for the Northern District of Georgia under multi-district litigation and certain other claims by the
Judicial Counsel Coordinated Proceedings in state court in Los Angeles County, California. As of December 25, 2016, there
were approximately 1,200 lawsuits pending in the multi-district federal court proceeding and consolidated California state court
proceeding, and an additional 30 cases pending in various state courts. As of that date, we have also entered into approximately
950 so called “tolling agreements” with potential claimants who have not yet filed suit. As of December 25, 2016, there were
also approximately 50 non-U.S. lawsuits presently pending. We believe we have data that supports the efficacy and safety of
the metal-on-metal hip replacement systems, and have been vigorously defending these cases.
While continuing to dispute liability, on November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with
Court-appointed attorneys representing plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to
settle 1,292 specifically identified claims associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the
eligibility requirements of the MSA and are either pending in the MDL or JCCP, or subject to court-approved tolling
agreements in the MDL or JCCP, for a settlement amount of $240 million.
Claims for personal injury have also been made against us associated with fractures of legacy Wright’s PROFEMUR® long
titanium modular neck product. We believe that the overall fracture rate for the product is low and the fractures appear, at least
in part, to relate to patient demographics, and have been vigorously defending these matters. While continuing to dispute
28
liability, we have been open to settling these claims in circumstances where we believe the settlement amount is reasonable
relative to the risk and expense of litigation.
Our material product liability litigation is discussed in Note 16 to our consolidated financial statements in “Item 8. Financial
Statements and Supplementary Data” of this report. These matters are subject to many uncertainties and outcomes are not
predictable. Regardless of the outcome of these matters, legal defenses are costly. We have incurred and expect to continue to
incur substantial legal expenses in connection with the defense of these matters. We could incur significant liabilities
associated with adverse outcomes that exceed our products liability insurance coverage, which could adversely affect our
operating results or results from discontinued operations and financial condition. The ultimate cost to us with respect to
product liability claims could be materially different than the amount of the current estimates and accruals and could have a
material adverse effect on our financial position, operating results or results from discontinued operations, and cash flows.
In the future, we may be subject to additional product liability claims. We also could experience a material design or
manufacturing failure in our products, a quality system failure, other safety issues, or heightened regulatory scrutiny that would
warrant a recall of some of our products. Product liability lawsuits and claims, safety alerts and product recalls, regardless of
their ultimate outcome, could result in decreased demand for our products, injury to our reputation, significant litigation and
other costs, substantial monetary awards to or costly settlements with patients, product recalls, loss of revenue, and the inability
to commercialize new products or product candidates, and otherwise have a material adverse effect on our business and
reputation and on our ability to attract and retain customers.
Our agreement to settle a substantial portion of our metal-on-metal hip litigation claims is limited to approximately 1,292
qualifying revision claims and will leave a substantial number of metal-on-metal hip claims unresolved.
On November 1, 2016, our subsidiary Wright Medical Technology, Inc. (WMT) entered into a Master Settlement Agreement
(MSA) with Court-appointed attorneys representing plaintiffs in the previously disclosed metal-on-metal hip litigation known
as In Re: Wright Medical Technology, Inc., CONSERVE® Hip Implant Products Liability Litigation, MDL No. 2329 (MDL) and
In re: Wright Hip System Cases, Judicial Council Coordination Proceeding No. 4710 (JCCP). Under the terms of the MSA, the
parties agreed, without admission of fault, to settle 1,292 specifically identified CONSERVE, DYNASTY or LINEAGE
revision claims which meet the eligibility requirements of the MSA and are either pending in the MDL or JCCP, or are subject
to tolling agreements approved in the MDL or JCCP, for a total settlement amount of $240 million. While the minimum opt-in
requirement for the MSA has been satisfied, the final MSA settlement amount (not to exceed $240 million), and the final
number of claims settled under the MSA, will depend on, among other things, the mix of products implanted in the settling
claimant group. Claims which do not meet the eligibility requirements of the MSA, new claims, and claims which have opted-
out of the settlement will not be settled under the MSA. We will continue to defend these claims, and the previously disclosed
risks, uncertainties and contingencies associated with these claims will remain unresolved. As of December 25, 2016, we
estimate there were approximately 630 existing revision claims that are ineligible to participate in the MSA. For additional
information regarding the MSA, see Note 16 to our consolidated financial statements.
Our agreement with three insurance carriers to settle pending coverage litigation includes broad releases of coverage for
present and future claims of personal injury alleged to be caused by metal-on-metal hip components or the release of metal
ions, which could result in inadequate insurance coverage to defend and resolve these claims. In addition, our settlement with
the three carriers does not resolve previously disclosed disputes with the remaining carriers concerning the extent of coverage
available for metal-on-metal hip claims.
On October 28, 2016, our WMT and WMG subsidiaries entered into a Settlement Agreement with a subgroup of three
insurance carriers, Columbia Casualty Company, St. Paul Surplus Lines Insurance Company and AXIS Surplus Lines Insurance
Company (Three Settling Insurers), pursuant to which the Three Settling Insurers paid $60 million (in addition to $10 million
previously paid) in full settlement of all potential liability of the Three Settling Insurers for metal ion and metal-on-metal hip
claims, including but not limited to all claims in the MDL and the JCCP. As part of the settlement, the Three Settling Insurers
repurchased their policies in the five policy years beginning with the 2007-2008 policy year. Consequently, we have no further
coverage from the Three Settling Insurers for present or future metal-on-metal or metal ion claims falling in these five policy
periods, or any other period in which a specifically released claim is asserted.
Our existing product liability insurance coverage may be inadequate to protect us from any liabilities we might incur.
If the product liability claims brought against us involve uninsured liabilities or result in liabilities that exceed our insurance
coverage, our business, financial condition, and operating results could be materially and adversely affected. Further, such
product liability matters may negatively impact our ability to obtain insurance coverage or cost-effective insurance coverage in
future periods. We remain in litigation with certain insurance carriers other than the Three Settling Insurers, concerning the
amount of coverage available to satisfy potential liabilities associated with the metal-on-metal hip claims against us. An
29
unfavorable outcome in this litigation could have an adverse effect on our financial condition and results from discontinued
operations if we ultimately are subject to liabilities associated with these claims that exceed coverage amounts not in dispute.
In addition, on September 29, 2015, we received notice that the third insurance carrier in the tower for product liability
insurance coverage relating to personal injury claims associated with fractures of legacy Wright’s PROFEMUR® long titanium
modular neck product (Modular Neck Claims) has asserted that the terms and conditions identified in its reservation of rights
will preclude coverage for the Modular Neck Claims. We strongly dispute the carrier’s position and, in accordance with the
dispute resolution provisions of the policy, have initiated an arbitration proceeding in London, England seeking payment of
(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3) (cid:73)(cid:88)(cid:81)(cid:71)(cid:86)(cid:17)(cid:3) (cid:3)(cid:58)(cid:72)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3) (cid:69)(cid:72)(cid:79)(cid:76)(cid:72)(cid:89)(cid:72)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:68)(cid:70)(cid:87)(cid:86)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:76)(cid:81)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:70)(cid:68)(cid:85)(cid:85)(cid:76)(cid:72)(cid:85)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3) (cid:72)(cid:81)(cid:73)(cid:82)(cid:85)(cid:70)(cid:72)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3) (cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3)(cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3)
would be responsible for any amounts that our insurance carriers do not cover or for the amount by which ultimate losses
exceed the amount of our third-party insurance coverage. An unfavorable outcome in this matter could have an adverse effect
on our financial condition and results from discontinued operations if we ultimately are subject to liabilities associated with
these claims that exceed coverage amounts not in dispute.
MicroPort’s recall of certain sizes of its cobalt chrome modular neck devices due to alleged fractures could result in additional
product liability claims against us. Although we have contested these claims, adverse outcomes could harm our business and
adversely affect our results from discontinued operations and financial condition.
In August 2015, MicroPort announced the voluntary recall of certain sizes of its PROFEMUR® Long Cobalt Chrome Modular
Neck devices manufactured from June 15, 2009 to July 22, 2015. Because MicroPort did not acquire the OrthoRecon business
until January 2014, many of the recalled devices were sold by legacy Wright prior to the acquisition by MicroPort. Under the
asset purchase agreement with MicroPort, legacy Wright retained responsibility, as between it and MicroPort, for claims for
personal injury relating to sales of these products prior to the acquisition. We were not consulted by MicroPort in connection
with its recall, and we presently are aware of only eight lawsuits alleging personal injury related to cobalt chrome neck
fractures (three in the United States and five outside the United States). However, if the number of product liability claims
alleging personal injury from fractures of cobalt chrome modular necks we sold prior to the MicroPort transaction were to
become significant, this could have an adverse effect on our results from discontinued operations and financial condition.
A competitor’s recall of its modular hip systems, and the liability claims and adverse publicity which ensued, could generate
copycat claims against modular hip systems legacy Wright sold.
On July 6, 2012, Stryker Corporation announced the voluntary recall of its Rejuvenate Modular and ABG II modular neck hip
stems citing risks including the potential for fretting and/or corrosion at or about the modular neck junction. Although
Stryker’s recalled modular neck hip stems differ in design and material from the PROFEMUR® modular neck systems legacy
Wright sold before divestiture of the OrthoRecon business, we have previously noted the risk that Stryker’s recall and the
resultant publicity could negatively impact sales of modular neck systems of other manufacturers, including the PROFEMUR®
system, and that Stryker’s action has increased industry focus on the safety of cobalt chrome modular neck products. We have
carefully monitored the clinical performance of the PROFEMUR® modular neck hip system, which combine a cobalt chrome
modular neck and a titanium stem. With over 33,000 units sold since this version was introduced in 2009, and an extremely
low complaint rate, we remain confident in the safety and efficacy of this product. Nevertheless, in light of Stryker’s recall, the
resulting product liability claims to which it has been subject, and the general negative publicity surrounding “metal-on-metal”
articulating surfaces (which do not involve modular hip stems), there remains a risk that, even in the absence of clinical
evidence, claims for personal injury relating to sales of these products before divestiture of the OrthoRecon business could
increase, which could have an adverse effect on our financial condition and results from discontinued operations since legacy
Wright retained responsibility, as between it and MicroPort, for these claims.
Although we believe the use of corporate entities in our corporate structure will preclude creditors of any one particular entity
within our corporate structure from reaching the assets of the other entities within our corporate structure not liable for the
underlying claims of the one particular entity, there is a risk that, despite our corporate structure, creditors could be successful
in piercing the corporate veil and reaching the assets of such other entities, which could have an adverse effect on us and our
operating results, results from discontinued operations, and financial condition.
We maintain separate legal entities within our overall corporate structure. We believe our ring-fenced structure with separate
legal entities should preclude any corporate veil-piercing, alter ego, control person, or other similar claims by creditors of any
one particular entity within our corporate structure from reaching the assets of the other entities within our corporate structure
to satisfy claims of the one particular entity. However, if a court were to disagree and allow a creditor to pierce the corporate
veil and reach the assets of such other entities within our corporate structure, despite such entities not being liable for the
underlying claims, it could have a material adverse effect on us and our operating results, results from discontinued operations,
and financial condition.
30
Failure to comply with the U.S. Foreign Corrupt Practices Act or other anticorruption laws could subject us to, among other
things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business,
operating results and financial condition.
Our international operations expose us to legal and regulatory risks. These risks include the risk that our international
distributors could engage in conduct violative of U.S. or local laws, including the U.S. Foreign Corrupt Practices Act (FCPA).
Our U.S. operations, including those of our U.S. operating subsidiaries, are subject to the FCPA, which generally prohibits
covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for
the purpose of obtaining or retaining business or other benefits. In addition, the FCPA imposes accounting standards and
requirements on publicly-traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of
corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of “off books” slush
funds from which such improper payments can be made. We also are subject to similar anti-corruption legislation implemented
in Europe under the Organization for Economic Co-operation and Development’s Convention on Combating Bribery of
Foreign Public Officials in International Business Transactions. We either operate or plan to operate in a number of
jurisdictions that pose a high risk of potential violations of the FCPA and other anti-corruption laws, and we utilize a number of
third-party sales representatives for whose actions we could be held liable under the FCPA. We inform our personnel and third-
party sales representatives of the requirements of the FCPA and other anti-corruption laws, including, but not limited to their
reporting requirements. We also have developed and will continue to develop and implement systems for formalizing
contracting processes, performing due diligence on agents, and improving our recordkeeping and auditing practices regarding
these regulations. However, there is no guarantee that our employees, third-party sales representatives, or other agents have not
or will not engage in conduct undetected by our processes and for which we might be held responsible under the FCPA or other
anti-corruption laws. Failure to comply with the FCPA or other anti-corruption laws could subject us to, among other things,
penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial
condition, and operating results.
If our employees, third-party sales representatives, or other agents are found to have engaged in such practices, we could suffer
severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures, including further changes
or enhancements to our procedures, policies and controls, as well as potential personnel changes and disciplinary actions.
Recent investigations of companies in our industry by the SEC and the U.S. Department of Justice have focused on potential
FCPA violations in connection with the sale of medical devices in foreign countries. We believe we have compliance systems,
which enable us to prevent these behaviors. However, if despite our efforts we are not successful in mitigating these risks, we
could become the target of enforcement actions by U.S. or local authorities. Any investigation of any potential violations of the
FCPA or other anti-corruption laws by U.S. or foreign authorities could have a material adverse effect on our business,
operating results, and financial condition.
Certain foreign companies, including some of our competitors, are not subject to prohibitions as strict as those under the FCPA
or, even if subjected to strict prohibitions, such prohibitions may be laxly enforced in practice. If our competitors engage in
corruption, extortion, bribery, pay-offs, theft, or other fraudulent practices, they may receive preferential treatment from
personnel of some companies, giving our competitors an advantage in securing business, or from government officials, who
might give them priority in obtaining new licenses, which would put us at a disadvantage.
A significant portion of our product sales are made through independent distributors and sales agents who we do not control.
A significant portion of our product sales are made through independent sales representatives and distributors. Because the
independent distributor often controls the customer relationships within its territory (and, in certain countries outside the United
States, the regulatory relationship), there is a risk that if our relationship with the distributor ends, our relationship with the
customer will be lost (and, in certain countries outside the United States, that we could experience delays in amending or
transferring our product registrations). Also, because we do not control a distributor’s field sales agents, there is a risk we will
be unable to ensure that our sales processes, compliance, and other priorities will be consistently communicated and executed
by the distributor. If we fail to maintain relationships with our key distributors, or fail to ensure that our distributors adhere to
our sales processes, compliance, and other priorities, this could have an adverse effect on our operations. In the past, we have
experienced turnover within our independent distributor organization. This adversely affected our short-term financial results
as we transitioned to direct sales employees or new independent representatives. In addition, prior to the merger, legacy
Tornier transitioned to direct selling models in certain geographies and transitioned its U.S. sales channel towards focusing
separately on upper and lower extremities products. While we believe these transitions were managed effectively and position
us to leverage our sales force and broad product portfolio, there is a risk that these or future transitions could have a greater
adverse effect on our operations than we have previously experienced or anticipate. Further, the legacy independent
distributors and sales agents of Wright and Tornier may decide not to renew or may decide to seek to terminate, change and/or
renegotiate their relationships with us. A loss of a significant number of our distributors or agents could have a material adverse
effect on our business and results of operations.
31
In addition, our success is partially dependent upon our ability to retain and motivate our distributors, independent sales
agencies, and their representatives to sell our products in certain territories. They may not be successful in implementing our
marketing plans. Some of our distributors and independent sales agencies do not sell our products exclusively and may offer
similar products from other orthopaedic companies. Our distributors and independent sales agencies may terminate their
contracts with us, may devote insufficient sales efforts to our products, or may focus their sales efforts on other products that
produce greater commissions for them, which could have an adverse effect on our operations and operating results.
Allegations of wrongdoing by the United States Department of Justice and Office of the Inspector General of the United States
Department of Health and Human Services and related publicity could lead to further governmental investigations or actions
by other third parties.
As a result of the allegations of wrongdoing made by the United States Attorney’s Office for the District of New Jersey and the
publicity surrounding legacy Wright’s settlement with the United States Department of Justice and OIG-HHS, and amendments
to the Deferred Prosecution Agreement and Corporate Integrity Agreement, other governmental agencies, including state
authorities, could conduct investigations or institute proceedings that are not precluded by the terms of settlements reflected in
the Deferred Prosecution Agreement and the CIA. In August 2012, legacy Wright received a subpoena from the United States
Attorney’s Office for the Western District of Tennessee requesting records and documentation relating to the PROFEMUR®
series of hip replacement devices for the period from January 1, 2000 to August 2, 2012. These interactions with the authorities
could increase our exposure to lawsuits by potential whistleblowers, including under the U.S. Federal False Claims Act, based
on new theories or allegations arising from the allegations made by the United States Attorney’s Office for the District of New
Jersey. The costs of defending or resolving any such investigations or proceedings could have a material adverse effect on our
financial condition, operating results and cash flows.
If we lose any existing or future intellectual property lawsuits, a court could require us to pay significant damages or prevent us
from selling our products.
The medical device industry is litigious with respect to patents and other intellectual property rights. Companies in the medical
device industry have used intellectual property litigation to gain a competitive advantage.
We are party to claims and lawsuits involving patents or other intellectual property. Legal proceedings, regardless of the
outcome, could drain our financial resources and divert the time and effort of our management. If we lose one of these
proceedings, a court, or a similar foreign governing body, could require us to pay significant damages to third parties,
indemnify third parties from loss, require us to seek licenses from third parties, pay ongoing royalties, redesign our products, or
prevent us from manufacturing, using or selling our products. In addition to being costly, protracted litigation to defend or
prosecute our intellectual property rights could result in our customers or potential customers deferring or limiting their
purchase or use of the affected products until resolution of the litigation.
If our patents and other intellectual property rights do not adequately protect our products, we may lose market share to our
competitors and be unable to operate our business profitably.
We rely on patents, trade secrets, copyrights, know-how, trademarks, license agreements, and contractual provisions to
establish our intellectual property rights and protect our products. These legal means, however, afford only limited protection
and may not completely protect our rights. In addition, we cannot be assured that any of our pending patent applications will
issue. The U.S. Patent and Trademark Office may deny or require a significant narrowing of the claims in its pending patent
applications and the patents issuing from such applications. Any patents issuing from the pending patent applications may not
provide us with significant commercial protection. We could incur substantial costs in proceedings before the U.S. Patent and
Trademark Office. These proceedings could result in adverse decisions as to the priority of our inventions and the narrowing or
invalidation of claims in issued patents. In addition, the laws of some of the countries in which our products are or may be sold
may not protect our intellectual property to the same extent as U.S. laws or at all. We also may be unable to protect our rights
in trade secrets and unpatented proprietary technology in these countries.
In addition, we hold licenses from third parties that are necessary to utilize certain technologies used in the design and
manufacturing of some of our products. The loss of such licenses would prevent us from manufacturing, marketing, and selling
these products, which could harm our business. If we, or the other parties from whom we would license intellectual property,
fail to obtain and maintain adequate patent or other intellectual property protection for intellectual property used in our
products, or if any protection is reduced or eliminated, others could use the intellectual property used in our products, resulting
in harm to our competitive business position.
We seek to protect our trade secrets, know-how, and other unpatented proprietary technology, in part, with confidentiality
agreements with our employees, independent distributors, and consultants. We cannot be assured, however, that the agreements
32
will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how, and other
unpatented proprietary technology will not otherwise become known to or independently developed by our competitors.
If we lose one of our key suppliers, we may be unable to meet customer orders for our products in a timely manner or within
our budget, which could adversely affect our sales and operating results.
We rely on a limited number of suppliers for certain of the components and materials used in our products. Our reconstructive
joint devices are produced from various surgical grades of titanium, cobalt chrome, stainless steel, various grades of high-
density polyethylenes and ceramics. We rely on one source to supply us with a certain grade of cobalt chrome alloy, one
supplier for the silicone elastomer used in some of our extremities products, and one supplier for our pyrocarbon products, and
one supplier to provide a key ingredient of AUGMENT® Bone Graft. The manufacture of our products is highly exacting and
complex, and our business could suffer if a sole source supply arrangement is unexpectedly terminated or interrupted, and we
are unable to obtain an acceptable new source of supply in a timely fashion.
In April 2016, we entered into a commercial supply agreement with FUJIFILM Diosynth Biotechnologies U.S.A., Inc. pursuant
to which Fujifilm agreed to manufacture and sell to us and we agreed to purchase recombinant human platelet-derived growth
factor (rhPDGF-BB) for use in AUGMENT® Bone Graft. The agreement reflects the culmination of a technology transfer from
our former supplier to Fujifilm which began in December 2013 when we were notified that our former supplier was exiting the
rhPDGF-BB business. Pursuant to our supply agreement with Fujifilm, commercial production of rhPDGF-BB is expected to
begin in 2019. Although we believe that our current supply of rhPDGF-BB from our former supplier should be sufficient to last
until after rhPDGF-BB becomes available under the new agreement, no assurance can be provided that it will be sufficient. In
addition, since Fujifilm has not previously manufactured rhPDGF-BB, its ability to do so and perform its obligations under the
agreement are not yet fully proven.
Our biologic product line includes a single sourced supplier for our GRAFTJACKET® family of soft tissue repair and graft
containment products. In addition, certain biologic products depend upon a single supplier as our source for demineralized
bone matrix (DBM) and cancellous bone matrix (CBM), and any failure to obtain DBM and CBM from this source in a timely
manner will deplete levels of on-hand raw materials inventory and could interfere with our ability to process and distribute
allograft products. We rely on a single not-for-profit tissue bank to meet all of our DBM and CBM order requirements, a key
component in the allograft products we currently produce, market, and distribute. In addition, we rely on a single supplier of
soft tissue graft for BIOTAPE® XM.
We cannot be sure that our supply of DBM, CBM and soft tissue graft for BIOTAPE® XM will continue to be available at
current levels or will be sufficient to meet our needs, or that future suppliers of DBM, CBM, and soft tissue graft for
BIOTAPE® XM will be free from FDA regulatory action impacting their sale of DBM, CBM and soft tissue graft for
BIOTAPE® XM. As there are a small number of suppliers, if we cannot continue to obtain DBM, CBM, and soft tissue graft for
BIOTAPE® XM from our current sources in volumes sufficient to meet our needs, we may not be able to locate replacement
sources of DBM, CBM, and soft tissue graft for BIOTAPE® XM on commercially reasonable terms, if at all. This could
interrupt our business, which could adversely affect our sales.
Suppliers of raw materials and components may decide, or be required, for reasons beyond our control to cease supplying raw
materials and components to us. FDA regulations may require additional testing of any raw materials or components from new
suppliers prior to our use of these materials or components, and in the case of a device with a PMA application, we may be
required to obtain prior FDA permission, either of which could delay or prevent our access to or use of such raw materials or
components.
We are dependent on various information technology systems, and failures of, interruptions to, or unauthorized tampering of
those systems could have a material adverse effect on our business.
We rely extensively on information technology systems to conduct business. These systems include, but are not limited to,
ordering and managing materials from suppliers, converting materials to finished products, shipping products to customers,
processing transactions, summarizing and reporting results of operations, complying with regulatory, legal or tax requirements,
and providing data security and other processes necessary to manage our business. Since the merger and through the end of
2016, we have consolidated into one enterprise resource planning (ERP) system in three of our top five international markets,
and we plan to continue our ERP system roll-outs during 2017. We may experience difficulties in our business operations, or
difficulties in operating our business under the ERP, either of which could disrupt our operations, including our ability to timely
ship and track product orders, project inventory requirements, manage our supply chain, and otherwise adequately service our
customers, and lead to increased costs and other difficulties. In the event we experience significant disruptions as a result of
the ERP implementation or otherwise, we may not be able to fix our systems in an efficient and timely manner. Accordingly,
such events may disrupt or reduce the efficiency of our entire operations and have a material adverse effect on our operating
results and cash flows. In addition, if our systems are damaged or cease to function properly due to any number of causes,
33
ranging from catastrophic events to power outages to security breaches, and our business continuity plans do not effectively
compensate timely, we may suffer interruptions in our ability to manage operations.
Fluctuations in insurance cost and availability could adversely affect our profitability or our risk management profile.
We hold a number of insurance policies, including product liability insurance, directors’ and officers’ liability insurance,
property insurance, and workers’ compensation insurance. If the costs of maintaining adequate insurance coverage should
increase significantly in the future, our operating results could be materially adversely impacted. Likewise, if any of our
current insurance coverage should become unavailable to us or become economically impractical, we would be required to
operate our business without indemnity from commercial insurance providers.
Modifications to our marketed devices may require FDA regulatory clearances or approvals or require us to cease marketing
or recall the modified devices until such additional clearances or approvals are obtained.
The FDA requires device manufacturers to make a determination of whether or not a modification to a cleared and
commercialized medical device requires a new approval or clearance. However, the FDA can review a manufacturer’s decision
not to submit for additional approvals or clearances. Any modification to an FDA approved or cleared device that would
significantly affect its safety or efficacy or that would constitute a major change in its intended use would require a new PMA
or 510(k) clearance and could be considered misbranded if the modified device is commercialized and such additional approval
or clearance was not obtained. We cannot assure you that the FDA will agree with our decisions not to seek approvals or
clearances for particular device modifications or that we will be successful in obtaining additional approvals or 510(k)
clearances for modifications.
We obtained 510(k) premarket clearance for certain devices we market or marketed in the United States. We have subsequently
modified some of those devices or device labeling since obtaining 510(k) clearance under the view that these modifications did
not significantly affect the safety or efficacy of the device, and did not require new approvals or clearances. If the FDA
disagrees with our decisions and requires us to obtain additional premarket approvals or 510(k) clearances for any
modifications to our products and we fail to obtain such approvals or clearances or fail to secure approvals or clearances in a
timely manner, we may be required to cease manufacturing and marketing the modified device or to recall such modified
device until we obtain FDA approval or clearance and we may be subject to significant regulatory fines or penalties.
Although our Corporate Integrity Agreement expired, if we were found to have breached it, we may be subject to criminal
prosecution and/or exclusion from U.S. federal healthcare programs.
On September 29, 2010, Wright Medical Technology, Inc. entered into a 12-month Deferred Prosecution Agreement with the
United States Attorney’s Office for the District of New Jersey (USAO). On September 15, 2011, WMT reached an agreement
with the USAO and the OIG-HHS under which WMT voluntarily agreed to extend the term of its the Deferred Prosecution
Agreement for 12 months. On October 4, 2012, the USAO issued a press release announcing that the amended Deferred
Prosecution Agreement expired on September 29, 2012, that the USAO had moved to dismiss the criminal complaint against
WMT because WMT had fully complied with the terms of the Deferred Prosecution Agreement, and that the court had ordered
dismissal of the complaint on October 4, 2012. On September 29, 2010, WMT also entered into a five-year Corporate Integrity
Agreement with the Office of the Inspector General of the United States Department of Health and Human Services. The CIA
was filed as Exhibit 10.2 to legacy Wright’s Current Report on Form 8-K filed on September 30, 2010. The CIA expired on
September 29, 2015 and on January 27, 2016, we received notification from the OIG-HHS that the term of the CIA has
concluded. While the term of the CIA has concluded, our failure to continue to maintain compliance with U.S. healthcare laws,
regulations and other requirements in the future could expose us to significant liability, including, but not limited to, exclusion
from federal healthcare program participation, including Medicaid and Medicare, potential prosecution, civil and criminal fines
or penalties, as well as additional litigation cost and expense, which would have a material adverse effect on our financial
condition, operating results and cash flows.
The European Union and many of its world markets rely on the CE-Mark as the path to market our products.
The European Medical Device Directive requires that many of our products that bear the CE-Mark be supported by post-market
clinical data. We are in the process of implementing systems and procedures to control this activity in order to comply with
these requirements, including establishing contractual relationships with the healthcare provider clinical study sites in
accordance with our internal compliance requirements. We intend to obtain the needed clinical data to support our marketed
products, but there can be no assurance that European regulators will accept the results. This could potentially impact business
performance. In addition, changes to the certification and oversight responsibilities of notified bodies presently under
consideration by the European Commission, if implemented, could result in more stringent notified body oversight
requirements, require additional resources to maintain compliance, and increase the risk of negative audit observations.
34
Our biologics business is subject to emerging governmental regulations that can significantly impact our business.
The FDA has statutory authority to regulate allograft-based products, processing, and materials. The FDA, European Union
and Health Canada have been working to establish more comprehensive regulatory frameworks for allograft-based, tissue-
containing products, which are principally derived from cadaveric tissue. The framework developed by the FDA establishes
risk-based criteria for determining whether a particular human tissue-based product will be classified as human tissue, a
medical device, or biologic drug requiring 510(k) clearance or PMA approval. All tissue-based products are subject to
extensive FDA regulation, including establishment of registration requirements, product listing requirements, good tissue
practice requirements for manufacturing, and screening requirements that ensure that diseases are not transmitted to tissue
recipients. The FDA has also proposed extensive additional requirements addressing sub-contracted tissue services, traceability
to the recipient/patient, and donor records review. If a tissue-based product is considered human tissue, FDA requirements
focus on preventing the introduction, transmission, and spread of communicable diseases to recipients. Clinical data or review
of safety and efficacy is not required before the tissue can be marketed. However, if tissue is considered a medical device or
biologic drug, then FDA clearance or approval is required.
Additionally, our biologics business involves the procurement and transplantation of allograft tissue, which is subject to federal
regulation under the National Organ Transplant Act (NOTA). NOTA prohibits the sale of human organs, including bone and
other human tissue, for valuable consideration within the meaning of NOTA. NOTA permits the payment of reasonable
expenses associated with the transportation, processing, preservation, quality control, and storage of human tissue. We
currently charge our customers for these expenses. In the future, if NOTA is amended or reinterpreted, we may not be able to
charge these expenses to our customers, and, as a result, our business could be adversely affected.
Our principal allograft-based biologics offerings include ALLOMATRIX®, GRAFTJACKET® and IGNITE® products.
The results of our clinical trials may not support our product claims or may result in the discovery of adverse side effects.
Our ongoing research and development, pre-clinical testing, and clinical trial activities are subject to extensive regulation and
review by numerous governmental authorities both in the United States and abroad. We are currently conducting post-market
clinical studies of some of our products to gather additional information about these products’ safety, efficacy, or optimal use.
In the future we may conduct additional clinical trials to support approval of new products. Clinical studies must be conducted
in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical trials may
ultimately be used to support market approval or clearance for these products or gather additional information about approved
or cleared products. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our
product claims or that the FDA or foreign authorities will agree with our conclusions regarding them. Success in pre-clinical
testing and early clinical trials does not always ensure that later clinical trials will be successful, and we cannot be sure that the
later trials will replicate the results of prior trials and studies. The clinical trial process may fail to demonstrate that our
products are safe and effective for the proposed indicated uses, which could cause us to abandon a product and may delay
development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and,
ultimately, our ability to commercialize our products and generate revenue. It is also possible that patients enrolled in clinical
trials will experience adverse side effects that are not currently part of the product’s profile.
If the third parties on which we rely to conduct our clinical trials and to assist us with clinical development do not perform as
contractually required or expected, we may not be able to obtain, or in some cases, maintain regulatory clearance or approval
for or commercialize our products.
We often must rely on third parties, such as contract research organizations, medical institutions, clinical investigators, and
contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or
regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the
data they obtain is compromised due to their failure to adhere to our clinical protocols or regulatory requirements, or for other
reasons, our pre-clinical and clinical development activities or clinical trials may be extended, delayed, suspended, or
terminated, and we may not be able to obtain or, in some cases maintain, regulatory clearance or approval for, or successfully
commercialize, our products on a timely basis, if at all, and our business, operating results, and prospects may be adversely
affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons
outside of their control.
If we fail to compete successfully in the future against our existing or potential competitors, our sales and operating results
may be negatively affected, and we may not achieve future growth.
The markets for our products are highly competitive and subject to rapid and profound technological change. Our success
depends, in part, on our ability to maintain a competitive position in the development of technologies and products for use by
our customers. Many of the companies developing or marketing competitive products enjoy several competitive advantages
35
(cid:82)(cid:89)(cid:72)(cid:85)(cid:3) (cid:88)(cid:86)(cid:15)(cid:3) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3) (cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:75)(cid:88)(cid:80)(cid:68)(cid:81)(cid:3) (cid:85)(cid:72)(cid:86)(cid:82)(cid:88)(cid:85)(cid:70)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3) (cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3) (cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3) (cid:81)(cid:68)(cid:80)(cid:72)(cid:3)
(cid:85)(cid:72)(cid:70)(cid:82)(cid:74)(cid:81)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:72)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:72)(cid:71)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:75)(cid:76)(cid:83)(cid:86)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:86)(cid:88)(cid:85)(cid:74)(cid:72)(cid:82)(cid:81)(cid:86)(cid:15)(cid:3)(cid:75)(cid:82)(cid:86)(cid:83)(cid:76)(cid:87)(cid:68)(cid:79)(cid:86)(cid:3)(cid:68)nd third-(cid:83)(cid:68)(cid:85)(cid:87)(cid:92)(cid:3) (cid:83)(cid:68)(cid:92)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3) (cid:69)(cid:85)(cid:82)(cid:68)(cid:71)(cid:72)(cid:85)(cid:3) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3) (cid:79)(cid:76)(cid:81)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3) (cid:87)(cid:82)(cid:3)
(cid:82)(cid:73)(cid:73)(cid:72)(cid:85)(cid:3)(cid:85)(cid:72)(cid:69)(cid:68)(cid:87)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:69)(cid:88)(cid:81)(cid:71)(cid:79)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:73)(cid:73)(cid:72)(cid:85)(cid:3)(cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3)(cid:71)(cid:76)(cid:86)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:74)(cid:68)(cid:76)(cid:81)(cid:3)(cid:68)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:71)(cid:89)(cid:68)(cid:81)(cid:87)(cid:68)(cid:74)(cid:72)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:72)(cid:71)(cid:3)(cid:86)(cid:68)les
and marketing and distribution networks. Some of our competitors have indicated an increased focus on the extremities and
biologics markets, which are our primary strategic focus. Our competitors may develop and patent processes or products
earlier than us, obtain regulatory clearances or approvals for competing products more rapidly than us, develop more effective
or less expensive products or technologies that render our technology or products obsolete or non-competitive or acquire
technologies and technology licenses complementary to our products or advantageous to our business, which could adversely
affect our business and operating results. Not all of our sales and other personnel have non-compete agreements. We also
compete with other organizations in recruiting and retaining qualified scientific, sales, and management personnel. If our
competitors are more successful than us in these matters, we may be unable to compete successfully against our existing or
future competitors. In addition, the orthopaedic industry has been subject to increasing consolidation recently and over the last
few years. Consolidation in our industry not involving our company could result in existing competitors increasing their
market share through business combinations and result in stronger competitors, which could have a material adverse effect on
our business, financial condition, and operating results. We may be unable to compete successfully in an increasingly
consolidated industry and cannot predict with certainty how industry consolidation will affect our competitors or us.
We operate in markets outside the United States that are subject to political, economic, and social instability and expose us to
additional risks.
Operations in countries outside of the United States accounted for approximately 26% of our net sales for our fiscal year ended
December 25, 2016. Our operations outside of the United States are accompanied by certain financial and other risks. We
intend to continue to pursue growth opportunities in sales outside the United States, especially in emerging markets, which
could expose us to greater risks associated with international sales operations. Our international sales operations expose us and
our representatives, agents, and distributors to risks inherent in operating in foreign jurisdictions. These risks include:
•
the imposition of additional U.S. and foreign governmental controls or regulations on orthopaedic implants and
(cid:69)(cid:76)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)
•
•
•
•
•
•
• withdrawal from or revision to international trade agreements and the imposition or increases in import and export
licensing and other compliance requirements, customs duties and tariffs, import and export quotas and other trade
restrictions, license obligations, and other non-(cid:87)(cid:68)(cid:85)(cid:76)(cid:73)(cid:73)(cid:3)(cid:69)(cid:68)(cid:85)(cid:85)(cid:76)(cid:72)(cid:85)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)(cid:72)(cid:30)
unexpected changes in tariffs, trade barriers and regulatory requirem(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)
the imposition of U.S. or international sanctions against a country, company, person, or entity with whom we do
(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:90)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3)(cid:85)(cid:72)(cid:86)(cid:87)(cid:85)(cid:76)(cid:70)(cid:87)(cid:3)(cid:82)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:75)(cid:76)(cid:69)(cid:76)(cid:87)(cid:3)(cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:72)(cid:71)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:85)(cid:92)(cid:15)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:15)(cid:3)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:72)(cid:81)(cid:87)(cid:76)(cid:87)(cid:92)(cid:30)
economic instability, including (cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:69)(cid:72)(cid:87)(cid:90)(cid:72)(cid:72)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:3)(cid:71)(cid:82)(cid:79)(cid:79)(cid:68)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3)(cid:76)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:87)(cid:68)(cid:85)(cid:74)(cid:72)(cid:87)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:86)(cid:30)
(cid:72)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)(cid:76)(cid:70)(cid:3)(cid:90)(cid:72)(cid:68)(cid:78)(cid:81)(cid:72)(cid:86)(cid:86)(cid:15)(cid:3)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:73)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:83)(cid:82)(cid:79)(cid:76)(cid:87)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:86)(cid:87)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:76)(cid:81)(cid:3)(cid:83)(cid:68)(cid:85)(cid:87)(cid:76)(cid:70)(cid:88)(cid:79)(cid:68)(cid:85)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:72)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:86)(cid:30)
the imposition of restrictions on the activities of foreign (cid:68)(cid:74)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)
scrutiny of foreign tax authorities, which could result in significant fines, penalties, and additional taxes being
(cid:76)(cid:80)(cid:83)(cid:82)(cid:86)(cid:72)(cid:71)(cid:3)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:88)(cid:86)(cid:30)(cid:3)
a shortage of high-(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:83)(cid:72)(cid:82)(cid:83)(cid:79)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)
loss of any key personnel who possess proprietary knowledge or are otherwise important to our success in
(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:86)(cid:30)(cid:3)
changes in third-party reimbursement policy that may require some of the patients who receive our products to
(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:79)(cid:92)(cid:3)(cid:68)(cid:69)(cid:86)(cid:82)(cid:85)(cid:69)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:81)(cid:72)(cid:70)(cid:72)(cid:86)(cid:86)(cid:76)(cid:87)(cid:68)(cid:87)(cid:72)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:85)(cid:72)(cid:71)(cid:88)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)
•
unexpected changes in foreign regulatory requ(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)
•
(cid:71)(cid:76)(cid:73)(cid:73)(cid:72)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:79)(cid:82)(cid:70)(cid:68)(cid:79)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:83)(cid:85)(cid:72)(cid:73)(cid:72)(cid:85)(cid:72)(cid:81)(cid:70)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)
•
changes in tariffs and other trade restrictions, particularly related to the exportation of our biologic produ(cid:70)(cid:87)(cid:86)(cid:30)
• work stoppages or strikes in the healthcare industry, such as those that have affected our operations in France,
•
•
•
(cid:38)(cid:68)(cid:81)(cid:68)(cid:71)(cid:68)(cid:15)(cid:3)(cid:54)(cid:82)(cid:88)(cid:87)(cid:75)(cid:3)(cid:46)(cid:82)(cid:85)(cid:72)(cid:68)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:41)(cid:76)(cid:81)(cid:79)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:68)(cid:86)(cid:87)(cid:30)(cid:3)
(cid:71)(cid:76)(cid:73)(cid:73)(cid:76)(cid:70)(cid:88)(cid:79)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:72)(cid:81)(cid:73)(cid:82)(cid:85)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:72)(cid:73)(cid:72)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:79)(cid:79)(cid:72)(cid:70)(cid:87)(cid:88)(cid:68)(cid:79)(cid:3)(cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:87)(cid:92)(cid:3)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:86)(cid:30)(cid:3)
foreign currency exchange controls that might prevent us from repatriating cash earned in countries outside the
(cid:49)(cid:72)(cid:87)(cid:75)(cid:72)(cid:85)(cid:79)(cid:68)(cid:81)(cid:71)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:91)(cid:3)(cid:71)(cid:68)(cid:87)(cid:68)(cid:3)(cid:83)(cid:85)(cid:76)(cid:89)(cid:68)(cid:70)(cid:92)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:79)(cid:68)(cid:69)(cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:79)(cid:68)(cid:90)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
exposure to different legal and political standards due to our conducting business in over 50 countries.
•
•
•
•
In addition, on June 23, 2016, the United Kingdom held a referendum in which voters approved an exit from the European
Union, commonly referred to as “Brexit.” As a result of the referendum, negotiations will determine the future terms of the
United Kingdom’s relationship with the European Union, including the terms of trade between the United Kingdom and the
European Union. Although it is unknown what those terms will be, it is possible that there will be greater restrictions on the
movement of goods and people between the United Kingdom and European Union countries and increased regulatory
36
complexities, which could affect our ability to sell our products in certain European Union countries. Brexit could adversely
affect European and worldwide economic and market conditions and could contribute to instability in global financial and
foreign exchange markets, including volatility in the value of the British pound and Euro. In addition, other European countries
may seek to conduct referenda with respect to continuing membership with the European Union. We do not know to what
extent these changes will impact our business. Any of these effects of Brexit, and others that we cannot anticipate, could
adversely affect our business, operations and financial results.
Since we conduct operations through U.S. operating subsidiaries, not only are we subject to the laws of non-U.S. jurisdictions,
but we also are subject to U.S. laws governing our activities in foreign countries, such as the FCPA, as well as various import-
export laws, regulations, and embargoes. If our business activities were determined to violate these laws, regulations, or rules,
we could suffer serious consequences.
Healthcare regulation and reimbursement for medical devices vary significantly from country to country. This changing
environment could adversely affect our ability to sell our products in some jurisdictions.
We have a significant amount of indebtedness. We may not be able to generate enough cash flow from our operations to service
our indebtedness, and we may incur additional indebtedness in the future, which could adversely affect our business, financial
condition, and operating results.
We have a significant amount of indebtedness, including $395.0 million in aggregate principal with additional accrued interest
under our 2.25% cash convertible senior notes due 2021 (2021 Notes), $587.5 million in aggregate principal with additional
accrued interest under WMG’s 2.00% cash convertible senior notes due 2020, which Wright Medical Group N.V. has
guaranteed (2020 Notes), and $2.0 million in aggregate principal with additional accrued interest under WMG’s 2.00% cash
convertible senior notes due 2017 (2017 Notes, together with the 2020 and 2021 Notes, the Notes) as of December 25, 2016.
In addition, in December 2016, we entered into a credit, security and guaranty agreement (ABL Credit Agreement) with
Midcap Financial Trust and the additional lenders from time to time party thereto (ABL Lenders) which provides WMG and
certain of our other wholly-owned U.S. subsidiaries with a $150.0 million senior secured asset based line of credit, subject to
the satisfaction of a borrowing base requirement, and which may be increased by up to $100.0 million upon our request, subject
to the consent of the ABL Lenders (ABL Facility). As of December 25, 2016, $30.0 million in aggregate principal plus
additional accrued interest was outstanding under the ABL Facility.
Our ability to make payments on, and to refinance, our indebtedness, including the Notes and amounts borrowed under the
ABL Facility, and our ability to fund planned capital expenditures, contractual cash obligations, research and development
efforts, working capital, acquisitions, and other general corporate purposes depends on our ability to generate cash in the future.
This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory, and other factors, some
of which are beyond our control. If we do not generate sufficient cash flow from operations or if future borrowings are not
available to us in an amount sufficient to pay our indebtedness, including payments of principal upon conversion of outstanding
Notes or on their respective maturity dates or in connection with a transaction involving us that constitutes a fundamental
change under the respective indenture governing the Notes, or to fund our liquidity needs, we may be forced to refinance all or
a portion of our indebtedness on or before the maturity dates thereof, sell assets, reduce or delay capital expenditures, seek to
raise additional capital, or take other similar actions. We may not be able to execute any of these actions on commercially
reasonable terms or at all. Our ability to refinance our indebtedness will depend on our financial condition at the time, the
restrictions in the instruments governing our indebtedness, and other factors, including market conditions. In addition, in the
event of a default under the Notes or under the ABL Facility, the holders and/or the trustee under the indentures governing the
Notes or the lenders under the ABL Facility may accelerate payment obligations under the Notes and/or the amounts borrowed
under the ABL Facility, respectfully, which could have a material adverse effect on our business, financial condition, and
operating results. In addition, the Notes and ABL Facility contain cross default provisions. Our inability to generate sufficient
cash flow to satisfy our debt service obligations, or to refinance or restructure our obligations on commercially reasonable
terms or at all, would likely have an adverse effect, which could be material, on our business, financial condition, and operating
results.
In addition, our significant indebtedness, combined with our other financial obligations and contractual commitments, could
have other important consequences. For example, it could:
• make us more vulnerable to adverse changes in general U.S. and worldwide economic, industry, and competitive
(cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:71)(cid:89)(cid:72)(cid:85)(cid:86)(cid:72)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:74)(cid:82)(cid:89)(cid:72)(cid:85)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)
limit our flexibility in planning for, or reacting to, changes in (cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:76)(cid:81)(cid:71)(cid:88)(cid:86)(cid:87)(cid:85)(cid:92)(cid:30)
(cid:85)(cid:72)(cid:86)(cid:87)(cid:85)(cid:76)(cid:70)(cid:87)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:68)(cid:78)(cid:72)(cid:3)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:76)(cid:70)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:76)(cid:86)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:72)(cid:91)(cid:83)(cid:79)(cid:82)(cid:76)(cid:87)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)
(cid:83)(cid:79)(cid:68)(cid:70)(cid:72)(cid:3)(cid:88)(cid:86)(cid:3)(cid:68)(cid:87)(cid:3)(cid:68)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:71)(cid:76)(cid:86)(cid:68)(cid:71)(cid:89)(cid:68)(cid:81)(cid:87)(cid:68)(cid:74)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:85)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:3)(cid:90)(cid:75)(cid:82)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:79)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:72)(cid:69)(cid:87)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
•
•
•
37
•
limit our ability to borrow additional amounts for working capital, capital expenditures, contractual obligations,
research and development efforts, acquisitions, debt service requirements, execution of our business strategy, or
other purposes.
Any of these factors could materially and adversely affect our business, financial condition, and operating results. In addition,
we may incur additional indebtedness, and if we do, the risks related to our business and our ability to service our indebtedness
would increase.
In addition, under our Notes, we are required to offer to repurchase the Notes upon the occurrence of a fundamental change,
which could include, among other things, any acquisition of ours for consideration other than publicly traded securities. The
repurchase price must be paid in cash, and this obligation may have the effect of discouraging, delaying, or preventing an
acquisition of ours that would otherwise be beneficial to our security holders.
With respect to the 2021 Notes which have been issued by Wright Medical Group N.V., we are dependent on the cash flow of,
and dividends and distributions to us from, our subsidiaries in order to service our indebtedness under these Notes. Our
subsidiaries are separate and distinct legal entities and have no obligation, contingent or otherwise, to pay any amounts due
pursuant to any indebtedness of ours or to make any funds available therefor, except for those subsidiaries that have guaranteed
our obligations under our outstanding indebtedness. The ability of our subsidiaries to pay any dividends and distributions will
be subject to, among other things, the terms of any debt instruments of our subsidiaries then in effect as well as among other
things, the availability of profits or funds and requirements of applicable laws, including surplus, solvency and other limits
imposed on the ability of companies to pay dividends. There can be no assurance that our subsidiaries will generate cash flow
sufficient to pay dividends or distributions to us that enable us to pay interest or principal on our existing indebtedness.
A failure to comply with the covenants and other provisions of the indentures governing the Notes or the ABL Credit
Agreement could result in events of default under such indentures or ABL Credit Agreement, especially in light of the cross
default provisions, which could require the immediate repayment of our outstanding indebtedness. If we are at any time unable
to generate sufficient cash flows from operations to service our indebtedness when payment is due, we may be required to
attempt to renegotiate the terms of the indentures, the ABL Credit Agreement and other agreements relating to the indebtedness,
seek to refinance all or a portion of the indebtedness, or obtain additional financing. There can be no assurance that we will be
able to successfully renegotiate such terms, that any such refinancing would be possible, or that any additional financing could
be obtained on terms that are favorable or acceptable to us.
Hedge and warrant transactions entered into in connection with the issuance of our Notes may affect the value of our ordinary
shares.
In connection with the issuance of the Notes, we entered into hedge transactions with various financial institutions with the
objective of reducing the potential dilutive effect of issuing our ordinary shares upon conversion of the Notes and the potential
cash outlay from the cash conversion of the Notes. We also entered into separate warrant transactions with the same financial
institutions.
In connection with the hedge and warrant transactions associated with the Notes, these financial institutions purchased our
ordinary shares in secondary market transactions and entered into various over-the-counter derivative transactions with respect
to our ordinary shares. These entities or their affiliates are likely to modify their hedge positions from time to time prior to
conversion or maturity of the Notes by purchasing and selling our ordinary shares, other of our securities, or other instruments
they may wish to use in connection with such hedging. Any of these transactions and activities could adversely affect the value
of our ordinary shares and, as a result, the number and value of the ordinary shares holders will receive upon conversion of the
Notes . In addition, subject to movement in the price of our ordinary shares, if the hedge transactions settle in our favor, we
could be exposed to credit risk related to the other party with respect to the payment we are owed from such other party. If any
of the participants in the hedge transactions is unwilling or unable to perform its obligations for any reason, we would not be
able to receive the benefit of such transaction. We cannot provide any assurances as to the financial stability or viability of any
of the participants in the hedge transactions.
Rating agencies may provide unsolicited ratings on the Notes or the ABL Credit Agreement that could reduce the market value
or liquidity of our ordinary shares.
We have not requested a rating of the Notes or the ABL Credit Agreement from any rating agency and we do not anticipate that
the Notes or the ABL Credit Agreement will be rated. However, if one or more rating agencies independently elects to rate the
Notes or the ABL Credit Agreement and assigns the Notes or the ABL Credit Agreement a rating lower than the rating expected
by investors, or reduces such rating in the future, the market price or liquidity of the Notes or the ABL Credit Agreement and
our ordinary shares could be harmed. Should a decline in the market price of the Notes, as compared to the price of our
38
ordinary shares occur, this may trigger the right of the holders of the Notes to convert such notes into cash and our ordinary
shares, as applicable.
The terms of the ABL Credit Agreement could limit our ability to conduct our business, take advantage of business
opportunities and respond to changing business, market, and economic conditions.
Our ABL Credit Agreement includes a number of significant financial and operating restrictions. For example, the ABL Credit
Agreement contains financial covenants that, among other things, require us to maintain minimum liquidity and achieve certain
revenue thresholds and contains provisions that restrict our ability, subject to specified exceptions, to, among other things:
• (cid:80)(cid:68)(cid:78)(cid:72)(cid:3)(cid:79)(cid:82)(cid:68)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:86)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:73)(cid:73)(cid:76)(cid:79)(cid:76)(cid:68)(cid:87)(cid:72)(cid:86)(cid:30)
•
•
•
•
•
(cid:70)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:3)(cid:79)(cid:76)(cid:72)(cid:81)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:72)(cid:81)(cid:70)(cid:88)(cid:80)(cid:69)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:30)
(cid:71)(cid:76)(cid:86)(cid:83)(cid:82)(cid:86)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:30)
(cid:72)(cid:81)(cid:87)(cid:72)(cid:85)(cid:3)(cid:76)(cid:81)(cid:87)(cid:82)(cid:3)(cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:69)(cid:79)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)
(cid:72)(cid:81)(cid:74)(cid:68)(cid:74)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:82)(cid:79)(cid:76)(cid:71)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
pay dividends.
Due to the terms of the ABL Credit Agreement, we may be unable to comply with these covenants, which could result in a
default under the ABL Facility. In addition, these provisions may limit our ability to conduct our business, take advantage of
business opportunities, and respond to changing business, market, and economic conditions. In addition, they may place us at a
competitive disadvantage relative to other companies that may be subject to fewer, if any, restrictions or may otherwise
adversely affect our business. Transactions that we may view as important opportunities, such as significant acquisitions, may
be subject to the consent of the ABL Lenders, which consent may be withheld or granted subject to conditions specified at the
time that may affect the attractiveness or viability of the transaction.
The ABL Facility involves additional risks that may adversely affect our liquidity, results of operations, and financial condition.
Availability under the ABL Credit Agreement is based on the amount of certain eligible receivables, eligible equipment, eligible
inventory and eligible surgical instrumentation less specified reserves as described in Note 9 to our consolidated financial
statements. As a result, our access to credit under the ABL Facility is potentially subject to fluctuations depending on the value
of the eligible assets in the borrowing base as of any valuation date. Our inability to borrow additional amounts under the ABL
Facility may adversely affect our liquidity, results of operations, and financial condition. In addition, all payments on our
accounts receivable are required under the ABL Credit Agreement to be directed to deposit accounts under the control of the
ABL Facility lenders for application to amounts outstanding under the ABL Facility. The lenders may exercise control over
such amounts when they are entitled to exercise default remedies, which may adversely affect our ability to fund our
operations.
Our outstanding indebtedness under the ABL Facility bears interest at variable rates, which subjects us to interest rate risk and
could increase the cost of servicing our indebtedness. The impact of increases in interest rates could be more significant for us
than it would be for some other companies because of our indebtedness, thereby affecting our profitability. In the event of a
default under any of our debt instruments, the lenders under the ABL Facility may terminate their commitments to lend
additional money and declare all amounts outstanding thereunder to be immediately due and payable. Additionally, a default
under the ABL Facility could result in a cross-default under the Notes. While an event of default is continuing under the ABL
Credit Agreement the lenders thereunder may elect to increase the rates at which interest accrues. Subject to certain exceptions,
amounts outstanding under the ABL Facility are secured by a senior first priority security interest in substantially all existing
and after-acquired assets of our company and each borrower. Accordingly, under certain circumstances, the lenders under the
ABL Facility could seek to enforce security interests in our assets securing our indebtedness under the ABL Facility, including
restricting our access to collections on our accounts receivable. Any acceleration of amounts due under our ABL Credit
Agreement or the exercise by the lenders thereto of their rights under the security documents, would have a material adverse
effect on us. In addition, the ABL Facility is subject to market deterioration or other factors that could jeopardize the
counterparty obligations of one or more of the ABL Lenders, which could have an adverse effect on our business if we are not
able to replace such ABL Facility or find other sources of liquidity on acceptable terms.
We likely will need additional financing to satisfy our anticipated future liquidity requirements, which may not be available on
favorable terms at the time it is needed and which could reduce our operational and strategic flexibility.
Although it is difficult for us to predict our future liquidity requirements, we believe that our cash, cash equivalents and
restricted cash balance of approximately $412.3 million, together with $120.0 million in availability under our ABL Facility, as
of December 25, 2016 will be sufficient for at least the next 12 months to fund our working capital requirements and
operations, permit anticipated capital expenditures in 2017, pay retained liabilities of the OrthoRecon business, including
39
without limitation amounts under the MSA, and meet our anticipated contractual cash obligations in 2017. We may face
liquidity challenges during the next few years in light of anticipated significant contingent liabilities and financial obligations
and commitments, including among others, acquisition-related contingent consideration payments, payments related to our
outstanding indebtedness, and costs and payments related to pending litigation.
In the event that we would require additional working capital to fund future operations, we could seek to acquire that through
borrowings under the additional $100.0 million that may be available under the ABL Facility or additional equity or debt
financing arrangements which may or may not be available on favorable terms at such time. If we raise additional funds by
issuing equity securities, our shareholders may experience dilution. Additional debt financing, if available, may involve
additional covenants restricting our operations or our ability to incur additional debt, in addition to those under our existing
indentures and the ABL Credit Agreement. Any additional debt financing or additional equity that we raise may contain terms
that are not favorable to us or our shareholders. If we do not have, or are not able to obtain, sufficient funds, we may not be
able to develop or enhance our products, execute our business plan, take advantage of future opportunities, or respond to
competitive pressures or unanticipated customer requirements or we may have to delay development or commercialization of
our products or scale back our operations.
Worldwide economic instability could adversely affect our net sales, financial condition, or results of operations.
The health of the global economy, and the credit markets and the financial services industry in particular, affects our business
and operating results. While the health of the credit markets and the financial services industry appears to have stabilized, there
is no assurance that it will remain stable and there can be no assurance that there will not be deterioration in the global
economy. If the credit markets are not favorable, we may be unable to raise additional financing when needed or on favorable
terms. Our customers may experience financial difficulties or be unable to borrow money to fund their operations which may
adversely impact their ability to purchase our products or to pay for our products on a timely basis, if at all. In addition, any
economic crisis could also adversely impact our suppliers’ ability to provide us with materials and components, either of which
may negatively impact our business. As with our customers and vendors, these economic conditions make it more difficult for
us to accurately forecast and plan our future business activities. Further, there are concerns for the overall stability and
suitability of the Euro as a single currency, given the economic and political challenges facing individual Eurozone countries
and Brexit. Continuing deterioration in the creditworthiness of the Eurozone countries, the withdrawal of one or more member
countries from the European Union, or the failure of the Euro as a common European currency could adversely affect our sales,
financial condition, or operating results.
The collectability of our accounts receivable may be affected by general economic conditions.
Our liquidity is dependent on, among other things, the collection of our accounts receivable. Collections of our receivables
may be affected by general economic conditions. Although current economic conditions have not had a material adverse effect
on our ability to collect such receivables, we can make no assurances regarding future economic conditions or their effect on
our ability to collect our receivables, particularly from our international stocking distributors. In addition, some of our trade
receivables are with national health care systems in many countries (including, but not limited to, Greece, Ireland, Portugal, and
Spain). Repayment of these receivables is dependent upon the financial stability of the economies of those countries. In light
of these global economic fluctuations, we continue to monitor the creditworthiness of customers located outside of the United
States. Failure to receive payment of all or a significant portion of these receivables could adversely affect our operating
results.
If we are unable to continue to develop and market new products and technologies, we may experience a decrease in demand
for our products, or our products could become obsolete, and our business would suffer.
We are continually engaged in product development and improvement programs, and new products represent a significant
component of our sales growth rate. We may be unable to compete effectively with our competitors unless we can keep up
with existing or new products and technologies in the orthopaedic market. If we do not continue to introduce new products and
technologies, or if those products and technologies are not accepted, we may not be successful. Moreover, research and
development efforts may require a substantial investment of time and resources before we are adequately able to determine the
commercial viability of a new product, technology, material, or innovation. Demand for our products also could change in
ways we may not anticipate due to evolving customer needs, changing demographics, slow industry growth rates, declines in
the extremities and biologics market, the introduction of new products and technologies, evolving surgical philosophies, and
evolving industry standards, among others. Additionally, our competitors’ new products and technologies may beat our
products to market, may be more effective or less expensive than our products, or may render our products obsolete. Our new
products and technologies also could render our existing products obsolete and thus adversely affect sales of our existing
products and lead to increased expense for excess and obsolete inventory.
40
Our inability to maintain contractual relationships with healthcare professionals could have a negative impact on our research
and development and medical education programs.
We maintain contractual relationships with respected surgeons and medical personnel in hospitals and universities who assist in
product research and development and in the training of surgeons on the safe and effective use of our products. We continue to
place emphasis on the development of proprietary products and product improvements to complement and expand our existing
product lines as well as providing high quality training on those products. If we are unable to maintain these relationships, our
ability to develop and market new and improved products and train on the use of those products could decrease, and our future
operating results could be unfavorably affected. In addition, it is possible that U.S. federal and state and international laws
requiring us to disclose payments or other transfers of value, such as free gifts or meals, to surgeons and other healthcare
providers could have a chilling effect on these relationships with individuals or entities that may, among other things, want to
avoid public scrutiny of their financial relationships with us.
Our business could suffer if the medical community does not continue to accept allograft technology.
New allograft products, technologies, and enhancements may never achieve broad market acceptance due to numerous factors,
including:
•
•
•
•
•
•
(cid:79)(cid:68)(cid:70)(cid:78)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:79)(cid:76)(cid:81)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:68)(cid:70)(cid:70)(cid:72)(cid:83)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:79)(cid:79)(cid:82)(cid:74)(cid:85)(cid:68)(cid:73)(cid:87)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)
the introduction of competitive tissue repair treatment options that render allograft products and technologies too
(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:69)(cid:86)(cid:82)(cid:79)(cid:72)(cid:87)(cid:72)(cid:30)(cid:3)
lack of available third-party reimburs(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:85)(cid:68)(cid:76)(cid:81)(cid:3)(cid:86)(cid:88)(cid:85)(cid:74)(cid:72)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:88)(cid:86)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:79)(cid:79)(cid:82)(cid:74)(cid:85)(cid:68)(cid:73)(cid:87)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:86)(cid:72)(cid:68)(cid:86)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:80)(cid:76)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
ethical concerns about the commercial aspects of harvesting cadaveric tissue.
Market acceptance also will depend on the ability to demonstrate that existing and new allograft products and technologies are
attractive alternatives to existing tissue repair treatment options. To demonstrate this, we rely upon surgeon evaluations of the
clinical safety, efficacy, ease of use, reliability, and cost effectiveness of our tissue repair options and technologies.
Recommendations and endorsements by influential surgeons are important to the commercial success of allograft products and
technologies. In addition, several countries, notably Japan, prohibit the use of allografts. If allograft products and technologies
are not broadly accepted in the marketplace, we may not achieve a competitive position in the market.
If adequate levels of reimbursement from third-party payors for our products are not obtained, surgeons and patients may be
reluctant to use our products and our sales may decline.
In the United States, healthcare providers who purchase our products generally rely on third-party payors, principally U.S.
federally-funded Medicare, state-funded Medicaid, and private health insurance plans, to pay for all or a portion of the cost of
joint reconstructive procedures and products utilized in those procedures. We may be unable to sell our products on a profitable
basis if third-party payors deny coverage or reduce their current levels of reimbursement. Our sales depend largely on
governmental healthcare programs and private health insurers reimbursing patients’ medical expenses. Surgeons, hospitals,
and other healthcare providers may not purchase our products if they do not receive appropriate reimbursement from third-
party payors for procedures using our products. In light of healthcare reform measures, payors continue to review their
coverage policies for existing and new therapies and may deny coverage for treatments that include the use of our products.
In addition, some healthcare providers in the United States have adopted or are considering bundled payment methodologies
and/or managed care systems in which the providers contract to provide comprehensive healthcare for a fixed cost per person.
Healthcare providers may attempt to control costs by authorizing fewer elective surgical procedures, including joint
reconstructive surgeries, or by requiring the use of the least expensive implant available. Changes in reimbursement policies or
healthcare cost containment initiatives that limit or restrict reimbursement for our products may cause our sales to decline.
If adequate levels of reimbursement from third-party payors outside of the United States are not obtained, international sales of
our products may decline. Outside of the United States, reimbursement systems vary significantly by country. Many foreign
markets have government-managed healthcare systems that govern reimbursement for medical devices and procedures.
Canada, and some European and Asian countries, in particular France, Japan, Taiwan, and South Korea, have tightened
reimbursement rates. Additionally, Brazil, China, Russia, and the United Kingdom have recently begun landmark reforms that
will significantly alter their healthcare systems. Finally, some foreign reimbursement systems provide for limited payments in
a given period and therefore result in extended payment periods.
41
Our business could be significantly and adversely impacted by healthcare reform legislation.
Comprehensive healthcare reform legislation has significantly and adversely impacted our business. For example, the
Affordable Care Act imposed a 2.3% excise tax on U.S. sales of medical devices. Although the medical device excise tax is
currently suspended until December 31, 2017, it is possible that the suspension may be lifted or expire. The Affordable Care
Act also includes numerous provisions to limit Medicare spending through reductions in various fee schedule payments and by
instituting more sweeping payment reforms, such as bundled payments for episodes of care and the establishment of
“accountable care organizations” under which hospitals and physicians will be able to share savings that result from cost
control efforts. Many of these provisions will be implemented through the regulatory process, and policy details have not yet
been finalized. Various healthcare reform proposals have also emerged at the state level. We cannot predict with certainty the
impact that these U.S. federal and state health reforms will have on us. However, an expansion in government’s role in the
U.S. healthcare industry may lower reimbursements for products, reduce medical procedure volumes, and adversely affect our
business and operating results, possibly materially.
There is an increasing trend for more criminal prosecutions and compliance enforcement activities for noncompliance with the
Health Insurance Portability and Accountability Act (HIPAA) as well as for data breaches involving protected health
information (PHI). In the ordinary course of our business, we may receive PHI. If we are unable to comply with HIPAA or
experiences a data breach involving PHI, we could be subject to criminal and civil sanctions.
If we cannot retain our key personnel, we may be unable to manage and operate our business successfully and meet our
strategic objectives.
Our future success depends, in part, upon our ability to retain and motivate key managerial, scientific, sales, and technical
personnel, as well as our ability to continue to attract and retain additional highly qualified personnel. We compete for such
personnel with other companies, academic institutions, governmental entities, and other organizations. There can be no
assurance that we will be successful in retaining our current personnel or in hiring or retaining qualified personnel in the future.
Key personnel may depart because of difficulties with change or a desire not to remain with our company, especially in light of
the Wright/Tornier merger. Any unanticipated loss or interruption of services of our management team and our key personnel
could significantly reduce our ability to meet our strategic objectives because it may not be possible for us to find appropriate
replacement personnel should the need arise. Loss of key personnel or the inability to hire or retain qualified personnel in the
future could have a material adverse effect on our ability to operate successfully. Further, any inability on our part to enforce
non-compete or non-solicitation arrangements related to key personnel who have left the business could have a material
adverse effect on our business.
If a natural or man-made disaster adversely affects our manufacturing facilities or distribution channels, we could be unable to
manufacture or distribute our products for a substantial amount of time, and our sales could be disrupted.
We principally rely on four manufacturing facilities, two of which are in France, one of which is in Ireland and one of which is
in Arlington, Tennessee. The facilities and the manufacturing equipment we use to produce our products would be difficult to
replace and could require substantial lead-time to repair or replace. For example, the machinery associated with our
manufacturing of pyrocarbon in one of our French facilities is highly specialized and would take substantial lead-time and
resources to replace. We also maintain a facility in Bloomington, Minnesota, a facility in Arlington, Tennessee, and a
warehouse in Montbonnot, France, which contain large amounts of our inventory. Our facilities, warehouses, or distribution
channels may be affected by natural or man-made disasters. For example, in the event of a natural or man-made disaster at one
of our warehouses, we may lose substantial amounts of inventory that would be difficult to replace. Our manufacturing facility
in Arlington, Tennessee is located near the New Madrid fault line. In the event our facilities, warehouses, or distribution
channels are affected by a disaster, we would be forced to rely on, among others, third-party manufacturers and alternative
warehouse space and distribution channels, which may or may not be available, and our sales could decline. Although we
believe we have adequate disaster recovery plans in place and possess adequate insurance for damage to our property and the
disruption of our business from casualties, such plans and insurance may not cover such disasters or be sufficient to cover all of
our potential losses and may not continue to be available to us on acceptable terms or at all.
To the extent transition activities related to the sale of our Large Joints business divert management attention or manufacturing
resources from our ongoing operations, or add additional costs to these operations, this could have an adverse effect on our
business.
On October 21, 2016, we sold our Large Joints business to Corin Orthopaedics Holdings Limited (Corin). In connection with
the transaction, we entered into a transitional services agreement pursuant to which we agreed to provide Corin certain support
services and a supply agreement pursuant to which we agreed to manufacture certain of the large joints products for Corin, in
each case for a transitional period of time. Our post-closing obligations under the transitional services agreement and supply
agreement require us to dedicate substantial resources, personnel and manufacturing capacity that may add costs to our ongoing
42
business, cause us to incur unanticipated costs and liabilities or result in manufacturing delays with respect to the production
and delivery of our own products.
Our business plan relies on certain assumptions about the markets for our products, which, if incorrect, may adversely affect
our business and operating results.
We believe that the aging of the general population and increasingly active lifestyles will continue and that these trends will
increase the need for our extremities and biologics products. The projected demand for our products could materially differ
from actual demand if our assumptions regarding these trends and acceptance of our products by the medical community prove
to be incorrect or do not materialize, or if non-surgical treatments gain more widespread acceptance as a viable alternative to
orthopaedic implants.
Fluctuations in foreign currency exchange rates could result in declines in our reported net sales and earnings.
Because a majority of our international sales are denominated in local currencies and not in U.S. dollars, our reported net sales
and earnings are subject to fluctuations in foreign currency exchange rates. Foreign currency exchange rate fluctuations
negatively impacted our net sales by $4.7 million during 2016. Operating costs related to these sales are largely denominated
in the same respective currencies, thereby partially limiting our transaction risk exposure. However, cost of sales related to
(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:83)(cid:85)(cid:76)(cid:80)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)(cid:3)(cid:71)(cid:72)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:3)(cid:71)(cid:82)(cid:79)(cid:79)(cid:68)(cid:85)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:68)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:3)(cid:71)(cid:82)(cid:79)(cid:79)(cid:68)(cid:85)(cid:3)(cid:86)(cid:87)(cid:85)(cid:72)(cid:81)(cid:74)(cid:87)(cid:75)(cid:72)(cid:81)(cid:86)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:74)(cid:85)(cid:82)(cid:86)(cid:86)(cid:3)(cid:80)(cid:68)(cid:85)(cid:74)(cid:76)(cid:81)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71) with
our sales denominated in foreign currencies experience declines.
We have employed a derivative program using foreign currency forward contracts to mitigate the risk of currency fluctuations
on our intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts are
expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts are not
designated as hedging instruments under Financial Accounting Standards Board (FASB) Accounting Standard Codification
(ASC) Section 815, Derivatives and Hedging Activities. Accordingly, the changes in the fair value and the settlement of the
contracts are recognized in the period incurred. Although we address currency risk management through regular operating and
financing activities, and more recently through hedging activities, these actions may not prove to be fully effective, and
hedging activities involve additional risks.
We incur significant expenditures of resources to maintain relatively high levels of instruments and we historically have had a
high level of inventory, which can adversely affect our operating results and reduce our cash flows.
The nature of our business requires us to maintain a certain level of instruments since in order to market effectively we often
must maintain and bring our customers instrument kits. In addition, we historically have maintained extra inventory in the
form of back-up products and products of different size in order to ensure that our customers have the right products when they
need them. This practice has resulted in us maintaining a relatively high level of inventory, which can adversely affect our
operating results and reduce our cash flows. In addition, to the extent that a substantial portion of our inventory becomes
obsolete, it could have a material adverse effect on our earnings and cash flows due to the resulting costs associated with
inventory impairment charges and costs required to replace such inventory.
Our quarterly operating results are subject to substantial fluctuations, and you should not rely on them as an indication of our
future results.
Our quarterly operating results may vary significantly due to a combination of factors, many of which are beyond our control.
These factors include:
•
•
•
•
•
•
•
•
•
•
•
(cid:71)(cid:72)(cid:80)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:15)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:75)(cid:76)(cid:86)(cid:87)(cid:82)(cid:85)(cid:76)(cid:70)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:75)(cid:68)(cid:86)(cid:3)(cid:69)(cid:72)(cid:72)(cid:81)(cid:3)(cid:79)(cid:82)(cid:90)(cid:72)(cid:86)(cid:87)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:30)(cid:3)
(cid:82)(cid:88)(cid:85)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:72)(cid:72)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:71)(cid:72)(cid:80)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)
the number, timing, and significance of new products and product introductions and enhancements by us and our
(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)
(cid:82)(cid:88)(cid:85)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:71)(cid:72)(cid:89)(cid:72)(cid:79)(cid:82)(cid:83)(cid:15)(cid:3)(cid:76)(cid:81)(cid:87)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:72)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:81)(cid:75)(cid:68)(cid:81)(cid:70)(cid:72)(cid:71)(cid:3)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:68)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:79)(cid:92)(cid:3)(cid:69)(cid:68)(cid:86)(cid:76)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:85)(cid:3)(cid:73)(cid:68)(cid:76)(cid:79)(cid:88)(cid:85)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:69)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:70)(cid:79)(cid:72)(cid:68)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:82)(cid:79)(cid:76)(cid:70)(cid:76)(cid:72)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:88)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:85)(cid:72)(cid:68)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:83)(cid:85)(cid:68)(cid:70)(cid:87)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:85)(cid:87)(cid:75)(cid:82)(cid:83)(cid:68)(cid:72)(cid:71)(cid:76)(cid:70)(cid:3)(cid:86)(cid:88)(cid:85)(cid:74)(cid:72)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:75)(cid:76)(cid:83)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:70)(cid:72)(cid:3)(cid:86)(cid:76)(cid:93)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)
the timing of material expense- or income-generating events and the related recognition of their associated
(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:76)(cid:80)(cid:83)(cid:68)(cid:70)(cid:87)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:76)(cid:91)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:86)(cid:82)(cid:79)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:74)(cid:72)(cid:82)(cid:74)(cid:85)(cid:68)(cid:83)(cid:75)(cid:76)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:92)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:86)(cid:82)(cid:79)(cid:71)(cid:30)(cid:3)
43
•
•
•
•
•
•
(cid:87)(cid:75)(cid:72)(cid:3)(cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:89)(cid:68)(cid:76)(cid:79)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:82)(cid:81)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:87)(cid:72)(cid:85)(cid:76)(cid:68)(cid:79)(cid:86)(cid:30)(cid:3)
(cid:83)(cid:85)(cid:72)(cid:89)(cid:68)(cid:76)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:86)(cid:86)(cid:3)(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:86)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:73)(cid:79)(cid:88)(cid:70)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:3)(cid:72)(cid:91)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87)(cid:3)(cid:82)(cid:85)(cid:71)(cid:72)(cid:85)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:75)(cid:76)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)
ability to obtain reimbursement for our products and the timing of patients’ use of their calendar year medical
(cid:76)(cid:81)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:71)(cid:72)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:69)(cid:79)(cid:72)(cid:86)(cid:30)(cid:3)
• (cid:90)(cid:82)(cid:85)(cid:78)(cid:3)(cid:86)(cid:87)(cid:82)(cid:83)(cid:83)(cid:68)(cid:74)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:87)(cid:85)(cid:76)(cid:78)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:75)(cid:72)(cid:68)(cid:79)(cid:87)(cid:75)(cid:70)(cid:68)(cid:85)(cid:72)(cid:3)(cid:76)(cid:81)(cid:71)(cid:88)(cid:86)(cid:87)(cid:85)(cid:92)(cid:30)(cid:3)
•
•
•
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:41)(cid:39)(cid:36)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:74)(cid:82)(cid:89)(cid:72)(cid:85)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:68)(cid:79)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:83)(cid:82)(cid:79)(cid:76)(cid:70)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:81)(cid:73)(cid:82)(cid:85)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:83)(cid:85)(cid:68)(cid:70)(cid:87)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:82)(cid:79)(cid:76)(cid:70)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3)(cid:72)(cid:86)(cid:87)(cid:76)(cid:80)(cid:68)(cid:87)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:85)(cid:72)(cid:68)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)
restructuring, impairment, and other special charges, costs associated with our pending litigation and U.S.
(cid:74)(cid:82)(cid:89)(cid:72)(cid:85)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:84)(cid:88)(cid:76)(cid:85)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)
variations in cost of sales due to the amount and timing of excess and obsolete inventory charges, commodity
(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:89)(cid:68)(cid:85)(cid:76)(cid:68)(cid:81)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)
(cid:76)(cid:81)(cid:70)(cid:82)(cid:80)(cid:72)(cid:3)(cid:87)(cid:68)(cid:91)(cid:3)(cid:73)(cid:79)(cid:88)(cid:70)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:3)(cid:72)(cid:70)(cid:82)(cid:81)(cid:82)(cid:80)(cid:76)(cid:70)(cid:3)(cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
increases of interest rates, which can increase the cost of borrowings under our ABL Credit Agreement, and
generally affect the level of economic activity.
•
•
•
•
We believe our quarterly sales and operating results may vary significantly in the future and period-to-period comparisons of
our results of operations are not necessarily meaningful and should not be relied upon as indications of future performance. We
cannot assure you that our sales will increase or be sustained in future periods or that we will be profitable in any future period.
Any shortfalls in sales or earnings from levels expected by securities or orthopaedic industry analysts could have an immediate
and significant adverse effect on the trading price of our ordinary shares in any given period.
We may not achieve our financial guidance or projected goals and objectives in the time periods that we anticipate or
announce publicly, which could have an adverse effect on our business and could cause the market price of our ordinary shares
to decline.
We typically provide projected financial information, such as our anticipated annual net sales, adjusted earnings and adjusted
earnings before interest, taxes, depreciation, and amortization. These financial projections are based on management’s then
current expectations and typically do not contain any significant margin of error or cushion for any specific uncertainties or for
the uncertainties inherent in all financial forecasting. The failure to achieve our financial projections or the projections of
analysts and investors could have an adverse effect on our business, disappoint analysts and investors, and cause the market
price of our ordinary shares to decline. Our net sales performance has been outside of our guidance range in certain quarters,
which negatively impacted the market price of our ordinary shares, and could do so in the future should our results fall below
our guidance range and the expectations of analysts and investors.
We also set goals and objectives for, and make public statements regarding, the timing of certain accomplishments and
milestones regarding our business or operating results, such as the timing of financial objectives, new products, regulatory
actions, pending litigation, and anticipated distributor and sales representative transitions. The actual timing of these events can
vary dramatically due to a number of factors, including the risk factors described in this report. As a result, there can be no
assurance that we will succeed in achieving our projected goals and objectives in the time periods that we anticipate or
announce publicly. The failure to achieve such projected goals and objectives in the time periods that we anticipate or
announce publicly could have an adverse effect on our business, disappoint investors and analysts, and cause the market price
of our ordinary shares to decline.
We are subject to additional risks in light of the material weakness that we have recently identified.
Effective internal controls are necessary for us to provide reliable and accurate financial reports and to effectively prevent
fraud. The integration of combined or acquired businesses is likely to result in our systems and controls becoming increasingly
complex and more difficult to manage. We devote significant resources and time to comply with the internal control over
financial reporting requirements of the Sarbanes-Oxley Act of 2002. However, we cannot be certain that these measures will
ensure that we design, implement, and maintain adequate control over our financial processes and reporting in the future,
especially in the context of acquisitions of other businesses.
As further described in Item 9A of this report, in the course of completing our assessment of internal control over financial
reporting as of December 25, 2016, management identified a material weakness in our internal control over financial reporting
related to information technology general controls. A “material weakness” is a deficiency, or a combination of deficiencies, in
internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or
44
interim financial statements would not be prevented or detected on a timely basis. As a result, management has concluded that,
because of this material weakness in our internal control over financial reporting, our internal control over financial reporting
and our disclosure controls and procedures were not effective as of December 25, 2016. If we fail to complete the remediation
of this material weakness in our internal control, or after having remediated such material weakness, thereafter fail to maintain
the adequacy of our internal control over financial reporting or our disclosure controls and procedures, we could be subjected to
regulatory scrutiny, civil or criminal penalties or shareholder litigation, the defense of any of which could cause the diversion of
management’s attention and resources, we could incur significant legal and other expenses, and we could be required to pay
damages to settle such actions if any such actions were not resolved in our favor. Continued or future failure to maintain
adequate internal control over financial reporting could also result in financial statements that do not accurately reflect our
financial condition or results of operations. There can be no assurance that we will not conclude in the future that this material
weakness continues to exist or that we will not identify any significant deficiencies or other material weaknesses that will
impair our ability to report our financial condition and results of operations accurately or on a timely basis. Inferior internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our ordinary shares and our access to capital.
We may be unable to maintain competitive global cash management and a competitive effective corporate tax rate.
We cannot give any assurance as to our future effective tax rate because of, among other things, uncertainty regarding the tax
policies of the jurisdictions where we operate and uncertainty regarding the level of net income that we will earn in those
jurisdictions in the future. Our actual effective tax rate may vary from this expectation and that variance may be material.
Additionally, the tax laws of the Netherlands and other jurisdictions in which we operate could change in the future, and such
changes could cause a material change in our effective tax rate.
Our provision for income taxes will be based on certain estimates and assumptions made by management in consultation with
our tax and other advisors. Our group income tax rate will be affected by, among other factors, the amount of net income
earned in our various operating jurisdictions, the availability of benefits under tax treaties, the rates of taxes payable in respect
of that income, and withholding taxes on dividends paid from one jurisdiction to the next. We will enter into many transactions
and arrangements in the ordinary course of business in respect of which the tax treatment is not entirely certain. We will,
therefore, make estimates and judgments based on our knowledge and understanding of applicable tax laws and tax treaties,
and the application of those tax laws and tax treaties to our business, in determining our consolidated tax provision. For
example, certain countries could seek to tax a greater share of income than will be provided for by us. The final outcome of
any audits by taxation authorities may differ from the estimates and assumptions we may use in determining our consolidated
tax provisions and accruals. This could result in a material adverse effect on our consolidated income tax provision, financial
condition, and the net income for the period in which such determinations are made.
In particular, dividends, distributions, and other intra-group payments from our U.S. affiliates to certain of our non-U.S.
subsidiaries may be subject to U.S. withholding tax at a rate of 30% unless the entity receiving such payments can demonstrate
that it qualifies for reduction or elimination of the U.S. withholding tax under the income tax treaty (if any) between the United
States and the jurisdiction in which the entity is organized or is a tax resident. In certain cases, treaty qualification may depend
on whether at least 50% of our ultimate beneficial owners are qualified residents of the United States or the treaty jurisdiction
within the meaning of the applicable treaty. There can be no assurance that we will satisfy this beneficial ownership
requirement at the time when such dividends, distributions, or other payments are made. Moreover, the U.S. Internal Revenue
Service (IRS) may challenge our determination that the beneficial ownership requirement is satisfied. If we do not satisfy the
beneficial ownership requirement, such dividends, distributions, or other payments may be subject to 30% U.S. withholding
tax.
We may face potential limitations on the utilization of our U.S. tax attributes.
Following the acquisition of a U.S. corporation by a non-U.S. corporation, Section 7874 of the Internal Revenue Code of 1986,
as amended (Code) can limit the ability of the acquired U.S. corporation and its U.S. affiliates to utilize U.S. tax attributes such
as net operating losses and certain tax credits to offset U.S. taxable income resulting from certain transactions. Based on the
limited guidance available, we currently expect that this limitation likely will not apply to us and as a result, our U.S. affiliates
likely will not be limited by Section 7874 of the Code in their ability to utilize their U.S. tax attributes to offset their U.S.
taxable income, if any, resulting from certain specified taxable transactions. However, no assurances can be given in this
regard. If, however, Section 7874 of the Code were to apply to the Wright/Tornier merger and if our U.S. affiliates engage in
transactions that would generate U.S. taxable income subject to this limitation in the future, it could take us longer to use our
net operating losses and tax credits and, thus, we could pay U.S. federal income tax sooner than we otherwise would have.
Additionally, if the limitation were to apply and if we do not generate taxable income consistent with our expectations, it is
possible that the limitation under Section 7874 on the utilization of U.S. tax attributes could prevent our U.S. affiliates from
fully utilizing their U.S. tax attributes prior to their expiration.
45
Future changes to U.S. tax laws could materially affect us, including our status as a non-U.S. corporation.
Under current U.S. federal income tax law, a corporation generally will be considered to be resident for U.S. federal income tax
purposes in its place of organization or incorporation. Accordingly, under the generally applicable U.S. federal income tax
rules, we, as a Netherlands incorporated entity, would be classified as a non-U.S. corporation (and, therefore, not a U.S. tax
resident). Section 7874 of Code, however, contains specific rules (more fully discussed below) that can cause a non-U.S.
corporation to be treated as a U.S. corporation for U.S. federal income tax purposes. These rules are complex and there is little
or no guidance as to their application.
We currently expect we should continue to be treated as a foreign corporation for U.S. federal tax purposes, however, it is
possible that the IRS could disagree with that position and assert that Section 7874 applies to treat us as a U.S. corporation. In
addition, new statutory or regulatory provisions under Section 7874 or otherwise could be enacted or promulgated that
adversely affect our status as a foreign corporation for U.S. federal tax purposes, and any such provisions could have
retroactive application. If we were to be treated as a U.S. corporation for federal tax purposes, we would be subject to U.S.
corporate income tax on our worldwide income, and the income of our foreign subsidiaries would be subject to U.S. tax when
repatriated or when deemed recognized under the U.S. tax rules for controlled foreign subsidiaries. In such a case, we would be
subject to substantially greater U.S. tax liability than currently contemplated. Moreover, in such a case, a non-U.S. shareholder
of our company would be subject to U.S. withholding tax on the gross amount of any dividends paid by us to such shareholder.
Any such U.S. corporate income or withholding tax could be imposed in addition to, rather than in lieu of, any Dutch corporate
income tax or withholding tax that may apply.
Our tax position may be adversely affected by changes in tax law relating to multinational corporations, or by increased
scrutiny by tax authorities.
Recent legislative proposals have aimed to expand the scope of U.S. corporate tax residence, limit the ability of foreign-owned
corporations to deduct interest expense, and make other changes in the taxation of multinational corporations.
Additionally, the U.S. Congress, government agencies in jurisdictions where we and our affiliates do business, and the
Organization for Economic Co-operation and Development have focused on issues related to the taxation of multinational
corporations. One example is in the area of “base erosion and profit shifting,” where payments are made between affiliates
from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. As a result, the tax laws in the United States, the
Netherlands and other countries in which we and our affiliates do business could change on a prospective or retroactive basis,
and any such changes could impact the expected tax treatment for us and adversely affect our financial results.
Moreover, U.S. and non-U.S. tax authorities may carefully scrutinize companies involved or recently involved in cross-border
business combinations, such as us, which may lead such authorities to assert that we owe additional taxes.
Our exposure to several tax jurisdictions may have an adverse effect on us and this may increase the aggregate tax burden on
us and our shareholders.
We are subject to a large number of different tax laws and regulations in the various jurisdictions in which we operate. These
laws and regulations are often complex and are subject to varying interpretations. The combined effect of the application of tax
laws, including the application or disapplication of tax treaties of one or more of these jurisdictions and their interpretation by
the relevant tax authorities could, under certain circumstances, produce contradictory results. We often rely on generally
available interpretations of tax laws and regulations to determine the existence, scope, and level of our liability to tax in the
jurisdictions in which we operate. In addition, we take positions in the course of our business with respect to various tax
matters, including the compliance with the arm’s length principles in respect of transactions with related parties, the tax
deductibility of interest and other costs, and the amount of depreciation or write-down of our assets that we can recognize for
tax purposes. There is no assurance that the tax authorities in the relevant jurisdictions will agree with such interpretation of
these laws and regulations or with the positions taken by us. If such tax positions are challenged by relevant tax authorities, the
imposition of additional taxes could increase our effective tax rate and cost of operations.
Furthermore, because we are incorporated under Dutch law, we are treated for Dutch corporate income tax purposes as a
resident of the Netherlands. Based on our management structure and the current tax laws of the United States and the
Netherlands, as well as applicable income tax treaties and current interpretations thereof, we expect to remain a tax resident
solely of the Netherlands. If we were to be treated as a tax resident of a jurisdiction other than or in addition to the
Netherlands, we could be subject to corporate income tax in that other jurisdiction, and could be required to withhold tax on
any dividends paid by us to our shareholders under the applicable laws of that jurisdiction.
46
Risks Relating to Our Ordinary Shares and Jurisdiction of Incorporation
The trading volume and prices of our ordinary shares have been and may continue to be volatile, which could result in
substantial losses to our shareholders.
The trading volume and prices of our ordinary shares have been and may continue to be volatile and could fluctuate widely due
to factors beyond our control. During 2016, the sale price of our ordinary shares ranged from $15.02 to $25.50. Such volatility
may be the result of broad market and industry factors. In addition to market and industry factors, the price and trading volume
for our ordinary shares may be highly volatile for factors specific to our own operations, including the following:
•
•
•
•
•
•
•
•
•
variations in our net sales, earnings, and cash flow, and in particular variations that deviate from our projected
(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)
(cid:68)(cid:81)(cid:81)(cid:82)(cid:88)(cid:81)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:86)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:15)(cid:3)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:76)(cid:70)(cid:3)(cid:83)(cid:68)(cid:85)(cid:87)(cid:81)(cid:72)(cid:85)(cid:86)(cid:75)(cid:76)(cid:83)(cid:86)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:77)(cid:82)(cid:76)(cid:81)(cid:87)(cid:3)(cid:89)(cid:72)(cid:81)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3)
announcemen(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:72)(cid:90)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:88)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)
(cid:68)(cid:81)(cid:81)(cid:82)(cid:88)(cid:81)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:76)(cid:86)(cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:72)(cid:86)(cid:87)(cid:76)(cid:80)(cid:68)(cid:87)(cid:72)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:68)(cid:79)(cid:92)(cid:86)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:72)(cid:83)(cid:68)(cid:85)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:78)(cid:72)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81)(cid:81)(cid:72)(cid:79)(cid:30)(cid:3)
sales of our equity securities by our significant shareholders or management or sales of additional equity
(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:69)(cid:92)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)(cid:3)
(cid:83)(cid:72)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:82)(cid:87)(cid:72)(cid:81)(cid:87)(cid:76)(cid:68)(cid:79)(cid:3)(cid:79)(cid:76)(cid:87)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
fluctuations in market prices for our products.
Any of these factors may result in large and sudden changes in the volume and price at which our ordinary shares trade.
Shareholders of a public company sometimes bring securities class action suits against the company following periods of
instability in the market price of that company’s securities. If we were involved in a class action suit, it could divert a
significant amount of our management’s attention and other resources from our business and operations, which could harm our
operating results and require us to incur significant expenses to defend the suit. Any such class action suit, whether or not
successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully
made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial
condition and operating results.
If securities or industry analysts do not publish research or reports about our business, or if they adversely change their
recommendations regarding our ordinary shares, the market price for our ordinary shares and trading volume could decline.
The trading market for our ordinary shares is influenced by research or reports that industry or securities analysts publish about
us or our business. If one or more analysts who cover us downgrade our ordinary shares, the market price for our ordinary
shares likely would decline. If one or more of these analysts cease coverage of us or fail to regularly publish reports on us, we
could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for our ordinary
shares to decline.
The sale or availability for sale of substantial amounts of our ordinary shares could adversely affect their market price.
Sales of substantial amounts of our ordinary shares in the public market, or the perception that these sales could occur, could
adversely affect the market price of our ordinary shares and could materially impair our ability to raise capital through equity
offerings in the future. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or
any other shareholder or the availability of these securities for future sale will have on the market price of our ordinary shares.
Rights of a holder of ordinary shares are governed by Dutch law and differ from the rights of shareholders under U.S. law.
We are a Dutch public company with limited liability (naamloze vennootschap). Our corporate affairs and the rights of holders
of our ordinary shares are governed by Dutch law and our articles of association. The rights of our shareholders and the
responsibilities of members of our board of directors may be different from those in companies governed by the laws of U.S.
jurisdictions. For example, Dutch law does not provide for a shareholder derivative action. In addition, in the performance of
its duties, our board of directors is required by Dutch law to act in the interest of our company and our affiliated business, and
to consider the interests of our company, our shareholders, our employees, and other stakeholders, in all cases with
reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to,
interests of our shareholders.
47
U.S. investors may not be able to enforce judgments obtained in U.S. courts in civil and commercial matters against us or
members of our board of directors or officers.
We are organized under the laws of the Netherlands, and, as such, the rights of holders of our ordinary shares and the civil
liability of our directors are governed by the laws of the Netherlands and our articles of association. The rights of shareholders
under the laws of the Netherlands may differ from the rights of shareholders of companies incorporated in other jurisdictions.
A substantial portion of our assets are located outside of the United States. As a result, it may be difficult for investors to effect
service of process within the United States on us, or to enforce outside the United States any judgments obtained against us in
U.S. courts in any action, including actions predicated upon the civil liability provisions of the U.S. federal securities laws. In
addition, it may be difficult for investors to enforce rights predicated upon the U.S. federal securities laws in original actions
brought in courts in jurisdictions located outside the United States (including the Netherlands) or enforce claims for punitive
damages.
The United States and the Netherlands currently do not have a treaty providing for the reciprocal recognition and enforcement
of judgments in civil and commercial matters (other than arbitral awards). A final judgment for the payment of money rendered
by any federal or state court in the United States which is enforceable in the United States, whether or not predicated solely
upon U.S. federal securities laws, would not automatically be recognized or enforceable in the Netherlands. In order to obtain
a judgment which is enforceable in the Netherlands, the party in whose favor a final and conclusive judgment of the U.S. court
has been rendered will be required to file its claim with a court of competent jurisdiction in the Netherlands. Such party may
submit to a Dutch court the final judgment rendered by the U.S. court. If and to the extent that the Dutch court finds that the
jurisdiction of the U.S. court has been based on grounds which are internationally acceptable and that proper legal procedures
have been observed, the Dutch court will generally tend to give binding effect to the judgment of the court of the United States
without substantive re-examination or re-litigation on the merits of the subject matter, unless the judgment contravenes
principles of public policy of the Netherlands.
There can be no assurance that U.S. investors will be able to enforce against us or members of our board of directors or officers
who are residents of the Netherlands or countries other than the United States any judgments obtained in U.S. courts in civil
and commercial matters, including judgments under the U.S. federal securities laws.
We do not anticipate paying dividends on our ordinary shares.
Our articles of association prescribe that profits or reserves appearing from our annual accounts adopted by the general meeting
shall be at the disposal of the general meeting. We have power to make distributions to shareholders and other persons entitled
to distributable profits only to the extent that our equity exceeds the sum of the paid and called-up portion of the ordinary share
capital and the reserves that must be maintained in accordance with provisions of Dutch law or our articles of association. The
profits must first be used to set up and maintain reserves required by law and must then be set off against certain financial
losses. We may not make any distribution of profits on ordinary shares that we hold. The general meeting, whether or not
upon the proposal of our board of directors, determines whether and how much of the remaining profit they will reserve and the
manner and date of such distribution. All calculations to determine the amounts available for dividends will be based on our
Dutch annual accounts, which may be different from our consolidated financial statements prepared in accordance with US
GAAP. Beginning with our fiscal year 2015, our statutory accounts have been prepared and we expect will continue to be
prepared under International Financial Reporting Standards and are deposited with the Trade Register in Amsterdam, the
Netherlands. We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in
the near future on our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future
earnings to operate and expand our business.
Item 1B.
Unresolved Staff Comments.
None.
Item 2.
Properties.
Our global corporate headquarters are located in Amsterdam, the Netherlands.
Our U.S. headquarters are located in Memphis, Tennessee, where we conduct our principal executive, research and
development, sales and marketing, and administrative activities. We lease 121,000 square feet of office space with research and
development facilities under a lease agreement that is renewable through 2034. Our upper extremities sales and marketing,
U.S. distribution and customer service operations are located in a 54,000 square foot facility in Bloomington, Minnesota that
we lease through 2022. Our U.S. manufacturing operations consist of a 100,000 square foot state of the art manufacturing
facility in Arlington, Tennessee. We lease the manufacturing facility from the Industrial Development Board of the Town of
48
Arlington. At this facility, we produce primarily orthopaedic implants and some related surgical instrumentation while utilizing
lean manufacturing philosophies. We also lease a 31,000 square foot manufacturing and warehousing facility in Franklin,
Tennessee and conduct research and development operations in an 11,000 square foot leased facility in Warsaw, Indiana.
Outside the United State(cid:86)(cid:15)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:83)(cid:85)(cid:76)(cid:80)(cid:68)(cid:85)(cid:92)(cid:3) (cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3) (cid:73)(cid:68)(cid:70)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3) (cid:68)(cid:85)(cid:72)(cid:3) (cid:79)(cid:82)(cid:70)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:3) (cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:42)(cid:85)(cid:72)(cid:81)(cid:82)(cid:69)(cid:79)(cid:72)(cid:15)(cid:3) (cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)
Macroom, Ireland. In the 92,000 square foot Montbonnot campus, we conduct manufacturing and manufacturing support
activities, sales and marketing, research and development, quality and regulatory assurance, distribution and administrative
functions. In our 73,000 square foot Macroom facility, we conduct manufacturing operations and manufacturing support, such
as purchasing, engineering, and quality assurance functions. Our pyrocarbon manufacturing is performed at our 9,900 square
foot facility in Grenoble, France. In addition, we maintain subsidiary sales offices and distribution warehouses in various
countries, including France, Germany, Italy, the Netherlands, Denmark, Switzerland, United Kingdom, Belgium, Japan,
Canada, and Australia. We have an international research and development facility in Costa Rica.
We believe that our facilities are adequate and suitable for their use.
Below is a summary of our material facilities. All of our reportable segments use the facilities described below except as
otherwise indicated:
City
Memphis
Arlington
Bloomington
Warsaw
Franklin
Montbonnot
Montbonnot
Grenoble
Macroom
State/Country
Tennessee,
United States
Tennessee,
United States
Minnesota,
United States
Indiana,
United States
Tennessee,
United States
France
France
France
Ireland
Owned or
Leased
Leased
Leased
Leased
Leased
Leased
Leased
Owned 51%
Leased
Leased
Occupancy
Offices/R&D
U.S. Lower Extremities & Biologics
Manufacturing/Warehouse/Distribution
U.S. Upper Extremities
Offices/Warehouse/Distribution
Offices/R&D
U.S. Lower Extremities & Biologics
Offices/Manufacturing/Warehouse
(cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:40)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:9)(cid:3)(cid:37)(cid:76)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:86)(cid:30)
U.S. Upper Extremities
Warehouse/Distribution/Offices/R&D
(cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:40)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:9)(cid:3)(cid:37)(cid:76)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:86)(cid:30)
U.S. Upper Extremities
Manufacturing/Offices
International Extremities & Biologics
Manufacturing/Offices/R&D
International Extremities & Biologics
Manufacturing/Offices
Item 3.
Legal Proceedings.
From time to time, we or our subsidiaries are subject to various pending or threatened legal actions and proceedings, including
those that arise in the ordinary course of our business and some of which involve claims for damages that are substantial in
amount. These actions and proceedings may relate to, among other things, product liability, intellectual property, distributor,
commercial, and other matters. These actions and proceedings could result in losses, including damages, fines, or penalties,
any of which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and
negative outcomes or verdicts can occur, we believe we have significant defenses in all of them, are vigorously defending all of
them, and do not believe any of them will have a material adverse effect on our financial position. However, we could incur
judgments, pay settlements, or revise our expectations regarding the outcome of any matter. Such developments, if any, could
have a material adverse effect on our results of operations in the period in which applicable amounts are accrued, or on our cash
flows in the period in which amounts are paid.
The actions and proceedings described in this section relate primarily to Wright Medical Technology, Inc. (WMT), an indirect
subsidiary of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated
entities. Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities. We believe our
ring-fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with
particular claims.
49
Governmental Inquiries
On August 3, 2012, we received a subpoena from the United States Attorney’s Office for the Western District of Tennessee
requesting records and documentation relating to our PROFEMUR® series of hip replacement devices. The subpoena covers
the period from January 1, 2000 to August 2, 2012. We continue to cooperate with the investigation.
Patent Litigation
On June 11, 2013, Anglefix, LLC filed suit in the United States District Court for the Western District of Tennessee, alleging
that our ORTHOLOC® products infringe Anglefix’s asserted patent. The lawsuit seeks monetary damages, costs and attorneys’
fees. On April 14, 2014, we filed a request for Inter Partes Review (IPR) with the U.S. Patent and Trademark Office. In
October 2014, the Court stayed the case pending outcome of the IPR. On June 30, 2015, the Patent Office Board entered
judgment in our favor as to all patent claims at issue in the IPR. Following the conclusion of the IPR, the District Court lifted
the stay, and we have been continuing with our defense as to remaining patent claims asserted by Anglefix. On June 27, 2016,
the Court granted in part our motion for summary judgment on Anglefix’s lack of standing and gave Anglefix 30 days to join
the University of North Carolina (UNC) as a co-plaintiff in the lawsuit. On July 25, 2016, Anglefix filed a motion asking the
Court to accept a waiver of claims by UNC as a substitute for joining UNC as a co-plaintiff in the lawsuit. The Court denied
Anglefix’s motion, but granted leave for additional time to properly join UNC as co-plaintiff. Anglefix moved to add UNC as
co-plaintiff on September 15, 2016. We opposed the motion and, on November 15, 2016, the Court allowed the motion, and
subsequently directed Anglefix and UNC to file an amended complaint by January 18, 2017. We have filed motions for
summary judgment of non-infringement and invalidity of the remaining patent claims asserted by Anglefix and a motion to
exclude testimony by Anglefix’s technical expert. Anglefix has filed a motion for summary judgment of infringement of
certain of the remaining asserted patent claims. The Court heard oral argument on those motions on January 31, 2017.
On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the United States District
Court in Minnesota, alleging that our X-REAM® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE
REAMER.” The lawsuit seeks injunctive relief, monetary damages, costs and attorneys’ fees. In January 2015, on the deadline
for service of its complaint, Spineology dismissed its complaint without prejudice and filed a new, identical complaint. We
filed an answer to the new complaint with the Court on April 27, 2015. The Court conducted a Markman hearing on March 23,
2016. Mediation was held on August 11, 2016, but no agreement could be reached. The Court issued a Markman decision on
August 30, 2016, in which it found all asserted product claims invalid as indefinite under applicable patent laws and construed
several additional claim terms. The parties have completed fact and expert discovery with respect to the remaining asserted
method claims. We have filed a motion for summary judgment of non-infringement of the remaining asserted patent claims
and motions to exclude testimony from Spineology’s technical and damages experts. Spineology has filed a motion for
summary judgment of infringement. The Court will hear oral argument on those motions on February 28, 2017.
On September 13, 2016, we filed a civil action, Case No. 2:16-cv-02737-JPM, against Spineology in the U.S. District Court for
the Western District of Tennessee alleging breach of contract, breach of implied warranty against infringement, and seeking a
judicial declaration of indemnification from Spineology for patent infringement claims brought against us stemming from our
sale and/or use of certain expandable reamers purchased from Spineology. Spineology filed a motion to dismiss on October 17,
2016, but withdrew the motion on November 28, 2016. On December 7, 2016, Spineology filed an answer to our complaint
and counterclaims, including counterclaims relating to a 2004 non-disclosure agreement between Spineology and WMT. On
December 28, 2016, we filed a motion to dismiss the counterclaims relating to that 2004 agreement. On January 4, 2017,
Spineology filed a motion for summary judgment on certain claims set forth in our complaint. We intend to oppose this
motion.
On March 1, 2016, Musculoskeletal Transplant Foundation (MTF) filed suit against Solana and WMT in the United States
District Court for the District of New Jersey alleging that the TenFUSE PIP product infringes U.S. Patent No. 6,432,436
entitled “Partially Demineralized Cortical Bone Constructs.” The lawsuit seeks monetary damages, costs and attorneys’ fees.
On May 25, 2016, we agreed to waive service of MTF’s complaint. Following a series of court-ordered extensions of time, we
filed our answer to MTF’s complaint and counterclaims on December 5, 2016. We have reached a settlement in principle with
MTF for an immaterial amount, which is in the process of being documented.
Subject to the provisions of the asset purchase agreement with MicroPort for the sale of the OrthoRecon business, we, as
between us and MicroPort, would continue to be responsible for defense of pre-existing patent infringement cases relating to
the OrthoRecon business, and for resulting liabilities, if any. All such pre-existing cases have been resolved.
50
Product Liability
We have been named as a defendant, in some cases with multiple other defendants, in lawsuits in which it is alleged that as yet
unspecified defects in the design, manufacture, or labeling of certain metal-on-metal hip replacement products rendered the
products defective. The lawsuits generally employ similar allegations that use of the products resulted in excessive metal ions
and particulate in the patients into whom the devices were implanted, in most cases resulting in revision surgery (collectively,
the CONSERVE® Claims) and generally seek monetary damages. We anticipate that additional lawsuits relating to metal-on-
metal hip replacement products may be brought.
Because of the similar nature of the allegations made by several plaintiffs whose cases were pending in federal courts, upon
motion of one plaintiff, Danny L. James, Sr., the United States Judicial Panel on Multidistrict Litigation on February 8, 2012
transferred certain actions pending in the federal court system related to metal-on-metal hip replacement products to the United
States District Court for the Northern District of Georgia, for consolidated pre-trial management of the cases before a single
United States District Court Judge (the MDL). The consolidated matter is known as In re: Wright Medical Technology, Inc.
Conserve Hip Implant Products Liability Litigation.
Certain plaintiffs have elected to file their lawsuits in state courts in California. In doing so, most of those plaintiffs have named
a surgeon involved in the design of the allegedly defective products as a defendant in the actions, along with his personal
corporation. Pursuant to contractual obligations, we have agreed to indemnify and defend the surgeon in those actions. Similar
to the MDL proceeding in federal court, because the lawsuits generally employ similar allegations, certain of those pending
lawsuits in California were consolidated for pre-trial handling on May 14, 2012 pursuant to procedures of California State
Judicial Counsel Coordinated Proceedings (the JCCP). The consolidated matter is known as In re: Wright Hip Systems Cases,
Judicial Counsel Coordination Proceeding No. 4710.
Every metal-on-metal hip case involves fundamental issues of law, science and medicine that often are uncertain, that continue
to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and
issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the
existence of actual, provable injury.
The first bellwether trial in the MDL commenced on November 9, 2015 in Atlanta, Georgia. On November 24, 2015, the jury
returned a verdict in favor of the plaintiff and awarded the plaintiff $1 million in compensatory damages and $10 million in
punitive damages. We believe there were significant trial irregularities and vigorously contested the trial result. On December
28, 2015, we filed a post-trial motion for judgment as a matter of law or, in the alternative, for a new trial or a reduction of
damages awarded. On April 5, 2016, the trial judge issued an order reducing the punitive damage award from $10 million to
$1.1 million, but otherwise denied our motion. On May 4, 2016, we filed a notice of appeal with the United States Court of
Appeals for the Eleventh Circuit. The United States Court of Appeals for the Eleventh Circuit heard oral arguments on January
26, 2017 and we are awaiting a decision of the Court.
The first bellwether trial in the JCCP, which was scheduled to commence on October 31, 2016, and subsequently rescheduled
to January 9, 2017, was settled for an immaterial amount.
The first state court metal-on-metal hip trial not part of the MDL or JCCP, Donald Deline v. Wright Medical Technology, Inc., et
al, commenced on October 24, 2016 in the Circuit Court of St. Louis County, Missouri. On November 3, 2016, the jury
returned a verdict in our favor. The plaintiff has appealed.
As of December 25, 2016, there were approximately 1,200 lawsuits pending in the MDL and JCCP, and an additional 30 cases
pending in various state courts. As of that date, we have also entered into approximately 950 so called “tolling agreements”
with potential claimants who have not yet filed suit. Based on presently available information, we believe at least 350 of these
lawsuits allege claims involving bilateral implants. As of December 25, 2016, there were also approximately 50 non-U.S.
lawsuits pending. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products. While
continuing to dispute liability, we have participated in court supervised non-binding mediation in the MDL and expect to begin
similar mediation in the JCCP.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing
plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified
CONSERVE, DYNASTY and LINEAGE claims that meet the eligibility requirements of the MSA and are either pending in the
MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million.
51
We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular
neck product (Titanium Modular Neck Claims). As of December 25, 2016, there were 26 pending U.S. lawsuits and 48
pending non-U.S. lawsuits alleging such claims. These lawsuits generally seek monetary damages.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged
fractures. As of December 25, 2016, there were three pending U.S. lawsuits and five pending non-U.S. lawsuits against us
alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These lawsuits generally seek monetary
damages.
In June 2015, a jury returned a $4.4 million verdict against us in a case involving a fractured hip implant stem sold prior to the
MicroPort closing. This was a one-of-a-kind case unrelated to the modular neck fracture cases we have previously reported.
There are no other cases pending related to this component, nor are we aware of other instances where this component has
fractured. The case, Alan Warner et al. vs. Wright Medical Technology, Inc. et al., case no. BC 475958, which was filed on
December 27, 2011, was tried in the Superior Court of the State of California for the County of Los Angeles, Central District.
In September 2015, the trial judge reduced the jury verdict to $1.025 million and indicated that if the plaintiff did not accept the
reduced award he would schedule a new trial solely on the issue of damages. The plaintiff elected not to accept the reduced
damage award, and both parties have appealed. The Court has not set a date for a new trial on the issue of damages and we do
not expect it will do so until the appeals are adjudicated.
Insurance Litigation
On June 10, 2014, St. Paul Surplus Lines Insurance Company (Travelers), which was an excess carrier in our coverage towers
across multiple policy years, filed a declaratory judgment action in the Chancery Court of Shelby County, Tennessee naming us
and certain of our other insurance carriers as defendants and asking the Court to rule on the rights and responsibilities of the
parties with regard to the CONSERVE® Claims. This case is known as St. Paul Surplus Lines Insurance Company v. Wright
Medical Group, Inc., et al. Among other things, Travelers appeared to dispute our contention that the CONSERVE® Claims
arise out of more than a single occurrence thereby triggering multiple policy periods of coverage. Travelers further sought a
determination as to the applicable policy period triggered by the alleged single occurrence. On June 17, 2014, we filed a
separate lawsuit in the Superior Court of the State of California, County of San Francisco for declaratory judgment against
certain carriers and breach of contract against the primary carrier, and moved to dismiss or stay the Tennessee action on a
number of grounds, including that California is the most appropriate jurisdiction. This case is known as Wright Medical Group,
Inc. et al. v. Federal Insurance Company, et al. On September 9, 2014, the California Court granted Travelers’ motion to stay
our California action. On April 29, 2016, we filed a dispositive motion seeking partial judgment in our favor in the Tennessee
action. That motion is pending, and will be decided after the parties complete discovery regarding certain issues relating to the
pending motion. On June 10, 2016, Travelers withdrew its motion for summary judgment in the Tennessee action. One of the
other insurance companies in the Tennessee action has stated that it will re-file a similar motion in the future.
On October 28, 2016, WMT and Wright Medical Group, Inc. (WMG) entered into a Settlement Agreement, Indemnity and
Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three
insurance carriers, namely Columbia Casualty Company (Columbia), Travelers and AXIS Surplus Lines Insurance Company
(collectively, the Three Settling Insurers), pursuant to which the Three Settling Insurers agreed to pay WMT an aggregate of
$60 million (in addition to $10 million previously paid by Columbia) in a lump sum on or before the 30th business day after
execution of the Insurance Settlement Agreement. This amount is in full satisfaction of all potential liability of the Three
Settling Insurers relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in
the MDL and the JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described
above. The amount due under the Insurance Settlement Agreement was paid in the fourth quarter of 2016.
On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against
the primary insurance carrier. The motion was subsequently amended on February 8, 2017 to add similar bad faith claims
against the remaining excess carriers. That motion is pending.
On September 29, 2015, Markel International Insurance Company Ltd., as successor to Max Insurance Europe Ltd. (Max
Insurance), which is the third insurance carrier in our coverage towers across multiple policy years, asserted that the terms and
conditions identified in its reservation of rights will preclude coverage for the Titanium Modular Neck Claims. We strongly
dispute the carrier’s position, and in accordance with the dispute resolution provisions of the policy, on January 18, 2016, we
filed a Notice of Arbitration against Max Insurance in London, England pursuant to the provisions of the Arbitration Act of
1996. We are seeking reimbursement, up to the policy limits of $25 million, of costs incurred in the defense and settlement of
the Titanium Modular Neck Claims.
52
Wright/Tornier Merger Related Litigation
On November 26, 2014, a class action complaint was filed in the Circuit Court of Tennessee, for the Thirtieth Judicial District,
at Memphis (Tennessee Circuit Court), by a purported shareholder of WMG under the caption City of Warwick Retirement
System v. Gary D. Blackford et al., CT-005015-14. An amended complaint in the action was filed on January 5, 2015. The
amended complaint names as defendants WMG, Tornier, Trooper Holdings Inc. (Holdco), Trooper Merger Sub Inc. (Merger
Sub), and the members of the WMG board of directors. The amended complaint asserts various causes of action, including,
among other things, that the members of the WMG board of directors breached their fiduciary duties owed to the WMG
shareholders in connection with entering into the merger agreement, approving the merger, and causing WMG to issue a
preliminary Form S-4 that allegedly fails to disclose material information about the merger. The amended complaint further
alleges that Tornier, Holdco, and Merger Sub aided and abetted the alleged breaches of fiduciary duties by the WMG board of
directors. The plaintiff is seeking, among other things, injunctive relief enjoining or rescinding the merger and an award of
attorneys’ fees and costs.
On December 2, 2014, a separate class action complaint was filed in the Tennessee Chancery Court by a purported shareholder
of WMG under the caption Paulette Jacques v. Wright Medical Group, Inc., et al., CH-14-1736-1. An amended complaint in
the action was filed on January 27, 2015. The amended complaint names as defendants WMG, Tornier, Holdco, Merger Sub,
Warburg Pincus LLC and the members of the WMG board of directors. The amended complaint asserts various causes of
action, including, among other things, that the members of the WMG board of directors breached their fiduciary duties owed to
the WMG shareholders in connection with entering into the merger agreement, approving the merger, and causing WMG to
issue a preliminary Form S-4 that allegedly fails to disclose material information about the merger. The amended complaint
further alleges that WMG, Tornier, Warburg Pincus LLC, Holdco and Merger Sub aided and abetted the alleged breaches of
fiduciary duties by the WMG board of directors. The plaintiff is seeking, among other things, injunctive relief enjoining or
rescinding the merger and an award of attorneys’ fees and costs.
In an order dated March 31, 2015, the Tennessee Circuit Court transferred City of Warwick Retirement System v. Gary D.
Blackford et al., CT-005015-14 to the Tennessee Chancery Court for consolidation with Paulette Jacques v. Wright Medical
Group, Inc., et al., CH-14-1736-1 (Consolidated Tennessee Action). In an order dated April 9, 2015, the Tennessee Chancery
(cid:38)(cid:82)(cid:88)(cid:85)(cid:87)(cid:3) (cid:86)(cid:87)(cid:68)(cid:92)(cid:72)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:38)(cid:82)(cid:81)(cid:86)(cid:82)(cid:79)(cid:76)(cid:71)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:3) (cid:36)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:86)(cid:87)(cid:68)(cid:92)(cid:3) (cid:72)(cid:91)(cid:83)(cid:76)(cid:85)(cid:72)(cid:71)(cid:3) (cid:88)(cid:83)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:72)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3) (cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:17) On
September 19, 2016, the Tennessee Chancery Court entered an agreed order, dismissing the Jacques case without prejudice.
Other
In addition to those noted above, we are subject to various other legal proceedings, product liability claims, corporate
governance, and other matters which arise in the ordinary course of business.
Item 4.
Mine Safety Disclosures.
Not applicable.
53
PART II
Item 5.
Securities.
Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity
Market Information
Our ordinary shares are traded on the NASDAQ Global Select Market under the symbol “WMGI.” Prior to the completion of
the Wright/Tornier merger on October 1, 2015, legacy Tornier ordinary shares traded under the symbol “TRNX” while legacy
Wright ordinary shares traded under the symbol “WMGI.” Due to the “reverse acquisition” nature of the Wright/Tornier
merger, historical information below reflects the high and low sales prices of legacy Tornier.
The following table sets forth, for the periods indicated, the high and low per share sales prices for our ordinary shares as
reported by the NASDAQ Global Select Market.
Fiscal Year 2016
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Fiscal Year 2015
First Quarter
Second Quarter
Third Quarter
Fourth Quarter
Holders
High
Low
24.43 $
20.75 $
25.50 $
25.15 $
26.98 $
27.06 $
26.13 $
23.86 $
15.02
15.52
15.85
20.50
23.32
24.45
21.43
18.03
$
$
$
$
$
$
$
$
As of February 17, 2017, there were 357 holders of record of our ordinary shares.
Dividends
We have not previously declared or paid cash dividends on our ordinary shares. We currently intend to retain all future
earnings for the operation and expansion of our business. We do not anticipate declaring or paying cash dividends on our
ordinary shares in the foreseeable future. Any payment of cash dividends on our ordinary shares will be at the discretion of our
board of directors and will depend upon our results of operations, earnings, capital requirements, contractual restrictions, and
other factors deemed relevant by our board of directors. Additionally, our ABL Credit Agreement restricts our ability to pay
dividends.
Purchases of Equity Securities by the Company
We did not purchase any ordinary shares or other equity securities of our company during the fourth fiscal quarter ended
December 25, 2016.
Recent Sales of Unregistered Securities
We did not issue any ordinary shares or other equity securities of our company that were not registered under the Securities Act
of 1933, as amended, during the fourth fiscal quarter ended December 25, 2016.
54
Comparison of Total Shareholder Returns
The graph below compares the cumulative total shareholder returns for legacy Tornier ordinary shares from the period from
December 31, 2011 to October 1, 2015, the date of the Wright/Tornier merger, and our combined company ordinary shares
from October 1, 2015 to December 25, 2016 (our fiscal year-end). The graph also reflects cumulative total shareholder returns
from an index composed of U.S. companies whose stock is listed on the NASDAQ Global Select Market (NASDAQ U.S.
Composite Index) and an index consisting of NASDAQ-listed companies in the surgical, medical and dental instruments and
supplies industry (NASDAQ Medical Equipment Subsector), as well as an index of companies with the SIC Code 384 -
Surgical, Medical, and Dental Instruments Supplies (Surgical, Medical, and Dental Instruments Index). Total returns for the
indices are weighted based on the market capitalization of the companies included therein. In addition, due to the “reverse
acquisition” nature of the Wright/Tornier merger and the fact that the historical financial statements of legacy Wright have
replaced the historical financial statements of legacy Tornier, the graph below also includes the cumulative total shareholder
returns for WMG common stock from December 31, 2011 to October 1, 2015, the date of the Wright/Tornier merger.
The graph assumes that $100.00 was invested on December 31, 2011, in legacy Tornier/Wright Medical Group N.V. ordinary
shares, legacy Wright common stock, the NASDAQ U.S. Composite Index, the NASDAQ Medical Equipment Subsector, and
the Surgical, Medical, and Dental Instruments Supplies Index, and that all dividends were reinvested. Total returns for the
NASDAQ indices are weighted based on the market capitalization of the companies included therein.
Historical price performance of our ordinary shares is not indicative of future share price performance. We do not make or
endorse any prediction as to future share price performance.
Legacy Tornier / Wright Medical Group N.V.
Legacy Wright
NASDAQ Stock Market (US Companies)
NASDAQ Medical Equipment Index
SIC Code 384 - Surgical, Medical, and Dental
Instruments and Supplies
2011
$ 100.00 $
100.00
100.00
100.00
2012
2013
2014
2015
2016
90.50 $ 101.61 $ 141.44 $ 130.89 $ 129.50
—
161.03
122.73
228.06
192.92
116.00
197.55
152.37
109.20
127.39
206.33
178.84
182.55
164.10
129.79
100.00
85.44
114.04
149.90
128.33
159.24
Prepared by Zacks Investment Research, Inc. Used with permission. All rights reserved. Copyright 1980-2017
55
Item 6.
Selected Financial Data.
The following tables set forth certain of our selected consolidated financial data as of the dates and for the years indicated. Due
to the “reverse acquisition” nature of the Wright/Tornier merger, the historical financial statements of legacy Wright replaced
the historical financial statements of legacy Tornier. Historical results are not necessarily indicative of the results to be
expected for any future period. These tables are presented in thousands, except per share data.
December
25, 2016
December
27, 2015 8
Fiscal year ended
December
31, 2014
December
31, 2013
December
31, 2012
Consolidated Statement of Operations:
Net sales
Cost of sales 1
Gross profit
Operating expenses:
Selling, general and administrative 1
Research and development 1
Amortization of intangible assets
BioMimetic impairment charges
Gain on sale of intellectual property 2
Restructuring charges 3
Total operating expenses
Operating (loss) income 4
Interest expense, net
Other (income) expense, net 5
Loss before income taxes
(Benefit) provision for income taxes 6
Net loss from continuing operations
(Loss) income from discontinued operations,
net of tax 1
Net (loss) income
Net loss from continuing operations per share — basic
and diluted 7:
Weighted-average number of ordinary shares outstanding —
basic and diluted 7
$ 690,362 $ 405,326 $ 298,027 $ 242,330 $ 214,105
48,239
165,866
192,407
497,955
73,223
224,804
59,721
182,609
113,622
291,704
541,558
50,514
28,841
—
—
—
620,913
(122,958)
58,530
(3,148)
(178,340)
(13,406)
424,377
39,339
16,754
—
—
—
480,470
(188,766)
41,358
10,884
(241,008)
(3,652)
289,620
24,963
10,027
—
—
—
324,610
(99,806)
17,398
129,626
(246,830)
(6,334)
230,785
20,305
7,476
206,249
—
—
464,815
(282,206)
16,040
(67,843)
(230,403)
49,765
$ (164,934) $ (237,356) $ (240,496) $ (280,168) $
150,296
13,905
4,417
—
(15,000)
431
154,049
11,817
10,113
5,089
(3,385)
2
(3,387)
$
$ (267,439) $ (61,345) $ (19,187) $
$ (432,373) $ (298,701) $ (259,683) $ (273,945) $
6,223
8,671
5,284
$
(1.60) $
(3.66) $
(4.69) $
(5.82) $
(0.08)
102,968
64,808
51,293
48,103
39,967
Consolidated Balance Sheet Data:
Cash and cash equivalents
Restricted cash
Marketable securities
Working capital 9, 10
Total assets 9, 10, 11
Long-term liabilities 9, 11
Shareholders’ equity
December 25,
2016
December 27,
2015
December 31,
2014
December 31,
2013
December 31,
2012
$ 262,265 $ 139,804 $ 227,326 $ 168,534 $ 320,360
—
12,646
545,611
937,014
337,184
523,441
150,000
—
285,107
2,290,586
1,129,204
686,864
—
—
352,946
2,073,494
811,530
1,055,026
—
2,575
249,958
885,068
419,204
278,803
—
14,548
375,901
990,090
411,711
459,714
December 25,
2016
December 27,
2015
Fiscal year ended
December 31,
2014
December 31,
2013
December 31,
2012
Other Data:
Cash flow provided by (used in) operating activities
Cash flow provided by (used in) investing activities
Cash flow provided by (used in) financing activities
Depreciation8
Share-based compensation expense
Capital expenditures 12
$
37,824 $ (195,870) $ (116,002) $
(34,241)
270,417
55,830
14,416
50,099
145,630
33,051
18,582
11,487
48,603
(15,970)
126,862
28,390
24,964
43,666
(36,601) $
(121,317)
6,257
26,296
15,368
37,530
68,822
(1,048)
98,721
38,275
10,974
19,323
56
___________________________
1
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Cost of sales
Selling, general and administrative
Research and development
Discontinued operations
December 25,
2016
December 27,
2015
Fiscal year ended
December 31,
2014
December 31,
2013
December 31,
2012
$
414 $
287 $
254 $
503 $
13,216
786
—
22,777
1,900
—
10,149
1,084
—
10,675
780
3,410
704
6,767
368
3,135
2 During the year ended December 31, 2012, we recorded income of $15 million related to a sale and license back transaction for
intellectual property.
3 During the year ended December 31, 2012, we recorded pre-tax charges associated with the cost improvement restructuring efforts
totaling $0.4 million.
4 During the year ended December 25, 2016, we recognized: (a) $32.3 million in costs for transaction and transition costs related to the
(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3)(cid:11)(cid:69)(cid:12)(cid:3)(cid:7)(cid:22)(cid:26)(cid:17)(cid:26)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)n of inventory step-(cid:88)(cid:83)(cid:3)(cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:11)(cid:70)(cid:12)(cid:3)(cid:7)(cid:23)(cid:17)(cid:20)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:82)(cid:81)-cash inventory provisions associated
(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:76)(cid:87)(cid:76)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:30)(cid:3)(cid:11)(cid:71)(cid:12)(cid:3)(cid:7)(cid:20)(cid:17)(cid:27)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:3)(cid:79)(cid:72)(cid:74)(cid:68)(cid:79)(cid:3)(cid:86)(cid:72)(cid:87)(cid:87)(cid:79)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:30)(cid:3)(cid:11)(cid:72)(cid:12)(cid:3)(cid:7)(cid:20)(cid:17)(cid:22)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86) associated with
executive manage(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:73)(cid:12)(cid:3)(cid:7)(cid:19)(cid:17)(cid:21)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:71)(cid:72)(cid:69)(cid:87)(cid:3)(cid:85)(cid:72)(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:81)(cid:74)(cid:17)(cid:3) During the year ended December 27, 2015,
we recognized: (a) $82.2 million in costs for due diligence, transaction, and transition costs related to the Wright/Tornier (cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3)
(b) $14.2 million of share-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:70)(cid:70)(cid:72)(cid:79)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:70)(cid:12)(cid:3) (cid:7)(cid:20)(cid:19)(cid:17)(cid:22)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:76)(cid:81)(cid:89)(cid:72)(cid:81)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3) (cid:86)(cid:87)(cid:72)(cid:83)-up amortization. During the year
ended December 31, 2014, we recognized: (a) $2.1 million in costs associated with distributor conversions and non-(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)
(b) $14.1 million in costs for due diligence, transaction, and transition costs related to the Biotech, Solana, and OrthoPro acquisitio(cid:81)(cid:86)(cid:30)(cid:3)
(c) (cid:7)(cid:20)(cid:20)(cid:17)(cid:28)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:81)(cid:3) (cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:3) (cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3) (cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3) (cid:11)(cid:71)(cid:12)(cid:3) (cid:7)(cid:24)(cid:17)(cid:28)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3) (cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:50)(cid:85)thoRecon
(cid:71)(cid:76)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:30)(cid:3)(cid:11)(cid:72)(cid:12)(cid:3)(cid:7)(cid:20)(cid:17)(cid:21)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:80)(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:73)(cid:12)(cid:3)(cid:7)(cid:19)(cid:17)(cid:28)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:3)(cid:83)(cid:68)tent dispute
settlement. During the year ended December 31, 2013, we recognized: (a) $3.7 million in costs associated with distributor conversions
and non-(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3) (cid:11)(cid:69)(cid:12)(cid:3) (cid:7)(cid:20)(cid:21)(cid:17)(cid:28)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:81)(cid:3) (cid:71)(cid:88)(cid:72)(cid:3) (cid:71)(cid:76)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3) (cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:37)(cid:76)(cid:82)(cid:48)(cid:76)(cid:80)(cid:72)(cid:87)(cid:76)(cid:70)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:37)(cid:76)(cid:82)(cid:87)(cid:72)(cid:70)(cid:75)(cid:3) (cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
(c) $21.6 (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:50)(cid:85)(cid:87)(cid:75)(cid:82)(cid:53)(cid:72)(cid:70)(cid:82)(cid:81)(cid:3)(cid:71)(cid:76)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:71)(cid:12)(cid:3)(cid:7)(cid:21)(cid:19)(cid:25)(cid:17)(cid:21)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:37)(cid:76)(cid:82)(cid:48)(cid:76)(cid:80)etic impairment charges.
5 During the year ended December 25, 2016, we recognized: (a) a $8.7 million loss from mark-to-market adjustments on the Contingent
(cid:57)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:53)(cid:76)(cid:74)(cid:75)(cid:87)(cid:86)(cid:3)(cid:11)(cid:38)(cid:57)(cid:53)(cid:86)(cid:12)(cid:3)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:81)(cid:81)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:37)(cid:76)(cid:82)(cid:48)(cid:76)(cid:80)(cid:72)(cid:87)(cid:76)(cid:70)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:11)(cid:69)(cid:12)(cid:3)(cid:7)(cid:21)(cid:27)(cid:17)(cid:22)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:74)(cid:68)(cid:76)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)the mark-to-market adjustment of
(cid:82)(cid:88)(cid:85)(cid:3) (cid:71)(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:76)(cid:81)(cid:86)(cid:87)(cid:85)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3) (cid:11)(cid:70)(cid:12)(cid:3) (cid:68)(cid:3) (cid:7)(cid:20)(cid:21)(cid:17)(cid:22)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:81)(cid:82)(cid:81)-cash loss on extinguishment of debt to write-off unamortized debt discount and
deferred financing fees associated with the partial settlement of 2017 and 2020 convertible (cid:81)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:71)(cid:12)(cid:3)(cid:7)(cid:22)(cid:25)(cid:17)(cid:25)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:82)(cid:81)-cash interest
(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:71)(cid:72)(cid:69)(cid:87)(cid:3)(cid:71)(cid:76)(cid:86)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:15)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:87)(cid:76)(cid:69)(cid:79)(cid:72)(cid:3)(cid:81)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:72)(cid:12)(cid:3)(cid:7)(cid:19)(cid:17)(cid:24)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)f charges
due to the fair value adjustment to contingent consideration. During the year ended December 27, 2015, we recognized: (a) a
$7.6 million gain from mark-to-market adjustments on the CVRs issued in connection with the BioMimetic acquisition and
(b) $9.8 million gain for the mark-to-market adjustment of our derivative instruments. During the year ended December 31, 2014, we
recognized: (a) approximately $125 million from mark-to-market adjustments on the CVRs issued in connection with the BioMimetic
(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:11)(cid:69)(cid:12)(cid:3)(cid:7)(cid:21)(cid:17)(cid:19)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)-to-market adjustment of our d(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:76)(cid:81)(cid:86)(cid:87)(cid:85)(cid:88)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:70)(cid:12) $1.8 million of charges
due to the fair value adjustment to contingent consideration associated with our acquisition of WG Healthcare. During the year ended
December 31, 2013, we recognized a $7.8 million gain related to the previously held investment in BioMimetic. During the year ended
December 31, 2012, we recognized: (a) $2.7 million for the write-off of unamortized deferred financing fees associated with the
(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:86)(cid:72)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3) (cid:70)(cid:85)(cid:72)(cid:71)(cid:76)(cid:87)(cid:3) (cid:73)(cid:68)(cid:70)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:30)(cid:3) (cid:11)(cid:69)(cid:12)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:85)(cid:72)(cid:71)(cid:72)(cid:80)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:91)(cid:76)(cid:80)(cid:68)(cid:87)(cid:72)(cid:79)(cid:92)(cid:3) (cid:7)(cid:21)(cid:24)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:21)(cid:19)(cid:20)(cid:23)(cid:3) (cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:87)(cid:76)(cid:69)(cid:79)(cid:72)(cid:3) (cid:81)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:70)(cid:12)(cid:3) (cid:68)(cid:3)
$1.1 million of charges for the mark-to-market adjustment of our derivative instruments. During the year ended December 31, 2011, we
recognized $4.1 million for the write-off of pro-rata unamortized deferred financing fees and transaction costs associated with the tender
offer for our convertible notes completed during 2011.
6 During the year ended December 25, 2016, we recognized a $3.1 million interest and income tax benefit related to the settlement of an
IRS audit. During the year ended December 31, 2013, we recognized a $119.6 million tax valuation allowance recorded against deferred
tax assets in our U.S. jurisdiction due to recent operating losses.
7
8
9
The 2014, 2013, and 2012 weighted-average shares outstanding and net loss per share amounts were converted in 2015 to meet post-
merger valuations as described within Note 13. The 2015 weighted-average shares outstanding includes additional shares issued on
October 1, 2015 as part of the Wright/Tornier merger as described in Note 13.
The 2015 results were restated for the divestiture of our Large Joints business. (See Note 4).
The prior year deferred tax balances were reclassified to account for early adoption of ASU 2015-17.
10 The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015 (See Note 4).
11 The prior period debt issuance costs were reclassified to account for adoptions of ASU 2015-03 and ASU 2015-15 (See Note 2).
12 During the year ended December 31, 2014, our capital expenditures included $9.4 million related to the expansion of our manufacturing
facility in Arlington, Tennessee.
57
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
The following management’s discussion and analysis of financial condition and results of operations describes the principal
factors affecting the results of our operations, financial condition, and changes in financial condition, as well as our critical
accounting estimates.
On October 1, 2015, we became Wright Medical Group N.V. following the merger of Wright Medical Group, Inc. with Tornier
N.V. Because of the structure of the merger and the governance of the combined company immediately post-merger, the
merger was accounted for as a “reverse acquisition” under US GAAP, and as such, legacy Wright was considered the acquiring
entity for accounting purposes. Therefore, legacy Wright’s historical results of operations replaced legacy Tornier’s historical
results of operations for all periods prior to the merger. More specifically, the accompanying consolidated financial statements
for periods prior to the merger are those of legacy Wright and its subsidiaries, and for periods subsequent to the merger also
include legacy Tornier and its subsidiaries.
During the first quarter of 2016, our management, including our chief executive officer, who is our chief operating decision
maker, began managing our operations as four operating business segments: U.S. Lower Extremities and Biologics, U.S. Upper
Extremities, International Extremities and Biologics, and Large Joints. We determined that each of these operating segments
represented a reportable segment.
On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, we, Corin Orthopaedics Holdings Limited
(Corin), and certain other entities related to us entered into a business sale agreement and simultaneously completed and closed
the sale of our Large Joints business. The financial results of our Large Joints business, including costs associated with
corporate employees and infrastructure transferred as a part of the sale, are reflected within discontinued operations for all
periods presented, unless otherwise noted. Further, all assets and associated liabilities transferred to Corin were classified as
assets and liabilities held for sale in our consolidated balance sheet as of December 27, 2015.
On January 9, 2014, legacy Wright completed the sale of its hip and knee (OrthoRecon) business to MicroPort Scientific
Corporation (MicroPort). The financial results of the OrthoRecon business are also reflected within discontinued operations for
all periods presented, unless otherwise noted.
References in this section to “we,” “our” and “us” refer to Wright Medical Group N.V. and its subsidiaries after the
Wright/Tornier merger and Wright Medical Group, Inc. and its subsidiaries before the merger. Beginning in 2015 as a result of
the Wright/Tornier merger, our fiscal year-end is generally determined on a 52-week basis and runs from the Monday nearest to
the 31st of December of a year, and ends on the Sunday nearest to the 31st of December of the following year. Every few
years, it is necessary to add an extra week to the year making it a 53-week period. References in this report to a particular year
generally refer to the applicable fiscal year. Accordingly, references to “2016” or “the year ended December 25, 2016” mean
the fiscal year ended December 25, 2016.
Executive Overview
Company Description. We are a global medical device company focused on extremities and biologics products. We are
committed to delivering innovative, value-added solutions improving quality of life for patients worldwide, and are a
recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and
ankle) and biologics markets, three of the fastest growing segments in orthopaedics.
Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in
Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative
(cid:68)(cid:70)(cid:87)(cid:76)(cid:89)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:12)(cid:30)(cid:3)(cid:37)(cid:79)(cid:82)(cid:82)(cid:80)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)(cid:11)(cid:88)(cid:83)(cid:83)(cid:72)(cid:85)(cid:3)(cid:72)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:36)(cid:85)(cid:79)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)ssee
(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:41)(cid:85)(cid:68)(cid:81)(cid:78)(cid:79)(cid:76)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:15)(cid:3)
(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:68)(cid:70)(cid:85)(cid:82)(cid:82)(cid:80)(cid:15)(cid:3)(cid:44)(cid:85)(cid:72)(cid:79)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:12)(cid:17)(cid:3)(cid:3)(cid:44)(cid:81)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:79)(cid:82)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:68)(cid:79)es
and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe.
We offer a broad product portfolio of approximately 180 extremities products and over 20 biologics products that are designed
to provide solutions to our surgeon customers, with the goal of improving clinical outcomes and the “quality of life” for their
patients. Our product portfolio consists of the following product categories:
• Upper extremities, which include joint implants and bone fixation devices for the shoulder, elbow, wrist, and
(cid:75)(cid:68)(cid:81)(cid:71)(cid:30)
• Lower extremities, which include joint implants and bone (cid:73)(cid:76)(cid:91)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:82)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:81)(cid:78)(cid:79)(cid:72)(cid:30)
58
• Biologics, which include products used to support treatment of damaged or diseased bone, tendons, and soft
(cid:87)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:86)(cid:87)(cid:76)(cid:80)(cid:88)(cid:79)(cid:68)(cid:87)(cid:72)(cid:3)(cid:69)(cid:82)(cid:81)(cid:72)(cid:3)(cid:74)(cid:85)(cid:82)(cid:90)(cid:87)(cid:75)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Sports medicine and other, which include products used across several anatomic sites to mechanically repair
tissue-to-tissue or tissue-to-bone injuries and other ancillary products.
Our sales and distribution system in the United States currently consists of 68 geographic sales territories that are staffed by
approximately 500 direct sales representatives and 24 independent sales agencies or distributors. These sales representatives
and independent sales agencies and distributors are generally aligned to selling either our upper extremities products or lower
extremities products, but, in some cases, certain agencies or direct sales representatives sell products from both our upper and
lower extremities product portfolios in their territories. Internationally, we utilize several distribution approaches that are
tailored to the needs and requirements of each individual market. Our international sales and distribution system currently
consists of 15 direct sales offices and approximately 90 distributors that sell our products in over 50 countries, with principal
markets outside the United States in Europe, Asia, Canada, Australia, and Latin America. Our U.S. sales accounted for 73.5%
of total net sales in 2016.
Principal Products. We have focused our efforts into growing our position in the high-growth extremities and biologics
markets. We believe a more active and aging patient population with higher expectations regarding “quality of life,” an
increasing global awareness of extremities and biologics solutions, improved clinical outcomes as a result of the use of such
products, and technological advances resulting in specific designs for such products that simplify procedures and address unmet
needs for early interventions, and the growing need for revisions and revision related solutions will drive the market for
extremities and biologics products.
The extremities market is one of the fastest growing market segments within orthopaedics, with annual growth rates of 7-10%.
We believe major trends in the extremities market include procedure-specific and anatomy-specific devices, locking plates, and
an increase in total ankle replacement or arthroplasty procedures. Upper extremities reconstruction involves implanting
devices to replace, reconstruct, or fixate injured or diseased joints and bones in the shoulder, elbow, wrist, and hand. It is
estimated that approximately 60% of the upper extremities market is in total shoulder replacement or arthroplasty implants. We
believe major trends in the upper extremities market include next-generation joint arthroplasty systems, bone preserving
solutions, virtual planning systems, and revision of failed previous shoulder replacements in older patients. Lower extremities
reconstruction involves implanting devices to replace, reconstruct, or fixate injured or diseased joints and bones in the foot and
ankle. A large segment of the lower extremities market is comprised of plating and screw systems for reconstructing and fusing
joints or repairing bones after traumatic injury. We believe major trends in the lower extremities market include the use of
external fixation devices in diabetic patients, total ankle arthroplasty, advanced tissue fixation devices, and biologics. New
technologies have been introduced into the lower extremities market in recent years, including next-generation total ankle
replacement systems. We believe that market adoption of total ankle replacement, which currently represents approximately
8% of the U.S. foot and ankle device market, will result in significant future growth in the lower extremities market.
Our principal lower extremities products include the INBONE® and INFINITY® Total Ankle Replacement Systems, both of
which can be used with our PROPHECY® Preoperative Navigation Guides, which combine computer imaging with a patient’s
CT scan, and are designed to provide alignment accuracy while reducing surgical steps. Our lower extremities products also
include the CLAW® II Polyaxial Compression Plating System, the ORTHOLOC® 3Di Reconstruction Plating System, the
PhaLinx® System used for hammertoe indications, PRO-TOE® VO Hammertoe System, the DARCO® family of locked plating
systems, the VALOR® ankle fusion nail system, and the Swanson line of toe joint replacement products. We expect to
commercially launch our most recent total ankle replacement product, the INVISION™ Total Ankle Revision System, in the
third quarter of 2017.
Our principal upper extremities products include the AEQUALIS ASCEND® and SIMPLICITI® total shoulder replacement
systems, the AEQUALIS® REVERSED II™ reversed shoulder system, and the AEQUALIS ASCEND® FLEX™ convertible
shoulder system. SIMPLICITI® is the first minimally invasive, ultra-short stem total shoulder available in the United States.
We believe SIMPLICITI® allows us to expand the market to include younger patients that historically have deferred these
procedures. In December 2016, we received FDA 510(k) clearance of our AEQUALIS® PERFORM™ REVERSED Glenoid
System, our first reverse augmented glenoid. Other principal upper extremities products include the EVOLVE® radial head
prosthesis for elbow fractures, the EVOLVE® Elbow Plating System, RAYHACK® osteotomy system, and the MICRONAIL®
intramedullary wrist fracture repair system.
Our biologic products use both biological tissue-based and synthetic materials to allow the body to regenerate damaged or
diseased bone and to repair damaged or diseased soft tissue. The newest addition to our biologics product portfolio is
AUGMENT® Bone Graft, which is based on recombinant human platelet-derived growth factor (rhPDGF-BB), a synthetic
copy of one of the body’s principal healing agents. FDA approval of AUGMENT® Bone Graft in the United States for ankle
and/or hindfoot fusion indications occurred during the third quarter of 2015. Prior to FDA approval, this product was available
for sale in Canada for foot and ankle fusion indications and in Australia and New Zealand for hindfoot and ankle fusion
59
indications. The AUGMENT® Bone Graft product line was acquired from BioMimetic Therapeutics, Inc. (BioMimetic) in
March 2013. Our other principal biologics products include the GRAFTJACKET® line of soft tissue repair and containment
membranes, the ALLOMATRIX® line of injectable tissue-based bone graft substitutes, the PRO-DENSE® Injectable Graft, the
OSTEOSET® synthetic bone graft substitute, and the PRO-STIM® Injectable Inductive Graft.
Supplemental Non-GAAP Pro Forma Information. Due to the significance of the legacy Tornier business that is not included
in our results of operations for the majority of the year ended December 27, 2015 and to supplement our consolidated financial
statements prepared in accordance with US GAAP, we use certain non-GAAP financial measures, including combined pro
forma net sales. Our non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may
be different from non-GAAP financial measures used by other companies. In addition, our non-GAAP financial measures are
not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of our non-
GAAP financial measures may differ from the definitions of other companies using the same or similar names limiting, to some
extent, the usefulness of such measures for comparison purposes. We believe that non-GAAP financial measures have
limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance
with GAAP and that these measures should only be used to evaluate our results of operations in conjunction with the
corresponding GAAP measures. See table under “Results of Operations” for a reconciliation of our non-GAAP combined pro
forma net sales for the year ended December 27, 2015 to our net sales for such period as calculated in accordance with US
GAAP.
Significant Business Developments. On December 23, 2016, we, together with WMG and certain of our other wholly-owned
U.S. subsidiaries, entered into a Credit, Security and Guaranty Agreement (ABL Agreement) with Midcap Financial Trust, as
administrative agent (Agent) and a lender and the additional lenders from time to time party thereto. The ABL Agreement
provides for a $150.0 million senior secured asset based line of credit, subject to the satisfaction of a borrowing base
requirement (ABL Facility). The ABL Facility may be increased by up to $100.0 million upon our request, subject to the
consent of the Agent and each of the other lenders providing such increase and the satisfaction of customary conditions. As of
December 25, 2016, we had $30 million in borrowings outstanding under the ABL Facility. See Note 9 to our consolidated
financial statements for additional discussion related to the ABL Facility and our other debt.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing
plaintiffs in the metal-on-metal hip replacement product liability litigation pending before the United States District Court for
the Northern District of Georgia (the MDL) and the California State Judicial Counsel Coordinated Proceedings (the JCCP).
Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims associated with CONSERVE®,
DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and are either pending in the MDL or
JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million. As of
December 25, 2016, our accrual for metal-on-metal claims totaled $256.7 million, of which $242.8 million is included in our
consolidated balance sheet within “Accrued expenses and other current liabilities” and $13.9 million is included within “Other
liabilities.” See Note 16 to our consolidated financial statements for additional discussion regarding the MSA and our accrual
methodologies for the metal-on-metal hip replacement product liability claims.
During the fourth quarter of 2016, WMT deposited $150.0 million into a restricted escrow account to secure its obligations
under the MSA. All individual settlements under the MSA will be funded first from the escrow account and then, if all funds
held in the escrow account have been exhausted, directly by WMT. As of December 25, 2016, $150.0 million was in the
restricted escrow account, and therefore, considered restricted cash under U.S. GAAP. See Note 16 and Note 17 to the
consolidated financial statements for further discussion regarding the MSA, the metal-on-metal hip litigation and the funding
for such claims.
On October 28, 2016, WMT and Wright Medical Group, Inc. (Wright Entities) entered into a Settlement Agreement, Indemnity
and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three
insurance carriers, namely Columbia Casualty Company (Columbia), Travelers and AXIS Surplus Lines Insurance Company
(collectively, the Three Settling Insurers), pursuant to which the Three Settling Insurers agreed to pay WMT an aggregate of
$60 million (in addition to $10 million previously paid by Columbia) in a lump sum on or before the 30th business day after
execution of the Insurance Settlement Agreement. This amount is in full satisfaction of all potential liability of the Three
Settling Insurers relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in
the MDL and the JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described
in the section entitled “Legal Proceedings.” The amount due to the Wright Entities under the Insurance Settlement Agreement
was paid in the fourth quarter of 2016. During the year ended December 25, 2016 and December 27, 2015, we received
insurance proceeds of $65.6 million and $6.1 million, respectively, related to metal-on-metal hip and similar metal ion release
claims. Additionally, during the year ended December 25, 2016 and December 27, 2015, our insurance carriers paid
$1.3 million and $3.3 million, respectively, directly to claimants in connection with various metal-on-metal settlements.
Management has recorded an insurance receivable of $8.7 million for the probable recovery of spending from the remaining
60
carriers (other than the Three Settling Carriers) in excess of our retention for a single occurrence. See Note 16 to our
consolidated financial statements for additional discussion regarding the Insurance Settlement Agreement.
On October 21, 2016, pursuant to a binding offer letter, dated as of July 8, 2016, we completed and closed the sale of our
business operations operating under the Large Joints operating segment (the Large Joints business) to Corin for approximately
€29.7 million in cash, less approximately €10.7 million for net working capital adjustments. All historical operating results for
the Large Joints business, including costs associated with corporate employees and infrastructure transferred as a part of the
sale, are reflected within discontinued operations in our consolidated statements of operations. Further, all assets and
associated liabilities transferred to Corin were classified as assets and liabilities held for sale in our consolidated balance sheet
as of December 27, 2015. See Note 4 to our consolidated financial statements for additional discussion related to our
discontinued operations.
In May 2016, we issued new convertible debt, resulting in net cash proceeds of approximately $237.5 million (including the
settlement and issuance of associated hedging transactions, and the exchange of certain previously outstanding convertible
debt). See Note 6 and Note 9 to our consolidated financial statements for additional information regarding these transactions.
On September 29, 2015, legacy Wright’s five-year Corporate Integrity Agreement with the Office of the Inspector General of
the United States Department of Health and Human Services expired, and on January 27, 2016, we received notification from
the OIG-HHS that the term of the CIA has concluded.
On September 1, 2015, FDA approval of AUGMENT® Bone Graft in the United States for ankle and/or hindfoot fusion
indications was obtained, and we commercially launched the product in the United States shortly thereafter.
On June 16, 2014, legacy Wright announced the full U.S. commercial launch of the INFINITY® Total Ankle Replacement
System, which complements our ankle portfolio and allows us to offer a total ankle replacement system that addresses the
continuum of care for end-stage ankle arthritis patients.
On January 30, 2014, legacy Wright completed the acquisition of Solana Surgical, LLC, and on February 5, 2014, completed
the acquisition of OrthoPro, L.L.C., both privately-held, high-growth extremities companies. These acquisitions added
complementary extremities product portfolios to further accelerate growth opportunities in our global extremities business.
Legacy Wright acquired 100% of the outstanding equity of Solana for approximately $48 million in cash and $41.4 million of
WMG common stock. Legacy Wright acquired 100% of OrthoPro’s outstanding equity for approximately $32.5 million in
cash.
On January 9, 2014, legacy Wright completed the sale of its OrthoRecon business to MicroPort. The financial results of the
OrthoRecon business have been reflected within discontinued operations for all periods presented, unless otherwise noted.
Financial Highlights. Net sales increased 70.3% totaling $690.4 million in 2016, compared to $405.3 million in 2015,
primarily due to the impact of the Wright/Tornier merger. Net sales in 2016 increased 12.2% as compared to 2015 non-GAAP
combined pro forma net sales (pro forma net sales), primarily driven by 14.3% growth in our U.S. businesses.
Our U.S. net sales increased by $207.7 million, or 69.3%, in 2016 as compared to 2015, primarily due to the impact of the
Wright/Tornier merger. Our U.S. sales in 2016 increased 14.3% as compared to 2015 combined pro forma net sales, driven
primarily by the continued success of our INFINITY® total ankle replacement system, and the ongoing rollouts of the
SIMPLICITI® shoulder system, AEQUALIS ASCEND® FLEXTM convertible shoulder system and AUGMENT® Bone Graft
product.
Our international net sales increased $77.3 million, or 73.3%, in 2016 as compared to 2015, primarily due to the impact of the
Wright/Tornier merger. Our international net sales in 2016 increased 6.6% as compared to 2015 combined pro forma net sales,
driven primarily by 20.1% combined pro forma net sales growth in Australia and 13.7% combined pro forma net sales growth
in Canada, which was partially offset by a $4.7 million unfavorable impact from foreign currency exchange rates.
In 2016, our net loss from continuing operations totaled $164.9 million, compared to a net loss from continuing operations of
$237.4 million in 2015. This decrease in net loss from continuing operations was primarily driven by the following:
•
•
$64.1 million decrease in transaction and transition expenses, including the $14.2 million charge in 2015 for
share-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:70)(cid:70)(cid:72)(cid:79)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:71)(cid:88)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)
$46.6 million increase in profitability of our U.S. Lower Extremities and Biologics segment driven by leverage on
(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:3)(cid:74)(cid:85)(cid:72)(cid:90)(cid:3)(cid:68)(cid:87)(cid:3)(cid:68)(cid:3)(cid:79)(cid:82)(cid:90)(cid:72)(cid:85)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:87)(cid:75)(cid:68)(cid:81)(cid:3)(cid:81)(cid:72)(cid:87)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:30)
61
•
•
•
$43.8 million increase in profitability of our U.S. Upper Extremities segment driven almost entirely by the
acquired (cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)
$11.4 million increase in profitability of our International Extremities and Biologics segment driven almost
(cid:72)(cid:81)(cid:87)(cid:76)(cid:85)(cid:72)(cid:79)(cid:92)(cid:3)(cid:69)(cid:92)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:71)(cid:3)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
$14.0 million decrease in other (income) expense, net, primarily driven by a $12.3 million charge in 2016 as
compared to a $25.1 million charge in 2015 for the write-off of pro-rata unamortized deferred financing fees and
debt discount.
The favorable changes in net loss from continuing operations were partially offset by:
•
•
•
$65.4 million (cid:82)(cid:73)(cid:3)(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:68)(cid:79)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:15)(cid:3)(cid:83)(cid:85)(cid:76)(cid:80)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)(cid:3)(cid:71)(cid:88)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:71)(cid:3)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)
$27.4 million of incremental cost of sales for the non-cash amortization of the inventory step-up fair value
adjustment associated with the Wright/Tornier merg(cid:72)(cid:85)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
$17.2 million of incremental interest expense, primarily due to cash interest and non-cash amortization of debt
discount and deferred financing charges associated with the 2021 Notes that were issued in the second quarter of
2016.
Opportunities and Challenges. With the sale of our Large Joints business to Corin, we believe we are now well positioned and
completely focused on accelerating growth in our extremities and biologics business. We intend to continue to leverage the
global strengths of both our legacy Wright and legacy Tornier product brands as a pure-play extremities and biologics business.
We believe our leadership has been and will continue to be further enhanced by the FDA approval of AUGMENT® Bone Graft,
a biologic solution that adds additional depth to one of the most comprehensive extremities product portfolios in the industry,
as well as provides a platform technology for future new product development. We believe the highly complementary nature of
legacy Wright’s and legacy Tornier’s businesses gives significant diversity and scale across a range of geographies and product
categories. We believe we are differentiated in the marketplace by our strategic focus on extremities and biologics, our full
portfolio of upper and lower extremities and biologics products, and our specialized and focused sales organization.
We are highly focused on ensuring that no business momentum is lost as we continue to integrate legacy Wright and legacy
Tornier. Since the merger and through the end of 2016, we have completed the integration of our global sales force, co-located
and consolidated into one enterprise resource planning (ERP) system in three of our top five international markets and
completed a substantial number of other integration activities, while incurring more cost synergies earlier and less sales dis-
synergies than we originally anticipated. Although we recognize that we will continue to have revenue dis-synergies during the
remaining integration period, we believe we have an excellent opportunity to improve efficiency and leverage fixed costs in our
business going forward. We also believe we have significant opportunity at the same time to advance certain balance sheet
initiatives, such as improving our inventory, instrument set utilization and days sales outstanding (DSO).
While our ultimate financial goal is to achieve sustained profitability in the short-term, we anticipate continuing operating
losses until we are able to grow our sales to a sufficient level to support our cost structure, including the inherent infrastructure
costs of our industry.
Significant Industry Factors. Our industry is affected by numerous competitive, regulatory, and other significant factors. The
growth of our business relies on our ability to continue to develop new products and innovative technologies, obtain regulatory
clearance and maintain compliance for our products, protect the proprietary technology of our products and our manufacturing
processes, manufacture our products cost-effectively, respond to competitive pressures specific to each of our geographic
markets, including our ability to enforce non-compete agreements, and successfully market and distribute our products in a
profitable manner. We, and the entire industry, are subject to extensive governmental regulation, primarily by the FDA.
Failure to comply with regulatory requirements could have a material adverse effect on our business, operating results, and
financial condition. We, as well as other participants in our industry, are subject to product liability claims, which could have a
material adverse effect on our business, operating results, and financial condition.
Results of Operations
On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, we closed the sale of our Large Joints business
to Corin. The financial results of our Large Joints business are reflected within discontinued operations for all periods
presented.
On January 9, 2014, legacy Wright completed the sale of its hip and knee (OrthoRecon) business to MicroPort. The financial
results of the OrthoRecon business are also reflected within discontinued operations for all periods presented.
The discussion below is on a continuing operations basis, unless otherwise noted.
62
Comparison of the year ended December 25, 2016 to the year ended December 27, 2015
The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands)
and as percentages of net sales:
Net sales
Cost of sales 1, 2
Gross profit
Operating expenses:
Selling, general and administrative 1
Research and development 1
Amortization of intangible assets
Total operating expenses
Operating loss
Interest expense, net
Other (income) expense, net
Loss from continuing operations before income taxes
Benefit for income taxes
Net loss from continuing operations
Loss from discontinued operations, net of tax
Net loss
Fiscal year ended
December 25, 2016
December 27, 2015 3
Amount
% of net sales
Amount
% of net sales
$
$
$
690,362
192,407
497,955
541,558
50,514
28,841
620,913
(122,958)
58,530
(3,148)
(178,340)
(13,406)
(164,934)
(267,439)
(432,373)
100.0 % $
27.9 %
72.1 %
405,326
113,622
291,704
78.4 %
7.3 %
4.2 %
89.9 %
(17.8 )%
8.5 %
(0.5)%
(25.8)%
(1.9)%
(23.9)% $
$
424,377
39,339
16,754
480,470
(188,766)
41,358
10,884
(241,008)
(3,652)
(237,356)
(61,345)
(298,701)
100.0 %
28.0 %
72.0 %
104.7 %
9.7 %
4.1 %
118.5 %
(46.6 )%
10.2 %
2.7 %
(59.5)%
(0.9)%
(58.6)%
___________________________
1
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Cost of sales
Selling, general and administrative
Research and development
Fiscal year ended
December 25,
2016
% of net sales
December 27,
2015
% of net sales
$
414
13,216
786
0.1% $
1.9%
0.1%
287
22,777
1,900
0.1%
5.6%
0.5%
2
3
Cost of sales includes amortization of inventory step-up adjustment of $37.7 million and $10.3 million for the years ended December 25,
2016 and December 27, 2015, respectively.
The 2015 results were restated for the divestiture of our Large Joints business.
The following table sets forth our net sales by product line for our U.S. and International businesses for the periods indicated
(in thousands) and the percentage of year-over-year change:
U.S.
Lower extremities
Upper extremities
Biologics
Sports med & other
Total U.S.
International
Lower extremities
Upper extremities
Biologics
Sports med & other
Total International
December
25, 2016
Fiscal year ended
December
27, 2015 1
% change
$ 222,936 $ 187,096
58,756
50,583
3,388
$ 507,547 $ 299,823
201,579
74,603
8,429
19.2 %
243.1 %
47.5 %
148.8 %
69.3 %
$
62,701 $
86,502
18,883
14,729
51,200
24,789
19,652
9,862
$ 182,815 $ 105,503
22.5 %
249.0 %
(3.9)%
49.4 %
73.3 %
Total net sales
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
$ 690,362 $ 405,326
70.3 %
63
The results of operations discussion that appears below has been presented utilizing a combination of historical unaudited and,
where relevant, non-GAAP combined pro forma unaudited information to include the effects on our consolidated financial
statements of our acquisition of Tornier, as if we had acquired Tornier as of January 1, 2014. The combined pro forma net sales
have been adjusted to reflect a combination of the historical results of operations of Tornier, as adjusted to reflect the effect on
our combined net sales of incremental revenues that would have been recognized had Tornier been acquired on January 1,
2014. The combined pro forma net sales have been developed based on available information and upon assumptions that our
management believes are reasonable in order to reflect, on a pro forma basis, the impact of the Wright/Tornier merger.
The pro forma financial data is not necessarily indicative of results of operations that would have occurred had the
Wright/Tornier merger been consummated at the beginning of the period presented or which might be attained in the future.
The following table reconciles our non-GAAP combined pro forma net sales by product line for the year ended December 27,
2015 (in thousands):
Legacy Tornier
N.V. standalone
nine months ended
September 27,
2015 2
Fiscal year ended December 27, 2015
Legacy Tornier
Stub Period
(September 28,
2015 - September
30, 2015) 3
Legacy Tornier
net sales divested 4
Net sales as
reported 1
187,096 $
58,756
50,583
3,388
299,823
—
299,823 $
51,200 $
24,789
19,652
9,862
105,503
—
105,503 $
238,296 $
83,545
70,235
13,250
405,326
—
405,326 $
29,637 $
115,846
1,290
5,021
151,794
119
151,913 $
7,402 $
51,293
357
5,372
64,424
29,921
94,345 $
37,039 $
167,139
1,647
10,393
216,218
30,040
246,258 $
279 $
1,773
66
4
2,122
—
2,122 $
152 $
1,260
13
132
1,557
753
2,310 $
431 $
3,033
79
136
3,679
753
4,432 $
(9,733) $
—
—
—
(9,733)
(119)
(9,852) $
— $
—
—
—
—
(30,674)
(30,674) $
(9,733) $
—
—
—
(9,733)
(30,793)
(40,526) $
Non-GAAP
combined pro
forma
net sales
207,279
176,375
51,939
8,413
444,006
—
444,006
58,754
77,342
20,022
15,366
171,484
—
171,484
266,033
253,717
71,961
23,779
615,490
—
615,490
U.S.
Lower extremities
Upper extremities
Biologics
Sports med & other
Total extremities & biologics
Large joint
Total U.S.
International
Lower extremities
Upper extremities
Biologics
Sports med & other
Total extremities & biologics
Large joint
Total International
Global
Lower extremities
Upper extremities
Biologics
Sports med & other
Total extremities & biologics
$
$
$
$
$
Large joint
Total net sales
___________________________
1
$
The 2015 results were restated for the divestiture of our Large Joints business.
2
3
4
Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical
Tornier product line “Large Joints and Other” to the product line associated with those revenues that will be utilized for future revenue
reporting.
To add revenues from Legacy Tornier’s fourth quarter for the period prior to the merger closing date when operations became
consolidated.
To reduce from Tornier’s historical sales the U.S. sales associated with Tornier’s Salto Talaris and Salto XT ankle replacement products
and silastic toe replacement products that were divested prior to the merger and the global sales associated with Tornier’s Large Joints
business that have been reflected in discontinued operations.
64
The following table sets forth our 2016 net sales growth rates by product line as compared to our 2015 non-GAAP combined
pro forma net sales for the periods indicated (in thousands) and the percentage of year-over-year change:
U.S.
Lower extremities
Upper extremities
Biologics
Sports med & other
Total U.S.
International
Lower extremities
Upper extremities
Biologics
Sports med & other
Total International
Global
Lower extremities
Upper extremities
Biologics
Sports med & other
Total net sales
Net sales
Net sales
Fiscal year ended
December 25, 2016
Non-GAAP
combined pro forma
net sales
Fiscal year ended
December 27, 2015
%
change
$
$
$
$
$
$
222,936 $
201,579
74,603
8,429
507,547 $
62,701 $
86,502
18,883
14,729
182,815 $
285,637 $
288,081
93,486
23,158
690,362 $
207,279
176,375
51,939
8,413
444,006
58,754
77,342
20,022
15,366
171,484
266,033
253,717
71,961
23,779
615,490
7.6 %
14.3 %
43.6 %
0.2 %
14.3 %
6.7 %
11.8 %
(5.7)%
(4.1)%
6.6 %
7.4 %
13.5 %
29.9 %
(2.6)%
12.2 %
U.S. net sales. U.S. net sales totaled $507.5 million in 2016, a 69.3% increase from $299.8 million in 2015, primarily due to the
impact of the Wright/Tornier merger. U.S. net sales in 2016 increased 14.3% as compared to 2015 pro forma net sales.
U.S. sales represented approximately 73.5% of total net sales in 2016, compared to 74.0% of total net sales in 2015.
Our U.S. lower extremities net sales increased to $222.9 million in 2016 from $187.1 million, representing growth of 19.2%,
driven by continued growth in legacy Wright’s lower extremities business, as well as the impact of the Wright/Tornier merger.
Our U.S. lower extremities net sales grew 7.6% in 2016 as compared to 2015 pro forma net sales. This pro forma net sales
growth was driven by 27.2% net sales growth in our total ankle replacement products, as well as sales from the recent launch of
our SALVATION® limb salvage system for treating Charcot foot and limb salvage cases, partially offset by declines in sales of
legacy Tornier foot and ankle products due to merger-related sales dis-synergies, which were anticipated and are expected to
continue.
Our U.S. upper extremities net sales increased to $201.6 million in 2016 from $58.8 million, representing growth of 243.1%.
This growth was driven almost entirely by the impact of the Wright/Tornier merger. Our U.S. upper extremities net sales grew
14.3% in 2016 as compared to 2015 pro forma net sales. This pro forma growth was driven by continued success of our
AEQUALIS ASCEND® shoulder products, including the AEQUALIS ASCEND® FLEXTM convertible shoulder system, as
well as sales from our SIMPLICITI® shoulder system that was launched late in the third quarter of 2015.
Our U.S. biologics net sales totaled $74.6 million in 2016, representing a 47.5% increase over 2015, driven primarily by sales
of AUGMENT® Bone Graft, which was commercially launched in the fourth quarter 2015. Our U.S. biologics net sales grew
43.6% in 2016 as compared to 2015 pro forma net sales, primarily driven by sales of AUGMENT® Bone Graft.
International net sales. Net sales of our extremities products in our international regions totaled $182.8 million in 2016, a
73.3% increase from $105.5 million in 2015, primarily due to the impact of the Wright/Tornier merger. Our international net
sales in 2016 increased 6.6% as compared to 2015 pro forma international net sales, and included a $4.7 million unfavorable
impact from foreign currency exchange rates (a 3 percentage point unfavorable impact to pro forma international net sales
growth rate).
Our international lower extremities net sales increased 22.5% to $62.7 million in 2016 from $51.2 million in 2015. Our
international lower extremities sales grew 6.7% in 2016 as compared to 2015 pro forma international lower extremities net
65
sales, primarily driven by a 16.7% increase in sales to stocking distributors and lower than normal sales in Latin America in the
prior year period. This increase was partially offset by merger-related sales dis-synergies, which are anticipated to continue,
and a $2.1 million unfavorable impact from foreign currency exchange rates (a 4 percentage point unfavorable impact to pro
forma international lower extremities sales growth rate).
Our international upper extremities net sales increased 249.0% to $86.5 million in 2016 from $24.8 million in 2015, driven
entirely by the impact of the Wright/Tornier merger. Our international upper extremities net sales grew 11.8% in 2016 as
compared to 2015 pro forma international upper extremities net sales, driven primarily by a 7.3% increase in sales in our direct
markets in Europe and a 37.9% increase in sales in Australia as a result of a stocking sale to a distributor, partially offset by a
$1.4 million unfavorable impact from foreign currency exchange rates (a 2 percentage point unfavorable impact to pro forma
international upper extremities sales growth rate).
Our international biologics net sales decreased 3.9% to $18.9 million in 2016 from $19.7 million in 2015. On a pro forma
basis, our international biologics net sales decreased 5.7% in 2016 as compared to 2015 pro forma international biologics net
sales. This decrease was primarily attributable to lower levels of sales to stocking distributors, as well as a $0.6 million
unfavorable impact from foreign currency exchange rates (a 3 percentage point unfavorable impact to pro forma international
biologics sales growth rate).
Cost of sales
Our cost of sales totaled $192.4 million, or 27.9% of net sales, in 2016, compared to $113.6 million, or 28.0% of net sales, in
2015, representing a decrease of 0.1 percentage points as a percentage of net sales. Cost of sales included $37.7 million (5.5%
of net sales) and $10.3 million (2.5% of net sales) of inventory step-up amortization in 2016 and 2015, respectively, associated
with inventory acquired from the Wright/Tornier merger. The remaining decrease in cost of sales as a percentage of net sales
was primarily driven by favorable geographic and product mix, as increased provisions for excess and obsolete inventory were
relatively flat as a percentage of sales due to the additional sales following the Wright/Tornier merger.
Our cost of sales and corresponding gross profit percentages can be expected to fluctuate in future periods depending upon,
among other factors, changes in our product sales mix and prices, distribution channels and geographies, manufacturing yields,
period expenses, levels of production volume, and currency exchange rates.
Selling, general and administrative
Our selling, general and administrative expenses totaled $541.6 million, or 78.4% of net sales, in 2016, compared to
$424.4 million, or 104.7% of net sales, in 2015. Selling, general and administrative expense for 2016 and 2015 included $31.9
million (4.6% of net sales) and $75.9 million (18.7% of net sales), respectively, of transition and transaction costs associated
with the Wright/Tornier merger. The remaining decrease in selling, general and administrative expenses as a percentage of net
sales was driven primarily by leveraged spending in our U.S. lower extremities and biologics segment as expense grew at a
significantly lower rate than net sales, the addition of the legacy Tornier U.S. upper extremities business with a lower
percentage of selling, general and administrative expenses as a percentage of net sales than legacy Wright, and lower levels of
corporate spending as a percentage of net sales following the Wright/Tornier merger.
Our selling, general and administrative expenses are expected to decrease as a percentage of sales in 2017, through a
combination of continued cost synergies and expense leverage as sales continue to increase at a higher rate than expenses.
Additionally, we anticipate that transition costs associated with the Wright/Tornier merger will decrease significantly in
absolute dollars in 2017.
Research and development
Our investment in research and development expense totaled $50.5 million in 2016 compared to $39.3 million in 2015. This
increase was almost entirely due to $15.1 million of additional research and development expenses associated with the acquired
Tornier business.
Our research and development expenses are estimated to range from 7% to 8% as a percentage of sales in 2017.
66
Amortization of intangible assets
Charges associated with amortization of intangible assets totaled $28.8 million in 2016, compared to $16.8 million in 2015.
This increase was driven by amortization of intangible assets acquired as part of the Wright/Tornier merger. Based on
intangible assets held at December 25, 2016, we expect to amortize approximately $27.2 million in 2017, $22.1 million in
2018, $20.4 million in 2019, $19.8 million in 2020, and $19.6 million in 2021.
Interest expense, net
Interest expense, net, totaled $58.5 million in 2016 and $41.4 million in 2015. Increased interest expense was driven by the
increase in debt outstanding following the issuance of the 2021 Notes in the second quarter of 2016 (see Note 9 to our
consolidated financial statements for further discussion of changes in our outstanding debt). Our interest expense in 2016
related primarily to non-cash interest expense associated with the amortization of the discount on the 2021 Notes and 2020
Notes of $9.8 million and $2(cid:24)(cid:17)(cid:28)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3) (cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3) (cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:71)(cid:72)(cid:73)(cid:72)(cid:85)(cid:85)(cid:72)(cid:71)(cid:3) (cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3) (cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:3) (cid:82)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:21)(cid:19)(cid:21)(cid:20)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:15)(cid:3) (cid:21)(cid:19)(cid:21)(cid:19)(cid:3)
(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:7)(cid:22)(cid:17)(cid:28)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:3)(cid:83)(cid:85)(cid:76)(cid:80)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86),
2020 Notes, and 2017 Notes totaling $17.8 million. Our interest expense in 2015 related primarily to non-cash interest expense
associated with the amortization of the discount on the 2020 Notes and 2017 Notes of $21.8 million and $2.9 million,
respectively, amortization of deferred financing charges on the 2020 Notes and 2017 Notes totaling $2.7 million and
$0.5 (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:7)(cid:20)(cid:21)(cid:17)(cid:27)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:17)(cid:3)(cid:3)(cid:36)(cid:81)(cid:3)(cid:76)(cid:81)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87)(cid:3)
amount of interest income was recorded during 2016 and 2015. The amount of interest income we expect to realize
in 2017 and beyond is subject to variability, dependent upon both the rate of invested returns we realize and the amount of
excess cash balances on hand.
Our interest expense, net, is anticipated to increase during 2017, due to the mid-year issuance of the 2021 Notes and the debt
outstanding under the ABL Facility entered into in December 2016.
Other (income) expense, net
Other (income) expense, net was $3.1 million of income in 2016, compared to $10.9 million of expense in 2015. In 2016, other
income, net included a gain of $28.3 million for the net mark-to-market adjustments on our derivative assets and liabilities.
This gain was partially offset by an unrealized loss of $8.7 million for the mark-to-market adjustment on CVRs issued in
connection with the BioMimetic acquisition. In 2015, other expense, net included a gain of $7.6 million for the mark-to-market
adjustment on the CVRs issued in connection with the BioMimetic acquisition, as well as an unrealized gain of $9.8 million for
the mark-to-market adjustment on our derivatives, offset by a $25.1 million charge for write-off of pro-rata unamortized
deferred financing fees and debt discount with repayment of $240 million of the 2017 Notes.
Benefit for income taxes
We recorded a tax benefit of $13.4 million in 2016 and $3.7 million in 2015. During 2016, our effective tax rate was
approximately 7.5%, as compared to 1.7% in 2015. Our 2016 tax benefit included a $5.6 million benefit representing the
deferred tax effects associated with the acquired Tornier operations, as well as a $2.3 million benefit related to the resolution of
an IRS tax audit. The remaining tax benefit in 2016 was primarily related to losses, including amortization of inventory fair
value step-up and intangible assets, in jurisdictions where we do not have a valuation allowance. Our 2015 tax benefit was
primarily attributable to losses benefited in jurisdictions where we did not have a valuation allowance. Our relatively low
effective tax rate in both periods was primarily related to the valuation allowance on our U.S. net deferred tax assets, resulting
in the inability to recognize a tax benefit for pre-tax losses in the United States except to the extent to which we recognize a
gain in discontinued operations.
Loss from discontinued operations, net of tax
Loss from discontinued operations, net of tax, consists of the operations of the Large Joints business that was sold to Corin, as
well as the costs associated with legal defense, income/loss associated with product liability insurance recoveries/denials, and
changes to any contingent liabilities associated with the OrthoRecon business that was sold to MicroPort. During 2016, we
recognized a $196.6 million charge, net of insurance proceeds, for certain retained metal-on-metal product liability claims
associated with the OrthoRecon business primarily as a result of the Master Settlement Agreement we entered into in
November 2016 (see Note 16 to our consolidated financial statements for further discussion). See Note 4 to our consolidated
financial statements for further discussion of our discontinued operations.
67
Reportable segments
The following tables set forth, for the periods indicated, net sales and operating income (loss) of our reportable segments
expressed as dollar amounts (in thousands) and as a percentage of net sales:
Net sales
Operating income
Operating income as a percent of net sales
Net sales
Operating income (loss)
Operating income (loss) as a percent of net sales
Fiscal year ended December 25, 2016
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
300,847
85,645
$
$
28.5%
206,700
65,231
$
$
31.6%
182,815
5,872
3.2%
Fiscal year ended December 27, 2015
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
239,748
39,008
$
$
16.3%
60,075
21,394
$
$
35.6%
105,503
(5,567)
(5.3)%
$
$
$
$
Net sales of our U.S. lower extremities and biologics segment increased $61.1 million in 2016 over the prior year. This
increase was driven by continued growth in legacy Wright’s lower extremities business, sales of AUGMENT® Bone Graft,
which was commercially launched in the fourth quarter 2015, as well as the impact of the Wright/Tornier merger. Operating
income of our U.S. lower extremities and biologics segment increased $46.6 million in 2016 over the prior year. This increase
was driven by leveraging expenses, as net sales increased at a higher rate than operating expenses.
Net sales of our U.S. upper extremities segment increased $146.6 million in 2016 over the prior year. This increase was driven
almost entirely by the impact of the Wright/Tornier merger. Operating income of our U.S. upper extremities segment increased
$43.8 million in 2016 over the prior year. This increase was driven almost entirely by the acquired Tornier business.
Net sales of our International extremities and biologics segment increased $77.3 million in 2016 over the prior year. This
increase was primarily due to the impact of the Wright/Tornier merger. Operating income of our International extremities and
biologics segment increased $11.4 million in 2016 over the prior year. This increase was primarily driven by the acquired
Tornier business.
Comparison of the year ended December 27, 2015 to the year ended December 31, 2014
The following table sets forth, for the periods indicated, our results of operations expressed as dollar amounts (in thousands)
and as percentages of net sales:
$
Net sales
Cost of sales1,2
Gross profit
Operating expenses:
Selling, general and administrative1
Research and development1
Amortization of intangible assets
Total operating expenses
Operating loss
Interest expense, net
Other expense, net
Loss from continuing operations before income taxes
Benefit for income taxes
Net loss from continuing operations
(Loss) income from discontinued operations, net of tax1
Net loss
$
$
68
December 27, 20153
December 31, 2014
Fiscal year ended
Amount
% of net sales
Amount
% of net sales
405,326
113,622
291,704
424,377
39,339
16,754
480,470
(188,766)
41,358
10,884
(241,008)
(3,652)
(237,356)
(61,345)
(298,701)
100.0 % $
28.0 %
72.0 %
104.7 %
9.7 %
4.1 %
118.5 %
(46.6)%
10.2 %
2.7 %
(59.5)%
(0.9)%
(58.6)% $
$
298,027
73,223
224,804
289,620
24,963
10,027
324,610
(99,806)
17,398
129,626
(246,830)
(6,334)
(240,496)
(19,187)
(259,683)
100.0 %
24.6 %
75.4 %
97.2 %
8.4 %
3.4 %
108.9 %
(33.5)%
5.8 %
43.5 %
(82.8)%
(2.1)%
(80.7)%
___________________________
1
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Cost of sales
Selling, general and administrative
Research and development
Fiscal year ended
December 27,
2015
% of net sales
December 31,
2014
% of net sales
$
287
22,777
1,900
0.1% $
5.6%
0.5%
254
10,149
1,084
0.1%
3.4%
0.4%
2
3
Cost of sales includes amortization of inventory step-up adjustment $10.3 million for the year ended December 27, 2015.
The 2015 results were restated for the divestiture of our Large Joints business.
The following table sets forth our net sales by product line for the periods indicated (in thousands) and the percentage of year-
over-year change:
U.S.
Lower extremities
Upper extremities
Biologics
Sports med & other
Total U.S.
International
Lower extremities
Upper extremities
Biologics
Sports med & other
Total International
Total net sales
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
Net sales
December
27, 2015 1
Fiscal year ended
December
31, 2014
% change
$ 187,096 $ 148,631
15,311
45,494
2,641
$ 299,823 $ 212,077
58,756
50,583
3,388
25.9 %
283.8 %
11.2 %
28.3 %
41.4 %
$
51,200 $
24,789
19,652
9,862
$ 105,503 $
47,001
11,312
20,590
7,047
85,950
8.9 %
119.1 %
(4.6)%
39.9 %
22.7 %
$ 405,326 $ 298,027
36.0 %
U.S. net sales. U.S. net sales totaled $299.8 million in 2015, a 41.4% increase from $212.1 million in 2014, representing
approximately 74.0% of total net sales in 2015, compared to 71.2% of total net sales in 2014. Products acquired as part of the
Wright/Tornier merger contributed sales of $51.6 million, which accounted for 24 percentage points of the increase from 2014.
Our U.S. lower extremities net sales increased to $187.1 million in 2015 from $148.6 million, representing growth of 25.9%
over 2014. Sales in 2015 included $6.7 million from products acquired from the Wright/Tornier merger, which accounted for 4
percentage points of the increase. The remaining $31.8 million increase was driven by continued success of our Total Ankle
Replacement products, as well as growth in our core foot and ankle plating systems.
Our U.S. upper extremities net sales increased to $58.8 million in 2015 from $15.3 million, representing growth of 283.8%,
driven entirely by $43.3 million of acquired product sales from the Wright/Tornier merger.
Our U.S. biologics net sales totaled $50.6 million in 2015, representing an 11.2% increase over 2014, primarily driven by sales
of recently launched biologic products, including AUGMENT® Bone Graft, which was commercially launched in the fourth
quarter of 2015.
International extremities net sales. Net sales of our extremities products in our international regions totaled $105.5 million in
2015, a 22.7% increase from $86.0 million in 2014. Products acquired as part of the Wright/Tornier merger contributed sales of
$21.7 million in 2015, which accounted for 25 percentage points of the increase from 2014. Our 2015 international extremities
sales included an unfavorable foreign currency impact of approximately $10.5 million when compared to 2014 net sales, which
had a 12 percentage point unfavorable impact on the growth rate.
69
Our international lower extremities net sales increased 8.9% to $51.2 million in 2015, including a $6.2 million unfavorable
foreign currency impact which had a 13 percentage point unfavorable impact on the growth rate. Sales in 2015 included
$2.5 million from products acquired from the Wright/Tornier merger, which accounted for 5 percentage points of the increase in
2015. The remaining increase was driven by an 8% increase in sales in our direct markets in Europe, a 50% increase in sales in
Australia and a 30% increase in sales in Canada.
Our international upper extremities net sales increased 119.1% to $24.8 million in 2015 from $11.3 million, driven entirely by
$17.3 million of acquired product sales from the Wright/Tornier merger. Additionally, 2015 sales included a $1.1 million
unfavorable foreign currency impact which had a 9 percentage point unfavorable impact on the growth rate.
Our international biologics net sales decreased 4.6% to $19.7 million, wholly attributable to a $2.0 million unfavorable foreign
currency impact, which had a 10 percentage point unfavorable impact on the growth rate.
Cost of sales
Our cost of sales totaled $113.6 million, or 28.0% of net sales, in 2015, compared to $73.2 million, or 24.6% of net sales, in
2014, representing an increase of 3.4 percentage points as a percentage of net sales. This increase was primarily driven by
$10.3 million (2.5% of net sales) of inventory step-up amortization in 2015 associated with inventory acquired from the
Wright/Tornier merger, as well as increased provisions for excess and obsolete inventory and inventory losses.
Selling, general and administrative
As a percentage of net sales, selling, general and administrative expenses increased to 104.7% in 2015, compared to 97.2% in
2014. Selling, general and administrative expense included $75.9 million (18.7% of net sales) and $31.9 million (10.7% of net
sales) of due diligence, transition, and transaction costs associated with the Wright/Tornier merger and other recent acquisitions
in 2015 and 2014, respectively. For 2015, selling, general and administrative expense also included a $13.1 million (3.2% of
net sales) share-based compensation charge for accelerated vesting of outstanding unvested awards upon closing of the
Wright/Tornier merger. For 2014, selling, general and administrative expense also included $1.2 million of costs related to
management changes (0.4% of net sales) and $0.9 million of costs related to a patent dispute settlement (0.3% of net sales).
The remaining selling, general and administrative expenses decrease as a percentage of sales was driven primarily by
leveraging general and administrative expenses over increased net sales.
Research and development
Our investment in research and development activities represented 9.7% and 8.4% of net sales in 2015 and 2014, respectively.
Research and development costs increased as a percentage of net sales in 2015 compared to 2014 primarily attributable to
spending to support our product portfolio.
Amortization of intangible assets
Charges associated with amortization of intangible assets totaled $16.8 million in 2015, compared to $10.0 million in 2014.
This increase was driven by amortization of intangible assets acquired as part of the Wright/Tornier merger, as well as a $1.8
million write-off of a legacy Wright intangible asset.
Interest expense, net
Interest expense, net totaled $41.4 million in 2015 and $17.4 million in 2014. Increased interest expense was driven by the
increase in debt outstanding following the issuance of the 2020 Notes in the first quarter of 2015. Our 2015 interest expense
related primarily to non-cash interest expense associated with the amortization of the discount on the 2020 Notes and 2017
(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:7)(cid:21)(cid:20)(cid:17)(cid:27)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:7)(cid:21)(cid:17)(cid:28)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)(cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:72)(cid:73)(cid:72)(cid:85)(cid:85)(cid:72)(cid:71)(cid:3)(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:3)
(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:7)(cid:21)(cid:17)(cid:26)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:7)(cid:19)(cid:17)(cid:24)(cid:3) (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3) (cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:70)(cid:68)(cid:86)(cid:75)(cid:3) (cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:3) (cid:82)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:21)(cid:19)(cid:21)(cid:19)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:21)(cid:19)(cid:20)(cid:26)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3) (cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:76)(cid:81)g
$12.8 million. Our 2014 interest expense related primarily to non-cash interest expense associated with the amortization of the
discount on the 2017 Notes of $9.3 million, as well as cash interest expense on the 2017 Notes totaling $6.0 million.
Our interest income generated in 2015 and 2014 was approximately $0.3 million in both years, and was generated by our
invested cash balances and investments in marketable securities.
70
Other expense, net
Other expense, net was $10.9 million of expense in 2015, compared to $129.6 million of income in 2014. For 2015, other
expense, net includes a gain of $7.6 million for the mark-to-market adjustment on the CVRs issued in connection with the
BioMimetic acquisition, as well as an unrealized gain of $9.8 million for the mark-to-market adjustment on our derivatives,
offset by a $25.1 million charge for write-off of pro-rata unamortized deferred financing fees and debt discount with repayment
of $240 million of the 2017 Notes. For 2014, other expense, net includes an unrealized loss of $125.0 million for the mark-to-
market adjustment on the CVRs issued in connection with the BioMimetic acquisition, $1.8 million for the fair value
adjustment for contingent consideration associated with the WG Healthcare acquisition, and an unrealized loss of $2.0 million
for net mark-to-market adjustments on our derivative asset and liability.
Benefit for income taxes
We recorded a tax benefit of $3.7 million in 2015 and $6.3 million in 2014. During 2015, our effective tax rate was
approximately 1.7%, as compared to 2.6% in 2014. Our 2015 tax benefit was primarily attributable to losses benefited in
jurisdictions where we did not have a valuation allowance. Our 2014 tax benefit included $5.5 million of benefit recorded in
continuing operations as a result of the gain realized in discontinued operations. Our relatively low effective tax rate in both
periods was primarily related to the valuation allowance on our U.S. net deferred tax assets, resulting in the inability to
recognize a tax benefit for pre-tax losses in the United States except to the extent to which we recognize a gain in discontinued
operations.
Loss from discontinued operations, net of tax
Loss from discontinued operations, net of tax consists of the operations of the OrthoRecon business that was sold to MicroPort
and, for 2015, the Large Joints business that was sold to Corin.
For 2014, net loss from discontinued operations included operations from January 1 through January 9, 2014, which was the
closing date of the MicroPort transaction, costs associated with external legal defense fees, and changes to any contingent
liabilities associated with the OrthoRecon business, as well as the $24.3 million gain on the sale of the OrthoRecon business.
Subsequent to the closing date, costs associated with legal defense, income/loss associated with product liability insurance
recoveries/denials, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected
within results of discontinued operations. For 2015, net loss from discontinued operations included legal defense and product
liability associated with the OrthoRecon business and the operations of the Large Joints business from October 1, 2015, the
date of the Wright/Tornier merger, through December 27, 2015.
Reportable segments
The following tables set forth, for the periods indicated, net sales and operating income (loss) of our reportable segments
expressed as dollar amounts (in thousands) and as a percentage of net sales:
Net sales
Operating income (loss)
Operating income (loss) as a percent of net sales
Net sales
Operating income (loss)
Operating income (loss) as a percent of net sales
Fiscal year ended December 27, 2015
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
239,748
39,008
$
$
16.3%
60,075
21,394
$
$
35.6%
105,503
(5,567)
(5.3)%
Fiscal year ended December 31, 2014
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
196,766
29,200
$
$
14.8%
15,311
6,582
$
$
43.0%
85,950
(3,187)
(3.7)%
$
$
$
$
Net sales of our U.S. lower extremities and biologics segment increased $43.0 million in 2015 over the prior year. This
increase was driven by continued success of our Total Ankle Replacement products, growth in our core foot and ankle plating
systems, as well as the impact of the Wright/Tornier merger. Operating income of our U.S. lower extremities and biologics
segment increased $9.8 million in 2015 as compared to 2014. This increase was driven by leveraging expenses, as net sales
increased at a higher rate than operating expenses.
71
Net sales of our U.S. upper extremities segment increased $44.8 million in 2015 over the prior year. This increase was driven
almost entirely by the impact of the Wright/Tornier merger. Operating income of our U.S. upper extremities segment increased
$14.8 million in 2015 as compared to 2014. This increase was driven almost entirely by the acquired Tornier business.
Net sales of our International extremities and biologics segment increased $19.6 million in 2015 over the prior year. This
increase was primarily due to the impact of the Wright/Tornier merger. Operating loss of our International extremities and
biologics segment increased $2.4 in 2015 as compared to 2014. This increase was primarily driven by the acquired Tornier
business.
Seasonality and Quarterly Fluctuations
We traditionally experience lower sales volumes in the third quarter than throughout the rest of the year as many of our
products are used in elective procedures, which generally decline during the summer months. This typically results in selling,
general and administrative expenses and research and development expenses as a percentage of net sales that are higher during
this period than throughout the rest of the year. In addition, our first quarter selling, general and administrative expenses
include additional expenses that we incur in connection with the annual meetings held by the American College of Foot and
Ankle Surgeons and the American Academy of Orthopaedic Surgeons. During these three-day events, we display our most
recent and innovative products in the lower extremities market.
We have experienced and expect to continue to experience meaningful variability in our net sales and cost of sales as a
percentage of net sales among quarters, as well as within each quarter, as a result of a number of factors including, among other
(cid:87)(cid:75)(cid:76)(cid:81)(cid:74)(cid:86)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3) (cid:80)(cid:76)(cid:91)(cid:3) (cid:82)(cid:73)(cid:3) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3) (cid:86)(cid:82)(cid:79)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:74)(cid:72)(cid:82)(cid:74)(cid:85)(cid:68)(cid:83)(cid:75)(cid:76)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3) (cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:92)(cid:3) (cid:68)(cid:85)(cid:72)(cid:3) (cid:86)(cid:82)(cid:79)(cid:71)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:71)(cid:72)(cid:80)(cid:68)(cid:81)(cid:71)(cid:3) (cid:73)(cid:82)(cid:85)(cid:15)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)
(cid:83)(cid:85)(cid:76)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:85)(cid:3)(cid:73)ailure to obtain regulatory clearances or approvals
(cid:73)(cid:82)(cid:85)(cid:3) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:30)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:15)(cid:3) (cid:69)(cid:72)(cid:81)(cid:72)(cid:73)(cid:76)(cid:87)(cid:86)(cid:15)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:73)(cid:3) (cid:81)(cid:72)(cid:90)(cid:3) (cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:3) (cid:76)(cid:81)(cid:87)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3) (cid:82)(cid:73)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3)
(cid:83)(cid:85)(cid:82)(cid:80)(cid:82)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3) (cid:83)(cid:85)(cid:76)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:85)(cid:3) (cid:89)(cid:82)(cid:79)(cid:88)(cid:80)(cid:72)(cid:3) (cid:71)(cid:76)(cid:86)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3) (cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3) (cid:76)(cid:81)(cid:3) (cid:68)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3) (cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3) (cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:68)vailability and cost of components and
(cid:80)(cid:68)(cid:87)(cid:72)(cid:85)(cid:76)(cid:68)(cid:79)(cid:86)(cid:30)(cid:3)(cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:72)(cid:79)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:86)(cid:30)(cid:3)(cid:73)(cid:79)(cid:88)(cid:70)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:72)(cid:76)(cid:74)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:92)(cid:3)(cid:72)(cid:91)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:76)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:86)’ use of their calendar
(cid:92)(cid:72)(cid:68)(cid:85)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:71)(cid:72)(cid:71)(cid:88)(cid:70)(cid:87)(cid:76)(cid:69)(cid:79)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:80)(cid:83)(cid:68)(cid:76)(cid:85)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:17)
Liquidity and Capital Resources
The following table sets forth, for the periods indicated, certain liquidity measures (in thousands):
Cash and cash equivalents
Restricted cash
Working capital
$
December 25,
2016
262,265 $
150,000
285,107
December 27,
2015
139,804
—
352,946
Operating activities. Cash provided by (used in) operating activities totaled $37.8 million, ($195.9 million), and
($116.0 million) in 2016, 2015, and 2014, respectively. The increase in cash provided by operating activities in 2016 as
compared to the cash used in operating activities in 2015 was driven by higher cash profitability due to decreased spending on
transition and transaction expenses and leveraged expenses following the Wright/Tornier merger, the receipt of $60 million
insurance proceeds associated with metal-on-metal product liabilities (see Note 16 to our consolidated financial statements
contained in “Item 8. Financial Statements and Supplementary Data” for further discussion), and a 2015 milestone payment
associated with the BioMimetic acquisition upon the FDA approval of AUGMENT® Bone Graft totaling $98 million, of which
$28 million represented the excess over the value originally assigned as part of the purchase price allocation and was included
as a cash outflow within operating activities.
The increase in cash used in operating activities in 2015 compared to 2014 was due to lower cash profitability, primarily due to
costs associated with the Wright/Tornier merger and the BioMimetic milestone payment.
Investing activities. Our capital expenditures totaled $50.1 million in 2016, $43.7 million in 2015, and $48.6 million in 2014.
Of the $50.1 million in capital expenditures in 2016, $35.1 million was for routine capital expenditures, primarily purchased
surgical instrumentation, and $15.0 million was for capital expenditures associated with integration activities of the
Wright/Tornier merger, including spending on computer systems and facilities as we integrated operations in certain
international markets. Historically, our capital expenditures have consisted principally of purchased instruments,
manufacturing equipment, research and testing equipment, and computer systems. However, capital expenditures in 2014 also
included expansion of our manufacturing facility in Arlington, Tennessee and our U.S. corporate headquarters and capital
expenditures in 2015 included capital spending on system integrations resulting from the Wright/Tornier merger and
completion of the expansion of our U.S. corporate headquarters.
72
During 2016, we received proceeds of $20.7 million related to the sale of the Large Joints business. See Note 4 to our
consolidated financial statements contained in “Item 8. Financial Statements and Supplementary Data” for additional
information regarding this sale.
During 2015, we acquired $30 million of cash, primarily as a result of the Wright/Tornier merger since the merger was an all-
stock transaction and we paid for the acquisition of the Surgical Specialties sales and distribution business. In 2014, we paid an
aggregate of $81 million in cash, net of cash acquired, for the Solana and OrthoPro acquisitions.
Financing activities. During 2016, cash provided by financing activities totaled $270.4 million, compared to $126.9 million in
2015 and $33.1 million in 2014. The cash provided by financing activities in both periods was primarily attributable to the net
proceeds received from the issuance of convertible notes, partially offset by the partial settlement of previously outstanding
convertible notes. During 2016, we also received $30 million from the ABL Facility. See Note 6 and Note 9 of our consolidated
financial statements contained in “Item 8. Financial Statements and Supplementary Data” for additional information regarding
our derivative and debt activity, respectively.
As of October 1, 2015, legacy Tornier had approximately $75 million in outstanding term debt and $7 million in a line of credit
under a pre-existing credit agreement. Upon completion of the Wright/Tornier merger, we terminated all commitments under
this credit agreement and repaid approximately $81 million in outstanding indebtedness. We did not incur any early
termination penalties in connection with such repayment and termination.
During 2015, we paid a milestone payment associated with the BioMimetic acquisition upon FDA approval of AUGMENT®
Bone Graft totaling $98 million, of which $70 million represented the value originally assigned as part of the purchase price
allocation and was included as a cash outflow from financing activities.
During 2016 and 2015, we received $8.5 million and $3.5 million, respectively, of cash in connection with the issuance of
shares under our share-based compensation plan, as compared to $37.2 million in 2014. The amount received in 2014 was
driven primarily by stock option exercises of former employees transferred to MicroPort following the sale of the OrthoRecon
business.
Repatriation. As of December 25, 2016, approximately $13.4 million of our cash, cash equivalents, and restricted cash was
held by certain U.S.-controlled non-U.S. subsidiaries which may not represent available liquidity for general corporate
purposes. We provide for tax liabilities in our consolidated financial statements with respect to amounts that we expect to
repatriate from subsidiaries (cid:11)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:83)(cid:68)(cid:87)(cid:85)(cid:76)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:90)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3)(cid:69)(cid:72)(cid:3)(cid:86)(cid:88)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:68)(cid:91)(cid:12)(cid:30)(cid:3)(cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3)(cid:81)(cid:82)(cid:3)(cid:87)(cid:68)(cid:91)(cid:3)(cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:85)(cid:72)(cid:70)(cid:82)(cid:85)(cid:71)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)
amounts that we consider to be permanently reinvested. Our current plans do not foresee a need to repatriate funds that are
designated as permanently reinvested in order to fund our operations or meet currently anticipated liquidity and capital
investment needs.
Discontinued operations. Cash flows from discontinued operations are combined with cash flows from continuing operations
in the consolidated statements of cash flows. Cash flows from discontinued operations include those related to both the Large
Joints and OrthoRecon businesses.
During the fiscal year ended December 25, 2016, cash provided by operating and investing activities from the Large Joints
business totaled $5.2 million and $20.7 million, respectively. Cash provided by operating activities from the OrthoRecon
business totaled $16.7 million, primarily due to the receipt of the $60 million insurance settlement offset by legal defense costs
and settlement of product liabilities.
During the fiscal year ended December 27, 2015, cash provided by operating activities from the Large Joints business totaled
$2.9 million. Cash used by operating activities from the OrthoRecon business was approximately $28 million associated with
legal defense costs and settlement of product liabilities, net of insurance proceeds received.
During the fiscal year ended December 31, 2014, cash provided by the OrthoRecon business was approximately $250.5 million
driven by the cash received from the sale of the OrthoRecon business.
During 2017 we expect significant cash outflows resulting from product liabilities, including the $240 million MSA settlement
described in Note 16. We do not expect that the future cash outflows from discontinued operations will have an impact on our
ability to meet contractual cash obligations and fund our working capital requirements, operations, and anticipated capital
expenditures.
73
Contractual cash obligations. At December 25, 2016, we had contractual cash obligations and commercial commitments as
follows (in thousands):
Contractual obligations
Amounts reflected in consolidated balance sheet:
Capital lease obligations(1)
Notes Payable(2)
Amounts not reflected in consolidated balance
sheet:
Operating leases
Interest on notes payable(3)
Total contractual cash obligations
___________________________
(1) Payments include amounts representing interest.
Payments due by periods
Total
Less than 1
year
1-3 years
3-5 years
More than 5
years
$
18,258 $
988,842
2,294 $
2,587
4,408 $
694
3,733 $
982,650
7,823
2,911
39,088
80,294
9,740
20,776
13,419
41,357
7,634
18,161
8,295
—
$ 1,126,482 $
35,397 $
59,878 $ 1,012,178 $
19,029
(2) Our notes payable include 2017 Notes, 2020 Notes, 2021 Notes, shareholder debt, and mortgages. See further discussion in Note 9 to
our consolidated financial statements contained in “Item 8. Financial Statements and Supplementary Data.”
(3) Represents interest on 2017 Notes, 2020 Notes, 2021 Notes, shareholder debt, and mortgages. See further discussion in Note 9 to our
consolidated financial statements contained in “Item 8. Financial Statements and Supplementary Data.”
The amounts reflected in the table above exclude product liabilities, including the $240 million settlement of certain metal-on-
metal hip replacement product liability litigation, described in Note 16.
Portions of these payments are denominated in foreign currencies and were translated in the table above based on their
respective U.S. dollar exchange rates at December 25, 2016. These future payments are subject to foreign currency exchange
rate risk.
The amounts reflected in the table above for capital lease obligations represent future minimum lease payments under our
capital lease agreements, which are primarily for certain property and equipment. The present value of the minimum lease
payments are recorded in our consolidated balance sheet at December 25, 2016. The minimum lease payments related to these
leases are discussed further in Note 9 to our consolidated financial statements contained in “Item 8. Financial Statements and
Supplementary Data.”
The amounts reflected in the table above for operating leases represent future minimum lease payments under non-cancelable
operating leases primarily for certain equipment and office space. In accordance with US GAAP, our operating leases are not
(cid:85)(cid:72)(cid:70)(cid:82)(cid:74)(cid:81)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:82)(cid:79)(cid:76)(cid:71)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:69)(cid:68)(cid:79)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:86)(cid:75)(cid:72)(cid:72)(cid:87)(cid:86)(cid:30)(cid:3)(cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:80)(cid:76)(cid:81)(cid:76)(cid:80)(cid:88)(cid:80)(cid:3)(cid:79)(cid:72)(cid:68)(cid:86)(cid:72)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:68)(cid:74)(cid:85)(cid:72)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:71)(cid:76)(cid:86)(cid:70)(cid:79)osed
in Note 16 to our consolidated financial statements contained in “Item 8. Financial Statements and Supplementary Data.”
The table above does not include the 2020 Notes Conversion Derivative (see “Item 7A. Quantitative and Qualitative
Disclosures About Market Risk” for quantitative analysis on possible cash obligations upon maturity at various assumed stock
prices).
The table above also does not include certain contingent consideration. Contingent consideration of up to $84 million may be
paid upon reaching certain revenue milestones related to the BioMimetic acquisition. If, prior to March 1, 2019, sales of
AUGMENT® Bone Graft reach $40 million over 12 consecutive months, a cash payment would be required at $1.50 per share,
or $42 million. Further, if, prior to March 1, 2019, sales of AUGMENT® Bone Graft reach $70 million over 12 consecutive
months, an additional cash payment would be required at $1.50 per share, or $42 million. In addition, contingent consideration
of up to $1.7 million and $0.4 million may be paid upon achieving revenue milestones related to the acquisitions of Surgical
Specialties Australia Pty and WG Healthcare, respectively. These potential additional cash payments are based on the future
financial performance of the acquired assets. The estimated fair value of these liabilities has been recorded on our consolidated
balance sheets within “Accrued expenses and other current liabilities” and “Other long-term liabilities” as described in Note 6.
In addition to the contractual cash obligations discussed above, all of our U.S. net sales and a portion of our international net
sales are subject to commissions based on net sales. A substantial portion of our global net sales are subject to royalties earned
based on product sales.
74
Additionally, as of December 25, 2016, we had approximately $8 million of unrecognized tax benefits recorded on our
consolidated balance sheet. This represents the tax benefits associated with various tax positions taken, or expected to be taken,
on U.S. and international tax returns that have not been recognized in our financial statements due to uncertainty regarding their
resolution. We are unable to make a reliable estimate of the eventual cash flows by period that may be required to settle these
matters. Certain of these matters may not require cash settlement due to the existence of net operating loss carryforwards.
Therefore, our unrecognized tax benefits are not included in the table above. See Note 11 to our consolidated financial
statements contained in “Item 8. Financial Statements and Supplementary Data.”
Other liquidity information. We have funded our cash needs since 2000 through various equity and debt issuances and through
cash flow from operations.
On December 23, 2016, we, together with WMG and certain of our other wholly-owned U.S. subsidiaries, entered into a Credit,
Security and Guaranty Agreement (ABL Credit Agreement) with Midcap Financial Trust, as administrative agent (Agent) and a
lender and the additional lenders from time to time party thereto. The ABL Credit Agreement provides for a $150 million
senior secured asset based line of credit, subject to the satisfaction of a borrowing base requirement (ABL Facility). The ABL
Facility may be increased by up to $100 million upon our request, subject to the consent of the Agent and each of the other
lenders providing such increase and the satisfaction of customary conditions. As of December 25, 2016, we had $30 million in
borrowings outstanding under the ABL Facility.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing
plaintiffs in the metal-on-metal hip replacement product liability litigation pending before the United States District Court for
the Northern District of Georgia (the MDL) and the California State Judicial Counsel Coordinated Proceedings (the JCCP).
Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims associated with CONSERVE®,
DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and are either pending in the MDL or
JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement amount of $240 million. As of
December 25, 2016, our accrual for metal-on-metal claims totaled $256.7 million, of which $242.8 million is included in our
consolidated balance sheet within “Accrued expenses and other current liabilities” and $13.9 million is included within “Other
liabilities.” See Note 16 to our consolidated financial statements for additional discussion regarding the MSA and our accrual
methodologies for the metal-on-metal hip replacement product liability claims.
During the fourth quarter of 2016, WMT deposited $150 million into a restricted escrow account to secure its obligations under
the MSA. All individual settlements under the MSA will be funded first from the escrow account and then, if all funds held in
the escrow account have been exhausted, directly by WMT. As of December 25, 2016, $150 million was in the restricted
escrow account, and therefore, considered restricted cash under U.S. GAAP. See Note 16 and Note 17 to the consolidated
financial statements for further discussion regarding the MSA, the metal-on-metal hip litigation and the funding for such
claims.
In May 2016, we issued $395 million aggregate principal amount of the 2021 Notes, which, after consideration of the exchange
of approximately $54 million principal amount of the 2017 Notes and $45 million principal amount of the 2020 Notes,
generated net proceeds of approximately $237.5 million. In connection with the offering of the 2021 Notes, we entered into
convertible note hedging transactions with two counterparties. We also entered into warrant transactions in which we sold
stock warrants for an aggregate of 18.5 million ordinary shares to these two counterparties. We used approximately $45 million
of the net proceeds from the offering to pay the cost of the convertible note hedging transactions (after such cost was partially
offset by the proceeds we received from the sale of the warrants).
In February 2015, WMG issued $632.5 million of the 2020 Notes, which generated net proceeds of approximately
$613 million. In connection with the offering of the 2020 Notes, WMG entered into convertible note hedging transactions with
three counterparties. WMG also entered into warrant transactions in which WMG sold warrants for an aggregate of 20,489,142
shares of WMG common stock to these three counterparties. WMG used approximately $58 million of the net proceeds from
the offering to pay the cost of the convertible note hedging transactions (after such cost was partially offset by the proceeds we
received from the sale of the warrants). WMG also used approximately $292 million of the net proceeds from the offering to
repurchase approximately $240 million aggregate principal amount of outstanding 2017 Notes in privately negotiated
transactions. On November 24, 2015, we entered into a supplemental indenture to the indenture governing the 2020 Notes
which provided for, among other things, our full and unconditional guarantee, on a senior unsecured basis, of all of WMG’s
obligations relating to the 2010 Notes and to make certain other adjustments to the terms of the indenture to give effect to the
Wright/Tornier merger. Also on November 24, 2015, we assumed the warrants initially issued by WMG in connection with the
2020 Notes offering.
Although it is difficult for us to predict our future liquidity requirements, we believe that our cash, cash equivalents and
restricted cash balance of approximately $412.3 million, together with $120 million in availability under our ABL Credit
Agreement as of December 25, 2016, will be sufficient for the next 12 months to fund our working capital requirements and
75
operations, permit anticipated capital expenditures in 2017 of approximately $50 million, pay retained liabilities of the
OrthoRecon business, including without limitation amounts under the MSA, and meet our anticipated contractual cash
obligations in 2017. However, our future funding requirements will depend on many factors, including our future net sales and
expenses.
In the event that we would require additional working capital to fund future operations, we could seek to acquire that through
additional equity or debt financing arrangements which may or may not be available on favorable terms at such time. If we
raise additional funds by issuing equity securities, our shareholders may experience dilution. Debt financing, if available, may
involve covenants restricting our operations or our ability to incur additional debt, in addition to those under our existing
indentures. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our
shareholders. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or
commercialization of our products or scale back our operations.
We intend to use our cash balance and any additional financing to fund transaction and transition costs associated with the
Wright/Tornier merger, to fund growth opportunities for our extremities and biologics business, and to pay certain retained
liabilities of the OrthoRecon business.
In-process research and development. In connection with the BioMimetic acquisition, we acquired in-process research and
development (IPRD) technology related to projects that had not yet reached technological feasibility as of the acquisition date,
which included AUGMENT® Injectable Bone Graft. The acquisition date fair value of the IPRD technology was $27.1 million
for AUGMENT® Injectable Bone Graft. The fair value of the IPRD technology was reduced to $0 as of December 31, 2014,
which reflects the impairment charges recognized in 2013 after receipt of the not approvable letter from the FDA in response to
a pre-market approval (PMA) application for AUGMENT® Bone Graft for use as an alternative to autograft in hindfoot and
ankle fusion procedures.
In connection with the Wright/Tornier merger, we acquired IPRD technology related to three projects that had not yet reached
technological feasibility as of the merger date. These projects included PerFORM Rev/Rev+, AEQUALIS® Adjustable
Reversed Ext (AARE) (re-branded in 2016 to AEQUALIS® Flex Revive), and PerFORM+ that were assigned fair values of
$14.5 million, $2.1 million, and $0.4 million, respectively, on the acquisition date. During 2016, we received FDA clearance of
PerFORM Rev/Rev+ and PerFORM+.
The current IPRD projects we acquired in our BioMimetic acquisition and the Wright/Tornier merger are as follows:
• AUGMENT® Injectable Bone Graft (Augment Injectable) combines rhPDGF-BB with an injectable bone matrix,
and is targeted to be used in either open (surgical) treatment of fusions and fractures or closed (non-surgical) or
minimally invasive treatment of fractures. AUGMENT® Injectable can be injected into a fusion or fracture site
during an open surgical procedure, or it can be injected through the skin into a fracture site, in either case locally
delivering rhPDGF-BB to promote fusion or fracture repair. Our initial clinical development program for
AUGMENT® Injectable has focused on securing regulatory approval for open indications in the United States and
in several markets outside the United States. We currently estimate it could take one to three years to complete
this project. We have incurred expenses of approximately $4.9 million for AUGMENT® Injectable since the date
of acquisition and $1.2 million in the year ended December 25, 2016. We are currently evaluating future costs
related to AUGMENT® Injectable following the FDA approval of AUGMENT®.
• AEQUALIS® Adjustable Reversed Ext (AARE) will ultimately be our second-generation revision product, with
an improved implant that is convertible and addresses more indications, and a revamped instrument set that
includes universal extraction instrumentation. The implants in this system are complete from a design standpoint,
have regulatory approval, and are being sold using a previous generation of instrumentation in a limited capacity.
The instruments for the new revision system are currently in design phase. We have an anticipated completion
date in 2018 and project cost to complete is estimated to be less than $1 million. However, the risks and
uncertainties associated with completion are dependent upon testing validations and FDA clearance.
Critical Accounting Estimates
All of our significant accounting policies and estimates are described in Note 2 to our consolidated financial statements
contained in “Item 8. Financial Statements and Supplementary Data.” Certain of our more critical accounting estimates require
the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate.
By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our
historical experience, terms of existing contracts, our observance of trends in the industry, information provided by our
customers, and information available from other outside sources, as appropriate. Different, reasonable estimates could have
been used in the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to
76
period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial
condition, or results of operations.
We believe that the following financial estimates are both important to the portrayal of our financial condition and results of
operations and require subjective or complex judgments. Further, we believe that the items discussed below are properly
recorded in our financial statements for all periods presented. Our management has discussed the development, selection, and
disclosure of our most critical financial estimates with the audit committee of our board of directors and with our independent
auditors. The judgments about those financial estimates are based on information available as of the date of our financial
statements. Those financial estimates include:
Discontinued operations. On October 21, 2016, pursuant to the binding offer letter dated as of July 8, 2016, we, Corin, and
certain other entities related to us entered into a business sale agreement and simultaneously completed and closed the sale of
our business operations formerly operating under the Large Joints segment. Pursuant to the terms of the agreement, we sold
substantially all of our assets related to our hip and knee, or large joints, business to Corin for approximately €29.7 million in
cash, less approximately €10.7 million for net working capital adjustments.
We determined that the Large Joints business meets the criteria for classification as discontinued operations. All historical
operating results for the Large Joints business, including costs associated with corporate employees and infrastructure to be
transferred as a part of the sale, are reflected within discontinued operations in our consolidated statements of operations.
Further, all assets and associated liabilities transferred to Corin were classified as assets and liabilities held for sale in our
consolidated balance sheets for all periods presented. We recognized an impairment loss on held for sale classification of $21.3
million before the effect of income taxes, during 2016 based on the difference between the net carrying value of the assets and
liabilities held for sale and the purchase price, less estimated adjustments and costs to sell. This loss was recorded within “Net
loss from discontinued operations” in our consolidated statements of operations. All current operating results for the Large
Joints business are reflected within discontinued operations in our consolidated financial statements.
On January 9, 2014, legacy Wright completed the sale of the OrthoRecon business, which consists of legacy Wright’s hip and
knee product implants, to MicroPort. We determined that this transaction meets the criteria for classification as discontinued
operations under the provisions of FASB ASC 205-20. As such, all historical operating results for the OrthoRecon business are
reflected within discontinued operations in our consolidated statements of operations. As this sale occurred in early 2014, costs
for 2014, 2015 and 2016 primarily relate to product liability claims, including legal defense, settlements and judgments, and
changes in contingent liabilities net of product liability insurance recoveries. Further, all assets and associated liabilities
transferred to MicroPort were classified as assets and liabilities held for sale on our consolidated balance sheet, in accordance
with FASB ASC 360.
Revenue recognition. Our revenues are primarily generated through two types of customers, hospitals and surgery centers and
stocking distributors, with the majority of our revenue derived from sales to hospitals and surgery centers. Our products are
sold through a network of employee and independent sales representatives in the United States and by a combination of
employee sales representatives, independent sales representatives, and stocking distributors outside the United States. We
record revenues from sales to hospitals and surgery centers when they take title to the product, which is generally when the
product is surgically implanted in a patient.
During the quarter ended December 27, 2015, following the Wright/Tornier merger, we changed our estimate of uninvoiced
revenue. While we have generally recognized revenue at the time that the product was surgically implanted, from a timing
perspective, we now recognize revenue at the time the surgery and associated products used are reported, as opposed to
previously when we received clerical documentation from the hospital. We accounted for this as a change in estimate and
recorded additional revenue of approximately $3 million in the quarter ended December 27, 2015.
We record revenues from sales to our stocking distributors at the time the product is shipped to the distributor. Our stocking
distributors, who sell the products to their customers, take title to the products and assume all risks of ownership. Our stocking
distributors are obligated to pay us within specified terms regardless of when, if ever, they sell the products. In general, our
(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:76)(cid:81)(cid:74)(cid:3) (cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:3) (cid:71)(cid:82)(cid:3) (cid:81)(cid:82)(cid:87)(cid:3) (cid:75)(cid:68)(cid:89)(cid:72)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:85)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:3) (cid:82)(cid:85)(cid:3) (cid:72)(cid:91)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:30)(cid:3) (cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3) (cid:76)(cid:81)(cid:3) (cid:79)(cid:76)(cid:80)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3) (cid:86)(cid:76)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3) (cid:75)(cid:68)(cid:89)(cid:72)(cid:3) (cid:85)(cid:72)(cid:83)(cid:88)(cid:85)(cid:70)(cid:75)(cid:68)(cid:86)(cid:72)(cid:3)
agreements with certain stocking distributors. Those certain agreements require us to repurchase a specified percentage of the
inventory purchased by the distributor within a specified period of time prior to the expiration of the contract. During those
specified periods, we defer the applicable percentage of the sales. An insignificant amount of sales related to these types of
agreements were deferred and not yet recognized as revenue as of December 25, 2016 and December 27, 2015.
We must make estimates of potential future product returns related to current period product sales. We base our estimate for
sales returns on historical sales and product return information, including historical experience and trend information. Our
reserve for sales returns has historically been immaterial. We charge our customers for shipping and handling and recognize
these amounts as part of revenue.
77
In 2011, we entered into a trademark license agreement with KCI Medical Resources, a subsidiary of Kinetic Concepts, Inc.
(KCI). In exchange for $8.5 million, of which $5.5 million was received immediately and $3 million was received in January
2012, this license agreement provides KCI with a non-transferable license to use our trademarks associated with our
GRAFTJACKET® line of products in connection with the marketing and distribution of KCI’s soft tissue graft containment
products used in the wound care field, subject to certain exceptions. License revenue under this agreement is being recognized
over 12 years on a straight-line basis.
Allowances for doubtful accounts. We experience cr(cid:72)(cid:71)(cid:76)(cid:87)(cid:3)(cid:79)(cid:82)(cid:86)(cid:86)(cid:72)(cid:86)(cid:3) (cid:82)(cid:81)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:3)(cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:68)(cid:69)(cid:79)(cid:72)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:79)(cid:92)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3) (cid:80)(cid:88)(cid:86)(cid:87)(cid:3)(cid:80)(cid:68)(cid:78)(cid:72)(cid:3)
estimates related to the ultimate collection of our accounts receivable. Specifically, we analyze our accounts receivable,
historical bad debt experience, customer concentrations, customer creditworthiness, and current economic trends when
evaluating the adequacy of our allowance for doubtful accounts.
The majority of our accounts receivable are from hospitals and surgery centers. Our collection history has been favorable with
minimal bad debts from these customers. We write off accounts receivable when we determine that the accounts receivable are
uncollectible, typically upon customer bankruptcy or the customer’s non-response to repeated collection efforts.
We believe that the amount included in our allowance for doubtful accounts has been a historically appropriate estimate of the
amount of accounts receivable that are ultimately not collected. While we believe that our allowance for doubtful accounts is
adequate, the financial condition of our customers and the geo-political factors that impact reimbursement under individual
countries’ healthcare systems can change rapidly, which would necessitate additional allowances in future periods. Our
allowances for doubtful accounts were $4.5 million and $1.2 million, at December 25, 2016 and December 27, 2015,
respectively.
Excess and obsolete inventories. We value our inventory at the lower of the actual cost to purchase and/or manufacture the
inventory on a first-in, first-out (FIFO) basis or its net realizable value. We regularly review inventory quantities on hand for
excess and obsolete inventory and, when circumstances indicate, we incur charges to write down inventories to their net
realizable value. We estimate excess and obsolete inventory based on both the current age of kit inventory as compared to its
estimated life cycle and our forecasted product demand and production requirements for other inventory items for the next 36
months. A significant decrease in demand could result in an increase in the amount of excess inventory quantities on hand.
Additionally, our industry is characterized by regular new product development that could result in an increase in the amount of
obsolete inventory quantities on hand due to cannibalization of existing products. Also, our estimates of future product demand
may prove to be inaccurate in which case we may be required to incur charges for excess and obsolete inventory.
Total charges incurred to write down excess and obsolete inventory to net realizable value included in “Cost of sales” were
approximately $21.5 million, $14.2 million, and $4.0 million for the years ended December 25, 2016, December 27, 2015, and
December 31, 2014, respectively. During the year ended December 25, 2016, we recorded $4.1 million of provisions for
excess and obsolete inventory for product rationalization initiatives. Additionally, charges in 2016 are higher than prior years
due to the additional inventories subject to reserves following the Wright/Tornier merger. During the quarter ended
December 27, 2015, we adjusted our estimate for excess and obsolete inventory which resulted in a charge of $4.1 million.
In the future, if additional inventory write-downs are required, we would recognize additional cost of goods sold at the time of
such determination. Regardless of changes in our estimates of future product demand, we do not increase the value of our
inventory above its adjusted cost basis. Therefore, although we make every effort to ensure the accuracy of our forecasts of
future product demand, significant unanticipated decreases in demand or technological developments could have a significant
impact on the value of our inventory and our reported operating results.
Business combinations, goodwill and long-lived assets. We account for acquired businesses using the purchase method of
accounting. Under the purchase method, our consolidated financial statements include the financial results of an acquired
business starting from the date the acquisition is completed. In addition, the assets acquired, liabilities assumed, and any
contingent consideration must be recorded at the date of acquisition at their respective estimated fair values, with any excess of
the purchase price over the estimated fair values of the net assets acquired recorded as goodwill. Significant judgment is
required in estimating the fair value of contingent consideration and intangible assets and in assigning their respective useful
lives. Accordingly, we typically obtain the assistance of third-party valuation specialists for significant acquisitions. The fair
value estimates are based on available historical information and on future expectations and assumptions deemed reasonable by
management, but are inherently uncertain.
We typically have used a discounted cash flow analysis to determine the fair value of contingent consideration on the date of
acquisition. Significant changes in the discount rate used could affect the accuracy of the fair value calculation. Contingent
consideration is adjusted based on experience in subsequent periods and the impact of changes related to assumptions are
recorded in operating expenses as incurred.
78
We typically use an income method to estimate the fair value of intangible assets, which is based on forecasts of the expected
future cash flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a
consideration of other marketplace participants and include the amount and timing of future cash flows (including expected
growth rates and profitability), the underlying product or technology life cycles, the economic barriers to entry, and the
discount rate applied to the cash flows. Unanticipated market or macroeconomic events and circumstances may result in a
triggering event for which we would test for impairment.
Determining the useful life of an intangible asset also requires judgment. Our assessment as to trademarks and brands that have
a finite life is based on a number of factors including competitive environment, market share, trademark and/or brand history,
underlying product life cycles, operating plans, and the macroeconomic environment of the countries in which the trademarks
or brands are sold. All of our acquired technology and customer-related intangibles are expected to have finite useful lives.
As of December 25, 2016, we had approximately $851.0 million of goodwill recorded as a result of our acquisition of
businesses, including most recently the Wright/Tornier merger. Goodwill is tested for impairment annually, or more frequently
if changes in circumstances or the occurrence of events suggest that impairment exists. The annual evaluation of goodwill
impairment may require the use of estimates and assumptions to determine the fair value of our reporting units using
projections of future cash flows. Unless circumstances otherwise dictate, the annual impairment test is performed on October 1
each year.
During the first quarter of 2016, we had a change in segment reporting that required an interim review of potential goodwill
impairment which we performed as of February 2016. Upon completion of this analysis, we determined that the fair value of
our reporting units, determined primarily by an income approach using projected cash flows, exceeded their carrying valu(cid:72)(cid:86)(cid:30)(cid:3)
and therefore, no goodwill was impaired.
We also performed a qualitative assessment of goodwill for impairment as of October 1, 2016 for our reporting units and
determined that it is not more likely than not that the respective carrying values of our reporting units exceeded their fair value,
indicating that goodwill was not impaired.
Our business is capital intensive, particularly as it relates to surgical instrumentation. We depreciate our property, plant and
equipment and amortize our intangible assets based upon our estimate of the respective asset’s useful life. Our estimate of the
useful life of an asset requires us to make judgments about future events, such as product life cycles, new product development,
product cannibalization, and technological obsolescence, as well as other competitive factors beyond our control. We account
for the impairment of finite, long-lived assets in accordance with the FASB ASC Section 360, Property, Plant and Equipment.
Accordingly, we evaluate impairments of our property, plant and equipment based upon an analysis of estimated undiscounted
future cash flows. If we determine that a change is required in the useful life of an asset, future depreciation and amortization
is adjusted accordingly. Alternatively, if we determine that an asset has been impaired, an adjustment would be charged to
income based on the asset’s fair market value, or discounted cash flows if the fair market value is not readily determinable,
reducing income in that period.
Valuation of in-process research and development. The estimated fair value attributed to IPRD represents an estimate of the
fair value of purchased in-process technology for research programs that have not reached technological feasibility and have no
alternative future use. Only those research programs that had advanced to a stage of development where management believed
reasonable net future cash flow forecasts could be prepared and a reasonable possibility of technical success existed were
included in the estimated fair value.
IPRD is recorded as an indefinite-lived intangible asset until completion or abandonment of the associated research and
development projects. Accordingly, no amortization expense is reflected in the results of operations. If a project is completed,
the carrying value of the related intangible asset will be amortized over the remaining estimated life of the asset beginning with
the period in which the project is completed. If a project becomes impaired or is abandoned, the carrying value of the related
intangible asset will be written down to its fair value and an impairment charge will be taken in the period the impairment
occurs. These intangible assets are tested for impairment on an annual basis, or earlier if impairment indicators are present.
Product liability claims and related insurance recoveries and other litigation. Periodically, claims arise involving the use of
our products. We make provisions for claims specifically identified for which we believe the likelihood of an unfavorable
outcome is probable and an estimate of the amount of loss has been developed. As additional information becomes available,
we reassess the estimated liability related to our pending claims and make revisions as necessary.
The product liability claims described in this section relate primarily to Wright Medical Technology, Inc., an indirect subsidiary
of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated entities.
Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities. We believe our ring-
79
fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with particular
claims.
We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular
neck product (PROFEMUR® Claims). As of December 25, 2016, there were 26 pending U.S. lawsuits and 48 pending non-
U.S. lawsuits alleging such claims. The overall fracture rate for the product is low and the fractures appear, at least in part, to
relate to patient demographics. Beginning in 2009, we began offering a cobalt-chrome version of our PROFEMUR® modular
neck, which has greater strength characteristics than the alternative titanium version. Historically, we have reflected our
liability for these claims as part of our standard product liability accruals on a case-by-case basis. However, during the quarter
ended September 30, 2011, as a result of an increase in the number and monetary amount of these claims, management
estimated our liability to patients in North America who have previously required a revision following a fracture of a
PROFEMUR® long titanium modular neck, or who may require a revision in the future. Management has estimated that this
aggregate liability ranges from approximately $21.9 million to $25.9 million. Any claims associated with this product outside
of North America, or for any other products, will be managed as part of our standard product liability accrual methodology on a
case-by-case basis.
Due to the uncertainty within our aggregate range of loss resulting from the estimation of the number of claims and related
monetary payments, we have recorded a liability of $21.9 million, which represents the low-end of our estimated aggregate
range of loss. We have classified $14.2 million of this liability as current in “Accrued expenses and other current liabilities,” as
we expect to pay such claims within the next twelve months, and $7.7 million as non-current in “Other liabilities” on our
consolidated balance sheet. We expect to pay the majority of these claims within the next three years.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged
fractures. As of December 25, 2016, there were three pending U.S. lawsuits and five pending non-U.S. lawsuits against us
alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These claims will be managed as part of
our standard product liability accrual methodology on a case-by-case basis.
We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended March 31, 2013,
we received a customary reservation of rights from our primary product liability insurance carrier asserting that present and
future claims related to fractures of our PROFEMUR® titanium modular neck hip products and which allege certain types of
injury (Titanium Modular Neck Claims) would be covered as a single occurrence under the policy year the first such claim was
asserted. The effect of this coverage position would be to place Titanium Modular Neck Claims into a single prior policy year
in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees
with the assertion that the Titanium Modular Neck Claims should be treated as a single occurrence, but notified the carrier that
it disputed the carrier’s selection of available policy years. During the second quarter of 2013, we received confirmation from
the primary carrier confirming their agreement with our policy year determination. Based on our insurer’s treatment of
Titanium Modular Neck Claims as a single occurrence, we increased our estimate of the total probable insurance recovery
related to Titanium Modular Neck Claims by $19.4 million, and recognized such additional recovery as a reduction to our
selling, general and administrative expenses for the three months ended March 31, 2013, within results of discontinued
operations. In the quarter ended June 30, 2013, we received payment from the primary insurance carrier of $5 million. In the
quarter ended September 30, 2013, we received payment of $10 million from the next insurance carrier in the tower. We have
requested, but not yet received, payment of the remaining $25 million from the third insurance carrier in the tower for that
policy period. The policies with the second and third carrier in this tower are “follow form” policies and management believes
the third carrier should follow the coverage position taken by the primary and secondary carriers. On September 29, 2015, that
third carrier asserted that the terms and conditions identified in its reservation of rights will preclude coverage for the Titanium
Modular Neck Claims. We strongly dispute the carrier’s position and, in accordance with the dispute resolution provisions of
the policy, have initiated an arbitration proceeding in London, England seeking payment of these funds. Pursuant to applicable
accounting standards, we reduced our insurance receivable balance for this claim to $0, and recorded a $25 million charge
within “Net loss from discontinued operations” during the year ended December 27, 2015. The arbitration proceeding is
ongoing.
Claims for personal injury have also been made against us associated with our metal-on-metal hip products (primarily our
CONSERVE® product line). The pre-trial management of certain of these claims has been consolidated in the federal court
system, in the United States District Court for the Northern District of Georgia under multi-district litigation (MDL) and certain
other claims by the Judicial Counsel Coordinated Proceedings (JCCP) in state court in Los Angeles County, California
(collectively the Consolidated Metal-on-Metal Claims).
As of December 25, 2016, there were approximately 1,200 lawsuits pending in the MDL and JCCP, and an additional 30 cases
pending in various state courts. As of that date, we have also entered into approximately 950 so called “tolling agreements”
with potential claimants who have not yet filed suit. Based on presently available information, we believe at least 350 of these
lawsuits allege claims involving bilateral implants. As of December 25, 2016, there were also approximately 50 non-U.S.
80
lawsuits pending. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products. While
continuing to dispute liability, we have participated in court supervised non-binding mediation in the MDL and expect to begin
similar mediation in the JCCP.
Every metal-on-metal hip case involves fundamental issues of law, science and medicine that often are uncertain, that continue
to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and
issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the
existence of actual, provable injury.
The first bellwether trial in the MDL commenced on November 9, 2015 in Atlanta, Georgia. On November 24, 2015, the jury
returned a verdict in favor of the plaintiff and awarded the plaintiff $1 million in compensatory damages and $10 million in
punitive damages. We believe there were significant trial irregularities and vigorously contested the trial result. On December
28, 2015, we filed a post-trial motion for judgment as a matter of law or, in the alternative, for a new trial or a reduction of
damages awarded. On April 5, 2016, the trial judge issued an order reducing the punitive damage award from $10 million to
$1.1 million, but otherwise denied our motion. On May 4, 2016, we filed a notice of appeal with the United States Court of
Appeals for the Eleventh Circuit. The United States Court of Appeals for the Eleventh Circuit heard oral arguments on January
26, 2017 and we are awaiting a decision of the Court. In light of the trial judge’s April 5th order, we recorded an accrual for this
verdict in the amount of $2.1 million within “Accrued expenses and other current liabilities,” and a $2.1 million receivable
associated with the probable recovery from product liability insurance is reflected within “Other current assets.”
The first bellwether trial in the JCCP, which was scheduled to commence on October 31, 2016, and subsequently rescheduled
to January 9, 2017, was settled for an immaterial amount.
The first state court metal-on-metal hip trial not part of the MDL or JCCP commenced on October 24, 2016, in St. Louis,
Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff has appealed.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing
plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims
associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and
are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement
amount of $240 million.
The $240 million settlement amount is a maximum settlement based on the pool of 1,292 specific, existing claims comprised of
an identified mix of CONSERVE®, DYNASTY® and LINEAGE® products (Initial Settlement Pool), with a value assigned to
each product type, resulting in a total settlement of $240 million for the 1,292 claims in the Initial Settlement Pool. The actual
settlement may be less, depending on several factors including the mix of products and claimants in the final settlement pool
(Final Settlement Pool) and the number of claimants electing to “opt-out” of the settlement.
Actual settlements paid to individual claimants will be determined under the claims administration procedures contained in the
MSA and may be more or less than the amounts used to calculate the $240 million settlement for the 1,292 claims in the Initial
Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect
WMT’s maximum settlement obligation of $240 million or the manner in which it may be reduced due to opt outs, final
product mix, or elimination of ineligible claims.
If it is determined a claim in the Initial Settlement Pool is ineligible due to failure to meet the eligibility criteria of the MSA,
such claim will be removed and, where possible, replaced with a new eligible claim involving the same product, with the goal
of having the number and mix of claims in the Final Settlement Pool (before opt-outs) equal, as nearly as possible, the number
and mix of claims in the Initial Settlement Pool. Additionally, if any DYNASTY® or LINEAGE® claims in the Final
Settlement Pool are determined to have been misidentified as CONSERVE® claims, or vice versa, the total settlement amount
will be adjusted based on the value for each product type (not to exceed $240 million).
The MSA contains specific eligibility requirements and establishes procedures for proof and administration of claims,
negotiation and execution of individual settlement agreements, determination of the final total settlement amount, and funding
of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim
pending or tolled in the MDL or JCCP, that the claimant has undergone a revision surgery within eight years of the original
implantation surgery, and that the claim has not been identified by WMT as having possible statute of limitation issues.
Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately
satisfy all eligibility criteria.
81
The MSA includes a 95% opt-in requirement, meaning the MSA may be terminated by WMT prior to any settlement
disbursement if claimants holding greater than 5% of eligible claims in the Final Settlement Pool elect to “opt-out” of the
settlement. WMT, in its sole discretion, may waive this 95% opt-in requirement. No funding of any individual plaintiff
settlement will occur until the 95% opt-in requirement has been satisfied or waived.
WMT has been notified pursuant to the MSA that greater than 95% of eligible claimants timely elected to opt-in to the MSA
settlement prior to the opt-in deadline. Accordingly, the 95% minimum opt-in rate appears to have been satisfied, subject to
WMT’s audit rights under the MSA.
WMT has escrowed $150 million to secure its obligations under the MSA. As additional security, Wright Medical Group N.V.,
the indirect parent company of WMT, agreed to guaranty WMT’s obligations under the MSA.
The MSA was entered into solely as a compromise of the disputed claims being settled and is not evidence that any claim has
merit nor is it an admission of wrongdoing or liability by WMT. WMT will continue to vigorously defend metal-on-metal hip
claims not settled pursuant to the MSA. As of December 25, 2016, we estimate there were approximately 630 outstanding
metal-on-metal hip revision claims that would not be included in the MSA settlement, including approximately 200 claims with
an implant duration of more than eight years, approximately 300 claims subject to possible statute of limitations preclusion,
approximately 30 claims pending in U.S courts other than the MDL and JCCP, approximately 50 claims pending in non-U.S.
courts, and approximately 50 claims that would be eligible for inclusion in the settlement but for the participation limitations
contained in the MSA. We also estimate that there were approximately 650 outstanding metal-on-metal hip non-revision
claims as of December 25, 2016. These non-revision cases are excluded from the MSA.
As of December 25, 2016, our accrual for metal-on-metal claims totaled $256.6 million, of which $242.7 million is included in
our condensed consolidated balance sheet within “Accrued expenses and other current liabilities” and $13.9 million is included
within “Other liabilities.” Our accrual is based on (i) case by case accruals for specific cases where facts and circumstances
warrant, including the $2.1 million accrual associated with the MDL bellwether verdict, and (ii) the implied settlement values
for eligible claims under the MSA (assuming, in the absence of opt-in data, a 100% opt-in rate). We are unable to reasonably
estimate the high-end of a possible range of loss for claims which may in the future elect to opt-out of the MSA settlement.
Claims we can confirm would meet MSA eligibility criteria but are excluded from settlement due to the $240 million maximum
settlement cap, or because they are state cases not part of the MDL or JCCP, have been accrued as though included in the
settlement. Due to the general uncertainties surrounding all metal-on metal claims as noted above, as well as insufficient
information about individual claims, we are presently unable to reasonably estimate a range of loss for revision claims that
(i) (cid:71)(cid:82)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:80)(cid:72)(cid:72)(cid:87)(cid:3)(cid:48)(cid:54)(cid:36)(cid:3)(cid:72)(cid:79)(cid:76)(cid:74)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:70)(cid:85)(cid:76)(cid:87)(cid:72)(cid:85)(cid:76)(cid:68)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:73)(cid:88)(cid:87)(cid:88)(cid:85)(cid:72)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3)(cid:75)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:90)(cid:72)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:3)(cid:68)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:76)me.
However, we believe the high-end of a possible range of loss for existing revision claims that do not meet MSA eligibility
criteria will not, on an average per case basis, exceed the average per case accrual we have taken for revision claims we can
confirm do meet MSA eligibility criteria. Future claims will be evaluated for accrual on a case by case basis using the accrual
methodologies described above (which could change if future facts and circumstances warrant).
We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended September 30,
2012, we received a customary reservation of rights from our primary product liability insurance carrier asserting that certain
present and future claims which allege certain types of injury related to our CONSERVE® metal-on-metal hip products
(CONSERVE® Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The
effect of this coverage position would be to place CONSERVE® Claims into a single prior policy year in which applicable
claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees that there is
insurance coverage for the CONSERVE® Claims, but has notified the carrier that it disputes the carrier’s characterization of the
CONSERVE® Claims as a single occurrence.
In June 2014, St. Paul Surplus Lines Insurance Company (Travelers), which was an excess carrier in our coverage towers
across multiple policy years, filed a declaratory judgment action in Tennessee state court naming us and certain of our other
insurance carriers as defendants and asking the court to rule on the rights and responsibilities of the parties with regard to the
CONSERVE® Claims. Among other things, Travelers appeared to dispute our contention that the CONSERVE® Claims arise
out of more than a single occurrence thereby triggering multiple policy periods of coverage. Travelers further sought a
determination as to the applicable policy period triggered by the alleged single occurrence. We filed a separate lawsuit in state
court in California for declaratory judgment against certain carriers and breach of contract against the primary carrier, and
moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate
jurisdiction. During the third quarter of 2014, the California Court granted Travelers’ motion to stay our California action. On
April 29, 2016, we filed a dispositive motion seeking partial judgment in our favor in the Tennessee action. That motion is
pending, and will be decided after the parties complete discovery regarding certain issues relating to the pending motion. On
June 10, 2016, Travelers withdrew its motion for summary judgment in the Tennessee action. One of the other insurance
companies in the Tennessee action has stated that it will re-file a similar motion in the future.
82
On October 28, 2016, WMT and Wright Medical Group, Inc. (Wright Entities), entered into a Settlement Agreement, Indemnity
and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three
insurance carriers, namely Columbia Casualty Company, Travelers and AXIS Surplus Lines Insurance Company (collectively,
the Three Settling Insurers), pursuant to which the Three Settling Insurers agreed to pay WMT an aggregate of $60 million (in
addition to $10 million previously paid by Columbia) in a lump sum on or before the 30th business day after execution of the
Insurance Settlement Agreement. This amount is in full satisfaction of all potential liability of the Three Settling Insurers
relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in the MDL and the
JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described above.
On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against
the primary insurance carrier. The motion was subsequently amended on February 8, 2017 to add similar bad faith claims
against the remaining excess carriers. That motion is pending.
As part of the settlement, the Three Settling Insurers bought back from WMT their policies in the five policy years beginning
with the August 15, 2007- August 15, 2008 policy year (Repurchased Policy Years). Consequently, the Wright Entities have no
further coverage from the Three Settling Insurers for any present or future claims falling in the Repurchased Policy Years, or
any other period in which a released claim is asserted. Additionally, the Insurance Settlement Agreement contains a so-called
most favored nation provision which could require us to refund a pro rata portion of the settlement amount if we voluntarily
enter into a settlement with the remaining carriers in the Repurchased Policy Years on certain terms more favorable than
analogous terms in the Insurance Settlement Agreement. The Tennessee action will continue as to the remaining defendant
insurers other than the Three Settling Insurers. The amount due to the Wright Entities under the Insurance Settlement
Agreement was paid in the fourth quarter of 2016.
Management has recorded an insurance receivable of $8.7 million for the probable recovery of spending from the remaining
carriers (other than the Three Settling Carriers) in excess of our retention for a single occurrence. As of December 25, 2016 we
have received $71.7 million of insurance proceeds, and our insurance carriers have paid a total of $4.6 million directly to
claimants in connection with various settlements, which represents amounts undisputed by the carriers. Our acceptance of
these proceeds was not a waiver of any other claim we may have against the insurance carriers. However, the amount we
ultimately receive will depend on the outcome of our dispute with the remaining carriers (other than the Three Settling
Carriers) concerning the number of policy years available. We believe our contracts with the insurance carriers are enforceable
(cid:73)(cid:82)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3) (cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:15)(cid:3) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3) (cid:69)(cid:72)(cid:79)(cid:76)(cid:72)(cid:89)(cid:72)(cid:3) (cid:76)(cid:87)(cid:3) (cid:76)(cid:86)(cid:3) (cid:83)(cid:85)(cid:82)(cid:69)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3) (cid:90)(cid:72)(cid:3) (cid:90)(cid:76)(cid:79)(cid:79)(cid:3) (cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:72)(cid:3) (cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3) (cid:85)(cid:72)(cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:76)(cid:72)(cid:86)(cid:3) (cid:73)rom the remaining carriers.
Settlement discussions with the remaining insurance carriers continue.
Given the substantial or indeterminate amounts sought in these matters, and the inherent unpredictability of such matters, an
adverse outcome in these matters in excess of the amounts included in our accrual for contingencies could have a material
adverse effect on our financial condition, results of operations and cash flow. Future revisions to our estimates of these
provisions could materially impact our results of operations and financial position. We use the best information available to
determine the level of accrued product liabilities, and believe our accruals are adequate.
In June 2015, a jury returned a $4.4 million verdict against us in a case involving a fractured hip implant stem sold prior to the
MicroPort closing. This was a one-of-a-kind case unrelated to the modular neck fracture cases we have been reporting. There
are no other cases pending related to this component, nor are we aware of other instances where this component has fractured.
In September 2015, the trial judge reduced the jury verdict to $1.025 million and indicated that if the plaintiff did not accept the
reduced award he would schedule a new trial solely on the issue of damages. The plaintiff elected not to accept the reduced
damage award, and both parties have appealed. The Court has not set a date for a new trial on the issue of damages and we do
not expect it will do so until the appeals are adjudicated. We will maintain our current $4.4 million accrual as a probable
liability until the matter is resolved. The $4.4 million probable liability associated with this matter is reflected within “Accrued
expenses and other current liabilities,” and a $4 million receivable associated with the probable recovery from product liability
insurance is reflected within “Other current assets.”
Accounting for income taxes. We account for income taxes in accordance with provisions which set forth an asset and liability
approach that requires the recognition of deferred tax assets and deferred tax liabilities for the expected future tax consequences
of temporary differences between the carrying amounts and the tax bases of assets and liabilities. Realization of deferred tax
assets in each taxable jurisdiction is dependent on our ability to generate future taxable income sufficient to realize the benefits.
Management evaluates deferred tax assets on an ongoing basis and provides valuation allowances to reduce net deferred tax
assets to the amount that is more likely than not to be realized.
Our valuation allowance balances totaled $479.4 million and $336.1 million as of December 25, 2016 and December 27, 2015,
respectively, due to uncertainties related to our ability to realize, before expiration, certain of our deferred tax assets for both
U.S. and foreign income tax purposes.
83
As a multinational corporation, we are subject to taxation in many jurisdictions and the calculation of our tax liabilities
involves dealing with uncertainties in the application of complex tax laws and regulations in various taxing jurisdictions. In
accordance with ASC 740 Income Taxes, we recognize the tax effects of an income tax position only if they are “more-likely-
than-not” to be sustained based solely on the technical merits as of the reporting date. If we ultimately determine that the
payment of these liabilities will be unnecessary, we will reverse the liability and recognize a tax benefit in the period in which
we determine the liability no longer applies. Conversely, we record additional tax charges in a period in which we determine
that a recorded tax liability is less than we expect the ultimate assessment to be. Our unrecognized tax benefits totaled
$8.1 million and $9.9 million as of December 25, 2016 and December 27, 2015, respectively.
Share-based compensation. We calculate the grant date fair value of restricted stock units as the closing sales price on the
trading day of the grant date. We use the Black-Scholes option pricing model to determine the fair value of stock options and
employee stock purchase plan shares. The determination of the fair value of these share-based payment awards on the date of
grant using an option-pricing model is affected by our stock price as well as assumptions regarding a number of complex and
subjective variables, which include the expected life of the award, the expected stock price volatility over the expected life of
the awards, expected dividend yield, and risk-free interest rate.
We estimate the expected life of options evaluating the historical activity as required by FASB ASC Topic 718, Compensation
— Stock Compensation. Prior to the Wright/Tornier merger, the expected life of options was estimated based on historical
option exercise and employee termination data. Post merger, the expected life of options was estimated based on the simplified
method due to a lack of comparable, historical option exercise, and employee termination data for the combined company. The
expected stock price volatility assumption was estimated based upon historical volatility of our ordinary shares for both legacy
Wright and legacy Tornier prior to October 1, 2015 for and the total combined company after the Wright/Tornier merger. The
risk-free interest rate is determined using U.S. Treasury rates where the term is consistent with the expected life of the stock
options. Expected dividend yield is not considered as we have never paid dividends and have no plans of doing so in the future.
The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no
vesting restrictions and are fully transferable, characteristics not present in our option grants and employee stock purchase plan
shares. Existing valuation models, including the Black-Scholes and lattice binomial models, may not provide reliable measures
of the fair values of our share-based compensation. Consequently, there is a risk that our estimates of the fair values of our
share-based compensation awards on the grant dates may bear little resemblance to the actual values realized upon the exercise,
expiration, early termination, or forfeiture of those share-based payments in the future. Certain share-based payments, such as
employee stock options, may expire worthless or otherwise result in zero intrinsic value as compared to the fair values
originally estimated on the grant date and reported in our financial statements. Alternatively, value may be realized from these
instruments that is significantly higher than the fair values originally estimated on the grant date and reported in our financial
statements. There is not currently a market-based mechanism or other practical application to verify the reliability and
accuracy of the estimates stemming from these valuation models.
We are required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures
differ from those estimates. We use historical data to estimate pre-vesting forfeitures and record share-based compensation
expense only for those awards that are expected to vest. All share-based awards are amortized on a straight-line basis over their
respective requisite service periods, which are generally the vesting periods.
If factors change and we employ different assumptions for estimating share-based compensation expense in future periods,
such share-based compensation expense in future periods may differ significantly from what we have recorded in the current
period and could materially affect our operating income, net income, and net income per share. A change in assumptions may
also result in a lack of comparability with other companies that use different models, methods, and assumptions.
See Note 14 to our consolidated financial statements contained in “Item 8. Financial Statements and Supplementary Data” for
further information regarding our share-based compensation.
Recent Accounting Pronouncements
Information regarding recent accounting pronouncements is included in Note 2 to the consolidated financial statements in “Item
8. Financial Statements and Supplementary Data”.
84
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Interest Rate Risk
Borrowings under our ABL Facility bear interest at variable rates. The interest rate margin applicable to borrowings under the
ABL Facility is, at the option of the Borrowers, equal to either (a) 3.25% for base rate loans or (b) 4.25% for LIBOR rate loans,
subject to a 0.75% LIBOR floor. As of December 25, 2016, we had $30.0 million of borrowings under our ABL Facility.
Based upon this debt level, and the LIBOR floor on our interest rate, a 100 basis point increase in the annual interest rate on
such borrowings would have an immaterial impact on our interest expense on an annual basis.
Our exposure to interest rate risk arises principally from the interest rates associated with our invested cash balances. On
December 25, 2016, we had invested cash, cash equivalents and restricted cash of approximately $412.3 million. We believe
that a 10 basis point change in interest rates is reasonably possible in the near term. Based on our current level of investment,
an increase or decrease of 10 basis points in interest rates would have an annual impact of approximately $412,000 to our
interest income.
As of December 25, 2016, we had outstanding $2.0 million, $587.5 million, and $395 million principal amount of our 2017,
2020, and 2021 Notes, respectively. We carry these instruments at face value less unamortized discount on our consolidated
balance sheets. Since these instruments bear interest at a fixed rate, we have no financial statement risk associated with
changes in interest rates. However, the fair value of these instruments fluctuates when interest rates change, and when the
market price of our ordinary shares fluctuates. We do not carry the 2017, 2020, and 2021 Notes at fair value, but present the
fair value of the principal amount of our 2017, 2020, and 2021 Notes for disclosure purposes.
Equity Price Risk
The 2017 Notes include conversion and settlement provisions that are based on the price of our ordinary shares and prior to the
Wright/Tornier merger, WMG common stock, at conversion or at maturity of the notes. On February 13, 2015, WMG issued
$632.5 million of the 2020 Notes, which generated net proceeds of approximately $613 million. Approximately $292 million
of the net proceeds from the offering were used to repurchase approximately $240 million aggregate principal amount of the
2017 Notes in privately negotiated transactions. In addition, all of the 2017 Notes Hedges were settled and all of the warrants
associated with the 2017 Notes were repurchased, generating net proceeds of approximately $10 million. On May 20, 2016, we
issued $395 million aggregate principal amount of the 2021 Notes. Concurrently with the issuance and sale of the 2021 Notes,
certain holders of $54.4 million aggregate principal amount of the 2017 Notes exchanged their 2017 Notes for the 2021 Notes.
Approximately $3.7 million of the net proceeds from the 2021 Notes offering were subsequently used to repurchase
approximately $3.6 million aggregate principal amount of the 2017 Notes in privately negotiated transactions. As of
December 25, 2016, we had approximately $2.0 million in outstanding debt under the 2017 Notes. The following table shows
the amount of cash that we would be required to provide holders of the 2017 Notes upon maturity assuming various closing
prices of our ordinary shares at the date of maturity:
Share price
$27.98
$30.53
$33.07
$35.62
$38.16
(10% greater than conversion price)
(20% greater than conversion price)
(30% greater than conversion price)
(40% greater than conversion price)
(50% greater than conversion price)
Cash payment in excess of principal (in
thousands)
$203
$405
$608
$811
$1,013
The fair value of our 2017 Notes Conversion Derivative is directly impacted by the price of our ordinary shares and prior to the
Wright/Tornier merger, WMG common stock. The following table presents the fair values of our 2017 Notes Conversion
Derivative as a result of a hypothetical 10% increase and decrease in the price of our ordinary shares. We believe that a 10%
change in our share price is reasonably possible in the near term:
(in thousands)
2017 Notes Conversion Derivative (Liability)
Fair value of security given
a 10% decrease in share
price
$83
Fair value of security as of
December 25, 2016
$164
Fair value of security given
a 10% increase in share
price
$277
The 2020 Notes includes conversion and settlement provisions that are based on the price of our ordinary shares at conversion
or at maturity of the notes. In addition, the hedges and warrants associated with these convertible notes also include settlement
provisions that are based on the price of our ordinary shares. The amount of cash we may be required to pay, or the number of
85
shares we may be required to provide to note holders at conversion or maturity of these notes, is determined by the price of our
ordinary shares. The amount of cash that we may receive from hedge counterparties in connection with the related hedges and
the number of shares that we may be required to provide warrant counterparties in connection with the related warrants are also
determined by the price of our ordinary shares.
Upon the expiration of our warrants issued in connection with the 2020 Notes, we will issue ordinary shares to the purchasers
of the warrants to the extent the price of our ordinary shares exceeds the warrant strike price of $40.00 at that time. On
November 24, 2015, Wright Medical Group N.V. assumed WMG’s obligations pursuant to the warrants, and the strike price of
the warrants was adjusted to $38.8010 per ordinary share. The following table shows the number of shares that we would issue
to warrant counterparties at expiration of the warrants assuming various closing prices of our ordinary shares on the date of
warrant expiration:
Share price
$42.68
$46.56
$50.44
$54.32
$58.20
(10% greater than strike price)
(20% greater than strike price)
(30% greater than strike price)
(40% greater than strike price)
(50% greater than strike price)
Shares (in thousands)
1,784
3,270
4,528
5,606
6,540
The fair value of the 2020 Notes Conversion Derivative and the 2020 Notes Hedge is directly impacted by the price of our
ordinary shares. We entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with the option
counterparties. The 2020 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments
that we are required to make upon conversion of the 2020 Notes in excess of the principal amount of converted notes if our
ordinary share price exceeds the conversion price. The following table presents the fair values of the 2020 Notes Conversion
Derivative and 2020 Notes Hedge as a result of a hypothetical 10% increase and decrease in the price of our ordinary shares.
We believe that a 10% change in our share price is reasonably possible in the near term:
(in thousands)
2020 Notes Hedges (Asset)
2020 Notes Conversion Derivative (Liability)
Fair value of security given
a 10% decrease in share
price
$56,608
$55,516
Fair value of security as of
December 25, 2016
$77,232
$77,758
Fair value of security given
a 10% increase in share
price
$100,727
$103,372
The 2021 Notes include conversion and settlement provisions that are based on the price of our ordinary shares at conversion or
at maturity of the notes. In addition, the hedges and warrants associated with these convertible notes also include settlement
provisions that are based on the price of our ordinary shares. The amount of cash we may be required to pay, or the number of
shares we may be required to provide to note holders at conversion or maturity of these notes, is determined by the price of our
ordinary shares. The amount of cash that we may receive from hedge counterparties in connection with the related hedges and
the number of shares that we may be required to provide warrant counterparties in connection with the related warrants are also
determined by the price of our ordinary shares.
Upon the expiration of our warrants issued in connection with the 2021 Notes, we will issue ordinary shares to the purchasers
of the warrants to the extent the price of our ordinary shares exceeds the warrant strike price of $30.00 at that time. The
following table shows the number of shares that we would issue to warrant counterparties at expiration of the warrants
assuming various closing prices of our ordinary shares on the date of warrant expiration:
Share price
$33.00
$36.00
$39.00
$42.00
$45.00
(10% greater than strike price)
(20% greater than strike price)
(30% greater than strike price)
(40% greater than strike price)
(50% greater than strike price)
Shares (in thousands)
1,681
3,082
4,268
5,284
6,164
86
The fair value of the 2021 Notes Conversion Derivative and the 2021 Notes Hedge is directly impacted by the price of our
ordinary shares. We entered into the 2021 Notes Hedges in connection with the issuance of the 2021 Notes with the option
counterparties. The 2021 Notes Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments
that we are required to make upon conversion of the 2021 Notes in excess of the principal amount of converted notes if our
ordinary share price exceeds the conversion price. The following table presents the fair values of the 2021 Notes Conversion
Derivative and 2021 Notes Hedge as a result of a hypothetical 10% increase and decrease in the price of our ordinary shares.
We believe that a 10% change in our share price is reasonably possible in the near term:
(in thousands)
2021 Notes Hedges (Asset)
2021 Notes Conversion Derivative (Liability)
Foreign Currency Exchange Rate Fluctuations
Fair value of security given
a 10% decrease in share
price
$129,202
$127,313
Fair value of security as of
December 25, 2016
$159,095
$161,601
Fair value of security given
a 10% increase in share
price
$190,663
$197,892
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies could adversely affect our financial results.
Approximately 24% of our net sales from continuing operations were denominated in foreign currencies during the year ended
December 25, 2016 and we expect that foreign currencies will continue to represent a similarly significant percentage of our
net sales in the future. (cid:38)(cid:82)(cid:86)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:83)(cid:85)(cid:76)(cid:80)(cid:68)(cid:85)(cid:76)(cid:79)(cid:92)(cid:3)(cid:71)(cid:72)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:3)(cid:71)(cid:82)(cid:79)(cid:79)(cid:68)(cid:85)(cid:86)(cid:30)(cid:3)(cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)
related to these sales are largely denominated in the same respective currencies, thereby partially limiting our transaction risk
exposure. For sales not denominated in U.S. dollars, an increase in the rate at which a foreign currency is exchanged for U.S.
dollars will require more of the foreign currency to equal a specified amount of U.S. dollars than before the rate increase. In
such cases, if we price our products in the foreign currency, we will receive less in U.S. dollars than we did before the rate
increase went into effect. If we price our products in U.S. dollars and our competitors price their products in local currency, an
increase in the relative strength of the U.S. dollar could result in our prices not being competitive in a market where business is
transacted in the local currency.
In 2016, approximately 91% of our net sales denominated in foreign currencies were derived from European Union countries,
(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3) (cid:71)(cid:72)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3)(cid:40)(cid:88)(cid:85)(cid:82)(cid:30)(cid:3) (cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:56)(cid:81)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3) (cid:46)(cid:76)(cid:81)(cid:74)(cid:71)(cid:82)(cid:80)(cid:15)(cid:3) (cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3) (cid:71)(cid:72)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:37)(cid:85)(cid:76)(cid:87)(cid:76)(cid:86)(cid:75)(cid:3) (cid:83)(cid:82)(cid:88)(cid:81)(cid:71)(cid:30)(cid:3) (cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:36)(cid:88)(cid:86)(cid:87)(cid:85)(cid:68)(cid:79)(cid:76)(cid:68)(cid:3)
(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:71)(cid:72)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:36)(cid:88)(cid:86)(cid:87)(cid:85)(cid:68)(cid:79)(cid:76)(cid:68)(cid:81)(cid:3)(cid:71)(cid:82)(cid:79)(cid:79)(cid:68)(cid:85)(cid:30)(cid:3)(cid:68)nd from Canada, which are denominated in the Canadian dollar. Additionally, we
have significant intercompany receivables, payables, and debt from our foreign subsidiaries that are denominated in foreign
currencies, principally the Euro, the Japanese yen, the British pound, the Australian dollar, and the Canadian dollar. Our
principal exchange rate risk, therefore, exists between the U.S. dollar and the Euro, British pound, Australian dollar, and the
Canadian dollar. Fluctuations from the beginning to the end of any given reporting period result in the revaluation of our
foreign currency-denominated intercompany receivables, payables, and debt generating currency translation gains or losses that
impact our non-operating income and expense levels in the respective period.
As discussed in Note 6 to the consolidated financial statements contained in “Item 8. Financial Statements and Supplementary
Data,” we enter into certain short-term derivative financial instruments in the form of foreign currency forward contracts.
These forward contracts are designed to mitigate our exposure to currency fluctuations in our intercompany balances
denominated currently in Euros, British pounds, and Canadian dollars. Any change in the fair value of these forward contracts
as a result of a fluctuation in a currency exchange rate is expected to be offset by a change in the value of the intercompany
balance. These contracts are effectively closed at the end of each reporting period.
A uniform 10% strengthening in the value of the U.S. dollar relative to the currencies in which our transactions are
denominated would have resulted in an increase in operating income of approximately $2.0 million for the year ended
December 25, 2016. This hypothetical calculation assumes that each exchange rate would change in the same direction relative
to the U.S. dollar. This sensitivity analysis of the effects of changes in foreign currency exchange rates does not factor in a
potential change in sales levels or local currency prices, which can also be affected by the change in exchange rates.
87
Item 8.
Financial Statements and Supplementary Data.
Wright Medical Group N.V.
Consolidated Financial Statements
for the Fiscal Years Ended December 25, 2016, December 27, 2015, and December 31, 2014
Index to Financial Statements
Reports of Independent Registered Public Accounting Firm
Consolidated Financial Statements:
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Comprehensive Loss
Consolidated Statements of Cash Flows
Consolidated Statements of Changes in Shareholders’ Equity
Notes to Consolidated Financial Statements
Page
89
92
93
94
95
97
98
88
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Wright Medical Group N.V.:
We have audited the accompanying consolidated balance sheets of Wright Medical Group N.V. and subsidiaries as of
December 25, 2016 and December 27, 2015, and the related consolidated statements of operations, comprehensive loss, cash
flows, and changes in shareholders’ equity for the years ended December 25, 2016, December 27, 2015, and December 31,
2014. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to
express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts
and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits
provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial
position of Wright Medical Group N.V. and subsidiaries as of December 25, 2016 and December 27, 2015, and the results of
their operations and their cash flows for the years ended December 25, 2016, December 27, 2015, and December 31, 2014, in
conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States),
Wright Medical Group N.V.’s internal control over financial reporting as of December 25, 2016, based on criteria established in
Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO, and our report dated February 23, 2017 expressed an adverse opinion on the effectiveness of the
Company’s internal control over financial reporting.
(signed) KPMG LLP
Memphis, Tennessee
February 23, 2017
89
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Wright Medical Group N.V.:
We have audited Wright Medical Group N.V.’s internal control over financial reporting as of December 25, 2016, based on
criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of
the Treadway Commission (COSO). Wright Medical Group N.V.’s management is responsible for maintaining effective
internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting,
included in the accompanying Management’s Annual Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal
control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design
and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other
procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our
opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures
that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and
(cid:71)(cid:76)(cid:86)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)(cid:3)(cid:11)(cid:21)(cid:12)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:3)(cid:85)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:68)(cid:86)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:85)(cid:72)(cid:70)(cid:82)(cid:85)(cid:71)(cid:72)(cid:71)(cid:3)(cid:68)(cid:86)(cid:3)(cid:81)(cid:72)(cid:70)(cid:72)(cid:86)(cid:86)(cid:68)(cid:85)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:83)(cid:72)rmit
preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and
expenditures of the company are being made only in accordance with authorizations of management and directors of the
(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:22)(cid:12)(cid:3) (cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:3)(cid:85)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3) (cid:68)(cid:86)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:85)(cid:72)(cid:74)(cid:68)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:83)(cid:85)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:85)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:79)(cid:92)(cid:3) (cid:71)(cid:72)(cid:87)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:88)nauthorized acquisition, use, or
disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate
because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not
be prevented or detected on a timely basis. A material weakness related to ineffective general information technology controls
has been identified and included in management’s assessment. The material weakness in internal control over financial
reporting related to ineffective design and operation of general information technology controls related to user access to certain
information technology systems that are relevant to the Company’s financial reporting processes and that are intended to ensure
that access to financial applications and data is adequately restricted to appropriate personnel and monitored to ensure
adherence to Company policies. As a result, the Company’s automated and manual controls that are dependent on the effective
design and operation of general information technology controls were also ineffective because they could have been adversely
impacted.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States),
the consolidated balance sheets of Wright Medical Group N.V. and subsidiaries as of December 25, 2016 and December 27,
2015, and the related consolidated statements of operations, comprehensive loss, cash flows, and changes in shareholders’
equity for the years ended December 25, 2016, December 27, 2015, and December 31, 2014. This material weakness was
considered in determining the nature, timing, and extent of audit tests applied in our audit of the 2016 consolidated financial
statements, and this report does not affect our report dated February 23, 2017, which expressed an unqualified opinion on those
consolidated financial statements.
In our opinion, because of the effect of the aforementioned material weakness on the achievement of the objectives of the
control criteria, Wright Medical Group N.V. has not maintained effective internal control over financial reporting as of
December 25, 2016, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission (COSO).
90
We do not express an opinion or any other form of assurance on management’s statements referring to corrective actions to be
taken after December 25, 2016, relative to the aforementioned material weakness in internal control over financial reporting.
(signed) KPMG LLP
Memphis, Tennessee
February 23, 2017
91
Wright Medical Group N.V.
Consolidated Balance Sheets
(In thousands, except share data)
Assets:
Current assets:
Cash and cash equivalents
Restricted cash (Note 17)
Accounts receivable, net
Inventories (Note 5) 1
Prepaid expenses 1
Other current assets
Current assets held for sale (Note 4) 1
Total current assets
Property, plant and equipment, net (Note 7) 1
Goodwill (Note 8) 1
Intangible assets, net (Note 8) 1
Deferred income taxes (Note 11)
Other assets 2
Non-current assets held for sale (Note 4) 1
Total assets 1, 2
Liabilities and Shareholders’ Equity:
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities (Note 12) 1
Current portion of long-term obligations (Note 9)
Current liabilities held for sale (Note 4) 1
Total current liabilities
Long-term debt and capital lease obligations (Note 9) 2
Deferred income taxes (Note 11)
Other liabilities (Note 12)
Total liabilities 1, 2
Commitments and contingencies (Note 16)
Shareholders’ equity:
(cid:50)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:15)(cid:3)(cid:188)(cid:19)(cid:17)(cid:19)(cid:22)(cid:3)(cid:83)(cid:68)(cid:85)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:15)(cid:3)(cid:68)(cid:88)(cid:87)(cid:75)(cid:82)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71)(cid:29)(cid:3)(cid:22)(cid:21)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:29)(cid:3)
103,400,995 shares at December 25, 2016 and 102,672,678 shares at December 27, 2015
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity 1, 2
December 25,
2016
December 27,
2015
$
262,265 $
150,000
130,602
150,849
11,678
54,231
—
759,625
139,804
—
131,050
210,701
14,923
44,919
18,487
559,884
201,732
851,042
231,797
1,498
244,892
—
224,256
866,989
250,928
2,580
137,174
31,683
$ 2,290,586 $ 2,073,494
$
32,866 $
407,704
33,948
—
474,518
30,904
171,171
2,171
2,692
206,938
780,407
27,550
321,247
1,603,722
561,201
41,755
208,574
1,018,468
3,815
3,790
1,835,586
(10,484)
(773,866)
1,055,026
$ 2,290,586 $ 2,073,494
1,908,749
(19,461)
(1,206,239)
686,864
___________________________
1
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015 (See Note 4).
2
The prior period debt issuance costs were reclassified to account for adoptions of ASU 2015-03 and ASU 2015-15 (See Note 2).
The accompanying notes are an integral part of these consolidated financial statements.
92
Wright Medical Group N.V.
Consolidated Statements of Operations
(In thousands, except per share data)
Net sales
Cost of sales 1, 2
Gross profit
Operating expenses:
Selling, general and administrative 1
Research and development 1
Amortization of intangible assets
Total operating expenses
Operating loss
Interest expense, net
Other (income) expense, net
Loss from continuing operations before income taxes
Benefit for income taxes (Note 11)
Net loss from continuing operations
Loss from discontinued operations, net of tax (Note 4)
Net loss
Net loss from continuing operations per share-basic and diluted (Note 13): 3
Net loss per share-basic and diluted (Note 13): 3
$
December 25,
2016
690,362 $
192,407
497,955
Fiscal year ended
December 27,
2015 4
December 31,
2014
298,027
73,223
224,804
405,326 $
113,622
291,704
541,558
50,514
28,841
620,913
(122,958)
58,530
(3,148)
(178,340)
(13,406)
(164,934) $
(267,439) $
(432,373) $
424,377
39,339
16,754
480,470
(188,766)
41,358
10,884
(241,008)
(3,652)
(237,356) $
(61,345) $
(298,701) $
289,620
24,963
10,027
324,610
(99,806)
17,398
129,626
(246,830)
(6,334)
(240,496)
(19,187)
(259,683)
(1.60) $
(3.66) $
(4.69)
(4.20) $
(4.61) $
(5.06)
102,968
64,808
51,293
$
$
$
$
$
Weighted-average number of ordinary shares outstanding-basic and diluted 3
___________________________
1
These line items include the following amounts of non-cash, share-based compensation expense for the periods indicated:
Cost of sales
Selling, general and administrative
Research and development
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
$
414 $
287 $
13,216
786
22,777
1,900
254
10,149
1,084
2
3
Cost of sales includes amortization of inventory step-up adjustment of $37.7 million and $10.3 million for the years ended December 25,
2016 and December 27, 2015, respectively.
The 2014 weighted-average shares outstanding and net loss per share amounts were converted to meet post-merger valuations as
described within Note 13. The 2015 weighted-average shares outstanding includes additional shares issued on October 1, 2015 as part
of the Wright/Tornier merger as described in Note 13.
4
The 2015 results were restated for the divestiture of our Large Joints business.
The accompanying notes are an integral part of these consolidated financial statements.
93
Wright Medical Group N.V.
Consolidated Statements of Comprehensive Loss
(In thousands)
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
Net loss
$
(432,373) $
(298,701) $
(259,683)
Other comprehensive income (loss), net of tax:
Changes in foreign currency translation
Reclassification of gain on equity securities, net of taxes
Reclassification of currency translation adjustment (CTA) write-off to
earnings related to liquidation of Japanese subsidiary
Reclassification of minimum pension liability to earnings
Other comprehensive loss
Comprehensive loss
(8,977)
—
—
—
(8,977)
(12,882)
—
—
—
(12,882)
(17,840)
1
2,628
(344)
(15,555)
$
(441,350) $
(311,583) $
(275,238)
The accompanying notes are an integral part of these consolidated financial statements.
94
Wright Medical Group N.V.
Consolidated Statements of Cash Flows
(In thousands)
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash provided by (used in)
operating activities:
Depreciation
Share-based compensation expense (Note 14)
Amortization of intangible assets
Amortization of deferred financing costs and debt discount
Deferred income taxes (Note 11)
Provision for excess and obsolete inventory 1
Write-off of deferred financing costs
Excess tax benefit from share-based compensation arrangements
Amortization of inventory step-up adjustment
Non-cash adjustment to derivative fair value
Loss (gain) on sale of business (Note 4)
Mark-to-market adjustment for CVRs (Note 2)
Reduction of insurance receivable
Other
Changes in assets and liabilities (net of acquisitions):
Accounts receivable
Inventories 1
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other liabilities
CVR payment in excess of value assigned as part of PPA
Provision for metal on metal product liabilities (Note 16)
Net cash provided by (used in) operating activities
Investing activities:
Capital expenditures
Acquisition of businesses
Purchase of intangible assets
Cash acquired from merger with Tornier
Sales and maturities of available-for-sale marketable securities
Proceeds from sale of businesses
Net cash (used in) provided by investing activities
Financing activities:
Issuance of ordinary shares
Proceeds from stock warrants
Payment of note hedge options
Repurchase of stock warrants
Payment of notes premium
Proceeds from notes hedge options
Payment of debt acquired from merger with Tornier
Proceeds from debt
Redemption of convertible notes
Payments of deferred financing costs and equity issuance costs
Payment of contingent consideration
Payments of capital leases
Excess tax benefit from share-based compensation arrangements
Net cash provided by financing activities
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
$
(432,373) $
(298,701) $
(259,683)
56,782
14,416
29,180
40,487
(20,583)
22,046
12,343
—
41,503
(28,273)
21,342
8,688
—
4,425
(1,118)
(187)
22,441
1,495
(11,251)
—
256,461
37,824
(50,099)
—
(4,845)
—
—
20,703
(34,241)
8,460
54,629
(99,816)
(3,319)
(1,619)
3,892
—
425,821
(102,974)
(11,108)
(1,035)
(2,514)
—
270,417
29,481
24,964
16,922
27,600
(3,087)
14,218
25,101
—
11,356
(10,045)
—
(7,571)
25,000
4,780
(13,078)
(24,695)
(10,471)
(2,919)
23,258
(27,983)
—
(195,870)
(43,666)
(4,905)
(82)
30,117
2,566
—
(15,970)
3,513
87,072
(144,843)
(59,803)
(49,152)
69,764
(81,367)
632,500
(240,000)
(20,081)
(70,120)
(621)
—
126,862
18,582
11,487
10,027
10,969
(396)
3,967
—
(59)
—
2,000
(24,277)
125,012
—
2,582
(11,970)
(25,317)
30,531
12,907
(22,364)
—
—
(116,002)
(48,603)
(80,556)
(11,693)
—
11,795
274,687
145,630
37,201
—
—
—
—
—
—
—
(3,768)
—
—
(441)
59
33,051
Effect of exchange rates on cash, cash equivalents and restricted cash
(1,539)
(2,544)
(4,088)
Net increase (decrease) in cash, cash equivalents and restricted cash
272,461
(87,522)
58,591
95
Wright Medical Group N.V.
Consolidated Statements of Cash Flows
(In thousands)
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
Cash, cash equivalents and restricted cash, beginning of year
139,804
227,326
168,735
Cash, cash equivalents and restricted cash, end of year (Note 17)
___________________________
1 During 2015, the 2014 balances were reclassified to show separate presentation related to provision for excess and obsolete inventory.
412,265 $
139,804 $
$
227,326
The accompanying notes are an integral part of these consolidated financial statements.
96
Wright Medical Group N.V.
Consolidated Statements of Changes in Shareholders’ Equity
For the fiscal years ended December 31, 2014, December 27, 2015, and December 25, 2016
(In thousands, except share data)
Ordinary shares
Number of
shares 1
49,476,738 $
Amount 1
Additional
paid-in
capital 1
Retained
earnings/
(accumulated
deficit)
(215,482) $
Accumulated
other
comprehensive
income
Total
shareholders’
equity
1
1
—
—
—
—
—
—
—
—
—
2,628
—
(344)
41,387
(344)
459,714
1,956 $
1,406,799
—
—
—
68
17,953 $
—
—
—
—
—
—
655,287 $
1,718,100
2,628
37,200
—
37,132
(259,683)
(17,840)
—
(17,840)
(259,683 )
—
57
—
—
20
—
2,101 $
—
—
(20)
15,683
749,469 $
—
—
—
—
—
(475,165) $
252,477
(24,051 )
83,030
—
52,913,093 $
Balance at December 31, 2013
2014 Activity:
Net loss
Foreign currency translation
Reclassification of gain on equity
securities, net of taxes
Minimum pension liability
adjustment 2
Currency translation adjustment (CTA)
write-off to earnings related to
liquidation of Japanese subsidiary 2
Issuances of ordinary shares
Ordinary shares issued in connection
with Solana acquisition
Grant of restricted stock awards
Forfeitures of restricted stock awards
Vesting of restricted stock units
Share-based compensation
Balance at December 31, 2014
2015 Activity:
Net loss
Foreign currency translation
Issuances of ordinary shares
Ordinary shares issued in connection
with Tornier merger
Grant of restricted stock awards
Forfeitures of restricted stock awards
Vesting of restricted stock units
Share-based compensation
Issuance of stock warrants, net of
equity issuance costs
Balance at December 27, 2015
2016 Activity:
Net loss
Foreign currency translation
Issuances of ordinary shares
Vesting of restricted stock units
Share-based compensation
Issuance of stock warrants, net of
repurchases and equity issuance costs
Balance at December 25, 2016
___________________________
1 During 2015, the 2014 balances of ordinary shares and additional paid in capital were restated to meet post-merger conversion values as
$
3,815 $ 1,908,749 $ (1,206,239) $
$ 1,034,236
—
—
—
24,803
(432,373) $
— $
— $
— $
— $
— $
— $
440,355 $
287,962 $
— $
—
—
—
—
—
2,398 $
$
5,246 $
(5,869 ) $
30,895 $
— $
— $
— $
8,455 $
(10) $
14,406 $
$
— $
— $
(17) $
24,803 $
— $
(8,977) $
— $
— $
— $
41,444
—
—
—
15,683
278,803
(432,373)
(8,977)
8,470
—
14,406
$
3,790 $ 1,835,586 $
25,247
(10,484) $ 1,055,026
(298,701) $
— $
— $
— $
— $
160,306 $
— $
(12,882) $
— $
— $
— $
15 $
10 $
— $
$
—
— $
— $
— $
— $
$
103,400,995 $
$
102,672,678 $
—
— $
— $
— $
— $
(298,701)
(12,882)
3,520
— $
— $
3,514 $
— $
— $
17 $
— $
$
—
(773,866) $
$
—
(19,461) $
— $
— $
6 $
50,312
686,864
$ 1,032,570
49,569,007
50,312
25,247
1,666
$
$
$
$
—
—
—
—
—
—
further described within Note 13.
2
The balances of CTA and minimum pension liability adjustment within AOCI were written-off in 2014 following the liquidation of our
former Japanese subsidiary as part of the sale of our OrthoRecon business. This was recorded within the gain on the sale of the
OrthoRecon business within results of discontinued operations.
The accompanying notes are an integral part of these consolidated financial statements.
97
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1.
Organization and Description of Business
Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. We are
committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and are a recognized
leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and
biologics markets, three of the fastest growing segments in orthopaedics. We market our products in over 50 countries
worldwide.
Our global corporate headquarters are located in Amsterdam, the Netherlands. We also have significant operations located in
Memphis, Tennessee (U.S. headquarters, research and development, sales and marketing administration, and administrative
(cid:68)(cid:70)(cid:87)(cid:76)(cid:89)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:12)(cid:30)(cid:3)(cid:37)(cid:79)(cid:82)(cid:82)(cid:80)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:48)(cid:76)(cid:81)(cid:81)(cid:72)(cid:86)(cid:82)(cid:87)(cid:68)(cid:3)(cid:11)(cid:88)(cid:83)(cid:83)(cid:72)(cid:85)(cid:3)(cid:72)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:68)(cid:85)(cid:78)(cid:72)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:36)(cid:85)(cid:79)(cid:76)(cid:81)(cid:74)(cid:87)(cid:82)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)see
(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3) (cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3) (cid:41)(cid:85)(cid:68)(cid:81)(cid:78)(cid:79)(cid:76)(cid:81)(cid:15)(cid:3)(cid:55)(cid:72)(cid:81)(cid:81)(cid:72)(cid:86)(cid:86)(cid:72)(cid:72)(cid:3) (cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3) (cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3) (cid:48)(cid:82)(cid:81)(cid:87)(cid:69)(cid:82)(cid:81)(cid:81)(cid:82)(cid:87)(cid:15)(cid:3)
(cid:41)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:12)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:68)(cid:70)(cid:85)(cid:82)(cid:82)(cid:80)(cid:15)(cid:3)(cid:44)(cid:85)(cid:72)(cid:79)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:80)(cid:68)(cid:81)(cid:88)(cid:73)(cid:68)(cid:70)(cid:87)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:12)(cid:17)(cid:3)(cid:3)(cid:44)(cid:81)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:79)(cid:82)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:68)(cid:79)(cid:72)s
and distribution offices in Canada, Australia, Asia, Latin America, and throughout Europe. For purposes of this report,
references to “international” or “foreign” relate to non-U.S. matters while references to “domestic” relate to U.S. matters.
Upon completion of the merger between Wright Medical Group, Inc. (legacy Wright or WMG) and Tornier N.V. (legacy
Tornier) (the Wright/Tornier merger or merger) effective October 1, 2015, Robert J. Palmisano, former President and Chief
Executive Officer (CEO) of legacy Wright, became President and CEO of the combined company, and Lance A. Berry, former
Senior Vice President (SVP) and Chief Financial Officer (CFO) of legacy Wright, became SVP and CFO. Immediately upon
completion of the merger, legacy Wright shareholders owned approximately 52% of the combined company and legacy Tornier
shareholders owned approximately 48% of the combined company, and our board of directors was comprised of five
representatives from legacy Wright’s board of directors and five representatives from legacy Tornier’s board of directors. In
connection with the merger, the trading symbol for our ordinary shares changed from “TRNX” to “WMGI.” Because of these
and other facts and circumstances, the merger was accounted for as a “reverse acquisition” under generally accepted accounting
principles in the United States (US GAAP), and as such, legacy Wright was considered the acquiring entity for accounting
purposes. Therefore, legacy Wright’s historical results of operations replaced legacy Tornier’s historical results of operations
for all periods prior to the merger. More specifically, the accompanying consolidated financial statements for periods prior to
the merger are those of legacy Wright and its subsidiaries, and for periods subsequent to the merger also include legacy Tornier
and its subsidiaries.
Beginning in 2015 as a result of the Wright/Tornier merger, our fiscal year-end is generally determined on a 52-week basis and
runs from the Monday nearest to the 31st of December of a year, and ends on the Sunday nearest to the 31st of December of the
following year. Every few years, it is necessary to add an extra week to the year making it a 53-week period. Prior to the
merger, our fiscal year ended December 31 each year.
The consolidated financial statements and accompanying notes present our consolidated results for each of the fiscal years in
the three-year period ended December 25, 2016, December 27, 2015, and December 31, 2014.
All amounts are presented in U.S. dollars ($), except where expressly stated as being in other currencies, e.g., Euros (€).
References in these notes to consolidated financial statements to “we,” “our” and “us” refer to Wright Medical Group N.V. and
its subsidiaries after the Wright/Tornier merger and Wright Medical Group, Inc. and its subsidiaries before the merger.
2.
Summary of Significant Accounting Policies
Principles of consolidation. The accompanying consolidated financial statements include our accounts and those of our
wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation.
Use of estimates. The preparation of financial statements in conformity with US GAAP requires management to make
estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results
could differ from those estimates. The most significant areas requiring the use of management estimates relate to revenue
recognition, the determination of allowances for doubtful accounts and excess and obsolete inventories, accounting for business
combinations and the evaluation of goodwill and long-lived assets, valuation of in-process research and development, product
liability claims, product liability insurance recoveries and other litigation, income taxes, and share-based compensation.
98
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Discontinued operations. On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France SAS
and certain other entities related to us and Corin Orthopaedics Holdings Limitied (Corin) entered into a business sale agreement
and simultaneously completed and closed the sale of our Large Joints business. Pursuant to the terms of the agreement, we sold
substantially all of our assets related to our Large Joints business to Corin for approximately €29.7 million in cash, less
approximately €10.7 million for net working capital adjustments. Upon closing, the parties also executed a transitional services
agreement and supply agreement, among other ancillary agreements required to implement the transaction. These agreements
are on arm’s length terms and are not expected to be material to our financial statements.
On January 9, 2014, pursuant to an Asset Purchase Agreement, dated as of June 18, 2013 (the MicroPort Agreement), by and
among us and MicroPort Scientific Corporation (MicroPort), we completed the divesture and sale of our business operations
operating under our prior OrthoRecon operating segment (the OrthoRecon Business) to MicroPort. Pursuant to the terms of the
MicroPort Agreement, the purchase price (as defined in the agreement) for the OrthoRecon Business was approximately
$283 million (including a working capital adjustment), which MicroPort paid in cash.
All historical operating results for the Large Joints and OrthoRecon businesses, including costs associated with corporate
employees and infrastructure transferred as a part of the sales, are reflected within discontinued operations in the consolidated
statements of operations. See Note 4 for further discussion of discontinued operations. Other than Note 4, unless otherwise
stated, all discussion of assets and liabilities in these Notes to the Consolidated Financial Statements reflect the assets and
liabilities held and used in our continuing operations, and all discussion of revenues and expenses reflect those associated with
our continuing operations.
Cash and cash equivalents. Cash and cash equivalents include all cash balances and short-term investments with original
maturities of three months or less. Any such investments are readily convertible into known amounts of cash, and are so near
their maturity that they present insignificant risk of changes in value because of interest rate variation.
Restricted cash. Amounts included in restricted cash represent those required to be held in a restricted escrow account by a
contractual agreement to secure the obligations of Wright Medical Technology, Inc. (WMT) under the Master Settlement
Agreement (MSA) as described in Note 16. For additional information regarding restricted cash, see Note 17.
Inventories. Our inventories are valued at the lower of cost or market on a first-in, first-out (FIFO) basis. Inventory costs
include material, labor costs, and manufacturing overhead.
During the quarter ended December 27, 2015, we adjusted our estimate for excess and obsolete (E&O) inventory which
resulted in a charge of $4.1 million. Our new E&O estimate was based on both the current age of kit inventory as compared to
its estimated life cycle and our forecasted product demand and production requirements for other inventory items for the next
36 months. Total charges incurred to write down excess and obsolete inventory to net realizable value included in “Cost of
sales” were approximately $21.5 million, $14.2 million, and $4.0 million for the years ended December 25, 2016,
December 27, 2015, and December 31, 2014, respectively. During the year ended December 25, 2016, we recorded
$4.1 million of provisions for excess and obsolete inventory for product rationalization initiatives. Additionally, charges in
2016 are higher than prior years due to the additional inventories subject to reserves following the Wright/Tornier merger.
Product liability claims and related insurance recoveries and other litigation. We are involved in legal proceedings involving
product liability claims as well as contract, patent protection, and other matters. See Note 16 for additional information
regarding product liability claims, product liability insurance recoveries, and other litigation.
We make provisions for claims specifically identified for which we believe the likelihood of an unfavorable outcome is
probable and the amount of loss can be estimated. For unresolved contingencies with potentially material exposure that are
deemed reasonably possible, we evaluate whether a potential loss or range of loss can be reasonably estimated. Our evaluation
of these matters is the result of a comprehensive process designed to ensure that recognition of a loss or disclosure of these
contingencies is made in a timely manner. In determining whether a loss should be accrued or a loss contingency disclosed, we
(cid:72)(cid:89)(cid:68)(cid:79)(cid:88)(cid:68)(cid:87)(cid:72)(cid:3) (cid:68)(cid:3) (cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3) (cid:82)(cid:73)(cid:3) (cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:3) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:29)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:83)(cid:85)(cid:82)(cid:70)(cid:72)(cid:71)(cid:88)(cid:85)(cid:68)(cid:79)(cid:3) (cid:86)(cid:87)(cid:68)(cid:87)(cid:88)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:72)(cid:68)(cid:70)(cid:75)(cid:3) (cid:79)(cid:68)(cid:90)(cid:86)(cid:88)(cid:76)(cid:87)(cid:30)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:71)(cid:76)(cid:86)(cid:80)issal of the lawsuit
(cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:3) (cid:87)(cid:85)(cid:76)(cid:68)(cid:79)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:76)(cid:80)(cid:72)(cid:3) (cid:85)(cid:72)(cid:80)(cid:68)(cid:76)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3) (cid:69)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:3) (cid:87)(cid:85)(cid:76)(cid:68)(cid:79)(cid:3) (cid:71)(cid:68)(cid:87)(cid:72)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:86)(cid:87)(cid:68)(cid:87)(cid:88)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:71)(cid:76)(cid:86)(cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:92)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:86)(cid:87)(cid:68)(cid:87)(cid:88)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:86)(cid:72)(cid:87)(cid:87)(cid:79)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:30)(cid:3) (cid:68)(cid:85)(cid:69)(cid:76)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) or
(cid:80)(cid:72)(cid:71)(cid:76)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:83)(cid:85)(cid:82)(cid:70)(cid:72)(cid:72)(cid:71)(cid:76)(cid:81)(cid:74)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:80)(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)’s estimate of the likelihood of success prior to or at trial. The estimates used to
establish a range of loss and the amounts to accrue are based on previous settlement experience, consultation with legal counsel,
and management’s settlement strategies. If the estimate of a probable loss is in a range and no amount within the range is more
likely, we accrue the minimum amount of the range. We recognize legal fees as an expense in the period incurred. These
expenses are reflected in either continuing or discontinued operations depending on the product associated with the claim.
99
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
We record insurance recoveries from product liability insurance that is in force when they are realized or realizable, normally
when we believe it is probable that the insurance carrier will settle the claim.
Property, plant and equipment. Our property, plant and equipment is stated at cost. Depreciation, which includes amortization
of assets under capital lease, is generally provided on a straight-line basis over the estimated useful lives generally based on the
following categories:
Land improvements
Buildings and building improvements
Machinery and equipment
Furniture, fixtures and office equipment
Surgical instruments
15 to 25 years
10 to 40 years
3 to 14 years
4 to 14 years
6 years
Expenditures for major renewals and betterments, including leasehold improvements, that extend the useful life of the assets are
capitalized and depreciated over the remaining life of the asset or lease term, if shorter. Maintenance and repair costs are
charged to expense as incurred. Upon sale or retirement, the asset cost and related accumulated depreciation are eliminated
from the respective accounts and any resulting gain or loss is included in income.
Valuation of long-lived assets. Management periodically evaluates carrying values of long-lived assets, including property,
plant and equipment and finite-lived intangible assets, when events and circumstances indicate that these assets may have been
impaired. We account for the impairment of long-lived assets in accordance with FASB ASC 360. Accordingly, we evaluate
impairment of our long-lived assets based upon an analysis of estimated undiscounted future cash flows. If it is determined that
a change is required in the useful life of an asset, future depreciation and amortization is adjusted accordingly. Alternatively,
should we determine that an asset is impaired, an adjustment would be charged to income based on the difference between the
asset’s fair market value and the asset’s carrying value.
Intangible assets and goodwill. Goodwill is recognized for the excess of the purchase price over the fair value of net assets of
businesses acquired. Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 350-30-35-18
requires companies to evaluate for impairment intangible assets not subject to amortization, such as our in-process research and
development (IPRD) assets, if events or changes in circumstances indicate than an asset might be impaired. Further, FASB
ASC 350-20-35-30 requires companies to evaluate goodwill and intangibles not subject to amortization for impairment between
annual impairment tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a
reporting unit below its carrying amount. Unless circumstances otherwise dictate, the annual impairment test is performed on
October 1 each year. See Note 8 for discussion of our 2016 goodwill impairment analysis.
Our intangible assets with estimable useful lives are amortized on a straight-line basis over their respective estimated useful
lives to their estimated residual values. This method of amortization approximates the expected future cash flow generated
from their use. Finite-lived intangibles are reviewed for impairment in accordance with FASB ASC Section 360, Property,
Plant and Equipment (FASB ASC 360). The weighted average amortization periods for completed technology, distribution
channels, trademarks, licenses, customer relationships, non-compete agreements, and other intangible assets are 10 years,
5 years, 5 years, 12 years, 18 years, 3 years and 3 years, respectively. The weighted average amortization period of our
intangible assets on a combined basis is 13 years.
Allowances for doubtful accounts. (cid:58)(cid:72)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:85)(cid:76)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3) (cid:70)(cid:85)(cid:72)(cid:71)(cid:76)(cid:87)(cid:3) (cid:79)(cid:82)(cid:86)(cid:86)(cid:72)(cid:86)(cid:3) (cid:82)(cid:81)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:3) (cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:68)(cid:69)(cid:79)(cid:72)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:68)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:79)(cid:92)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3) (cid:80)(cid:88)(cid:86)(cid:87)(cid:3) (cid:80)(cid:68)(cid:78)(cid:72)(cid:3)
estimates related to the ultimate collection of our accounts receivable. Specifically, we analyze our accounts receivable,
historical bad debt experience, customer concentrations, customer creditworthiness, and current economic trends when
evaluating the adequacy of our allowance for doubtful accounts.
The majority of our accounts receivable are from hospitals and surgery centers. Our collection history has been favorable with
minimal bad debts from these customers. We write off accounts receivable when we determine that the accounts receivable are
uncollectible, typically upon customer bankruptcy or the customer’s non-response to repeated collection efforts. Our allowance
for doubtful accounts totaled $4.5 million and $1.2 million at December 25, 2016 and December 27, 2015, respectively.
Concentration of credit risk. Financial instruments that potentially subject us to concentrations of credit risk consist principally
of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit history before extending
credit and by monitoring credit exposure on a regular basis. Collateral or other security is generally not required for accounts
receivable.
100
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Concentrations of supply of raw material. We rely on a limited number of suppliers for the components used in our products.
For certain human biologic products, such as AllomatrixTM, we depend on one supplier of demineralized bone matrix and
cancellous bone matrix. We rely on one supplier for our GRAFTJACKET® family of soft tissue repair and graft containment
products. We maintain adequate stock from these suppliers in order to meet market demand. Additionally, we have other soft
tissue repair products which include our CONEXA™ Reconstructive Tissue Matrix, ACTISHIELD™ and ACTISHIELD™ CF
Amniotic Barrier Membranes, VIAFLOW™ and VIAFLOW™ C Flowable Placental Tissue Matrices, BIOFIBER® biologic
absorbable scaffold products, and PHANTOM FIBER™ high strength, resorbable suture products.
We rely on one supplier for a key component of our AUGMENT® Bone Graft. In December 2013, our supplier notified us of its
intent to terminate the supply agreement in December 2015. This supplier was contractually required to meet our supply
requirements until the termination date, and to use commercially reasonable efforts to assist us in identifying a new supplier and
support the transfer of technology and supporting documentation to produce this component. In April 2016, we entered into a
commercial supply agreement with FUJIFILM Diosynth Biotechnologies U.S.A., Inc. pursuant to which Fujifilm agreed to
manufacture and sell to us and we agreed to purchase the key component of our AUGMENT® Bone Graft. Pursuant to our
supply agreement with Fujifilm, commercial production of the key component is expected to begin in 2019. Although we
believe that our current supply of the key component from our former supplier should be sufficient to last until after the
component becomes available under the new agreement, no assurance can be provided that it will be sufficient.
Income taxes. Income taxes are accounted for pursuant to the provisions of FASB ASC Section 740, Income Taxes (FASB ASC
740). Our effective tax rate is based on income by tax jurisdiction, statutory rates, and tax saving initiatives available to us in
the various jurisdictions in which we operate. Significant judgment is required in determining our effective tax rate and
evaluating our tax positions. This process includes assessing temporary differences resulting from differing recognition of
items for income tax and financial accounting purposes. These differences result in deferred tax assets and liabilities, which are
included within our consolidated balance sheet. The measurement of deferred tax assets is reduced by a valuation allowance if,
based upon available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. See
Note 11 for further discussion of our consolidated deferred tax assets and liabilities, and the associated valuation allowance.
We provide for unrecognized tax benefits based upon our assessment of whether a tax position is “more-likely-than-not” to be
sustained upon examination by the tax authorities. If a tax position meets the more-likely-than-not standard, then the related tax
benefit is measured based on a cumulative probability analysis of the amount that is more-likely-than-not to be realized upon
ultimate settlement or disposition of the underlying tax position.
Other taxes. Taxes assessed by a governmental authority that are imposed concurrent with our revenue transactions with
customers are presented on a net basis in our consolidated statements of operations.
Revenue recognition. Our revenues are primarily generated through two types of customers, hospitals and surgery centers, and
stocking distributors, with the majority of our revenue derived from sales to hospitals. Our products are primarily sold through
a network of employee sales representatives and independent sales representatives in the United States and by a combination of
employee sales representatives, independent sales representatives, and stocking distributors outside the United States.
Revenues from sales to hospitals are recorded when the hospital takes title to the product, which is generally when the product
is surgically implanted in a patient.
During the quarter ended December 27, 2015, following the Wright/Tornier merger, we changed our estimate of uninvoiced
revenue. While we have generally recognized revenue at the time that the product was surgically implanted, from a timing
perspective, we now recognize revenue at the time the surgery and associated products used are reported, as opposed to
previously when we received clerical documentation from the hospital. We have accounted for this as a change in estimate and
recorded additional revenue of approximately $3 million in the quarter ended December 27, 2015.
We record revenues from sales to our stocking distributors outside the United States at the time the product is shipped to the
distributor. Stocking distributors, who sell the products to their customers, take title to the products and assume all risks of
ownership. Our distributors are obligated to pay within specified terms regardless of when, if ever, they sell the products. In
(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:15)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:71)(cid:76)(cid:86)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:82)(cid:85)(cid:86)(cid:3) (cid:71)(cid:82)(cid:3) (cid:81)(cid:82)(cid:87)(cid:3) (cid:75)(cid:68)(cid:89)(cid:72)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:85)(cid:72)(cid:87)(cid:88)(cid:85)(cid:81)(cid:3) (cid:82)(cid:85)(cid:3) (cid:72)(cid:91)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:30)(cid:3) (cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3) (cid:76)(cid:81)(cid:3) (cid:79)(cid:76)(cid:80)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3) (cid:86)(cid:76)(cid:87)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)s, we have repurchase
agreements with certain stocking distributors. These repurchase agreements require us to repurchase a specified percentage of
the inventory purchased by the distributor within a specified period of time prior to the expiration of the contract. During those
specified periods, we defer the applicable percentage of the sales. An insignificant amount of deferred revenue related to these
types of agreements was recorded at December 25, 2016 and December 27, 2015.
101
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
We must make estimates of potential future product returns related to current period product revenue. We develop these
estimates by analyzing historical experience related to product returns. Judgment must be used and estimates made in
connection with establishing the allowance for sales returns in any accounting period. Our reserve for sales returns has
historically been immaterial.
Shipping and handling costs. We incur shipping and handling costs associated with the shipment of goods to customers,
independent distributors, and our subsidiaries. Amounts billed to customers for shipping and handling of products are included
in net sales. Costs incurred related to shipping and handling of products to customers are included in selling, general and
administrative expenses. All other shipping and handling costs are included in cost of sales. These amounts totaled $17.9
million, $9.8 million, and $7.6 million for the years ended December 25, 2016, December 27, 2015, and December 31, 2014,
respectively.
Research and development costs. Research and development costs are charged to expense as incurred.
Foreign currency translation. The financial statements of our subsidiaries whose functional currency is the local currency are
translated into U.S. dollars using the exchange rate at the balance sheet date for assets and liabilities and the weighted average
exchange rate for the applicable period for revenues, expenses, gains, and losses. Translation adjustments are recorded as a
separate component of comprehensive income in shareholders’ equity. Gains and losses resulting from transactions
denominated in a currency other than the local functional currency are included in “Other (income) expense, net” in our
consolidated statements of operations.
Comprehensive income. Comprehensive income is defined as the change in equity during a period related to transactions and
other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting
from investments by owners and distributions to owners. The difference between our net loss and our comprehensive loss is
attributable to foreign currency translation.
Share-based compensation. We account for share-based compensation in accordance with FASB ASC Section 718,
Compensation — Stock Compensation (FASB ASC 718). Under the fair value recognition provisions of FASB ASC 718, share-
based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense on a
straight-line basis over the requisite service period, which is the vesting period. The determination of the fair value of share-
based payment awards, such as options, on the date of grant using an option-pricing model is affected by our stock price, as
well as assumptions regarding a number of complex and subjective variables, which include the expected life of the award, the
expected stock price volatility over the expected life of the awards, expected dividend yield, and risk-free interest rate.
We recorded share-based compensation expense of $14.4 million, $25.0 million, and $11.5 million during the years ended
December 25, 2016, December 27, 2015, and December 31, 2014, respectively, within our results of continuing operations.
The increase in expense in 2015 related to accelerated vesting of all unvested awards upon the closing of the Wright/Tornier
merger. See Note 14 for further information regarding our share-based compensation assumptions and expenses.
Derivative instruments. We account for derivative instruments and hedging activities under FASB ASC Section 815,
Derivatives and Hedging (FASB ASC 815). Accordingly, all of our derivative instruments are recorded in the accompanying
consolidated balance sheets as either an asset or liability and measured at fair value. The changes in the derivative’s fair value
are recognized currently in earnings unless specific hedge accounting criteria are met.
We employ a derivative program using foreign currency forward contracts to mitigate the risk of currency fluctuations on our
intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts are
expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts are not
designated as hedging instruments under FASB ASC 815. Accordingly, the changes in the fair value and the settlement of the
contracts are recognized in the period incurred in the accompanying consolidated statements of operations.
We recorded a net loss of approximately $0.8 million and $0.3 million on our foreign currency contracts for the years ended
December 25, 2016 and December 27, 2015, and a net gain of approximately $0.4 million for the year ended December 31,
2014. These gains and losses substantially offset translation losses and gains recorded on our intercompany receivable and
payable balances, and are also included in “Other (income) expense, net.” At December 25, 2016 and December 27, 2015, we
had $0.4 million and $3.6 million in foreign currency contracts outstanding, respectively.
102
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
On August 31, 2012, February 13, 2015, and May 20, 2016, we issued the 2017 Notes, 2020 Notes, and 2021 Notes,
respectively, as defined and described in Note 9. The 2017 Notes Conversion Derivatives, 2020 Notes Conversion Derivatives,
and 2021 Notes Conversion Derivatives, each as defined and described in Note 6, requires bifurcation from the 2017 Notes,
2020 Notes, and 2021 Notes in accordance with ASC Topic 815, and are accounted for as derivative liabilities. We also entered
into 2017, 2020, and 2021 Notes Hedges, as defined and described in Note 6, in connection with the issuance of the 2017, 2020,
and 2021 Notes. As of December 25, 2016, the 2020 and 2021 Notes Hedges were outstanding. The 2020 and 2021 Notes
Hedges, which are cash-settled, are intended to reduce our exposure to potential cash payments that we are required to make
upon conversion of the 2020 and 2021 Notes in excess of the principal amount of converted notes if our ordinary share price
exceeds the conversion price. The 2020 and 2021 Notes Hedges are accounted for as derivative assets in accordance with ASC
Topic 815. The 2017 Notes Hedges, as defined and described in Note 6, were fully settled in February 2015 when the 2020
Notes were issued.
Reclassifications. Certain prior period amounts in our consolidated financial statements have been reclassified to account for
adoption of recent accounting guidance or to conform to the current period presentation.
Supplemental cash flow information. Cash paid for interest and income taxes was as follows (in thousands):
Interest
Income taxes
December 25,
2016
18,678 $
4,334 $
$
$
Fiscal year ended
December 27,
2015
11,198 $
1,051 $
December 31,
2014
6,518
1,525
Recent Accounting Pronouncements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers,
and has subsequently issued several supplemental and/or clarifying ASUs (collectively “ASC 606”). ASC 606 prescribes a
single common revenue standard that replaces most existing U.S. GAAP revenue recognition guidance. ASC 606 outlines a
five-step model, under which we will recognize revenue as performance obligations within a customer contract are satisfied.
ASC 606 is intended to provide more consistent interpretation and application of the principles outlined in the standard across
filers in multiple industries and within the same industries compared to current practices, which should improve comparability.
Adoption of ASC 606 is required for annual reporting periods beginning after December 15, 2017 (fiscal year 2018 for Wright),
including interim periods within the reporting period. Upon adoption, we must elect to adopt either retrospectively to each
prior reporting period presented or using the cumulative effect transition method with the cumulative effect of initial adoption
recognized at the date of initial application. We have not determined what transition method we will use. We are currently
assessing the impact that the future adoption of ASC 606 may have on our consolidated financial statements by analyzing our
current portfolio of customer contracts, including a review of historical accounting policies and practices to identify potential
differences in applying the guidance of ASC 606. Based on our preliminary review of our customer contracts, we expect that
revenue on the majority of our customer contracts will continue to be recognized at a point in time, generally upon surgical
implantation or shipment of products to distributors, consistent with our current revenue recognition model.
On April 7, 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs, as part of its
simplification initiative. The ASU changes the presentation of debt issuance costs in financial statements to present such costs
in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is
reported as interest expense. Further, on August 16, 2015, the FASB issued ASU 2015-15 Presentation and Subsequent
Measurement of Debt Issuance Costs Associated With Line-of-Credit Arrangements to clarify the Securities and Exchange
Commission (SEC) staff’s position on presenting and measuring debt issuance costs incurred in connection with line-of-credit
arrangements given the lack of guidance on this topic in ASU 2015-03. The SEC staff has announced that it would not object to
an entity deferring and presenting debt issuance costs as an asset and subsequently amortizing the deferred debt issuance costs
ratably over the term of the line-of-credit arrangement. We adopted this guidance during the first quarter of 2016 on a
retrospective basis. Accordingly, we reclassified debt issuance costs on our December 27, 2015 consolidated balance sheet,
which decreased other assets and long-term debt by $16.2 million.
FASB ASU 2015-11 Simplifying the Measurement of Inventory was issued in July 2015. This requires entities to measure most
inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must
measure inventory at the lower of cost or market. The ASU will not apply to inventories that are measured by using either the
last-in, first-out method or the retail inventory method. The ASU will be effective for us fiscal year 2017. The adoption of this
ASU is not expected to have a material impact on our consolidated financial statements.
103
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
On September 25, 2015, the FASB issued ASU 2015-16, Simplifying the Accounting for Measurement-Period Adjustments to
simplify the accounting for measurement-period adjustments. The ASU, which is part of the FASB’s simplification initiative,
was issued in response to stakeholder feedback that restatements of prior periods to reflect adjustments made to provisional
amounts recognized in a business combination increase the cost and complexity of financial reporting but do not significantly
improve the usefulness of the information. We adopted this ASU during fiscal year 2016. As detailed in Note 3, purchase price
allocations for the Wright/Tornier merger are subject to adjustment during the measurement period. Under this ASU, an
acquirer must recognize adjustments to provisional amounts that are identified during the measurement period in the reporting
period in which the adjustment amounts are determined and must present these amounts separately on the face of the income
statement or disclose in the notes, the portion of the amount recorded in current-period earnings by line item that would have
been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the
acquisition date.
On November 20, 2015, the FASB issued ASU 2015-17, Balance Sheet Classification of Deferred Taxes, as part of its
simplification initiative (i.e., the FASB’s effort to reduce the cost and complexity of certain aspects of US GAAP). The ASU
requires entities to present deferred tax assets and deferred tax liabilities as noncurrent in a classified balance sheet. It thus
simplifies the prior guidance, which required entities to separately present deferred tax assets and deferred tax liabilities as
current or noncurrent in a classified balance sheet. We elected to early adopt this guidance for the year ended December 27,
2015 and retrospectively applied this guidance to the 2014 tax balances. We noted that this change did not significantly impact
our consolidated financial statements.
On February 25, 2016, the FASB issued ASU 2016-02, Leases, which introduces a lessee model that brings most leases on the
balance sheet. The new standard also aligns many of the underlying principles of the new lessor model with those in FASB
ASC 606, the FASB’s new revenue recognition standard (e.g., those related to evaluating when profit can be recognized).
Furthermore, the ASU addresses other concerns related to the current leases model. The ASU will be effective for us beginning
(cid:76)(cid:81)(cid:3)(cid:73)(cid:76)(cid:86)(cid:70)(cid:68)(cid:79)(cid:3)(cid:92)(cid:72)(cid:68)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:28)(cid:17)(cid:3)(cid:3)(cid:58)(cid:72)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:76)(cid:87)(cid:76)(cid:68)(cid:79)(cid:3)(cid:83)(cid:75)(cid:68)(cid:86)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:68)(cid:71)(cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:30)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:79)(cid:92)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:88)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:72)(cid:86)(cid:87)(cid:76)(cid:80)(cid:68)(cid:87)(cid:72)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)ct this
may have on our consolidated financial statements.
On March 30, 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (Topic 718): Improvements to
Employee Share-Based Payment Accounting, which is to simplify accounting for income taxes, forfeitures, and withholding
taxes, and reduce ambiguity in cash flow reporting. The ASU will be effective for us fiscal year 2017. We do not expect this
change to significantly impact our consolidated financial statements.
On August 26, 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments, which
amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. The
primary purpose of the ASU is to reduce the diversity in practice that has resulted from the lack of consistent principles on this
topic. The ASU’s amendments add or clarify guidance on eight cash flow issues, including contingent consideration payments
made after a business combination, and proceeds from the settlement of insurance claims. The guidance in the ASU is effective
for us beginning in 2018 with early adoption permitted. We have elected to early adopt this guidance for the year ended
December 25, 2016 and retrospectively applied this guidance to all periods presented. We noted that the application of this
guidance did not impact the historical presentation of our statement of cash flows.
In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows: Restricted Cash, which amends ASC 230 to add
or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows. The amendments
require that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts
generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash
and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and
end-of-period total amounts shown on the statement of cash flows. ASU 2016-18 is effective for public business entities for
fiscal years beginning after December 15, 2017. However, early adoption is permitted. We have elected to early adopt the
methodology for presenting restricted cash resulting from the Escrow Agreement described in Note 17 for the year ended
December 25, 2016.
104
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
3.
Acquisitions and Disposition
Wright/Tornier Merger
On October 1, 2015, we completed the Wright/Tornier merger. Immediately upon completion of the merger, legacy Wright
shareholders owned approximately 52% of the combined company and legacy Tornier shareholders owned approximately 48%
of the combined company. Effective upon completion of the merger, we have operated under the leadership of the legacy
Wright management team and our board of directors was comprised of five representatives from legacy Wright’s board of
directors and five representatives from legacy Tornier’s board of directors. Because of these and other facts and circumstances,
the merger was accounted for as a “reverse acquisition” under US GAAP. As such, legacy Wright was considered the acquiring
(cid:72)(cid:81)(cid:87)(cid:76)(cid:87)(cid:92)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3) (cid:83)(cid:88)(cid:85)(cid:83)(cid:82)(cid:86)(cid:72)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)fore, legacy Wright’s historical results of operations replaced legacy Tornier’s
historical results of operations for all periods prior to the merger. As part of the merger, each legacy Wright share was
converted into the right to receive 1.0309 ordinary shares of the combined company. The Wright/Tornier merger added legacy
Tornier’s complementary extremities product portfolio to further accelerate growth opportunities in our global extremities
business. The results of operations of both companies are included in our consolidated financial statements for all periods after
completion of the merger.
The acquired business contributed net sales of $307.4 million and operating loss of $23.9 million to our consolidated results of
operations for the fiscal year ended December 25, 2016, which includes $37.7 million of inventory step-up amortization and
$16.8 million of intangible asset amortization. Additionally, the acquired business contributed net sales of $73.3 million and
operating loss of $13.4 million to our consolidated results of operations from the date of acquisition through December 27,
2015, which includes $10.3 million of inventory step-up amortization and $4.0 million of intangible asset amortization. This
operating loss does not include the merger-related transaction costs discussed below.
Merger-Related Transaction Costs
In conjunction with the merger, we incurred approximately $20.1 million and $8.7 million of merger-related transaction costs in
the years ended December 27, 2015 and December 31, 2014, respectively, all of which were recognized as selling, general and
administrative expense in our consolidated statements of operations. These expenses primarily related to advisory fees, legal
fees, and accounting and tax professional fees.
Purchase Consideration and Net Assets Acquired
The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting
acquirer, legacy Wright, would have had to issue to the owners of the accounting acquiree, legacy Tornier, to give them the
same percentage interest in the combined entity. The fair value of WMG common stock used in determining the purchase price
was $21.02 per share, the closing price on September 30, 2015, which resulted in a total purchase consideration of $1.034
billion.
The calculation of the purchase consideration is as follows (in thousands):
Fair value of ordinary shares effectively transferred to Tornier shareholders
Fair value of ordinary shares effectively transferred to Tornier share award holders
Fair value of ordinary shares effectively issued to Tornier stock option holders
Fair value of total consideration
$
$
1,005,468
8,091
20,676
1,034,235
The acquisition was recorded by allocating the costs of the assets acquired based on their estimated fair values at the acquisition
date. The excess of the cost of the acquisition over the fair value of the assets acquired is recorded as goodwill. The fair values
were based on management’s analysis, including work performed by third-party valuation specialists.
105
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following presents the allocation of the purchase consideration to the assets acquired and liabilities assumed on October 1,
2015 (in thousands):
Cash and cash equivalents
Accounts receivable
Inventories
Other current assets
Property, plant and equipment, net
Intangible assets, net
Deferred income taxes
Other assets
Total assets acquired
Current liabilities
Long-term debt
Deferred income taxes
Other non-current liabilities
Total liabilities assumed
Net assets acquired
Goodwill
Total preliminary purchase consideration
$
$
$
30,117
63,797
138,659
9,256
122,927
213,600
1,399
8,658
588,413
(101,623)
(79,554)
(31,878)
(8,434)
(221,489)
366,924
667,311
1,034,235
We made various changes to the purchase allocation during the measurement period. These changes were recorded in the
reporting period in which the adjustment amounts were determined in accordance with ASU 2015-16.
During the three months ended March 27, 2016, we revised the opening balances of current liabilities and goodwill acquired as
part of the Wright/Tornier merger by $0.6 million.
During the three months ended June 26, 2016, we revised the opening balances of intangible assets, accounts receivable,
inventories, current liabilities, and goodwill acquired as part of the Wright/Tornier merger based on new information that
existed as of the acquisition date. As a result of the completion of the valuation of acquired intangible assets by our third-party
valuation firm, we increased the opening balance of acquired intangible assets by $9.4 million, with a corresponding decrease to
goodwill. This allocation adjustment resulted in an increase to amortization expense of $0.3 million for the six months ended
June 26, 2016, of which $0.1 million related to each of the previous two quarters. We also revised the opening balance of
acquired working capital accounts by a net decrease of $0.5 million, with a corresponding increase to goodwill.
During the three months ended September 25, 2016, as a result of the finalization of the valuation of acquired intangible assets
by tax jurisdiction, we reduced the opening balance of deferred income taxes by $4.7 million, with a corresponding decrease to
goodwill. This allocation adjustment resulted in a $0.4 million decrease to our income tax benefit for the nine months ended
September 25, 2016. We revised the opening balance of property, plant, and equipment by $0.2 million with a corresponding
increase to goodwill. The decrease in property, plant, and equipment resulted in an immaterial impact to depreciation expense.
We also revised the opening balance of acquired working capital accounts by a net increase of $2.1 million, with a
corresponding decrease to goodwill, primarily due to the completion of our assessment on inventory and current liabilities. The
purchase price allocation is now considered final.
The acquisition was recorded by allocating the costs of the net assets acquired based on their estimated fair values at the
acquisition date. Trade receivables and payables, as well as certain other current and non-current assets and liabilities, were
valued at the existing carrying values as they represented the fair value of those items at the acquisition date, based on
management’s judgments and estimates. Trade receivables included gross contractual amounts of $73.9 million and our best
estimate of $10.1 million which represents contractual cash flows not expected to be collected at the acquisition date.
Inventory was recorded at estimated selling price less costs of disposal and a reasonable selling profit. The resulting inventory
step-up adjustment is being recognized in cost of sales as the related inventory is sold. The fair value of property, plant and
equipment utilized a combination of the cost and market approaches, depending on the characteristics of the asset classification.
106
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
In determining the fair value of intangibles, we used an income method which is based on forecasts of the expected future cash
flows attributable to the respective assets. Significant estimates and assumptions inherent in the valuations reflect a
consideration of other marketplace participants and include the amount and timing of future cash flows (including expected
growth rates and profitability), the underlying product or technology life cycles, the economic barriers to entry, and the discount
rate applied to the cash flows.
Of the $213.6 million of acquired intangible assets, $99.9 million was assigned to customer relationships (20 year life), $89.5
million was assigned to developed technology (10 year life), $15.9 million was assigned to in-process research and
development, and $8.3 million was assigned to trade names (2.6 year life).
The excess of the cost of the acquisition over the fair value of the net assets acquired is recorded as goodwill. The goodwill is
primarily attributable to strategic opportunities that arose from the acquisition of Tornier. The goodwill is not expected to be
deductible for tax purposes.
The assets acquired in connection with the acquisition of Tornier and included in the above allocation of the purchase
consideration include, among other assets, assets associated with legacy Tornier’s Large Joints business. As described in more
detail in Note 4, on October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France SAS and certain
other entities related to us and Corin entered into a business sale agreement and simultaneously completed and closed the sale
of our Large Joints business. Pursuant to the terms of the agreement, we sold substantially all of our assets related to our Large
Joints business to Corin for approximately €29.7 million in cash, less approximately €10.7 million for net working capital
adjustments.
Pro Forma Combined Financial Information (Unaudited)
The following unaudited pro forma combined financial information (in thousands) summarizes the results of operations for the
periods indicated as if the Wright/Tornier merger had been completed as of January 1, 2014.
Net sales
Net loss from continuing operations
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
Fiscal year ended
December 27, 2015 1 December 31, 2014
574,076
$
(329,961)
$
615,490 $
(293,055) $
The pro forma net loss for the year ended December 27, 2015 includes the following non-recurring items: $32.1 million of
merger-related transaction expenses, $30.1 million of non-cash share-based compensation charges, and $5.5 million of
contractual change-in-control severance charges. The pro forma net loss for the year ended December 31, 2014 includes
$12.4 million of non-recurring merger-related transaction expenses.
Pro forma information reflects adjustments that are expected to have a continuing impact on our results of operations and are
directly attributable to the merger. The pro forma results include adjustments to reflect, among other things, the amortization of
the inventory step-up, the incremental intangible asset amortization to be incurred based on the fair values of each identifiable
intangible asset, and to eliminate interest expense related to legacy Tornier’s former bank term debt and line of credit, which
were repaid upon completion of the Wright/Tornier merger. The pro forma amounts do not purport to be indicative of the
results that would have actually been obtained if the merger had occurred as of January 1, 2014 or that may be obtained in the
future, and do not reflect future synergies, integration costs, or other such costs or savings.
Divestiture of Certain Legacy Tornier Ankle Replacement and Toe Assets
On October 1, 2015, simultaneous with the completion of the Wright/Tornier merger, we completed the divestiture of the U.S.
rights to legacy Tornier’s SALTO TALARIS® and SALTO TALARIS® XT™ line of ankle replacement products and line of
silastic toe replacement products, among other assets, for cash. We retained the right to sell these products outside the United
States for up to 20 years unless the purchaser exercises an option to purchase the ex-United States rights to the products. The
completion of the asset divestiture was subject to and contingent upon the completion of the Wright/Tornier merger and we
believe was necessary in order to obtain U.S. Federal Trade Commission approval of the Wright/Tornier merger. As these
assets were not part of Wright/Tornier merger, they were not part of the purchase allocation. Additionally, the pro forma results
exclude the divested operations as if the divestiture were to have occurred on January 1, 2014.
107
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Solana Surgical, LLC
On January 30, 2014, we acquired 100% of the outstanding equity of Solana Surgical, LLC (Solana), a privately held Memphis,
Tennessee orthopaedic company, for approximately $48.0 million in cash and $41.4 million of WMG common stock. The
transaction added Solana’s complementary extremity product portfolio to further accelerate growth opportunities in our global
extremities business. The operating results from this acquisition are included in our consolidated financial statements from the
acquisition date.
The acquisition was recorded by allocating the costs of the assets acquired based on their estimated fair values at the acquisition
date. The excess of the cost of the acquisition over the fair value of the assets acquired was recorded as goodwill. The
following is a summary of the estimated fair values of the assets acquired (in thousands):
Cash and cash equivalents
Accounts receivable
Inventories
Other current assets
Property, plant and equipment, net
Intangible assets, net
Accounts payable and accrued liabilities
Total net assets acquired
Goodwill
Total purchase consideration
$
$
$
416
2,366
2,244
372
360
21,584
(2,196)
25,146
64,326
89,472
The purchase price allocation was adjusted in the quarter ended June 30, 2014 for the finalization of the valuation of the
acquired intangible assets. Intangible assets decreased $0.5 million during the quarter ended June 30, 2014. During the quarter
ended September 30, 2014 the purchase price allocation was adjusted to record certain tax-related liabilities existing at the date
of acquisition. Accrued liabilities increased $0.2 million during the quarter ended September 30, 2014. The purchase price
allocation is now considered final.
The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of Solana. The goodwill is
deductible for tax purposes.
Of the $21.6 million of acquired intangible assets, $11.7 million was assigned to purchased technology (10 year life),
$9.3 million was assigned to customer relationships (12 year life), and $0.6 million was assigned to trademarks (2 year life).
The acquired business contributed revenues of $14.3 million and operating income of $1.3 million, which excludes transaction
and transition costs, to our consolidated results from the date of acquisition through December 31, 2014. Our consolidated
results include $7.2 million of transaction and transition expenses recognized in the year ended December 31, 2014.
OrthoPro, L.L.C.
On February 5, 2014, we acquired 100% of the outstanding equity of OrthoPro L.L.C., a privately held Salt Lake City, Utah
orthopaedic company, for approximately $32.5 million in cash at closing, subject to a working capital adjustment, plus
contingent consideration to be paid upon the achievement of certain revenue milestones in 2014 and 2015 (estimated fair value
of contingent consideration is $0 as of December 31, 2014 and December 27, 2015). The transaction added OrthoPro’s
complementary extremity product portfolio to further accelerate growth opportunities in our global extremities business. The
operating results from this acquisition are included in our consolidated financial statements from the acquisition date.
During the quarter ended June 30, 2014, we finalized the calculation of the acquisition date fair value of contingent
consideration, which was reduced by $2.9 million at that time.
108
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The acquisition was recorded by allocating the costs of the assets acquired based on their estimated fair values at the acquisition
date. The excess of the cost of the acquisition over the fair value of the assets acquired was recorded as goodwill. The
following is a summary of the estimated fair values of the assets acquired (in thousands):
Cash and cash equivalents
Accounts receivable
Inventories
Prepaid and other current assets
Property, plant and equipment
Intangible assets
Accounts payable and accrued liabilities
Total net assets acquired
Goodwill
Total purchase consideration
$
$
$
98
1,308
2,156
49
1,801
7,772
(949)
12,235
20,801
33,036
The purchase price allocation was adjusted in the quarter ended June 30, 2014 for the finalization of the valuation of acquired
intangible assets. Intangible assets decreased $1.8 million during the quarter ended June 30, 2014. The purchase price
allocation was adjusted in the quarter ended September 30, 2014 to record certain tax related liabilities that existed at the date
of acquisition. Accrued liabilities increased $0.4 million during the quarter ended September 30, 2014. The purchase price
allocation is now considered final.
The goodwill is primarily attributable to strategic opportunities that arose from the acquisition of OrthoPro. The goodwill is
expected to be deductible for tax purposes.
Of the $7.8 million of acquired intangible assets, $4.2 million was assigned to customer relationships (12 year life),
$3.4 million was assigned to purchased technology (10 year life), and $0.2 million was assigned to trademarks (2 year life).
The acquired business contributed revenues of $8.1 million and operating income of $0.5 million, which excludes transaction
and transition costs, to our consolidated results from the date of acquisition through December 31, 2014. Our consolidated
results include $5.1 million of transaction and transition expenses recognized in the year ended December 31, 2014.
4.
Discontinued Operations
For the years ended December 25, 2016 and December 27, 2015, our loss from discontinued operations, net of tax, totaled
$267.4 million and $61.3 million and was attributable to the divestiture of the Large Joints Business and the OrthoRecon
Business. For the year ended December 31, 2014, our loss from discontinued operations, net of tax, totaled $19.2 million and
was attributable to the OrthoRecon Business. The basic and diluted weighted-average number of ordinary shares outstanding
was 103.0 million, 64.8 million and 51.3 million for 2016, 2015, and 2014, respectively. The basic and diluted net loss from
discontinued operations per share was $2.60, $0.95 and $0.37 for 2016, 2015 and 2014, respectively.
Large Joints Business
On October 21, 2016, pursuant to a binding offer letter dated as of July 8, 2016, Tornier France, Corin, and certain other entities
related to us and Corin entered into a business sale agreement and simultaneously completed and closed the sale of our Large
Joints business. Pursuant to the terms of the agreement, we sold substantially all of the assets related to our Large Joints
business to Corin for approximately €29.7 million in cash, less approximately €10.7 million for net working capital
adjustments. Upon closing, the parties also executed a transitional services agreement and supply agreement, among other
ancillary agreements required to implement the transaction. These agreements are on arm’s length terms and are not expected
to be material to our consolidated financial statements.
All historical operating results for the Large Joints business, including costs associated with corporate employees and
infrastructure transferred as a part of the sale, are reflected within discontinued operations in the consolidated statements of
operations. Further, all assets and associated liabilities transferred to Corin were classified as assets and liabilities held for sale
in our consolidated balance sheet for the year ended December 27, 2015. We recognized an impairment loss on assets held for
sale of $21.3 million, before the effect of income taxes during 2016, based on the difference between the net carrying value of
109
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
the assets and liabilities held for sale and the purchase price, less estimated adjustments and costs to sell. This loss was
recorded within “Net loss from discontinued operations” in our consolidated statements of operations for the year ended
December 25, 2016.
The following table summarizes the results of discontinued operations for the Large Joints business (in thousands, except per
share data):
Net sales
Cost of sales
Selling, general and administrative
Other
Loss from discontinued operations before income taxes
Impairment loss on assets held for sale, before income taxes
Total loss from discontinued operations before income taxes
Benefit for income taxes
Total loss from discontinued operations, net of tax
Net loss from discontinued operations per share-basic and diluted (Note 13) 1
Weighted-average number of ordinary shares outstanding-basic and diluted
(Note 13) 1
___________________________
1
Fiscal year ended
December 25, 2016
December 27, 2015
$
$
$
35,318 $
20,244
18,808
—
(3,734)
21,342
(25,076)
5,615
(19,461) $
(0.19) $
10,135
5,633
5,021
684
(1,203)
—
(1,203)
199
(1,004)
(0.02)
102,968
64,808
The prior period weighted-average shares outstanding and net loss per share amounts were converted to meet post-merger valuations as
described within Note 13.
The following table summarizes the assets and liabilities held for sale (in thousands):
Assets:
Inventories, net
Prepaid expenses
Property, plant and equipment, net
Goodwill
Intangible assets, net
Total assets held for sale
Liabilities:
Other current liabilities
Total liabilities held for sale
December 25, 2016
December 27, 2015
$
$
$
$
— $
—
—
—
—
— $
— $
— $
18,408
79
16,513
9,355
5,815
50,170
2,692
2,692
Cash provided by operating activities and investing activities from the Large Joints business totaled $5.2 million and
$20.7 million for the year ended December 25, 2016, respectively. Cash provided by operating activities from the Large Joints
business totaled $2.9 million for the fiscal year ended December 27, 2015.
110
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
OrthoRecon Business
On January 9, 2014, legacy Wright completed the divestiture and sale of its OrthoRecon business to MicroPort Scientific
Corporation. Pursuant to the terms of the agreement with MicroPort, the purchase price (as defined in the agreement) was
approximately $283 million (including a working capital adjustment), which MicroPort paid in cash. As a result of the
transaction, we recognized approximately $24.3 million as the gain on disposal of the OrthoRecon business, before the effect of
income taxes.
All current and historical operating results for the OrthoRecon business are reflected within discontinued operations in the
consolidated financial statements. The following table summarizes the results of discontinued operations for the OrthoRecon
business (in thousands, except per share data):
Net sales
Selling, general and administrative
Loss from discontinued operations before income taxes
Provision for income taxes
Total loss from discontinued operations, net of tax
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
$
— $
— $
247,978
(247,978)
—
60,341
(60,341)
—
$
(247,978) $
(60,341) $
3,056
16,577
(13,521)
5,666
(19,187)
Net loss from discontinued operations per share-basic and diluted (Note 13) 1 $
(2.41) $
(0.93) $
(0.37)
Weighted-average number of ordinary shares outstanding-basic and diluted
(Note 13) 1
___________________________
1
The prior period weighted-average shares outstanding and net loss per share amounts were converted to meet post-merger valuations as
described within Note 13.
102,968
64,808
51,293
Certain liabilities associated with the OrthoRecon business, including product liability claims associated with hip and knee
products sold by legacy Wright prior to the closing, were not assumed by MicroPort. Charges associated with these product
liability claims, including legal defense, settlements and judgments, income associated with product liability insurance
recoveries, and changes to any contingent liabilities associated with the OrthoRecon business have been reflected within results
of discontinued operations, and we will continue to reflect these within results of discontinued operations in future periods.
During the fiscal year ended December 25, 2016, we recognized a $196.6 million charge, net of insurance proceeds, within
discontinued operations related to the retained metal-on-metal product liability claims associated with the OrthoRecon business
(see Note 16 for additional discussion). We will incur continuing cash outflows associated with legal defense costs and the
ultimate resolution of these contingent liabilities until these liabilities are resolved.
During the fiscal year ended December 27, 2015, we recognized a $25 million charge to write down an insurance receivable
associated with product liability claims. Additionally, during 2015, we increased our estimated product liability by
approximately $4 million for claims that had been incurred in prior periods. We have analyzed the impact of this adjustment
and determined that this out-of-period charge did not have a material impact to the prior period financial statements. See Note
16 for additional information regarding our product liabilities and the associated insurance.
The 2014 effective tax rate within the results of discontinued operations reflects the sale of non-deductible goodwill of
$25.8 million associated with the OrthoRecon business.
Cash provided by operating activities from the OrthoRecon business totaled $16.7 million for the year ended December 25,
2016 primarily due to the receipt of the $60 million insurance settlement, offset by legal defense costs and settlement of product
liabilities. See further discussion in Note 16. Cash used in operating activities from the OrthoRecon business for the year
ended December 27, 2015 was $28 million associated with legal defense costs and settlement of product liabilities, net of
insurance proceeds received. During 2014, cash provided by the OrthoRecon business was approximately $250.5 million
driven by the cash received from the sale of the OrthoRecon business.
111
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
5.
Inventories
Inventories consist of the following (in thousands):
Raw materials
Work-in-process
Finished goods
$
December 25,
2016
15,319 $
22,422
113,108
150,849 $
$
December 27,
2015 1
18,057
27,946
164,698
210,701
___________________________
1
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015.
Finished goods inventories held as of December 27, 2015 include an inventory fair value step-up of $37.7 million which was
fully amortized during 2016.
6.
Fair Value of Financial Instruments and Derivatives
We account for derivatives in accordance with FASB ASC 815, which establishes accounting and reporting standards requiring
that derivative instruments be recorded on the balance sheet as either an asset or liability measured at fair value. Additionally,
changes in the derivatives’ fair value are recognized currently in earnings unless specific hedge accounting criteria are met.
FASB ASC Section 820, Fair Value Measurements and Disclosures requires fair value measurements be classified and
disclosed in one of the following three categories:
Level 1:
Financial instruments with unadjusted, quoted prices listed on active market exchanges.
Level 2:
Level 3:
Financial instruments determined using prices for recently traded financial instruments with similar
underlying terms as well as directly or indirectly observable inputs, such as interest rates and yield
curves that are observable at commonly quoted intervals.
Financial instruments that are not actively traded on a market exchange. This category includes
situations where there is little, if any, market activity for the financial instrument. The prices are
determined using significant unobservable inputs or valuation techniques.
2021 Conversion Derivative and Notes Hedging
On May 20, 2016, we issued $395 million aggregate principal amount of 2.25% cash convertible senior notes due 2021 (the
2021 Notes). See Note 9 of the consolidated financial statements for additional information regarding the 2021 Notes. The
2021 Notes have a conversion derivative feature (2021 Notes Conversion Derivative) that requires bifurcation from the 2021
Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2021 Notes
Conversion Derivative at the time of issuance of the 2021 Notes was $117.2 million.
In connection with the issuance of the 2021 Notes, we entered into hedges (2021 Notes Hedges) with two option counterparties.
The 2021 Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that
we are required to make upon conversion of the 2021 Notes in excess of the principal amount of converted notes if our ordinary
share price exceeds the conversion price. The aggregate cost of the 2021 Notes Hedges was $99.8 million and is accounted for
as a derivative asset in accordance with ASC Topic 815. However, in connection with certain events, these option
counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of
the 2021 Note Hedges.
112
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following table summarizes the fair value and the presentation in the consolidated balance sheet (in thousands) of the 2021
Notes Hedges and 2021 Notes Conversion Derivative:
2021 Notes Hedges
2021 Notes Conversion Derivative
Location on consolidated balance
sheet
Other assets
Other liabilities
December 25,
2016
159,095
161,601
$
$
The 2021 Notes Hedges and the 2021 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These
instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market
data for inputs.
(cid:49)(cid:72)(cid:76)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:38)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:39)(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:81)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:73)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:72)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:87)(cid:75)(cid:88)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)
fair value of the derivatives is recognized immediately in the consolidated statements of operations.
The following table summarizes the net gain on changes in fair value (in thousands) related to the 2021 Notes Hedges and 2021
Notes Conversion Derivative:
2021 Notes Hedges
2021 Notes Conversion Derivative
Net gain on changes in fair value
2020 Conversion Derivative and Notes Hedging
Fiscal year ended
December 25,
2016
$
$
59,278
(44,377 )
14,901
On February 13, 2015, WMG issued $632.5 million aggregate principal amount of 2.00% cash convertible senior notes due
2020 (the 2020 Notes). See Note 9 of the consolidated financial statements for additional information regarding the 2020
Notes. The 2020 Notes have a conversion derivative feature (2020 Notes Conversion Derivative) that requires bifurcation from
the 2020 Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2020
Notes Conversion Derivative at the time of issuance of the 2020 Notes was $149.8 million.
In connection with the issuance of the 2020 Notes, WMG entered into hedges (2020 Notes Hedges) with three option
counterparties. The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG’s exposure to potential
cash payments that WMG is required to make upon conversion of the 2020 Notes in excess of the principal amount of
converted notes if our ordinary share price exceeds the conversion price. The aggregate cost of the 2020 Notes Hedges was
$144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. However, in connection with
certain events, these option counterparties have the discretion to make certain adjustments to the 2020 Note Hedges, which may
reduce the effectiveness of the 2020 Note Hedges.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately
$45 million aggregate principal amount of 2020 Notes (including the 2020 Notes Conversion Derivative) for the 2021 Notes.
For each $1,000 principal amount of 2020 Notes validly submitted for exchange, we delivered $990 principal amount of the
2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the difference
being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2020 Notes and
the rounded amount at an aggregate cost of approximately $44.6 million. We settled the associated portion of the 2020 Notes
Conversion Derivative at a benefit of approximately $0.4 million and satisfied the accrued interest, which was not material.
In addition, during the second quarter of 2016, we settled a portion of the 2020 Notes Hedges (receiving $3.9 million) and
repurchased a portion of the warrants associated with the 2020 Notes (paying $3.3 million), generating net proceeds of
approximately $0.6 million.
113
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following table summarizes the fair value and the presentation in the consolidated balance sheet (in thousands) of the 2020
Notes Hedges and 2020 Notes Conversion Derivative:
2020 Notes Hedges
2020 Notes Conversion Derivative
Location on consolidated
balance sheet
Other assets
Other liabilities
$
$
December 25,
2016
December 27,
2015
77,232 $
77,758 $
127,758
129,107
The 2020 Notes Hedges and the 2020 Notes Conversion Derivative are measured at fair value using Level 3 inputs. These
instruments are not actively traded and are valued using an option pricing model that uses observable and unobservable market
data for inputs.
(cid:49)(cid:72)(cid:76)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:38)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:39)(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:81)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:73)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:72)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:87)(cid:75)(cid:88)(cid:86)(cid:15) any change in the
fair value of the derivatives is recognized immediately in the consolidated statements of operations.
The following table summarizes the net gain on changes in fair value (in thousands) related to the 2020 Notes Hedges and 2020
Notes Conversion Derivative:
2020 Notes Hedges
2020 Notes Conversion Derivative
Net gain on changes in fair value
2017 Conversion Derivative and Notes Hedging
Fiscal year ended
December 25,
2016
(46,634) $
51,799
5,165 $
$
$
December 27,
2015
(17,085)
20,677
3,592
On August 31, 2012, WMG issued $300 million aggregate principal amount of 2.00% cash convertible senior notes due 2017
(the 2017 Notes). See Note 9 of the consolidated financial statements for additional information regarding the 2017 Notes. The
2017 Notes have a conversion derivative feature (2017 Notes Conversion Derivative) that requires bifurcation from the 2017
Notes in accordance with ASC Topic 815, and is accounted for as a derivative liability. The fair value of the 2017 Notes
Conversion Derivative at the time of issuance of the 2017 Notes was $48.1 million.
In connection with the issuance of the 2017 Notes, WMG entered into hedges (2017 Notes Hedges) with three option
counterparties. The aggregate cost of the 2017 Notes Hedges was $56.2 million and was accounted for as a derivative asset in
accordance with ASC Topic 815.
In connection with the issuance of the 2020 Notes, WMG used approximately $292 million of the 2020 Notes’ net proceeds to
repurchase and extinguish approximately $240 million aggregate principal amount of the 2017 Notes, settle the associated
portion of the 2017 Notes Conversion Derivative at a cost of approximately $49 million, and satisfy the accrued interest of
$2.4 million. WMG also settled all of the 2017 Notes Hedges (receiving $70 million) and repurchased all of the warrants
associated with the 2017 Notes (paying $60 million), generating net proceeds of approximately $10 million.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes exchanged approximately
$54.4 million aggregate principal amount of 2017 Notes (including the 2017 Notes Conversion Derivative) for the 2021 Notes.
For each $1,000 principal amount of 2017 Notes validly submitted for exchange, we delivered $1,035.40 principal amount of
the 2021 Notes (subject, in each case, to rounding down to the nearest $1,000 principal amount of the 2021 Notes, the
difference being referred as the rounded amount) to the investor plus an amount of cash equal to the unpaid interest on the 2017
Notes and the rounded amount at a cost of approximately $56.3 million. We settled the associated portion of the 2017 Notes
Conversion Derivative at a cost of approximately $1.9 million and satisfied the accrued interest, which was not material.
In addition, during the second quarter of 2016, we repurchased and extinguished an additional $3.6 million aggregate principal
amount of the 2017 Notes in privately negotiated transactions and settled the associated portion of the 2017 Notes Conversion
Derivative at a cost of approximately $0.1 million, and satisfied the accrued interest, which was not material.
114
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following table summarizes the fair value and the presentation in the consolidated balance sheet (in thousands) of the 2017
Notes Conversion Derivative:
2017 Notes Conversion Derivative
Location on consolidated
balance sheet
Other liabilities
December 25,
2016
December 27,
2015
$
164 $
10,440
The 2017 Notes Conversion Derivative is measured at fair value using Level 3 inputs. This instrument is not actively traded
and is valued using an option pricing model that uses observable and unobservable market data for inputs.
Neither the 2017 Notes Co(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:39)(cid:72)(cid:85)(cid:76)(cid:89)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:81)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:73)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:72)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:87)(cid:75)(cid:88)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)
fair value of the derivatives is recognized immediately in the consolidated statements of operations.
The following table summarizes the net gain on changes in fair value (in thousands) related to the 2017 Notes Hedges and 2017
Notes Conversion Derivative:
2017 Notes Hedges
2017 Notes Conversion Derivative
Net gain on changes in fair value
Fiscal year ended
December 25,
2016
$
$
— $
8,207
8,207 $
December 27,
2015
(10,236)
16,408
6,172
To determine the fair value of the embedded conversion option in the 2017 Notes Conversion Derivative, 2020 Notes
Conversion Derivative, and 2021 Notes Conversion Derivative, a trinomial lattice model was used. A trinomial stock price
lattice model generates three possible outcomes of stock price - one up, one down, and one stable. This lattice generates a
distribution of stock prices at the maturity date and throughout the life of the 2017 Notes, 2020 Notes, and 2021 Notes. Using
this stock price lattice, a convertible note lattice was created where the value of the embedded conversion option was estimated
by comparing the value produced in a convertible note lattice with the option to convert against the value without the ability to
convert. In each case, the convertible note lattice first calculates the possible convertible note values at the maturity date, using
the distribution of stock prices, which equals to the maximum of (x) the remaining bond cash flows and (y) stock price times
the conversion price. The values of the 2017 Notes Conversion Derivative, 2020 Notes Conversion Derivative, and 2021 Notes
Conversion Derivative at the valuation date were estimated using the values at the maturity date and moving back in time on the
lattices (both for the lattice with the conversion option and without the conversion option). Specifically, at each node, if the
2017 Notes, 2020 Notes, or 2021 Notes are eligible for early conversion, the value at this node is the maximum of
(i) converting to stock, which is the stock price times the conversion price, and (ii) holding onto the 2017 Notes, 2020 Notes,
and 2021 Notes, which is the discounted and probability-weighted value from the three possible outcomes at the future nodes
plus any accrued but unpaid coupons that are not considered at the future nodes. If the 2017 Notes, 2020 Notes, or 2021 Notes
are not eligible for early conversion, the value of the conversion option at this node equals to (ii). In the lattice, a credit
adjustment was applied to the discount for each cash flow in the model as the embedded conversion option, as well as the
coupon and notional payments, is settled with cash instead of shares.
To estimate the fair value of the 2020 Notes Hedges and 2021 Notes Hedges, we used the Black-Scholes formula combined
with credit adjustments, as the option counterparties have credit risk and the call options are cash settled. We assumed that the
call options will be exercised at the maturity since our ordinary shares do not pay any dividends and management does not
expect to declare dividends in the near term.
115
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following assumptions were used in the fair market valuations of the 2017 Notes Conversion Derivative, 2020 Notes
Conversion Derivative, 2020 Notes Hedge, 2021 Notes Conversion Derivative, and 2021 Notes Hedge as of December 25,
2016:
Stock Price Volatility 1
Credit Spread for Wright 2
Credit Spread for Deutsche Bank AG 3
Credit Spread for Wells Fargo
Securities, LLC 3
Credit Spread for JPMorgan Chase
Bank 3
2017 Notes
Conversion
Derivative
34.94%
6.00%
N/A
2020 Notes
Conversion
Derivative
34.81%
3.03%
N/A
2020 Notes
Hedge
34.81%
N/A
1.41%
2021 Notes
Conversion
Derivative
36.76%
3.80%
N/A
N/A
N/A
0.30%
N/A
2021 Notes
Hedge
36.76%
N/A
N/A
N/A
0.75%
0.65%
Credit Spread for Bank of America 3
___________________________
1 Volatility selected based on historical and implied volatility of ordinary shares of Wright Medical Group N.V.
N/A
N/A
N/A
N/A
0.44%
N/A
N/A
N/A
2 Credit spread implied from traded price.
3 Credit spread of each bank is estimated using CDS curves. Source: Bloomberg.
The fair value of our notes conversion derivatives is determined using a trinomial lattice model and is classified in Level 3. We
used a stock price volatility, which is one of the most significant assumptions, of 34.94%, 34.81%, and 36.76% in calculating
the fair value of our 2017 Notes Conversion Derivative, 2020 Notes Conversion Derivative, and 2021 Notes Conversion
Derivative, respectively, as of December 25, 2016. The change in the fair value resulting from a change in the stock price
volatility would have a direct impact on net profit, with an increase in volatility resulting in an increase in the net loss and a
decrease in volatility resulting in a decrease in the net loss for the period.
The following table depicts the impact that a 10% change in the stock price volatility would have on the fair value of the 2017
Notes Conversion Derivative, 2020 Notes Conversion Derivative, and 2021 Notes Conversion Derivative (in thousands except
for percentages):
2017 Notes Conversion Derivative
2020 Notes Conversion Derivative
2021 Notes Conversion Derivative
Stock price volatility
34.94%
34.81%
36.76%
$
$
$
Fair value at
December 25, 2016
Fair value with 10%
decrease in stock
price volatility
Fair value with 10%
increase in stock price
volatility
164 $
77,758 $
161,601 $
103 $
45,616 $
129,991 $
226
110,119
192,664
The fair value of our notes hedges is determined using the Black-Scholes formula combined with credit adjustments and is
classified in Level 3. The stock price volatility as of December 25, 2016 was 34.81% and 36.76% for the 2020 Notes Hedges
and 2021 Notes Hedges, respectively. A significant change in the stock price volatility price would result in a significant
change in the fair value. We used a stock price volatility, which is one of the most significant assumptions, of 34.81% and
36.76% in calculating the fair value of the 2020 Notes Hedges and 2021 Notes Hedges, respectively, as of December 25, 2016.
The change in the fair value resulting from a change in the stock price volatility would have a direct impact on net profit, with
an increase in volatility resulting in a decrease in the net loss and a decrease in volatility resulting in an increase in the net loss
for the period. The impact on profit would be offset due to volatility of notes hedges by a similar change in volatility of the
notes conversion derivatives.
The following table depicts the impact that a 10% change in the stock price volatility would have on the fair value of the 2020
Notes Hedges and 2021 Notes Hedges (in thousands except for percentages):
2020 Notes Hedges
2021 Notes Hedges
Stock price volatility
34.81%
36.76%
$
$
Fair value at
December 25, 2016
Fair value with 10%
decrease in stock
price volatility
Fair value with 10%
increase in stock price
volatility
77,232 $
159,095 $
46,017 $
128,733 $
108,566
188,581
116
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Derivatives not Designated as Hedging Instruments
We employ a derivative program using foreign currency forward contracts to mitigate the risk of currency fluctuations on our
intercompany receivable and payable balances that are denominated in foreign currencies. These forward contracts are
expected to offset the transactional gains and losses on the related intercompany balances. These forward contracts are not
designated as hedging instruments under FASB ASC Topic 815. Accordingly, the changes in the fair value and the settlement of
the contracts are recognized in the period incurred in the accompanying consolidated statements of operations. At
December 25, 2016 and December 27, 2015, we had $0.4 million and $3.6 million in foreign currency contracts outstanding,
respectively.
Financial Instruments
As part of our acquisition of WG Healthcare on January 7, 2013, we may be obligated to pay contingent consideration upon the
(cid:68)(cid:70)(cid:75)(cid:76)(cid:72)(cid:89)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3) (cid:85)(cid:72)(cid:89)(cid:72)(cid:81)(cid:88)(cid:72)(cid:3) (cid:80)(cid:76)(cid:79)(cid:72)(cid:86)(cid:87)(cid:82)(cid:81)(cid:72)(cid:86)(cid:30)(cid:3) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3) (cid:90)(cid:72)(cid:3) (cid:75)(cid:68)(cid:89)(cid:72)(cid:3) (cid:85)(cid:72)(cid:70)(cid:82)(cid:85)(cid:71)(cid:72)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:72)(cid:86)(cid:87)(cid:76)(cid:80)(cid:68)(cid:87)ed fair value of future contingent
consideration of approximately $0.4 million and $0.6 million as of December 25, 2016 and December 27, 2015, respectively.
As a result of the acquired sales and distribution business of Surgical Specialties Australia Pty. Ltd in 2015, we recorded
contingent consideration of approximately $1.7 million and $1.5 million as of December 25, 2016 and December 27, 2015,
respectively.
The fair value of the contingent consideration as of December 25, 2016 and December 27, 2015 was determined using a
discounted cash flow model and probability adjusted estimates of the future earnings and is classified in Level 3. The 2016
discount rate is 12% for WG Healthcare and 14% for Surgical Specialties Australia Pty. Ltd. A change in the discount rate
would have limited impact on our profits or the fair value of this contingent consideration. Changes in the fair value of
contingent consideration are recorded in “Other expense (income), net” in our consolidated statements of operations.
On March 1, 2013, as part of our acquisition of BioMimetic Therapeutics, Inc. (BioMimetic), we issued Contingent Value
Rights (CVRs) as part of the merger consideration. Each CVR entitles its holder to receive additional cash payments of up to
$6.50 per share, which are payable upon receipt of FDA approval of AUGMENT® Bone Graft and upon achieving certain
revenue milestones. On September 1, 2015, AUGMENT® Bone Graft received FDA approval and the first of the milestone
payments associated with the CVRs was paid out at $3.50 per share, which totaled $98.1 million. The fair value of the CVRs
outstanding at December 25, 2016 and December 27, 2015 was $37 million and $28 million, respectively, and was determined
using the closing price of the security in the active market (Level 1). For the years ended December 25, 2016 and
December 27, 2015, the change in the value of the CVRs resulted in expense of $8.7 million and income of $7.6 million,
respectively, which was recorded in “Other expense (income), net” in our consolidated statements of operations. If, prior to
March 1, 2019, sales of AUGMENT® Bone Graft reach $40 million over 12 consecutive months, cash payment would be
required at $1.50 per share, or $42 million. Further, if, prior to March 1, 2019, sales of AUGMENT® Bone Graft reach $70
million over 12 consecutive months, an additional cash payment would be required at $1.50 per share, or $42 million.
The carrying value of cash and cash equivalents, accounts receivable, and accounts payable approximates the fair value of these
financial instruments at December 25, 2016 and December 27, 2015 due to their short maturities and variable rates.
117
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The following table summarizes the valuation of our financial instruments (in thousands):
At December 25, 2016
Assets
Cash and cash equivalents
Restricted cash
2020 Notes Hedges
2021 Notes Hedges
Total
Liabilities
2017 Notes Conversion Derivative
2020 Notes Conversion Derivative
2021 Notes Conversion Derivative
Contingent consideration
Contingent consideration (CVRs)
Total
At December 27, 2015
Assets
Cash and cash equivalents
2020 Notes Hedges
Total
Liabilities
2017 Notes Conversion Derivative
2020 Notes Conversion Derivative
Contingent consideration
Contingent consideration (CVRs)
Total
Quoted prices
in active
markets
(Level 1)
Prices with
other
observable
inputs
(Level 2)
Prices with
unobservable
inputs
(Level 3)
Total
262,265 $
150,000
77,232
159,095
648,592 $
262,265 $
150,000
—
—
412,265 $
164 $
77,758
161,601
2,249
36,999
278,771 $
— $
—
—
—
36,999
36,999 $
— $
—
—
—
— $
— $
—
—
—
—
— $
—
—
77,232
159,095
236,327
164
77,758
161,601
2,249
—
241,772
Quoted prices
in active
markets
(Level 1)
Prices with
other
observable
inputs
(Level 2)
Prices with
unobservable
inputs
(Level 3)
Total
139,804 $
127,758
267,562 $
139,804 $
—
139,804 $
— $
—
— $
—
127,758
127,758
10,440 $
129,107
2,340
28,310
170,197 $
— $
—
—
28,310
28,310 $
— $
—
—
—
— $
10,440
129,107
2,340
—
141,887
$
$
$
$
$
$
$
$
The following is a roll forward of our assets and liabilities measured at fair value (in thousands) on a recurring basis using
unobservable inputs (Level 3):
2017 Notes Conversion
Derivative
2020 Notes Hedges
2020 Notes Conversion
Derivative
2021 Notes Hedges
2021 Notes Conversion
Derivative
Contingent consideration
Balance at
December 27,
2015
Additions
Transfers
into Level 3
Gain/(loss)
included in
earnings
Settlements
Currency
Balance at
December 25,
2016
$
(10,440) $
127,758
$
—
—
$
—
—
$
8,207
(46,634)
$
2,069
(3,892)
$
—
—
(164)
77,232
(129,107)
—
—
99,817
—
(2,340)
(117,224)
(477)
—
—
—
—
51,799
59,278
(44,377)
(592)
(450)
—
—
1,035
—
—
—
125
(77,758)
159,095
(161,601)
(2,249)
118
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
7.
Property, Plant and Equipment
Property, plant and equipment, net consists of the following (in thousands):
Land and land improvements
Buildings
Machinery and equipment
Furniture, fixtures and office equipment
Construction in progress
Surgical instruments
Less: Accumulated depreciation
December 25,
2016
December 27,
2015 1
$
$
1,952 $
40,570
45,141
125,844
7,058
147,713
368,278
(166,546)
201,732 $
1,986
36,746
38,003
98,521
21,505
134,655
331,416
(107,160 )
224,256
___________________________
1
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015
The components of property, plant and equipment recorded under capital leases consist of the following (in thousands):
Buildings
Machinery and equipment
Less: Accumulated depreciation
$
December 25,
2016
15,529 $
5,356
20,885
(4,482)
16,403 $
December 27,
2015
12,408
3,302
15,710
(3,052 )
12,658
$
Depreciation expense recognized within results of continuing operations approximated $55.8 million, $28.4 million, and $18.5
million for the fiscal years ended December 25, 2016, December 27, 2015, and December 31, 2014, respectively, and included
depreciation of assets under capital leases.
8.
Goodwill and Intangibles
Changes in the carrying amount of goodwill occurring during the year ended December 25, 2016, are as follows (in thousands):
Goodwill at December 27, 2015 1
Goodwill adjustment associated with Wright/Tornier merger
Foreign currency translation
Goodwill at December 25, 2016
___________________________
1
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
$
$
221,327 $
(2,802)
—
218,525 $
555,312 $
3,357
—
558,669 $
90,350 $
(14,223) $
(2,279) $
73,848 $
Total
866,989
(13,668)
(2,279)
851,042
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015 (See Note 4).
Goodwill is recognized for the excess of the purchase price over the fair value of net assets of businesses acquired.
During the first quarter of 2016, our management, including our chief executive officer, who is our chief operating decision
maker, began managing our operations as four operating segments: U.S. Lower Extremities & Biologics, U.S. Upper
Extremities, International Extremities & Biologics, and Large Joints, based on our chief executive officer’s review of financial
information at the operating segment level to allocate resources and to assess the operating results and financial performance of
each segment. Management’s change to the way it monitors performance, aligns strategies, and allocates resources resulted in a
change in our reportable segments (see Note 20). We determined that each reportable segment represents a reporting unit and,
in accordance with ASC 350, the change required a re-allocation of goodwill to each reporting unit. We allocated $219 million,
119
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
$559 million, and $74 million of goodwill to the U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and
International Extremities & Biologics reportable segments, respectively. As a result of the sale of the Large Joints business,
$9.4 million of goodwill which was allocated to the Large Joints reportable segment has been reclassified to assets held for sale
within our consolidated balance sheet as of December 27, 2015.
The change in segment reporting also required an interim review of potential goodwill impairment which we performed as of
February 2016, the segment reorganization date. Upon completion of this analysis, we determined that the fair value of our
reporting units, determined primarily by an income approach using projected cash flo(cid:90)(cid:86)(cid:15)(cid:3) (cid:72)(cid:91)(cid:70)(cid:72)(cid:72)(cid:71)(cid:72)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3) (cid:70)(cid:68)(cid:85)(cid:85)(cid:92)(cid:76)(cid:81)(cid:74)(cid:3) (cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
therefore, no goodwill was impaired.
(cid:39)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:85)(cid:72)(cid:89)(cid:76)(cid:86)(cid:72)(cid:71)(cid:3)(cid:82)(cid:83)(cid:72)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3)(cid:69)(cid:68)(cid:79)(cid:68)(cid:81)(cid:70)(cid:72)(cid:86)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:71)(cid:3)(cid:68)(cid:86)(cid:3)(cid:68)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:3)(cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:68)(cid:69)(cid:79)(cid:72)(cid:30)(cid:3)(cid:76)(cid:81)(cid:89)(cid:72)(cid:81)(cid:87)(cid:82)(cid:85)(cid:92)(cid:30)(cid:3)
(cid:76)(cid:81)(cid:87)(cid:68)(cid:81)(cid:74)(cid:76)(cid:69)(cid:79)(cid:72)(cid:3) (cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:30)(cid:3) (cid:83)(cid:85)(cid:82)(cid:83)(cid:72)(cid:85)(cid:87)(cid:92)(cid:15)(cid:3) (cid:83)(cid:79)(cid:68)(cid:81)(cid:87)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:72)(cid:84)(cid:88)(cid:76)(cid:83)(cid:80)(cid:72)(cid:81)(cid:87)(cid:30)(cid:3) (cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3) (cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3) (cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:71)(cid:72)(cid:73)(cid:72)(cid:85)(cid:85)(cid:72)(cid:71)(cid:3) (cid:87)(cid:68)(cid:91)(cid:3) (cid:79)(cid:76)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)s
which resulted in a $13.7 million decrease in the preliminary value of goodwill determined as of December 27, 2015. See Note
3 for additional discussion of these adjustments.
Goodwill is also required to be tested for impairment at least annually. As of October 1, 2016, we performed a qualitative
assessment of goodwill for impairment and determined that it is not more likely than not that the carrying value of our U.S.
Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics reporting units exceeded
their respective fair values, indicating that goodwill was not impaired.
The components of our identifiable intangible assets, net are as follows (in thousands):
Indefinite life intangibles:
IPRD technology
Finite life intangibles:
Distribution channels
Completed technology
Licenses
Customer relationships
Trademarks
Non-compete agreements
Other
Total finite life intangibles
Total intangibles
Less: Accumulated amortization
Intangible assets, net
___________________________
1
December 25, 2016
December 27, 2015 1
Cost
Accumulated
amortization
Cost
Accumulated
amortization
$
938
$
15,290
900 $
133,966
4,868
122,974
13,950
11,810
524
288,992 $
374
26,550
1,115
15,133
6,881
7,833
247
58,133
250 $
122,604
4,868
115,457
14,440
7,521
527
265,667 $
219
14,828
703
7,918
3,393
2,917
51
30,029
289,930
(58,133)
231,797
$
280,957
(30,029)
250,928
$
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015
During 2016, we received FDA clearance of PerFORM Rev/Rev+ and PerFORM+, which resulted in a $14.9 million
reclassification from IPRD technology to completed technology.
Based on the total finite life intangible assets held at December 25, 2016, we expect to amortize approximately $27.2 million in
2017, $22.1 million in 2018, $20.4 million in 2019, $19.8 million in 2020, and $19.6 million in 2021.
120
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
9.
Debt and Capital Lease Obligations
Debt and capital lease obligations consist of the following (in thousands):
Capital lease obligations
2021 Notes
2020 Notes 1
2017 Notes 1
Asset-based line of credit
Mortgages
Shareholder debt
Less: current portion
December 25,
2016
14,892 $
December 27,
2015
13,763
$
280,811
482,364
1,971
30,000
2,544
1,773
814,355
(33,948)
780,407 $
—
489,006
55,865
—
2,740
1,998
563,372
(2,171 )
561,201
$
___________________________
1
The prior period debt issuance costs were reclassified to account for adoptions of ASU 2015-03 and ASU 2015-15 (See Note 2).
2021 Notes
On May 20, 2016, we issued $395 million aggregate principal amount of the 2021 Notes pursuant to an indenture (2021 Notes
Indenture) dated as of May 20, 2016 between us and The Bank of New York Mellon Trust Company, N.A., as trustee. The 2021
Notes require interest to be paid at an annual rate of 2.25% semi-annually in arrears on each May 15 and November 15, and
mature on November 15, 2021 unless earlier converted or repurchased. The 2021 Notes are convertible, subject to certain
conditions, solely into cash. The initial conversion rate for the 2021 Notes will be 46.8165 ordinary shares (subject to
adjustment as provided in the 2021 Notes Indenture) per $1,000 principal amount of the 2021 Notes (subject to, and in
accordance with, the settlement provisions of the 2021 Notes Indenture), which is equal to an initial conversion price of
approximately $21.36 per ordinary share. We may not redeem the 2021 Notes prior to the maturity date, and no “sinking fund”
is available for the 2021 Notes, which means that we are not required to redeem or retire the 2021 Notes periodically.
The holders of the 2021 Notes may convert their 2021 Notes at any time prior to May 15, 2021 solely into cash, in multiples of
$1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter
commencing after the calendar quarter ending on June 30, 2016 (and only during such calendar quarter), if the last reported sale
price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading
days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the
(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:30)(cid:3)(cid:11)(cid:21)(cid:12)(cid:3)(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:68)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)ing day
period in which the trading price per $1,000 principal amount of 2021 Notes for each trading day of the measurement period
was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each such
(cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:22)(cid:12)(cid:3)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:82)(cid:70)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:73)(cid:76)(cid:72)(cid:71)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17) On or after May 15, 2021 until the close of business on
the second scheduled trading day immediately preceding the maturity date, holders may convert their 2021 Notes solely into
cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000
principal amount of the 2021 Notes, equal to the settlement amount as calculated under the 2021 Notes Indenture. If we
undergo a fundamental change, as defined in the 2021 Notes Indenture, subject to certain conditions, holders of the 2021 Notes
will have the option to require us to repurchase for cash all or a portion of their 2021 Notes at a repurchase price equal
to 100% of the principal amount of the 2021 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding,
the fundamental change repurchase date, as defined in the 2021 Notes Indenture. In addition, following certain corporate
transactions, we, under certain circumstances, will increase the applicable conversion rate for a holder that elects to convert its
2021 Notes in connection with such corporate transaction. The 2021 Notes are senior unsecured obligations that rank: (i) senior
in right of payment to any of ou(cid:85)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:76)(cid:86)(cid:3)(cid:72)(cid:91)(cid:83)(cid:85)(cid:72)(cid:86)(cid:86)(cid:79)(cid:92)(cid:3)(cid:86)(cid:88)(cid:69)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:72)(cid:84)(cid:88)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:3)
(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:88)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:76)(cid:86)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:86)(cid:82)(cid:3)(cid:86)(cid:88)(cid:69)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:3)(cid:77)(cid:88)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:3)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)nt to
any of our secured indebte(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:3)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12) structurally junior
to all indebtedness and other liabilities (including trade payables) of our subsidiaries. As a result of the issuance of the 2021
Notes, we recorded deferred financing charges of approximately $7.3 million, which are being amortized over the term of the
2021 Notes using the effective interest method.
121
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The 2021 Notes Conversion Derivative requires bifurcation from the 2021 Notes in accordance with ASC Topic
815, Derivatives and Hedging, and is accounted for as a derivative liability. See Note 6 for additional information regarding the
2021 Notes Conversion Derivative. The fair value of the 2021 Notes Conversion Derivative at the time of issuance of the 2021
Notes was $117.2 million and was recorded as original debt discount for purposes of accounting for the debt component of the
2021 Notes. This discount is amortized as interest expense using the effective interest method over the term of the 2021 Notes.
For the year ended December 25, 2016, we recorded $9.8 million of interest expense related to the amortization of the debt
discount based upon an effective rate of 9.72%.
The components of the 2021 Notes were as follows (in thousands):
Principal amount of 2021 Notes
Unamortized debt discount
Unamortized debt issuance costs
Net carrying amount of 2021 Notes
December 25, 2016
395,000
(107,441 )
(6,748 )
280,811
$
$
The estimated fair value of the 2021 Notes was approximately $497.0 million at December 25, 2016, based on a quoted price in
an active market (Level 1).
We entered into 2021 Notes Hedges in connection with the issuance of the 2021 Notes with two counterparties. The 2021
Notes Hedges, which are cash-settled, are generally intended to reduce our exposure to potential cash payments that we would
be required to make if holders elect to convert the 2021 Notes at a time when our ordinary share price exceeds the conversion
price. However, in connection with certain events, including, among others, (i) a merger or other make-whole fundamental
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:11)(cid:68)(cid:86)(cid:3)(cid:71)(cid:72)(cid:73)(cid:76)(cid:81)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:44)(cid:81)(cid:71)(cid:72)(cid:81)(cid:87)(cid:88)(cid:85)(cid:72)(cid:12)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:76)(cid:86)(cid:85)(cid:88)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)events, which may include changes in tax laws,
an increase in the cost of borrowing our ordinary shares in the market or other material increases in the cost to the option
(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:72)(cid:85)(cid:83)(cid:68)(cid:85)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:73)(cid:68)(cid:76)(cid:79)(cid:88)(cid:85)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81) obligations under the 2021 Notes Indenture
(cid:82)(cid:85)(cid:3)(cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:20)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:71)(cid:72)(cid:73)(cid:68)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:72)(cid:91)(cid:76)(cid:86)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:7)(cid:21)(cid:24)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:89)(cid:12)(cid:3)(cid:76)f
we or any of our significant subsidiaries become insolvent or otherwise becomes subject to bankruptcy proceedings, the option
counterparties have the discretion to terminate the 2021 Notes Hedges, which may reduce the effectiveness of the 2021 Notes
Hedges. In addition, the option counterparties have broad discretion to make certain adjustments to the 2021 Notes Hedges and
warrant transactions upon the occurrence of certain other events, including, among others, (i) any adjustment to the conversion
(cid:85)(cid:68)(cid:87)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:21)(cid:19)(cid:21)(cid:20)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3) (cid:82)(cid:85)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12)(cid:3) (cid:88)(cid:83)(cid:82)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:68)(cid:81)(cid:81)(cid:82)(cid:88)(cid:81)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3) (cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87)(cid:3) (cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3) (cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86), including events that may give
rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such adjustment
may also reduce the effectiveness of the 2021 Note Hedges. The aggregate cost of the 2021 Notes Hedges was $99.8
million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 6 of the consolidated financial
statements for additional information regarding the 2021 Notes Hedges.
We also entered into warrant transactions in which we sold warrants for an aggregate of 18.5 million ordinary shares to the two
option counterparties, subject to adjustment, for an aggregate of $54.6 million. The strike price of the warrants is $30.00 per
share, which was 69% above the last reported sale price of our ordinary shares on May 12, 2016. The warrants are expected to
be net-share settled and exercisable over the 100 trading day period beginning on February 15, 2022. The warrant transactions
will have a dilutive effect on our ordinary shares to the extent that the market value per ordinary share during such period
exceeds the applicable strike price of the warrants. However, in connection with certain events, these option counterparties have
the discretion to make certain adjustments to warrant transactions, which may increase our obligations under the warrant
transactions.
Aside from the initial payment of the $99.8 million premium in the aggregate to the two option counterparties and subject to the
right of the option counterparties to terminate the 2021 Notes Hedges in certain circumstances, we do not expect to be required
to make any cash payments to the option counterparties under the 2021 Notes Hedges and expect to be entitled to receive from
the option counterparties cash, generally equal to the amount by which the market price per ordinary share exceeds the strike
price of the convertible note hedging transactions during the relevant valuation period. The strike price under the 2021 Notes
Hedges is initially equal to the conversion price of the 2021 Notes. However, in connection with certain events, these option
counterparties have the discretion to make certain adjustments to the 2021 Note Hedges, which may reduce the effectiveness of
the 2021 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any settlement date
under the warrant transaction, we will generally be obligated to issue to the option counterparties in the aggregate a number of
shares equal in value to one percent of the amount by which the then-current market value of one ordinary share exceeds the
122
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
then-effective strike price of each warrant, multiplied by the number of ordinary shares into which the 2021 Notes are initially
convertible. We will not receive any additional proceeds if warrants are exercised.
As described in more detail below, concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes
and the 2020 Notes exchanged their 2017 Notes or 2020 Notes for the 2021 Notes.
2020 Notes
On February 13, 2015, WMG issued $632.5 million aggregate principal amount of the 2020 Notes pursuant to an indenture
(2020 Notes Indenture) dated as of February 13, 2015 between WMG and The Bank of New York Mellon Trust Company,
N.A., as trustee. The 2020 Notes require interest to be paid semi-annually on each February 15 and August 15 at an annual rate
of 2.00%, and mature on February 15, 2020 unless earlier converted or repurchased. The 2020 Notes are convertible at the
option of the holder, during certain periods and subject to certain conditions described below, solely into cash at an initial
conversion rate of 32.3939 shares of WMG common stock per $1,000 principal amount of the 2020 Notes, subject to
adjustment upon the occurrence of certain events, which represents an initial conversion price of approximately $30.87 per
share of WMG common stock. On November 24, 2015, Wright Medical Group N.V. executed a supplemental indenture, fully
and unconditionally guaranteeing, on a senior unsecured basis, WMG’s obligations relating to the 2020 Notes, changing the
underlying reference securities from WMG common stock to Wright Medical Group N.V. ordinary shares and making a
corresponding adjustment to the conversion price. From and after the effective time of the Wright/Tornier merger, (i) all
calculations and other determinations with respect to the 2020 Notes previously based on references to WMG common stock
are calculated or determined by reference to our ordinary shares, and (ii) the conversion rate (as defined in the 2020 Notes
Indenture) for the 2020 Notes was adjusted to an initial conversion rate of 33.39487 ordinary shares (subject to adjustment as
provided in the 2020 Notes Indenture) per $1,000 principal amount of the 2020 Notes, which represents an initial conversion
price of approximately $29.94 per ordinary share (subject to, and in accordance with, the settlement provisions of the 2020
Notes Indenture). The 2020 Notes may not be redeemed by WMG prior to the maturity date, and no “sinking fund” is available
for the 2020 Notes, which means that WMG is not required to redeem or retire the 2020 Notes periodically.
The holders of the 2020 Notes may convert their notes at any time prior to August 15, 2019 solely into cash, in multiples of
$1,000 principal amount, upon satisfaction of one or more of the following circumstances: (1) during any calendar quarter
commencing after the calendar quarter ending on March 31, 2015 (and only during such calendar quarter), if the last reported
sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive
trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of
(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:30)(cid:3)(cid:11)(cid:21)(cid:12)(cid:3)(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:68)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)(cid:76)ng
day period in which the trading price per $1,000 principal amount of 2020 Notes for each trading day of the measurement
period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each
(cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:71)(cid:68)(cid:92)(cid:30)(cid:3) (cid:82)(cid:85)(cid:3) (cid:11)(cid:22)(cid:12)(cid:3) (cid:88)(cid:83)(cid:82)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:82)(cid:70)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:73)(cid:76)(cid:72)(cid:71)(cid:3) (cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3) (cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)(cid:3) (cid:55)(cid:75)(cid:72)(cid:3) (cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3) (cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:3) did not result in a
conversion right for holders of the 2020 Notes. On or after August 15, 2019 until the close of business on the second scheduled
trading day immediately preceding the maturity date, holders may convert their 2020 Notes solely into cash, regardless of the
foregoing circumstances. Upon conversion, a holder will receive an amount in cash, per $1,000 principal amount of the 2020
Notes, equal to the settlement amount as calculated under the 2020 Notes Indenture. If WMG undergoes a fundamental change,
as defined in the 2020 Notes Indenture, subject to certain conditions, holders of the 2020 Notes will have the option to require
WMG to repurchase for cash all or a portion of their notes at a purchase price equal to 100% of the principal amount of the
2020 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding, the fundamental change repurchase date,
as defined in the 2020 Notes Indenture. In addition, following certain corporate transactions, WMG, under certain
circumstances, will increase the applicable conversion rate for a holder that elects to convert its 2020 Notes in connection with
such corporate transaction. The 2020 Notes are senior unsecured obligations that rank: (i) senior in right of payment to any of
WMG’(cid:86)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:76)(cid:86)(cid:3)(cid:72)(cid:91)(cid:83)(cid:85)(cid:72)(cid:86)(cid:86)(cid:79)(cid:92)(cid:3)(cid:86)(cid:88)(cid:69)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:72)(cid:84)(cid:88)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:3)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)
of WMG’(cid:86)(cid:3) (cid:88)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:76)(cid:86)(cid:3) (cid:81)(cid:82)(cid:87)(cid:3) (cid:86)(cid:82)(cid:3) (cid:86)(cid:88)(cid:69)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3) (cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:3) (cid:77)(cid:88)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3) (cid:76)(cid:81)(cid:3) (cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:87)(cid:82)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:72)(cid:71)(cid:3)
indebtedness (cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:86)(cid:86)(cid:72)(cid:87)(cid:86)(cid:3)(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12)(cid:3)(cid:86)(cid:87)(cid:85)(cid:88)(cid:70)(cid:87)(cid:88)(cid:85)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:77)(cid:88)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:79)(cid:79)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)
and other liabilities (including trade payables) of WMG’s subsidiaries. In conjunction with the issuance of the 2020 Notes, we
recorded deferred financing charges of approximately $18.1 million, which are being amortized over the term of the 2020 Notes
using the effective interest method.
The 2020 Notes Conversion Derivative requires bifurcation from the 2020 Notes in accordance with ASC Topic 815,
Derivatives and Hedging, and is accounted for as a derivative liability. See Note 6 of the consolidated financial statements for
additional information regarding the 2020 Notes Conversion Derivative. The fair value of the 2020 Notes Conversion
Derivative at the time of issuance of the 2020 Notes was $149.8 million and was recorded as original debt discount for purposes
123
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
of accounting for the debt component of the 2020 Notes. This discount is amortized as interest expense using the effective
interest method over the term of the 2020 Notes. For the years ended December 25, 2016 and December 27, 2015, we recorded
$25.9 million and $21.8 million, respectively, of interest expense related to the amortization of the debt discount based upon an
effective rate of 8.54%.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2020 Notes exchanged approximately
$45.0 million aggregate principal amount of their 2020 Notes for the 2021 Notes. For each $1,000 principal amount of 2020
Notes validly submitted for exchange, we delivered $990.0 principal amount of the 2021 Notes (subject to rounding down to
the nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus
an amount of cash equal to the unpaid interest on the 2020 Notes and the rounded amount. As a result of this note exchange
and retirement of $45.0 million aggregate principal amount of the 2020 Notes, we recognized approximately $9.3 million for
the write-off of related pro-rata unamortized deferred financing fees and debt discount within “Other expense (income), net” in
our consolidated statements of operations during the year ended December 25, 2016.
The components of the 2020 Notes were as follows (in thousands):
Principal amount of 2020 Notes
Unamortized debt discount
Unamortized debt issuance costs
Net carrying amount of 2020 Notes 1
___________________________
1
December 25, 2016
December 27, 2015
$
$
587,500 $
(93,749)
(11,387)
482,364 $
632,500
(127,953 )
(15,541 )
489,006
The prior period debt issuance costs were reclassified to account for adoption of ASU 2015-03 and ASU 2015-15 (See Note 2).
The estimated fair value of the 2020 Notes was approximately $629 million at December 25, 2016, based on a quoted price in
an active market (Level 1).
WMG entered into the 2020 Notes Hedges in connection with the issuance of the 2020 Notes with three option counterparties.
The 2020 Notes Hedges, which are cash-settled, are generally intended to reduce WMG’s exposure to potential cash payments
that WMG would be required to make if holders elect to convert the 2020 Notes at a time when our ordinary share price
exceeds the conversion price. However, in connection with certain events, including, among others, (i) a merger or other make-
whole fundamental cha(cid:81)(cid:74)(cid:72)(cid:3)(cid:11)(cid:68)(cid:86)(cid:3)(cid:71)(cid:72)(cid:73)(cid:76)(cid:81)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:81)(cid:87)(cid:88)(cid:85)(cid:72)(cid:12)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:76)(cid:86)(cid:85)(cid:88)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:3)
changes in tax laws, an increase in the cost of borrowing our ordinary shares in the market or other material increases in the
cost to the option counte(cid:85)(cid:83)(cid:68)(cid:85)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:75)(cid:72)(cid:71)(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:3)(cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:58)(cid:48)(cid:42)’s failure to perform certain obligations under the
(cid:21)(cid:19)(cid:21)(cid:19)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3) (cid:44)(cid:81)(cid:71)(cid:72)(cid:81)(cid:87)(cid:88)(cid:85)(cid:72)(cid:3) (cid:82)(cid:85)(cid:3) (cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:21)(cid:19)(cid:21)(cid:19)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3) (cid:43)(cid:72)(cid:71)(cid:74)(cid:72)(cid:86)(cid:30)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:71)(cid:72)(cid:73)(cid:68)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3) (cid:82)(cid:81)(cid:3) (cid:58)(cid:48)(cid:42)’s existing indebtedness in
(cid:72)(cid:91)(cid:70)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:7)(cid:21)(cid:24)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:89)(cid:12)(cid:3)(cid:76)(cid:73)(cid:3)(cid:58)(cid:48)(cid:42) or any of its significant subsidiaries become insolvent or otherwise becomes subject to
bankruptcy proceedings, the option counterparties have the discretion to terminate the 2020 Note Hedges at a value determined
by them in a commercially reasonable manner and/or adjust the terms of the 2020 Note Hedges, which may reduce the
effectiveness of the 2020 Note Hedges. In addition, the option counterparties have broad discretion to make certain adjustments
to the 2020 Notes Hedges upon the occurrence of certain other events, including, among others, (i) any adjustment to the
(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:21)(cid:19)(cid:21)(cid:19)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:81)(cid:81)(cid:82)(cid:88)(cid:81)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:72)(cid:85)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:87)(cid:75)at
may give rise to a termination event as described above, such as the announcement of a third-party tender offer. Any such
adjustment may also reduce the effectiveness of the 2020 Note Hedges. The aggregate cost of the 2020 Notes Hedges was
$144.8 million and is accounted for as a derivative asset in accordance with ASC Topic 815. See Note 6 of the consolidated
financial statements for additional information regarding the 2020 Notes Hedges.
WMG also entered into warrant transactions in which it sold warrants for an aggregate of 20.5 million shares of WMG common
stock to the three option counterparties, subject to adjustment. The strike price of the warrants was initially $40 per share of
WMG common stock, which was 59% above the last reported sale price of WMG common stock on February 9, 2015. On
November 24, 2015, Wright Medical Group N.V. assumed WMG’s obligations pursuant to the warrants. Following the
assumption, the warrants became exercisable for 21.1 million Wright Medical Group N.V. ordinary shares and the strike price
of the warrants was adjusted to $38.8010 per ordinary share. The warrants are expected to be net-share settled and exercisable
over the 200 trading day period beginning on May 15, 2020. The warrant transactions will have a dilutive effect on our
ordinary shares to the extent that the market value per ordinary share during such period exceeds the applicable strike price of
the warrants. However, in connection with certain events, these option counterparties have the discretion to make certain
adjustments to warrant transactions, which may increase our obligations under the warrant transactions.
124
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
During the three months ended June 26, 2016, we settled a portion of the 2020 Notes Hedges (receiving $3.9 million) and
repurchased warrants for an aggregate of 1.5 million ordinary shares (paying $3.3 million) associated with the 2020 Notes.
Aside from the initial payment of the $144.8 million premium in the aggregate to the option counterparties, we do not expect to
be required to make any cash payments to the option counterparties under the 2020 Notes Hedges and expect to be entitled to
receive from the option counterparties cash, generally equal to the amount by which the market price per ordinary share
exceeds the strike price of the convertible note hedging transactions during the relevant valuation period. The strike price under
the 2020 Notes Hedges is initially equal to the conversion price of the 2020 Notes. However, in connection with certain events,
these option counterparties have the discretion to make certain adjustments to the 2020 Note Hedges, which may reduce the
effectiveness of the 2020 Note Hedges. Additionally, if the market value per ordinary share exceeds the strike price on any
settlement date under the warrant transaction, we will generally be obligated to issue to the option counterparties in the
aggregate a number of ordinary shares equal in value to one half of one percent of the amount by which the then-current market
value of one ordinary share exceeds the then-effective strike price of each warrant, multiplied by the number of reference
ordinary shares into which the 2020 Notes are initially convertible. We will not receive any additional proceeds if warrants are
exercised.
2017 Notes
On August 31, 2012, WMG issued $300 million aggregate principal amount of the 2017 Notes pursuant to an indenture (2017
Notes Indenture) dated as of August 31, 2012 between WMG and The Bank of New York Mellon Trust Company, N.A., as
trustee. The 2017 Notes mature on August 15, 2017, and we pay interest on the 2017 Notes semi-annually on each February 15
and August 15 at an annual rate of 2.00%. WMG may not redeem the 2017 Notes prior to the maturity date, and no “sinking
fund” is available for the 2017 Notes, which means that WMG is not required to redeem or retire the 2017 Notes periodically.
The 2017 Notes are convertible at the option of the holder, during certain periods and subject to certain conditions as described
below, solely into cash at an initial conversion rate of 39.3140 shares per $1,000 principal amount of the 2017 Notes, subject to
adjustment upon the occurrence of specified events, which represents an initial conversion price of $25.44 per share. Holders
may convert their 2017 Notes at any time prior to February 15, 2017 only under the following circumstances: (1) during any
calendar quarter commencing after the calendar quarter ending December 31, 2012 (and only during such calendar quarter), if
the last reported sale price of our ordinary shares for at least 20 trading days (whether or not consecutive) during a period of 30
consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to
130% of (cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:68)(cid:83)(cid:83)(cid:79)(cid:76)(cid:70)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:68)(cid:92)(cid:30)(cid:3)(cid:11)(cid:21)(cid:12)(cid:3)(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:71)(cid:68)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3)(cid:68)(cid:73)(cid:87)(cid:72)(cid:85)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:73)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)
trading day period in which the trading price per $1,000 principal amount of notes for each trading day of the measurement
period was less than 98% of the product of the last reported sale price of our ordinary shares and the conversion rate on each
(cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:87)(cid:85)(cid:68)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:71)(cid:68)(cid:92)(cid:30)(cid:3) (cid:82)(cid:85)(cid:3) (cid:11)(cid:22)(cid:12)(cid:3) (cid:88)(cid:83)(cid:82)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:82)(cid:70)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:73)(cid:76)(cid:72)(cid:71)(cid:3) (cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3) (cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17) While we currently do not expect significant
conversions because the 2017 Notes currently trade at a premium to the as-converted value, and a converting holder would
forego future interest payments, any conversions would reduce our cash resources. On or after February 15, 2017 until the
close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert their 2017
Notes solely into cash, regardless of the foregoing circumstances. Upon conversion, a holder will receive an amount in cash,
per $1,000 principal amount of the 2017 Notes, equal to the settlement amount as calculated under the 2017 Notes Indenture. If
we undergo a fundamental change, as defined in the 2017 Notes Indenture, subject to certain conditions, holders of the 2017
Notes will have the option to require WMG to repurchase for cash all or a portion of their 2017 Notes at a purchase price equal
to 100% of the principal amount of the 2017 Notes to be repurchased, plus any accrued and unpaid interest to, but excluding,
the fundamental change repurchase date, as defined in the 2017 Notes Indenture. In addition, following certain corporate
transactions, WMG, under certain circumstances, will pay a cash make-whole premium by increasing the applicable conversion
rate for a holder that elects to convert its 2017 Notes in connection with such corporate transaction. The 2017 Notes are senior
unsecured obligations that rank: (i) senior in right of payment to any of WMG’s indebtedness that is expressly subordinated in
(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:21)(cid:19)(cid:20)(cid:26)(cid:3) (cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12)(cid:3) (cid:72)(cid:84)(cid:88)(cid:68)(cid:79)(cid:3) (cid:76)(cid:81)(cid:3) (cid:85)(cid:76)ght of payment to any of WMG’s unsecured indebtedness that is not so
(cid:86)(cid:88)(cid:69)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:87)(cid:72)(cid:71)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3) (cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:3) (cid:77)(cid:88)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3) (cid:76)(cid:81)(cid:3) (cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:87)(cid:82)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:72)(cid:91)(cid:87)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:68)(cid:86)(cid:86)(cid:72)ts
(cid:86)(cid:72)(cid:70)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:76)(cid:81)(cid:71)(cid:72)(cid:69)(cid:87)(cid:72)(cid:71)(cid:81)(cid:72)(cid:86)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:86)(cid:87)(cid:85)(cid:88)(cid:70)(cid:87)(cid:88)(cid:85)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3) (cid:77)(cid:88)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3) (cid:87)(cid:82) all indebtedness and other liabilities (including trade payables) of
WMG’s subsidiaries. As a result of the issuance of the 2017 Notes, we recognized deferred financing charges of approximately
$8.8 million, which are being amortized over the term of the 2017 Notes using the effective interest method.
The 2017 Notes Conversion Derivative requires bifurcation from the 2017 Notes in accordance with ASC Topic 815,
Derivatives and Hedging, and is accounted for as a derivative liability. See Note 6 of the consolidated financial statements for
additional information regarding the 2017 Notes Conversion Derivative. The fair value of the 2017 Notes Conversion
Derivative at the time of issuance of the 2017 Notes was $48.1 million and was recorded as original debt discount for purposes
of accounting for the debt component of the 2017 Notes. This discount is amortized as interest expense using the effective
125
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
interest method over the term of the 2017 Notes. For the years ended December 25, 2016 and December 27, 2015, we recorded
$0.9 million and $2.9 million of interest expense related to the amortization of the debt discount, respectively, based upon an
effective rate of 6.47%.
In connection with the issuance of the 2020 Notes, on February 13, 2015, WMG repurchased and extinguished
$240 million aggregate principal amount of the 2017 Notes and settled all of the 2017 Notes Hedges (receiving $70 million)
and repurchased all of the warrants (paying $60 million) associated with the 2017 Notes. As a result of the repurchase, we
recognized approximately $25.1 million for the write-off of related pro-rata unamortized deferred financing fees and debt
discount within “Other expense (income), net” in our consolidated statements of operations during the year ended December
27, 2015.
Concurrently with the issuance and sale of the 2021 Notes, certain holders of the 2017 Notes exchanged approximately
$54.4 million aggregate principal amount their 2017 Notes for the 2021 Notes. For each $1,000 principal amount of 2017 Notes
validly submitted for exchange, we delivered $1,035.40 principal amount of 2021 Notes (subject to rounding down to the
nearest $1,000 principal amount of the 2021 Notes, the difference being referred as the rounded amount) to the investor plus an
amount of cash equal to the unpaid interest on the 2017 Notes and the rounded amount. In addition, during the three months
ended June 26, 2016, we repurchased and extinguished an additional $3.6 million aggregate principal amount of the 2017 Notes
in privately negotiated transactions. As a result of this exchange and these repurchases, we recognized approximately
$3.0 million for the write-off of related pro-rata unamortized deferred financing fees and debt discount within “Other expense
(income), net” in our consolidated statements of operations during the year ended December 25, 2016.
The components of the 2017 Notes were as follows (in thousands):
December 25, 2016
December 27, 2015
Principal amount of 2017 Notes
Unamortized debt discount
Unamortized debt issuance costs
Net carrying amount of 2017 Notes 1
___________________________
1 The prior period debt issuance costs were reclassified to account for adoption of ASU 2015-03 and ASU 2015-15 (See
2,026 $
(47)
(8)
1,971 $
60,000
(3,495 )
(640 )
55,865
$
$
Note 2).
The estimated fair value of the 2017 Notes was approximately $2.1 million at December 25, 2016, based on a quoted price in an
active market (Level 1).
ABL Facility
On December 23, 2016, we, together with WMG and certain of our other wholly-owned U.S. subsidiaries (collectively,
Borrowers), entered into a Credit, Security and Guaranty Agreement (ABL Credit Agreement) with Midcap Financial Trust, as
administrative agent (Agent) and a lender and the additional lenders from time to time party thereto. The ABL Credit
Agreement provides for a $150.0 million senior secured asset based line of credit, subject to the satisfaction of a borrowing
base requirement (ABL Facility). The ABL Facility may be increased by up to $100.0 million upon the Borrowers’ request,
subject to the consent of the Agent and each of the other lenders providing such increase. All borrowings under the ABL
Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations
and warranties in all material respects and the delivery of an updated borrowing base certificate. As of December 25, 2016, we
had $30.0 million in borrowings outstanding under the ABL Facility. We have reflected this debt as a current liability on our
consolidated balance sheet as of December 25, 2016, as required by US GAAP due to the weekly lockbox repayment/re-
borrowing arrangement underlying the agreement, as well as the ability for the bank to accelerate the repayment of the debt
under certain circumstances as described below. In conjunction with the ABL Facility, we incurred $2.5 million of debt
issuance costs related to the ABL Facility, which is included within “Other assets” on our consolidated balance sheet as of
December 25, 2016. These costs will be amortized over the five-year term of the ABL Facility as described below.
The interest rate margin applicable to borrowings under the ABL Facility is, at the option of the Borrowers, equal to either
(a) 3.25% for base rate loans or (b) 4.25% for LIBOR rate loans, subject to a 0.75% LIBOR floor. In addition to paying interest
on the outstanding loans under the ABL Facility, the Borrowers also are required to pay a customary unused line fee equal to
0.50% per annum in respect of unutilized commitments and certain other customary fees related to Agent’s administration of
the ABL Facility. Beginning January 1, 2017, the Borrowers are required to maintain a minimum drawn balance on the ABL
126
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Facility equal to 20% of the average borrowing base for each month. To the extent the actual drawn balance is less than 20%,
the Borrowers must pay a fee equal to the amount the lenders under the ABL Facility would have earned had the Borrowers
maintained a minimum drawn balance equal to 20% of the average borrowing base for such month.
The ABL Credit Agreement requires that the Borrowers calculate the borrowing base for the ABL Facility on at least a monthly
basis and each time the Borrowers make a draw on the ABL Facility in accordance with the formula set forth in the ABL Credit
Agreement. The borrowing base is subject to adjustment and the implementation of reserves by the Agent in its permitted
discretion, as further described in the ABL Credit Agreement. If at any time the outstanding drawn balance under the ABL
Facility exceeds the borrowing base as in effect at such time, Borrowers will be required to prepay loans under the ABL Facility
in an amount equal to such excess. Certain accounts receivables and proceeds of collateral of the Borrowers will be applied to
reduce the outstanding principal amount of the ABL Facility on a periodic basis.
There is no scheduled amortization under the ABL Facility and (subject to borrowing base requirements and applicable
conditions to borrowing) the available revolving commitment may be borrowed, repaid and reborrowed without restriction. All
outstanding loans under the ABL Facility will be due and payable in full on the date that is the earliest to occur of
(x) December 23, 2021, (y) the date that is 91 days prior to the maturity date of the 2020 Notes or (z) the date that is 91 days
prior to the maturity date of the 2021 Notes, provided that, the springing maturity under clauses (y) and (z) are subject to the
Borrowers’ ability to refinance, extend, renew or replace the 2020 Notes and/or the 2021 Notes, as applicable, in full pursuant
to the terms of the ABL Credit Agreement. Any voluntary or mandatory permanent reduction or termination of the revolving
commitments under the ABL Facility is subject to a prepayment premium applicable to such reduced or terminated amount
equal to (i) 3.0% through December 23, 2017, (ii) 2.0% from December 24, 2017 through December 23, 2018 and (iii) 0.75% at
any time thereafter.
The ABL Credit Agreement contains certain negative covenants that restrict our ability to take certain actions as specified in the
Credit Agreement and an affirmative covenant that we maintain net revenue at or above minimum levels and maintain liquidity
in the United States at a level specified in the ABL Credit Agreement, subject to certain exceptions. All of the obligations under
the ABL Facility are guaranteed jointly and severally by Wright Medical Group N.V. and each of the Borrowers on the terms set
forth in the ABL Credit Agreement. Subject to certain exceptions set forth in the ABL Credit Agreement, amounts outstanding
under the ABL Facility are secured by a senior first priority security interest in substantially all existing and after-acquired
assets of Wright Medical Group N.V. and each Borrower.
Mortgages and Shareholder Debt
We have mortgages and other debt that had an outstanding balance of $2.5 million and $2.7 million at December 25, 2016 and
December 27, 2015, respectively. The majority of this debt is mortgages that were acquired as a result of the Wright/Tornier
merger. These mortgages are secured by an office building in Montbonnot, France and bear fixed annual interest rates of
2.55%-4.9%.
The shareholder debt acquired was the result of a 2008 transaction where a 51%-owned and consolidated subsidiary of legacy
Tornier borrowed $2.2 million from a then-current member of the legacy Tornier board of directors, who was also a 49% owner
of the consolidated subsidiary. This loan was used to partially fund the purchase of real estate in Grenoble, France, to be used
as a manufacturing facility. Interest on the debt is variable-based on the three-month Euro Libor rate plus 0.5% and has no
stated term. The outstanding balance on this debt was $1.8 million and $2.0 million as of December 25, 2016 and December
27, 2015, respectively. See Note 18 of the consolidated financial statements for additional information regarding this related
party transaction.
As of October 1, 2015, legacy Tornier had approximately $74 million in outstanding term debt and $7 million in a line of credit
under a pre-existing credit agreement. Upon completion of the Wright/Tornier merger, we terminated all commitments under
this credit agreement and repaid approximately $81 million in outstanding indebtedness. We did not incur any early
termination penalties in connection with such repayment and termination.
127
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Maturities
Aggregate annual maturities of our current and long-term obligations at December 25, 2016, excluding capital lease obligations
and the ABL Facility, are as follows (in thousands):
2017
2018
2019
2020
2021
Thereafter
$
$
2,587
490
204
587,650
395,000
2,911
988,842
The table set forth above excludes amounts borrowed under the ABL Facility. As described previously, all outstanding loans
under the ABL Facility will be due and payable in full on December 23, 2021 or earlier under certain specified circumstances as
previously described.
As discussed in Note 7, we have acquired certain property and equipment pursuant to capital leases. At December 25, 2016,
future minimum lease payments under capital lease obligations, together with the present value of the net minimum lease
payments, are as follows (in thousands):
2017
2018
2019
2020
2021
Thereafter
Total minimum payments
Less amount representing interest
Present value of minimum lease payments
Current portion
Long-term portion
$
$
2,294
2,244
2,164
2,013
1,720
7,823
18,258
(3,366 )
14,892
(1,360 )
13,532
10.
Accumulated Other Comprehensive Income (AOCI)
Other comprehensive income (OCI) includes certain gains and losses that under US GAAP are included in comprehensive
income but are excluded from net income as these amounts are initially recorded as an adjustment to shareholders’ equity.
Amounts in OCI may be reclassified to net income upon the occurrence of certain events.
Our 2014 OCI is comprised of foreign currency translation adjustments, unrealized gains and losses on available-for-sale
securities, and adjustments to our minimum pension liability. Our 2015 and 2016 OCI is comprised solely of foreign currency
translation adjustments. Foreign currency translation adjustments are reclassified to net income upon sale or upon a complete
or substantially complete liquidation of an investment in a foreign entity. Unrealized gains and losses on available-for-sale
securities are reclassified to net income if we sell the security before maturity or if the unrealized loss in a security is considered
to be other-than-temporary.
128
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Changes in and reclassifications out of AOCI, net of tax, for the fiscal years ended December 31, 2014, December 27, 2015,
and December 25, 2016 were as follows (in thousands):
Balance December 31, 2013
Other comprehensive income loss, net of tax
Reclassification to CTA and minimum pension
liability adjustment 1
Balance December 31, 2014
Other comprehensive income loss, net of tax
Balance December 27, 2015
Other comprehensive income loss, net of tax
Balance December 25, 2016
___________________________
1
Currency
translation
adjustment
Unrealized
gain (loss) on
marketable
securities
Minimum
pension
liability
adjustment
$
$
$
$
17,610 $
(17,840)
2,628
2,398 $
(12,882)
(10,484) $
(8,977)
(19,461) $
(1) $
1
—
— $
—
— $
—
— $
344 $
—
(344)
— $
—
— $
—
— $
Total
17,953
(17,839 )
2,284
2,398
(12,882 )
(10,484 )
(8,977 )
(19,461 )
The balances of CTA and minimum pension liability adjustment within AOCI were written-off following the liquidation of our former
Japanese subsidiary as part of the sale of our OrthoRecon business. This was recorded within the gain on the sale of the OrthoRecon
business within results of discontinued operations.
11.
Income Taxes
The components of our loss from continuing operations before income taxes are as follows (in thousands):
U.S.
Foreign 1
Loss from continuing operations before income taxes 1
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
The components of our benefit for income taxes are as follows (in thousands):
Current provision (benefit):
U.S.:
Federal
State
Foreign 1
Total current provision 1
Deferred (benefit) provision:
U.S.:
Federal
State
Foreign 1
Total deferred benefit 1
Total benefit for income taxes 1
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
129
December 25,
2016
(140,190) $
(38,150)
(178,340) $
Fiscal year ended
December 27,
2015
(225,473) $
(15,535)
(241,008) $
$
$
December 31,
2014
(242,998 )
(3,832 )
(246,830 )
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
$
$
(1,971) $
(281)
3,860
1,608
— $
255
562
817
1,244
142
(16,400)
(15,014)
(13,406) $
(1,450)
(166)
(2,853)
(4,469)
(3,652) $
(48 )
198
1,674
1,824
(3,164 )
(1,411 )
(3,583 )
(8,158 )
(6,334 )
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
A reconciliation of the statutory U.S. federal income tax rate to our effective income tax rate for continuing operations is as
follows:
December 25,
2016
Fiscal year ended
December 27,
2015
December 31,
2014
35.0 %
2.9 %
(32.6)%
(1.7)%
3.3 %
0.6 %
7.5 %
35.0 %
3.7 %
(36.5)%
1.1 %
(0.9)%
(0.7)%
1.7 %
35.0 %
1.8 %
(15.9 )%
(17.7 )%
0.2 %
(0.8 )%
2.6 %
Income tax benefit at statutory rate
State income taxes
Change in valuation allowance
CVR fair market value adjustment
Foreign income tax rate differential 1
Other, net
Total 1
___________________________
1
The 2015 rates were revised to reflect the historical results of our Large Joints business within results from discontinued operations.
The significant components of our deferred income taxes as of December 25, 2016 and December 27, 2015 are as follows (in
thousands):
Deferred tax assets:
Net operating loss carryforwards
General business credit carryforwards
Reserves and allowances
Share-based compensation expense
Convertible debt notes and conversion options
Other
Valuation allowance
Total deferred tax assets
Deferred tax liabilities:
Depreciation
Intangible assets
Convertible notes bond hedges
Other
Total deferred tax liabilities
Net deferred tax liabilities
Fiscal year ended
December 25,
2016
December 27,
2015
$
333,282 $
5,671
158,834
20,818
28,437
1,173
(479,404)
289,715
6,121
52,482
18,423
46,631
6,720
(336,060 )
68,811
84,032
10,055
52,123
30,120
2,565
8,455
58,266
49,826
6,660
94,863
123,207
$
(26,052) $
(39,175 )
At December 25, 2016, we had net operating loss carryforwards for U.S. federal income tax purposes of approximately
$793 million, of which approximately $8 million related to equity compensation deductions, for which when realized, the
resulting benefit will be credited to shareholders’ equity. The federal net operating losses begin to expire in 2017 and extend
through 2036. State net operating loss carryforwards at December 25, 2016 totaled approximately $761 million, which begin to
expire in 2017 and extend through 2036. Additionally, we had general business credit carryforwards of approximately
$6 million, which begin to expire in 2017 and extend through 2036. At December 25, 2016, we had foreign net operating loss
carryforwards of approximately $105 million, $49 million of which do not expire and $56 million which begin to expire in
2017 and extend through 2029.
At December 25, 2016 and December 27, 2015, we had a valuation allowance of $479 million and $336 million, respectively,
related to certain U.S. and foreign deferred tax assets. Our December 27, 2015 valuation allowance balance includes
approximately $56 million allocated from the preliminary purchase consideration with respect to the merger with Tornier. As a
result of the finalization of the valuation of acquired intangible assets by tax jurisdiction with respect to the merger, we reduced
our valuation allowance by approximately $6 million. We recognized income tax expense for an increase in the valuation
130
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
allowance of $149 million during the year ended December 25, 2016, primarily related to additional net operating losses and an
increase in deferred tax assets associated with reserves and allowances incurred in the United States. The ultimate realization of
deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary
differences become deductible. Management considers the scheduled reversal of deferred tax liabilities (including the impact
of available carryback and carryforward periods), projected future taxable income, and tax planning strategies in making this
assessment. Based upon the levels of historical taxable income, projections of future taxable income and the reversal of
deferred tax liabilities over the periods in which the deferred tax assets are deductible, management believes it is more likely
than not that we will realize the benefits of these deductible differences, net of the existing valuation allowance.
It is our current practice and intention to reinvest the earnings of our subsidiaries in those operations. Therefore, we do not
provide for deferred taxes on the excess of the financial reporting over the tax basis in our investments in subsidiaries that are
essentially permanent in duration. We would recognize a deferred income tax liability if we were to determine that such
earnings are no longer indefinitely reinvested. At December 25, 2016, undistributed earnings of our U.S. controlled foreign
subsidiaries amounted to approximately $10 million. Due to the number of tax jurisdictions involved and the complexity of our
legal entity structure, the complexity of the tax laws in the relevant jurisdictions, including, but not limited to, the rules
pertaining to the utilization of foreign tax credits in the United States and the impact of projections of income for future years to
all calculations, we believe it is not practicable to estimate the amount of additional taxes which may be payable upon
distribution of these earnings, however it is not expected to be significant.
As of December 25, 2016, our unrecognized tax benefits totaled approximately $8 million. The total amount of net
unrecognized tax benefits that, if recognized, would affect the tax rate was approximately $3 million at December 25, 2016.
Our 2014 U.S. federal income tax return is currently under examination by the Internal Revenue Service. It is, therefore,
reasonably possible that our unrecognized tax benefits could change in the next twelve months as a result of settlements with
taxing authorities as well as expirations of the statutes of limitations.
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):
Balance at December 28, 2015
Additions for tax positions related to current year
Additions for tax positions of prior years
Reductions for tax positions of prior years
Settlements
Foreign currency translation
Balance at December 25, 2016
$
$
9,941
407
721
(2,657 )
(74 )
(243 )
8,095
We accrue interest required to be paid by the tax law for the underpayment of taxes on the difference between the amount
claimed or expected to be claimed on the tax return and the tax benefit recognized in the financial statements. Management has
made the policy election to record this interest as interest expense and penalties, that if incurred, would be recognized as
penalty expense within “Other expense (income)” on our consolidated statements of operations. As of December 25, 2016,
accrued interest and penalties related to our unrecognized tax benefits totaled approximately $0.2 million.
We file numerous consolidated and separate company income tax returns in the United States and in many foreign jurisdictions.
We are no longer subject to foreign income tax examinations by tax authorities in significant jurisdictions for years before 2007.
With few exceptions, we are subject to U.S. federal, state, and local income tax examinations for years 2013 through 2015.
However, tax authorities have the ability to review years prior to these to the extent that we utilize tax attributes carried forward
from those prior years.
131
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
12.
Other Balance Sheet Information
Other long-term liabilities consist of the following (in thousands):
Product liability reserves (Note 16)
Notes Conversion Derivatives (Note 6)
Contingent consideration and CVRs (Note 6)
Other
Accrued expenses and other current liabilities consist of the following (in thousands):
Employee bonuses
Other employee benefits 1
Royalties 1
Taxes other than income
Commissions
Professional and legal fees
Contingent consideration (Note 6)
Product liability and other legal accruals (Note 16)
Other
$
December 25,
2016
21,605 $
239,523
37,918
22,201
321,247 $
December 27,
2015
13,990
139,547
29,858
25,179
208,574
$
$
December 25,
2016
28,791 $
20,383
8,534
19,559
16,891
11,031
1,330
264,827
36,358
407,704 $
December 27,
2015
27,515
21,366
11,676
18,895
15,196
21,048
792
16,630
38,053
171,171
$
___________________________
1
The prior period amounts have been adjusted to reflect balances associated with our Large Joints business, as these amounts were
classified as held for sale at December 27, 2015 (See Note 4).
13.
Capital Stock and Earnings Per Share
We are authorized to issue up to 320 million ordinary shares, each share with a par value of three Euro cents (€0.03). We had
103.4 million and 102.7 million ordinary shares issued and outstanding as of December 25, 2016 and December 27, 2015,
respectively. As discussed in Note 3, the Wright/Tornier merger completed on October 1, 2015 has been accounted for as a
“reverse acquisition” under US GAAP. As such, legacy Wright was considered (cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:72)(cid:81)(cid:87)(cid:76)(cid:87)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:83)(cid:88)(cid:85)(cid:83)(cid:82)(cid:86)(cid:72)(cid:86)(cid:30)
and therefore, legacy Wright’s historical results of operations replaced legacy Tornier’s historical results of operations for all
periods prior to the merger. Additionally, each legacy Wright share was converted into the right to receive 1.0309 ordinary
shares of the combined company and the par value was revised to reflect the €0.03 par value as compared to the legacy Wright
par value of $0.01. As a result of the 2015 share conversion, the following amounts have been restated:
•
•
•
•
•
ordinary shares and APIC balances for the 2013 and 2014 periods included within the statements of shareholders’
(cid:72)(cid:84)(cid:88)(cid:76)(cid:87)(cid:92)(cid:30)
(cid:21)(cid:19)(cid:20)(cid:23)(cid:3)(cid:72)(cid:68)(cid:85)(cid:81)(cid:76)(cid:81)(cid:74)(cid:86)(cid:3)(cid:83)(cid:72)(cid:85)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:72)(cid:76)(cid:74)(cid:75)(cid:87)(cid:72)(cid:71)(cid:3)(cid:68)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:3)(cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:87)(cid:68)(cid:87)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
2014 wei(cid:74)(cid:75)(cid:87)(cid:72)(cid:71)(cid:3)(cid:68)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:3)(cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:69)(cid:72)(cid:79)(cid:82)(cid:90)(cid:30)(cid:3)
2014 impact of share-based compensation on earnings per share in Note 14(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
quarterly earnings per share and weighted average ordinary shares outstanding for the first, second and third
quarters of 2015 as presented in Note 19.
FASB ASC Topic 260, Earnings Per Share, requires the presentation of basic and diluted earnings per share. Basic earnings
per share is calculated based on the weighted-average number of ordinary shares outstanding during the period. Diluted
earnings per share is calculated to include any dilutive effect of our ordinary share equivalents. For the fiscal years ended
December 25, 2016 and December 27, 2015, our ordinary share equivalents consisted of stock options, restricted stock units,
and warrants. For the fiscal year ended December 31, 2014, our ordinary share equivalents consisted of stock options,
restricted stock awards, restricted stock units, and warrants. The dilutive effect of the stock options, restricted stock awards,
restricted stock units, and warrants is calculated using the treasury-stock method. Net-share settled warrants on the 2020 Notes
132
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
and 2021 Notes were anti-dilutive for the years ended December 25, 2016 and December 27, 2015. Net-share settled warrants
on the 2017 Notes were anti-dilutive for the year ended December 31, 2014.
We had outstanding options to purchase 10.4 million ordinary shares and 1.3 million restricted stock units at December 25,
2016, 9.9 million ordinary shares and 1.1 million restricted stock units at December 27, 2015, and 4.3 million ordinary shares
and 0.3 million restricted stock units and restricted stock awards at December 31, 2014. None of the options, restricted stock
units, or restricted stock awards were included in diluted earnings per share for the years ended December 25, 2016,
December 27, 2015, and December 31, 2014 because we recorded a net loss for al(cid:79)(cid:3) (cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)
instruments would be anti-dilutive.
The weighted-average number of ordinary shares outstanding for basic and diluted earnings per share purposes is as follows (in
thousands):
Weighted-average number of ordinary shares outstanding — basic1
Ordinary share equivalents
Weighted-average number of ordinary shares outstanding — diluted1
___________________________
1 During 2015, the 2014 balances were converted to meet post-merger valuations as described above.
December 25,
2016
102,968
—
102,968
Fiscal year ended
December 27,
2015
64,808
—
64,808
December 31,
2014
51,293
—
51,293
14.
Share-Based Compensation
We currently have two share-based compensation plans under which share-based awards may be granted - the Wright Medical
Group N.V. Amended and Restated 2010 Incentive Plan and the Wright Medical Group N.V. Amended and Restated Employee
Stock Purchase Plan, which are described below. In addition, we have several legacy Wright and legacy Tornier share-based
compensation plans and agreements under which stock options are outstanding, but no future share-based awards may be
granted.
Amounts recognized in the consolidated financial statements with respect to share-based compensation are as follows:
Total cost of share-based payment plans
Amounts capitalized into inventory
Amortization of capitalized amounts
Charged against income before income taxes
Amount of related income tax benefit recognized in income
Impact to net loss from continuing operations
Impact to net loss from discontinued operations
Impact to net loss
Impact to basic and diluted loss per share, continuing operations 1
Impact to basic and diluted loss per share 1
Weighted-average number of shares outstanding - basic and diluted 1
___________________________
1
$
December 25,
2016
14,406 $
(416)
426
14,416
—
$
$
$
$
14,416 $
—
14,416 $
0.14 $
0.14 $
Fiscal year ended
December 27,
2015
24,716 $
(51)
299
24,964
—
24,964 $
—
24,964 $
0.39 $
0.39 $
December 31,
2014
11,287
(66 )
266
11,487
—
11,487
8,845
20,332
0.22
0.40
51,293
102,968
64,808
The prior year balances were converted to meet post-merger valuations as described in Note 13.
As of December 25, 2016, we had $40.6 million of total unrecognized share-based compensation cost related to unvested share-
based compensation arrangements. This cost is expected to be recognized over a weighted-average period of 3.0 years.
On October 1, 2015, all stock options, restricted stock units and restricted stock awards outstanding as of the effective time of
the Wright/Tornier merger automatically vested, resulting in $14.2 million in share-based compensation expense. Upon this
acceleration, 1.3 million stock options vested with a weighted-average exercise price of $25.53 per share, and 0.3 million
restricted stock units and restricted stock awards vested with a weighted-average grant-date fair value of $26.30 per share.
133
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
During 2014, as part of the divestiture of our OrthoRecon business to MicroPort, we modified share-based compensation
awards held by employees assigned to MicroPort to accelerate vesting for unvested share-based compensation awards, as an
incentive to induce each employee to accept and continue employment with MicroPort, contingent upon the closing of the sale.
On January 12, 2014, all unvested share-based compensation awards held by these former 65 employees were vested, which
was comprised of approximately 0.5 million unvested options with a weighted-average exercise price of $22.50 per share and
0.3 million restricted stock awards. The incremental cost associated with the modified share-based compensation totaled $8.8
million, and was recognized as a reduction to our gain realized on the sale of the OrthoRecon business in the first quarter of
2014. There were no outstanding stock options held by these former employees as of December 31, 2014.
Equity Incentive Plans
The Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan (the 2010 Plan), which is an amended and restated
version of legacy Tornier’s Tornier N.V. Amended and Restated 2010 Incentive Plan, was approved by our shareholders on June
18, 2015 and became effective upon completion of the Wright/Tornier merger on October 1, 2015. The 2010 Plan authorizes us
to grant a wide variety of share-based and cash-based awards, including incentive and non-qualified options, stock appreciation
rights, stock grants, stock unit grants, cash-based awards, and other share-based awards. To date, only stock options and stock
grants in the form of restricted stock units (RSUs) have been granted. Both types of awards generally have graded vesting
periods of 3 or 4 years and the options expire 10 years after the grant date. Options are granted with exercise prices equal to the
fair market value of our ordinary shares on the date of grant.
The 2010 Plan reserves for issuance a number of ordinary shares equal to the sum of (i) the number of ordinary shares available
for grant under legacy Tornier’s prior stock option plan as of February 2, 2011 (not including issued or outstanding shares
(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:72)(cid:71)(cid:3)(cid:83)(cid:88)(cid:85)(cid:86)(cid:88)(cid:68)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:12)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12) the number of ordinary shares forfeited upon the expiration,
cancellation, forfeiture, cash settlement, or other termination following February 2, 2011 of an option outstanding as of
February 2, 2011 under legacy Tornier’(cid:86)(cid:3) (cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:3) (cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3) (cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:83)(cid:79)(cid:68)(cid:81)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3) (cid:27)(cid:15)(cid:21)(cid:19)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:3) (cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:17)(cid:3) (cid:3) (cid:36)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:39)(cid:72)(cid:70)(cid:72)(cid:80)(cid:69)(cid:72)(cid:85) 25, 2016,
1,233,923 ordinary shares remained available for grant under the 2010 Plan, and there were 7,813,930 ordinary shares covering
outstanding awards under such plan as of such date.
In addition to the legacy Tornier prior stock option plan mentioned above under which previously granted vested options
remained outstanding as of December 25, 2016, there are two legacy Wright share-based compensation plans and four non-plan
inducement option agreements under which previously granted vested options remained outstanding as of December 25, 2016,
including the Wright Medical Group, Inc. Second Amended and Restated 2009 Equity Incentive Plan (the Legacy Wright 2009
Plan) and the Wright Medical Group, Inc. Fifth Amended and Restated 1999 Equity Incentive Plan. All of these plans and
agreements were terminated with respect to future awards, and thus, no future share-based awards may be granted under any of
these legacy plans and agreements.
No stock options or other share-based awards were granted under legacy Wright’s share-based compensation plans during 2015
due to the pending Wright/Tornier merger. During 2014, legacy Wright granted 0.9 million stock options and 0.3 million
restricted stock awards and restricted stock units to employees under the Legacy Wright 2009 Plan. All of the options issued
under the Legacy Wright 2009 Plan expire after 10 years from the date of grant. All outstanding awards under the legacy
(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:86)(cid:3)(cid:68)(cid:88)(cid:87)(cid:82)(cid:80)(cid:68)(cid:87)(cid:76)(cid:70)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:89)(cid:72)(cid:86)(cid:87)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:50)(cid:70)(cid:87)(cid:82)(cid:69)(cid:72)(cid:85)(cid:3)(cid:20)(cid:15)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:3)(cid:68)(cid:86)(cid:3)(cid:68)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:81)(cid:82)(cid:3)(cid:85)(cid:72)(cid:86)(cid:87)(cid:85)(cid:76)cted
stock units or restricted stock awards outstanding at December 25, 2016 under these plans. However, there were 3,008,427
stock options outstanding as of December 25, 2016 under the legacy Wright plans.
Stock options
We estimate the fair value of stock options using the Black-Scholes valuation model. The Black-Scholes option-pricing model
requires the input of estimates, including the expected life of stock options, expected stock price volatility, the risk-free interest
rate and the expected dividend yield. Prior to the Wright/Tornier merger, the expected life of options was estimated based on
historical option exercise and employee termination data. Post merger, the expected life of options was estimated based on the
simplified method due to a lack of comparable, historical option exercise and employee termination data for the combined
company. The expected stock price volatility assumption was estimated based upon historical volatility of our ordinary shares
for both legacy Wright and legacy Tornier prior to October 1, 2015 and for the combined company after the Wright/Tornier
merger. The risk-free interest rate was determined using U.S. Treasury rates where the term is consistent with the expected life
of the stock options. Expected dividend yield is not considered as we have never paid dividends and have no plans of doing so
in the future. We are required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if
actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting forfeitures and record share-based
134
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
compensation expense only for those awards that are expected to vest. The fair value of stock options is amortized on a
straight-line basis over the respective requisite service period, which is generally the vesting period.
The weighted-average grant date fair value of stock options granted to employees in 2016, 2015, and 2014 was $7.36 per share,
$7.05 per share, and $9.98 per share, respectively. The fair value of each option grant is estimated on the date of grant using the
Black-Scholes option valuation model using the following assumptions:
Risk-free interest rate
Expected option life
Expected price volatility
A summary of our stock option activity during 2016 is as follows:
Outstanding at December 27, 2015
Granted
Exercised
Forfeited or expired
Outstanding at December 25, 2016
Exercisable at December 25, 2016
___________________________
*
December 25,
2016
Fiscal year ended
December 27,
2015
1.1% - 1.4% 1.4% - 1.6% 1.5% - 1.8%
6 years
33%
December 31,
2014
6 years
34%
6 years
31%
Shares
(000’s)
Weighted-
average
exercise
price
Weighted-
average
remaining
contractual life
Aggregate
intrinsic value*
($000’s)
8,950 $
1,870
(440)
(892)
9,488 $
5,948 $
21.66
21.16
19.23
21.38
21.70
22.18
7.0 $
5.7 $
22,235
13,698
The aggregate intrinsic value is calculated as the difference between the market value of our ordinary shares as of December 25, 2016
and the exercise price of the options. The market value as of December 25, 2016 was $23.31 per share, which is the closing sale price of
our ordinary shares on December 23, 2016, the last trading day prior to December 25, 2016, as reported by the NASDAQ Global Select
Market.
The total intrinsic value of options exercised during 2016, 2015, and 2014 was $2.1 million, $0.4 million, and $5.3 million,
respectively.
A summary of our stock options outstanding and exercisable at December 25, 2016 is as follows (shares in thousands):
Range of exercise prices
$2.00 — $16.00
$16.01 — $24.00
$24.01 — $35.87
Options outstanding
Weighted-
average
remaining
contractual life
Weighted-
average
exercise
price
Number
outstanding
Options exercisable
Number
exercisable
Weighted-
average
exercise
price
327
7,858
1,303
9,488
3.5 $
7.4
5.7
7.0 $
13.40
20.95
28.32
21.70
327 $
4,320
1,301
5,948 $
13.40
20.99
28.33
22.18
Restricted stock units and restricted stock awards
We calculate the grant date fair value of restricted stock units and restricted stock awards using the closing sale prices on the
trading day of the grant date. We are required to estimate forfeitures at the time of grant and revise those estimates in
subsequent periods if actual forfeitures differ from those estimates. We use historical data to estimate pre-vesting forfeitures
and record share-based compensation expense only for those awards that are expected to vest.
During 2016 and 2015, we granted 0.7 million and 1.1 million restricted stock units to employees with weighted-average grant-
date fair values of $21.17 and $20.60 per share, respectively. During 2014, we granted 0.3 million restricted stock units and
restricted stock awards to employees with a weighted-average grant-date fair value of $30.04. The fair value of the unvested
135
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
restricted stock units granted after completion of the Wright/Tornier merger will be recognized on a straight-line basis over the
respective requisite service period, which is generally the vesting period.
During 2016, we did not grant any restricted stock units to non-employees (other than non-employee directors who received
such grants in consideration of their director service). During 2015 and 2014, we granted a negligible amount of restricted
stock awards to non-employees.
A summary of our restricted stock unit activity during 2016 is as follows:
Shares
(000’s)
1,133 $
706
(298)
(206)
1,335 $
Weighted-
average
grant-date
fair value
Aggregate
intrinsic value*
($000’s)
20.63
21.17
20.63
20.70
20.91 $
31,112
Unvested at December 27, 2015
Granted
Vested
Forfeited
Unvested at December 25, 2016
___________________________
*
The aggregate intrinsic value is calculated as the market value of our ordinary shares as of December 25, 2016. The market value as of
December 25, 2016 was $23.31 per share, which is the closing sale price of our ordinary shares on December 23, 2016, the last trading
day prior to December 25, 2016, as reported by the NASDAQ Global Select Market.
The total fair value of shares vested during 2016, 2015, and 2014 was $7.0 million, $11.8 million, and $5.4 million,
respectively.
Inducement Stock Options
On occasion, legacy Wright granted stock options under an inducement stock option agreement, in order to induce candidates to
commence employment with legacy Wright as a member of the executive management team. These options vested over a
service period ranging from three to four years. All of the options issued under this agreement will expire after 10 years from
the date of grant.
A summary of our inducement grant stock option activity during 2016 is as follows:
Outstanding at December 27, 2015
Granted
Exercised
Forfeited or expired
Outstanding at December 25, 2016
Exercisable at December 25, 2016
___________________________
*
Shares
(000’s)
Weighted-
average
exercise
price
Weighted-
average
remaining
contractual life
Aggregate
intrinsic value*
($000’s)
917 $
—
—
—
917 $
917 $
16.69
—
—
—
16.69
16.69
5.0 $
5.0 $
6,071
6,071
The aggregate intrinsic value is calculated as the difference between the market value of ordinary shares as of December 25, 2016 and
the exercise price of the shares. The market value as of December 25, 2016 was $23.31 per share, which is the closing sale price of our
ordinary shares on December 23, 2016, the last trading day prior to December 25, 2016, as reported by the NASDAQ Global Select
Market.
136
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
A summary of our inducement grant stock options outstanding and exercisable at December 25, 2016, is as follows (shares in
thousands):
Range of exercise prices
$2.00 — $16.00
$16.01 — $35.87
Employee Stock Purchase Plan
Options outstanding
Weighted-
average
remaining
contractual life
Weighted-
average
exercise
price
Number
outstanding
Options exercisable
Number
exercisable
Weighted-
average
exercise
price
696
221
917
7.80 $
5.80
3.00 $
15.57
20.22
16.69
696 $
221
917 $
15.57
20.22
16.69
The Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan (the ESPP), which is an amended and
restated version of the Tornier N.V. 2010 Employee Stock Purchase Plan, was approved by our shareholders on June 28, 2016.
Under the ESPP, we are authorized to issue and sell up to the sum of (i) 333,333 ordinary shares registered previously under the
Tornier N.V. 2010 Employee Stock Purchase Plan and (ii) 216,227 additional ordinary shares approved under the ESPP. The
total of 550,000 ordinary shares are authorized to be issued to employees of our company and certain designated subsidiaries
who work at least 20 hours per week. Under the ESPP, there are two six-month plan periods during each calendar year, one
beginning January 1 and ending on June 30, and the other beginning July 1 and ending on December 31. However the
compensation committee of the board of directors determined that the first plan period would be the three months beginning
October 1, 2016 and ending December 31, 2016. Under the terms of the ESPP, each eligible employee can choose each
offering period to have up to 20% of his or her eligible earnings withheld to purchase up to 1,000 of our ordinary shares. The
purchase price of the shares is 85% of the market price on the first or last trading day of the offering period, whichever is lower.
As of December 25, 2016, there were 502,512 ordinary shares available for future issuance under the ESPP.
Under the ESPP, the first plan purchase occurred on December 31, 2016 during the 2017 fiscal year. During 2016, we accrued
a nominal amount of non-cash, share-based compensation expense related to the ESPP for the first plan purchase.
In applying the Black-Scholes methodology to purchase rights granted under the ESPP, we used the following assumptions:
Risk-free interest rate
Expected option life
Expected price volatility
Fiscal year
ended
December 25,
2016
1.2% - 1.3%
3 months
33%
Legacy Wright also had a similar employee stock purchase plan (the Legacy Wright ESPP), under which its employees could
choose each offering period to have up to 5% of his or her earnings, limited to $5,000, withheld to purchase WMG common
stock. The purchase price of the stock was 85% of the lower of its beginning-of-period or end-of-period market price. Legacy
Wright terminated the Legacy Wright ESPP after the completion of the second half of 2014 offering period due to the then
pending Wright/Tornier m(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3) (cid:68)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:39)(cid:72)(cid:70)(cid:72)(cid:80)(cid:69)(cid:72)(cid:85) 27, 2015, there were no shares available for future issuance
under the Legacy Wright ESPP.
Under the Legacy Wright ESPP, legacy Wright sold to employees approximately 22,000 shares of WMG common stock in 2014
with weighted-average fair value of $8.18 per share. During 2014, we recorded a nominal amount of non-cash, share-based
compensation expense related to the Legacy Wright ESPP.
137
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
In applying the Black-Scholes methodology to the purchase rights granted under the Legacy Wright ESPP, we used the
following assumptions:
Risk-free interest rate
Expected option life
Expected price volatility
15.
Retirement Benefit Plans
Fiscal year
ended
December 31,
2014
0.3% - 0.6%
6 months
31%
During the year ended December 25, 2016, we consolidated our retirement benefit plans into one defined contribution plan.
Prior to this change, we offered one plan sponsored by legacy Wright and another sponsored by legacy Tornier.
Our defined contribution plan under Section 401(k) of the Internal Revenue Code of 1986, as amended (Code), covers U.S.
employees who are 18 years of age and over. Under this plan, we have elected to make matching contributions to all eligible
participants in an amount equal to 100% of the first three percent of eligible compensation, and 50% of the next two percent of
eligible compensation, contributed to the Plan as deferral contributions. Employees are 100% vested in their rollover
contributions, employer nonelective contributions, employer matching contributions, qualified nonelective contributions,
deferral contributions, safe harbor matching employer contributions and any earnings thereon. The expense related to this plan
recognized within our results from continuing operations was $4.9 million in 2016.
Expense related to the Legacy Wright defined contribution plan recognized within our results from continuing operations was
$2.5 million in 2015 and $1.6 million in 2014.
Expense related to the Legacy Tornier qualified defined contribution plan recognized within our results from continuing
operations was $0.2 million in 2015.
16.
Commitments and Contingencies
Operating Leases
We lease certain equipment and office space under non-cancelable operating leases. Rental expense under operating leases
approximated $10.5 million, $8.6 million, and $7.1 million for the years ended December 25, 2016, December 27, 2015, and
December 31, 2014, respectively. Future minimum payments, by year and in the aggregate, under non-cancelable operating
leases with initial or remaining lease terms of one year or more, are as follows at December 25, 2016 (in thousands):
2017
2018
2019
2020
2021
Thereafter
$
$
9,740
7,823
5,596
4,106
3,528
8,295
39,088
Portions of our payments for operating leases are denominated in foreign currencies and were translated in the table above
based on their respective U.S. dollar exchange rates at December 25, 2016. These future payments are subject to foreign
currency exchange rate risk.
Purchase Obligations
We have entered into certain supply agreements for our products which include minimum purchase obligations. As of
December 25, 2016, we have minimum purchase obligations of $1.5 million and $3 million for 2017 and 2018, respectively.
138
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Legal Contingencies
The legal contingencies described in this footnote relate primarily to Wright Medical Technology, Inc. (WMT), an indirect
subsidiary of Wright Medical Group N.V., and are not necessarily applicable to Wright Medical Group N.V. or other affiliated
entities. Maintaining separate legal entities within our corporate structure is intended to ring-fence liabilities. We believe our
ring-fenced structure should preclude corporate veil-piercing efforts against entities whose assets are not associated with
particular claims.
As described below, our business is subject to various contingencies, including patent and other litigation, product liability
claims, and a government inquiry. These contingencies could result in losses, including damages, fines, or penalties, any of
which could be substantial, as well as criminal charges. Although such matters are inherently unpredictable, and negative
outcomes or verdicts can occur, we believe we have significant defenses in all of them, and are vigorously defending all of
them. However, we could incur judgments, pay settlements, or revise our expectations regarding the outcome of any matter.
Such developments, if any, could have a material adverse effect on our results of operations in the period in which applicable
amounts are accrued, or on our cash flows in the period in which amounts are paid, however, unless otherwise indicated, we do
not believe any of them will have a material adverse effect on our financial position.
Our legal contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss or the
measurement of a loss can be complex. We have accrued for losses that are both probable and reasonably estimable. Unless
otherwise indicated, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our
assessment process relies on estimates and assumptions that may prove to be incomplete or inaccurate. Unanticipated events
and circumstances may occur that could cause us to change our estimates and assumptions.
Governmental Inquiries
On August 3, 2012, we received a subpoena from the United States Attorney’s Office for the Western District of Tennessee
requesting records and documentation relating to our PROFEMUR® series of hip replacement devices. The subpoena covers
the period from January 1, 2000 to August 2, 2012. We continue to cooperate with the investigation.
Patent Litigation
In June 2013, Anglefix, LLC filed suit in the United States District Court for the Western District of Tennessee, alleging that
our ORTHOLOC® products infringe Anglefix’s asserted patent. On April 14, 2014, we filed a request for Inter Partes Review
(IPR) with the U.S. Patent and Trademark Office. In October 2014, the Court stayed the case pending outcome of the IPR. On
June 30, 2015, the Patent Office Board entered judgment in our favor as to all patent claims at issue in the IPR. Following the
conclusion of the IPR, the District Court lifted the stay, and we have been continuing with our defense as to remaining patent
claims asserted by Anglefix. On June 27, 2016, the Court granted in part our motion for summary judgment on Anglefix’s lack
of standing and gave Anglefix 30 days to join the University of North Carolina (UNC) as a co-plaintiff in the lawsuit. On July
25, 2016, Anglefix filed a motion asking the Court to accept a waiver of claims by UNC as a substitute for joining UNC as a co-
plaintiff in the lawsuit. The Court denied Anglefix’s motion, but granted leave for additional time to properly join UNC as co-
plaintiff. Anglefix moved to add UNC as co-plaintiff on September 15, 2016. We opposed the motion and, on November 15,
2016, the Court allowed the motion, and subsequently directed Anglefix and UNC to file an amended complaint by January 18,
2017. We have filed motions for summary judgment of non-infringement and invalidity of the remaining patent claims asserted
by Anglefix and a motion to exclude testimony by Anglefix’s technical expert. Anglefix has filed a motion for summary
judgment of infringement of certain of the remaining asserted patent claims. The Court heard oral argument on those motions
on January 31, 2017.
On September 23, 2014, Spineology filed a patent infringement lawsuit, Case No. 0:14-cv-03767, in the U.S. District Court in
Minnesota, alleging that our X-REAM® bone reamer infringes U.S. Patent No. RE42,757 entitled “EXPANDABLE
REAMER.” In January 2015, on the deadline for service of its complaint, Spineology dismissed its complaint without
prejudice and filed a new, identical complaint. We filed an answer to the new complaint with the Court on April 27, 2015. The
Court conducted a Markman hearing on March 23, 2016. Mediation was held on August 11, 2016, but no agreement could be
reached. The Court issued a Markman decision on August 30, 2016, in which it found all asserted product claims invalid as
indefinite under applicable patent laws and construed several additional claim terms. The parties have completed fact and
expert discovery with respect to the remaining asserted method claims. We have filed a motion for summary judgment of non-
infringement of the remaining asserted patent claims and motions to exclude testimony from Spineology’s technical and
139
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
damages experts. Spineology has filed a motion for summary judgment of infringement. The Court will hear oral argument on
those motions on February 28, 2017.
On September 13, 2016, we filed a civil action, Case No. 2:16-cv-02737-JPM, against Spineology in the U.S. District Court for
the Western District of Tennessee alleging breach of contract, breach of implied warranty against infringement, and seeking a
judicial declaration of indemnification from Spineology for patent infringement claims brought against us stemming from our
sale and/or use of certain expandable reamers purchased from Spineology. Spineology filed a motion to dismiss on October 17,
2016, but withdrew the motion on November 28, 2016. On December 7, 2016, Spineology filed an answer to our complaint
and counterclaims, including counterclaims relating to a 2004 non-disclosure agreement between Spineology and WMT. On
December 28, 2016, we filed a motion to dismiss the counterclaims relating to that 2004 agreement. On January 4, 2017,
Spineology filed a motion for summary judgment on certain claims set forth in our complaint. We intend to oppose this motion.
On March 1, 2016, Musculoskeletal Transplant Foundation (MTF) filed suit against Solana and WMT in the United States
District Court for the District of New Jersey alleging that the TenFUSE PIP product infringes U.S. Patent No. 6,432,436 entitled
“Partially Demineralized Cortical Bone Constructs.” On May 25, 2016, we agreed to waive service of MTF’s complaint.
Following a series of court-ordered extensions of time, we filed our answer to MTF’s complaint and counterclaims on
December 5, 2016. We have reached a settlement in principle with MTF for an immaterial amount, which is in the process of
being documented.
Subject to the provisions of the asset purchase agreement with MicroPort for the sale of the OrthoRecon business, we, as
between us and MicroPort, would continue to be responsible for defense of pre-existing patent infringement cases relating to
the OrthoRecon business, and for resulting liabilities, if any. All such pre-existing cases have been resolved.
Product Liability
We have received claims for personal injury against us associated with fractures of our PROFEMUR® long titanium modular
neck product (PROFEMUR® Claims). As of December 25, 2016, there were 26 pending U.S. lawsuits and 48 pending non-
U.S. lawsuits alleging such claims. The overall fracture rate for the product is low and the fractures appear, at least in part, to
relate to patient demographics. Beginning in 2009, we began offering a cobalt-chrome version of our PROFEMUR® modular
neck, which has greater strength characteristics than the alternative titanium version. Historically, we have reflected our
liability for these claims as part of our standard product liability accruals on a case-by-case basis. However, during the quarter
ended September 30, 2011, as a result of an increase in the number and monetary amount of these claims, management
estimated our liability to patients in North America who have previously required a revision following a fracture of a
PROFEMUR® long titanium modular neck, or who may require a revision in the future. Management has estimated that this
aggregate liability ranges from approximately $21.9 million to $25.9 million. Any claims associated with this product outside
of North America, or for any other products, will be managed as part of our standard product liability accrual methodology on a
case-by-case basis.
Due to the uncertainty within our aggregate range of loss resulting from the estimation of the number of claims and related
monetary payments, we have recorded a liability of $21.9 million, which represents the low-end of our estimated aggregate
range of loss. We have classified $14.2 million of this liability as current in “Accrued expenses and other current liabilities,” as
we expect to pay such claims within the next twelve months, and $7.7 million as non-current in “Other liabilities” on our
consolidated balance sheet. We expect to pay the majority of these claims within the next three years.
We are aware that MicroPort has recalled certain sizes of its cobalt chrome modular neck products as a result of alleged
fractures. As of December 25, 2016, there were three pending U.S. lawsuits and five pending non-U.S. lawsuits against us
alleging personal injury resulting from the fracture of a cobalt chrome modular neck. These claims will be managed as part of
our standard product liability accrual methodology on a case-by-case basis.
We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended March 31, 2013,
we received a customary reservation of rights from our primary product liability insurance carrier asserting that present and
future claims related to fractures of our PROFEMUR® titanium modular neck hip products and which allege certain types of
injury (Titanium Modular Neck Claims) would be covered as a single occurrence under the policy year the first such claim was
asserted. The effect of this coverage position would be to place Titanium Modular Neck Claims into a single prior policy year
in which applicable claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees
with the assertion that the Titanium Modular Neck Claims should be treated as a single occurrence, but notified the carrier that
it disputed the carrier’s selection of available policy years. During the second quarter of 2013, we received confirmation from
140
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
the primary carrier confirming their agreement with our policy year determination. Based on our insurer’s treatment of
Titanium Modular Neck Claims as a single occurrence, we increased our estimate of the total probable insurance recovery
related to Titanium Modular Neck Claims by $19.4 million, and recognized such additional recovery as a reduction to our
selling, general and administrative expenses for the three months ended March 31, 2013, within results of discontinued
operations. In the quarter ended June 30, 2013, we received payment from the primary insurance carrier of $5 million. In the
quarter ended September 30, 2013, we received payment of $10 million from the next insurance carrier in the tower. We have
requested, but not yet received, payment of the remaining $25 million from the third insurance carrier in the tower for that
policy period. The policies with the second and third carrier in this tower are “follow form” policies and management believes
the third carrier should follow the coverage position taken by the primary and secondary carriers. On September 29, 2015, that
third carrier asserted that the terms and conditions identified in its reservation of rights will preclude coverage for the Titanium
Modular Neck Claims. We strongly dispute the carrier’s position and, in accordance with the dispute resolution provisions of
the policy, have initiated an arbitration proceeding in London, England seeking payment of these funds. Pursuant to applicable
accounting standards, we reduced our insurance receivable balance for this claim to $0, and recorded a $25 million charge
within “Net loss from discontinued operations” during the year ended December 27, 2015. The arbitration proceeding is
ongoing.
Claims for personal injury have also been made against us associated with our metal-on-metal hip products (primarily our
CONSERVE® product line). The pre-trial management of certain of these claims has been consolidated in the federal court
system, in the United States District Court for the Northern District of Georgia under multi-district litigation (MDL) and certain
other claims by the Judicial Counsel Coordinated Proceedings (JCCP) in state court in Los Angeles County, California
(collectively the Consolidated Metal-on-Metal Claims).
As of December 25, 2016, there were approximately 1,200 lawsuits pending in the MDL and JCCP, and an additional 30 cases
pending in various state courts. As of that date, we have also entered into approximately 950 so called “tolling agreements”
with potential claimants who have not yet filed suit. Based on presently available information, we believe at least 350 of these
lawsuits allege claims involving bilateral implants. As of December 25, 2016, there were also approximately 50 non-U.S.
lawsuits pending. We believe we have data that supports the efficacy and safety of our metal-on-metal hip products. While
continuing to dispute liability, we have participated in court supervised non-binding mediation in the MDL and expect to begin
similar mediation in the JCCP.
Every metal-on-metal hip case involves fundamental issues of law, science and medicine that often are uncertain, that continue
to evolve, and which present contested facts and issues that can differ significantly from case to case. Such contested facts and
issues include medical causation, individual patient characteristics, surgery specific factors, statutes of limitation, and the
existence of actual, provable injury.
The first bellwether trial in the MDL commenced on November 9, 2015 in Atlanta, Georgia. On November 24, 2015, the jury
returned a verdict in favor of the plaintiff and awarded the plaintiff $1 million in compensatory damages and $10 million in
punitive damages. We believe there were significant trial irregularities and vigorously contested the trial result. On December
28, 2015, we filed a post-trial motion for judgment as a matter of law or, in the alternative, for a new trial or a reduction of
damages awarded. On April 5, 2016, the trial judge issued an order reducing the punitive damage award from $10 million to
$1.1 million, but otherwise denied our motion. On May 4, 2016, we filed a notice of appeal with the United States Court of
Appeals for the Eleventh Circuit. The United States Court of Appeals for the Eleventh Circuit heard oral arguments on January
26, 2017 and we are awaiting a decision of the Court. In light of the trial judge’s April 5th order, we recorded an accrual for this
verdict in the amount of $2.1 million within “Accrued expenses and other current liabilities.”
The first bellwether trial in the JCCP, which was scheduled to commence on October 31, 2016, and subsequently rescheduled to
January 9, 2017, was settled for an immaterial amount.
The first state court metal-on-metal hip trial not part of the MDL or JCCP commenced on October 24, 2016, in St. Louis,
Missouri. On November 3, 2016, the jury returned a verdict in our favor. The plaintiff has appealed.
On November 1, 2016, WMT entered into a Master Settlement Agreement (MSA) with Court-appointed attorneys representing
plaintiffs in the MDL and JCCP. Under the terms of the MSA, the parties agreed to settle 1,292 specifically identified claims
associated with CONSERVE®, DYNASTY® and LINEAGE® products that meet the eligibility requirements of the MSA and
are either pending in the MDL or JCCP, or subject to court-approved tolling agreements in the MDL or JCCP, for a settlement
amount of $240 million.
141
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
The $240 million settlement amount is a maximum settlement based on the pool of 1,292 specific, existing claims comprised of
an identified mix of CONSERVE®, DYNASTY® and LINEAGE® products (Initial Settlement Pool), with a value assigned to
each product type, resulting in a total settlement of $240 million for the 1,292 claims in the Initial Settlement Pool. The actual
settlement may be less, depending on several factors including the mix of products and claimants in the final settlement pool
(Final Settlement Pool) and the number of claimants electing to “opt-out” of the settlement.
Actual settlements paid to individual claimants will be determined under the claims administration procedures contained in the
MSA and may be more or less than the amounts used to calculate the $240 million settlement for the 1,292 claims in the Initial
Settlement Pool. However in no event will variations in actual settlement amounts payable to individual claimants affect
WMT’s maximum settlement obligation of $240 million or the manner in which it may be reduced due to opt outs, final
product mix, or elimination of ineligible claims.
If it is determined a claim in the Initial Settlement Pool is ineligible due to failure to meet the eligibility criteria of the MSA,
such claim will be removed and, where possible, replaced with a new eligible claim involving the same product, with the goal
of having the number and mix of claims in the Final Settlement Pool (before opt-outs) equal, as nearly as possible, the number
and mix of claims in the Initial Settlement Pool. Additionally, if any DYNASTY® or LINEAGE® claims in the Final Settlement
Pool are determined to have been misidentified as CONSERVE® claims, or vice versa, the total settlement amount will be
adjusted based on the value for each product type (not to exceed $240 million).
The MSA contains specific eligibility requirements and establishes procedures for proof and administration of claims,
negotiation and execution of individual settlement agreements, determination of the final total settlement amount, and funding
of individual settlement amounts by WMT. Eligibility requirements include, without limitation, that the claimant has a claim
pending or tolled in the MDL or JCCP, that the claimant has undergone a revision surgery within eight years of the original
implantation surgery, and that the claim has not been identified by WMT as having possible statute of limitation issues.
Claimants who have had bilateral revision surgeries will be counted as two claims but only to the extent both claims separately
satisfy all eligibility criteria.
The MSA includes a 95% opt-in requirement, meaning the MSA may be terminated by WMT prior to any settlement
disbursement if claimants holding greater than 5% of eligible claims in the Final Settlement Pool elect to “opt-out” of the
settlement. WMT, in its sole discretion, may waive this 95% opt-in requirement. No funding of any individual plaintiff
settlement will occur until the 95% opt-in requirement has been satisfied or waived.
WMT has been notified pursuant to the MSA that greater than 95% of eligible claimants timely elected to opt-in to the MSA
settlement prior to the opt-in deadline. Accordingly, the 95% minimum opt-in rate appears to have been satisfied, subject to
WMT’s audit rights under the MSA.
WMT has escrowed $150 million to secure its obligations under the MSA. As additional security, Wright Medical Group N.V.,
the indirect parent company of WMT, agreed to guaranty WMT’s obligations under the MSA.
The MSA was entered into solely as a compromise of the disputed claims being settled and is not evidence that any claim has
merit nor is it an admission of wrongdoing or liability by WMT. WMT will continue to vigorously defend metal-on-metal hip
claims not settled pursuant to the MSA. As of December 25, 2016, we estimate there were approximately 630 outstanding
metal-on-metal hip revision claims that would not be included in the MSA settlement, including approximately 200 claims with
an implant duration of more than eight years, approximately 300 claims subject to possible statute of limitations preclusion,
approximately 30 claims pending in U.S courts other than the MDL and JCCP, approximately 50 claims pending in non-U.S.
courts, and approximately 50 claims that would be eligible for inclusion in the settlement but for the participation limitations
contained in the MSA. We also estimate that there were approximately 650 outstanding metal-on-metal hip non-revision claims
as of December 25, 2016. These non-revision cases are excluded from the MSA.
As of December 25, 2016, our accrual for metal-on-metal claims totaled $256.6 million, of which $242.7 million is included in
our consolidated balance sheet within “Accrued expenses and other current liabilities” and $13.9 million is included within
“Other liabilities.” Our accrual is based on (i) case by case accruals for specific cases where facts and circumstances warrant,
including the $2.1 million accrual associated with the MDL bellwether verdict, and (ii) the implied settlement values for
eligible claims under the MSA (assuming, in the absence of opt-in data, a 100% opt-in rate). We are unable to reasonably
estimate the high-end of a possible range of loss for claims which may in the future elect to opt-out of the MSA settlement.
Claims we can confirm would meet MSA eligibility criteria but are excluded from settlement due to the $240 million maximum
settlement cap, or because they are state cases not part of the MDL or JCCP, have been accrued as though included in the
142
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
settlement. Due to the general uncertainties surrounding all metal-on metal claims as noted above, as well as insufficient
information about individual claims, we are presently unable to reasonably estimate a range of loss for revision claims that
(i) (cid:71)(cid:82)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:80)(cid:72)(cid:72)(cid:87)(cid:3)(cid:48)(cid:54)(cid:36)(cid:3)(cid:72)(cid:79)(cid:76)(cid:74)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:70)(cid:85)(cid:76)(cid:87)(cid:72)(cid:85)(cid:76)(cid:68)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:73)(cid:88)(cid:87)(cid:88)(cid:85)(cid:72)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3)(cid:75)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:90)(cid:72)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:3)(cid:68)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:76)me.
However, we believe the high-end of a possible range of loss for existing revision claims that do not meet MSA eligibility
criteria will not, on an average per case basis, exceed the average per case accrual we have taken for revision claims we can
confirm do meet MSA eligibility criteria. Future claims will be evaluated for accrual on a case by case basis using the accrual
methodologies described above (which could change if future facts and circumstances warrant).
We have maintained product liability insurance coverage on a claims-made basis. During the quarter ended September 30,
2012, we received a customary reservation of rights from our primary product liability insurance carrier asserting that certain
present and future claims which allege certain types of injury related to our CONSERVE® metal-on-metal hip products
(CONSERVE® Claims) would be covered as a single occurrence under the policy year the first such claim was asserted. The
effect of this coverage position would be to place CONSERVE® Claims into a single prior policy year in which applicable
claims-made coverage was available, subject to the overall policy limits then in effect. Management agrees that there is
insurance coverage for the CONSERVE® Claims, but has notified the carrier that it disputes the carrier’s characterization of the
CONSERVE® Claims as a single occurrence.
In June 2014, St. Paul Surplus Lines Insurance Company (Travelers), which was an excess carrier in our coverage towers across
multiple policy years, filed a declaratory judgment action in Tennessee state court naming us and certain of our other insurance
carriers as defendants and asking the court to rule on the rights and responsibilities of the parties with regard to the
CONSERVE® Claims. Among other things, Travelers appeared to dispute our contention that the CONSERVE® Claims arise
out of more than a single occurrence thereby triggering multiple policy periods of coverage. Travelers further sought a
determination as to the applicable policy period triggered by the alleged single occurrence. We filed a separate lawsuit in state
court in California for declaratory judgment against certain carriers and breach of contract against the primary carrier, and
moved to dismiss or stay the Tennessee action on a number of grounds, including that California is the most appropriate
jurisdiction. During the third quarter of 2014, the California Court granted Travelers’ motion to stay our California action. On
April 29, 2016, we filed a dispositive motion seeking partial judgment in our favor in the Tennessee action. That motion is
pending, and will be decided after the parties complete discovery regarding certain issues relating to the pending motion. On
June 10, 2016, Travelers withdrew its motion for summary judgment in the Tennessee action. One of the other insurance
companies in the Tennessee action has stated that it will re-file a similar motion in the future.
On October 28, 2016, WMT and Wright Medical Group, Inc. (Wright Entities), entered into a Settlement Agreement, Indemnity
and Hold Harmless Agreement and Policy Buyback Agreement (Insurance Settlement Agreement) with a subgroup of three
insurance carriers, namely Columbia Casualty Company, Travelers and AXIS Surplus Lines Insurance Company (collectively,
the Three Settling Insurers), pursuant to which the Three Settling Insurers agreed to pay WMT an aggregate of $60 million (in
addition to $10 million previously paid by Columbia) in a lump sum on or before the 30th business day after execution of the
Insurance Settlement Agreement. This amount is in full satisfaction of all potential liability of the Three Settling Insurers
relating to metal-on-metal hip and similar metal ion release claims, including but not limited to all claims in the MDL and the
JCCP, and all claims asserted by WMT against the Three Settling Insurers in the Tennessee action described above.
On December 13, 2016, we filed a motion in the Tennessee action described above to include allegations of bad faith against
the primary insurance carrier. The motion was subsequently amended on February 8, 2017 to add similar bad faith claims
against the remaining excess carriers. That motion is pending.
As part of the settlement, the Three Settling Insurers bought back from WMT their policies in the five policy years beginning
with the August 15, 2007- August 15, 2008 policy year (Repurchased Policy Years). Consequently, the Wright Entities have no
further coverage from the Three Settling Insurers for any present or future claims falling in the Repurchased Policy Years, or
any other period in which a released claim is asserted. Additionally, the Insurance Settlement Agreement contains a so-called
most favored nation provision which could require us to refund a pro rata portion of the settlement amount if we voluntarily
enter into a settlement with the remaining carriers in the Repurchased Policy Years on certain terms more favorable than
analogous terms in the Insurance Settlement Agreement. The Tennessee action will continue as to the remaining defendant
insurers other than the Three Settling Insurers. The amount due to the Wright Entities under the Insurance Settlement
Agreement was paid in the fourth quarter of 2016.
Management has recorded an insurance receivable of $8.7 million for the probable recovery of spending from the remaining
carriers (other than the Three Settling Carriers) in excess of our retention for a single occurrence. As of December 25, 2016 we
have received $71.7 million of insurance proceeds, and our insurance carriers have paid a total of $4.6 million directly to
143
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
claimants in connection with various settlements, which represents amounts undisputed by the carriers. Our acceptance of these
proceeds was not a waiver of any other claim we may have against the insurance carriers. However, the amount we ultimately
receive will depend on the outcome of our dispute with the remaining carriers (other than the Three Settling Carriers)
concerning the number of policy years available. We believe our contracts with the insurance carriers are enforceable for these
(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:69)(cid:72)(cid:79)(cid:76)(cid:72)(cid:89)(cid:72)(cid:3)(cid:76)(cid:87)(cid:3)(cid:76)(cid:86)(cid:3)(cid:83)(cid:85)(cid:82)(cid:69)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3) (cid:90)(cid:72)(cid:3) (cid:90)(cid:76)(cid:79)(cid:79)(cid:3)(cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:85)(cid:72)(cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:76)(cid:72)(cid:86)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:80)(cid:68)(cid:76)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:68)(cid:85)(cid:85)(cid:76)(cid:72)(cid:85)(cid:86)(cid:17)(cid:3)(cid:54)(cid:72)(cid:87)(cid:87)(cid:79)(cid:72)(cid:80)(cid:72)nt
discussions with the remaining insurance carriers continue.
Given the substantial or indeterminate amounts sought in these matters, and the inherent unpredictability of such matters, an
adverse outcome in these matters in excess of the amounts included in our accrual for contingencies could have a material
adverse effect on our financial condition, results of operations and cash flow. Future revisions to our estimates of these
provisions could materially impact our results of operations and financial position. We use the best information available to
determine the level of accrued product liabilities, and believe our accruals are adequate.
In June 2015, a jury returned a $4.4 million verdict against us in a case involving a fractured hip implant stem sold prior to the
MicroPort closing. This was a one-of-a-kind case unrelated to the modular neck fracture cases we have been reporting. There
are no other cases pending related to this component, nor are we aware of other instances where this component has fractured.
In September 2015, the trial judge reduced the jury verdict to $1.025 million and indicated that if the plaintiff did not accept the
reduced award he would schedule a new trial solely on the issue of damages. The plaintiff elected not to accept the reduced
damage award, and both parties have appealed. The Court has not set a date for a new trial on the issue of damages and we do
not expect it will do so until the appeals are adjudicated. We will maintain our current $4.4 million accrual as a probable
liability until the matter is resolved. The $4.4 million probable liability associated with this matter is reflected within “Accrued
expenses and other current liabilities,” and a $4 million receivable associated with the probable recovery from product liability
insurance is reflected within “Other current assets.”
Other
In addition to those noted above, we are subject to various other legal proceedings, product liability claims, corporate
governance, and other matters which arise in the ordinary course of business.
17.
Restricted Cash
During the fourth quarter of 2016, WMT deposited $150.0 million into a restricted escrow account to secure its obligations
under the MSA that WMT entered into in connection with the metal-on-metal hip litigation, as further described in Note 16 to
the consolidated financial statements. All individual settlements under the MSA will be funded first from the escrow account
and then, if all funds held in the escrow account have been exhausted, directly by WMT. The claims administrator has not
provided a funding request to WMT as of the date of the filing of this report. Funding requests may be submitted on the 15th
and last day of each month, beginning March 31, 2017. Within 30 days of each funding request, unless WMT in good faith
objects to the accuracy of any payment request, WMT will instruct the escrow agent to transfer funds from the restricted escrow
account to a master account designated by plaintiffs’ counsel, who will then arrange for disbursements of individual settlement
amounts. As of December 25, 2016, $150.0 million was in the restricted escrow account, and therefore, considered restricted
cash under US GAAP. See Note 16 to the consolidated financial statements for further discussion regarding the MSA and the
metal-on-metal hip litigation.
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within our consolidated
balance sheets that sum to the totals of the same such amounts shown in the consolidated statements of cash flows (in
thousands):
Cash and cash equivalents
Restricted cash
Total cash, cash equivalents, and restricted cash shown in the consolidated
statements of cash flows
December 25, 2016
December 27, 2015
$
$
262,265 $
150,000
412,265
$
139,804
—
139,804
144
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
18.
Certain Relationships and Related-Party Transactions
The related party disclosures in this note relate to transactions with a former director of legacy Tornier, Alain Tornier.
Mr. Tornier departed from our board of directors effective October 1, 2015 in connection with the closing of the Wright/Tornier
merger. Accordingly, the indebtedness and lease agreements described below are not related party transactions during 2016.
On July 29, 2008, Tornier SAS, a subsidiary of legacy Tornier, formed a real estate holding company (SCI Calyx) together with
Alain Tornier, a former director of legacy Tornier (Mr. Tornier). SCI Calyx is owned 51% by Tornier SAS and 49% by
Mr. Tornier. SCI Calyx was initially capitalized by a contribution of capital of €10,000 funded 51% by Tornier SAS and 49% by
Mr. Tornier. SCI Calyx then acquired a combined manufacturing and office facility in Montbonnot, France, for approximately
$6.1 million. The manufacturing and office facility acquired was to be used to support the manufacture of certain of legacy
Tornier’s current products and house certain operations already located in Montbonnot, France. This real estate purchase was
funded through mortgage borrowings of $4.1 million and $2.0 million cash borrowed from the two current shareholders of SCI
Calyx. The $2.0 million cash borrowed from the SCI Calyx shareholders originally consisted of a $1.0 million note due to
Mr. Tornier and a $1.0 million note due to Tornier SAS. Both of the notes issued by SCI Calyx bear annual interest at the three-
month Euro Libor rate plus 0.5% and have no stated term. During 2010, SCI Calyx borrowed approximately $1.4 million from
Mr. Tornier in order to fund on-going leasehold improvements necessary to prepare the Montbonnot facility for its intended use.
This cash was borrowed under the same terms as the original notes. On September 3, 2008, Tornier SAS entered into a lease
agreement with SCI Calyx relating to these facilities. The agreement, which terminates in 2018, provides for an annual rent
payment of €440,000, which has subsequently been increased and is currently €965,655 annually. Annual lease payments to
SCI Calyx amounted to $2.2 million during the year ended December 27, 2015, $0.6 million of which is reflected in our
consolidated financial statements in light of the timing of the Wright/Tornier merger. As of December 27, 2015, future
minimum payments under this lease were $12.3 million in the aggregate. As of December 27, 2015, SCI Calyx had related-
party debt outstanding to Mr. Tornier of $2.0 million. The SCI Calyx entity is consolidated by us, and the related real estate and
liabilities are included on our consolidated balance sheets.
Since 2006, Tornier SAS has entered into various lease agreements with entities affiliated with Mr. Tornier or members of his
family. On December 29, 2007, Tornier SAS entered into a lease agreement with Animus SCI, relating to our facilities in
Montbonnot Saint Martin, France. On August 18, 2012, the parties amended the lease agreement to extend the term until May
31, 2022 and reduce the annual rent. The amended agreement provides for an initial annual rent payment of €279,506, which
was subsequently increased to €296,861. Animus SCI is wholly owned by Mr. Tornier. On February 6, 2008, Tornier SAS
entered into a lease agreement with Balux SCI, effective as of May 22, 2006, relating to our facilities in Montbonnot Saint
Martin, France. On August 18, 2012, the parties amended the lease agreement to extend the term until May 31, 2022 and
reduce the annual rent. The amended agreement provides for an initial annual rent payment of €252,254, which was
subsequently increased to €564,229. Balux SCI is wholly-owned by Mr. Tornier and his sister, Colette Tornier.
145
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
19.
Quarterly Results of Operations (unaudited):
The following table presents a summary of our unaudited quarterly operating results for each of the four quarters in 2016 and
2015, respectively (in thousands). This information was derived from unaudited interim financial statements that, in the opinion
of management, have been prepared on a basis consistent with the financial statements contained elsewhere in this report and
include all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of such information
when read in conjunction with our audited financial statements and related notes. The operating results for any quarter are not
necessarily indicative of results for any future period.
Net sales
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Amortization of intangible assets
Total operating expenses
Operating loss
Net loss from continuing operations, net of tax
Loss from discontinued operations, net of tax
Net loss
Net loss, continuing operations per share, basic and diluted
Net loss per share, basic and diluted
Weighted-average number of shares outstanding-basic and
diluted
2016
First
quarter 1
$
169,291 $
46,666
122,625
Second
quarter
170,716 $
49,009
121,707
Third
quarter
157,332 $
46,149
111,183
Fourth
quarter
193,023
50,583
142,440
134,746
12,116
6,457
153,319
(30,694) $
(40,193) $
(7,799) $
(47,992) $
(0.39) $
(0.47) $
136,483
12,108
7,484
156,075
(34,368) $
(42,031) $
(187,329) $
(229,360) $
(0.41) $
(2.23) $
129,840
12,481
7,466
149,787
(38,604) $
(52,709) $
(57,436) $
(110,145) $
(0.51) $
(1.07) $
140,489
13,809
7,434
161,732
(19,292 )
(30,002 )
(14,874 )
(44,876 )
(0.29 )
(0.43 )
$
$
$
$
$
$
102,704
102,785
103,072
103,309
___________________________
1 Our first quarter 2016 results were restated for the divestiture of our Large Joints business.
Our 2016 operating loss included the following:
•
•
•
•
•
•
transaction and transition costs totaling $10.8 million, $7.1 million, $6.5 million, and $7.9 million during the first,
(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
amortization of inventory step-up of $10.2 million, $10.4 million, $10.3 million, and $6.8 million in the first,
second, third, and fourth quarters of 2016, respectively, associated with inventory acquired from the
(cid:58)(cid:85)(cid:76)(cid:74)(cid:75)(cid:87)(cid:18)(cid:55)(cid:82)(cid:85)(cid:81)(cid:76)(cid:72)(cid:85)(cid:3)(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)
non-cash inventory provisions associated with a product rationalization initiative totaling $2.0 million,
$1.6 (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:7)(cid:19)(cid:17)(cid:24)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)
(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:80)(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:7)(cid:20)(cid:17)(cid:22)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:30)
costs related to a legal settlement of $1.8 million (cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
costs associated with debt refinancing of $0.2 million in the second quarter of 2016.
Our 2016 net loss from continuing operations included the following:
•
•
•
•
the after-(cid:87)(cid:68)(cid:91)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:69)(cid:82)(cid:89)(cid:72)(cid:3)(cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:30)
the after-tax effects of our CVR mark-to-market adjustments of $5.3 million unrealized loss, $1.4 million
unrealized loss, $2.2 million unrealized loss, and $0.3 million unrealized gain recognized in the first, second,
(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
the after-tax effects of $12.3 million non-cash loss on extinguishment of debt to write-off unamortized debt
discount and deferred financing fees associated with the partial settlement of 2017 Notes and 2020 Notes in the
(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:30)
the after-tax effects of non-cash interest expense related to the amortization of the debt discount on our 2017
Notes, 2020 Notes and 2021 Notes totaling $7.1 million, $8.2 million, $10.5 million, and $10.8 million during the
first, second, third, and fourth quarters of 2016(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
146
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
•
•
•
•
the after-tax effects of our mark-to-market adjustments on derivative assets and liabilities totaling a $6.6 million
gain, $16.6 million gain, $3.2 million gain, and $1.8 million gain recognized in the first, second, third, and fourth
quar(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)
the after-tax effects of charges due to the fair value adjustment to contingent consideration totaled $0.3 million,
$0.1 (cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:7)(cid:19)(cid:17)(cid:20)(cid:3)(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)
the after-tax effects of a $3.1 million interest and income tax benefit related to the settlement of an IRS audit in
(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
a $5.6 million income tax benefit representing the deferred tax effects associated with the acquired Tornier
operations in the fourth quarter of 2016.
Net sales
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Amortization of intangible assets
Total operating expenses
Operating loss
Net loss, continuing operations, net of tax
Net loss, discontinued operations, net of tax
Net loss
Net loss, continuing operations per share, basic and diluted 1
Net loss per share, basic and diluted 1
Weighted-average number of shares outstanding-basic and
diluted 1
2015
First
quarter
Second
quarter
Third
quarter
Fourth
quarter 2
77,934 $
19,125
58,809
80,420 $
21,635
58,785
80,139 $
23,052
57,087
166,833
49,810
117,023
82,199
7,117
2,614
91,930
(33,121) $
(46,248) $
(3,500) $
(49,748) $
(0.88) $
(0.95) $
82,605
7,957
2,565
93,127
(34,342) $
(37,306) $
(7,009) $
(44,315) $
(0.71) $
(0.84) $
85,997
9,570
2,562
98,129
(41,042) $
(62,650) $
(36,211) $
(98,861) $
(1.19) $
(1.87) $
173,576
14,695
9,013
197,284
(80,261 )
(91,152 )
(14,624 )
(105,776 )
(0.89 )
(1.03 )
52,437
52,631
52,750
102,659
$
$
$
$
$
$
$
___________________________
1 During 2015, we restated the first, second, and third quarter balances to meet post-merger valuations as described within Note 13.
2 Our fourth quarter 2015 results of operations include results of the legacy Tornier business, effective upon October 1, 2015, the closing
date of the Wright/Tornier merger, and have been restated for the divestiture of our Large Joints business.
Our 2015 operating loss included the following:
•
•
•
transaction and transition costs totaling $11.0 million, $12.1 million, $19.9 million, and $39.2 million during the
(cid:73)(cid:76)(cid:85)(cid:86)(cid:87)(cid:15)(cid:3)(cid:86)(cid:72)(cid:70)(cid:82)(cid:81)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
non-cash share-based compensation expense of $14.2 million in the fourth quarter of 2015 associated with the
accelerated vesting of legacy Wright’s unvested awards outstanding upon the closing of the Wright/Tornier
(cid:80)(cid:72)(cid:85)(cid:74)(cid:72)(cid:85)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
amortization of inventory step-up of $10.3 million in the fourth quarter of 2015 associated with inventory
acquired from the Wright/Tornier merger.
Our 2015 net loss from continuing operations included the following:
•
•
•
•
the after-(cid:87)(cid:68)(cid:91)(cid:3)(cid:72)(cid:73)(cid:73)(cid:72)(cid:70)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:69)(cid:82)(cid:89)(cid:72)(cid:3)(cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:30)
the after-tax effects of our CVR mark-to-market adjustments of $13.5 million unrealized gain, $8.5 million
unrealized gain, $14.6 million unrealized loss, and $0.3 million unrealized gain recognized in the first, second,
(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
the after-tax effects of $25.2 million of charges related to the write-off of unamortized debt discount and deferred
(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3)(cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:72)(cid:87)(cid:87)(cid:79)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:26)(cid:3)(cid:49)(cid:82)(cid:87)(cid:72)(cid:86)(cid:3)(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:76)(cid:85)(cid:86)(cid:87)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:30)
the after-tax effects of non-cash interest expense related to the amortization of the debt discount on our 2017
Notes and 2020 Notes totaling $4.5 million, $6.6 million, $6.8 million, and $6.9 million during the first, second,
(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:88)(cid:85)(cid:87)(cid:75)(cid:3)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)
147
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
•
•
the after-tax effects of our mark-to-market adjustments on derivative assets and liabilities totaling a $6.9 million
gain, $0.4 million gain, $4.7 million gain, and $2.3 million loss recognized in the first, second, third, and fourth
(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:15)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
the after-tax effects of charges due to the fair value adjustment to contingent consideration totaled $0.2 million in
the second quarter of 2015.
20.
Segment and Geographic Data
During the first quarter of 2016, our management, including our Chief Executive Officer, who is our chief operating decision
maker, began managing our operations as four operating business segments: U.S. Lower Extremities & Biologics, U.S. Upper
Extremities, International Extremities & Biologics, and Large Joints. We determined that each of these operating segments
represented a reportable segment. Our Chief Executive Officer reviews financial information at the operating segment level to
allocate resources and to assess the operating results and performance of each segment. As a result of the classification of the
Large Joints business as a discontinued operation during the second quarter of 2016, the Large Joints reportable segment is
presented in our consolidated statements of operations as discontinued operations and is excluded from segment results for all
periods presented. See Note 4 of the consolidated financial statements for additional information regarding this divestiture.
U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics are our remaining
three reportable segments as of December 25, 2016.
Our U.S. Lower Extremities & Biologics segment consists of our operations focused on the sale in the United States of our
lower extremities products, such as joint implants and bone fixation devices for the foot and ankle, and our biologics products
used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. Our U.S. Upper
Extremities segment consists of our operations focused on the sale in the United States of our upper extremities products, such
as joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand and products used across several anatomic
sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries and other ancillary products. Our International
Extremities & Biologics segment consists of our operations focused on the sale outside the United States of all lower and upper
extremities products, including associated biologics products.
Management measures segment profitability using an internal operating performance measure that excludes the impact of
inventory step-up amortization and due diligence, transaction and transition costs associated with acquisitions, as such items are
not considered representative of segment results. Management’s change to the way it monitors performance, aligns strategies,
and allocates resources results in a change in our reportable segments and a change in reporting units for goodwill impairment
measurement purposes. We have determined that each reportable segment represents a reporting unit and, in accordance with
ASC 350, requires an allocation of goodwill to each reporting unit. As of December 25, 2016, we have allocated $219 million,
$559 million, and $74 million of goodwill to the U.S. Lower Extremities & Biologics, U.S. Upper Extremities, and
International Extremities & Biologics reportable segments, respectively.
Net sales by product line are as follows (in thousands):
U.S.
Lower extremities
Upper extremities
Biologics
Sports med & other
Total U.S.
International
Lower extremities
Upper extremities
Biologics
Sports med & other
Total International
Total
December 25,
2016
Fiscal year ended
December 27,
2015 1
December 31,
2014
$
$
$
$
$
222,936 $
201,579
74,603
8,429
507,547 $
187,096 $
58,756
50,583
3,388
299,823 $
148,631
15,311
45,494
2,641
212,077
62,701 $
86,502
18,883
14,729
182,815 $
51,200 $
24,789
19,652
9,862
105,503 $
47,001
11,312
20,590
7,047
85,950
690,362 $
405,326 $
298,027
148
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
___________________________
1
The 2015 results were restated for the divestiture of our Large Joints business.
Our principal geographic regions consist of the United States, EMEA (which includes Europe, the Middle East and Africa), and
Other (which principally represents Asia, Australia, Canada, and Latin America). Net sales attributed to each geographic region
are based on the location in which the products were sold.
Net sales by geographic region are as follows (in thousands):
Net sales by geographic region:
United States
EMEA
Other
Total
December 25,
2016
Fiscal year ended
December 27,
2015 1
December 31,
2014
$
$
507,547 $
117,268
65,547
690,362 $
299,823 $
62,662
42,841
405,326 $
212,077
48,991
36,959
298,027
___________________________
1 The 2015 results were restated for the divestiture of our Large Joints business.
No single foreign country accounted for more than 10% of our total net sales during 2016, 2015, or 2014.
Assets in the U.S. Upper Extremities, U.S. Lower Extremities & Biologics, and International Extremities & Biologics segments
are those assets used exclusively in the operations of each business segment or allocated when used jointly. Assets in the
Corporate category are principally cash and cash equivalents, derivative assets, property, plant and equipment associated with
our corporate headquarters, assets associated with discontinued operations, product liability insurance receivables, and assets
associated with income taxes. Total assets by business segment as of December 25, 2016 and December 27, 2015 are as
follows (in thousands):
Total assets
$ 491,531 $ 845,102 $ 264,680 $ 689,273 $
— $ 2,290,586
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
Corporate
Assets held
for sale
Total
December 25, 2016
Total assets
December 27, 2015
U.S. Lower
Extremities
& Biologics
U.S. Upper
Extremities
International
Extremities
& Biologics
Corporate
Assets held
for sale
Total
$ 490,798 $ 833,432 $ 365,621 $ 333,473 $
50,170 $ 2,073,494
149
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Selected financial information related to our segments is presented below for the fiscal years ended December 25, 2016,
December 27, 2015, and December 31, 2014 (in thousands):
Net sales from external customers
Depreciation expense
Amortization expense
Segment operating income (loss)
Other:
Inventory step-up amortization
Transaction and transition expenses
Product rationalization
Legal settlement
Management changes
Costs associated with new convertible debt
Operating loss
Interest expense, net
Other income, net
Loss before income taxes
Capital expenditures
Net sales from external customers
Depreciation expense
Amortization expense
Segment operating income (loss)
Other:
Inventory step-up amortization
Due diligence, transaction and transition expenses
Share-based compensation acceleration
Distributor conversions and non-competes
Operating loss
Interest expense, net
Other expense (income), net
Loss before income taxes
Capital expenditures
U.S. Lower
Extremities
& Biologics
Fiscal year ended December 25, 2016
International
Extremities
& Biologics Corporate 1
U.S. Upper
Extremities
$ 300,847 $ 206,700 $ 182,815 $
13,000
—
85,645 $
11,190
—
65,231 $
$
11,427
—
5,872 $ (202,261) $
Total
20,213
28,841
— $ 690,362
55,830
28,841
(45,513)
37,689
32,300
4,074
1,800
1,348
234
(122,958)
58,530
(3,148)
$ (178,340)
50,099
13,336 $
$
13,145 $
10,101 $
13,517 $
U.S. Lower
Extremities
& Biologics
$ 239,748 $
10,502
—
39,008 $
$
Fiscal year ended December 27, 2015
International
Extremities
& Biologics Corporate 1
U.S. Upper
Extremities
Total
60,075 $ 105,503 $
1,092
—
21,394 $
5,795
—
12,119
16,754
— $ 405,326
29,508
16,754
(82,001)
(5,567) $ (136,836) $
10,315
82,195
14,190
65
(188,766)
41,358
10,884
$ (241,008)
43,666
4,213 $
$
25,410 $
6,903 $
7,140 $
150
WRIGHT MEDICAL GROUP N.V.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(continued)
Net sales from external customers
Depreciation expense
Amortization expense
Segment operating income (loss)
Other:
Inventory step-up amortization
Distributor conversion and non-compete charges
Patent dispute settlement
Management changes
Acquisition due diligence, transaction and transition
expenses
Tornier merger costs
Operating loss
Interest expense, net
Other expense, net
Loss before income taxes
Capital expenditures
___________________________
1
U.S. Lower
Extremities
& Biologics
$ 196,766 $
9,006
—
29,200 $
$
Fiscal year ended December 31, 2014
International
Extremities
& Biologics Corporate 1
U.S. Upper
Extremities
Total
15,311 $
701
—
6,582 $
85,950 $
3,046
—
(3,187) $
— $ 298,027
18,456
10,027
(62,233)
5,703
10,027
(94,828) $
1,535
2,071
900
1,203
19,964
11,900
(99,806)
17,398
129,626
$ (246,830)
48,603
16,304 $
$
23,949 $
1,864 $
6,486 $
The Corporate category primarily reflects general and administrative expenses not specifically associated with the U.S. Lower
Extremities & Biologics, U.S. Upper Extremities, and International Extremities & Biologics segments. These non-allocated corporate
expenses relate to global administrative expenses that support all segments, including salaries and benefits of certain executive officers
(cid:68)(cid:81)(cid:71)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:3) (cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:68)(cid:86)(cid:29)(cid:3) (cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3) (cid:68)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:86)(cid:88)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:30)(cid:3) (cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3) (cid:75)(cid:72)(cid:68)(cid:71)(cid:84)(cid:88)(cid:68)(cid:85)(cid:87)(cid:72)(cid:85)(cid:86)(cid:30)(cid:3) (cid:79)(cid:72)(cid:74)(cid:68)(cid:79)(cid:15)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:79)(cid:76)(cid:68)(cid:81)(cid:70)(cid:72)(cid:15)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:70)(cid:82)(cid:85)(cid:83)(cid:82)rate
(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:73)(cid:88)(cid:81)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30) (cid:76)(cid:81)(cid:86)(cid:88)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:79)(cid:79)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)-based compensation.
151
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Not applicable.
Item 9A. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of
1934, as amended) are designed to ensure that information required to be disclosed in the reports that we file or submit under
the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of
the Securities and Exchange Commission and to ensure that information required to be disclosed is accumulated and
communicated to management, including our principal executive officer and principal financial officer, to allow timely
decisions regarding disclosure. The Chief Executive Officer (CEO) and the Chief Financial Officer (CFO), with assistance
from other members of management, have reviewed the design and effectiveness of our disclosure controls and procedures as
of December 25, 2016 and, based on their evaluation, have concluded that the disclosure controls and procedures were not
effective as of such date, due to a material weakness in our internal control over financial reporting.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in
Rules 13a-15(f) under the Exchange Act.
A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that
there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented
or detected on a timely basis.
Management assessed the effectiveness of our internal control over financial reporting as of December 25, 2016, based on the
criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control -
Integrated Framework (2013). Based on this assessment, management concluded that our internal control over financial
reporting as of December 25, 2016 was not effective due to the identification of a material weakness. The material weakness in
internal control over financial reporting related to ineffective design and operation of general information technology controls
related to user access to certain information technology systems that are relevant to our financial reporting processes and that
are intended to ensure that access to financial applications and data is adequately restricted to appropriate personnel and
monitored to ensure adherence to Company policies. This material weakness was due to a lack of sufficiently trained resources
with knowledge of our internal control over financial reporting related to general information technology systems, and therefore
we did not conduct an effective risk assessment process to evaluate requests for provisioning of user access, did not effectively
communicate granted access to the appropriate approvers, and did not effectively monitor ongoing user access as it related to
certain information technology systems. As a result, our automated and manual controls that are dependent on the effective
design and operation of general information technology controls were also ineffective because they could have been adversely
impacted. This material weakness did not result in any identified misstatements to our consolidated financial statements or
restatement of our prior-period consolidated financial statements, and there were no changes in our previously released
financial results.
As a result of the material weakness noted above, we completed additional procedures prior to filing this Annual Report on
Form 10-K for the year ended December 25, 2016 (Form 10-K). Our CEO and CFO have certified that, based on such officer’s
knowledge, the consolidated financial statements, and other financial information included in this Form 10-K, fairly present in
all material respects our financial condition, results of operations and cash flows as of, and for, the periods presented in this
Form 10-K. In addition, we have developed a remediation plan for this material weakness, which is described below.
Our independent registered public accounting firm has issued an adverse audit report on the effectiveness of our internal control
over financial reporting as of December 25, 2016.
Changes in Internal Control Over Financial Reporting
Except for the control deficiencies discussed above that have been assessed as a material weakness as of December 25, 2016,
there have been no other changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of
the Exchange Act) that occurred during the fourth quarter of fiscal 2016 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.
152
Remediation Plan
Management is actively implementing a remediation plan to ensure that control deficiencies contributing to the material
weakness are remediated such that new controls will be designed effectively and existing controls will operate effectively. The
remediation actions we are taking, and expect to take, include: (i) improving the design, operation and monitoring of control
activities and procedures associated with user access to our information tech(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3)(cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:75)(cid:76)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:71)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)
(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:85)(cid:87)(cid:76)(cid:86)(cid:72)(cid:3) (cid:87)(cid:82)(cid:3) (cid:86)(cid:88)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:86)(cid:3) (cid:82)(cid:89)(cid:72)(cid:85)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)(cid:80)(cid:82)(cid:81)(cid:76)(cid:87)(cid:82)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:87)(cid:72)(cid:70)(cid:75)(cid:81)(cid:82)(cid:79)(cid:82)(cid:74)(cid:92)(cid:3) (cid:86)(cid:92)(cid:86)(cid:87)(cid:72)(cid:80)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12) educating
and re-training control owners regarding internal control processes to mitigate identified risks and maintaining adequate
documentation to evidence the effective design and operation of such processes.
We believe that these actions, and the improvements we expect to achieve as a result, will effectively remediate the material
weakness. However, the material weakness in our internal control over financial reporting will not be considered remediated
until the remediated controls operate for a sufficient period of time and management has concluded, through testing, that these
controls are designed and operating effectively. We expect that the remediation of this material weakness will be completed in
fiscal 2017.
Item 9B. Other Information.
Not applicable.
153
Item 10.
Directors, Executive Officers and Corporate Governance.
Directors and Executive Officers
PART III
The table below sets forth, as of February 17, 2017, certain information concerning our current directors and executive officers.
No family relationships exist among any of our directors or executive officers.
Position
Name
Robert J. Palmisano
Lance A. Berry
Robert P. Burrows
James A. Lightman
Gregory Morrison
J. Wesley Porter
Julie D. Tracy
Jennifer S. Walker
Kevin D. Cordell
Peter S. Cooke
Timothy L. Lanier
Patrick Fisher
Julie B. Andrews
David D. Stevens(1)(2)
Gary D. Blackford(3)
Sean D. Carney(1)(4)
John L. Miclot(4)
Kevin C. O’Boyle(3)
Amy S. Paul(1)
Richard F. Wallman(2)(3)
Elizabeth H. Weatherman(1)(2)(4)
___________________________
(1) Member of the nominating, corporate governance and compliance committee.
Age
72 President and Chief Executive Officer and Executive Director
44 Senior Vice President and Chief Financial Officer
70 Senior Vice President, Supply Chain
59 Senior Vice President, General Counsel and Secretary
53 Senior Vice President, Human Resources
47 Senior Vice President and Chief Compliance Officer
55 Senior Vice President and Chief Communications Officer
49 Senior Vice President, Process Improvement
51 President, U.S.
51 President, International
55 President, Upper Extremities
43 President. Lower Extremities
45 Vice President and Chief Accounting Officer
63 Chairman and Non-Executive Director
59 Non-Executive Director
47 Non-Executive Director
57 Non-Executive Director
60 Non-Executive Director
65 Non-Executive Director
65 Non-Executive Director
56 Non-Executive Director
(2) Member of the strategic transactions committee.
(3) Member of the audit committee.
(4) Member of the compensation committee.
The following is a biographical summary of the experience of our directors and executive officers:
Robert J. Palmisano was appointed our President and Chief Executive Officer and an executive director and member of our
board of directors in October 2015 in connection with the Wright/Tornier merger. Mr. Palmisano has served as President and
Chief Executive Officer of Wright Medical Group, Inc. since September 2011. Prior to joining legacy Wright, Mr. Palmisano
served as President and Chief Executive Officer of ev3 Inc., a global endovascular device company, from April 2008 to July
2010, when it was acquired by Covidien plc. From 2003 to 2007, Mr. Palmisano was President and Chief Executive Officer of
IntraLase Corp. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem
Corporation from 2001 to 2003. Mr. Palmisano currently serves on the Providence College Board of Trustees and serves on the
board of directors of Avedro Inc., a privately held ophthalmic medical device and pharmaceutical company. Mr. Palmisano
previously served on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held
companies, and Bausch & Lomb, a privately held company. Under the terms of his employment agreement, we have agreed
that Mr. Palmisano will be nominated by our board of directors for election as an executive director and a member of our board
of directors at each annual general meeting of shareholders during the term of his employment as President and Chief Executive
Officer of our company. Mr. Palmisano’s qualifications to serve on our board of directors include his day-to-day knowledge of
our company and business due to his position as President and Chief Executive Officer, his experience serving on other public
companies’ boards of directors, and his extensive business knowledge working with other public companies in the medical
device industry.
Lance A. Berry was appointed our Senior Vice President and Chief Financial Officer in October 2015 in connection with the
Wright/Tornier merger. Mr. Berry has served as Senior Vice President and Chief Financial Officer of Wright Medical Group,
Inc. since 2009. He joined legacy Wright in 2002, and, until his appointment as Chief Financial Officer, served as Vice
154
President and Corporate Controller. Prior to joining Wright, Mr. Berry served as audit manager with the Memphis, Tennessee
office of Arthur Andersen LLP from 1995 to 2002. Mr. Berry is a certified public accountant, inactive.
Robert P. Burrows was appointed our Senior Vice President, Supply Chain in October 2015 in connection with the
Wright/Tornier merger. Mr. Burrows joined Wright Medical Group, Inc. in August 2014 as Senior Vice President, Supply
Chain. Prior to joining legacy Wright, he served as Managing Principal of The On-Point Group, a privately held logistics and
supply chain consultancy, from July 1994 through July 2014. While at On-Point, Mr. Burrows led over 40 client engagements,
most recently as an operations consultant overseeing the transition and expansion of legacy Wright’s extremities and biologics
manufacturing.
James A. Lightman was appointed our Senior Vice President, General Counsel and Secretary in October 2015 in connection
with the Wright/Tornier merger. Mr. Lightman joined Wright Medical Group, Inc. in December 2011 as Senior Vice President,
General Counsel and Secretary. Prior to joining legacy Wright, Mr. Lightman served in various legal and executive positions
with Bausch & Lomb Incorporated, a privately held supplier of eye health products. From February 2008 to November 2009,
Mr. Lightman served as Vice President and Assistant General Counsel of Bausch & Lomb, and most recently held the position
of Vice President, Global Sales Operations until August 2011. From June 2007 to February 2008, he served as Vice President
and General Counsel of Eyeonics, Inc. Prior to joining Eyeonics, Mr. Lightman served as Senior Vice President and General
Counsel of IntraLase Corp. from February 2005 to April 2007.
Gregory Morrison was appointed our Senior Vice President, Human Resources in October 2015 in connection with the
Wright/Tornier merger. Mr. Morrison served as Senior Vice President, Global Human Resources and HPMS (High
Performance Management System) of Tornier from January 2014 to October 2015 and served as Global Vice President, Human
Resources from December 2010 to January 2014. Prior to joining Tornier, Mr. Morrison served as Senior Vice President,
Human Resources of ev3 Inc., a global endovascular device company acquired by Covidien plc in July 2010, from August 2007
to December 2010, and as Vice President, Human Resources from May 2002 to August 2007. Prior to joining ev3,
Mr. Morrison served as Vice President of Organizational Effectiveness of Thomson Legal & Regulatory from March 1999 to
February 2002 and Vice President of Global Human Resources of Schneider Worldwide, which was acquired by Boston
Scientific Corporation, from 1988 to March 1999.
J. Wesley Porter was appointed our Senior Vice President and Chief Compliance Officer in October 2015 in connection with
the Wright/Tornier merger. Mr. Porter joined Wright Medical Group, Inc. in July 2014 as Vice President, Compliance and
became Senior Vice President and Chief Compliance Officer in October 2014. Prior to joining legacy Wright, Mr. Porter
served as Vice President, Deputy Compliance Officer of Allergan, Inc. from September 2012 to February 2014, Vice President,
Ethics and Compliance of CareFusion Corp. from June 2009 to September 2012, and Senior Corporate Counsel, Compliance,
HIPAA and Reimbursement of Smith & Nephew, Inc. from April 2006 to May 2009.
Julie D. Tracy was appointed our Senior Vice President and Chief Communications Officer in October 2015 in connection with
the Wright/Tornier merger. Ms. Tracy served as Senior Vice President, Chief Communications Officer of Wright Medical
Group, Inc. from October 2011 to October 2015. Prior to joining legacy Wright, Ms. Tracy served as Chief Communications
Officer of Epocrates, Inc., a publicly held company that sold physician platforms for clinical content, practice tools and health
industry engagement, from March 2011 to October 2011. From January 2008 to July 2010, Ms. Tracy was Senior Vice
President and Chief Communications Officer of ev3 Inc. Prior to ev3, Ms. Tracy held marketing and investor relations
positions at Kyphon Inc. from January 2003 to November 2007 and Thoratec Corporation from January 1998 to January 2003.
Ms. Tracy currently serves as a member of the board of directors for the National Investor Relations Institute, the professional
association of corporate officers and investor relations consultants responsible for communication among corporate
management, shareholders, securities analysts and other financial community constituents.
Jennifer S. Walker was appointed our Senior Vice President, Process Improvement in October 2015 in connection with the
Wright/Tornier merger. Ms. Walker served as Senior Vice President, Process Improvement of Wright Medical Group, Inc. from
December 2011 to October 2015 and Vice President and Corporate Controller from December 2009 to December 2011. Since
joining legacy Wright’s financial organization in 1993, she served as Assistant Controller, Director, Financial Reporting & Risk
Management, Director, Corporate Tax & Risk Management, and Tax Manager of legacy Wright. Prior to joining legacy Wright,
Ms. Walker was a senior tax accountant with Arthur Andersen LLP. Ms. Walker is a certified public accountant.
Kevin D. Cordell was appointed our President, U.S. in June 2016. From October 2015 to June 2016, he served as our President,
Lower Extremities and Biologics. Mr. Cordell served as President, U.S. Extremities of Wright Medical Group, Inc. from
September 2014 to October 2015. Prior to joining legacy Wright, Mr. Cordell served as Vice President of Sales for the GI
Solutions business at Covidien plc, a global healthcare products company, from May 2012 to September 2014. While at
Covidien, he served as Vice President of Sales and Global Marketing for its Peripheral Vascular business from July 2010 to
May 2012. He joined Covidien in July 2010 through the acquisition of ev3 Inc., a global endovascular device company, where
he served as Vice President of U.S. Sales from January 2009 to July 2010. Prior to ev3, Mr. Cordell served as Vice President,
155
Global Sales of FoxHollow Technologies, Inc. from March 2007 until it was acquired by ev3 in October 2007. Earlier in his
career, Mr. Cordell held various positions of increasing responsibility for Johnson & Johnson’s Cordis Cardiology and Centocor
companies. Mr. Cordell serves on the board of directors of TissueGen, Inc., a privately-held developer of biodegradable
polymer technology for implantable drug delivery.
Peter S. Cooke was appointed our President, International in October 2015 in connection with the Wright/Tornier merger.
Mr. Cooke served as President, International of Wright Medical Group, Inc. from January 2014 to October 2015 and served as
Senior Vice President, International from January 2013 to January 2014. Prior to joining legacy Wright, Mr. Cooke served as
Vice President and General Manager, Vascular Therapies Emerging Markets of Covidien plc, a global healthcare products
company, from July 2010 to January 2013. Prior to Covidien, Mr. Cooke served in various general management roles for ev3
Inc., a global endovascular device company acquired by Covidien in July 2010, including Vice President and General Manager,
(cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:45)(cid:88)(cid:79)(cid:92)(cid:3)(cid:21)(cid:19)(cid:19)(cid:27)(cid:3)(cid:87)(cid:82)(cid:3)(cid:45)(cid:88)(cid:79)(cid:92)(cid:3)(cid:21)(cid:19)(cid:20)(cid:19)(cid:30)(cid:3)(cid:57)(cid:76)(cid:70)(cid:72)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:76)(cid:71)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3)(cid:42)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:3)(cid:48)(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:85)(cid:15)(cid:3)(cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:49)(cid:82)(cid:89)(cid:72)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3)(cid:21)(cid:19)(cid:19)(cid:25)(cid:3)(cid:87)(cid:82)(cid:3)(cid:45)(cid:88)(cid:81)(cid:72)(cid:3)(cid:21)(cid:19)(cid:19)(cid:27)(cid:30)(cid:3)
(cid:57)(cid:76)(cid:70)(cid:72)(cid:3) (cid:51)(cid:85)(cid:72)(cid:86)(cid:76)(cid:71)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3) (cid:54)(cid:68)(cid:79)(cid:72)(cid:86)(cid:3) (cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3) (cid:73)(cid:85)(cid:82)(cid:80)(cid:3) (cid:45)(cid:68)(cid:81)(cid:88)(cid:68)(cid:85)(cid:92)(cid:3) (cid:21)(cid:19)(cid:19)(cid:24)(cid:3) (cid:88)(cid:81)(cid:87)(cid:76)(cid:79)(cid:3) (cid:49)(cid:82)(cid:89)(cid:72)(cid:80)(cid:69)(cid:72)(cid:85)(cid:3) (cid:21)(cid:19)(cid:19)(cid:25)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:53)(cid:72)(cid:74)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3) (cid:39)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:3)(cid:36)(cid:86)(cid:76)(cid:68)(cid:3) (cid:51)(cid:68)(cid:70)(cid:76)(cid:73)(cid:76)(cid:70)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:38)(cid:75)(cid:76)(cid:81)(cid:68)(cid:3)
from February 2003 until January 2005. Prior to ev3, Mr. Cooke spent eleven years at Guidant Corporation, three years at
Baxter Healthcare Corporation and two years at St. Jude Medical, Inc.
Timothy L. Lanier was appointed our President, Upper Extremities in June 2016. Mr. Lanier has over 25 years of experience in
medical device and commercial operations in both small and large companies that include various medical specialties such as
orthopedics, vascular, oncology and ophthalmology. Prior to joining Wright, from September 2013 to June 2016, Mr. Lanier
served as Vice President of Sales of DFINE Inc., a company committed to the treatment of metastatic tumors and other diseases
of the spine. From July 2010 to September 2013, Mr. Lanier served as Vice President of US Sales for the Endovascular
Division of Covidien plc, a global healthcare products company, where he built a world-class sales organization dedicated to
treating both arterial and venous disease. He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served
as Area Vice President from January 2008 to July 2010. Prior to ev3, Mr. Lanier served as Vice President of Commercial
Operations at Anulex Technologies, Inc. from January 2007 to January 2008. He also had increasing executive responsibility at
Zimmer Orthopedics, Spine Division and Spine-Tech, Inc. from 1997 to 2007, including Vice President of Commercial
Operations.
Patrick Fisher was appointed our President, Lower Extremities in June 2016. From October 2015 to June 2016, Mr. Fisher
served as our Vice President, U.S. Sales. From October 2012 to October 2015, Mr. Fisher served as Vice President, U.S. Sales
of Wright Medical Group, Inc., and from October 2010 to October 2012, Mr. Fisher served as Regional Vice President of Sales
- West Region.
Julie B. Andrews was appointed our Vice President and Chief Accounting Officer in October 2015 in connection with the
Wright/Tornier merger. Ms. Andrews served as Vice President and Chief Accounting Officer of Wright Medical Group, Inc.
from May 2012 to October 2015. From February 1998 to May 2012, Ms. Andrews held numerous key financial positions with
Medtronic, Inc., a global medical device company. Most recently, Ms. Andrews served as Medtronic’s Vice President, Finance
for its spinal and biologics business units. Ms. Andrews has significant accounting, finance, and business skills as well as
global experience, having held positions in worldwide planning and analysis in Medtronic Sofamor Danek and in Medtronic’s
spinal and biologics business. Prior to joining Medtronic, Ms. Andrews worked with Thomas & Betts Corporation in Memphis,
Tennessee and Thomas Havey, LLP in Chicago, Illinois.
David D. Stevens joined our board of directors as a non-executive director in October 2015 in connection with the
Wright/Tornier merger. Mr. Stevens serves as our Chairman. Mr. Stevens was a member of the board of directors of Wright
Medical Group, Inc. from 2004 to 2015 and served as Chairman of the Board from 2009 to October 2015 and interim Chief
Executive Officer of Wright from April 2011 to September 2011. He has been a private investor since 2006. Mr. Stevens
served as Chief Executive Officer of Accredo Health Group, Inc., a subsidiary of Medco Health Solutions, Inc., from 2005 to
2006. He was Chief Executive Officer of Accredo Health, Inc. from 1996 to 2005, served as Chairman of the Board from 1999
to 2005, and was President and Chief Operating Officer of the predecessor companies of Accredo Health from their inception in
1983 until 1996. He serves on the board of directors of Allscripts Healthcare Solutions, Inc., a publicly held company. He
previously served on the board of directors of Viasystems Group, Inc., a publicly held company, from 2012 until May 2015
when it was acquired by TTM Technologies, Inc., Medco Health Solutions, Inc., a publicly held company, from 2006 until 2012
when it was acquired by Express Scripts Holding Company, and Thomas & Betts Corporation, a publicly held company, from
2004 to 2012 when it was acquired by ABB Ltd. Mr. Stevens’s qualifications to serve on our board of directors include his
extensive experience serving as a chief executive officer, including as interim chief executive officer of legacy Wright, his close
familiarity with our business, and his prior experience as a director of legacy Wright.
Gary D. Blackford joined our board of directors as a non-executive director in October 2015 in connection with the
Wright/Tornier merger. Mr. Blackford was a member of the board of directors of Wright Medical Group, Inc. from 2008 to
2015. From 2002 to February 2015, Mr. Blackford served as President and Chief Executive Officer and a member of the board
of directors of Universal Hospital Services, Inc., a provider of medical technology outsourcing and services to the healthcare
156
industry, and from 2007 to February 2015, served as Chairman of the Board. From 2001 to 2002, Mr. Blackford served as
Chief Executive Officer of Curative Health Services Inc. From 1999 to 2001, Mr. Blackford served as Chief Executive Officer
of ShopforSchool, Inc. He served as Chief Operating Officer for Value Rx from 1995 to 1998 and Chief Operating Officer and
Chief Financial Officer of MedIntel Systems Corporation from 1993 to 1994. Mr. Blackford currently serves on the board of
directors of Halyard Health, Inc. and EnteroMedics Inc., both publicly held companies. He also serves on the board of directors
of Pipeline Rx, Inc., a privately held telepharmacy company. Mr. Blackford previously served on the board of directors of
Compex Technologies, Inc., a publicly held medical device company, from 2005 until its acquisition by Encore Medical
Corporation in 2006. Mr. Blackford’s qualifications to serve as a member of our board of directors include his experience as a
chief executive officer and director of a healthcare services company and other companies and as a director of other public
companies in the healthcare industry, his extensive experience leading healthcare companies, and his prior experience as a
director of legacy Wright.
Sean D. Carney has served as a non-executive director and member of our board of directors since July 2006. Mr. Carney
served as Chairman of legacy Tornier from May 2010 to October 2015. Mr. Carney was initially appointed as a director of
Tornier in connection with a former securityholders’ agreement that Tornier entered into with certain of its shareholders. For
more information regarding the securityholders’ agreement, please refer to the discussion below under “-Board Structure and
Composition.” The securityholders’ agreement terminated by its terms in May 2016. Mr. Carney is currently a private investor.
From 1996 to December 2016, Mr. Carney was employed by Warburg Pincus LLC, a private equity firm, and served as a
Member and Managing Director of Warburg Pincus LLC and a General Partner of Warburg Pincus & Co. from January 2001 to
December 2016. Prior to joining Warburg Pincus, Mr. Carney was a consultant at McKinsey & Company, Inc., a management
consulting company. Mr. Carney previously served on the board of directors of DexCom, Inc., Arch Capital Group Ltd. and
MBIA Inc., each publicly held companies, and several privately held companies. Mr. Carney’s qualifications to serve as a
member of our board of directors include his substantial experience as an investor in medical device companies, his experience
as a public company director, and his experience evaluating financial results.
John L. Miclot joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier
merger. Mr. Miclot was a member of the board of directors of Wright Medical Group, Inc. from 2007 to 2015. Mr. Miclot has
served as President and Chief Executive Officer and a member of the board of directors of LinguaFlex, Inc., a medical device
company focused on treatment of sleep disordered breathing, since August 2015. From December 2011 to December 2014, he
served as Chief Executive Officer and a member of the board of directors of Tengion Inc., a publicly held company that focused
on organ and cell regeneration. Prior to joining Tengion, Mr. Miclot was an Executive-in Residence at Warburg Pincus, LLC.
From 2008 to 2010, he was President and Chief Executive Officer of CCS Medical, Inc., a provider of products and services for
patients with chronic diseases. From 2003 until 2008, he served as President and Chief Executive Officer of Respironics, Inc.,
a provider of sleep and respiratory products, and prior to such time, served in various positions at Respironics, Inc. from 1998
to 2003, including Chief Strategic Officer and President of the Homecare Division. From 1995 to 1998, he served as Senior
Vice President, Sales and Marketing of Healthdyne Technologies, Inc., a medical device company that was acquired by
Respironics, Inc. in 1998. Mr. Miclot spent the early part of his medical career at DeRoyal Industries, Inc., Baxter International
Inc., Ohmeda Medical, Inc. and Medix Inc. Mr. Miclot serves as Chairman and a member of the board of directors of Breathe
Technologies, Inc., a privately held company. Mr. Miclot also serves as a director of the Pittsburgh Zoo and PPG Aquarium,
charitable and educational institutions, serves on the University of Iowa Tippie College of Business board of advisors and
serves as an industrial advisor to EQT Partners, an investment company. Mr. Miclot previously served on the board of directors
of DENTSPLY International Inc., a dental products company, prior to its merger with Sirona Dental Systems, Inc. in February
2016, and ev3 Inc., a global endovascular device company, prior to the sale of the company in 2010. Mr. Miclot’s
qualifications to serve on our board of directors include his substantial experience as a chief executive officer of several
medical device companies, his deep knowledge of the medical device industry, and his prior experience as a director of legacy
Wright.
Kevin C. O’Boyle has served as a non-executive director and member of our board of directors since June 2010. In November
2012, Mr. O’Boyle was appointed as Interim Vice Chairman of Tornier, a position he held for about a year. From December
2010 to July 2011, Mr. O’Boyle served as Senior Vice President and Chief Financial Officer of Advanced BioHealing Inc., a
medical device company that was acquired by Shire plc in July 2011. From January 2003 until December 2009, Mr. O’Boyle
served as Chief Financial Officer of NuVasive, Inc., a medical device orthopedics company specializing in spinal disorders.
Prior to that time, Mr. O’Boyle served in various positions during his six years with ChromaVision Medical Systems, Inc., a
publicly held medical device company specializing in the oncology market, including as its Chief Financial Officer and Chief
Operating Officer. Mr. O’Boyle also held various positions during his seven years with Albert Fisher North America, Inc., a
publicly held international food company, including Chief Financial Officer and Senior Vice President of Operations.
Mr. O’Boyle serves on the board of directors of GenMark Diagnostics, Inc., ZELTIQ Aesthetics, Inc., and Sientra, Inc., all
publicly held companies. Mr. O’Boyle previously served on the board of directors of Durata Therapeutics, Inc. until its
acquisition by Actavis plc in November 2014. Mr. O’Boyle’s qualifications to serve on our board of directors includes his
executive experience in the healthcare industry, his experience with companies during their transition from being privately held
to publicly held, and his financial and accounting expertise.
157
Amy S. Paul joined our board of directors as a non-executive director in October 2015 in connection with the Wright/Tornier
merger. Ms. Paul was a member of the board of directors of Wright Medical Group, Inc. from 2008 to 2015. Ms. Paul retired
in 2008 following a 26-year career with C.R. Bard, Inc., a medical device company, most recently serving as the Group Vice
President-International since 2003. She served in various positions at C.R. Bard, Inc. from 1982 to 2003, including President of
Bard Access Systems, Inc., President of Bard Endoscopic Technologies, Vice President and Business Manager of Bard
Ventures, Vice President of Marketing of Bard Cardiopulmonary Division, Marketing Manager for Davol Inc., and Senior
Product Manager for Davol Inc. Ms. Paul previously served on the board of directors of Derma Sciences, Inc., a publicly held
company, Viking Systems, Inc., a publicly held company, until October 2012 when it was acquired by Conmed Corporation,
and was a commissioner of the Northwest Commission on Colleges and Universities from 2010 to 2013. Ms. Paul serves on
the President’s Innovation Network at Westminster College. Ms. Paul’s qualifications to serve on our board of directors
include her over three decades of experience in the medical device industry, including having served in various executive roles
with responsibilities that include international and divisional operations as well as marketing and sales functions, her
experience as a director of other public companies in the healthcare industry, and her prior experience as a director of legacy
Wright.
Richard F. Wallman has served as a non-executive director and member of our board of directors since December 2008. From
1995 through his retirement in 2003, Mr. Wallman served as Senior Vice President and Chief Financial Officer of Honeywell
International, Inc., a diversified technology company, and AlliedSignal, Inc., a diversified technology company (prior to its
merger with Honeywell International, Inc.). Prior to joining AlliedSignal, Inc., Mr. Wallman served as Controller of
International Business Machines Corporation. Mr. Wallman serves on the board of directors of Charles River Laboratories
International, Inc., Convergys Corporation and Roper Technologies, Inc., all publicly held companies. Mr. Wallman also serves
on the board of directors of Extended Stay America, Inc. and its wholly subsidiary ESH Hospitality, Inc., both publicly held
companies, although he will be leaving the board of directors of ESH Hospitality, Inc. in May 2017. Mr. Wallman previously
served on the board of directors of Ariba, Inc. and Dana Holding Corporation, both publicly held companies. Mr. Wallman’s
qualifications to serve on our board of directors include his prior public company experience, including as Chief Financial
Officer of Honeywell, his significant public company director experience, and his financial experience and expertise.
Elizabeth H. Weatherman has served as a non-executive director and member of our board of directors since July 2006.
Ms. Weatherman was initially appointed as a director of Tornier in connection with the securityholders’ agreement that Tornier
entered into with certain shareholders. For more information regarding the securityholders’ agreement, please refer to the
discussion below under “-Board Structure and Composition.” The securityholders’ agreement terminated by its terms in May
2016. Ms. Weatherman has been a Special Limited Partner of Warburg Pincus LLC, a private equity firm, since January 2016.
Ms. Weatherman previously was a Partner of Warburg Pincus & Co., a Member and Managing Director of Warburg Pincus
LLC and a member of the firm’s Executive Management Group. Ms. Weatherman joined Warburg Pincus in 1988 and
primarily focused on the firm’s healthcare investment activities. Ms. Weatherman serves on the board of directors of several
privately held companies. Ms. Weatherman previously served on the boards of directors of several publicly held companies,
primarily in the medical device industry, including ev3 Inc., Wright Medical Group, Inc., and Kyphon Inc. Ms. Weatherman’s
qualifications to serve on our board of directors include her extensive experience as a director of several public and private
companies in the medical device industry.
Board Structure and Composition
We have a one-tier board structure. Our articles of association provide that the number of members of our board of directors
will be determined by our board of directors, provided that our board of directors will be comprised of at least one executive
director and two non-executive directors. Our board of directors currently consists of nine directors, one of whom is an
executive director and eight of whom are non-executive directors.
All eight of our non-executive directors are “independent directors” under the Listing Rules of the NASDAQ Stock Market.
Independence requirements for service on our audit committee are discussed below under “Audit Committee” and independence
requirements for service on our compensation committee are discussed below under “Compensation Committee.” All of our
non-executive directors are independent under the independence definition in the Dutch Corporate Governance Code.
The general meeting of shareholders appoints the members of our board of directors, subject to a binding nomination of our
board of directors in accordance with the relevant provisions of the Dutch Civil Code. Our board of directors makes the
binding nomination based on a recommendation of our nominating, corporate governance and compliance committee. If the
list of candidates contains one candidate for each open position to be filled, such candidate will be appointed by the general
meeting of shareholders unless the binding nature of the nominations by our board of directors is set aside by the general
meeting of shareholders. The binding nature of nomination(s) by our board of directors can only be set aside by a vote of at
least two-thirds of the votes cast at an annual or extraordinary general meeting of shareholders, provided such two-thirds vote
constitutes more than one-half of our issued share capital. In such case, a new meeting is called at which the resolution for
158
appointment of a member of our board of directors will require a majority of at least two-thirds of the votes cast representing
more than one-half of our issued share capital.
A resolution of the general meeting of shareholders to suspend a member of our board of directors requires the affirmative vote
of an absolute majority of the votes cast. A resolution of the general meeting of shareholders to suspend or dismiss members of
our board of directors, other than pursuant to a proposal by our board of directors, requires a majority of at least two-thirds of
the votes cast, representing more than one-half of our issued share capital.
With respect to the composition of our board of directors, under the terms of his employment agreement, we have agreed that
Mr. Palmisano will be nominated by our board of directors for election as an executive director and a member of our board of
directors at each annual general meeting of shareholders. Pursuant to a former securityholders’ agreement among our company
and certain of our former shareholders, including TMG Holdings Coöperatief U.A. (TMG), TMG had the right to designate
three directors to be nominated to our board of directors for so long as TMG beneficially owned at least 25% of our outstanding
ordinary shares, two directors for so long as TMG beneficially owned at least 10% but less than 25% of our outstanding
ordinary shares and one director for so long as TMG beneficially owned at least 5% but less than 10% of our outstanding
ordinary shares. We agreed to use our reasonable best efforts to cause the TMG designees to be elected. Although Mr. Carney
and Ms. Weatherman were initially elected to our board of directors as designees of TMG, they are no longer designees since
TMG no longer owns at least 5% of our outstanding ordinary shares. The securityholders’ agreement terminated by its terms in
May 2016 upon the sale by TMG of its entire remaining ownership stake in our company.
Under our articles of association, our internal rules for the board of directors, and Dutch law, the members of our board of
directors are collectively responsible for our management, general and financial affairs, and policy and strategy. Our executive
director is primarily responsible for managing our day-to-day affairs as well as other responsibilities that have been delegated to
him in accordance with our articles of association and internal rules for the board of directors. Our non-executive directors
supervise our executive director and our general affairs and provide general advice to him. In performing their duties, our
directors are guided by the interests of our company and, within the boundaries set by relevant Dutch law, must take into
account the relevant interests of our stakeholders. The internal affairs of our board of directors are governed by our internal
rules for the board of directors, a copy of which is available on the Investor Relations-Corporate Information-Governance
Documents & Charters section of our corporate website at www.wright.com.
Mr. Stevens serves as our Chairman. The duties and responsibilities of the Chairman include, among others: determining the
agenda and chairing the meetings of our board of directors, managing our board of directors to ensure that it operates
effectively, ensuring that the members of our board of directors receive accurate, timely and clear information, encouraging
active engagement by all the members of our board of directors, promoting effective relationships and open communication
between the non-executive directors and the executive director, and monitoring effective implementation of our board of
directors decisions.
All regular meetings of our board of directors are scheduled to be held in the Netherlands. Each director has the right to cast
one vote and may be represented at a meeting of our board of directors by a fellow director. Our board of directors may pass
resolutions only if a majority of the directors is present at the meeting and all resolutions must be passed by a majority of the
directors that have no conflict of interest present or represented. As required by Dutch law, our articles of association provide
that when one or more members of our board of directors is absent or prevented from acting, the remaining members of our
board of directors will be entrusted with the management of our company. The intent of this provision is to satisfy certain
requirements under Dutch law and provide that, in rare circumstances, when a director is incapacitated, severely ill, or similarly
absent or prevented from acting, the remaining members of our board of directors (or, in the event there are no such remaining
members, a person appointed by our shareholders at a general meeting) will be entitled to act on behalf of our board of directors
in the management of our company, notwithstanding the general requirement that otherwise requires a majority of our board of
directors be present. In these limited circumstances, our articles of association permit our board of directors to pass resolutions
even if a majority of the directors is not present at the meeting.
Subject to Dutch law and any director’s objection, resolutions may be passed in writing by all of the directors in office. Under
Dutch law, members of the board of directors may not participate in the deliberation and the decision-making process on a
subject or transaction in relation to which he or she has a direct or indirect personal interest that conflicts with the interest of
our company and business enterprise. If all directors are conflicted and in the absence of a supervisory board, the resolution
will be adopted by the general meeting of shareholders, except if the articles of association prescribe otherwise. Our articles of
association provide that a director will not take part in any vote on a subject or transaction in relation to which he or she has a
direct or indirect personal interest that conflicts with the interest of our company and business enterprise. In such event, the
other directors will be authorized to adopt the resolution. If all directors have a conflict of interest as mentioned above, the
resolution will be adopted by the non-executive directors.
159
Board Committees
Our board of directors has four standing board committees: audit committee, compensation committee, nominating, corporate
governance and compliance committee, and strategic transactions committee. Each of these committees has the composition
described in the table below and the responsibilities described in the sections below. Our board of directors has adopted a
written charter for each committee of our board of directors. These charters are available on the Investor Relations-Corporate
Information-Governance Documents & Charters section of our corporate website at www.wright.com. Our board of directors
from time to time may establish other committees.
The following table summarizes the current membership of each of our four board committees.
Director
Robert J. Palmisano
Gary D. Blackford
Sean D. Carney
John L. Miclot
Kevin C. O’Boyle
Amy S. Paul
David D. Stevens
Richard F. Wallman
Elizabeth H. Weatherman
Audit Committee
Audit
—
(cid:165)
—
—
(cid:165)
—
—
Chair
—
Compensation
—
—
Chair
(cid:165)
—
—
—
—
(cid:165)
Nominating, corporate
governance and compliance
—
—
(cid:165)
—
—
Chair
(cid:165)
—
(cid:165)
Strategic transactions
—
—
—
—
—
—
(cid:165)
(cid:165)
Chair
The audit committee oversees a broad range of issues surrounding our accounting and financial reporting processes and audits
of our financial statements. The primary responsibilities of the audit committee include:
•
•
•
•
•
assisting our board of directors in monitoring the integrity of our financial statements, our compliance with legal
and regulatory requirements insofar as they relate to our financial statements and financial reporting obligations
and any accounting, internal accounting controls or auditing matters, our independent auditor’s qualifications and
(cid:76)(cid:81)(cid:71)(cid:72)(cid:83)(cid:72)(cid:81)(cid:71)(cid:72)(cid:81)(cid:70)(cid:72)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:3)(cid:73)(cid:88)(cid:81)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:81)(cid:71)(cid:72)(cid:83)(cid:72)(cid:81)(cid:71)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)
appointing, compensating, retaining, and overseeing the work of any independent auditor engaged for the purpose
(cid:82)(cid:73)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:15)(cid:3)(cid:85)(cid:72)(cid:89)(cid:76)(cid:72)(cid:90)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:87)(cid:87)(cid:72)(cid:86)(cid:87)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:72)(cid:68)(cid:79)(cid:76)(cid:81)(cid:74)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:79)(cid:92)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:73)(cid:76)(cid:85)(cid:80)(cid:30)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:15)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)
such appointment will be subject to shareholder ratification or decision in the case of the auditor for our Dutch
(cid:86)(cid:87)(cid:68)(cid:87)(cid:88)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)
(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:88)(cid:80)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:80)(cid:68)(cid:87)(cid:87)(cid:72)(cid:85)(cid:86)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:3)(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86)(cid:30)(cid:3)
establishing procedures for the receipt, retention, and treatment of complaints received by us regarding
accounting, internal accounting controls, or auditing matters, and for the confidential, anonymous submission by
(cid:82)(cid:88)(cid:85)(cid:3)(cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:72)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:70)(cid:82)(cid:81)(cid:70)(cid:72)(cid:85)(cid:81)(cid:86)(cid:3)(cid:85)(cid:72)(cid:74)(cid:68)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:84)(cid:88)(cid:72)(cid:86)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:88)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:80)(cid:68)(cid:87)(cid:87)(cid:72)(cid:85)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
reviewing and approving all related party transactions required to be disclosed under the U.S. federal securities
laws.
The audit committee reviews and evaluates, at least annually, the performance of the audit committee and its members,
including compliance of the committee with its charter.
The audit committee has the sole authority to select, retain, oversee, and terminate its own counsel, consultants, and advisors
and approve the fees and other retention terms of such counsel, consultants, and advisors, as it deems appropriate.
The audit committee consists of Mr. Wallman (Chair), Mr. Blackford, and Mr. O’Boyle. We believe that the composition of the
audit committee complies with the applicable rules of the SEC and the NASDAQ Stock Market. Our board of directors has
determined that each of Mr. Wallman, Mr. Blackford, and Mr. O’Boyle is an “independent director” under the rules of the
NASDAQ Stock Market, an “audit committee financial expert,” as defined in SEC rules, and satisfies the financial
sophistication requirements of the NASDAQ Stock Market. Our board of directors also has determined that each of
Mr. Wallman, Mr. Blackford, and Mr. O’Boyle meets the more stringent independence requirements for audit committee
members of Rule 10A-3(b)(1) under the Exchange Act and the Listing Rules of the NASDAQ Stock Market and is independent
under the Dutch Corporate Governance Code.
160
Compensation Committee
The primary responsibilities of our compensation committee, which are within the scope of the board of directors compensation
policy adopted by the general meeting of our shareholders, include:
•
reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive
Officer and other executive officers, evaluating the performance of these officers in light of those goals and
(cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:72)(cid:87)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:86)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:72)(cid:89)(cid:68)(cid:79)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
•
•
• making recommendations to our board of directors with respect to incentive compensation and equity-based plans
that are subject to board and shareholder approval, administering or overseeing all of our incentive compensation
and equity-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:76)(cid:86)(cid:70)(cid:75)(cid:68)(cid:85)(cid:74)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:76)(cid:80)(cid:83)(cid:82)(cid:86)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:76)(cid:87)(cid:87)(cid:72)(cid:72)(cid:3)(cid:69)(cid:92)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:86)(cid:72)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:86)(cid:30)
reviewing and recommending to our board of directors any severance or similar termination payments proposed to
be made to our Chief Executive Officer and reviewing and approving any severance or similar termination
(cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:86)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:69)(cid:72)(cid:3)(cid:80)(cid:68)(cid:71)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:30)
reviewing and discussing with our Chief Executive Officer and reporting periodically to our board of directors
plans for development and corporate succession plans for our executive officers and other key employees, which
(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:3)(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:79)(cid:72)(cid:68)(cid:71)(cid:72)(cid:85)(cid:86)(cid:75)(cid:76)(cid:83)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:88)(cid:81)(cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:72)(cid:71)(cid:3)(cid:89)(cid:68)(cid:70)(cid:68)(cid:81)(cid:70)(cid:92)(cid:30)
reviewing and discussing with management the “Compensation Discussion and Analysis” section of this report
and based on such discussions, recommending to our board of directors whether the “Compensation Discussion
and Analysis” section should be included in (cid:87)(cid:75)(cid:76)(cid:86)(cid:3)(cid:85)(cid:72)(cid:83)(cid:82)(cid:85)(cid:87)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
approving, or recommending to our board of directors for approval, the compensation programs, and the payouts
for all programs, applying to our non-executive directors, including reviewing the competitiveness of our non-
executive director compensation programs and reviewing the terms to make sure they are consistent with our
board of directors compensation policy adopted by the general meeting of our shareholders.
•
•
The compensation committee reviews and evaluates, at least annually, the performance of the compensation committee and its
members, including compliance of the committee with its charter.
The compensation committee has the sole authority to select, retain, oversee, and terminate its own counsel, consultants, and
advisors and approve the fees and other retention terms of such counsel, consultants, and advisors, as it deems appropriate.
Before selecting any such counsel, consultant or advisor, the compensation committee reviews and considers the independence
of such counsel, consultant or advisor, including any other services the counsel, consultant or other advisor is providing to our
company and management.
The compensation committee consists of Mr. Carney (Chair), Mr. Miclot, and Ms. Weatherman. We believe that the
composition of our compensation committee complies with the applicable rules of the SEC and the NASDAQ Stock Market.
Our board of directors has determined that each of Mr. Carney, Mr. Miclot, and Ms. Weatherman is an “independent director”
under the rules of the NASDAQ Stock Market, meets the more stringent independence requirements for compensation
committee members of Rule 10C-1 under the Exchange Act and the Listing Rules of the NASDAQ Stock Market and is
independent under the Dutch Corporate Governance Code. None of our executive officers has served as a member of the board
of directors or compensation committee of any entity that has an executive officer serving as a member of our board of
directors.
Nominating, Corporate Governance and Compliance Committee
The primary responsibilities of our nominating, corporate governance and compliance committee include:
•
reviewing and making recommendations to our board of directors regarding the size and composition of our board
(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)
identifying, reviewing, and recommen(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:81)(cid:82)(cid:80)(cid:76)(cid:81)(cid:72)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:72)(cid:79)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:86)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)
•
• making recommendations to our board of directors regarding corporate governance matters and practices,
•
(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:85)(cid:72)(cid:89)(cid:76)(cid:86)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79)(cid:3)(cid:85)(cid:88)(cid:79)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:82)(cid:68)(cid:85)(cid:71)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
overseeing our compliance efforts with respect to our legal, regulatory, and quality systems requirements and
ethical programs, including our code of business conduct, other than with respect to matters relating to our
financial statements and financial reporting obligations and any accounting, internal accounting controls or
auditing matters, which are within the purview of the audit committee.
The nominating, corporate governance and compliance committee reviews and evaluates, at least annually, the performance of
the nominating, corporate governance and compliance committee and its members, including compliance of the committee with
its charter.
161
The nominating, corporate governance and compliance committee has the sole authority to select, retain, oversee, and terminate
its own counsel, consultants, and advisors and approve the fees and other retention terms of such counsel, consultants, and
advisors, as it deems appropriate.
The nominating, corporate governance and compliance committee consists of Ms. Paul (Chair), Mr. Carney, Mr. Stevens, and
Ms. Weatherman. We believe that the composition of our nominating, corporate governance and compliance committee
complies under the applicable rules of the NASDAQ Stock Market. Our board of directors has determined that each of
Ms. Paul, Mr. Carney, Mr. Stevens, and Ms. Weatherman is an “independent director” under the rules of the NASDAQ Stock
Market.
The nominating, corporate governance and compliance committee considers all candidates recommended by our shareholders
pursuant to specific minimum qualifications that the nominating, corporate governance and compliance committee believes
must be met by a recommended nominee for a position on our board of directors, which qualifications are described in the
nominating, corporate governance and compliance committee’s charter, a copy of which is available on the Investor Relations-
Corporate Information-Governance Documents & Charters section of our corporate website www.wright.com. We have made
no material changes to the procedures by which shareholders may recommend nominees to our board of directors as described
in our most recent proxy statement.
Strategic Transactions Committee
The primary responsibilities of our strategic transactions committee include:
•
•
reviewing and evaluating potential opportunities for strategic business combinations, acquisitions, mergers,
dispositions, divestitures, investments, and similar strategic transactions involving our company or any one or
more of our subsidiaries outside the ordinary course of our business t(cid:75)(cid:68)(cid:87)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:68)(cid:85)(cid:76)(cid:86)(cid:72)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:30)
approving on behalf of our board of directors any strategic transaction that may arise from time to time and is
deemed appropriate by the strategic transactions committee and involves total cash consideration of less than $5.0
(cid:80)(cid:76)(cid:79)(cid:79)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:15)(cid:3) (cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:76)(cid:70)(cid:3) (cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3) (cid:70)(cid:82)(cid:80)(cid:80)(cid:76)(cid:87)(cid:87)(cid:72)(cid:72)(cid:3) (cid:76)(cid:86)(cid:3) (cid:81)(cid:82)(cid:87)(cid:3) (cid:68)(cid:88)(cid:87)(cid:75)(cid:82)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71)(cid:3) (cid:87)(cid:82)(cid:3) (cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:72)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:76)(cid:70)(cid:3)
transaction involving the issuance of capital stock or in which any director, officer, or affiliate of our company has
(cid:68)(cid:3)(cid:80)(cid:68)(cid:87)(cid:72)(cid:85)(cid:76)(cid:68)(cid:79)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:30)
•
•
• making recommendations to our board of directors concerning approval of any strategic transactions that may
arise from time to time and are deemed appropriate by the strategic transactions committee and are beyond the
authority of the strategic transactio(cid:81)(cid:86)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:76)(cid:87)(cid:87)(cid:72)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:72)(cid:30)
reviewing integration efforts with respect to completed strategic transactions from time to time and making
(cid:85)(cid:72)(cid:70)(cid:82)(cid:80)(cid:80)(cid:72)(cid:81)(cid:71)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:80)(cid:68)(cid:81)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:82)(cid:68)(cid:85)(cid:71)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:15)(cid:3)(cid:68)(cid:86)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:68)(cid:87)(cid:72)(cid:30)
assisting management in developing, implementing, and adhering to a strategic plan and direction for its activities
with respect to strategic transactions and making recommendations to management and our board of directors, as
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:68)(cid:87)(cid:72)(cid:30)(cid:3)
reviewing and approving the settlement or compromise of any mate(cid:85)(cid:76)(cid:68)(cid:79)(cid:3)(cid:79)(cid:76)(cid:87)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:85)(cid:3)(cid:70)(cid:79)(cid:68)(cid:76)(cid:80)(cid:3)(cid:68)(cid:74)(cid:68)(cid:76)(cid:81)(cid:86)(cid:87)(cid:3)(cid:88)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
reviewing and evaluating potential opportunities for restructuring our business in response to completed strategic
transactions or otherwise in an effort to realize anticipated cost and expense savings for, and other benefits, to our
company and making recommendations to management and our board of directors, as appropriate.
•
•
The strategic transactions committee reviews and evaluates periodically the performance of the committee and its members,
including compliance of the committee with its charter.
The strategic transactions committee has the sole authority to select, retain, oversee, and terminate its own counsel, consultants,
and advisors and approve the fees and other retention terms of such counsel, consultants, and advisors, as it deems appropriate.
The strategic transactions committee consists of Ms. Weatherman (Chair), Mr. Stevens, and Mr. Wallman.
Code of Business Conduct
We have adopted a code of business conduct, which applies to all of our directors, officers, and employees. The code of
business conduct is available on the Investor Relations-Corporate Information-Governance Documents & Charters section of
our corporate website at www.wright.com. Any person may request a copy free of charge by writing to James A. Lightman,
Senior Vice President, General Counsel and Secretary, Wright Medical Group N.V., Prins Bernhardplein 200, 1097 JB
Amsterdam, the Netherlands. We intend to disclose on our corporate website any amendment to, or waiver from, a provision of
our code of business conduct that applies to directors and executive officers and that is required to be disclosed pursuant to the
rules of the SEC and the NASDAQ Stock Market.
162
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors, executive officers, and all persons who beneficially own more than
10% of our outstanding ordinary shares to file with the SEC initial reports of ownership and reports of changes in ownership of
our ordinary shares. Directors, executive officers, and greater than 10% beneficial owners also are required to furnish us with
copies of all Section 16(a) forms they file. To our knowledge, based on review of the copies of such reports and amendments to
such reports furnished to us with respect to the year ended December 25, 2016, and based on written representations by our
directors and executive officers, all required Section 16 reports under the Exchange Act for our directors, executive officers,
and beneficial owners of greater than 10% of our ordinary shares were filed on a timely basis during the year ended December
25, 2016.
Item 11.
Executive Compensation.
Compensation Discussion and Analysis
In this Compensation Discussion and Analysis (CD&A), we describe the key principles and approaches we use to determine
elements of compensation paid to, awarded to and earned by the following executive officers, whose compensation is set forth
in the Summary Compensation Table found under “-Executive Compensation Tables and Narratives-Summary Compensation
Information”:
• (cid:53)(cid:82)(cid:69)(cid:72)(cid:85)(cid:87)(cid:3)(cid:45)(cid:17)(cid:3)(cid:51)(cid:68)(cid:79)(cid:80)(cid:76)(cid:86)(cid:68)(cid:81)(cid:82)(cid:15)(cid:3)(cid:90)(cid:75)(cid:82)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:72)(cid:86)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:76)(cid:71)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:38)(cid:75)(cid:76)(cid:72)(cid:73)(cid:3)(cid:40)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:50)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:30)
• Lance A. Berry, who serves as our Senior Vice President and Ch(cid:76)(cid:72)(cid:73)(cid:3)(cid:41)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:50)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:30)
• (cid:46)(cid:72)(cid:89)(cid:76)(cid:81)(cid:3)(cid:39)(cid:17)(cid:3)(cid:38)(cid:82)(cid:85)(cid:71)(cid:72)(cid:79)(cid:79)(cid:15)(cid:3)(cid:90)(cid:75)(cid:82)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:72)(cid:86)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:76)(cid:71)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3)(cid:56)(cid:17)(cid:54)(cid:17)(cid:30)(cid:3)
• (cid:51)(cid:72)(cid:87)(cid:72)(cid:85)(cid:3)(cid:54)(cid:17)(cid:3)(cid:38)(cid:82)(cid:82)(cid:78)(cid:72)(cid:15)(cid:3)(cid:90)(cid:75)(cid:82)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:72)(cid:86)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:51)(cid:85)(cid:72)(cid:86)(cid:76)(cid:71)(cid:72)(cid:81)(cid:87)(cid:15)(cid:3)(cid:44)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Robert P. Burrows, who serves as our Senior Vice President, Supply Chain.
We refer to these executive officers as our “named executive officers” and our President and Chief Executive Officer as our
“CEO” in this CD&A. This CD&A should be read in conjunction with the accompanying compensation tables, corresponding
notes and narrative discussion, as they provide additional information and context to our compensation disclosures.
Executive Summary
We devoted significant time and resources during 2016 to integrating the operations of legacy Wright and legacy Tornier and
aligning our executives with our combined company mission, vision and values. During 2016, we made significant and
measurable progress towards key business and financial objectives:
• We completed over 80% of our approximately 300 integration milestones, including the integration of our global
sales forces and the co-location of three of our top five international markets and consolidation into one enterprise
resource planning (ERP) system.
• We enjoyed better-than-expected timing of anticipated revenue dis-synergies and cost synergies from the merger.
• We materially improved our balance sheet, including our days on hand (DOH) inventory, instrument set utilization
and days sales outstanding (DSO).
• We sold our non-core European Large Joints business in October 2016.
• We removed significant uncertainty with our agreement to settle a substantial portion of our metal-on-metal hip
litigation claims in November 2016.
• We grew our core net sales at above-market growth rates. Our total net sales from continuing operations were
$690.4 million for 2016, representing annual growth of 70.3% over 2015.
One of our key executive compensation objectives is to link pay to performance by aligning the financial interests of our
executives with those of our shareholders and by emphasizing pay for performance in our compensation programs. We strive to
accomplish this objective primarily through our annual performance incentive plan (PIP), which compensates executives for
achieving annual corporate and divisional financial and other goals. For 2016, we had four corporate performance measures.
163
The table below sets forth the three corporate performance measures for 2016, in each case, from continuing operations and as
adjusted for certain items, which resulted in a payout.
2016 corporate performance metric
Global extremities and biologics net sales
Adjusted EBITDA
Free cash flow
Overall weighted corporate performance achievement rating
Payout
Between target and above target
At maximum
At maximum
155.8%
For each corporate performance measure, except one, we achieved between target and maximum levels of performance,
resulting in an overall weighted corporate performance achievement rating of 155.8% of target. The fourth corporate
performance goal related to AUGMENT® Bone Graft, as to which there was no payout. For our divisional performance
measures, we also achieved overall performance achievement weighted average ratings above target. These annual PIP payouts
resulted in overall executive compensation levels that are above our target positioning, which align with our above-market sales
growth and significant progress towards key business and financial objectives during 2016.
Shareholder Outreach Efforts and 2017 Changes to Our Executive Compensation
Looking forward to 2017, we intend to continue to align and focus our executives on key strategic priorities and financial
objectives. In furtherance of this objective, we have spent considerable time reviewing our executive compensation program to
ensure that it not only motivates our executives, but also aligns with shareholder interests and prevailing market practice.
As part of this review, we reached out and listened to shareholders. In fiscal 2016, we contacted our top 50 institutional
shareholders, representing approximately 86% of our outstanding ordinary shares and attended over 300 meetings for investors
and interested investors. For the individual investor meetings, our CEO, Chief Financial Officer and/or Chief Communications
Officer attended. The agenda for these meetings requested feedback from investors and shareholders and generally included:
(cid:11)(cid:20)(cid:12)(cid:3)(cid:68)(cid:3)(cid:85)(cid:72)(cid:89)(cid:76)(cid:72)(cid:90)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:82)(cid:83)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:30)(cid:3)(cid:11)(cid:21)(cid:12)(cid:3)(cid:68)(cid:3)(cid:86)(cid:88)(cid:80)(cid:80)(cid:68)(cid:85)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:72)(cid:74)(cid:76)(cid:70)(cid:3)(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:73)(cid:82)(cid:70)(cid:88)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:22)(cid:12)(cid:3)(cid:68)(cid:3)(cid:85)(cid:72)(cid:89)(cid:76)(cid:72)(cid:90)(cid:3)(cid:82)(cid:73)(cid:3)our
compensation philosophy and its alignment with our strategic direction. The three most common themes noted from investors
and shareholders include incorporating the use of performance-based equity awards, eliminating our single trigger change-in-
control provision in our equity plan and holding an annual say-on-pay vote.
As a result of this review and based on feedback from investors and shareholders, we intend to implement the following new
executive compensation practices during 2017:
Performance-Based Awards
Double Trigger Vesting
Minimum Vesting Periods
Clawback Policy
Annual Say-on-Pay Vote
We intend to change the mix of our executive long-term incentive awards to
incorporate performance-based awards. We plan to move to a mix comprised of one-
third performance-based awards, one-third time-based stock options and one-third
time-based restricted stock unit awards. We anticipate that the performance-based
awards will vest upon achievement of performance goals over a three-year
performance period.
We intend to submit a new equity and incentive plan to a vote of our shareholders at
our 2017 annual general meeting in June. We anticipate this new plan will
incorporate several new features, one of which is a new double trigger change-in-
control vesting provision.
We intend to incorporate into the new plan minimum vesting provisions that will
require all equity awards under the new plan to contain minimum vesting periods of
at least one year and three years for time-based full value awards granted to
employees.
We intend to adopt a clawback policy that will authorize recovery of gains from
incentive compensation, including equity awards, in the event of certain financial
restatements.
We intend to provide our shareholders with a say-on-pay vote every year as opposed
to our current practice of every three years.
164
Compensation Highlights and Best Practices
Our compensation practices include many best pay practices that support our executive compensation objectives and principles,
and benefit our shareholders.
What We Do:
Pay for Performance
Bonus Caps
We tie compensation directly to financial and other performance metrics. Our
annual PIP pays out only if certain levels of performance are met. In 2017, we
intend to grant performance-based awards, which will comprise of one-third of
executives’ long-term incentive and be paid out only if certain levels of
performance are met.
We cap our PIP bonuses and will cap our new performance-based awards at 200%
of target.
Performance Measure Mix
We use a mix of performance measures within our PIP.
At-risk Pay
Equity-based Pay
LTI Grant Guidelines
Long-term Vesting
Clawback Policy
A significant portion of our executive compensation is “performance-based” or “at
risk.”
A significant portion of our executive compensation is “equity-based” and in the
form of equity awards.
We have adopted and review annually long-term incentive guidelines for the grant
of equity awards.
Value received under equity awards is tied to three to four-year vesting and any
value from stock options is contingent upon long-term stock price performance.
Our performance-based awards will vest only if certain levels of performance are
achieved over a three-year performance period.
Our PIP and stock incentive plan include “clawback” mechanisms to recoup
incentive compensation if it is determined that executives engaged in certain
conduct adverse to our interests.
Stock Ownership Guidelines
We maintain stock ownership guidelines for all our executives.
Independent Committee and
Consultant
We have an independent compensation committee which is advised by an
independent external compensation consultant.
What We Don’t Do:
No Repricing
We do not allow repricing or exchange of any equity awards without shareholder
approval.
No Excessive Perquisites
We do not provide excessive perquisites to our executives.
No Tax Gross-Ups
No Hedging or Pledging
We do not provide tax “gross-up” payments to our executives, other than customary
tax gross-up payments under our relocation policy and to our CEO under his
employment agreement.
We do not allow our employees to engage in hedging transactions, including short
sales, transactions in publicly traded options, such as puts, calls and other
derivatives, and pledging our securities.
No Dividends on Unvested Awards
We do not pay dividends on unvested equity awards.
165
Say-on-Pay Vote
We are required to provide our shareholders with an advisory non-binding vote on the compensation paid to our named
executive officers, or say-on-pay vote. In addition, we are required every six years to ask our shareholders to indicate the
frequency with which they believe a say-on-pay vote should occur. We last asked our shareholders to indicate their preferred
frequency of a say-on-pay vote at our 2011 annual general meeting. At this meeting, our shareholders voted overwhelmingly
for a frequency of every three years. Accordingly, we last submitted a say-on-pay proposal to our shareholders at our 2014
annual general meeting held on June 26, 2014. At this meeting, over 99% of the votes cast by our shareholders were in favor of
our say-on-pay vote.
At our 2017 annual general meeting to be held in June 2017, our shareholders will have the opportunity again to vote on a say-
on-pay proposal. In addition, our shareholders will have the opportunity again to provide an advisory vote on the frequency of
our say-on-pay vote.
Because of the change in our shareholder base since 2011 and the current preference of several shareholders as expressed to us
during our shareholder outreach efforts, our board of directors, upon recommendation of the compensation committee, intends
to recommend a say-on-pay vote frequency of every year. We have determined that a say-on-pay vote every year is the best
approach for our company and shareholders for a number of reasons, including:
•
•
•
•
It is consistent with the preference of many of our shareholders.
It allows our shareholders to provide timely, direct input on our executive compensation philosophy, policies and
practices as disclosed in our proxy statement each year.
It is consistent with our review of core elements of our executive compensation program annually.
It is consistent with our efforts to engage in an ongoing dialogue with shareholders on executive compensation
and corporate governance matters.
Compensation Objectives and Philosophies
Our executive compensation policies, plans and programs seek to enhance our financial performance, and thus shareholder
value, by aligning the financial interests of our executives with those of our shareholders and by emphasizing pay-for-
performance. Specifically, our executive compensation programs are designed to:
• (cid:53)(cid:72)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:70)(cid:72)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:72)(cid:3)(cid:80)(cid:76)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:89)(cid:76)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:86)(cid:30)
• (cid:36)(cid:87)(cid:87)(cid:85)(cid:68)(cid:70)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:76)(cid:80)(cid:83)(cid:82)(cid:85)(cid:87)(cid:68)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)
• Align the interests of our (cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:79)(cid:71)(cid:72)(cid:85)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
• Reward executives for the achievement of company performance objectives, the creation of shareholder value in
the short- and long-term, and their contributions to the success of our company.
To achieve these objectives, the compensation committee makes executive compensation decisions based on the following
philosophies:
• Base salary and total compensation levels will generally be targeted to be within a reasonable range of the 67th
percentile of a group of similarly-sized peer companies. However, the specific competitiveness of any individual
executive’s salary and compensation will be determined considering factors like the executive’s experience, skills
and capabilities, contributions as a member of the executive management team, contributions to our overall
performance, and the sufficiency of total compensation potential to ensure the retention of an executive when
considering the compensation potential that may be available elsewhere.
• At least two-thirds of the CEO’s compensation and half of other executives’ compensation opportunity should be
in the form of variable compensation that is tied to financial results and/or creation of shareholder value.
• The portion of total compensation that is performance-based or at-risk should increase with an executive’s overall
responsibilities, job level, and compensation. However, compensation programs should not encourage excessive
risk-taking behavior among executives and should support our commitment to corporate compliance.
• Primary emphasis should be placed on company performance as measured against goals approved by the
compensation committee rather than on individual performance.
• At least half of the CEO’s compensation and one-third of other executives’ compensation opportunity should be
in the form of stock-based incentive awards.
166
(cid:40)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:38)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:38)(cid:82)(cid:80)(cid:83)(cid:82)(cid:81)(cid:72)(cid:81)(cid:87)(cid:86)
(cid:55)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:76)(cid:81)(cid:70)(cid:76)(cid:83)(cid:68)(cid:79)(cid:3)(cid:72)(cid:79)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:68)(cid:80)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:3)(cid:90)(cid:72)(cid:85)(cid:72)(cid:29)
•
•
•
•
(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:30)
(cid:86)(cid:75)(cid:82)(cid:85)(cid:87)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)
(cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3) (cid:72)(cid:84)(cid:88)(cid:76)(cid:87)(cid:92)-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3) (cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:80)(cid:3) (cid:82)(cid:73)(cid:3) (cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3) (cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:85)(cid:72)(cid:86)(cid:87)(cid:85)(cid:76)(cid:70)(cid:87)(cid:72)(cid:71)(cid:3) (cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3) (cid:88)(cid:81)(cid:76)(cid:87)(cid:3) (cid:11)(cid:53)(cid:54)(cid:56)(cid:12)(cid:3)
(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:85)(cid:85)(cid:68)(cid:81)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:15)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:68)(cid:86)(cid:3)(cid:69)(cid:72)(cid:81)(cid:72)(cid:73)(cid:76)(cid:87)(cid:86)(cid:3)(cid:80)(cid:68)(cid:71)(cid:72)(cid:3)(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:68)(cid:89)(cid:68)(cid:76)(cid:79)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:72)(cid:86)(cid:15)(cid:3)(cid:79)(cid:76)(cid:80)(cid:76)(cid:87)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
(cid:80)(cid:82)(cid:71)(cid:72)(cid:86)(cid:87)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:69)(cid:72)(cid:81)(cid:72)(cid:73)(cid:76)(cid:87)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:83)(cid:72)(cid:85)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:72)(cid:86)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:3)(cid:68)(cid:85)(cid:85)(cid:68)(cid:81)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)
(cid:40)(cid:91)(cid:70)(cid:72)(cid:83)(cid:87)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:90)(cid:76)(cid:86)(cid:72)(cid:3)(cid:71)(cid:72)(cid:86)(cid:70)(cid:85)(cid:76)(cid:69)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:76)(cid:86)(cid:3)(cid:38)(cid:39)(cid:9)(cid:36)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:76)(cid:87)(cid:87)(cid:72)(cid:72)(cid:3)(cid:75)(cid:68)(cid:86)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:71)(cid:82)(cid:83)(cid:87)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:79)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:79)(cid:3)(cid:83)(cid:82)(cid:79)(cid:76)(cid:70)(cid:76)(cid:72)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)
(cid:74)(cid:88)(cid:76)(cid:71)(cid:72)(cid:79)(cid:76)(cid:81)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:79)(cid:79)(cid:82)(cid:70)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:69)(cid:72)(cid:87)(cid:90)(cid:72)(cid:72)(cid:81)(cid:3) (cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:87)(cid:79)(cid:92)(cid:3) (cid:83)(cid:68)(cid:76)(cid:71)(cid:3) (cid:82)(cid:88)(cid:87)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3) (cid:69)(cid:72)(cid:87)(cid:90)(cid:72)(cid:72)(cid:81)(cid:3) (cid:70)(cid:68)(cid:86)(cid:75)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:81)(cid:82)(cid:81)-(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:80)(cid:82)(cid:81)(cid:74)(cid:3)(cid:71)(cid:76)(cid:73)(cid:73)(cid:72)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:73)(cid:82)(cid:85)(cid:80)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:81)(cid:82)(cid:81)-(cid:70)(cid:68)(cid:86)(cid:75)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:17)(cid:3)(cid:3)(cid:43)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:70)(cid:82)(cid:80)(cid:80)(cid:76)(cid:87)(cid:87)(cid:72)(cid:72)(cid:182)(cid:86)(cid:3)(cid:83)(cid:75)(cid:76)(cid:79)(cid:82)(cid:86)(cid:82)(cid:83)(cid:75)(cid:92)(cid:3)(cid:76)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)
(cid:80)(cid:68)(cid:78)(cid:72)(cid:3)(cid:68)(cid:3)(cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3)(cid:83)(cid:72)(cid:85)(cid:70)(cid:72)(cid:81)(cid:87)(cid:68)(cid:74)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:182)(cid:86)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:3)(cid:68)(cid:87)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:15)(cid:3)(cid:68)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:182)(cid:86)(cid:3)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)
(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:68)(cid:86)(cid:72)(cid:86)(cid:3)(cid:74)(cid:76)(cid:89)(cid:72)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:73)(cid:79)(cid:88)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:80)(cid:82)(cid:85)(cid:72)(cid:3)(cid:86)(cid:72)(cid:81)(cid:76)(cid:82)(cid:85)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:74)(cid:72)(cid:81)(cid:72)(cid:85)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:75)(cid:68)(cid:89)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:17)(cid:3)(cid:3)
(cid:55)(cid:75)(cid:88)(cid:86)(cid:15)(cid:3) (cid:76)(cid:81)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:88)(cid:68)(cid:79)(cid:86)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3) (cid:85)(cid:82)(cid:79)(cid:72)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3) (cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:68)(cid:70)(cid:75)(cid:76)(cid:72)(cid:89)(cid:76)(cid:81)(cid:74)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3) (cid:86)(cid:75)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3) (cid:69)(cid:72)(cid:68)(cid:85)(cid:3) (cid:68)(cid:3) (cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3)
(cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:85)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:87)(cid:75)(cid:82)(cid:86)(cid:72)(cid:3)(cid:74)(cid:82)(cid:68)(cid:79)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:70)(cid:75)(cid:76)(cid:72)(cid:89)(cid:72)(cid:71)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:75)(cid:82)(cid:88)(cid:79)(cid:71)(cid:3)(cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:3)(cid:74)(cid:85)(cid:72)(cid:68)(cid:87)(cid:72)(cid:85)(cid:3)(cid:83)(cid:85)(cid:82)(cid:83)(cid:82)(cid:85)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:85)(cid:72)(cid:90)(cid:68)(cid:85)(cid:71)(cid:3)(cid:76)(cid:73)(cid:3)(cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)
(cid:80)(cid:72)(cid:87)(cid:3) (cid:82)(cid:85)(cid:3) (cid:86)(cid:88)(cid:85)(cid:83)(cid:68)(cid:86)(cid:86)(cid:72)(cid:71)(cid:17)(cid:3) (cid:3) (cid:36)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:74)(cid:79)(cid:92)(cid:15)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:76)(cid:86)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:68)(cid:87)(cid:3) (cid:79)(cid:72)(cid:68)(cid:86)(cid:87)(cid:3) (cid:87)(cid:90)(cid:82)-(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:38)(cid:40)(cid:50)(cid:182)(cid:86)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:82)(cid:81)(cid:72)-(cid:75)(cid:68)(cid:79)(cid:73)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)
(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:182)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:92)(cid:3)(cid:69)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:80)(cid:3)(cid:82)(cid:73)(cid:3)(cid:89)(cid:68)(cid:85)(cid:76)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:76)(cid:86)(cid:3)(cid:87)(cid:76)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3)(cid:85)(cid:72)(cid:86)(cid:88)(cid:79)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
(cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:68)(cid:87)(cid:3) (cid:79)(cid:72)(cid:68)(cid:86)(cid:87)(cid:3) (cid:75)(cid:68)(cid:79)(cid:73)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:38)(cid:40)(cid:50)(cid:182)(cid:86)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:82)(cid:81)(cid:72)-(cid:87)(cid:75)(cid:76)(cid:85)(cid:71)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3) (cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:182)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:83)(cid:83)(cid:82)(cid:85)(cid:87)(cid:88)(cid:81)(cid:76)(cid:87)(cid:92)(cid:3) (cid:69)(cid:72)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:80)(cid:3) (cid:82)(cid:73)(cid:3)
(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:17)
(cid:55)(cid:75)(cid:72)(cid:3) (cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79)(cid:79)(cid:3) (cid:80)(cid:76)(cid:91)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:69)(cid:68)(cid:86)(cid:72)(cid:3) (cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:76)(cid:72)(cid:86)(cid:15)(cid:3) (cid:87)(cid:68)(cid:85)(cid:74)(cid:72)(cid:87)(cid:3) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:70)(cid:68)(cid:86)(cid:75)(cid:3) (cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:3) (cid:71)(cid:68)(cid:87)(cid:72)(cid:3) (cid:73)(cid:68)(cid:76)(cid:85)(cid:3) (cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3) (cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3) (cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)
(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:68)(cid:86)(cid:3)(cid:68)(cid:3)(cid:83)(cid:72)(cid:85)(cid:70)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:68)(cid:85)(cid:74)(cid:72)(cid:87)(cid:3)(cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:38)(cid:40)(cid:50)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:81)(cid:68)(cid:80)(cid:72)(cid:71)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:86)(cid:3)(cid:68)(cid:86)(cid:3)(cid:68)(cid:3)(cid:74)(cid:85)(cid:82)(cid:88)(cid:83)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:3)(cid:76)(cid:86)(cid:3)
(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:3)(cid:69)(cid:72)(cid:79)(cid:82)(cid:90)(cid:17)(cid:3)(cid:3)(cid:55)(cid:75)(cid:72)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:86)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:3)(cid:73)(cid:68)(cid:76)(cid:85)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3) (cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)
(cid:53)(cid:54)(cid:56)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:72)(cid:71)(cid:3)(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:17)(cid:3)(cid:3)(cid:36)(cid:70)(cid:87)(cid:88)(cid:68)(cid:79)(cid:3)(cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:90)(cid:76)(cid:79)(cid:79)(cid:3)(cid:69)(cid:72)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:82)(cid:81)(cid:3)(cid:79)(cid:82)(cid:81)(cid:74)-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3)(cid:83)(cid:85)(cid:76)(cid:70)(cid:72)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:17)(cid:3)(cid:3)(cid:36)(cid:79)(cid:79)(cid:3)
(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:86)(cid:3)(cid:72)(cid:91)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:71)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:87)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:69)(cid:72)(cid:79)(cid:82)(cid:90)(cid:17)
(cid:37)(cid:68)(cid:86)(cid:72)(cid:3)(cid:54)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)
(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)
(cid:50)(cid:89)(cid:72)(cid:85)(cid:89)(cid:76)(cid:72)(cid:90)(cid:17)(cid:3)(cid:3)(cid:58)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:3)(cid:68)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:81)(cid:68)(cid:80)(cid:72)(cid:71)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:15)(cid:3)(cid:88)(cid:81)(cid:79)(cid:76)(cid:78)(cid:72)(cid:3)(cid:86)(cid:82)(cid:80)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:72)(cid:79)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)
(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:85)(cid:82)(cid:74)(cid:85)(cid:68)(cid:80)(cid:15)(cid:3)(cid:76)(cid:86)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:86)(cid:88)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:88)(cid:68)(cid:79)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:17)(cid:3)(cid:3)(cid:58)(cid:72)(cid:3)(cid:85)(cid:72)(cid:70)(cid:82)(cid:74)(cid:81)(cid:76)(cid:93)(cid:72)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:81)(cid:72)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:80)(cid:82)(cid:86)(cid:87)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)
(cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:72)(cid:3) (cid:68)(cid:87)(cid:3) (cid:79)(cid:72)(cid:68)(cid:86)(cid:87)(cid:3) (cid:68)(cid:3) (cid:83)(cid:82)(cid:85)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3) (cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:80)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:3) (cid:74)(cid:88)(cid:68)(cid:85)(cid:68)(cid:81)(cid:87)(cid:72)(cid:72)(cid:71)(cid:3) (cid:69)(cid:68)(cid:86)(cid:72)(cid:3) (cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:76)(cid:86)(cid:3) (cid:83)(cid:68)(cid:76)(cid:71)(cid:3) (cid:76)(cid:81)(cid:3) (cid:70)(cid:68)(cid:86)(cid:75)(cid:3) (cid:85)(cid:72)(cid:74)(cid:88)(cid:79)(cid:68)(cid:85)(cid:79)(cid:92)(cid:3)
(cid:87)(cid:75)(cid:85)(cid:82)(cid:88)(cid:74)(cid:75)(cid:82)(cid:88)(cid:87)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:92)(cid:72)(cid:68)(cid:85)(cid:17)(cid:3)(cid:3)(cid:37)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:72)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:72)(cid:71)(cid:3)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:75)(cid:76)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:15)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:68)(cid:85)(cid:72)(cid:3)(cid:86)(cid:88)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:86)(cid:88)(cid:69)(cid:86)(cid:72)(cid:84)(cid:88)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:68)(cid:71)(cid:77)(cid:88)(cid:86)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:17)
(cid:54)(cid:72)(cid:87)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:44)(cid:81)(cid:76)(cid:87)(cid:76)(cid:68)(cid:79)(cid:3)(cid:54)(cid:68)(cid:79)(cid:68)(cid:85)(cid:76)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:49)(cid:72)(cid:90)(cid:3)(cid:40)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:17)(cid:3)(cid:3)(cid:58)(cid:72)(cid:3)(cid:76)(cid:81)(cid:76)(cid:87)(cid:76)(cid:68)(cid:79)(cid:79)(cid:92)(cid:3)(cid:73)(cid:76)(cid:91)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:76)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:3)(cid:68)(cid:87)(cid:3)(cid:68)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:90)(cid:72)(cid:3)(cid:69)(cid:72)(cid:79)(cid:76)(cid:72)(cid:89)(cid:72)(cid:3)(cid:72)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:86)(cid:3)(cid:88)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:75)(cid:76)(cid:85)(cid:72)(cid:3)
(cid:68)(cid:81)(cid:71)(cid:3) (cid:85)(cid:72)(cid:87)(cid:68)(cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:80)(cid:3) (cid:76)(cid:81)(cid:3) (cid:68)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:87)(cid:76)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:72)(cid:81)(cid:89)(cid:76)(cid:85)(cid:82)(cid:81)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:87)(cid:82)(cid:3) (cid:85)(cid:72)(cid:90)(cid:68)(cid:85)(cid:71)(cid:3) (cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3) (cid:76)(cid:81)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:88)(cid:68)(cid:79)(cid:3) (cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:68)(cid:3) (cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:68)(cid:70)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3) (cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3) (cid:82)(cid:73)(cid:3)
(cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79)(cid:79)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:17)
167
Annual Salary Increases. We review the base salaries of our named executive officers each year following the completion of
our prior year individual performance reviews. If appropriate, we increase base salaries to recognize annual increases in the
cost of living and superior individual performance and to ensure that our base salaries remain market competitive. In addition,
with respect to Mr. Palmisano, we also take into consideration his employment agreement which provides that we review his
base salary at least annually for any increase. We refer to annual base salary increases as a result of cost of living adjustments
and individual performance as “merit increases.” In addition, we may make additional upward adjustments to an executive’s
base salary to compensate the executive for assuming increased roles and responsibilities, to retain an executive at risk of
recruitment by other companies, and/or to bring an executive’s base salary closer to our target market positioning of companies
in our peer group. We refer to these base salary increases as “market adjustments.”
The 2016 base salary merit increases for our named executive officers ranged from zero to 4.0% over their respective 2015 base
salaries. The only upward market adjustment made during 2016 was a 10.0% increase in Mr. Cordell’s base salary in
connection with his promotion to President, U.S. in June 2016 to bring his base salary closer to our target market positioning of
companies in our peer group. We believe the base salaries of all of our named executive officers are within a reasonable range
of our targeted positioning among our peer group, other than Mr. Burrows whose 2016 base salary was above the range.
Mr. Burrows was a consultant for legacy Wright prior to becoming a full-time employee and his base salary reflects a premium
that was required to recruit him to a full-time position.
2016 Base Salaries. The table below sets forth the 2015 base salaries (which were effective October 1, 2015 with the
completion of the Wright/Tornier merger) of our named executive officers, their 2016 base salaries effective April 1, 2016, and
in the case of Mr. Cordell, effective June 10, 2016 with his promotion to President, U.S., and the percentage increase compared
to their 2015 base salaries:
Name
2015
base salary
($)
$886,200
397,500
397,500
384,000
503,500
2016
base salary
($)
$921,648
413,400
454,740
384,000
518,605
2016 base salary %
increase compared to
2015 base salary
4.0%
4.0%
14.4%
0.0%
3.0%
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell (1)
Peter S. Cooke
Robert P. Burrows
___________________________
(1) Mr. Cordell’s 2016 base salary reflects his 4% merit increase in February 2016 and his 10% market adjustment in connection with his
promotion in June 2016.
2017 Base Salaries. In February 2017, we set the following base salaries for 2017 for our named executive officers effective
April 1, 2017: Mr. Palmisano ($958,514), Mr. Berry ($450,000), Mr. Cordell ($470,656), Mr. Cooke ($397,440) and
Mr. Burrows ($534,163). The 2017 base salaries represent merit increases of 3.0% to 4.0% over their respective 2016 base
salaries. No upward market adjustments were made.
Short-Term Cash Incentive Compensation
Our short-term cash incentive compensation is paid as an annual cash bonus under our PIP and is intended to compensate
executives for achieving annual corporate financial performance goals and, in some cases, divisional financial and individual
performance goals. The PIP provides broad discretion to the compensation committee in interpreting and administering the
plan. All 2016 short-term cash incentive bonuses to our named executive officers are expected to be paid out in early March
2017 and were dependent upon executives’ continued service through the end of fiscal 2016.
Target Bonus Percentages. Target short-term cash incentive bonuses for 2016 for each executive were based on a percentage of
base salary and were as follows for each named executive officer:
Name
Percentage of base salary
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
___________________________
* Mr. Cordell’s target bonus percentage increased to 60% in June 2016 in connection with his promotion to President, U.S.
100%
65%
55%/60% *
55%
50%
168
The 2016 target bonus percentages for our named executive officers did not change from their second half of 2015 levels,
except in the case of Mr. Berry whose percentage increased to 65% and Mr. Cordell, whose percentage increased from 55% to
60% in connection with his promotion in June 2016. Based on an executive compensation analysis by our compensation
consultant, we believe the target bonus percentages for our named executive officers are generally aligned with our target
market positioning within our peer group.
Performance Goal Mix. 2016 bonuses to our named executive officers were based upon achievement of corporate performance
goals for all executives, as well as divisional performance goals for Messrs. Cordell and Cooke, and individual performance
goals for Mr. Burrows.
Named executive officer
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
Percentage based upon
corporate
performance goals
100%
100%
40%
40%
80%
Percentage based upon
divisional
performance goals
0%
0%
60%
60%
0%
Percentage based upon
individual
performance goals
0%
0%
0%
0%
20%
Corporate Performance Goals. For 2016, we had four corporate performance measures, three of which resulted in a payout and
one of which did not. The three corporate performance measures which resulted in a payout and their weightings for 2016 are
set forth in the table below. The fourth corporate performance goal related to AUGMENT® Bone Graft, as to which there was
no payout. These four measures were selected because they were determined to be the four most important indicators of our
financial performance for 2016 as evaluated by management and analysts.
2016 corporate performance metric
Global extremities and biologics net sales (1)
Adjusted EBITDA (2)
Free cash flow (3)
___________________________
(1) This performance measure was calculated using a non-GAAP financial measure, which we believe provides meaningful supplemental
information regarding our core operational performance. The global extremities and biologics net sales goal and actual results were
calculated based on a foreign currency exchange planning rate to adjust for any impact of foreign currency on underlying performance.
Weighting
30%
30%
30%
(2) This performance measure was calculated using a non-GAAP financial measure, which we believe provides meaningful supplemental
information regarding our core operational performance. Adjusted EBITDA from continuing operations means net loss from continuing
operations plus charges for interest, income taxes, depreciation and amortization expenses, non-cash share-based compensation expense
and non-operating income and expense. Additionally, adjusted EBITDA from continuing operations excluded due diligence, transaction
(cid:68)(cid:81)(cid:71)(cid:3)
(cid:86)(cid:87)(cid:72)(cid:83)-(cid:88)(cid:83)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:69)(cid:82)(cid:81)(cid:88)(cid:86)(cid:3)
compensation. Notwithstanding the foregoing, adjusted EBITDA included the results of operations for our Large Joints business through
the third quarter of 2016.
(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:86)(cid:3) (cid:68)(cid:86)(cid:86)(cid:82)(cid:70)(cid:76)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:71)(cid:76)(cid:89)(cid:72)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3) (cid:68)(cid:80)(cid:82)(cid:85)(cid:87)(cid:76)(cid:93)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3)
(cid:76)(cid:81)(cid:89)(cid:72)(cid:81)(cid:87)(cid:82)(cid:85)(cid:92)(cid:3)
(3) This performance measure was calculated using a non-GAAP financial measure, which we believe provides meaningful supplemental
information regarding our core operational performance. Adjusted free cash flow means net cash flow provided by operating activities,
excluding net cash flow from certain discontinued operations, less capital expenditures. In 2016, we excluded OrthoRecon for the entire
year plus the amount of transition costs related to the divestiture of our Large Joints business to Corin, as well as the forecasted EBITDA
from the Large Joints segment after the divestiture of that business.
The percentage of the target bonus earned by bonus objective was based on the following performance levels:
Performance level
Minimum
Threshold (50% payout)
Target (100% payout)
Above target (150% payout)
High (200% payout)
Percent of target bonus earned
0%
50.1% to 99.9%
100%
100.1% to 150%
150.1% to 200%
A participant would not be paid for a performance measure where achievement was below the threshold performance goal. If
the target performance goal was exceeded, we would pay a bonus in excess of the target performance bonus. However, no
participant would be paid an amount which exceeded twice the target performance bonus.
In setting the threshold, target, above target, and maximum performance achievement levels, we considered past performance,
market conditions, and the financial, strategic, and operational plans presented by management. When setting the target
169
performance levels, we sought to ensure that at- or above-market performance was the goal. For above-target performance
levels, the achievement levels required “stretch” performance by the management team to achieve this level of performance. At
the threshold level, targets would be set on a steeper slope than at the above target/maximum categories, so that missed target
performance would result in more rapidly declining bonus opportunity, and below the threshold level, no bonus was paid for
that performance level.
The performance level of each corporate performance measure for 2016 in which a payout resulted is set forth in the table
below.
Performance level
Minimum
Threshold (50% payout)
Target (100% payout)
Above target (150% payout)
High (200% payout)
Global extremities and
biologics net sales
$628.1 million
$652.3 million
$677.0 million
$697.9 million
$727.8 million
Adjusted EBITDA
$43.8 million
$52.4 million
$60.9 million
$70.3 million
$91.9 million
Free cash flow
$(81.0) million
$(72.1) million
$(63.6) million
$(55.1) million
$(46.2) million
The adjusted EBITDA performance goals were adjusted by the compensation committee in October 2016 to reflect the
anticipated impact to fourth quarter 2016 adjusted EBITDA from the sale of our Large Joints business. Although our free cash
flow goals for 2016 were also impacted by the sale of our Large Joints business, the compensation committee decided not to
adjust the goals but rather to adjust the actual result to reflect the sale since the latter would be more precise.
The table below sets forth our actual performance for each corporate performance measure in which a payout resulted and the
resulting payout for each and the overall weighted corporate performance achievement rating, which was 155.8% of target.
2016 corporate performance measures and weighting
Global extremities and biologics net sales (30%)
Adjusted EBITDA (30%)
Free cash flow (30%)
Overall weighted achievement rating
Actual
$685.1 million
$92.5 million
$(26.3) million
Payout
119.3%
200%
200%
155.8%
The fourth corporate performance goal related to AUGMENT® Bone Graft, as to which there was no payout.
Divisional Performance Goals. As President of a business unit, Mr. Cordell’s 2016 PIP bonus was based 40% on corporate
performance goals and 60% on divisional performance goals. For the first six months of 2016, Mr. Cordell was President,
(cid:47)(cid:82)(cid:90)(cid:72)(cid:85)(cid:3)(cid:40)(cid:91)(cid:87)(cid:85)(cid:72)(cid:80)(cid:76)(cid:87)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:37)(cid:76)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:71)(cid:76)(cid:89)(cid:76)(cid:86)(cid:76)(cid:82)(cid:81)(cid:68)(cid:79)(cid:3)(cid:83)(cid:82)(cid:85)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:3)(cid:51)(cid:44)(cid:51)(cid:3)(cid:69)(cid:82)(cid:81)(cid:88)s was based on the performance of
the U.S. lower extremities and biologics business. In June 2016, Mr. Cordell was promoted to President, U.S. and given his
new responsibilities, the compensation committee determined that it was appropriate that the divisional performance portion of
his 2016 PIP bonus for the remainder of 2016 be tied to the U.S. business and reflect the performance of that business for the
full year 2016 as opposed to just the last six months. Accordingly, 55% of Mr. Cordell’s 2016 PIP bonus was based on the
performance of the U.S. lower extremities and biologics business during the first six months of 2016, and the remainder was
based on the performance of the entire U.S. business during all of 2016.
The portion of Mr. Cordell’s 2016 PIP bonus that was tied to the performance of the U.S. lower extremities and biologics
business was based on net sales. With respect to this performance measure, the U.S. lower extremities and biologics business
performed above target, resulting in a weighted achievement rating of 150.7% of target for that portion of Mr. Cordell’s 2016
PIP bonus. The portion of Mr. Cordell’s 2016 PIP bonus that was tied to the performance of the entire U.S. business was based
on five divisional performance measures. The table below sets forth the four U.S. divisional performance measures in which a
payout resulted and reflects how that business unit performed in 2016 and the overall weighted average divisional performance
achievement rating. The fifth performance measure related to AUGMENT® Bone Graft, as to which there was no payout.
Taking into account the two components, Mr. Cordell’s 2016 PIP bonus reflected an overall weighted average achievement
rating of 152.7% of target.
2016 divisional performance measures and weighting
U.S. net sales (32%)
Adjusted EBITDA for U.S. business (30%)
DOH for U.S. business (15%)
DSO for U.S. business (15%)
Overall weighted achievement rating
2016 performance
Between target and above target
Slightly below maximum
Between above target and maximum
Between target and above target
Between target and above target
170
As President, International, Mr. Cooke’s 2016 annual PIP bonus was also based 40% on corporate performance goals and 60%
on international divisional performance goals. The table below sets forth the divisional performance measures for the
international business and reflects how that business unit performed in 2016 and the overall weighted average divisional
performance achievement rating. Taking into account the two components, Mr. Cooke’s 2016 PIP bonus reflected an overall
weighted average achievement rating of 137.3% of target.
International divisional performance measures and weightings
International extremities and biologics net sales (35%)
Adjusted EBITDA for international extremities and biologics (35%)
DOH for international extremities and biologics (15%)
DSO for international (15%)
Overall weighted achievement rating
2016 performance
Between threshold and target
Above target
Between threshold and target
At maximum
Between target and above target
The specific performance levels for each divisional performance measure are maintained as proprietary and confidential. We
believe that disclosure of these specific performance levels would represent competitive harm to us as these divisional goals
and results are not publicly disclosed and are competitively sensitive. For each divisional performance measure, the target goal
reflects the annual financial business plan goal set for each respective division. Based on historical performance, the
compensation committee believes the attainment of the target performance level, while uncertain, could be reasonably
anticipated. Threshold goals represent the minimum level of performance necessary for there to be a payout for that
performance measure and the compensation committee believes the threshold goals are likely to be achieved. Maximum goals
represent levels of performance at which the compensation committee determines a payout of 200% of target would be
appropriate. The compensation committee believes that the maximum goals established for each division performance measure
are more aggressive goals.
Individual Performance Goals. To foster cooperation and communication among executives, the compensation committee
places primary emphasis on overall corporate and divisional performance goals rather than on individual performance goals.
For named executive officers, at least 80% of their 2016 annual PIP bonuses were determined based on the achievement of
corporate or divisional performance goals and only 20% or less were based on achievement of individual performance goals.
The individual performance goals used to determine annual PIP bonuses were management by objectives, known internally as
MBOs. MBOs are generally two to three written, specific and measurable objectives agreed to and approved by the executive,
CEO and compensation committee in the beginning of the year. The only named executive officer with MBOs was
Mr. Burrows and his MBO achievement rating was 4.15. Mr. Burrows’s MBOs related to supply chain vital few initiatives that
would have a positive cash impact, Wright/Tornier merger integration activities related to supply chain, and future cash flow
opportunities in supply chain.
2016 Actual PIP Bonuses. The table below sets for the 2016 PIP bonuses for all named executive officers, which bonuses are
anticipated to be paid at the beginning of March 2017:
Named executive officer
2016 PIP bonus
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
$
1,435,928
418,650
376,693
289,893
404,875
PIP Performance Goals for 2017. In February 2017, the compensation committee approved PIP performance goals for 2017.
The 2017 target bonus percentages for our named executive officers did not change from their 2016 levels. Consistent with the
design for 2016 plan, the annual bonus for our CEO will be based 100% on achievement of corporate performance goals, with
no individual performance components. Bonuses for our other named executive officers will be based 100% on achievement of
corporate performance goals for Mr. Berry, 40% on achievement of corporate performance goals and 60% on achievement of
divisional performance goals for Messrs. Cordell and Cooke, and 80% on achievement of corporate performance goals and
20% on achievement of individual goals for Mr. Burrows. Mr. Cordell’s divisional performance goals will be split equally
between the U.S. lower extremities and biologics business and the U.S. upper extremities business and Mr. Cooke’s divisional
performance goals will be based on the international business. The corporate performance measures for 2017 will be based on
net sales, adjusted EBITDA from continuing operations, and free cash flow. The divisional performance goals for
Messrs. Cordell and Cooke will be similar to the goals for 2016. The individual goals for Mr. Burrows will relate to our high
performance management system supply chain initiatives.
171
Long-Term Equity-Based Incentive Compensation
Generally. The compensation committee’s primary objectives with respect to long-term equity-based incentives are to align the
interests of our executives with the long-term interests of our shareholders, promote stock ownership, and create significant
incentives for executive retention. Long-term equity-based incentives typically comprise a significant portion of each named
executive officer’s compensation package, consistent with our executive compensation philosophy.
Types of Equity Grants. Under our long-term incentive grant guidelines, our board of directors, on recommendation of the
compensation committee, generally grants two types of equity-based incentive awards to our named executive officers:
performance recognition grants and talent acquisition grants. On limited occasion, we may make special recognition grants or
discretionary grants to executive officers for retention or other purposes. Such grants may vest based on the passage of time
and/or the achievement of certain performance goals. During 2016, only annual performance recognition grants were made to
one or more of our named executive officers, as described in more detail under “-2016 Equity Awards.”
Performance recognition grants are discretionary annual grants that are made during mid-year to give the compensation
committee another formal opportunity during the year to review executive compensation and recognize executive and other key
employee performance. The recipients and size of the annual performance recognition grants are determined based on our
long-term incentive grant guidelines, which we review annually to ensure continued alignment with our target positioning.
Under our long-term incentive grant guidelines for annual performance recognition grants, named executive officers received a
certain percentage of their respective base salaries in stock options and RSU awards. Consistent with the principle that the
interests of our executives should be aligned with those of our shareholders and that the portion of an executive’s total
compensation that varies with performance and is at risk should increase with the executive’s level of responsibility, incentive
grants, expressed as a percentage of base salary and dollar values, increase as an executive’s level of responsibility increases.
The table below describes our long-term incentive grant guidelines for annual performance recognition grants that applied to
our named executive officers for 2016.
Named executive officer
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
Incentive grant guideline
expressed as % of base salary
400%
200%
175%
100%
100%
$
Dollar value of
incentive grant guideline ($)
3,686,592
826,800
795,795
384,000
518,605
Once the target total long-term equity value was determined for each executive based on the executive’s relevant percentage of
base salary, half of the value was provided in stock options and the other half was provided in RSU awards. The reasons why
we use stock options and RSU awards are described below under “-Stock Options” and “-RSU Awards.”
Talent acquisition grants are used for new hires. These grants of options and RSU awards are considered and approved as part
of the executive’s compensation package at the time of hire (with the grant date and exercise price delayed until the hire date).
As with our performance recognition grants, the size of our talent acquisition grants is determined by dollar amount (as
opposed to number of underlying shares), and under our long-term incentive grant guidelines, is generally two times the long-
term incentive grant guidelines for annual performance recognition grants, as recommended by our compensation consultant.
We recognize that higher initial grants often are necessary to attract a new executive, especially one who may have accumulated
a substantial amount of equity-based long-term incentive awards at a previous employer that would typically be forfeited upon
acceptance of employment with us. In some cases, we may need to further increase a talent acquisition grant to attract an
executive. No talent acquisitions grants were made to any of our named executive officers during 2016.
Stock Options. Historically, we have granted stock options to our named executive officers, as well as other key employees.
We believe that options effectively incentivize employees to maximize company performance, as the value of awards is directly
tied to an appreciation in the value of our ordinary shares. They also provide an effective retention mechanism because of
vesting provisions. An important objective of our long-term incentive program is to strengthen the relationship between the
long-term value of our ordinary shares and the potential financial gain for employees. Stock options provide recipients with the
opportunity to purchase our ordinary shares at a price fixed on the grant date regardless of future market price. The vesting of
our stock options is generally time-based, with 25% of the shares underlying the stock option typically vesting on the one-year
anniversary of the grant date and the remaining 75% of the underlying shares vesting over a three-year period thereafter in 36
nearly equal monthly installments. Our policy is to grant options only with an exercise price equal to or more than the fair
market value of an ordinary share on the grant date.
172
Because stock options become valuable only if the share price increases above the exercise price and the option holder remains
employed during the period required for the option to vest, they provide an incentive for an executive to remain employed. In
addition, stock options link a portion of an employee’s compensation to the interests of our shareholders by providing an
incentive to achieve corporate goals and increase the market price of our ordinary shares over the four-year vesting period.
RSU Awards. RSU awards are intended to retain key employees, including named executive officers, through vesting periods.
RSU awards provide the opportunity for capital accumulation and more predictable long-term incentive value than stock
options. All of our RSU awards are a commitment by us to issue ordinary shares at the time the RSU award vests. The specific
terms of vesting of an RSU award depends on whether the award is a performance recognition grant or talent acquisition grant.
Performance recognition grants of RSU awards are made mid-year and vest in four annual installments on June 1st of each
year. Talent acquisition grants of RSU awards to new hires vest in a similar manner, except that the first installment is often
pro-rated, depending on the grant date.
2016 Equity Awards. The table below sets forth the number of stock options and RSU awards granted to each of our named
executive officers in 2016.
Named executive officer
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
Stock
options
RSU
awards
271,076
60,795
58,515
29,083
38,133
94,334
21,157
20,363
10,121
13,270
Additional information concerning the long-term incentive compensation information for our named executive officers for 2016
is included in the Summary Compensation Table and Grants of Plan-Based Awards Table under the heading “Executive
Compensation Tables and Narratives.”
2017 Equity Awards. We intend to change the mix of our executive long-term incentive awards to incorporate performance-
based awards in 2017. We plan to move to a mix comprised of one-third performance-based awards, one-third time-based stock
options and one-third time-based RSUs. We anticipate that the performance-based awards will vest only upon achievement of
certain performance goals to be achieved over a three-year performance period.
All Other Compensation
Retirement Benefits. In 2016, our named executive officers had the opportunity to participate in retirement plans maintained by
our operating subsidiaries, including a 401(k) plan, on the same basis as our other employees. We believe these plans provide
an opportunity for our executives to plan for and meet their retirement savings needs. Except for these plans, we do not provide
pension arrangements or post-retirement health coverage for our employees, including named executive officers. We also do
not provide any nonqualified defined contribution or other deferred compensation plans.
Relocation, Assignment and Expat Benefits. We provide our executive officers with customary relocation assistance benefits if
they relocate at our request. For international assignments, we also provide customary assignment and expat benefits that are
consistent with local policies and practices. Tax protection may be provided in these situations to avoid an executive being
penalized from a tax perspective for a relocation or expat service on behalf of our company. During 2016, we asked
Mr. Cooke, President, International, to relocate his family to the United Kingdom and build an international headquarters and
team. To compensate and incentivize Mr. Cooke to relocate, we agreed to provide him standard and customary relocation,
temporary assignment and expat benefits. These are described in more detail under “Executive Compensation Tables and
Narratives-Summary Compensation Information-All Other Compensation for 2016-Supplemental” and include cost-of-living
adjustments, medical coverage, housing allowance, educational tuition fees and related transportation costs, car lease,
reimbursement of certain relocation expenses and tax and tax equalization benefits.
Perquisites and Other Benefits. We provide our executive officers with modest perquisites to attract and retain them. The
perquisites provided to our named executive officers during 2016 included $1,000 for certain personal insurance premiums and
up to $5,000 reimbursement for financial and tax planning and tax preparation. In addition, we are required to provide our
CEO additional perquisites under the terms of his employment agreement, which we agreed upon at the time of his initial hiring
by legacy Wright to attract him to our company. These additional perquisites include additional reimbursement for financial
and tax planning and tax preparation, a monthly allowance of $7,500 for housing and automobile expenses, reimbursement for
reasonable travel expenses between Memphis, Tennessee and his residences, and an annual physical examination. To the extent
that the reimbursements for his housing and automobile expenses and travel expenses between Memphis, Tennessee and his
residences are not deductible by Mr. Palmisano for income tax purposes, such amounts are “grossed-up” for income tax
173
purposes so that the reimbursed items will be received net of any deduction for income and payroll taxes. We agreed to this
gross-up provision at the time of his initial hiring by legacy Wright to attract him to our company and ease the financial burden
on him to travel between Memphis, Tennessee and his residences. We believe these perquisites are an important part of our
overall compensation package and help us accomplish our goal of attracting, retaining, and rewarding top executive talent. The
value of all of the perquisites provided to our named executive officers for 2016 can be found under “Executive Compensation
Tables and Narratives- Summary Compensation Information-All Other Compensation for 2016-Supplemental.”
Change in Control and Post-Termination Severance Arrangements
Change in Control Arrangements. To encourage continuity, stability and retention when considering the potential disruptive
impact of an actual or potential corporate transaction, we have established change in control arrangements, including provisions
in our equity-based compensation plans, separation pay agreements with our executives, and our employment agreement with
our CEO, which are described in more detail below and under “Executive Compensation Tables and Narratives-Potential
Payments Upon a Termination or Change in Control.” These arrangements are designed to incentivize our executives to
remain with our company in the event of a change in control or potential change in control.
Under the terms of our current stock incentive plan and the individual award documents provided to recipients of awards under
that plan, all stock options and RSU awards will become immediately vested (and, in the case of options, exercisable) upon the
completion of a change in control of our company. Thus, the immediate vesting of stock options and RSU awards is triggered
by the change in control, itself, and thus is known as a “single trigger” change in control arrangement. We believe our current
“single trigger” equity acceleration change in control arrangements provide important retention incentives during what can
often be an uncertain time for employees. They also provide executives with additional monetary motivation to focus on and
complete a transaction that our board of directors believes is in the best interests of our company and shareholders rather than to
seek new employment opportunities. We also believe that the immediate acceleration of equity-based awards aligns the
interests of our executives and other employees with those of our shareholders by allowing our executives to participate fully in
the benefits of a change in control as to all of their equity. If an executive were to leave before the completion of the change in
control, unvested awards held by the executive would terminate.
However, despite our belief that single trigger change in control arrangements play an important role in our executive
compensation program, we recognize that our single trigger change in control arrangements no longer align with current market
practice and the desires of many of our shareholders. Accordingly, in connection with our new equity and incentive plan that we
intend to submit to a vote of our shareholders at our 2017 annual general meeting, we intend to implement a new “double
trigger” change in control provision with respect to future equity awards. Under this new provision, equity awards granted
under the new plan will not vest in connection with a change in control unless there is a termination event or the equity awards
are not continued, assumed or substituted with like awards by the successor.
In addition to our change in control provisions in our stock incentive plan, we have entered into an employment agreement with
our CEO and separation pay agreements with our other named executive officers and other officers which provide certain
payments and benefits in the event of a termination of employment in connection with a change in control. These “double
trigger” change in control protections are intended to induce executives to accept or continue employment with our company,
provide consideration to executives for certain restrictive covenants that apply following termination of employment, and
provide continuity of management in connection with a threatened or actual change in control transaction. If an executive’s
employment is terminated without cause or by the executive for “good reason” (as defined in the agreements) within 12 months
(24 months for our CEO) following a change in control, the executive will be entitled to receive a severance payment and
certain benefits. These arrangements and a quantification of the payment and benefits provided under these arrangements are
described in more detail under “Executive Compensation Tables and Narratives-Potential Payments Upon a Termination or
Change in Control.” These additional payments and benefits will not be triggered just by a change in control, but require a
termination event not within the control of the executive, and thus are known as “double trigger” change in control
arrangements. As opposed to the immediate acceleration of equity-based awards, we believe that other change in control
payments and benefits should properly be tied to termination following a change in control, given the intent that these amounts
provide economic security to ease in the executive’s transition to new employment.
We believe our change in control arrangements are an important part of our executive compensation program in part because
they mitigate some of the risk for executives working in a smaller company where there is a meaningful likelihood that the
company may be acquired. Change in control benefits are intended to attract and retain qualified executives who, absent these
arrangements and in anticipation of a possible change in control of our company, might consider seeking employment
alternatives to be less risky than remaining with our company through the transaction. We believe that relative to our
company’s overall value, our potential change in control benefits are relatively small and are aligned with current peer
company practices.
174
Other Severance Arrangements. Each of our named executive officers is entitled to receive severance benefits upon certain
other qualifying terminations of employment, other than a change in control, pursuant to the provisions of an employment
agreement for our CEO and separation pay agreements for our other named executive officers. These severance arrangements
are intended to induce the executives to accept or continue employment with our company and are primarily intended to retain
our executives and provide consideration to those executives for certain restrictive covenants that apply following a termination
of employment. Additionally, we entered into these agreements because they provide us valuable protection by subjecting the
executives to restrictive covenants that prohibit the disclosure of confidential information during and following their
employment and limit their ability to engage in competition with us or otherwise interfere with our business relationships
following their termination of employment.
In the beginning of 2016, as part of our merger integration efforts, we asked Mr. Cooke, our President, International to relocate
his family to the United Kingdom and build an international headquarters and team. Despite his initial hesitation to do so, Mr.
Cooke agreed. To incentivize him to relocate, we entered into a retention letter agreement with him under which we agreed to
provide him certain expat relocation and temporary assignment benefits customarily provided to executives in such situations.
We also agreed to pay him a $1.2 million retention payment on the second anniversary of his relocation, subject to his
continuing employment through such date and other specified terms and conditions. This retention payment, if made, would be
in lieu of any future change in control or severance payment Mr. Cooke otherwise would be entitled to receive under his
separation pay agreement. If Mr. Cooke voluntarily terminates his employment prior to the completion of his two-year
assignment, he will not receive the retention payment. If we terminate his employment without cause or he terminates his
employment for good reason prior to the completion of his two-year assignment, he will receive the retention payment.
For more information on our severance arrangements with our named executive officers, see the discussions below under “-
Executive Compensation Tables and Narratives-Potential Payments Upon a Termination or Change in Control.”
Stock Ownership Guidelines
We have established stock ownership guidelines that are intended to further align the interests of our executives with those of
our shareholders. Stock ownership targets for each of our executive officers have been set at that number of our ordinary shares
with a value equal to a multiple of the executive’s annual base salary. Each of the executive officers has five years from the
date of hire or, if the ownership multiple has increased during his or her tenure, five years from the date established in
connection with such increase to reach his or her stock ownership targets. Until his or her stock ownership target is achieved,
each executive is required to retain an amount equal to 75% of the net shares received as a result of the exercise of stock
options or the vesting of RSU awards. If there is a significant decline in the price of our ordinary shares that causes executives
to be out of compliance, such executives will be subject to the 75% retention ratio, but will not be required to purchase
additional shares to meet the applicable targets. Our compensation committee reports on compliance with the guidelines at least
annually to our board of directors.
Named executive officer
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
Anti-Hedging and Pledging
Stock ownership target as a
multiple of
base salary
4x
2x
2x
2x
2x
In
compliance (yes/no)
Yes
Yes
Yes
Yes
Yes
Our code of conduct on insider trading and confidentiality prohibits our executive officers from engaging in hedging
transactions, such as short sales, transactions in publicly traded options, such as puts, calls and other derivatives, and pledging
our ordinary shares.
Clawback Policy
During 2017, we intend to adopt a clawback policy that will authorize recovery of gains from incentive compensation,
including equity awards, in the event of certain financial restatements. In addition, our stock incentive plan and PIP currently
contain “clawback” provisions. Under our stock incentive plan, if an executive is determined by the compensation committee
to have taken action that would constitute “cause” or an “adverse action,” as those terms are defined in the plan, during or
within one year after the termination of the executive’s employment, all rights of the executive under the plan and any
agreements evidencing an award then held by the executive will terminate and be forfeited. In addition, the compensation
committee may require the executive to surrender and return to us any shares received, and/or to disgorge any profits or any
175
other economic value made or realized by the executive in connection with any awards or any shares issued upon the exercise
or vesting of any awards during or within one year after the termination of the executive’s employment or other service. Under
our PIP, we have the right to take all actions necessary, to recover any awards or amounts paid to any plan participant to the
extent required or permitted by applicable laws, rules or regulations, securities exchange listing requirements or any policy of
our company implementing the foregoing.
Risk Assessment
As a result of our annual assessment on risk in our compensation programs, we concluded that our compensation policies,
practices, and programs and related compensation governance structure, work together in a manner so as to encourage our
executives to pursue growth strategies that emphasize shareholder value creation, but not to take unnecessary or excessive risks
that could threaten the value of our company. For more information on this assessment, see the discussions below under “-
Executive Compensation Tables and Narratives-Risk Assessment of Compensation Policies, Practices and Programs.”
Executive Compensation Decision Making
Role of Compensation Committee and Board. The responsibilities of the compensation committee include reviewing and
approving corporate goals and objectives relevant to the compensation of our executive officers, evaluating each executive’s
performance in light of those goals and objectives and, either as a committee or together with the other directors, determining
and approving each executive’s compensation, including performance-based compensation based on these evaluations (and, in
the case of executives, other than the CEO, the CEO’s evaluation of such executive’s individual performance). Consistent with
our shareholder-approved board of directors compensation policy, the compensation package for our CEO, who also serves as
executive director of our company, is determined by our non-executive directors, based upon recommendations from the
compensation committee.
In setting or recommending executive compensation for our named executive officers, the compensation committee considers
the following primary factors:
•
•
•
•
•
•
•
•
•
•
•
•
each executive’(cid:86)(cid:3)(cid:83)(cid:82)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:82)(cid:73)(cid:3)(cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:76)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:30)(cid:3)
(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:87)(cid:82)(cid:3)(cid:76)(cid:80)(cid:83)(cid:68)(cid:70)(cid:87)(cid:3)(cid:78)(cid:72)(cid:92)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:76)(cid:81)(cid:76)(cid:87)(cid:76)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:30)
the executive’(cid:86)(cid:3)(cid:76)(cid:81)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:88)(cid:68)(cid:79)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:85)(cid:76)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)(cid:3)
compensation paid to executives of comparable positions by companies (cid:86)(cid:76)(cid:80)(cid:76)(cid:79)(cid:68)(cid:85)(cid:3)(cid:87)(cid:82)(cid:3)(cid:88)(cid:86)(cid:30)
company performance, as compared to specific pre-(cid:72)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:72)(cid:71)(cid:3)(cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:30)(cid:3)
individual performance, generally and as compared to specific pre-(cid:72)(cid:86)(cid:87)(cid:68)(cid:69)(cid:79)(cid:76)(cid:86)(cid:75)(cid:72)(cid:71)(cid:3)(cid:82)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:76)(cid:89)(cid:72)(cid:86)(cid:30)(cid:3)
the executive’(cid:86)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:75)(cid:76)(cid:86)(cid:87)(cid:82)(cid:85)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:86)(cid:30)(cid:3)
advancement (cid:83)(cid:82)(cid:87)(cid:72)(cid:81)(cid:87)(cid:76)(cid:68)(cid:79)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:86)(cid:88)(cid:70)(cid:70)(cid:72)(cid:86)(cid:86)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:76)(cid:71)(cid:72)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:30)
an assessment of the risk that the executive would leave us and the harm to our business initiatives if the executive
(cid:79)(cid:72)(cid:73)(cid:87)(cid:30)(cid:3)
the retention value of executive equity holdings, including outstanding stock opt(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:53)(cid:54)(cid:56)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)
the dilutive effect on the interests of our shareholders of long-term equity-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
anticipated share-based compensation expense as determined under applicable accounting rules.
The compensation committee also considers the recommendations of our CEO with respect to executive compensation to be
paid to other executives. In making its final decision regarding the form and amount of compensation to be paid to our named
executive officers (other than the CEO), the compensation committee considers and gives great weight to the recommendations
of the CEO recognizing that due to his reporting and otherwise close relationship with each executive, the CEO often is in a
better position than the compensation committee to evaluate the performance of each executive (other than himself). In making
its final decision regarding the form and amount of compensation to be paid to the CEO, the compensation committee considers
the results of the CEO’s self-review and his individual annual performance review by the compensation committee,
benchmarking data gathered by our compensation consultant, and the recommendations of our non-executive directors.
Role of Management. Three members of our executive team play a role in our executive compensation process and regularly
attend meetings of the compensation committee - the CEO, Senior Vice President, Human Resources, and Senior Vice
President, General Counsel and Secretary. The CEO assists the compensation committee primarily by making formal
recommendations regarding the amount and type of compensation to be paid to executives (other than himself). In making
these recommendations, the CEO considers many of the same factors listed above that the compensation committee considers
in setting executive compensation, including in particular the results of each executive’s annual performance review and the
executive’s achievement of his or her individual management performance objectives established in connection with our PIP,
described below. The Senior Vice President, Human Resources assists the compensation committee primarily by gathering
compensation related data regarding executives and coordinating the exchange of this information and other executive
176
compensation information among the members of the compensation committee, the compensation committee’s compensation
consultant and management in anticipation of compensation committee meetings. The Senior Vice President, General Counsel
and Secretary assists the compensation committee primarily by ensuring compliance with legal and regulatory requirements and
educating the committee on executive compensation trends and best practices from a corporate governance perspective and
acting as corporate secretary of meetings. Final deliberations and decisions regarding the compensation to be paid to each
executive, however, are made by our board of directors or compensation committee without the presence of the executive.
Role of Consultant. The compensation committee has retained the services of Mercer (US) Inc. (Mercer) to provide executive
compensation advice. Mercer’s engagement by the compensation committee includes reviewing and advising on all significant
aspects of executive compensation, as well as non-executive director compensation. This includes base salaries, short-term
cash incentives and long-term equity incentives for executives. At the request of the compensation committee, each year,
Mercer recommends a peer group of companies, collects relevant market data from these companies to allow the compensation
committee to compare elements of our compensation program to those of our peers, provides information on executive
compensation trends and implications for us and makes other recommendations to the compensation committee regarding
certain aspects of our executive compensation program. Our management, principally the Senior Vice President, Human
Resources and the chair of the compensation committee, regularly consult with a representative of Mercer before compensation
committee meetings. A representative of Mercer regularly attends meetings of the compensation committee. In making its final
decision regarding the form and amount of compensation to be paid to executives, the compensation committee considers the
information gathered by and recommendations of Mercer. The compensation committee values Mercer’s benchmarking
information and input regarding best practices and trends in executive compensation matters.
Use of Peer Group and Other Market Data. To help determine appropriate levels of compensation for certain elements of our
executive compensation program, the compensation committee reviews annually the compensation levels of our named
executive officers and other executives against the compensation levels of comparable positions with companies similar to us in
terms of industry, revenues, products and operations. The elements of our executive compensation program to which the
compensation committee “benchmarks” or uses to base or justify a compensation decision or to structure a framework for
compensating executives include base salary, short-term cash incentive opportunity, and long-term equity incentives. With
respect to other elements of our executive compensation program, such as perquisites, severance, and change in control
arrangements, the compensation committee benchmarks these elements on a periodic or as needed basis and in some cases uses
peer group or market data more as a “market check” after determining the compensation on some other basis. The
compensation committee believes that compensation paid by peer group companies is more representative of the compensation
required to attract, retain, and motivate our executive talent than broader survey data and that compensation paid by peer
companies that are in the same industry, with similar products and operations, and with revenues in a range similar to us,
generally provides more relevant comparisons.
In 2015, Mercer worked with the post-Wright/Tornier merger compensation committee to identify a peer group of 13
companies that the compensation committee approved at its first in-person meeting in the Netherlands after completion of the
merger in October 2015. Companies in the peer group are public companies in the health care equipment and supplies business
with products and operations similar to ours and that had annual revenues generally within a range of our then-anticipated post-
merger annual revenues. The peer group included the following companies:
The Cooper Companies, Inc.
Globus Medical, Inc.
Greatbatch, Inc.
Haemonetics Corporation
Integra LifeSciences Holdings Corporation
Masimo Corporation
Merit Medical Systems, Inc.
Natus Medical Incorporated
NxStage Medical, Inc.
NuVasive, Inc.
ResMed Inc.
Sirona Dental Systems, Inc.
Thoratec Corporation
The table below sets forth certain revenue and other financial information as of a date available prior to the date Mercer used to
compile the proposed peer group and market capitalization information as of February 28, 2015 regarding the peer group that
the compensation committee used in connection with its recommendations and decisions regarding executive compensation for
2016. The percentile rank was the anticipated rank of the combined company based on then anticipated 12-month revenue and
market capitalization.
25th percentile
50th percentile
75th percentile
Percentile rank
Trailing 12-month revenue
(in millions)
$478
688
928
51%
Three-year
revenue growth
25%
34%
42%
N/A
Trailing
12-month EBIT
$69
93
143
N/A
Market capitalization
(in millions)
$1,325
2,171
2,299
78%
177
In reviewing benchmarking data, the compensation committee recognizes that benchmarking may not always be appropriate as
a stand-alone tool for setting compensation due to aspects of our business and objectives that may be unique to us.
Nevertheless, the compensation committee believes that gathering this information is an important part of its compensation-
related decision-making process. However, where a sufficient basis for comparison does not exist between the peer group data
and an executive, the compensation committee gives less weight to the peer group data. For example, relative compensation
benchmarking analysis does not consider individual specific performance or experience or other case-by-case factors that may
be relevant in hiring or retaining a particular executive.
Market Positioning. In general, we target base salary and total compensation levels to be within a reasonable range of the 67th
percentile of our peer group. However, the specific competitiveness of any individual executive’s pay will be determined
considering factors like the executive’s experience, skills and capabilities, contributions as a member of the executive
management team, and contributions to our overall performance. The compensation committee will also consider the
sufficiency of total compensation potential and the structure of pay plans to ensure the hiring or retention of an executive when
considering the compensation potential that may be available elsewhere.
Tax Deductibility of Compensation
In designing our executive compensation program, we consider the deductibility of executive compensation under Code
Section 162(m), which provides that we may not deduct more than $1 million paid to certain executive officers, other than
“performance-based” compensation meeting certain requirements. Our stock incentive plan incorporates provisions intended to
satisfy the requirements for awarding “performance-based” compensation as defined in Code Section 162(m) under the plan.
Other than stock options, we did not grant any other “performance-based” compensation under the plan during 2016. In
addition, while we designed our plan to operate in a manner intended to qualify as “performance-based” under Code Section
162(m), the compensation committee may administer the plan in a manner that does not satisfy the requirements of Code
Section 162(m) to achieve a result that the compensation committee determines to be appropriate.
Compensation Committee Report
The compensation committee has reviewed and discussed the foregoing “-Compensation Discussion and Analysis” with our
management. Based on this review and these discussions, the compensation committee has recommended to our board of
directors that the foregoing “-Compensation Discussion and Analysis” be included in our Annual Report on Form 10-K for the
year ended December 25, 2016 and proxy statement in connection with our 2017 annual general meeting of shareholders.
Compensation Committee
Sean D. Carney
John L. Miclot
Elizabeth H. Weatherman
178
Executive Compensation Tables and Narratives
Summary Compensation Information
The table below provides summary information concerning all compensation awarded to, earned by, or paid to the individuals
that served as our principal executive officer or principal financial officer during the year ended December 25, 2016 and other
named executive officers for each of the last three fiscal years of which they served as an executive officer.
SUMMARY COMPENSATION TABLE - 2016
Name and principal position
Option
awards(4)
($)
All other
compen-
sation(6)
($)
Non-equity
incentive plan
compensation(5)
Total
($)
($)
1,435,928
6,575,177
264,272
1,247,655 1,668,463 15,025,738
Year
2016
2015
Salary(1)
($)
Bonus(2)
($)
866,499 —
222,068 —
Stock awards(3)
($)
2,003,654
5,972,830
2016
2015
2,004,824
5,914,722
409,119 —
105,894 —
Robert J. Palmisano(7)
President and Chief Executive
Officer and Executive Director
Lance A. Berry(8)
Senior Vice President and
Chief Financial Officer
Kevin D. Cordell(9)
President, U.S.
Peter S. Cooke(10)
President, International
Robert P. Burrows(11)
Senior Vice President, Supply
Chain
___________________________
(1) Five percent of Mr. Palmisano’s annual base salary was allocated to his service as an executive director and member of our board of
1,744,202
2,369,037
418,650
343,379
17,430
253,346
449,375
837,275
449,628
829,143
429,789 —
514,538 —
384,000 —
1,688,357
1,493,892
1,379,789
376,693
404,875
289,893
275,834
214,970
215,092
432,510
432,765
281,855
282,024
16,600
10,600
2016
2016
2016
directors.
(2) We generally do not pay any discretionary bonuses or bonuses that are subjectively determined and did not pay any such bonuses to any
named executive officers in 2016. Annual cash incentive bonus payouts based on performance against pre-established performance
goals under our performance incentive plan are reported in the “Non-equity incentive plan compensation” column.
(3) Amounts reported represent the aggregate grant date fair value for RSU awards granted to each named executive officer computed in
accordance with FASB ASC Topic 718. The grant date fair value is determined based on the per share closing sale price of our ordinary
shares on the grant date.
(4) Amounts reported represent the aggregate grant date fair value for option awards granted to each named executive officer computed in
accordance with FASB ASC Topic 718. The grant date fair value is determined based on our Black-Scholes option pricing model. The
table below sets forth the specific assumptions used in the valuation of each such option award:
Grant
date
07/19/2016
10/13/2015
Grant date
fair value
per share ($)
7.40
7.06
Risk free
interest rate
1.125%
1.375%
Expected
life
6.08 years
6.08 years
Expected
volatility
34.00%
32.70%
Expected
dividend
yield
—
—
(5) Amounts reported represent payouts under our performance incentive plan and for each year reflect the amounts earned for that year
but paid during the following year.
(6) Amounts reported in this column for 2016 are described under “-All Other Compensation for 2016 - Supplemental.”
(7) Mr. Palmisano was appointed our President and Chief Executive Officer effective upon completion of the Wright/Tornier merger, on
October 1, 2015. Prior to such time, Mr. Palmisano served as President and Chief Executive Officer of Wright Medical Group, Inc.
and, in such capacity, earned or was awarded or paid salary and other compensation by legacy Wright prior to October 1, 2015, which
amounts are not included in the above table.
(8) Mr. Berry was appointed our Senior Vice President and Chief Financial Officer effective upon completion of the Wright/Tornier
merger, on October 1, 2015. Prior to such time, Mr. Berry served as Senior Vice President and Chief Financial Officer of Wright
Medical Group, Inc. and, in such capacity, earned or was paid salary and other compensation by legacy Wright prior to October 1,
2015, which amounts are not included in the above table.
(9) Mr. Cordell was not a n(cid:68)(cid:80)(cid:72)(cid:71)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:3)(cid:76)(cid:81)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:3)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:23)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:86)(cid:3)(cid:82)(cid:81)(cid:79)(cid:92)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:17)
(10) (cid:48)(cid:85)(cid:17)(cid:3)(cid:38)(cid:82)(cid:82)(cid:78)(cid:72)(cid:3)(cid:90)(cid:68)(cid:86)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:3)(cid:81)(cid:68)(cid:80)(cid:72)(cid:71)(cid:3)(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:3)(cid:76)(cid:81)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:3)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:23)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:86)(cid:3)(cid:82)(cid:81)(cid:79)(cid:92)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:17)
(11) Mr. Burrows was not a named executive (cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:3)(cid:76)(cid:81)(cid:3)(cid:21)(cid:19)(cid:20)(cid:24)(cid:3)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:23)(cid:30)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72)(cid:73)(cid:82)(cid:85)(cid:72)(cid:15)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:76)(cid:81)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:86)(cid:3)(cid:82)(cid:81)(cid:79)(cid:92)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:17)
179
Agreements with Robert J. Palmisano. Effective October 1, 2015, we entered into a service agreement and one of our
subsidiaries entered into an employment agreement with Robert J. Palmisano, our President and Chief Executive Officer.
The service agreement deals with certain Dutch law matters relating to Mr. Palmisano’s role as an executive director. Under the
terms of the service agreement, we have allocated a portion of Mr. Palmisano’s annual base salary to his service as an executive
director, which amounts are paid after deduction of applicable withholdings for taxes and social security contributions. In
addition, under the terms of the service agreement, we have agreed to provide Mr. Palmisano with indemnification and director
and officer liability insurance, on terms and conditions that are at least as favorable to Mr. Palmisano as those then provided to
any other current or former director or executive officer of our company or any of our affiliates.
The employment agreement provides that during the term of the agreement, Mr. Palmisano will serve as President and Chief
Executive Officer of our company and each principal operating subsidiary and will report to our Chairman and board of
directors. During the term, we agreed to nominate Mr. Palmisano for election as an executive director and member of our
board of directors at each annual general meeting of shareholders. The employment agreement expires on December 31, 2018,
subject to earlier termination under certain circumstances. Commencing on October 1, 2017 and on each anniversary
thereafter, the term will automatically extend for an additional one-year period, unless at least 30 days prior to such date, either
party gives notice of non-extension to the other.
With respect to compensation, the employment agreement established an annual base salary for Mr. Palmisano and provides
that our board of directors will review his compensation at least annually for any increase. The employment agreement
acknowledges that a certain percentage of Mr. Palmisano’s base salary will be paid by Wright Medical Group N.V. in
consideration for his services as an executive director under the service agreement described above. The employment
agreement provides that Mr. Palmisano is eligible to receive an annual performance incentive bonus pursuant to the Wright
Medical Group N.V. Performance Incentive Plan and, if applicable, the Wright Medical Group N.V. Amended and Restated
2010 Incentive Plan, depending on whether, and to what extent, certain performance goals established by the compensation
committee for such year have been achieved. The amount of the performance incentive bonus payable to Mr. Palmisano will be
targeted at 100% of his annual base salary and will not exceed 200% of his annual base salary. The employment agreement
provides that Mr. Palmisano will receive an annual equity grant under our stock incentive plan (or any successor plan) equal to
300% of his annual base salary, and comprised 50% non-qualified stock options and 50% RSU awards, unless the board of
directors establishes a different percentage as specified in the agreement. In addition, the employment agreement provides that
Mr. Palmisano is eligible to participate in the fringe benefit programs, including those for medical and disability insurance and
retirement benefits that we generally make available to our executive officers from time to time. During the term,
Mr. Palmisano will be reimbursed for up to $1,000 for personal insurance premiums, other than for insurance coverage that
pays for medical, prescription drug, dental, vision, or other medical care expenses. In addition, he may elect, in accordance
with our cafeteria plan rules, not to participate in the medical and disability insurance programs provided by us, in which case,
we will pay him up to $900 per month (or such greater amount that we would otherwise pay for medical and disability coverage
for him and his spouse under our benefits programs). Mr. Palmisano is also entitled to receive reimbursement for up to $15,000
for financial and tax planning and tax preparation, and an annual physical examination at our expense. The employment
agreement also provides for a monthly allowance of $7,500 for housing and automobile expenses, and Mr. Palmisano will be
reimbursed for reasonable travel expenses between Memphis, Tennessee and his residences. To the extent that these
reimbursements are not deductible by Mr. Palmisano for income tax purposes, such amounts will be “grossed-up” for income
tax purposes so that the reimbursed items will be received net of any deduction for income and payroll taxes. The employment
agreement contains severance provisions as described in more detail under “-Potential Payments Upon a Termination or
Change in Control.” We have guaranteed the obligations of our subsidiary under Mr. Palmisano’s employment agreement.
Mr. Palmisano and one of our subsidiaries also entered into a confidentiality, non-competition, non-solicitation and intellectual
property rights agreement, pursuant to which Mr. Palmisano agreed to certain covenants that impose obligations on him
regarding confidentiality of information, transfer of inventions, non-solicitation of employees, customers and suppliers, and
non-competition with our business.
Agreements with Other Named Executive Officers. Each of the other named executive officers also is a party to a
confidentiality, non-competition, non-solicitation and intellectual property rights agreement with us, the material terms of
which are substantially similar to Mr. Palmisano’s agreement, as described above. In addition, through one of our subsidiaries,
we have entered into separation pay agreements with our named executive officers who are currently executive officers, other
than Mr. Palmisano, which agreements are described in more detail under “-Potential Payments Upon a Termination or Change
in Control.”
In the beginning of 2016, as part of our merger integration efforts, we asked Peter S. Cooke, our President, International to
relocate his family to the United Kingdom and build an international headquarters and team. Despite his initial hesitation to do
so, Mr. Cooke agreed. To incentivize him to relocate, we entered into a retention letter agreement with him under which we
agreed to provide him certain expat relocation and temporary assignment benefits customarily provided to executives in such
180
situations. We also agreed to pay him a $1.2 million retention payment on the second anniversary of his relocation, subject to
his continuing employment through such date and other specified terms and conditions. This retention payment, if made, would
be in lieu of any future change in control or severance payment Mr. Cooke otherwise would be entitled to receive under his
separation pay agreement. If Mr. Cooke voluntarily terminates his employment prior to the completion of his two-year
assignment, he will not receive the retention payment. If we terminate his employment without cause or he terminates his
employment for good reason prior to the completion of his two-year assignment, he will receive the retention payment. His
expat relocation and temporary assignment benefits are standard and customary for executives relocating to the United
Kingdom and are described in more detail under “-All Other Compensation for 2016-Supplemental.”
Indemnification Agreements. We have entered into indemnification agreements with all of our named executive officers. The
indemnification agreements are governed by the laws of the State of Delaware (USA) and provide, among other things, for
indemnification to the fullest extent permitted by law and our articles of association against any and all expenses (including
attorneys’ fees) and liabilities, judgments, fines and amounts paid in settlement that are paid or incurred by the executive or on
his or her behalf in connection with such action, suit or proceeding. We will be obligated to pay these amounts only if the
executive acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of our
company. The indemnification agreements provide that the executive will not be indemnified and expenses advanced with
respect to an action, suit or proceeding initiated by the executive unless (i) so authorized or consented to by our board of
directors or the company has joined in such action, suit or proceeding or (ii) the action, suit or proceeding is one to enforce the
executive’s rights under the indemnification agreement. The company’s indemnification and expense advance obligations are
subject to the condition that an appropriate person or body not party to the particular action, suit or proceeding shall not have
determined that the executive is not permitted to be indemnified under applicable law. The indemnification agreements also set
forth procedures that apply in the event an executive requests indemnification or an expense advance.
All Other Compensation for 2016 - Supplemental. The table below provides information concerning amounts reported in the
“All other compensation” column of the Summary Compensation Table for 2016 with respect to each named executive officer.
Additional detail on these amounts are provided below the table.
Retirement
benefits
$
10,600
10,600
10,600
—
10,600
Housing/
car
allowance
$
90,000
—
—
199,841
—
Commu-
ting
expense
$
49,854
—
—
—
—
Relocation
benefits
$
—
—
—
10,000
—
Financial
and tax
planning
$
5,000
5,000
5,000
—
—
Name
Mr. Palmisano
Mr. Berry
Mr. Cordell
Mr. Cooke
Mr. Burrows
Insurance
premium
$
Gross-
up
$
Office
allowance
$
COLA
$
10,800 98,018
—
1,000
—
1,000
—
—
—
—
—
—
—
—
—
—
36,000 12,401
—
—
Educa-
tional
expenses
$
Other
$
— —
—
830
— —
17,592 —
— —
Total
other
compen-
sation
$
264,272
17,430
16,600
275,834
10,600
Retirement Benefits. Under our 401(k) Plan, participants, including our named executive officers, may voluntarily request that
we reduce his or her pre-tax compensation and contribute such amounts to the 401(k) plan’s trust up to certain statutory
maximums. We contribute matching contributions in an amount equal to 3% of the participant’s eligible earnings for a pay
period, or if less, 50% of the participant’s pre-tax 401(k) contributions (other than catch-up contributions) for that pay period.
We do not provide any nonqualified defined contribution or other deferred compensation plans for our executives.
Relocation, Assignment and Expat Benefits. We provide our named executive officers with customary relocation assistance
benefits if they relocate at our request. For international assignments, we also provide customary assignment and expat benefits
that are consistent with local policies and practices. Tax protection may be provided in these situations to avoid an executive
being penalized from a tax perspective for a relocation or expat service on behalf of our company. As described above, during
2016, we asked Mr. Cooke, President, International, to relocate his family to the United Kingdom and build an international
headquarters and team. To compensate and incentivize Mr. Cooke to relocate, we agreed to provide him standard and
customary relocation, temporary assignment and expat benefits. These include cost-of-living adjustments, medical coverage,
housing allowance, educational tuition fees and related transportation costs, car lease, reimbursement of certain relocation
expenses and tax and tax equalization benefits.
Perquisites and Personal Benefits. The only perquisites and personal benefits provided to our named executive officers are
$1,000 for certain personal insurance premiums and up to $5,000 reimbursement for financial and tax planning and tax
preparation, except in the case of Mr. Palmisano who is entitled to certain additional perquisites and personal benefits under his
employment agreement, including up to $15,000 reimbursement for financial and tax planning and tax preparation, a monthly
allowance of $7,500 for housing and automobile expenses, reimbursement for reasonable travel expenses between Memphis,
Tennessee and his residences, and an annual physical examination. To the extent that the reimbursements for his housing and
automobile expenses and travel expenses between Memphis, Tennessee and his residences are not deductible by Mr. Palmisano
181
for income tax purposes, such amounts are “grossed-up” for income tax purposes so that the reimbursed items will be received
net of any deduction for income and payroll taxes.
Grants of Plan-Based Awards
The table below provides information concerning grants of plan-based awards to each of our named executive officers during
the year ended December 25, 2016. Non-equity incentive plan-based awards were granted to our named executive officers
under our performance incentive plan, the material terms of which are described under “-Compensation Discussion and
Analysis.” Stock awards (in the form of RSU awards) and option awards were granted under our stock incentive plan. The
material terms of these awards and the material plan provisions relevant to these awards are described under “-Compensation
Discussion and Analysis,” or in the notes to the table below or the narrative following the table below. We did not grant any
“equity incentive plan” awards within the meaning of the SEC rules during the year ended December 25, 2016.
GRANTS OF PLAN-BASED AWARDS - 2016
Estimated future payouts under
non-equity incentive plan awards(1)
Name
Grant
date
Board
approval
date
Thres-
hold(2) ($)
Target
($)
Maxi-
mum(3) ($)
All other
stock
awards:
number of
shares of
stock or
units(4) (#)
All other
option
awards:
number of
securities
underlying
options(5) (#)
Exercise or
base price
of option
awards
($/Sh)
Grant date
fair value
stock and
option
awards(6)
($)
N/A
N/A
N/A
—
—
—
21.24
—
—
—
94,334
46,082
—
—
13,436
—
—
—
271,076
—
268,710
—
—
537,420
—
—
—
2,004,824
2,003,654
921,648 1,843,296
—
—
2/16/16
7/19/16 7/19/16
7/19/16 7/19/16
2/16/16
7/19/16 7/19/16
7/19/16 7/19/16
Robert J. Palmisano
Cash incentive award
Stock option
Stock grant
Lance A. Berry
Cash incentive award
Stock option
Stock grant
Kevin D. Cordell
Cash incentive award
Stock option
Stock grant
Peter S. Cooke
Cash incentive award
Stock option
Stock grant
Robert P. Burrows
Cash incentive award
Stock option
Stock grant
___________________________
(1) Amounts reported represent estimated future payouts under our performance incentive plan. Actual payouts under these performance
2/16/16
7/19/16 7/19/16
7/19/16 7/19/16
2/16/16
7/19/16 7/19/16
7/19/16 7/19/16
2/16/16
7/19/16 7/19/16
7/19/16 7/19/16
545,688
—
—
272,844
—
—
518,606
—
—
259,303
—
—
422,400
—
—
211,200
—
—
10,914
—
—
12,965
—
—
15,840
—
—
—
432,765
432,510
—
449,628
449,375
—
282,024
281,855
—
215,092
214,970
—
—
20,363
—
—
21,157
—
—
13,270
—
58,515
—
—
60,795
—
—
38,133
—
—
—
10,121
—
29,083
—
—
21.24
—
—
21.24
—
—
21.24
—
—
21.24
—
N/A
N/A
incentive plans are reflected in the “Non-equity incentive compensation” column of the Summary Compensation Table.
(2) Threshold amounts for awards payable under the performance incentive plans assume the satisfaction of the threshold level of the lowest
weighted corporate performance goal.
(3) Maximum amounts reflect payouts at a maximum rate of 200% of target for our performance incentive plan.
(4) Amounts reported represent stock grants in the form of RSU awards granted under our stock incentive plan. The RSU awards granted on
July 19, 2016 vest and become issuable over time, with the last tranche becoming issuable on June 1, 2020, in each case, so long as the
individual remains an employee or consultant of our company.
(5) Amounts reported represent options granted under our stock incentive plan. All options have a ten-year term and vest over a four-year
period, with 25% of the underlying shares vesting on the one-year anniversary of the grant date and the remaining 75% of the underlying
shares vesting over a three-year period thereafter in 36 as nearly equal as possible monthly installments.
(6) See notes (3) and (4) to the Summary Compensation Table for a discussion of the assumptions made in calculating the grant date fair
value of stock awards and option awards.
Wright Medical Group N.V. Performance Incentive Plan. Under the terms of the Wright Medical Group N.V. Performance
Incentive Plan, our named executive officers, as well as other employees, earned cash incentive bonuses based on our financial
performance for 2016. The material terms of the plan are described in detail under “-Compensation Discussion and Analysis-
Short-Term Cash Incentive Compensation.”
182
Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan. At an extraordinary general meeting of shareholders
held on June 18, 2015, our shareholders approved the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan,
which permits the grant of a wide variety of stock-based and cash-based awards, including incentive and non-qualified options,
stock appreciation rights, stock grants, stock unit grants, cash-based awards, and other stock-based awards. Our stock incentive
plan is designed to assist us in attracting and retaining employees, directors and consultants, provide an additional incentive to
such individuals to work to increase the value of our ordinary shares, and provide such individuals with a stake in our future
which corresponds to the stake of our shareholders.
The stock incentive plan reserves for issuance a number of ordinary shares equal to the sum of (i) the number of ordinary shares
available for grant under the Tornier N.V. Amended and Restated Stock Option Plan as of February 2, 2011 (not including
(cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:71)(cid:3)(cid:82)(cid:85)(cid:3)(cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:72)(cid:71)(cid:3)(cid:83)(cid:88)(cid:85)(cid:86)(cid:88)(cid:68)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:12)(cid:15)(cid:3)(cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3)(cid:90)(cid:68)(cid:86)(cid:3)(cid:20)(cid:15)(cid:20)(cid:28)(cid:28)(cid:15)(cid:21)(cid:28)(cid:25)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12) the number
of ordinary shares forfeited upon the expiration, cancellation, forfeiture, cash settlement, or other termination following
(cid:41)(cid:72)(cid:69)(cid:85)(cid:88)(cid:68)(cid:85)(cid:92)(cid:3)(cid:21)(cid:15)(cid:3)(cid:21)(cid:19)(cid:20)(cid:20)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:41)(cid:72)(cid:69)(cid:85)(cid:88)(cid:68)(cid:85)(cid:92)(cid:3)(cid:21)(cid:15)(cid:3)(cid:21)(cid:19)(cid:20)(cid:20)(cid:3)(cid:88)(cid:81)(cid:71)(cid:72)(cid:85)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:83)(cid:85)(cid:76)(cid:82)(cid:85)(cid:3)(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3)(cid:82)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:27)(cid:15)(cid:21)(cid:19)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:17)(cid:3)(cid:3)(cid:36)(cid:86)(cid:3)of
December 25, 2016, 1,233,923 ordinary shares remained available for grant under the stock incentive plan, and there were
7,813,930 ordinary shares covering outstanding awards under such plan as of such date. For purposes of determining the
remaining ordinary shares available for grant under the stock incentive plan, to the extent that an award expires or is cancelled,
forfeited, settled in cash, or otherwise terminated without a delivery to the participant of the full number of ordinary shares to
which the award related, the undelivered ordinary shares will again be available for grant. Any ordinary shares withheld to
satisfy tax withholding obligations in respect of awards issued under the plan, any ordinary shares withheld to pay the exercise
price of awards issued under the plan and any ordinary shares not issued or delivered as a result of the “net exercise” of an
outstanding option after June 18, 2015 are counted against the ordinary shares authorized for issuance under the plan.
The maximum aggregate number of ordinary shares subject to non-employee director awards to any one non-employee director
(cid:76)(cid:81)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:82)(cid:81)(cid:72)(cid:3)(cid:73)(cid:76)(cid:86)(cid:70)(cid:68)(cid:79)(cid:3)(cid:92)(cid:72)(cid:68)(cid:85)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:72)(cid:71)(cid:3)(cid:20)(cid:19)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:3)(cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:30)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:79)(cid:76)(cid:80)(cid:76)(cid:87)(cid:3)(cid:90)(cid:76)(cid:79)(cid:79)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:68)(cid:83)(cid:83)(cid:79)(cid:92)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:72)(cid:79)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:69)(cid:92)(cid:3)(cid:68)(cid:3)(cid:81)on-
employee director to receive shares in lieu of cash retainers and meeting fees. The following additional limits apply to awards
payable to any participant in any calendar year. With respect to awards of stock options and SARs, no more than 2,000,000
ordinary shares may underlie awards issued to any one participant in a calendar year. For cash-based awards, no more than
$5,000,000 may be payable to any one participant in a calendar year, and for any other award based on, denominated in or
otherwise related to shares, no more than 2,000,000 ordinary shares may be issued to any one participant in a calendar year.
The total number of ordinary shares available for issuance under the stock incentive plan, the number of ordinary shares subject
to outstanding awards and the sub-limits on certain types of award grants are subject to adjustment in the event of any
reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, stock split, combination of
shares, rights offering, divestiture, or extraordinary dividend (including a spin off) or any other similar change in our corporate
structure or ordinary shares.
Our board of directors has the ability to amend the stock incentive plan or any awards granted thereunder at any time, provided
that, certain amendments are subject to approval by our shareholders and subject to certain exceptions, no amendment may
adversely affect any outstanding award without the consent of the affected participant. Our board of directors also may suspend
or terminate the stock incentive plan at any time, and, unless sooner terminated, the stock incentive plan will terminate on
August 25, 2020.
Under the terms of the stock incentive plan, stock options must be granted with a per share exercise price equal to at least 100%
of the fair market value of an ordinary share on the grant date. For purposes of the plan, the fair market value of an ordinary
share is the closing sale price of our ordinary shares, as reported by the NASDAQ Global Select Market. We set the per share
exercise price of all stock options granted under the plan at an amount at least equal to 100% of the fair market value of our
ordinary shares on the grant date. Options become exercisable at such times and in such installments as may be determined by
our board of directors, provided that most options may not be exercisable after 10 years from their grant date. The vesting of
our stock options is generally time-based and is as follows: 25% of the shares underlying the stock option vest on the one-year
anniversary of the grant date and the remaining 75% of the underlying shares vest over a three-year period thereafter in 36 as
nearly equal as possible monthly installments, in each case so long as the individual remains an employee or consultant of our
company.
Currently, optionees must pay the exercise price of stock options in cash, except that the compensation committee may allow
payment to be made (in whole or in part) by a “cashless exercise” effected through an unrelated broker through a sale on the
open market, by a “net exercise” of the option, or by a combination of such methods. In the case of a “net exercise” of an
option, we will not require a payment of the exercise price of the option from the grantee but will reduce the number of our
ordinary shares issued upon the exercise by the largest number of whole shares that has a fair market value that does not exceed
the aggregate exercise price for the shares exercised under this method.
183
Under the terms of the grant certificates under which stock options have been granted to our named executive officers, if an
executive’s employment or service with our company terminates for any reason, other than upon a “life event,” the unvested
portion of the option will immediately terminate and the executive’s right to exercise the then vested portion of the option
will immediately terminate, if the executive’s employment or service relationship with our company terminated for cause or
continue for a period of 90 days if the executive’s employment or service relationship with our company terminated for any
reason, other than for cause or upon death or disability. Upon a “life event,” defined as the executive’s death, disability or
qualified retirement, a pro rata portion of the unvested portion of the option will immediately vest and the remaining unvested
portion will immediately terminate and the executive’s right to exercise the then vested portion of the option will continue for a
period of one year if the executive’s employment or service relationship with our company terminated as a result of his or her
death or disability or continue for a period of 90 days if the executive’s employment or service relationship with our company
terminated by reason of a qualified retirement.
Stock grants under the plan are made in the form of RSU awards and assuming the recipient continuously provides services to
our company (whether as an employee or as a consultant) typically vest and the ordinary shares underlying such awards are
issued over time. The specific terms of vesting of an RSU award depend upon whether the award is a performance recognition
grant, talent acquisition grant, special recognition grant, or discretionary grant. Performance recognition grants are typically
made in mid-year and vest, or become issuable, in four as nearly equal as possible annual installments on June 1st of each year.
Promotional performance recognition grants and talent acquisition grants granted to promoted employees and new employees
and special recognition grants vest in a similar manner, except that the first installment is pro-rated, depending upon the grant
date. Grants also may vest upon the achievement of certain financial performance goals.
As a condition of receiving stock options or RSU awards, recipients, including our named executive officers, must agree to pay
all applicable tax withholding obligations in connection with the awards, and in the case of our RSU grants, must agree upon
acceptance of the award to a “sell-to-cover” instruction pursuant to which the executive gives instructions to, and authorizes, a
brokerage firm to sell on the executive’s behalf that number of ordinary shares issuable upon vesting of the RSU award as
determined to be appropriate to generate cash proceeds sufficient to satisfy any applicable tax withholding obligations.
Under the terms of the grant certificates under which RSU awards have been granted to the named executive officers, if an
executive’s employment or service with our company terminates for any reason, other than death or disability or a qualified
retirement, the unvested portion of the RSU award will immediately terminate. Upon an executive’s death, the unvested
portion of the RSU award will immediately vest and the underlying shares will become issuable. Upon the termination of an
executive’s employment or service relationship due to the executive’s disability or a qualified retirement, a pro rata portion of
the unvested RSU award will immediately vest and such underlying shares will become issuable and the remaining unvested
portion will immediately terminate.
As described in more detail under “-Potential Payments Upon Termination or Change in Control,” if a change in control of our
company occurs, then, under the terms of our incentive plan, all outstanding options become immediately exercisable in full
and remain exercisable for the remainder of their terms and all issuance conditions on all outstanding RSU awards will be
(cid:71)(cid:72)(cid:72)(cid:80)(cid:72)(cid:71)(cid:3)(cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:76)(cid:72)(cid:71)(cid:30)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:15)(cid:3)(cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:76)(cid:73)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:76)(cid:86)(cid:86)(cid:88)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:86)(cid:3)(cid:87)(cid:82)(cid:3)(cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:92)(cid:76)(cid:81)(cid:74)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:74)(cid:82)(cid:68)(cid:79)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:87)(cid:75)(cid:72)(cid:85)(cid:72) is
a target for the goal, the issuance condition will be deemed satisfied generally only to the extent of the stated target.
184
Outstanding Equity Awards at Fiscal Year-End
The table below provides information regarding unexercised stock options and unvested stock awards for each of our named
executive officers that remained outstanding at our fiscal year-end, December 25, 2016. We did not have any “equity incentive
plan” awards within the meaning of the SEC rules outstanding on December 25, 2016.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END - 2016
Name
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
Number of securities
underlying
unexercised
options (#) exercisable
628,849
4,112
145,500
9,771
144,625
7,939
129,462
244,413
—
10,309
6,575
9,635
12,528
1,924
19,557
30,602
18,262
34,262
—
34,626
19,578
—
54,122
18,709
18,915
—
20,721
10,329
9,884
24,798
—
Option awards
Number of securities
underlying unexercised
option (#)
unexercisable(1)
Option
exercise
price ($)
Option
expiration
date(2)
Stock awards
Number of
shares or units of
stock that have
not vested(3) (#)
Market value of
shares or units
that have not
vested(4) ($)
—
—
—
—
—
—
—
593,770
271,076
—
—
—
—
—
—
—
—
83,237
60,795
—
47,564
58,515
—
—
45,955
29,083
—
—
—
60,249
38,133
15.55 09/17/2021
17.70 04/16/2022
20.75 05/09/2022
22.55 04/17/2023
23.93 05/14/2023
30.14 04/01/2024
29.06 05/13/2024
20.62 10/13/2025
21.24 07/19/2026
28.32 05/14/2018
15.01 05/13/2019
17.82 05/13/2020
15.04 05/11/2021
17.70 04/16/2022
20.75 05/09/2022
23.93 05/14/2023
29.06 05/13/2024
20.62 10/13/2025
21.24 07/19/2026
30.08 09/26/2024
20.62 10/13/2025
21.24 07/19/2026
20.21 01/31/2023
29.06 05/13/2024
20.62 10/13/2025
21.24 07/19/2026
26.72 07/25/2023
29.06 05/13/2024
30.37 07/25/2024
20.62 10/13/2025
21.24 07/19/2026
311,581
7,262,953
51,612
1,203,076
37,766
880,325
26,936
627,878
___________________________
(1) All stock options vest over a four-year period, with 25% of the underlying shares vesting on the one-year anniversary of the grant date
and the remaining 75% of the underlying shares vesting over a three-year period thereafter in 36 as nearly equal as possible monthly
installments, in each case so long as the individual remains an employee or consultant of our company. If a change in control of our
company occurs, all outstanding options become immediately exercisable in full and remain exercisable for the remainder of their terms.
For more information, see the discussion under “-Potential Payments Upon a Termination or Change in Control.”
(2) All option awards have a 10-year term, but may terminate earlier if the recipient’s employment or service relationship with our company
35,313
823,146
terminates.
185
(3) The release dates and release amounts for the unvested stock awards are as follows:
Name
06/01/2017
06/01/2018
06/01/2019
06/01/2020
Mr. Palmisano
Mr. Berry
Mr. Cordell
Mr. Cooke
Mr. Burrows
95,998
15,441
10,891
8,135
10,665
95,999
15,440
10,891
8,135
10,665
96,000
15,441
10,893
8,135
10,665
23,584
5,290
5,091
2,531
3,318
If a change in control of our company occurs, all issuance conditions on all outstanding stock awards will be deemed satisfie(cid:71)(cid:30)(cid:3)(cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:15)(cid:3)
however, that if any such issuance condition relates to satisfying any performance goal and there is a target for the goal, the issuance or
condition will be deemed satisfied generally only to the extent of the stated target.
(4) The market value of stock awards that had not vested as of December 25, 2016 is based on the per share closing sale price of our
ordinary shares on the last trading day of our fiscal year, December 23, 2016 ($23.31), as reported by the NASDAQ Global Select
Market.
Options Exercised and Stock Vested During Fiscal Year
The table below provides information regarding stock awards that vested for each of our named executive officers during the
fiscal year ended December 25, 2016. No option awards were exercised by any of our named executive officers during the
fiscal year ended December 25, 2016.
Name
Robert J. Palmisano
Restricted stock units
Lance A. Berry
Restricted stock units
Kevin D. Cordell
Restricted stock units
Peter S. Cooke
Restricted stock units
Robert P. Burrows
Restricted stock units
Stock awards(1)
Number of shares
acquired on vesting
(#)
Value realized on
vesting
($)
72,415
10,150
5,800
5,603
7,347
1,420,782
199,143
113,796
109,931
144,148
___________________________
(1) The number of shares acquired upon vesting reflects the gross number of shares acquired absent netting of shares surrendered or sold to
satisfy tax withholding requirements. The value realized on vesting of the RSU awards held by each of the named executive represents
the gross number of ordinary shares acquired, multiplied by the closing sale price of our ordinary shares on the vesting date or the last
trading day prior to the vesting date if the vesting date was not a trading day, as reported by the NASDAQ Global Select Market.
Potential Payments Upon a Termination or Change in Control
Employment Agreement with Robert J. Palmisano. Effective October 1, 2015, Wright Medical Group, Inc., one of our
subsidiaries, entered into an employment agreement with Robert J. Palmisano, our President and Chief Executive Officer.
Under the terms of our employment agreement with Mr. Palmisano, in the event of a termination of his employment, the post-
employment pay and benefits, if any, to be received by him will vary according to the basis for his termination. We have
guaranteed the obligations under the employment agreement since our subsidiary, Wright Medical Group, Inc., is party to the
agreement. The employment agreement will continue until December 31, 2018, subject to earlier termination under certain
circumstances, and commencing on October 1, 2017, will automatically renew for additional one-year periods unless we or
Mr. Palmisano provides notice of non-extension of the agreement.
In the event that Mr. Palmisano’s employment is terminated for cause or he terminates his employment other than for “good
reason” (as defined in the employment agreement) or disability, we will have no obligations to him, other than payment of
(cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:82)(cid:69)(cid:79)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17)(cid:3)(cid:3)(cid:36)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:82)(cid:69)(cid:79)(cid:76)(cid:74)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3)(cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:72)(cid:29)(cid:3)(cid:11)(cid:76)(cid:12)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:3)(cid:87)(cid:75)(cid:85)(cid:82)(cid:88)(cid:74)(cid:75)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)al
cash incentive compen(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:72)(cid:68)(cid:85)(cid:81)(cid:72)(cid:71)(cid:3)(cid:69)(cid:88)(cid:87)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:92)(cid:72)(cid:87)(cid:3)(cid:83)(cid:68)(cid:76)(cid:71)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3)(cid:89)(cid:68)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12)(cid:3)(cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)
(cid:88)(cid:81)(cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:71)(cid:3) (cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3) (cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:89)(cid:12)(cid:3) (cid:82)(cid:81)(cid:79)(cid:92)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:70)(cid:68)(cid:86)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:87)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:87)(cid:76)(cid:80)(cid:72)(cid:3) (cid:69)(cid:92)(cid:3) (cid:85)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:3) (cid:82)(cid:73)(cid:3) (cid:71)(cid:72)(cid:68)(cid:87)(cid:75)(cid:3) (cid:82)(cid:85)(cid:3) (cid:71)(cid:76)(cid:86)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:15)(cid:3) (cid:75)(cid:76)(cid:86)(cid:3)
annual target incentive payment for the year that includes the date of termination.
186
In the event of an involuntary termination of his employment, we will be required to provide him, in addition to his accrued
obligations: (i) a lump sum payment equal to two and one-half times the (cid:86)(cid:88)(cid:80)(cid:3)(cid:82)(cid:73)(cid:29)(cid:3)(cid:11)(cid:68)(cid:12)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:30)(cid:3)(cid:83)(cid:79)(cid:88)(cid:86)(cid:3)
(b) (cid:75)(cid:76)(cid:86)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:87)(cid:68)(cid:85)(cid:74)(cid:72)(cid:87)(cid:3) (cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:69)(cid:82)(cid:81)(cid:88)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:85)(cid:3)(cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:38)(cid:50)(cid:37)(cid:53)(cid:36)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:88)(cid:83)(cid:3) (cid:87)(cid:82)(cid:3)
12 (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:82)(cid:88)(cid:87)(cid:83)(cid:79)(cid:68)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:86)(cid:86)(cid:76)(cid:86)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:68)(cid:3)(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3)(cid:82)(cid:73)(cid:3)(cid:20)(cid:21)(cid:3)(cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:15)(cid:3)(cid:86)(cid:88)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)termination if Mr. Palmisano accepts employment
(cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:68)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3) (cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:85)(cid:30)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3) (cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:3) (cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3) (cid:82)(cid:73)(cid:3) (cid:20)(cid:21)(cid:3) (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:89)(cid:12)(cid:3) (cid:68)(cid:81)(cid:3) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:83)(cid:75)(cid:92)(cid:86)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3) (cid:72)(cid:91)(cid:68)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)
within 12 months of termination.
In the event of a termination of his employment due to death or disability, we will be required to provide him, in addition to his
accrued obligations, his annual target incentive bonus.
In the event of an involuntary termination of his employment in anticipation of or within a 24-month period following a
“change in control,” we will be required to provide him, in addition to his accrued obligations: (i) a lump sum payment equal to
(cid:87)(cid:75)(cid:85)(cid:72)(cid:72)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:88)(cid:80)(cid:3)(cid:82)(cid:73)(cid:29)(cid:3)(cid:11)(cid:68)(cid:12)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:81)(cid:3)(cid:70)(cid:88)(cid:85)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:69)(cid:68)(cid:86)(cid:72)(cid:3)(cid:86)(cid:68)(cid:79)(cid:68)(cid:85)(cid:92)(cid:15)(cid:3)(cid:83)(cid:79)(cid:88)(cid:86)(cid:3)(cid:11)(cid:69)(cid:12)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:87)(cid:68)(cid:85)(cid:74)(cid:72)(cid:87)(cid:3)(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:69)(cid:82)(cid:81)(cid:88)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:12)(cid:3)(cid:75)(cid:76)(cid:86)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)target
(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:69)(cid:82)(cid:81)(cid:88)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:92)(cid:72)(cid:68)(cid:85)(cid:3) (cid:76)(cid:81)(cid:3) (cid:90)(cid:75)(cid:76)(cid:70)(cid:75)(cid:3) (cid:75)(cid:76)(cid:86)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:82)(cid:70)(cid:70)(cid:88)(cid:85)(cid:86)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:85)(cid:3) (cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:38)(cid:50)(cid:37)(cid:53)(cid:36)(cid:3)
(cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:88)(cid:83)(cid:3)(cid:87)(cid:82)(cid:3) (cid:20)(cid:21)(cid:3)(cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:30)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:82)(cid:88)(cid:87)(cid:83)(cid:79)(cid:68)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:68)(cid:86)(cid:86)(cid:76)(cid:86)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:3)(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3) (cid:82)(cid:73)(cid:3) (cid:20)(cid:21)(cid:3) (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:15)(cid:3) (cid:86)(cid:88)(cid:69)(cid:77)(cid:72)(cid:70)(cid:87)(cid:3) (cid:87)(cid:82)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:73)(cid:3)
Mr. Palmisano (cid:68)(cid:70)(cid:70)(cid:72)(cid:83)(cid:87)(cid:86)(cid:3) (cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:68)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3) (cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:85)(cid:30)(cid:3) (cid:11)(cid:89)(cid:12)(cid:3) (cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3) (cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:3) (cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3) (cid:82)(cid:73)(cid:3) (cid:20)(cid:21)(cid:3) (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3)
(vi) an annual physical examination within 12 months of termination.
Upon termination for any reason other than for cause, disability, or death, Mr. Palmisano must enter into a release of all claims
within 30 days after the date of termination before any payments will be made to him under the employment agreement, other
than accrued obligations. If he breaches the terms of the confidentiality, non-competition, non-solicitation, intellectual property
rights agreement, then our obligations to make payments or provide benefits will cease immediately and permanently, and he
will be required to repay an amount equal to 30% of the post-employment payments and benefits previously provided to him
under the employment agreement, with interest. The employment agreement provides for other clawback and forfeiture
provisions, including if we are required to restate our financial statements under certain circumstances. All payments under his
employment agreement will be net of applicable tax withholding obligations. The agreement also provides that if any
severance payments or other payments or benefits deemed made in connection with a future change in control are subject to the
“golden parachute” excise tax under Code Section 4999, the payments will be reduced to one dollar less than the amount that
would subject him to the excise tax if the reduction results in him receiving a greater amount on a net-after tax basis than would
be received if he received the payments and benefits and paid the excise tax.
Severance Pay Agreements with Other Named Executive Officers. Our subsidiary, Wright Medical Group, Inc., has entered into
separation pay agreements with our named executive officers, other than Mr. Palmisano. We have guaranteed the obligations
under these separation pay agreements. The separation pay agreements will continue until October 1, 2018 and, commencing
on October 1, 2017, will automatically renew for additional one-year periods unless we or the executive provides notice of
termination of the agreement.
Under the terms of the separation pay agreement, in the event that the executive is terminated for cause or the executive
terminates his employment other than for good reason or disability, we will have no obligations, other than payment of accrued
obligations. Accrued obligations include: (i) any accrued base salary through th(cid:72)(cid:3) (cid:71)(cid:68)(cid:87)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:70)(cid:68)(cid:86)(cid:75)(cid:3)
(cid:76)(cid:81)(cid:70)(cid:72)(cid:81)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3) (cid:72)(cid:68)(cid:85)(cid:81)(cid:72)(cid:71)(cid:3) (cid:69)(cid:88)(cid:87)(cid:3) (cid:81)(cid:82)(cid:87)(cid:3) (cid:92)(cid:72)(cid:87)(cid:3) (cid:83)(cid:68)(cid:76)(cid:71)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:68)(cid:70)(cid:70)(cid:85)(cid:88)(cid:72)(cid:71)(cid:3) (cid:89)(cid:68)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3)
(cid:88)(cid:81)(cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:71)(cid:3)(cid:69)(cid:88)(cid:86)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:81)(cid:86)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:89)(cid:12)(cid:3)(cid:82)(cid:81)(cid:79)(cid:92)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:70)(cid:68)(cid:86)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:3)(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:68)(cid:87)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:87)(cid:76)(cid:80)(cid:72)(cid:3)(cid:69)(cid:92)(cid:3)reason of death or disability, an annual
incentive target bonus for the year that includes the date of termination, prorated for the portion of the year that the executive
was employed.
In the event of an involuntary termination of the executive’s employment, other than for cause, we will be obligated to pay a
severance payment and accrued obligations and provide certain benefits to the executive. The severance payment will equal the
sum of (i) the executive’s then current annual base salary, plus (ii) an amount equal to his then current annual target bonus.
Half of the total severance payment amount will be payable at or within a reasonable time after the date of termination and the
remaining half will be payable in installments beginning six months after the date of termination, with a final installment to be
made on or before March 15 of the calendar year following the year of termination. In the event of an involuntary termination
of the executive’s employment in connection with a change in control, then his severance payment will equal two times the
amount of his severance payment as described above. Under the separation pay agreement, an involuntary termination of the
executive’s employment will occur if we terminate the executive’s employment other than for cause, disability, voluntary
retirement, or death or if the executive resigns for good reason, in each case as defined in the separation pay agreement.
In addition to a severance payment, the executive also will be entitled to receive the following benefits in the event of an
involuntary termination of his employment: (i) a pro rata portion of the executive’s annual cash incentive compensation award
for the fiscal year that includes the termination date, if earned pursuant to the terms thereof and at such time and in such manner
as determined pursuant to the terms thereof, less any payments thereof already made during such fiscal year (or, in the event of
an involuntary termination in connection with a change in control, a pro rata portion of the executive’s target annual cash
187
incentive compensation award for the fiscal year that includes the termination date, less any payments thereof already made
(cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:73)(cid:76)(cid:86)(cid:70)(cid:68)(cid:79)(cid:3) (cid:92)(cid:72)(cid:68)(cid:85)(cid:12)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:85)(cid:3) (cid:85)(cid:72)(cid:76)(cid:80)(cid:69)(cid:88)(cid:85)(cid:86)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:70)(cid:82)(cid:86)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:38)(cid:50)(cid:37)(cid:53)(cid:36)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:76)(cid:81)(cid:88)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:70)(cid:82)(cid:89)(cid:72)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3) (cid:73)(cid:82)(cid:85) up to 12 months
(18 (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:3)(cid:76)(cid:81)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:3)(cid:76)(cid:81)(cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3)(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:81)(cid:81)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:3)(cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3)(cid:76)(cid:81)(cid:3)(cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:12)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12)(cid:3)(cid:82)(cid:88)(cid:87)(cid:83)(cid:79)(cid:68)(cid:70)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:68)(cid:86)(cid:86)(cid:76)(cid:86)(cid:87)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)
a period of one year (two years in the event of an involuntary termination in connection with a change in control), subject to
(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:76)(cid:73)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:68)(cid:70)(cid:70)(cid:72)(cid:83)(cid:87)(cid:86)(cid:3) (cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3) (cid:68)(cid:81)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3) (cid:72)(cid:80)(cid:83)(cid:79)(cid:82)(cid:92)(cid:72)(cid:85)(cid:30)(cid:3) (cid:11)(cid:76)(cid:89)(cid:12)(cid:3) (cid:73)(cid:76)(cid:81)(cid:68)(cid:81)(cid:70)(cid:76)(cid:68)(cid:79)(cid:3) (cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:76)(cid:81)(cid:74)(cid:3) (cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:68)(cid:3) (cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:3) (cid:82)(cid:73)(cid:3) (cid:82)(cid:81)(cid:72)(cid:3)
(cid:92)(cid:72)(cid:68)(cid:85)(cid:3) (cid:11)(cid:87)(cid:90)(cid:82)(cid:3) (cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:3) (cid:76)(cid:81)(cid:3) (cid:87)(cid:75)(cid:72)(cid:3) (cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3) (cid:68)(cid:81)(cid:3)(cid:76)(cid:81)(cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:76)(cid:81)(cid:3) (cid:70)(cid:82)(cid:81)(cid:81)(cid:72)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:68)(cid:3) (cid:70)(cid:75)(cid:68)(cid:81)(cid:74)(cid:72)(cid:3) (cid:76)(cid:81)(cid:3) (cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:12)(cid:30)(cid:3) (cid:11)(cid:89)(cid:12)(cid:3) (cid:83)(cid:68)(cid:92)(cid:80)(cid:72)(cid:81)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3) continue
insurance coverage equal to the executive’s annual supplemental insurance premium benefit provided to him or her prior to the
date of termination (twice the premium benefit in the event of an involuntary termination in connection with a change in
(cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:12)(cid:30)(cid:3) (cid:11)(cid:89)(cid:76)(cid:12)(cid:3) (cid:68)(cid:81)(cid:3) (cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:83)(cid:75)(cid:92)(cid:86)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3) (cid:72)(cid:91)(cid:68)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:76)(cid:81)(cid:3) (cid:20)(cid:21)(cid:3) (cid:80)(cid:82)(cid:81)(cid:87)(cid:75)(cid:86)(cid:3) (cid:82)(cid:73)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:89)(cid:76)(cid:76)(cid:12)(cid:3) (cid:85)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3) (cid:68)(cid:87)(cid:87)(cid:82)(cid:85)(cid:81)(cid:72)(cid:92)(cid:86)’ fees and
expenses if any such fees or expenses are incurred to recover benefits rightfully owed under the separation pay agreement.
In the event of a termination of an executive’s employment due to death or disability, we will be required to provide the
executive, in addition to his or her accrued obligations, a pro rata portion of his or her annual target incentive bonus.
Upon termination for any reason other than cause, disability, or death, the executive must enter into a release of all claims
within 30 days after the date of termination before any payments will be made to the executive under the separation pay
agreement, other than accrued obligations. If the executive breaches the terms of the confidentiality, non-competition, non-
solicitation, and intellectual property rights agreement or the release, then our obligations to make payments or provide benefits
will cease immediately and permanently, and the executive will be required to repay an amount equal 90% of the payments and
benefits previously provided to the executive under the separation pay agreement, with interest. The separation pay agreement
provides for other clawback and forfeiture provisions, including if we are required to restate our financial statements under
certain circumstances. All payments under the separation pay agreement will be net of applicable tax withholding obligations.
The separation pay agreement provides that if any severance payments or other payments or benefits deemed made in
connection with a future change in control are subject to the “golden parachute” excise tax under Code Section 4999, the
payments will be reduced to one dollar less than the amount that would subject the executive to the excise tax if the reduction
results in the executive receiving a greater amount on a net-after tax basis than would be received if the executive received the
payments and benefits and paid the excise tax.
Retention Agreement with Mr. Cooke. As described earlier, in the beginning of 2016, as part of our merger integration efforts,
we asked Mr. Cooke, our President, International to relocate his family to the United Kingdom and build an international
headquarters and team. Despite his initial hesitation to do so, Mr. Cooke agreed. To incentivize him to relocate, we entered into
a retention letter agreement with him under which we agreed to provide him certain expat relocation and temporary assignment
benefits customarily provided to executives in such situations. We also agreed to pay him a $1.2 million retention payment on
the second anniversary of his relocation, subject to his continuing employment through such date and other specified terms and
conditions. This retention payment, if made, would be in lieu of any future change in control or severance payment Mr. Cooke
otherwise would be entitled to receive under his separation pay agreement. If Mr. Cooke voluntarily terminates his employment
prior to the completion of his two-year assignment, he will not receive the retention payment. If we terminate his employment
without cause or he terminates his employment for good reason prior to the completion of his two-year assignment, he will
receive the retention payment.
Change in Control Provisions in Stock Incentive Plan. In addition to the change in control severance protections provided in
Mr. Palmisano’s employment agreement and the separation pay agreements with our executives, our stock incentive plan under
which stock options and RSU awards have been granted to our named executive officers contains “change in control”
provisions. Under the terms of our stock incentive plan, if there is a change in control of our company, then, all outstanding
options become immediately exercisable in full and remain exercisable for the remainder of their terms and all issuance
(cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:3) (cid:82)(cid:81)(cid:3) (cid:68)(cid:79)(cid:79)(cid:3) (cid:82)(cid:88)(cid:87)(cid:86)(cid:87)(cid:68)(cid:81)(cid:71)(cid:76)(cid:81)(cid:74)(cid:3) (cid:53)(cid:54)(cid:56)(cid:3) (cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3) (cid:90)(cid:76)(cid:79)(cid:79)(cid:3) (cid:69)(cid:72)(cid:3) (cid:71)(cid:72)(cid:72)(cid:80)(cid:72)(cid:71)(cid:3) (cid:86)(cid:68)(cid:87)(cid:76)(cid:86)(cid:73)(cid:76)(cid:72)(cid:71)(cid:30)(cid:3) (cid:83)(cid:85)(cid:82)(cid:89)(cid:76)(cid:71)(cid:72)(cid:71)(cid:15)(cid:3) (cid:75)(cid:82)(cid:90)(cid:72)(cid:89)(cid:72)(cid:85)(cid:15)(cid:3) (cid:87)(cid:75)(cid:68)(cid:87)(cid:3) (cid:76)(cid:73)(cid:3) (cid:68)(cid:81)(cid:92)(cid:3) (cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:76)(cid:86)(cid:86)(cid:88)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3) (cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)
relates to satisfying any performance goal and there is a target for the goal, the issuance condition will be deemed satisfied
generally only to the extent of the stated target. Alternatively, the compensation committee may determine that outstanding
awards will be cancelled as of the consummation of the change in control and that holders of cancelled awards will receive a
payment in respect of such cancellation based on the amount of per share consideration being paid in connection with the
change in control less, in the case of options and other awards subject to exercise, the applicable exercise price.
A “change in control” under our stock incentive plan means:
•
•
the acquisition (other than from us) by any person, entity or group, subject to certain exceptions, of 50% or more
of either our then-outstanding ordinary shares or the combined voting power of our then-outstanding ordinary
shares or the combined voting power of our then-outstanding capital stock entitled to vote generally in the election
(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)
the “continuity directors” cease fo(cid:85)(cid:3)(cid:68)(cid:81)(cid:92)(cid:3)(cid:85)(cid:72)(cid:68)(cid:86)(cid:82)(cid:81)(cid:3)(cid:87)(cid:82)(cid:3)(cid:70)(cid:82)(cid:81)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:87)(cid:72)(cid:3)(cid:68)(cid:87)(cid:3)(cid:79)(cid:72)(cid:68)(cid:86)(cid:87)(cid:3)(cid:68)(cid:3)(cid:80)(cid:68)(cid:77)(cid:82)(cid:85)(cid:76)(cid:87)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:82)(cid:68)(cid:85)(cid:71)(cid:3)(cid:82)(cid:73)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:86)(cid:30)(cid:3)
188
•
•
•
consummation of a reorganization, merger or consolidation, in each case, with respect to which persons who were
our shareholders immediately prior to such reorganization, merger or consolidation do not, immediately thereafter,
own more than 50% of the combined voting power entitled to vote generally in the election of directors of the
then-outstanding voting securities of the reorganized, merged, consolidated, or other surviving corporation (or its
(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:3)(cid:83)(cid:68)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:70)(cid:82)(cid:85)(cid:83)(cid:82)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:12)(cid:30)
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:68)(cid:79)(cid:3)(cid:69)(cid:92)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:75)(cid:82)(cid:79)(cid:71)(cid:72)(cid:85)(cid:86)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:3)(cid:79)(cid:76)(cid:84)(cid:88)(cid:76)(cid:71)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:85)(cid:3)(cid:71)(cid:76)(cid:86)(cid:86)(cid:82)(cid:79)(cid:88)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)(cid:3)(cid:82)(cid:85)(cid:3)
the consummation of the sale of all or substantially all of our assets with respect to which persons who were our
shareholders immediately prior to such sale do not, immediately thereafter, own more than 50% of the combined
voting power entitled to vote generally in the election of directors of the then-outstanding voting securities of the
acquiring corporation (or its direct or indirect parent corporation).
Potential Payments to Named Executive Officers. The table below reflects the amount of compensation and benefits payable to
each named executive officer, in the event of (i) any voluntary resignation or termination or (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:73)(cid:82)(cid:85)(cid:3) (cid:70)(cid:68)(cid:88)(cid:86)(cid:72)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12) an
(cid:76)(cid:81)(cid:89)(cid:82)(cid:79)(cid:88)(cid:81)(cid:87)(cid:68)(cid:85)(cid:92)(cid:3) (cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3) (cid:90)(cid:76)(cid:87)(cid:75)(cid:82)(cid:88)(cid:87)(cid:3) (cid:70)(cid:68)(cid:88)(cid:86)(cid:72)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:76)(cid:12) an involuntary termination without cause or a resignation for good reason within
12 months (24 months in the case of Mr. Palmisano) following a change in control, or a qualifying change in control
(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12) termination by reason of an executive’s death or disability. The amounts reported in the table assume that
the applicable triggering event occurred on December 25, 2016, and, therefore, are estimates of the amounts that would be paid
to the named executive officers upon the occurrence of such triggering event.
Name
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Type of payment(1)
Cash severance
Benefit continuation
Annual bonus(2)
Outplacement benefits
Other termination benefits(3)
Option award acceleration(4)
RSU award acceleration(5)
Total
Cash severance
Benefit continuation
Annual bonus(2)
Outplacement benefits
Other termination benefits(3)
Option award acceleration(4)
RSU award acceleration(5)
Total
Cash severance
Benefit continuation
Annual bonus(2)
Outplacement benefits
Other termination benefits(3)
Option award acceleration(4)
RSU award acceleration(5)
Total
Cash severance(6)
Benefit continuation
Annual bonus(2)
Outplacement benefits
Other termination benefits(3)
Option award acceleration(4)
RSU award acceleration(5)
Total
Involuntary
termination
without
cause
($)
4,608,240
19,920
921,648
30,000
6,000
—
—
5,585,808
Qualifying
change in
control
termination
($)
5,529,888
19,920
921,648
30,000
6,000
2,158,369
7,262,953
15,928,778
682,110
19,920
268,710
30,000
6,000
—
—
1,006,740
727,584
19,920
272,844
30,000
6,000
—
—
1,056,348
1,226,112
19,920
211,200
30,000
6,000
—
—
1,493,232
1,364,220
29,880
268,710
60,000
12,000
349,753
1,203,076
3,287,639
1,455,168
29,880
272,844
60,000
12,000
249,073
880,325
2,959,290
1,226,112
29,880
211,200
60,000
12,000
183,821
627,878
2,350,891
Death/
disability
($)
—
—
921,648
—
—
—
—
921,648
—
—
268,710
—
—
—
—
268,710
—
—
272,844
—
—
—
—
272,844
—
—
211,200
—
—
—
—
211,200
Voluntary/
for cause
termination
($)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
189
Name
Type of payment(1)
Voluntary/
for cause
termination
($)
Death/
disability
($)
Involuntary
termination
without
cause
($)
777,908
19,920
259,303
30,000
6,000
—
—
1,093,131
Qualifying
change in
control
termination
($)
1,555,816
29,880
259,303
60,000
12,000
241,005
823,146
2,981,150
Robert P. Burrows
Cash severance
Benefit continuation
Annual bonus(2)
Outplacement benefits
Other termination benefits(3)
Option award acceleration(4)
RSU award acceleration(5)
Total
___________________________
(1) The benefit amounts set forth in the table do not reflect any reduction that may be necessary to prevent the payment from being subject
—
—
259,303
—
—
—
—
259,303
—
—
—
—
—
—
—
—
to an excise tax under Code Section 280G, if applicable.
(2) Assumes payment equal to full target annual bonus for the year in which the termination date occurs.
(3) Reflects the cost of financial planning services and continued executive insurance. Reimbursement of reasonable attorneys’ fees and
expenses is not included as the amount is not estimable.
(4) Based on the difference between: (i) the per share market price of the ordinary shares underlying the unvested stock options held by such
executive as of December 23, 2016, the last trading day of fiscal 2016, based upon the per share closing sale price of our ordinary shares
on such date ($23.31), as reported by the NASDAQ Global Select Market, and (ii) the per share exercise price of the options held by
such executive. The per share exercise price of all unvested stock options held by our named executive officers included in the table as
of December 25, 2016 is $20.62 and $21.24.
(5) Based on: (i) the number of unvested RSU awards held by such executive as of December 25, 2016, multiplied by (ii) the per share
market price of our ordinary shares as of December 23, 2016, the last trading day of fiscal 2016, based upon the per share closing sale
price of our ordinary shares on December 23, 2016 ($23.31), as reported by the NASDAQ Global Select Market.
(6) Represents retention payment under Mr. Cooke’s retention letter agreement.
Risk Assessment of Compensation Policies, Practices, and Programs
As a result of our annual assessment on risk in our compensation programs, we concluded that our compensation policies,
practices, and programs and related compensation governance structure, work together in a manner so as to encourage our
employees, including our named executive officers, to pursue growth strategies that emphasize shareholder value creation, but
not to take unnecessary or excessive risks that could threaten the value of our company. As part of our assessment, we noted in
particular the following:
•
annual base salaries for employees are not subject to performance risk and, for most non-executive employees,
(cid:70)(cid:82)(cid:81)(cid:86)(cid:87)(cid:76)(cid:87)(cid:88)(cid:87)(cid:72)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:79)(cid:68)(cid:85)(cid:74)(cid:72)(cid:86)(cid:87)(cid:3)(cid:83)(cid:68)(cid:85)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:76)(cid:85)(cid:3)(cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3)
•
•
• while performance-based, or at risk, compensation constitutes a significant percentage of the overall total
compensation of many of our employees, including our executives, non-performance based compensation for
most employees for most years is still a sufficiently high percentage of their overall total compensation that the
performance-based (cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:71)(cid:82)(cid:72)(cid:86)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:72)(cid:81)(cid:70)(cid:82)(cid:88)(cid:85)(cid:68)(cid:74)(cid:72)(cid:3)(cid:88)(cid:81)(cid:81)(cid:72)(cid:70)(cid:72)(cid:86)(cid:86)(cid:68)(cid:85)(cid:92)(cid:3)(cid:82)(cid:85)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:86)(cid:86)(cid:76)(cid:89)(cid:72)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:87)(cid:68)(cid:78)(cid:76)(cid:81)(cid:74)(cid:30)
for most employees, our performance-(cid:69)(cid:68)(cid:86)(cid:72)(cid:71)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:72)(cid:81)(cid:86)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:3)(cid:75)(cid:68)(cid:86)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:68)(cid:87)(cid:72)(cid:3)(cid:80)(cid:68)(cid:91)(cid:76)(cid:80)(cid:88)(cid:80)(cid:86)(cid:30)
a significant portion of performance-based compensation of our employees is in the form of long-term equity
incentives which do not encourage unnecessary or excessive risk because they generally vest over a three to four-
year period of time thereby focusing our employees on our long-(cid:87)(cid:72)(cid:85)(cid:80)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:86)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
performance-based or variable compensation awarded to our employees, which for our higher-level employees,
including our named executive officers, constitutes the largest part of their total compensation, is appropriately
balanced between annual and long-term performance and cash and equity compensation, and utilizes several
different performance measures and goals that are drivers of long-term success for our company and shareholders.
•
As a matter of best practice, we will continue to monitor our compensation policies, practices, and programs to ensure that they
continue to align the interest of our employees, including in particular our executive officers, with those of our long-term
shareholders while avoiding unnecessary or excessive risk.
190
Compensation Committee Interlocks and Insider Participation
Sean D. Carney, John L. Miclot, and Elizabeth H. Weatherman, served as members of the compensation committee of our board
of directors during 2016. No member of the compensation committee is or was an officer or employee of ours or any of our
subsidiaries while serving on the compensation committee. In addition, no executive officer of ours served during 2016 as a
director or a member of the compensation committee of any entity that had an executive officer serving as our director or a
member of the compensation committee.
Director Compensation
Overview
Under the terms of our board of directors compensation policy, which was approved by the general meeting of our shareholders
on August 26, 2010 and was amended on October 28, 2010, the compensation packages for our non-executive directors are
determined by our non-executive directors, based upon a recommendation by the compensation committee. Such compensation
is determined by our non-executive directors pursuant to the terms of our articles of association, which provide that if all
directors have a conflict of interest in the matter to be acted upon, the matter shall be approved by our non-executive directors.
In determining non-executive director compensation, we target compensation in the market median range of our peer
(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:76)(cid:72)(cid:86)(cid:30)(cid:3)(cid:68)(cid:79)(cid:87)(cid:75)(cid:82)(cid:88)(cid:74)(cid:75)(cid:15)(cid:3)(cid:90)(cid:72)(cid:3)(cid:80)(cid:68)(cid:92)(cid:3)(cid:71)(cid:72)(cid:89)(cid:76)(cid:68)(cid:87)(cid:72)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:80)(cid:72)(cid:71)(cid:76)(cid:68)(cid:81)(cid:3)(cid:76)(cid:73)(cid:3)(cid:90)(cid:72)(cid:3)(cid:71)(cid:72)(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:72)(cid:3)(cid:81)(cid:72)(cid:70)(cid:72)(cid:86)(cid:86)(cid:68)(cid:85)(cid:92)(cid:3)(cid:82)(cid:85)(cid:3)(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:83)(cid:85)(cid:76)(cid:68)(cid:87)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:68)(cid:3)(cid:70)(cid:68)(cid:86)(cid:72)-by-case basis.
Under the terms of our non-executive director compensation program, compensation for our non-executive directors is
comprised of both cash compensation and equity-based compensation. Cash compensation is in the form of annual or other
retainers for non-executive directors, chairman, committee chairs, and committee members. Equity-based compensation is in
the form of initial and annual stock option and stock grants (in the form of RSU awards). Each of these components is
described in more detail below. We do not provide perquisites and other personal benefits to our non-executive directors.
Recent Changes
In October 2016, the compensation committee engaged Mercer to review our non-executive director compensation program. In
so doing, Mercer analyzed the outside director compensation levels and practices of our peer companies. Although Mercer
used the same peer group as was approved by the compensation committee and used to gather compensation information for
our executive officers for 2016, it was updated to reflect certain changes due to acquisitions and other peer group changes.
Based on Mercer’s recommendations, the compensation committee recommended and our board of directors approved certain
changes to our non-executive director compensation program, effective January 1, 2016. These changes include a $15,000
increase in our annual non-executive director retainer, a $25,000 increase in the premium for our chairman, a $5,000 increase in
the premium for the chair of our audit committee, a $3,000 increase in the premium for the chair of our compensation
committee, and a $35,000 increase in the annual equity-based compensation award. Our non-executive director compensation
program is consistent with our shareholder-approved board of directors compensation policy.
Cash Compensation
The table below sets forth the annual cash retainers paid to each non-executive director and the additional annual cash retainers
paid to the chairman and each board committee chair and board committee member as of during 2016 and that will be paid
effective as of January 1, 2017:
Description
Non-executive director
Chairman premium
Audit committee chair premium
Compensation committee chair premium
Nominating, corporate governance and compliance committee chair premium
Strategic transactions committee chair premium
Audit committee member (including chair)
Compensation committee member (including chair)
Nominating, corporate governance and compliance committee member (including chair)
Strategic transactions committee member (including chair)
Annual cash retainer ($)
2016
45,000
50,000
15,000
10,000
10,000
10,000
15,000
7,000
7,000
5,000
Effective 01/01/2017
60,000
75,000
20,000
13,000
10,000
10,000
15,000
7,000
7,000
5,000
The annual cash retainers are paid on a quarterly basis in arrears within 30 days of the end of each calendar quarter. For
example, the retainers for the first calendar quarter covering the period from January 1 through March 31 are paid within
191
30 days of March 31. In addition, each non-executive director receives a cash travel stipend of $2,000 for each board meeting
attended in person that takes place in the Netherlands or other location outside the United States.
Equity-Based Compensation
The equity-based compensation component of our non-executive director compensation consists of initial stock option and
RSUs awards to new non-executive directors upon their first appointment or election to our board of directors and annual stock
option and RSU awards to all non-executive directors on the same date that annual performance recognition grants of equity
awards are made to our employees.
Non-executive directors, upon their initial election to our board of directors and on an annual basis thereafter effective as of the
same date that annual performance recognition grants of equity awards are made to our employees, receive a certain dollar
amount equal to $160,000 during 2016 and $195,000 during 2017, one-half of which is paid in stock options and the remaining
one-half of which is paid in RSU awards. The number of ordinary shares underlying the stock options and RSU awards is
determined based on the 10-trading day average closing sale price of an ordinary share, as reported by the NASDAQ Global
Select Market, and as determined prior to the date of anticipated corporate approval of the award. The stock options have a
term of 10 years and a per share exercise price equal to 100% of the fair market value of an ordinary share on the grant date.
The stock options vest over a two-year period, with one-half of the underlying shares vesting on each of the one-year and two-
year anniversaries of the grant date, in each case so long as the director is still a director as of such date. The RSU awards vest
in full on the one-year anniversary of the grant date so long as the director is still a director as of such date.
Election to Receive Equity-Based Compensation in Lieu of Cash Compensation
Our non-executive director compensation policy allows our non-executive directors to elect to receive an RSU award in lieu of
100% of their annual cash retainers payable for services to be rendered as a non-executive director, chairman and chair or
member of any board committee. Each non-executive director who elects to receive an RSU award in lieu of such director’s
annual cash retainers is granted an RSU award under our stock incentive plan for that number of ordinary shares as determined
by dividing the aggregate dollar amount of all annual cash retainers anticipated to payable to such director for the period
commencing on July 1 of each year to June 30 of the following year by the 10-trading day average closing sale price of our
ordinary shares as reported by the NASDAQ Global Select Market and as determined one week prior to the date of anticipated
corporate approval of the award. These RSU awards are typically granted effective as of the same date that other director
equity grants are made and annual performance recognition grants of equity awards are made to our employees. These RSU
awards vest in four equal installments on the following September 30th, December 31st, March 31st and June 30th.
If a non-executive director who elected to receive an RSU award in lieu of such director’s annual cash retainers is no longer a
director before such director’s interest in all of the ordinary shares underlying RSU award have vested and become issuable,
then such director will forfeit his or her rights to receive all of the shares underling such RSU award that have not vested and
been issued as of the date such director’s status as a director so terminates. In such case, the non-executive director will receive
in cash a pro rata portion of his or her annual cash retainers for the quarter in which the director’s status as a director
terminates.
If a non-executive director who elected to receive an RSU award in lieu of such director’s annual cash retainers becomes
entitled to receive an increased or additional annual cash retainer during the period from July 1 to June 30 of the next year, such
director will receive such increased or additional annual cash retainer in cash until July 1 of the next year when the director
may elect (on or prior to June 15 of the next year) to receive an RSU award in lieu of such director’s annual cash retainers.
If a non-executive director who elected to receive an RSU award in lieu of such director’s annual cash retainers experiences a
change in the director’s membership on one or more board committees or chair positions prior to June 30 of the next year such
that the director becomes entitled to receive annual cash retainers for the period from July 1 to June 30 of the next year
aggregating an amount less than the aggregate amount used to calculate the director’s most recent RSU award received, the
director will forfeit as of the effective date of such board committee or chair change his or her rights to receive a pro rata
portion of the shares underlying such RSU award reflecting the decrease in the director’s aggregate annual cash retainers and
the date on which such decrease occurred. In addition, the vesting of the RSU award will be revised appropriately to reflect
any such change in the number of shares underlying the RSU award and the date on which such change occurred.
192
Summary of Cash and Other Director Compensation
The table below summarizes the compensation received by each individual who served as a non-executive director of our
company during the year ended December 25, 2016. While Mr. Palmisano did not receive additional compensation for his
service as executive director, a portion of his compensation was allocated to his service as executive director. For more
information regarding the allocation of Mr. Palmisano’s compensation, please refer to note (1) to the Summary Compensation
Table under “-Executive Compensation Tables and Narratives-Summary Compensation.”
DIRECTOR COMPENSATION- 2016
All other
compensation(6)(7)
($)
Name
Fees earned or
paid in cash(1)
($)
Stock
awards(2)(3)
($)
86,957
161,955
86,957
86,957
86,957
86,957
86,957
167,392
Option
awards(4)(5)
($)
87,012
87,012
87,012
87,012
87,012
87,012
87,012
87,012
60,000
69,000
52,000
60,000
62,000
106,368
79,368
72,104
Gary D. Blackford
Sean D. Carney
John L. Miclot
Kevin C. O’Boyle
Amy S. Paul
David D. Stevens
Richard F. Wallman
Elizabeth H. Weatherman
___________________________
(1) Unless a director otherwise elects to convert all of his or her annual retainers into RSU awards, annual retainers are paid in cash on a
quarterly basis in arrears within 30 days of the end of each calendar quarter. Two of our non-executive directors elected to convert all of
their annual retainers covering the period of service from July 1, 2015 to June 30, 2016 and from July 1, 2016 to June 30, 2017 into RSU
awards under our stock incentive plan. Accordingly, these two non-executive directors were granted RSU awards on October 13, 2015
and July 19, 2016 for that number of ordinary shares as determined based on the following formula: (a) the aggregate dollar amount of
all annual cash retainers that otherwise would have been payable to the non-executive director for services to be rendered as a non-
executive director, chairman and chair or member of any board committee (based on such director’s board committee memberships and
chair positions as of the grant date), divided by (b) the 10-trading day average closing sale price of an ordinary share, as reported by the
NASDAQ Global Select Market, and as determined prior to the date of anticipated corporate approval of the award. Such RSU awards
vest and the underlying shares become issuable in four as nearly equal as possible quarterly installments, on September 30, December
31, March 31 and June 30, in each case so long as the non-executive director is a director of our company as of such date.
8,000
6,000
8,000
6,000
6,000
8,000
8,000
8,000
Total
($)
241,969
323,967
233,969
239,969
241,969
288,337
261,337
334,508
The table below sets forth for each non-executive director that elected to convert his or her annual retainers into RSU awards: (a) the
number of RSU awards granted to each non-(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:3)(cid:82)(cid:81)(cid:3)(cid:45)(cid:88)(cid:79)(cid:92)(cid:3)(cid:20)(cid:28)(cid:15)(cid:3)(cid:21)(cid:19)(cid:20)(cid:25)(cid:30)(cid:3)(cid:11)(cid:69)(cid:12) the total amount of annual retainers converted by
(cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:3) (cid:76)(cid:81)(cid:87)(cid:82)(cid:3) (cid:53)(cid:54)(cid:56)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)(cid:11)(cid:70)(cid:12)(cid:3) (cid:82)(cid:73)(cid:3) (cid:86)(cid:88)(cid:70)(cid:75)(cid:3) (cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:3) (cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3) (cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3) (cid:85)(cid:72)(cid:87)(cid:68)(cid:76)(cid:81)(cid:72)(cid:85)(cid:86)(cid:3) (cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:87)(cid:82)(cid:3) (cid:53)(cid:54)(cid:56)(cid:3) (cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:15)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3) (cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3) (cid:68)(cid:87)(cid:87)(cid:85)(cid:76)(cid:69)(cid:88)(cid:87)(cid:72)(cid:71)(cid:3)to the
director’s service during 2016, which amount is included in the “Fees earned or paid in cash” (cid:70)(cid:82)(cid:79)(cid:88)(cid:80)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:30)(cid:3)(cid:11)(cid:71)(cid:12)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:3)
(cid:73)(cid:68)(cid:76)(cid:85)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:88)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:41)(cid:36)(cid:54)(cid:37)(cid:3)(cid:36)(cid:54)(cid:38)(cid:3)(cid:55)(cid:82)(cid:83)(cid:76)(cid:70)(cid:3)(cid:26)(cid:20)(cid:27)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:72)(cid:12)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:76)(cid:81)(cid:70)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:68)(cid:79)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:3)(cid:73)(cid:68)(cid:76)(cid:85)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)for the
stock awards above and beyond the amount of annual retainers for 2016 service converted into RSU awards computed in accordance
with FASB ASC Topic 718.
Total amount of
retainers converted
into RSU awards
($)
69,000
72,104
Number of
RSU awards
(#)
3,531
3,787
Amount of retainer
converted into RSU
awards attributable to
2016 service
($)
34,500
36,052
Grant date fair
value of RSU
awards
($)
74,998
80,436
Incremental grant date
fair value of RSU
awards received during
2016
($)
40,498
44,384
Name
Mr. Carney
Ms. Weatherman
The table below sets forth: (a) the number of RSU awards granted to each non-(cid:72)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3) (cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:3) (cid:82)(cid:81)(cid:3) (cid:50)(cid:70)(cid:87)(cid:82)(cid:69)(cid:72)(cid:85)(cid:3)(cid:20)(cid:22)(cid:15)(cid:3) (cid:21)(cid:19)(cid:20)(cid:24)(cid:30)(cid:3) (cid:11)(cid:69)(cid:12) the total
(cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)(cid:68)(cid:81)(cid:81)(cid:88)(cid:68)(cid:79)(cid:3)(cid:85)(cid:72)(cid:87)(cid:68)(cid:76)(cid:81)(cid:72)(cid:85)(cid:86)(cid:3)(cid:70)(cid:82)(cid:81)(cid:89)(cid:72)(cid:85)(cid:87)(cid:72)(cid:71)(cid:3)(cid:69)(cid:92)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:87)(cid:82)(cid:3)(cid:53)(cid:54)(cid:56)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:30)(cid:3)(cid:11)(cid:70)(cid:12)(cid:3)(cid:82)(cid:73)(cid:3)(cid:86)(cid:88)(cid:70)(cid:75)(cid:3)(cid:87)(cid:82)(cid:87)(cid:68)(cid:79)(cid:3)(cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:3)(cid:82)(cid:73)(cid:3)annual retainers converted into RSU
awards, the amount attributed to the director’s service during 2015, which amount is included in the “Fees earned or paid in cash”
(cid:70)(cid:82)(cid:79)(cid:88)(cid:80)(cid:81)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:72)(cid:68)(cid:70)(cid:75)(cid:3)(cid:71)(cid:76)(cid:85)(cid:72)(cid:70)(cid:87)(cid:82)(cid:85)(cid:30)(cid:3)(cid:11)(cid:71)(cid:12)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:74)(cid:85)(cid:68)(cid:81)(cid:87)(cid:3)(cid:71)(cid:68)(cid:87)(cid:72)(cid:3)(cid:73)(cid:68)(cid:76)(cid:85)(cid:3)(cid:89)(cid:68)(cid:79)(cid:88)(cid:72)(cid:3)(cid:82)(cid:73)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:87)(cid:82)(cid:70)(cid:78)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:88)(cid:87)(cid:72)(cid:71)(cid:3)(cid:76)(cid:81)(cid:3)(cid:68)(cid:70)(cid:70)(cid:82)(cid:85)(cid:71)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:41)(cid:36)(cid:54)(cid:37)(cid:3)(cid:36)(cid:54)(cid:38)(cid:3)(cid:55)(cid:82)(cid:83)(cid:76)(cid:70)(cid:3)(cid:26)(cid:20)(cid:27)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:11)(cid:72)(cid:12)(cid:3)
the incremental grant date fair value for the stock awards above and beyond the amount of annual retainers for 2015 service converted
into RSU awards computed in accordance with FASB ASC Topic 718.
Total amount of
retainers converted
into RSU awards
($)
81,750
55,500
Number of
RSU awards
(#)
3,891
2,642
Amount of retainer
converted into RSU
awards attributable to
2015 service
($)
40,875
27,750
Grant date fair
value of RSU
awards
($)
80,232
54,478
Incremental grant date
fair value of RSU
awards received during
2015
($)
39,357
26,728
Name
Mr. Carney
Ms. Weatherman
(2) On July 19, 2016, each non-executive director received an RSU award for 4,094 ordinary shares granted under our stock incentive plan.
The RSU award vests and the underlying shares become issuable on the one-year anniversary of the grant date, July 19, 2017, so long as
193
the non-executive director is a director of our company as of such date. In addition, as described above in note (1), two non-executive
directors elected to convert their annual retainers covering the period of service from July 1, 2016 to June 30, 2017 into RSU awards
under our stock incentive plan. The amount reported in the “Stock awards” column represents the aggregate grant date fair value for the
July 19, 2016 RSU awards granted to each director in 2016 and for those directors who elected to convert their annual retainers covering
the period of service from July 1, 2016 to June 30, 2017, the grant date fair value for the additional July 19, 2016 RSU awards granted to
such director in 2016, in each case as computed in accordance with FASB ASC Topic 718. The grant date fair value for RSU awards is
determined based on the closing sale price of our ordinary shares on the grant date.
(3) As of December 25, 2016, each non-executive director held the following number of unvested stock awards (all of which are in the form
(cid:82)(cid:73)(cid:3)(cid:53)(cid:54)(cid:56)(cid:3)(cid:68)(cid:90)(cid:68)(cid:85)(cid:71)(cid:86)(cid:12)(cid:29)(cid:3)(cid:48)(cid:85)(cid:17)(cid:3)(cid:37)(cid:79)(cid:68)(cid:70)(cid:78)(cid:73)(cid:82)(cid:85)(cid:71)(cid:3)(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:48)(cid:85)(cid:17)(cid:3)(cid:38)(cid:68)(cid:85)(cid:81)(cid:72)(cid:92)(cid:3)(cid:11)(cid:25)(cid:15)(cid:26)(cid:23)(cid:22)(cid:12)(cid:30)(cid:3)(cid:48)(cid:85)(cid:17) (cid:48)(cid:76)(cid:70)(cid:79)(cid:82)(cid:87)(cid:3)(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:48)(cid:85)(cid:17)(cid:3)(cid:50)’(cid:37)(cid:82)(cid:92)(cid:79)(cid:72)(cid:3)(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:48)(cid:86)(cid:17)(cid:3)(cid:51)(cid:68)(cid:88)(cid:79)(cid:3)(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:48)(cid:85)(cid:17) Stevens
(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:48)(cid:85)(cid:17) (cid:58)(cid:68)(cid:79)(cid:79)(cid:80)(cid:68)(cid:81)(cid:3)(cid:11)(cid:23)(cid:15)(cid:19)(cid:28)(cid:23)(cid:12)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:48)(cid:86)(cid:17) Weatherman (6,935).
(4) On July 19, 2016, each non-executive director received a stock option to purchase 11,765 ordinary shares at an exercise price of $21.24
per share granted under our stock incentive plan. Such option expires on July 19, 2026 and vests with respect to one-half of the
underlying ordinary shares on each of the following dates, so long as the individual remains a director of our company as of such date:
July 19, 2017 and July 19, 2018. Amounts reported in the “Option awards” column represent the aggregate grant date fair value for
option awards granted to each non-executive director in 2016 computed in accordance with FASB ASC Topic 718. The grant date fair
value is determined based on our Black-Scholes option pricing model. The grant date value per share for the option granted on July 19,
201(cid:25)(cid:3)(cid:90)(cid:68)(cid:86)(cid:3)(cid:7)(cid:26)(cid:17)(cid:23)(cid:19)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:90)(cid:68)(cid:86)(cid:3)(cid:71)(cid:72)(cid:87)(cid:72)(cid:85)(cid:80)(cid:76)(cid:81)(cid:72)(cid:71)(cid:3)(cid:88)(cid:86)(cid:76)(cid:81)(cid:74)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:73)(cid:82)(cid:79)(cid:79)(cid:82)(cid:90)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:73)(cid:76)(cid:70)(cid:3)(cid:68)(cid:86)(cid:86)(cid:88)(cid:80)(cid:83)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:29)(cid:3)(cid:85)(cid:76)(cid:86)(cid:78)(cid:3)(cid:73)(cid:85)(cid:72)(cid:72)(cid:3)(cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:72)(cid:86)(cid:87)(cid:3)(cid:85)(cid:68)(cid:87)(cid:72)(cid:29)(cid:3)(cid:3)(cid:20)(cid:17)(cid:20)(cid:21)(cid:24)(cid:8)(cid:30)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:70)(cid:87)(cid:72)(cid:71)(cid:3)(cid:79)(cid:76)(cid:73)(cid:72)(cid:29)(cid:3)(cid:25)(cid:17)(cid:19)(cid:27)(cid:3)(cid:92)(cid:72)(cid:68)(cid:85)(cid:86)(cid:30)(cid:3)
(cid:72)(cid:91)(cid:83)(cid:72)(cid:70)(cid:87)(cid:72)(cid:71)(cid:3)(cid:89)(cid:82)(cid:79)(cid:68)(cid:87)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:29)(cid:3)(cid:22)(cid:23)(cid:17)(cid:19)(cid:8)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:72)(cid:91)(cid:83)(cid:72)(cid:70)(cid:87)(cid:72)(cid:71)(cid:3)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:72)(cid:81)(cid:71)(cid:3)(cid:92)(cid:76)(cid:72)(cid:79)(cid:71)(cid:29)(cid:3)(cid:19)(cid:17)
(5) The table below provides information regarding the aggregate number of options to purchase ordinary shares outstanding at
December 25, 2016 and held by each of our non-executive directors:
Name
Mr. Blackford
Mr. Carney
Mr. Miclot
Mr. O’Boyle
Ms. Paul
Mr. Stevens
Mr. Wallman
Ms. Weatherman
Aggregate number of
shares underlying
options
Exercisable/
unexercisable
84,635
25,074
115,564
100,603
100,100
87,214
84,978
25,074
67,361/17,274
7,800/17,274
98,290/17,274
83,329/17,274
82,826/17,274
69,940/17,274
67,704/17,274
7,800/17,274
Range of
exercise
price(s) ($)
15.01-29.06
20.62-25.20
15.01-29.06
18.04-25.20
15.01-29.06
15.01-29.06
16.98-25.20
20.62-25.20
Range of
expiration
date(s)
05/14/2018-07/19/2026
05/12/2021-07/19/2026
03/30/2017-07/19/2026
06/03/2020-07/19/2026
05/14/2018-07/19/2026
05/17/2017-07/19/2026
12/08/2018-07/19/2026
05/12/2021-07/19/2026
(6) Represents travel stipends of $2,000 for each board meeting attended in person that takes place in the Netherlands or other location
outside the United States.
(7) We do not provide perquisites and other personal benefits to our non-executive directors. Any perquisites or personal benefits actually
provided to any non-executive director were less than $10,000 in the aggregate.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Security Ownership of Certain Beneficial Owners
The table below sets forth certain information concerning the beneficial ownership of our ordinary shares as of February 17,
2017, by each person known by us to beneficially own more than 5% of our ordinary shares. The calculations in the table
below assume that there are 103,625,395 ordinary shares outstanding. Beneficial ownership is determined in accordance with
the rules and regulations of the SEC. In computing the number of ordinary shares beneficially owned by a person and the
percentage ownership of that person, we have included ordinary shares that the person has the right to acquire within 60 days,
including through the exercise of any option, warrant or other right, the conversion of any other security, and the issuance of
ordinary shares upon the vesting of stock awards granted in the form of restricted stock units. The ordinary shares that a
shareholder has the right to acquire within 60 days, however, are not included in the computation of the percentage ownership
of any other person.
Name and address of beneficial owner
Class of
securities
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
___________________________
FMR LLC(1)
T. Rowe Price Associates, Inc. (2)
The Vanguard Group, Inc. (3)
OrbiMed Advisors LLC (4)
Invesco Ltd.(5)
BlackRock, Inc. (6)
194
Ordinary shares
beneficially owned
Number
15,494,818
12,287,578
7,745,958
7,584,334
7,147,734
6,629,691
Percent
15.0%
11.9%
7.5%
7.3%
6.9%
6.4%
* Represents beneficial ownership of less than 1% of our outstanding ordinary shares.
(1) Based solely on information contained in a Schedule 13G/A of FMR LLC, an investment advisor, filed with the SEC on February 14,
2017, with sole investment discretion with respect to all such shares and sole voting authority with respect to 1,430,114 shares. Abigail P.
Johnson is a Director, the Vice Chairman, Chief Executive Officer and President of FMR LLC. Members of the Johnson family,
including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC,
representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a
shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of
Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders’
voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling
group with respect to FMR. Neither FMR nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned
directly by the various investment companies registered under the Investment Company Act (“Fidelity Funds”) advised by Fidelity
Management & Research Company (“FMR Co”), a wholly owned subsidiary of FMR, which power resides with the Fidelity Funds’
Boards of Trustees. Fidelity Co carries out the voting of the shares under written guidelines established by the Fidelity Funds’ Boards of
Trustees. The business address of FMR LLC is 245 Summer Street, Boston, Massachusetts 02210.
(2) Based solely on information contained in a Schedule 13G/A of T. Rowe Price Associates, Inc., an investment advisor, filed with the SEC
on February 7, 2017, reflecting beneficial ownership as of December 31, 2016, with sole investment discretion with respect to all such
shares, and sole voting authority with respect to 1,669,333 shares. The address of T. Rowe Price Associates, Inc. is 100 East Pratt Street,
Baltimore, Maryland 21202.
(3) Based solely on information contained in a Schedule 13G/A of The Vanguard Group, Inc., an investment adviser, filed with the SEC on
February 10, 2017, reflecting beneficial ownership as of December 31, 2016, with sole investment discretion with respect to 7,614,853
shares, sole voting authority with respect to 122,465 shares, shared investment discretion with respect to 131,105 shares and shared
voting authority with respect to 13,275 shares. The address of The Vanguard Group, Inc. is 100 Vanguard Boulevard, Malvern,
Pennsylvania 19355.
(4) Based solely on a Schedule 13G/A filed on February 13, 2017 by OrbiMed Advisors LLC, OrbiMed Capital LLC, and Samuel D. Isaly
reflecting beneficial ownership as of December 31, 2016. The beneficial ownership reflected in the table includes 2,456,550 ordinary
shares beneficially owned by OrbiMed Advisors LLC with shared voting and investment (cid:71)(cid:76)(cid:86)(cid:70)(cid:85)(cid:72)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:24)(cid:15)(cid:20)(cid:21)(cid:26)(cid:15)(cid:26)(cid:27)(cid:23)(cid:3) (cid:82)(cid:85)(cid:71)(cid:76)(cid:81)(cid:68)(cid:85)(cid:92)(cid:3) (cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:86)(cid:3)
beneficially owned by OrbiMed Capital LLC with shared voting and investment discretion, and 7,584,334 ordinary shares beneficially
owned by Samuel D. Isaly with shared voting and investment discretion. The address of their principal business office is 601 Lexington
Avenue, 54th Floor, New York, New York 10022
(5) Based solely on information contained in a Schedule 13G/A of Invesco Ltd., a parent holding company, filed with the SEC on February
8, 2017, reflecting beneficial ownership as of December 31, 2016, with sole investment discretion with respect to all such shares and
sole voting authority with respect to 6,655,361 shares. The address of Invesco Ltd. is 1555 Peachtree Street NE, Suite 1800, Atlanta,
Georgia 30309.
(6) Based solely on information contained in a Schedule 13G of BlackRock, Inc., a parent holding company, filed with the SEC on January
30, 2017, reflecting beneficial ownership as of December 31, 2016, with sole investment discretion with respect to all such shares, and
sole voting authority with respect to 6,409,512 shares. The address of BlackRock, Inc. is 55 East 52nd Street, New York, New York
10055.
Security Ownership of Management
The table below sets forth certain information concerning the beneficial ownership of our ordinary shares as of February 17,
2017, by each of our directors and named executive officers and all of our current directors and executive officers as a group.
The calculations in the table below assume that there are 103,625,395 ordinary shares outstanding. Beneficial ownership is
determined in accordance with the rules and regulations of the SEC. In computing the number of ordinary shares beneficially
owned by a person and the percentage ownership of that person, we have included ordinary shares that the person has the right
to acquire within 60 days, including through the exercise of any option, warrant or other right, the conversion of any other
security, and the issuance of ordinary shares upon the vesting of stock awards granted in the form of restricted stock units. The
ordinary shares that a shareholder has the right to acquire within 60 days, however, are not included in the computation of the
percentage ownership of any other person.
Class of
securities
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Name and address of beneficial owner
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
David D. Stevens
Gary D. Blackford
195
Number
Ordinary shares
beneficially owned(1)
Percent
1.5%
*
*
*
*
*
*
1,607,778
217,098
70,130
109,996
101,678
139,537
126,382
Name and address of beneficial owner
Class of
securities
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
Ordinary shares
___________________________
* Represents beneficial ownership of less than 1% of our outstanding ordinary shares.
Sean D. Carney
John L. Miclot
Kevin C. O’Boyle
Amy S. Paul
Richard F. Wallman
Elizabeth H. Weatherman
All directors and executive officers as a group (21 persons)
Number
Ordinary shares
beneficially owned(1)
Percent
*
*
*
*
*
*
3.3%
12,285
130,074
96,288
116,074
105,236
12,776
3,563,759
(1) Includes for the persons listed below the following ordinary shares subject to options held by that person that are currently exercisable or
become exercisable within 60 days of February 17, 2017 and ordinary shares issuable upon the vesting of RSU awards within 60 days of
February 17, 2017:
Name
Options
RSU awards
Robert J. Palmisano
Lance A. Berry
Kevin D. Cordell
Peter S. Cooke
Robert P. Burrows
David D. Stevens
Gary D. Blackford
Sean D. Carney
John L. Miclot
Kevin C. O’Boyle
Amy S. Paul
Richard F. Wallman
Elizabeth H. Weatherman
All directors and executive officers as a group (21 persons)
1,384,408
153,430
59,790
97,143
72,809
69,940
67,361
7,800
98,290
83,329
82,826
49,704
7,800
2,805,920
—
—
—
—
—
—
—
883
—
—
—
—
947
1,830
Securities Authorized for Issuance Under Equity Compensation Plans
The table below provides information regarding the number of ordinary shares to be issued upon the exercise of outstanding
stock options and RSU awards granted under our equity compensation plans and the number of ordinary shares remaining
available for future issuance our equity compensation plans as of December 25, 2016.
EQUITY COMPENSATION PLAN INFORMATION
Number of securities
to be issued upon
exercise of outstanding
options, warrants and rights
(a)
7,813,930 (1)(2)(3)
—
7,813,930 (1)(2)(3)
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
$20.80 (4)
—
$20.80 (4)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding securities
reflected in column (a))
(c)
1,736,435 (5)
—
1,736,435 (5)
Plan category
Equity compensation plans approved by security holders
Equity compensation plans not approved by security holders
Total
___________________________
(1) Amount includes ordinary shares issuable upon the exercise of stock options granted under the Wright Medical Group N.V. Amended
and Restated 2010 Incentive Plan and Tornier N.V. Amended and Restated Stock Option Plan and ordinary shares issuable upon the
vesting of RSU awards granted under the Wright Medical Group N.V. Amended and Restated 2010 Incentive Plan.
(2) Excludes employee stock purchase rights under the Wright Medical Group N.V. Amended and Restated Employee Stock Purchase Plan,
which is an amended and restated version of the Tornier N.V. 2010 Employee Stock Purchase Plan, was approved by our shareholders on
June 28, 2016. Under such plan, each eligible employee may purchase ordinary shares at semi-annual intervals on June 30th and
December 31st each calendar year at a purchase price per share equal to 85% of the closing sales price per share of our ordinary shares
on the last day of the offering period. However the compensation committee of the board of directors determined that the first plan
period would be the three months beginning October 1, 2016 and ending December 31, 2016. Under the ESPP, the first plan purchase
occurred on December 31, 2016 during the 2017 fiscal year.
196
(3) Excludes an aggregate of 3,925,412 ordinary shares issuable upon the exercise of stock options granted under legacy Wright equity
compensation plans and non-plan inducement option agreements assumed by us in connection with the Wright/Tornier merger. The
weighted-average per share exercise price of these assumed stock options as of December 25, 2016 was $22.01. No further grants or
awards will be made under these assumed legacy Wright equity compensation plans and non-plan inducement option agreements.
(4) Not included in the weighted-average exercise price calculation are 1,334,713 RSU awards.
(5) Amount includes 1,233,923 ordinary shares remaining available for future issuance under the Wright Medical Group N.V. Amended and
Restated 2010 Incentive Plan and 502,512 ordinary shares remaining available for future issuance under the Wright Medical Group N.V.
Amended and Restated Employee Stock Purchase Plan. No shares remain available for grant under the Tornier N.V. Amended and
Restated Stock Option Plan or any of the legacy Wright equity compensation plans since such plans have been terminated with respect to
future grants.
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
Introduction
Below under the heading “-Description of Related Party Transactions” is a description of transactions that have occurred since
the beginning of our last fiscal year, or any currently proposed transactions, to which we were or are a participant and in which:
•
(cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:80)(cid:82)(cid:88)(cid:81)(cid:87)(cid:86)(cid:3)(cid:76)(cid:81)(cid:89)(cid:82)(cid:79)(cid:89)(cid:72)(cid:71)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:72)(cid:71)(cid:72)(cid:71)(cid:3)(cid:82)(cid:85)(cid:3)(cid:90)(cid:76)(cid:79)(cid:79)(cid:3)(cid:72)(cid:91)(cid:70)(cid:72)(cid:72)(cid:71)(cid:3)(cid:7)(cid:20)(cid:21)(cid:19)(cid:15)(cid:19)(cid:19)(cid:19)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)
•
a related person (including any director, director nominee, executive officer, holder of more than 5% of our ordinary
shares or any member of their immediate family) had or will have a direct or indirect material interest.
These transactions are referred to as “related party transactions.”
Procedures Regarding Approval of Related Party Transactions
As provided in our audit committee charter, all related party transactions are to be reviewed and pre-approved by the audit
committee. In determining whether to approve a related party transaction, the audit committee generally will evaluate the
transaction in terms of (i) (cid:87)(cid:75)(cid:72)(cid:3) (cid:69)(cid:72)(cid:81)(cid:72)(cid:73)(cid:76)(cid:87)(cid:86)(cid:3) (cid:87)(cid:82)(cid:3) (cid:82)(cid:88)(cid:85)(cid:3) (cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:81)(cid:92)(cid:30)(cid:3) (cid:11)(cid:76)(cid:76)(cid:12) the impact on a director’s independence in the event the related
person is a director, an immediate family member of a director, or an entity in which a director is a partner, shareholder or
ex(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72)(cid:3)(cid:82)(cid:73)(cid:73)(cid:76)(cid:70)(cid:72)(cid:85)(cid:30)(cid:3)(cid:11)(cid:76)(cid:76)(cid:76)(cid:12) (cid:87)(cid:75)(cid:72)(cid:3)(cid:68)(cid:89)(cid:68)(cid:76)(cid:79)(cid:68)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:92)(cid:3)(cid:82)(cid:73)(cid:3)(cid:82)(cid:87)(cid:75)(cid:72)(cid:85)(cid:3)(cid:86)(cid:82)(cid:88)(cid:85)(cid:70)(cid:72)(cid:86)(cid:3)(cid:73)(cid:82)(cid:85)(cid:3)(cid:70)(cid:82)(cid:80)(cid:83)(cid:68)(cid:85)(cid:68)(cid:69)(cid:79)(cid:72)(cid:3)(cid:83)(cid:85)(cid:82)(cid:71)(cid:88)(cid:70)(cid:87)(cid:86)(cid:3)(cid:82)(cid:85)(cid:3)(cid:86)(cid:72)(cid:85)(cid:89)(cid:76)(cid:70)(cid:72)(cid:86)(cid:30)(cid:3)(cid:11)(cid:76)(cid:89)(cid:12) the terms and conditions of the
(cid:87)(cid:85)(cid:68)(cid:81)(cid:86)(cid:68)(cid:70)(cid:87)(cid:76)(cid:82)(cid:81)(cid:30)(cid:3) (cid:68)(cid:81)(cid:71)(cid:3) (cid:11)(cid:89)(cid:12) the terms available to unrelated third parties or to employees generally. The audit committee will then
document its findings and conclusions in written minutes. In the event a transaction relates to a member of the audit
committee, that member will not participate in the audit committee’s deliberations.
Description of Related Party Transactions
The following persons and entities that participated in the transactions described in this section were related persons at the time
of the transaction:
TMG Holdings Coöperatief U.A., Warburg Pincus (Bermuda) Private Equity IX, L.P., Sean D. Carney and Elizabeth H.
Weatherman. TMG Holdings Coöperatief U.A. is a former shareholder. Two of our directors were affiliated with TMG. Sean
D. Carney and Elizabeth H. Weatherman are former Managing Directors of Warburg Pincus LLC, which manages TMG as well
as its parent entities Warburg Pincus (Bermuda) Private Equity IX, L.P., or WP Bermuda, WP (Bermuda) IX PE One Ltd. and
Warburg Pincus (Bermuda) Private Equity Ltd. (“WPPE”). Furthermore, Mr. Carney and Ms. Weatherman are former Partners
of Warburg Pincus & Co., the sole member of WPPE.
We were party to a securityholders’ agreement with TMG under which TMG had the right to designate three directors to be
nominated to our board of directors for so long as TMG beneficially owned at least 25% of our outstanding ordinary shares,
two directors for so long as TMG beneficially owned at least 10% but less than 25% of our outstanding ordinary shares and one
director for so long as TMG beneficially owned at least 5% but less than 10% of our outstanding ordinary shares. We agreed to
use our reasonable best efforts to cause the TMG designees to be elected as directors. Mr. Carney and Ms. Weatherman served
as designees of TMG. The securityholders’ agreement terminated by its terms in May 2016 upon the sale by TMG of its entire
ownership interest in our company.
We also were a party to a registration rights agreement with TMG which also terminated by its terms in May 2016. Pursuant to
the registration rights agreement, we agreed to (i) use our reasonable best efforts to effect up to three registered offerings of at
least $10 million each upon a demand of TMG or its affiliates, (ii) use our reasonable best efforts to become eligible for use of
Form S-3 for registration statements and once we become eligible TMG or its affiliates shall have the right to demand an
197
unlimited number of registrations of at least $10 million each on Form S-3 and (iii) maintain the effectiveness of each such
registration statement for a period of 120 days or until the distribution of the registrable securities pursuant to the registration
statement is complete. We also had granted certain incidental or “piggyback” registration rights with respect to the registrable
shares, subject to certain limitations and restrictions, including volume and marketing restrictions imposed by the underwriters
of the offering with respect to which the rights are exercised. Under the registration rights agreement, we agreed to bear the
expenses, including the fees and disbursements of one legal counsel for the holders, in connection with the registration of the
registrable securities, except for any underwriting commissions relating to the sale of the registrable securities.
Director Independence
The information regarding director independence is disclosed in “Part III - Item 10. Directors, Executive Officers and
Corporate Governance—Board Structure and Composition” and in “Part III - Item 10. Directors, Executive Officers and
Corporate Governance—Board Committees” of this report.
Item 14.
Principal Accounting Fees and Services.
Appointment of Independent Registered Public Accounting Firms
The audit committee of our board of directors is directly responsible for the appointment, compensation, and oversight of our
independent auditor or independent registered public accounting firm. Our general meeting of shareholders is directly
responsible for the appointment of the auditor audits our Dutch statutory annual accounts prepared in accordance with Dutch
law each year.
Audit, Audit-Related, Tax, and All Other Fees
The following table shows the fees that we or legacy Wright paid or accrued for audit and other services provided by our
current independent registered public accounting firm, KPMG LLP, for 2016 and 2015:
Fees
Audit fees
Audit-related fees
Tax fees
All other fees
Total
$
$
2016
2,400,253 $
43,000
265,000
120,000
2,828,253 $
2015
2,009,760
41,000
15,000
350,000
2,415,760
The following table shows the fees that we or legacy Tornier paid or accrued for audit and other services provided by our
former independent registered public accounting firm, Ernst & Young LLP, for 2015:
Fees
Audit fees
Total
$
$
2015
461,000
461,000
In the above table, in accordance with the SEC’s definitions and rules, “audit fees” are fees for professional services for the
audit of our consolidated financial statements included in this annual report on Form 10-K, and the review of our consolidated
financial statements included in quarterly reports on Form 10-Q and registration statements and for services that are normally
provided by our independent registered public accounting firm in connection with statutory and regulatory filings or
(cid:72)(cid:81)(cid:74)(cid:68)(cid:74)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:86)(cid:30)(cid:3)“audit-related fees” are fees for assurance and related services that are reasonably related to the performance of
the audit or review of our consolidated financial statements and are not included in “audit fees” and include fees for services
(cid:83)(cid:72)(cid:85)(cid:73)(cid:82)(cid:85)(cid:80)(cid:72)(cid:71)(cid:3)(cid:85)(cid:72)(cid:79)(cid:68)(cid:87)(cid:72)(cid:71)(cid:3)(cid:87)(cid:82)(cid:3)(cid:68)(cid:88)(cid:71)(cid:76)(cid:87)(cid:86)(cid:3)(cid:82)(cid:81)(cid:3)(cid:82)(cid:88)(cid:85)(cid:3)(cid:69)(cid:72)(cid:81)(cid:72)(cid:73)(cid:76)(cid:87)(cid:3)(cid:83)(cid:79)(cid:68)(cid:81)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:71)(cid:88)(cid:72)(cid:3)(cid:71)(cid:76)(cid:79)(cid:76)(cid:74)(cid:72)(cid:81)(cid:70)(cid:72)(cid:3)(cid:82)(cid:81)(cid:3)(cid:68)(cid:70)(cid:84)(cid:88)(cid:76)(cid:86)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:17)(cid:30)(cid:3)“tax fees” are fees for tax compliance and
consultation primarily related to assistance with international tax compliance and tax audits, tax advice on acquisitions, and tax
(cid:83)(cid:79)(cid:68)(cid:81)(cid:81)(cid:76)(cid:81)(cid:74)(cid:30)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)“all other fees” are fees for any services not included in the first three categories, which includes fees for a risk
management review and assessment.
198
Pre-Approval Policies and Procedures
In addition to retaining KPMG LLP to audit our consolidated financial statements for 2017, the audit committee retained
KPMG LLP to provide other auditing and advisory services in 2017. The audit committee understands the need for our
independent registered public accounting firm to maintain objectivity and independence in its audits of our consolidated
financial statements. The audit committee has reviewed all non-audit services provided by KPMG LLP in 2016 and has
concluded that the provision of such services was compatible with maintaining KPMG LLP’s independence in the conduct of
its auditing functions.
To help ensure the independence of the independent auditor, the audit committee pre-approves all audit and permissible non-
audit services to be provided to us by our independent registered public accounting firm prior to commencement of services.
Our audit committee chairman has the delegated authority to pre-approve such services up to a specified aggregate fee amount.
These pre-approval decisions are presented to the full audit committee at its next scheduled meeting.
Change in Independent Registered Public Accounting Firms
At our Annual General Meeting held on June 18, 2016, our shareholders ratified the appointment of KPMG LLP as our
independent registered public accounting firm for the fiscal year ending December 25, 2016. Similarly, at the Annual General
Meeting, our shareholders appointed KPMG N.V. to serve as our auditor who will audit our Dutch statutory annual accounts to
be prepared in accordance with Dutch law for the year ending December 25, 2016. KPMG LLP has served as legacy Wright’s
independent registered public accounting firm since 2002.
On December 3, 2015, the audit committee of our board of directors formally dismissed Ernst & Young LLP and engaged
KPMG LLP, as our independent registered public accounting firm. In addition, on December 3, 2015, the audit committee of
our board of directors formally dismissed E&Y Accountants LLP and engaged KPMG N.V. as our auditor who will audit our
Dutch statutory annual accounts to be prepared in accordance with Dutch law for the year ending December 25, 2016.
199
Item 15.
Exhibits, Financial Statement Schedules.
Financial Statements
PART IV
See Index to Consolidated Financial Statements in “Item 8. Financial Statements and Supplementary Data.”
Financial Statement Schedules
See Schedule II — Valuation and Qualifying Accounts on page S-1 of this report.
Exhibits
The exhibits to this report are listed on an Exhibit Index, which follows the signature page to this report. A copy of any of the
exhibits will be furnished at a reasonable cost, upon receipt of a written request for any such exhibit. Such request should be
sent to James A. Lightman, Senior Vice President, General Counsel and Secretary, Wright Medical Group N.V., Prins
Bernhardplein 200, 1097 JB Amsterdam, the Netherlands. The Exhibit Index indicates each management contract or
compensatory plan or arrangement required to be filed as an exhibit to this report.
200
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
February 23, 2017
WRIGHT MEDICAL GROUP N.V.
By:
/s/ Robert J. Palmisano
Robert J. Palmisano
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following
persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Robert J. Palmisano
Robert J. Palmisano
President, Chief Executive Officer and
Executive Director
(Principal Executive Officer)
February 23, 2017
February 23, 2017
February 23, 2017
Senior Vice President and Chief
Financial Officer
(Principal Financial Officer )
Vice President and Chief Accounting
Officer
(Principal Accounting Officer )
Chairman
February 23, 2017
Non-Executive Director
February 23, 2017
Non-Executive Director
February 23, 2017
Non-Executive Director
February 23, 2017
Non-Executive Director
February 23, 2017
Non-Executive Director
February 23, 2017
Non-Executive Director
February 23, 2017
/s/ Lance A. Berry
Lance A. Berry
/s/ Julie B. Andrews
Julie B. Andrews
/s/ David D. Stevens
David D. Stevens
/s/ Gary D. Blackford
Gary D. Blackford
/s/ Sean D. Carney
Sean D. Carney
/s/ John L. Miclot
John L. Miclot
/s/ Kevin C. O’Boyle
Kevin C. O’Boyle
/s/ Amy S. Paul
Amy S. Paul
/s/ Richard F. Wallman
Richard F. Wallman
/s/ Elizabeth H. Weatherman
Elizabeth H. Weatherman
Non-Executive Director
February 23, 2017
201
WRIGHT MEDICAL GROUP N.V.
EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 25, 2016
Exhibit No.
2.1
2.2
2.3
2.4
2.5
2.6
Exhibit
Business Sale Agreement dated October 21,
2016 between Tornier SAS, Corin France
SAS, Corin Orthopaedics Holdings Limited
and Certain Related Entities Party Thereto*
Method of Filing
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 24,
2016 (File No. 001-35065)
to Exhibit 2.1
to
Agreement and Plan of Merger dated as of
October 27, 2014 among Tornier N.V.,
Trooper Holdings Inc., Trooper Merger Sub
Inc. and Wright Medical Group, Inc.*
Agreement and Plan of Merger dated as of
January 30, 2014 among Wright Medical
Group, Inc., WMMS, LLC, OrthoPro, L.L.C.
and OP CHA, Inc., as Company Holders’
Agent*
Agreement and Plan of Merger dated as of
January 30, 2014 among Wright Medical
Group, Inc., Winter Solstice LLC, Solana
Surgical, LLC, and Alan Taylor, as Members’
Representative*
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 27,
2014 (File No. 001-35065)
to Exhibit 2.1
to
Incorporated by reference to Exhibit 2.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
January 31, 2014 (File No. 001-35823)
Incorporated by reference to Exhibit 2.2 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
January 31, 2014 (File No. 001-35823)
Asset Purchase Agreement dated as of June
18, 2013 among MicroPort Medical B.V.,
MicroPort Scientific Corporation and Wright
Medical Group, Inc.*
Incorporated by reference to Exhibit 2.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
June 21, 2013 (File No. 001-35823)
Agreement and Plan of Merger dated as of
November 19, 2012 among BioMimetic
Therapeutics, Inc., Wright Medical Group,
Inc., Achilles Merger Subsidiary, Inc. and
Achilles Acquisition Subsidiary, LLC*
Incorporated by reference to Exhibit 2.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
November 19, 2012 (File No. 001-32883)
3.1
Articles of Association of Wright Medical
Group N.V.
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on July 1,
2016 (File No. 001-35065)
to Exhibit 3.2
to
4.1
4.2
4.3
4.4
Indenture dated as of May 20, 2016 between
Wright Medical Group N.V. and The Bank of
New York Mellon Trust Company, N.A.
(including the Form of the 2.25% Cash
Convertible Senior Note due 2021)
Indenture dated as of February 13, 2015
between Wright Medical Group, Inc. and
Bank of New York Mellon Trust Company,
N.A. (including the Form of the 2.00% Cash
Convertible Senior Note due 2020)
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on May 25,
2016 (File No. 001-35065)
to Exhibit 4.1
to
Incorporated by reference to Exhibit 4.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Supplemental
dated
of
Indenture
November 24, 2015 among Wright Medical
Group, Inc., Wright Medical Group N.V., as
Guarantor, and The Bank of New York
Mellon Trust Company, N.A., as Trustee
as
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 4.1
to
Contingent Value Rights Agreement dated as
of March 1, 2013 between Wright Medical
Group, Inc. and American Stock Transfer &
Trust Company, LLC
Incorporated by reference to Exhibit 10.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
March 1, 2013 (File No. 001-32883)
202
Method of Filing
Incorporated by reference
the
Registrant’s Registration Statement on Form 8-A as filed
with the Securities and Exchange Commission on
October 1, 2015 (File No. 001-35065)
to Exhibit 4.2
to
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on June 19,
2015 (File No. 001-35065)
to Exhibit 10.2
to
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.2
to
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.3
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.4
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.5
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.6
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.7
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.8
to
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.9
to
Exhibit No.
4.5
Exhibit
Assignment and Assumption Agreement
dated as of October 1, 2015 between Wright
Medical Group, Inc., Wright Medical Group
N.V. and American Stock Transfer & Trust
Company, LLC, as Trustee
10.1
Wright Medical Group N.V. Amended and
Restated 2010 Incentive Plan**
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
Form of Option Certificate under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Stock
Options Granted to Executive Officers**
Form of Stock Grant Certificate (in the Form
of a Restricted Stock Unit) under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Restricted
Stock Units Granted to Executive Officers**
Form of Stock Grant Certificate (in the Form
of a Restricted Stock Unit) under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Restricted
Stock Units Granted to New Executive
Officers**
Form of Option Certificate under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Stock
Options Granted to Robert J. Palmisano**
Form of Stock Grant Certificate (in the Form
of a Restricted Stock Unit) under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Restricted
Stock Units Granted
J.
Palmisano**
to Robert
Form of Option Certificate under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Stock
to Non-Executive
Options Granted
Directors**
Form of Stock Grant Certificate (in the Form
of a Restricted Stock Unit) under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Restricted
Stock Units Granted
to Non-Executive
Directors**
Form of Stock Grant Certificate (in the Form
of a Restricted Stock Unit) under the Wright
Medical Group N.V. Amended and Restated
2010 Incentive Plan Representing Restricted
to Non-Executive
Stock Units Granted
Directors in Lieu of Cash Retainers**
203
10.14
10.15
10.16
Exhibit No.
10.10
Exhibit
Tornier N.V. Amended and Restated 2010
Incentive Plan**
10.11
Form of Option Certificate under the Tornier
N.V. 2010 Incentive Plan**
10.12
Tornier N.V. Amended and Restated Stock
Option Plan**
10.13
Form of Option Agreement under
the
Tornier N.V. Stock Option Plan for Directors
and Officers**
Wright Medical Group,
Inc. Second
and Restated 2009 Equity
Amended
Incentive Plan**
Method of Filing
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on June 19,
2015 (File No. 001-35065)
to Exhibit 10.1
to
Incorporated by reference
the
Registrant’s Annual Report on Form 10-K for the fiscal
year ended December 29, 2013 (File No. 001-35065)
to Exhibit 10.9
to
Incorporated by reference to Exhibit 10.10 to the
Registrant’s Amendment No. 9 to Registration Statement
on Form S-1 as filed with the Securities and Exchange
Commission on January 18, 2011 (Registration No. 333-
167370)
Incorporated by reference
the
Registrant’s Registration Statement on Form S-1 as filed
with the Securities and Exchange Commission on June
8, 2010 (Registration No. 333-167370)
to Exhibit 10.9
to
Incorporated by reference to Wright Medical Group,
Inc.’s Definitive Proxy Statement as filed with the
Securities and Exchange Commission on April 4, 2013
(File No. 001-35823)
Form of Executive Stock Option Agreement
the Wright Medical Group, Inc.
under
Second Amended and Restated 2009 Equity
Incentive Plan**
Incorporated by reference to Exhibit 10.4 to Wright
Medical Group, Inc.’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2012 (File No. 001-
32883)
Form of Non-Employee Director Stock
Option Agreement under the Wright Medical
Group, Inc. Second Amended and Restated
2009 Equity Incentive Plan**
Incorporated by reference to Exhibit 10.6 to Wright
Medical Group, Inc.’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2012 (File No. 001-
32883)
10.17
Wright Medical Group, Inc. Fifth Amended
and Restated 1999 Equity Incentive Plan**
10.18
First Amendment to the Wright Medical
Group, Inc. Fifth Amended and Restated
1999 Equity Incentive Plan**
Incorporated by reference to Wright Medical Group,
Inc.’s Definitive Proxy Statement as filed with the
Securities and Exchange Commission on April 14, 2008
(File No. 001-32883)
Incorporated by reference to Exhibit 10.2 to Wright
Medical Group, Inc.’s Quarterly Report on Form 10-Q
for the fiscal quarter ended September 30, 2008 (File
No. 001-32883)
10.19
10.20
Form of Executive Stock Option Agreement
under the Wright Medical Group, Inc. Fifth
Amended
and Restated 1999 Equity
Incentive Plan**
Incorporated by reference to Exhibit 10.13 to Wright
Medical Group, Inc.’s Quarterly Report on Form 10-Q
for the fiscal quarter ended June 30, 2009 (File No. 001-
32883)
Form of Non-Employee Director Stock
Option Agreement under the Wright Medical
Group, Inc. Fifth Amended and Restated
1999 Equity Incentive Plan**
Incorporated by reference to Exhibit 10.15 to Wright
Medical Group, Inc.’s Quarterly Report on Form 10-Q
for the fiscal quarter ended June 30, 2009 (File No. 001-
32883)
10.21
Wright Medical Group N.V. Amended and
Restated Employee Stock Purchase Plan**
10.22
Wright Medical Group N.V. Performance
Incentive Plan**
204
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on July 1,
2016 (File No. 001-35065)
to Exhibit 10.1
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
to Exhibit 10.1
to
Exhibit No.
10.23
Form of Indemnification Agreement**
Exhibit
Method of Filing
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 1,
2015 (File No. 001-35065)
to Exhibit 10.1
to
Incorporated by reference to Exhibit 10.10 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
Incorporated by reference to Exhibit 10.11 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
Incorporated by reference to Exhibit 10.12 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
Incorporated by reference to Exhibit 10.13 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
10.24
Service Agreement effective as of October 1,
2015 between Wright Medical Group N.V.
and Robert J. Palmisano**
10.25
Employment Agreement effective as of
October 1, 2015 between Wright Medical
Group, Inc. and Robert J. Palmisano**
Guaranty by Wright Medical Group N.V.
effective as of October 1, 2015 with respect
to Wright Medical Group, Inc. Obligations
under Employment Agreement with Robert J.
Palmisano**
Confidentiality, Non-Competition, Non-
Solicitation and Intellectual Property Rights
Agreement effective as of October 1, 2015
between Wright Medical Group, Inc. and
Robert J. Palmisano**
10.26
10.27
10.28
10.29
Inducement Stock Option Grant Agreement
dated as of September 17, 2011 between
Wright Medical Group, Inc. and Robert J.
Palmisano**
Incorporated by reference to Exhibit 10.2 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
September 22, 2011 (File No. 001-32883)
Confidentiality, Non-Competition, Non-
Solicitation and Intellectual Property Rights
Agreement effective as of October 1, 2015
between Wright Medical Group, Inc. and
Lance A. Berry**
Incorporated by reference to Exhibit 10.16 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
10.30
Separation Pay Agreement effective as of
October 1, 2015 between Wright Medical
Group, Inc. and Lance A. Berry**
Incorporated by reference to Exhibit 10.20 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
10.31
10.32
10.33
Confidentiality, Non-Competition, Non-
Solicitation and Intellectual Property Rights
Agreement effective as of October 1, 2015
between Wright Medical Group, Inc. and
Kevin D. Cordell**
Separation Pay Agreement effective as of
October 1, 2015 between Wright Medical
Group, Inc. and Kevin D. Cordell**
Confidentiality, Non-Competition, Non-
Solicitation and Intellectual Property Rights
Agreement dated as of August 1, 2014
between Wright Medical Group, Inc. and
Robert P. Burrows**
Filed herewith
Filed herewith
Filed herewith
10.34
Separation Pay Agreement effective as of
October 1, 2015 between Wright Medical
Group, Inc. and Robert P. Burrows**
Filed herewith
205
Exhibit
Method of Filing
Exhibit No.
10.35
Confidentiality, Non-Competition, Non-
Solicitation and Intellectual Property Rights
Agreement effective as of October 1, 2015
between Wright Medical Group, Inc. and
Peter S. Cooke**
10.36
10.37
10.38
10.39
10.40
Separation Pay Agreement effective as of
October 1, 2015 between Wright Medical
Group, Inc. and Peter S. Cooke**
Letter of Agreement dated as of June 8, 2016
regarding Assignment Offer and Assignment
and Relocation Benefit Policy between
Wright Medical Technology, Inc. and Peter S.
Cooke**
Letter of Agreement dated as of June 8, 2016
between Wright Medical Technology, Inc.
and Peter S. Cooke**
Form of Guaranty by Wright Medical Group
N.V. with respect to Wright Medical Group,
Inc. or Tornier, Inc. Obligations under
Separation Pay Agreements with Executive
Officers**
Credit, Security and Guaranty Agreement
dated as of December 23, 2016 among
Wright Medical Group N.V. (as Guarantor),
Wright Medical Group, Inc. (as Borrower),
Indirect
Certain Other Direct
Subsidiaries Listed on the Signature Pages
Thereto
as Borrower), Midcap
Financial Trust (as Lender and Agent) and
the Financial Institutions or Other Entities
Parties Thereto
(each
and
Filed herewith
Filed herewith
Filed herewith
Filed herewith
Incorporated by reference to Exhibit 10.23 to the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on October 16,
2015 (File No. 001-35065)
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on December
29, 2016 (File No. 001-35065)
to Exhibit 10.1
to
10.41
Form of Exchange/Subscription Agreement
dated as of May 12, 2016 between Wright
Medical Group N.V. and Each Investor Party
Thereto
10.42
Form of Subscription Agreement dated as of
May 12, 2016 between Wright Medical
Group N.V. and Each Investor Party Thereto
10.43
10.44
10.45
Call Option Transaction Confirmation dated
as of May 12, 2016 between Wright Medical
Group N.V. and JPMorgan Chase Bank,
National Association
Call Option Transaction Confirmation dated
as of May 12, 2016 between Wright Medical
Group N.V. and Bank of America, N.A.
Warrants Confirmation dated as of May 12,
2016 between Wright Medical Group N.V.
JPMorgan Chase Bank, National
and
Association
10.46
Warrants Confirmation dated as of May 12,
2016 between Wright Medical Group N.V.
and Bank of America, N.A.
206
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on May 18,
2016 (File No. 001-35065)
to Exhibit 10.1
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on May 18,
2016 (File No. 001-35065)
to Exhibit 10.2
to
Incorporated by reference
the
Registrant’s Quarterly Report on Form 10-Q for the
fiscal quarter ended June 26, 2016 (File No. 001-35065)
to Exhibit 10.3
to
Incorporated by reference
the
Registrant’s Quarterly Report on Form 10-Q for the
fiscal quarter ended June 26, 2016 (File No. 001-35065)
to Exhibit 10.4
to
Incorporated by reference
the
Registrant’s Quarterly Report on Form 10-Q for the
fiscal quarter ended June 26, 2016 (File No. 001-35065)
to Exhibit 10.5
to
Incorporated by reference
the
Registrant’s Quarterly Report on Form 10-Q for the
fiscal quarter ended June 26, 2016 (File No. 001-35065)
to Exhibit 10.6
to
Exhibit No.
10.47
Exhibit
Base Call Option Transaction Confirmation
dated as of February 9, 2015 between Wright
Medical Group, Inc. and Deutsche Bank AG,
London Branch
Method of Filing
Incorporated by reference to Exhibit 10.1 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
10.48
10.49
10.50
10.51
10.52
10.53
10.54
10.55
10.56
10.57
10.58
10.59
Base Call Option Transaction Confirmation
dated as of February 9, 2015 between Wright
Medical Group, Inc. and JPMorgan Chase
Bank, National Association
Incorporated by reference to Exhibit 10.3 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Base Call Option Transaction Confirmation
dated as of February 9, 2015 between Wright
Medical Group, Inc. and Wells Fargo Bank,
National Association
Incorporated by reference to Exhibit 10.5 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Base Warrants Confirmation dated as of
February 9, 2015 between Wright Medical
Group, Inc. and Deutsche Bank AG, London
Branch
Incorporated by reference to Exhibit 10.7 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Base Warrants Confirmation dated as of
February 9, 2015 between Wright Medical
Group, Inc. and JPMorgan Chase Bank,
National Association
Incorporated by reference to Exhibit 10.9 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Base Warrants Confirmation dated as of
February 9, 2015 between Wright Medical
Group, Inc. and Wells Fargo Bank, National
Association
Incorporated by reference to Exhibit 10.11 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional
Transaction
Call Option
Confirmation dated as of February 10, 2015
between Wright Medical Group, Inc. and
Deutsche Bank AG, London Branch
Incorporated by reference to Exhibit 10.2 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional
Transaction
Call Option
Confirmation dated as of February 10, 2015
between Wright Medical Group, Inc. and
JPMorgan Chase Bank, National Association
Incorporated by reference to Exhibit 10.4 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional
Transaction
Call Option
Confirmation dated as of February 10, 2015
between Wright Medical Group, Inc. and
Wells Fargo Bank, National Association
Incorporated by reference to Exhibit 10.6 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional Warrants Confirmation dated as
of February 10, 2015 between Wright
Medical Group, Inc. and Deutsche Bank AG,
London Branch
Incorporated by reference to Exhibit 10.8 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional Warrants Confirmation dated as
of February 10, 2015 between Wright
Medical Group, Inc. and JPMorgan Chase
Bank, National Association
Incorporated by reference to Exhibit 10.10 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Additional Warrants Confirmation dated as
of February 10, 2015 between Wright
Medical Group, Inc. and Wells Fargo Bank,
National Association
Incorporated by reference to Exhibit 10.12 to Wright
Medical Group, Inc.’s Current Report on Form 8-K as
filed with the Securities and Exchange Commission on
February 13, 2015 (File No. 001-35823)
Amendment
to
the Base Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
Deutsche Bank AG, London Branch
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.1
to
207
Exhibit No.
10.60
Exhibit
Method of Filing
Amendment
to
the Base Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
JPMorgan Chase Bank, National Association
Amendment
to
the Base Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
Wells Fargo Bank, National Association
Amendment
to
the Additional Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
Deutsche Bank AG, London Branch
Amendment
to
the Additional Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
JPMorgan Chase Bank, National Association
Amendment
to
the Additional Warrant
Confirmation dated as of November 24, 2015
between Wright Medical Group N.V. and
Wells Fargo Bank, National Association
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.2
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.3
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.4
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.5
to
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on November
27, 2015 (File No. 001-35065)
to Exhibit 10.6
to
Form of Partial Termination Confirmation
among Wright Medical Group N.V., Wright
Medical Group, Inc. and each of JPMorgan
Chase
Incorporated by reference
the
Registrant’s Current Report on Form 8-K (with respect
to Item 1.01) as filed with the Securities and Exchange
Commission on June 16, 2016 (File No. 001-35065)
to Exhibit 10.1
to
Agreement of Lease dated as of December
31, 2013 between RBM Cherry Road
Partners and Wright Medical Technology,
Inc.
Incorporated by reference to Exhibit 10.94 to Wright
Medical Group Inc.’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2013 (File No. 001-
35823)
First Amendment to Agreement of Lease
dated as of January 1, 2014 between RBM
Cherry Road Partners and Wright Medical
Technology, Inc.
Second Amendment to Agreement of Lease
dated as of January 1, 2014 between RBM
Cherry Road Partners and Wright Medical
Technology, Inc.
Third Amendment to Agreement of Lease
dated as of May 1, 2015 between RBM
Cherry Road Partners and Wright Medical
Technology, Inc.
Filed herewith
Filed herewith
Filed herewith
Lease Agreement dated as of May 14, 2012
between
Limited
Partnership, as Landlord, and Tornier, Inc., as
Tenant
Property
Liberty
the
Incorporated by reference
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on May 15,
2012 (File No. 001-35065)
to Exhibit 10.1
to
10.61
10.62
10.63
10.64
10.65
10.66
10.67
10.68
10.69
10.70
10.71
Commercial Lease dated December 23, 2008
between Seamus Geaney and Tornier
Orthopedics Ireland Limited
Incorporated by reference to Exhibit 10.27 to the
Registrant’s Amendment No. 1 to Registration Statement
on Form S-1 as filed with the Securities and Exchange
Commission on July 15, 2010 (Registration No. 333-
167370)
10.72
Commercial Supply Agreement dated March
29, 2016 between BioMimetic Therapeutics,
LLC
Diosynth
Biotechnologies U.S.A., Inc. (1)
FUJIFILM
and
Incorporated by reference
the
Registrant’s Current Report on Form 8-K as filed with
the Securities and Exchange Commission on April 7,
2016 (File No. 001-35065)
to Exhibit 10.1
to
208
Exhibit No.
10.73
Exhibit
Settlement Agreement dated as of November
1, 2016 between Wright Medical Technology,
Inc. and the Counsel Listed on the Signature
Pages Thereto
Method of Filing
Incorporated by reference
the
Registrant’s Quarterly Report on Form 10-Q for the
fiscal quarter ended September 25, 2016 (File No. 001-
35065)
to Exhibit 10.1
to
12.1
Computation of Ratio of Earnings to Fixed
Filed herewith
Charges
21.1
23.1
31.1
31.2
32.1
101
Subsidiaries of Wright Medical Group N.V.
Filed herewith
Consent of KPMG LLP, an Independent
Filed herewith
Registered Public Accounting Firm
Filed herewith
Filed herewith
Furnished herewith
Filed herewith
Certification of Chief Executive Officer
to Exchange Act Rules 13a-
pursuant
14(a)/15d-14(a), as adopted pursuant
to
Section 302 of the Sarbanes-Oxley Act of
2002
Certification of Chief Financial Officer
to Exchange Act Rules 13a-
pursuant
to
14(a)/15d-14(a), as adopted pursuant
Section 302 of the Sarbanes-Oxley Act of
2002
Certification of Chief Executive Officer and
Chief Financial Officer pursuant to 18 U.S.C.
Section 1350, as
to
Section 906 of the Sarbanes-Oxley Act of
2002
adopted pursuant
The
following materials
from Wright
Medical Group N.V.’s Annual Report on
Form 10-K for
the fiscal year ended
December 25, 2016, formatted in XBRL
(Extensible Business Reporting Language):
(i) the Consolidated Balance Sheets as of
December 25, 2016 and December 27, 2015,
(ii)
of
the Consolidated Statements
Operations for each of the fiscal years in the
three-year period ended December 25, 2016,
(iii)
of
the Consolidated Statements
Comprehensive Loss for each of the fiscal
years
three-year period ended
December 25, 2016, (iv) the Consolidated
Statements of Cash Flows for each of the
fiscal years in the three-year period ended
December 25, 2016,
(v) Consolidated
Statements of Shareholders’ Equity for each
of the fiscal years in the three-year period
ended December 25, 2016, and (vi) Notes to
Consolidated Financial Statements
the
in
__________________________
*
All exhibits and schedules to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The
Registrant will furnish the omitted exhibits and schedules to the Securities and Exchange Commission upon request by
the Securities and Exchange Commission.
**
(1)
A management contract or compensatory plan or arrangement.
Portions of this exhibit have been redacted and are subject to an order granting confidential treatment under Rule 24b-
2 of the Securities Exchange Act of 1934, as amended (File No. 001-35065, CF #33696). The redacted material was
filed separately with the Securities and Exchange Commission.
209
Note: Certain instruments defining the rights of holders of long-term debt securities of the Registrant or its subsidiaries are
omitted pursuant to Item 601(b)(4)(iii) of SEC Regulation S-K. The Registrant hereby undertakes to furnish to the
Securities and Exchange Commission, upon request, copies of any such instruments.
210
Report of Independent Registered Public Accounting Firm
The Board of Directors and Shareholders
Wright Medical Group N.V.:
Under date of February 23, 2017, we reported on the consolidated balance sheets of Wright Medical Group N.V. and
subsidiaries (the Company) as of December 25, 2016 and December 27, 2015, and the related consolidated statements of
operations, comprehensive loss, cash flows, and changes in shareholders’ equity for the years ended December 25, 2016,
December 27, 2015 and December 31, 2014, which are included in the annual report on Form 10-K for the year ended
December 25, 2016. In connection with our audits of the aforementioned consolidated financial statements, we also audited the
related financial statement schedule listed in Item 15 in the annual report on Form 10-K. The financial statement schedule is
the responsibility of the Company’s management. Our responsibility is to express an opinion on the financial statement
schedule based on our audits.
In our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements
taken as a whole, presents fairly, in all material respects, the information set forth therein.
(signed) KPMG LLP
Memphis, Tennessee
February 23, 2017
211
Wright Medical Group N.V.
Schedule II-Valuation and Qualifying Accounts
(In thousands)
Allowance for doubtful accounts:
For the period ended:
December 25, 2016
December 27, 2015
December 31, 2014
Balance at
Beginning of
Period
Charged to
Cost and
Expenses
Deductions
and Other
Balance at
End of
Period
$
$
$
1,189 $
930 $
272 $
3,475 $
(878) $
(684) $
(195) $
1,137 $
1,342 $
4,469
1,189
930
212
Senior Management
Directors
Robert J. Palmisano
President & Chief Executive Officer
Lance A. Berry
SVP, Chief Financial Officer
Robert P. Burrows
SVP, Supply Chain
James A. Lightman
SVP, General Counsel & Secretary
Gregory Morrison
SVP, Human Resources
J. Wesley Porter
SVP, Chief Compliance Officer
Julie D. Tracy
SVP, Chief Communications Officer
Jennifer S. Walker
SVP, Process Improvement
Kevin D. Cordell
President, US
Peter S. Cooke
President, International
Timothy L. Lanier
President, Upper Extremities
Patrick Fisher
President, Lower Extremities
Julie B. Andrews
VP, Finance & Chief Accounting
Officer
David D. Stevens 1,2
Chairman, Non-
Executive Director
Most recently Chief
Executive Officer,
Accredo Health Group,
Inc., a subsidiary of
Medco Health Solutions,
Inc.
Gary D. Blackford 1,3
Non-Executive Director
Most recently President &
Chief Executive Officer,
Universal Hospital
Services, Inc.
John L. Miclot 4
Non-Executive Director
President and Chief
Executive Officer,
LinguaFlex, Inc.
Kevin C. O’Boyle 3,4
Non-Executive Director
Most recently Senior Vice
President and Chief
Financial Officer,
Advanced BioHealing, Inc.
Amy S. Paul 1
Non-Executive Director
Most recently Group Vice
President, International,
C.R. Bard, Inc.
Richard F. Wallman 2,3
Non-Executive Director
Most recently Senior
Vice President and
Chief Financial Officer of
Honeywell International,
Inc.
Elizabeth H. Weatherman 1,2,4
Non-Executive Director
Special Limited Partner,
Warburg Pincus LLC
Robert J. Palmisano
Executive Director
President and Chief
Executive Officer,
Wright Medical Group N.V.
Committees of the Board of Directors
1 – member of the nominating, corporate
governance and compliance committee
2 – member of the strategic transactions
committee
3 – member of the audit committee
4 – member of the compensation committee
Shareholder Information
Independent Auditors
KPMG LLP
Memphis, TN
Transfer Agent & Registrar
American Stock Transfer & Trust Company,
Inc.
6201 15th Avenue, Brooklyn, NY 11219
718.921.8124
800.937.5449
info@astfinancial.com
Share Information
Our ordinary shares are traded on the
NASDAQ Global Select Market under
the symbol “WMGI.”
Investor & Media Inquiries
Julie D. Tracy
SVP, Chief Communications Officer
901.290.5817
julie.tracy@wright.com
Annual General Meeting
The annual general meeting of
our shareholders will be held on
Friday, June 23, 2017, beginning at
9am (Central European Time) at:
Worldwide Headquarters:
Prins Bernhardplein 200
1097 JB Amsterdam, The Netherlands
213
015479A_02-May-2017_Annual Report 2016.indd 9
5/2/2017 12:01:25 PM
1023 Cherry Road
Memphis, TN 38117
800 238 7117
901 867 9971
www.wright.com
56 Kingston Road
Staines-upon-Thames
Surrey TW18 4NL
United Kingdom
+44 (0)845 833 4435
161 Rue Lavoisier
38330 Montbonnot
Saint Martin
France
+33 (0)4 76 61 35 00
Prins Bernhardplein 200
1097 JB Amsterdam,
The Netherlands
™Trademarks and ®Registered marks of Wright Medical Group N.V. or its affiliates.
©2017 Wright Medical Group N.V. or its affiliates. All Rights Reserved. 015479A_02-May-2017
015479A_02-May-2017_Annual Report 2016.indd 10
5/2/2017 12:01:26 PM